

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 November 2001 (29.11.2001)

PCT

(10) International Publication Number
WO 01/90337 A2

(51) International Patent Classification⁷: **C12N 9/22**,
9/12, C12Q 1/68

(21) International Application Number: **PCT/US01/17086**

(22) International Filing Date: 24 May 2001 (24.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/577,304 24 May 2000 (24.05.2000) US
09/758,282 11 January 2001 (11.01.2001) US
09/864,426 24 May 2001 (24.05.2001) US
09/864,636 24 May 2001 (24.05.2001) US

(71) Applicant (for all designated States except US): **THIRD WAVE TECHNOLOGIES, INC.**, [US/US]; 502 South Rosa Road, Madison, WI 53719 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALLAWI, Hatim** [JO/US]; 33 Oakbridge Court #21, Madison, WI 53717 (US); **BARTHOLOMAV, Christian, Tor** [US/US]; 1913 Reetz Road, Madison, WI 53711 (US); **CHEHAK, Lu-Anne** [US/US]; 3211 Vold Court, Apartment 8, Janesville, WI 53546 (US); **CURTIS, Michelle, L.** [US/US]; 2740 Nadeau Road, Cottage Grove, WI 53527 (US); **EIS, Peggy, S.** [US/US]; 5781 Pembroke Drive, Madison, WI 53711 (US); **HALL, Jeff, G.** [US/US]; 6305 Dylan Drive, Madison, WI 53719 (US); **IP, Hon, S.** [CA/US]; 6310 Pilgrim Road, Madison, WI 53711 (US); **KAI SER, Michael** [US/US]; 2901 Shefford Drive, Madison, WI 53719 (US); **KWATKOWSKI, Robert, W., Jr.** [US/US]; 506 Azurrene Lane, Verona, WI 53593 (US); **LUKOWIAK, Andrew, A.** [US/US]; 2254 High Ridge Trail, Madison, WI 53713 (US); **LYAMICHEV, Victor** [RU/US]; 2523 Carriedale Court, Madison, WI 53711 (US); **MA, WuPo** [CN/US]; 1110 N. Westfield Road,

Madison, WI 53717 (US); **OLSON-MUNOZ, Marilyn, C.** [US/US]; 5878 Tree Line Drive, Madison, WI 53711 (US); **OLSON, Sarah, M.** [US/US]; 2968 Thines Street, Cross Plains, WI 53528 (US); **SCHAEFER, James, J.** [US/US]; 4369 Crawford Drive, Madison, WI 53711 (US); **SKRZYP CZYN SKI, Zbigniew** [PL/US]; 881 Orchid Street, Verona, WI 53953 (US); **TAKOVA, Tsetska, Y.** [US/US]; 9 Oak Glen Court, Madison, WI 53717 (US); **VEDVIK, Kevin, L.** [US/US]; 1302 Monica Lane, Madison, WI 53704 (US); **LYAMICHEV, Natalie, E.** [RU/US]; 2523 Carriedale Court, Madison, WI 53711 (US); **NERI, Bruce, P.** [US/US]; 5714 Kilkenny Place, Madison, WI 53711 (US).

(74) Agents: **CASIMIR, David, A.** et al.; Meilien & Carroll, LLP, 220 Montgomery Street, Suite 2200, San Francisco, CA 94104 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidelines Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/90337 A2

(54) Title: DETECTION OF RNA

(57) Abstract: The present invention provides novel cleavage agents and polymerases for the cleavage and modification of nucleic acid. The cleavage agents and polymerases find use, for example, for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. In some embodiments, the 5' nuclease activity of a variety of enzymes is used to cleave a target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

DETECTION OF RNA

The present application is a continuation-in-part of U.S. Patent Application No. 09/577,304 and 09/758,282 and is a continuation-in-part of U.S. Patent Application No. 5 09/350,309, which is a divisional application U.S. Patent No. 5,985,557, and is also a continuation-in-part of co-pending application serial no. 09/381,212 which is a national entry of PCT application no. US 98/05809, which claims priority to U.S. Patent Nos. 5,994,069, 6,090,543, 5,985,557, 6,001,567, and 5,846,717 and PCT application no. US 97/01072.

10

FIELD OF THE INVENTION

The present invention relates to compositions and methods for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. The present invention relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. For example, in some embodiments, the 5' nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

15
20

BACKGROUND OF THE INVENTION

Methods for the detection and characterization of specific nucleic acid sequences and sequence variations have been used to detect the presence of viral or bacterial nucleic acid sequences indicative of an infection, to detect the presence of variants or alleles of genes associated with disease and cancers. These methods also find application in the identification of sources of nucleic acids, as for forensic analysis or for paternity determinations.

Various methods are known to the art that may be used to detect and characterize specific nucleic acid sequences and sequence variants. Nonetheless, with the completion of the nucleic acid sequencing of the human genome, as well as the genomes of numerous pathogenic organisms, the demand for fast, reliable, cost-effective and user-friendly tests for the detection of specific nucleic acid sequences continues to grow. Importantly, these

tests must be able to create a detectable signal from samples that contain very few copies of the sequence of interest. The following discussion examines two levels of nucleic acid detection assays currently in use: I. Signal Amplification Technology for detection of rare sequences II. Direct Detection Technology for quantitative detection of sequences,
5 and III. Direct Detection of RNA.

I. Signal Amplification Technology Methods For Amplification

The "Polymerase Chain Reaction" (PCR) comprises the first generation of methods for nucleic acid amplification. However, several other methods have been
10 developed that employ the same basis of specificity, but create signal by different amplification mechanisms. These methods include the "Ligase Chain Reaction" (LCR), "Self-Sustained Synthetic Reaction" (3SR/NASBA), and "Q β -Replicase" (Q β).

Polymerase Chain Reaction (PCR)

15 The polymerase chain reaction (PCR), as described in U.S. Patent Nos. 4,683,195, 4,683,202, and 4,965,188 to Mullis and Mullis *et al.* (the disclosures of which are hereby incorporated by reference), describe a method for increasing the concentration of a segment of target sequence in a mixture of genomic DNA without cloning or purification. This technology provides one approach to the problems of low target sequence
20 concentration. PCR can be used to directly increase the concentration of the target to an easily detectable level. This process for amplifying the target sequence involves introducing a molar excess of two oligonucleotide primers that are complementary to their respective strands of the double-stranded target sequence to the DNA mixture containing the desired target sequence. The mixture is denatured and then allowed to
25 hybridize. Following hybridization, the primers are extended with polymerase so as to form complementary strands. The steps of denaturation, hybridization, and polymerase extension can be repeated as often as needed, in order to obtain relatively high concentrations of a segment of the desired target sequence.

The length of the segment of the desired target sequence is determined by the
30 relative positions of the primers with respect to each other, and, therefore, this length is a

controllable parameter. Because the desired segments of the target sequence become the dominant sequences (in terms of concentration) in the mixture, they are said to be "PCR-amplified."

Ligase Chain Reaction (LCR or LAR)

5 The ligase chain reaction (LCR; sometimes referred to as "Ligase Amplification Reaction" (LAR) described by Barany, Proc. Natl. Acad. Sci., 88:189 (1991); Barany, PCR Methods and Appl., 1:5 (1991); and Wu and Wallace, Genomics 4:560 (1989) has developed into a well-recognized alternative method for amplifying nucleic acids. In
10 LCR, four oligonucleotides, two adjacent oligonucleotides that uniquely hybridize to one strand of target DNA, and a complementary set of adjacent oligonucleotides, that hybridize to the opposite strand are mixed and DNA ligase is added to the mixture. Provided that there is complete complementarity at the junction, ligase will covalently link each set of hybridized molecules. Importantly, in LCR, two probes are ligated together only when they base-pair with sequences in the target sample, without gaps or
15 mismatches. Repeated cycles of denaturation, hybridization and ligation amplify a short segment of DNA. LCR has also been used in combination with PCR to achieve enhanced detection of single-base changes. Segev, PCT Public. No. WO9001069 A1 (1990). However, because the four oligonucleotides used in this assay can pair to form two short ligatable fragments, there is the potential for the generation of target-independent
20 background signal. The use of LCR for mutant screening is limited to the examination of specific nucleic acid positions.

Self-Sustained Synthetic Reaction (3SR/NASBA)

The self-sustained sequence replication reaction (3SR) (Guatelli *et al.*, Proc. Natl. Acad. Sci., 87:1874-1878 [1990], with an erratum at Proc. Natl. Acad. Sci., 87:7797
25 [1990]) is a transcription-based *in vitro* amplification system (Kwok *et al.*, Proc. Natl. Acad. Sci., 86:1173-1177 [1989]) that can exponentially amplify RNA sequences at a uniform temperature. The amplified RNA can then be utilized for mutation detection (Fahy *et al.*, PCR Meth. Appl., 1:25 [1991]). In this method, an oligonucleotide primer is used to add a phage RNA polymerase promoter to the 5' end of the sequence of interest.
30 In a cocktail of enzymes and substrates that includes a second primer, reverse

transcriptase, RNase H, RNA polymerase and ribo-and deoxyribonucleoside triphosphates, the target sequence undergoes repeated rounds of transcription, cDNA synthesis and second-strand synthesis to amplify the area of interest. The use of 3SR to detect mutations is kinetically limited to screening small segments of DNA (e.g., 200-300 base pairs).

Q-Beta (Q β) Replicase

In this method, a probe that recognizes the sequence of interest is attached to the replicatable RNA template for Q β replicase. A previously identified major problem with false positives resulting from the replication of unhybridized probes has been addressed through use of a sequence-specific ligation step. However, available thermostable DNA ligases are not effective on this RNA substrate, so the ligation must be performed by T4 DNA ligase at low temperatures (37°C). This prevents the use of high temperature as a means of achieving specificity as in the LCR, the ligation event can be used to detect a mutation at the junction site, but not elsewhere.

Table 2 below, lists some of the features desirable for systems useful in sensitive nucleic acid diagnostics, and summarizes the abilities of each of the major amplification methods (*See also, Landgren, Trends in Genetics 9:199 [1993]*).

A successful diagnostic method must be very specific. A straight-forward method of controlling the specificity of nucleic acid hybridization is by controlling the temperature of the reaction. While the 3SR/NASBA, and Q β systems are all able to generate a large quantity of signal, one or more of the enzymes involved in each cannot be used at high temperature (*i.e.*, >55°C). Therefore the reaction temperatures cannot be raised to prevent non-specific hybridization of the probes. If probes are shortened in order to make them melt more easily at low temperatures, the likelihood of having more than one perfect match in a complex genome increases. For these reasons, PCR and LCR currently dominate the research field in detection technologies.

TABLE 1

Feature	Method				
	PCR	LCR	PCR & LCR	3SR NASBA	Qβ
Amplifies Target	+	+	+	+	
Recognition of Independent Sequences Required	+	+	+	+	+
Performed at High Temp.	+	+			
Operates at Fixed Temp.				+	+
Exponential Amplification	+	+	+	+	+
Generic Signal Generation					+
Easily Automatable					

The basis of the amplification procedure in the PCR and LCR is the fact that the products of one cycle become usable templates in all subsequent cycles, consequently 5 doubling the population with each cycle. The final yield of any such doubling system can be expressed as: $(1+X)^n = y$, where "X" is the mean efficiency (percent copied in each cycle), "n" is the number of cycles, and "y" is the overall efficiency, or yield of the reaction (Mullis, PCR Methods Applic., 1:1 [1991]). If every copy of a target DNA is utilized as a template in every cycle of a polymerase chain reaction, then the mean 10 efficiency is 100%. If 20 cycles of PCR are performed, then the yield will be 2^{20} , or 1,048,576 copies of the starting material. If the reaction conditions reduce the mean efficiency to 85%, then the yield in those 20 cycles will be only 1.85^{20} , or 220,513 copies of the starting material. In other words, a PCR running at 85% efficiency will yield only 21% as much final product, compared to a reaction running at 100% efficiency. A

reaction that is reduced to 50% mean efficiency will yield less than 1% of the possible product.

In practice, routine polymerase chain reactions rarely achieve the theoretical maximum yield, and PCRs are usually run for more than 20 cycles to compensate for the lower yield. At 50% mean efficiency, it would take 34 cycles to achieve the million-fold amplification theoretically possible in 20, and at lower efficiencies, the number of cycles required becomes prohibitive. In addition, any background products that amplify with a better mean efficiency than the intended target will become the dominant products.

Also, many variables can influence the mean efficiency of PCR, including target DNA length and secondary structure, primer length and design, primer and dNTP concentrations, and buffer composition, to name but a few. Contamination of the reaction with exogenous DNA (e.g., DNA spilled onto lab surfaces) or cross-contamination is also a major consideration. Reaction conditions must be carefully optimized for each different primer pair and target sequence, and the process can take days, even for an experienced investigator. The laboriousness of this process, including numerous technical considerations and other factors, presents a significant drawback to using PCR in the clinical setting. Indeed, PCR has yet to penetrate the clinical market in a significant way. The same concerns arise with LCR, as LCR must also be optimized to use different oligonucleotide sequences for each target sequence. In addition, both methods require expensive equipment, capable of precise temperature cycling.

Many applications of nucleic acid detection technologies, such as in studies of allelic variation, involve not only detection of a specific sequence in a complex background, but also the discrimination between sequences with few, or single, nucleotide differences. One method for the detection of allele-specific variants by PCR is based upon the fact that it is difficult for *Taq* polymerase to synthesize a DNA strand when there is a mismatch between the template strand and the 3' end of the primer. An allele-specific variant may be detected by the use of a primer that is perfectly matched with only one of the possible alleles; the mismatch to the other allele acts to prevent the extension of the primer, thereby preventing the amplification of that sequence. This method has a substantial limitation in that the base composition of the mismatch influences the ability to prevent extension across the mismatch, and certain mismatches

do not prevent extension or have only a minimal effect (Kwok *et al.*, Nucl. Acids Res., 18:999 [1990]).)

A similar 3'-mismatch strategy is used with greater effect to prevent ligation in the LCR (Barany, PCR Meth. Applic., 1:5 [1991]). Any mismatch effectively blocks the 5 action of the thermostable ligase, but LCR still has the drawback of target-independent background ligation products initiating the amplification. Moreover, the combination of PCR with subsequent LCR to identify the nucleotides at individual positions is also a clearly cumbersome proposition for the clinical laboratory.

10 II. Direct Detection Technology

When a sufficient amount of a nucleic acid to be detected is available, there are advantages to detecting that sequence directly, instead of making more copies of that target, (e.g., as in PCR and LCR). Most notably, a method that does not amplify the signal exponentially is more amenable to quantitative analysis. Even if the signal is 15 enhanced by attaching multiple dyes to a single oligonucleotide, the correlation between the final signal intensity and amount of target is direct. Such a system has an additional advantage that the products of the reaction will not themselves promote further reaction, so contamination of lab surfaces by the products is not as much of a concern. Traditional methods of direct detection including Northern and Southern blotting and RNase 20 protection assays usually require the use of radioactivity and are not amenable to automation. Recently devised techniques have sought to eliminate the use of radioactivity and/or improve the sensitivity in automatable formats. Two examples are the "Cycling Probe Reaction" (CPR), and "Branched DNA" (bDNA).

The cycling probe reaction (CPR) (Duck *et al.*, BioTech., 9:142 [1990]), uses a 25 long chimeric oligonucleotide in which a central portion is made of RNA while the two termini are made of DNA. Hybridization of the probe to a target DNA and exposure to a thermostable RNase H causes the RNA portion to be digested. This destabilizes the remaining DNA portions of the duplex, releasing the remainder of the probe from the target DNA and allowing another probe molecule to repeat the process. The signal, in the 30 form of cleaved probe molecules, accumulates at a linear rate. While the repeating

process increases the signal, the RNA portion of the oligonucleotide is vulnerable to RNases that may be carried through sample preparation.

Branched DNA (bDNA), described by Urdea *et al.*, Gene 61:253-264 (1987), involves oligonucleotides with branched structures that allow each individual

- 5 oligonucleotide to carry 35 to 40 labels (*e.g.*, alkaline phosphatase enzymes). While this enhances the signal from a hybridization event, signal from non-specific binding is similarly increased.

While both of these methods have the advantages of direct detection discussed above, neither the CPR or bDNA methods can make use of the specificity allowed by the

- 10 requirement of independent recognition by two or more probe (oligonucleotide) sequences, as is common in the signal amplification methods described in Section I. above. The requirement that two oligonucleotides must hybridize to a target nucleic acid in order for a detectable signal to be generated confers an extra measure of stringency on any detection assay. Requiring two oligonucleotides to bind to a target nucleic acid
15 reduces the chance that false "positive" results will be produced due to the non-specific binding of a probe to the target. The further requirement that the two oligonucleotides must bind in a specific orientation relative to the target, as is required in PCR, where oligonucleotides must be oppositely but appropriately oriented such that the DNA polymerase can bridge the gap between the two oligonucleotides in both directions,
20 further enhances specificity of the detection reaction. However, it is well known to those in the art that even though PCR utilizes two oligonucleotide probes (termed primers) "non-specific" amplification (*i.e.*, amplification of sequences not directed by the two primers used) is a common artifact. This is in part because the DNA polymerase used in PCR can accommodate very large distances, measured in nucleotides, between the
25 oligonucleotides and thus there is a large window in which non-specific binding of an oligonucleotide can lead to exponential amplification of inappropriate product. The LCR, in contrast, cannot proceed unless the oligonucleotides used are bound to the target adjacent to each other and so the full benefit of the dual oligonucleotide hybridization is realized.

An ideal direct detection method would combine the advantages of the direct detection assays (*e.g.*, easy quantification and minimal risk of carry-over contamination) with the specificity provided by a dual oligonucleotide hybridization assay.

5 **III. Direct Detection of RNA**

In molecular medicine, a simple and cost-effective method for direct and quantitative RNA detection would greatly facilitate the analysis of RNA viruses and the measurement of specific gene expression. Both of these issues are currently pressing problems in the field. Despite this need, few techniques have emerged that are truly
10 direct. PCR-based detection assays require conversion of RNA to DNA by reverse transcriptase before amplification, introducing a variable that can compromise accurate quantification. Furthermore, PCR and other methods based on exponential amplification (*e.g.*, NASBA) require painstaking containment measures to avoid cross-contamination, and have difficulty distinguishing small differences (*e.g.*, 2 to 3-fold) in quantity. Other
15 tests that directly examine RNA suffer from a variety of drawbacks, including time consuming autoradiography steps (*e.g.*, RNase protection assays), or overnight reaction times (*e.g.*, branched DNA assays). With over 1.5 million viral load measurements being performed in the U.S. every year, there is clearly an enormous potential for an inexpensive, rapid, high-throughput system for the quantitative measurement of RNA.
20 Techniques for direct, quantitative detection of mRNA are vital for monitoring expression of a number of different genes. In particular, levels of cytokine expression (*e.g.*, interleukins and lymphokines) are being exploited as clinical measures of immune response in the progression of a wide variety of diseases (Van Deuren *et al.*, J. Int. Fed. Clin. Chem., 5:216 [1993], Van Deuren *et al.*, J. Inf. Dis., 169:157 [1994], Perenboom *et al.*, Eur. J. Clin. Invest., 26:159 [1996], Guidotti *et al.*, Immunity 4:25 [1996]) as well as in monitoring transplant recipients (Grant *et al.*, Transplantation 62:910 [1996]). Additionally, the monitoring of viral load and identification of viral genotype have great clinical significance for individuals suffering viral infections by such pathogens as HIV or Hepatitis C virus (HCV). There is a high correlation between viral load (*i.e.*, the
25 absolute number of viral particles in the bloodstream) and time to progression to AIDS (Mellors *et al.*, Science 272:1167 [1996], Saag *et al.*, Nature Medicine 2:625 [1996]).

For that reason, viral load, as measured by quantitative nucleic acid based testing, is becoming a standard monitoring procedure for evaluating the efficacy of treatment and the clinical status of HIV positive patients. It is thought to be essential to reduce viral load as early in the course of infection as possible and to evaluate viral levels on a regular

- 5 basis. In the case of HCV, viral genotype has great clinical significance, with correlations to severity of liver disease and responsiveness to interferon therapy. Furthermore, because HCV cannot be grown in culture, it is only by establishing correlations between characteristics like viral genotype and clinical outcome that new antiviral treatments can be evaluated.

- 10 While the above mentioned methods have been serviceable for low throughput, research applications, or for limited clinical application, it is clear that large scale quantitative analysis of RNA readily adaptable to any genetic system will require a more innovative approach. An ideal direct detection method would combine the advantages of the direct detection assays (e.g., easy quantification and minimal risk of carry-over 15 contamination) with the specificity provided by a dual oligonucleotide hybridization assay.

- Many of the methods described above rely on hybridization alone to distinguish a target molecule from other nucleic acids. Although some of these methods can be highly sensitive, they often cannot quantitate and distinguish closely related mRNAs accurately, 20 especially such RNAs expressed at different levels in the same sample. While the above-mentioned methods are serviceable for some purposes, a need exists for a technology that is particularly adept at distinguishing particular RNAs from closely related molecules.

25 SUMMARY OF THE INVENTION

The present invention relates to compositions and methods for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. The present invention relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner.

- 30 For example, in some embodiments, the 5' nuclease activity of a variety of enzymes is

used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

- The present invention provides structure-specific cleavage agents (e.g., nucleases) from a variety of sources, including mesophilic, psychrophilic, thermophilic, and hyperthermophilic organisms. The preferred structure-specific nucleases are thermostable. Thermostable structure-specific nucleases are contemplated as particularly useful in that they operate at temperatures where nucleic acid hybridization is extremely specific, allowing for allele-specific detection (including single-base mismatches). In one embodiment, the thermostable structure-specific nucleases are thermostable 5' nucleases comprising altered polymerases derived from the native polymerases of *Thermus* species, including, but not limited to *Thermus aquaticus*, *Thermus flavus*, and *Thermus thermophilus*. However, the invention is not limited to the use of thermostable 5' nucleases. Thermostable structure-specific nucleases from the FEN-1, RAD2 and XPG class of nucleases are also preferred.
- 15 The present invention provides a method for detecting a target sequence (e.g., a mutation, polymorphism, etc), comprising providing a sample suspected of containing the target sequence; oligonucleotides capable of forming an invasive cleavage structure in the presence of the target sequence; and an agent for detecting the presence of an invasive cleavage structure; and exposing the sample to the oligonucleotides and the agent. In some embodiments, the method further comprises the step of detecting a complex comprising the agent and the invasive cleavage structure (directly or indirectly). In some embodiments, the agent comprises a cleavage agent. In some preferred embodiments, the exposing of the sample to the oligonucleotides and the agent comprises exposing the sample to the oligonucleotides and the agent under conditions wherein an invasive 20 cleavage structure is formed between the target sequence and the oligonucleotides if the target sequence is present in the sample, wherein the invasive cleavage structure is cleaved by the cleavage agent to form a cleavage product. In some embodiments, the method further comprises the step of detecting the cleavage product. In some embodiments, the target sequence comprises a first region and a second region, the second region downstream of and contiguous to the first region, and wherein the oligonucleotides comprise first and second oligonucleotides, wherein at least a portion of 25 30

the first oligonucleotide is completely complementary to the first portion of the target sequence and wherein the second oligonucleotide comprises a 3' portion and a 5' portion, wherein the 5' portion is completely complementary to the second portion of said target nucleic acid.

- 5 The present invention also provides a kit for detecting such target sequences, said kit comprising oligonucleotides capable of forming an invasive cleavage structure in the presence of the target sequence. In some embodiments, the kit further comprises an agent for detecting the presence of an invasive cleavage structure (e.g., a cleavage agent). In some embodiments, the oligonucleotides comprise first and second oligonucleotides, said
- 10 first oligonucleotide comprising a 5' portion complementary to a first region of the target nucleic acid and said second oligonucleotide comprising a 3' portion and a 5' portion, said 5' portion complementary to a second region of the target nucleic acid downstream of and contiguous to the first portion. In some preferred embodiments, the target sequence comprises
- 15 The present invention also provides methods for detecting the presence of a target nucleic acid molecule by detecting non-target cleavage products comprising providing: a cleavage agent; a source of target nucleic acid, the target nucleic acid comprising a first region and a second region, the second region downstream of and contiguous to the first region; a first oligonucleotide, wherein at least a portion of the first oligonucleotide is
- 20 completely complementary to the first portion of the target nucleic acid; and a second oligonucleotide comprising a 3' portion and a 5' portion, wherein the 5' portion is completely complementary to the second portion of the target nucleic acid; mixing the cleavage agent, the target nucleic acid, the first oligonucleotide and the second oligonucleotide to create a reaction mixture under reaction conditions such that at least
- 25 the portion of the first oligonucleotide is annealed to the first region of said target nucleic acid and wherein at least the 5' portion of the second oligonucleotide is annealed to the second region of the target nucleic acid so as to create a cleavage structure, and wherein cleavage of the cleavage structure occurs to generate non-target cleavage product; and detecting the cleavage of the cleavage structure.
- 30 The detection of the cleavage of the cleavage structure can be carried out in any manner. In some embodiments, the detection of the cleavage of the cleavage structure

comprises detecting the non-target cleavage product. In yet other embodiments, the detection of the cleavage of the cleavage structure comprises detection of fluorescence, mass, or fluorescence energy transfer. Other detection methods include, but are not limited to detection of radioactivity, luminescence, phosphorescence, fluorescence

- 5 polarization, and charge. In some embodiments, detection is carried out by a method comprising providing the non-target cleavage product; a composition comprising two single-stranded nucleic acids annealed so as to define a single-stranded portion of a protein binding region; and a protein; and exposing the non-target cleavage product to the single-stranded portion of the protein binding region under conditions such that the
- 10 protein binds to the protein binding region. In some embodiments, the protein comprises a nucleic acid producing protein, wherein the nucleic acid producing protein binds to the protein-binding region and produces nucleic acid. In some embodiments, the protein-binding region is a template-dependent RNA polymerase binding region (e.g., a T7 RNA polymerase binding region). In other embodiments, the detection is carried out by a
- 15 method comprising providing the non-target cleavage product; a single continuous strand of nucleic acid comprising a sequence defining a single strand of an RNA polymerase binding region; a template-dependent DNA polymerase; and a template-dependent RNA polymerase; exposing the non-target cleavage product to the RNA polymerase binding region under conditions such that the non-target cleavage product binds to a portion of
- 20 the single strand of the RNA polymerase binding region to produce a bound non-target cleavage product; exposing the bound non-target cleavage product to the template-dependent DNA polymerase under conditions such that a double-stranded RNA polymerase binding region is produced; and exposing the double-stranded RNA polymerase binding region to the template-dependent RNA polymerase under conditions
- 25 such that RNA transcripts are produced. In some embodiments, the method further comprises the step of detecting the RNA transcripts. In some embodiments, the template-dependent RNA polymerase is T7 RNA polymerase.

- The present invention is not limited by the nature of the 3' portion of the second oligonucleotide. In some preferred embodiments, the 3' portion of the second
- 30 oligonucleotide comprises a 3' terminal nucleotide not complementary to the target

nucleic acid. In some embodiments, the 3' portion of the second oligonucleotide consists of a single nucleotide not complementary to the target nucleic acid.

Any of the components of the method may be attached to a solid support. For example, in some embodiments, the first oligonucleotide is attached to a solid support. In other embodiments, the second oligonucleotide is attached to a solid support.

The cleavage agent can be any agent that is capable of cleaving invasive cleavage structures. In some preferred embodiments, the cleavage agent comprises a structure-specific nuclease. In particularly preferred embodiments, the structure-specific nuclease comprises a thermostable structure-specific nuclease (e.g., a thermostable 5' nuclease).

- 10 Thermostable structure-specific nucleases include, but are not limited to, those having an amino acid sequence homologous to a portion of the amino acid sequence of a thermostable DNA polymerase derived from a thermophilic organism (e.g., *Thermus aquaticus*, *Thermus flavus*, and *Thermus thermophilus*). In other embodiments, the thermostable structure-specific nuclease comprises a nuclease from the FEN-1, RAD2 or
- 15 XPG classes of nucleases, or chimerical structures containing one or more portions of any of the above cleavage agents.

The method is not limited by the nature of the target nucleic acid. In some embodiments, the target nucleic acid is single stranded or double stranded DNA or RNA. In some embodiments, double stranded nucleic acid is rendered single stranded (e.g., by heat) prior to formation of the cleavage structure. In some embodiment, the source of target nucleic acid comprises a sample containing genomic DNA. Sample include, but are not limited to, blood, saliva, cerebral spinal fluid, pleural fluid, milk, lymph, sputum and semen.

- 20 In some embodiments, the reaction conditions for the method comprise providing a source of divalent cations. In some preferred embodiments, the divalent cation is selected from the group comprising Mn²⁺ and Mg²⁺ ions. In some embodiments, the reaction conditions for the method comprise providing the first and the second oligonucleotides in concentration excess compared to the target nucleic acid.

- 25 In some embodiments, the method further comprises providing a third oligonucleotide complementary to a third portion of said target nucleic acid upstream of

the first portion of the target nucleic acid, wherein the third oligonucleotide is mixed with the reaction mixture.

The present invention also provides a method for detecting the presence of a target nucleic acid molecule by detecting non-target cleavage products comprising

- 5 providing: a cleavage agent; a source of target nucleic acid, the target nucleic acid comprising a first region and a second region, the second region downstream of and contiguous to the first region; a plurality of first oligonucleotides, wherein at least a portion of the first oligonucleotides is completely complementary to the first portion of the target nucleic acid; a second oligonucleotide comprising a 3' portion and a 5' portion,
- 10 wherein said 5' portion is completely complementary to the second portion of the target nucleic acid; mixing the cleavage agent, the target nucleic acid, the plurality of first oligonucleotides and second oligonucleotide to create a reaction mixture under reaction conditions such that at least the portion of a first oligonucleotide is annealed to the first region of the target nucleic acid and wherein at least the 5' portion of the second
- 15 oligonucleotide is annealed to the second region of the target nucleic acid so as to create a cleavage structure, and wherein cleavage of the cleavage structure occurs to generate non-target cleavage product, wherein the conditions permit multiple cleavage structures to form and be cleaved from the target nucleic acid; and detecting the cleavage of said cleavage structures. In some embodiments, the conditions comprise isothermal
- 20 conditions that permit the plurality of first oligonucleotides to dissociate from the target nucleic acid. While the present invention is limited by the number of cleavage structure formed on a particular target nucleic acid, in some preferred embodiments, two or more (3, 4, 5, . . . , 10, . . . , 10000, . . .) of the plurality of first oligonucleotides form cleavage structures with a particular target nucleic acid, wherein the cleavage structures are
- 25 cleaved to produce the non-target cleavage products.

The present invention also provides methods wherein a cleavage product from the above methods is used in a further invasive cleavage reaction. For example, the present invention provides a method comprising providing a cleavage agent; a first target nucleic acid, the first target nucleic acid comprising a first region and a second region, the second region downstream of and contiguous to the first region; a first oligonucleotide, wherein at least a portion of the first oligonucleotide is completely complementary to the first

portion of the first target nucleic acid; a second oligonucleotide comprising a 3' portion and a 5' portion, wherein the 5' portion is completely complementary to the second portion of the first target nucleic acid; a second target nucleic acid, said second target nucleic acid comprising a first region and a second region, the second region downstream of and contiguous to the first region; and a third oligonucleotide, wherein at least a portion of the third oligonucleotide is completely complementary to the first portion of the second target nucleic acid; generating a first cleavage structure wherein at least said portion of the first oligonucleotide is annealed to the first region of the first target nucleic acid and wherein at least the 5' portion of the second oligonucleotide is annealed to the second region of the first target nucleic acid and wherein cleavage of the first cleavage structure occurs via the cleavage agent thereby cleaving the first oligonucleotide to generate a fourth oligonucleotide, said fourth oligonucleotide comprising a 3' portion and a 5' portion, wherein the 5' portion is completely complementary to the second portion of the second target nucleic acid; generating a second cleavage structure under conditions 5
10
15
20
25
30 wherein at least said portion of the third oligonucleotide is annealed to the first region of the second target nucleic acid and wherein at least the 5' portion of the fourth oligonucleotide is annealed to the second region of the second target nucleic acid and wherein cleavage of the second cleavage structure occurs to generate a cleavage fragment; and detecting the cleavage of the second cleavage structure. In some preferred embodiments, the 3' portion of the fourth oligonucleotide comprises a 3' terminal nucleotide not complementary to the second target nucleic acid. In some embodiments, the 3' portion of the third oligonucleotide is covalently linked to the second target nucleic acid. In some embodiments, the second target nucleic acid further comprises a 5' region, wherein the 5' region of the second target nucleic acid is the third oligonucleotide.

The present invention further provides kits comprising: a cleavage agent; a first oligonucleotide comprising a 5' portion complementary to a first region of a target nucleic acid; and a second oligonucleotide comprising a 3' portion and a 5' portion, said 5' portion complementary to a second region of the target nucleic acid downstream of and contiguous to the first portion. In some embodiments, the 3' portion of the second oligonucleotide comprises a 3' terminal nucleotide not complementary to the target nucleic acid. In preferred embodiments, the 3' portion of the second oligonucleotide

consists of a single nucleotide not complementary to the target nucleic acid. In some embodiments, the kit further comprises a solid support. For example, in some embodiments, the first and/or second oligonucleotide is attached to said solid support. In some embodiments, the kit further comprises a buffer solution. In some preferred

- 5 embodiments, the buffer solution comprises a source of divalent cations (e.g., Mn²⁺ and/or Mg²⁺ ions). In some specific embodiments, the kit further comprises a third oligonucleotide complementary to a third portion of the target nucleic acid upstream of the first portion of the first target nucleic acid. In yet other embodiments, the kit further comprises a target nucleic acid. In some embodiments, the kit further comprises a second
10 target nucleic acid. In yet other embodiments, the kit further comprises a third oligonucleotide comprising a 5' portion complementary to a first region of the second target nucleic acid. In some specific embodiments, the 3' portion of the third oligonucleotide is covalently linked to the second target nucleic acid. In other specific embodiments, the second target nucleic acid further comprises a 5' portion, wherein the 5'
15 portion of the second target nucleic acid is the third oligonucleotide. In still other embodiments, the kit further comprises an ARRESTOR molecule (e.g., ARRESTOR oligonucleotide).

- The present invention further provides a composition comprising a cleavage structure, the cleavage structure comprising: a) a target nucleic acid, the target nucleic acid having a first region, a second region, a third region and a fourth region, wherein the first region is located adjacent to and downstream from the second region, the second region is located adjacent to and downstream from the third region and the third region is located adjacent to and downstream from the fourth region; b) a first oligonucleotide complementary to the fourth region of the target nucleic acid; c) a second oligonucleotide having a 5' portion and a 3' portion wherein the 5' portion of the second oligonucleotide contains a sequence complementary to the second region of the target nucleic acid and wherein the 3' portion of the second oligonucleotide contains a sequence complementary to the third region of the target nucleic acid; and d) a third oligonucleotide having a 5'
20 portion and a 3' portion wherein the 5' portion of the third oligonucleotide contains a sequence complementary to the first region of the target nucleic acid and wherein the 3'
25 portion of the third oligonucleotide contains a sequence complementary to the second region of the target nucleic acid; and e) a fourth oligonucleotide having a 5' portion and a 3' portion wherein the 5' portion of the fourth oligonucleotide contains a sequence complementary to the third region of the target nucleic acid and wherein the 3' portion of the fourth oligonucleotide contains a sequence complementary to the first region of the target nucleic acid.
- 30

portion of the third oligonucleotide contains a sequence complementary to the second region of the target nucleic acid.

The present invention is not limited by the length of the four regions of the target nucleic acid. In one embodiment, the first region of the target nucleic acid has a length of 5 11 to 50 nucleotides. In another embodiment, the second region of the target nucleic acid has a length of one to three nucleotides. In another embodiment, the third region of the target nucleic acid has a length of six to nine nucleotides. In yet another embodiment, the fourth region of the target nucleic acid has a length of 6 to 50 nucleotides.

The invention is not limited by the nature or composition of the of the first, 10 second, third and fourth oligonucleotides; these oligonucleotides may comprise DNA, RNA, PNA and combinations thereof as well as comprise modified nucleotides, universal bases, adducts, etc. Further, one or more of the first, second, third and the fourth oligonucleotides may contain a dideoxynucleotide at the 3' terminus.

In one preferred embodiment, the target nucleic acid is not completely 15 complementary to at least one of the first, the second, the third and the fourth oligonucleotides. In a particularly preferred embodiment, the target nucleic acid is not completely complementary to the second oligonucleotide.

As noted above, the present invention contemplates the use of structure-specific nucleases in detection methods. In one embodiment, the present invention provides a 20 method of detecting the presence of a target nucleic acid molecule by detecting non-target cleavage products comprising: a) providing: i) a cleavage means, ii) a source of target nucleic acid, the target nucleic acid having a first region, a second region, a third region and a fourth region, wherein the first region is located adjacent to and downstream from the second region, the second region is located adjacent to and downstream from the 25 third region and the third region is located adjacent to and downstream from the fourth region; iii) a first oligonucleotide complementary to the fourth region of the target nucleic acid; iv) a second oligonucleotide having a 5' portion and a 3' portion wherein the 5' portion of the second oligonucleotide contains a sequence complementary to the second region of the target nucleic acid and wherein the 3' portion of the second oligonucleotide 30 contains a sequence complementary to the third region of the target nucleic acid; iv) a third oligonucleotide having a 5' and a 3' portion wherein the 5' portion of the third

oligonucleotide contains a sequence complementary to the first region of the target nucleic acid and wherein the 3' portion of the third oligonucleotide contains a sequence complementary to the second region of the target nucleic acid; b) mixing the cleavage means, the target nucleic acid, the first oligonucleotide, the second oligonucleotide and 5 the third oligonucleotide to create a reaction mixture under reaction conditions such that the first oligonucleotide is annealed to the fourth region of the target nucleic acid and wherein at least the 3' portion of the second oligonucleotide is annealed to the target nucleic acid and wherein at least the 5' portion of the third oligonucleotide is annealed to the target nucleic acid so as to create a cleavage structure and wherein cleavage of the 10 cleavage structure occurs to generate non-target cleavage products, each non-target cleavage product having a 3'-hydroxyl group; and c) detecting the non-target cleavage products.

The invention is not limited by the nature of the target nucleic acid. In one embodiment, the target nucleic acid comprises single-stranded DNA. In another 15 embodiment, the target nucleic acid comprises double-stranded DNA and prior to step c), the reaction mixture is treated such that the double-stranded DNA is rendered substantially single-stranded. In another embodiment, the target nucleic acid comprises RNA and the first and second oligonucleotides comprise DNA.

The invention is not limited by the nature of the cleavage means. In one 20 embodiment, the cleavage means is a structure-specific nuclease; particularly preferred structure-specific nucleases are thermostable structure-specific nucleases.

In another preferred embodiment the thermostable structure specific nuclease is a chimerical nuclease.

In an alternative preferred embodiment, the detection of the non-target cleavage 25 products comprises electrophoretic separation of the products of the reaction followed by visualization of the separated non-target cleavage products.

In another preferred embodiment, one or more of the first, second, and third oligonucleotides contain a dideoxynucleotide at the 3' terminus. When 30 dideoxynucleotide-containing oligonucleotides are employed, the detection of the non-target cleavage products preferably comprises: a) incubating the non-target cleavage products with a template-independent polymerase and at least one labeled nucleoside

triphosphate under conditions such that at least one labeled nucleotide is added to the 3'-hydroxyl group of the non-target cleavage products to generate labeled non-target cleavage products; and b) detecting the presence of the labeled non-target cleavage products. The invention is not limited by the nature of the template-independent

- 5 polymerase employed; in one embodiment, the template-independent polymerase is selected from the group consisting of terminal deoxynucleotidyl transferase (TdT) and poly A polymerase. When TdT or polyA polymerase are employed in the detection step, the second oligonucleotide may contain a 5' end label, the 5' end label being a different label than the label present upon the labeled nucleoside triphosphate. The invention is
10 not limited by the nature of the 5' end label; a wide variety of suitable 5' end labels are known to the art and include biotin, fluorescein, tetrachlorofluorescein, hexachlorofluorescein, Cy3 amidite, Cy5 amidite and digoxigenin.

- In another embodiment, detecting the non-target cleavage products comprises: a) incubating the non-target cleavage products with a template-independent polymerase and
15 at least one nucleoside triphosphate under conditions such that at least one nucleotide is added to the 3'-hydroxyl group of the non-target cleavage products to generate tailed non-target cleavage products; and b) detecting the presence of the tailed non-target cleavage products. The invention is not limited by the nature of the template-independent polymerase employed; in one embodiment, the template-independent polymerase is selected from the group consisting of terminal deoxynucleotidyl transferase (TdT) and
20 poly A polymerase. When TdT or polyA polymerases are employed in the detection step, the second oligonucleotide may contain a 5' end label. The invention is not limited by the nature of the 5' end label; a wide variety of suitable 5' end labels are known to the art and include biotin, fluorescein, tetrachlorofluorescein, hexachlorofluorescein, Cy3 amidite,
25 Cy5 amidite and digoxigenin.

In a preferred embodiment, the reaction conditions comprise providing a source of divalent cations; particularly preferred divalent cations are Mn²⁺ and Mg²⁺ ions.

- The present invention further provides a method of detecting the presence of a target nucleic acid molecule by detecting non-target cleavage products comprising: a)
30 providing: i) a cleavage means, ii) a source of target nucleic acid, the target nucleic acid having a first region, a second region and a third region, wherein the first region is

- located adjacent to and downstream from the second region and wherein the second region is located adjacent to and downstream from the third region; iii) a first oligonucleotide having a 5' and a 3' portion wherein the 5' portion of the first oligonucleotide contains a sequence complementary to the second region of the target nucleic acid and wherein the 3' portion of the first oligonucleotide contains a sequence complementary to the third region of the target nucleic acid; iv) a second oligonucleotide having a length between eleven to fifteen nucleotides and further having a 5' and a 3' portion wherein the 5' portion of the second oligonucleotide contains a sequence complementary to the first region of the target nucleic acid and wherein the 3' portion of the second oligonucleotide contains a sequence complementary to the second region of the target nucleic acid; b) mixing the cleavage means, the target nucleic acid, the first oligonucleotide and the second oligonucleotide to create a reaction mixture under reaction conditions such that at least the 3' portion of the first oligonucleotide is annealed to the target nucleic acid and wherein at least the 5' portion of the second oligonucleotide is annealed to the target nucleic acid so as to create a cleavage structure and wherein cleavage of the cleavage structure occurs to generate non-target cleavage products, each non-target cleavage product having a 3'-hydroxyl group; and c) detecting the non-target cleavage products. In a preferred embodiment the cleavage means is a structure-specific nuclease, preferably a thermostable structure-specific nuclease.
- The invention is not limited by the length of the various regions of the target nucleic acid. In a preferred embodiment, the second region of the target nucleic acid has a length between one to five nucleotides. In another preferred embodiment, one or more of the first and the second oligonucleotides contain a dideoxynucleotide at the 3' terminus. When dideoxynucleotide-containing oligonucleotides are employed, the detection of the non-target cleavage products preferably comprises: a) incubating the non-target cleavage products with a template-independent polymerase and at least one labeled nucleoside triphosphate under conditions such that at least one labeled nucleotide is added to the 3'-hydroxyl group of the non-target cleavage products to generate labeled non-target cleavage products; and b) detecting the presence of the labeled non-target cleavage products. The invention is not limited by the nature of the template-independent polymerase employed; in one embodiment, the template-independent polymerase is

- selected from the group consisting of terminal deoxynucleotidyl transferase (TdT) and poly A polymerase. When TdT or polyA polymerase is employed in the detection step, the second oligonucleotide may contain a 5' end label, the 5' end label being a different label than the label present upon the labeled nucleoside triphosphate. The invention is
5 not limited by the nature of the 5' end label; a wide variety of suitable 5' end labels are known to the art and include biotin, fluorescein, tetrachlorofluorescein, hexachlorofluorescein, Cy3 amidite, Cy5 amidite and digoxigenin.

- In another embodiment, detecting the non-target cleavage products comprises: a) incubating the non-target cleavage products with a template-independent polymerase and
10 at least one nucleoside triphosphate under conditions such that at least one nucleotide is added to the 3'-hydroxyl group of the non-target cleavage products to generate tailed non-target cleavage products; and b) detecting the presence of the tailed non-target cleavage products. The invention is not limited by the nature of the template-independent polymerase employed; in one embodiment, the template-independent polymerase is
15 selected from the group consisting of terminal deoxynucleotidyl transferase (TdT) and poly A polymerase. When TdT or polyA polymerases are employed in the detection step, the second oligonucleotide may contain a 5' end label. The invention is not limited by the nature of the 5' end label; a wide variety of suitable 5' end labels are known to the art and include biotin, fluorescein, tetrachlorofluorescein, hexachlorofluorescein, Cy3 amidite,
20 Cy5 amidite and digoxigenin.

- The novel detection methods of the invention may be employed for the detection of target DNAs and RNAs including, but not limited to, target DNAs and RNAs comprising wild type and mutant alleles of genes, including genes from humans or other animals that are or may be associated with disease or cancer. In addition, the methods of
25 the invention may be used for the detection of and/or identification of strains of microorganisms, including bacteria, fungi, protozoa, ciliates and viruses (and in particular for the detection and identification of RNA viruses, such as HCV).

- The present invention further provides novel enzymes designed for direct detection, characterization and quantitation of nucleic acids, particularly RNA. The
30 present invention provides enzymes that recognize specific nucleic acid cleavage structures formed on a target RNA sequence and that cleave the nucleic acid cleavage

structure in a site-specific manner to produce non-target cleavage products. The present invention provides enzymes having an improved ability to specifically cleave a DNA member of a complex comprising DNA and RNA nucleic acid strands.

For example, the present invention provides DNA polymerases that are altered in structure relative to the native DNA polymerases, such that they exhibit altered (e.g., improved) performance in detection assays based on the cleavage of a structure comprising nucleic acid (e.g., RNA). In particular, the altered polymerases of the present invention exhibit improved performance in detection assays based on the cleavage of a DNA member of a cleavage structure (e.g., an invasive cleavage structure) that comprises 10 an RNA target strand.

The improved performance in a detection assay may arise from any one of, or a combination of several improved features. For example, in one embodiment, the enzyme of the present invention may have an improved rate of cleavage (k_{cat}) on a specific targeted structure, such that a larger amount of a cleavage product may be produced in a given time span. In another embodiment, the enzyme of the present invention may have 15 a reduced activity or rate in the cleavage of inappropriate or non-specific structures. For example, in certain embodiments of the present invention, one aspect of improvement is that the differential between the detectable amount of cleavage of a specific structure and the detectable amount of cleavage of any alternative structures is increased. As such, it is within the scope of the present invention to provide an enzyme having a reduced rate of 20 cleavage of a specific target structure compared to the rate of the native enzyme, and having a further reduced rate of cleavage of any alternative structures, such that the differential between the detectable amount of cleavage of the specific structure and the detectable amount of cleavage of any alternative structures is increased. However, the 25 present invention is not limited to enzymes that have an improved differential.

In a preferred embodiment, the enzyme of the present invention is a DNA polymerase having an altered nuclease activity as described above, and also having altered synthetic activity, compared to that of any native DNA polymerase from which the enzyme has been derived. It is especially preferred that the DNA polymerase is altered such that it exhibits reduced synthetic activity as well as improved nuclease 30 activity on RNA targets, compared to that of the native DNA polymerase. Enzymes and

genes encoding enzymes having reduced synthetic activity have been described (*See e.g.*, Kaiser *et al.*, J. Biol. Chem., 274:21387 [1999], Lyamichev *et al.*, Prot. Natl. Acad. Sci., 96:6143 [1999], US. Patents 5,541,311, 5,614,402, 5,795,763 and 6,090,606, incorporated herein by reference in their entireties). The present invention contemplates

- 5 combined modifications, such that the resulting 5' nucleases are without interfering synthetic activity, and have improved performance in RNA detection assays.

The present invention contemplates a DNA sequence encoding a DNA polymerase altered in sequence relative to the native sequence, such that it exhibits altered nuclease activity from that of the native DNA polymerase. For example, in one 10 embodiment, the DNA sequence encodes an enzyme having an improved rate of cleavage (k_{cat}) on a specific targeted structure, such that a larger amount of a cleavage product may be produced in a given time span. In another embodiment, the DNA encodes an enzyme having a reduced activity or rate in the cleavage of inappropriate or non-specific structures. In certain embodiments, one aspect of improvement is that the differential 15 between the detectable amount of cleavage of a specific structure and the detectable amount of cleavage of any alternative structures is increased. It is within the scope of the present invention to provide a DNA encoding an enzyme having a reduced rate of cleavage of a specific target structure compared to the rate of the native enzyme, and having a further reduced rate of cleavage of any alternative structures, such that the 20 differential between the detectable amount of cleavage of the specific structure and the detectable amount of cleavage of any alternative structures is increased. However, the present invention is not limited to polymerases that have an improved differential.

In a preferred embodiment, the DNA sequence encodes a DNA polymerase having the altered nuclease activity described above, and also having altered synthetic 25 activity, compared to that of any native DNA polymerase from which the improved enzyme is derived. It is especially preferred that the encoded DNA polymerase is altered such that it exhibits reduced synthetic activity as well as improved nuclease activity on RNA targets, compared to that of the native DNA polymerase.

It is not intended that the invention be limited by the nature of the alteration 30 required to introduce altered nuclease activity. Nor is it intended that the invention be limited by the extent of either the alteration, or in the improvement observed. If the

polymerase is also altered so as to be synthesis modified, it is not intended that the invention be limited by the polymerase activity of the modified or unmodified protein, or by the nature of the alteration to render the polymerase synthesis modified.

- The present invention contemplates structure-specific nucleases from a variety of sources, including, but not limited to, mesophilic, psychrophilic, thermophilic, and hyperthermophilic organisms. The preferred structure-specific nucleases are thermostable. Thermostable structure-specific nucleases are contemplated as particularly useful in that they allow the INVADER assay (*See e.g.*, U.S. Pat. Nos. 5,846,717, 5,985,557, 5,994,069, 6,001,567, and 6,090,543 and PCT Publications WO 97/27214 and 10 WO 98/42873, incorporated herein by reference in their entirities) to be operated near the melting temperature (T_m) of the downstream probe oligonucleotide, so that cleaved and uncleaved probes may cycle on and off the target during the course of the reaction. In one embodiment, the thermostable structure-specific enzymes are thermostable 5' nucleases that are selected from the group comprising altered polymerases derived from 15 the native polymerases of *Thermus* species, including, but not limited to, *Thermus aquaticus*, *Thermus flavus*, *Thermus thermophilus*, *Thermus filiformis*, and *Thermus scotoductus*. However, the invention is not limited to the use of thermostable 5' nucleases. For example, certain embodiments of the present invention utilize short oligonucleotide probes that may cycle on and off of the target at low temperatures, 20 allowing the use of non-thermostable enzymes.

In some preferred embodiments, the present invention provides a composition comprising an enzyme, wherein the enzyme comprises a heterologous functional domain, wherein the heterologous functional domain provides altered (*e.g.*, improved) functionality in a nucleic acid cleavage assay. The present invention is not limited by the 25 nature of the nucleic acid cleavage assay. For example, nucleic acid cleavage assays include any assay in which a nucleic acid is cleaved, directly or indirectly, in the presence of the enzyme. In certain preferred embodiments, the nucleic acid cleavage assay is an invasive cleavage assay. In particularly preferred embodiments, the cleavage assay utilizes a cleavage structure having at least one RNA component. In another particularly 30 preferred embodiment, the cleavage assay utilizes a cleavage structure having at least one RNA component, wherein a DNA member of the cleavage structure is cleaved.

In some preferred embodiments, the enzyme comprises a 5' nuclease or a polymerase. In certain preferred embodiments, the 5' nuclease comprises a thermostable 5' nuclease. In other preferred embodiments, the polymerase is altered in sequence relative to a naturally occurring sequence of a polymerase such that it exhibits reduced

- 5 DNA synthetic activity from that of the naturally occurring polymerase. In certain preferred embodiments, the polymerase comprises a thermostable polymerase (e.g., a polymerase from a *Thermus* species including, but not limited to, *Thermus aquaticus*, *Thermus flavus*, *Thermus thermophilus*, *Thermus filiformis*, and *Thermus scotoductus*).

The present invention is not limited by the nature of the altered functionality provided by the heterologous functional domain. Illustrative examples of alterations include, but are not limited to, enzymes where the heterologous functional domain comprises an amino acid sequence (e.g., one or more amino acids) that provides an improved nuclease activity, an improved substrate binding activity and/or improved background specificity in a nucleic acid cleavage assay.

15 The present invention is not limited by the nature of the heterologous functional domain. For example, in some embodiments, the heterologous functional domain comprises two or more amino acids from a polymerase domain of a polymerase (e.g., introduced into the enzyme by insertion of a chimeric functional domain or created by mutation). In certain preferred embodiment, at least one of the two or more amino acids 20 is from a palm or thumb region of the polymerase domain. The present invention is not limited by the identity of the polymerase from which the two or more amino acids are selected. In certain preferred embodiments, the polymerase comprises *Thermus thermophilus* polymerase. In particularly preferred embodiments, the two or more amino acids are from amino acids 300-650 of SEQ ID NO:1.

25 The novel enzymes of the invention may be employed for the detection of target DNAs and RNAs including, but not limited to, target DNAs and RNAs comprising wild type and mutant alleles of genes, including, but not limited to, genes from humans, other animal, or plants that are or may be associated with disease or other conditions. In addition, the enzymes of the invention may be used for the detection of and/or 30 identification of strains of microorganisms, including bacteria, fungi, protozoa, ciliates and viruses (and in particular for the detection and identification of viruses having RNA

genomes, such as the Hepatitis C and Human Immunodeficiency viruses). For example, the present invention provides methods for cleaving a nucleic acid comprising providing: an enzyme of the present invention and a substrate nucleic acid; and exposing the substrate nucleic acid to the enzyme (e.g., to produce a cleavage product that may be

5 detected).

In one embodiment, the present invention provides a thermostable 5' nuclease having an amino acid sequence selected from the group comprising SEQ ID NOS:2, 3, 4, 5, 6, 7, 8, 9, 10, 11 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 10 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 341, 346, 348, 351, 353, 359, 365, 367, 369, 374, 376, 380, 384, 388, 392, 396, 400, 402, 406, 408, 410, 412, 416, 418, 420, 424, 427, 429, 432, 436, 440, 444, 446, 448, 450, 456, 460, 464, 468, 472, 476, 482, 485, 488, 491, 494, 496, 498, 500, 502, 506, 510, 514, 518, 522, 526, 530, 534, 538, 542, 544, 15 550, 553, 560, 564, 566, 568, 572, 574, 576, 578, 580, 582, 584, 586, 588, and 590. In another embodiment, the 5' nuclease is encoded by a DNA sequence selected from the group comprising of SEQ ID NOS:69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 340, 345, 347, 350, 352, 20 358, 364, 366, 368, 373, 375, 379, 383, 387, 391, 395, 399, 401, 405, 407, 409, 411, 415, 417, 419, 423, 426, 428, 431, 435, 439, 443, 445, 447, 449, 452, 454, 455, 459, 463, 467, 471, 475, 481, 484, 495, 497, 499, 501, 505, 509, 513, 517, 521, 525, 529, 533, 537, 541, 543, 549, 552, 559, 563, 565, 567, 571, 573, 575, 577, 579, 581, 583, 585, 587, and 589.

The present invention also provides a recombinant DNA vector comprising DNA having a nucleotide sequence encoding a 5' nuclease, the nucleotide sequence selected from the group comprising SEQ ID NOS: 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 340, 345, 347, 350, 352, 358, 364, 366, 368, 373, 375, 379, 383, 387, 391, 395, 399, 401, 405, 407, 409, 411, 415, 417, 419, 423, 426, 428, 431, 435, 439, 443, 445, 447, 449, 452, 454, 455, 459,

463, 467, 471, 475, 481, 484, 495, 497, 499, 501, 505, 509, 513, 517, 521, 525, 529, 533,
537, 541, 543, 549, 552, 559, 563, 565, 567, 571, 573, 575, 577, 579, 581, 583, 585, 587,
and 589. In a preferred embodiment, the invention provides a host cell transformed with
a recombinant DNA vector comprising DNA having a nucleotide sequence encoding a
5 structure-specific nuclease, the nucleotide selected from the group comprising sequence
SEQ ID NOS: 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108,
109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126,
127, 128, 129, 130, 131, 132, 133, 134, 135, 340, 345, 347, 350, 352, 358, 364, 366, 368,
10 373, 375, 379, 383, 387, 391, 395, 399, 401, 405, 407, 409, 411, 415, 417, 419, 423, 426,
428, 431, 435, 439, 443, 445, 447, 449, 452, 454, 455, 459, 463, 467, 471, 475, 481, 484,
495, 497, 499, 501, 505, 509, 513, 517, 521, 525, 529, 533, 537, 541, 543, 549, 552, 559,
563, 565, 567, 571, 573, 575, 577, 579, 581, 583, 585, 587, and 589. The invention is not
limited by the nature of the host cell employed. The art is well aware of expression
15 vectors suitable for the expression of nucleotide sequences encoding structure-specific
nucleases that can be expressed in a variety of prokaryotic and eukaryotic host cells. In a
preferred embodiment, the host cell is an *Escherichia coli* cell.

The present invention provides a method of altering 5' nuclease enzymes relative
to native 5' nuclease enzymes, such that they exhibit improved performance in detection
20 assays based on the cleavage of a structure comprising RNA. In particular, the altered 5'
nucleases produced by the method of the present invention exhibit improved performance
in detection assays based on the cleavage of a DNA member of a cleavage structure (e.g.,
an invasive cleavage structure) that comprises an RNA target strand. The improved 5'
nucleases resulting from the methods of the present invention may be improved in any of
25 the ways discussed herein. Examples of processes for assessing improvement in any
candidate enzyme are provided.

For example, the present invention provides methods for producing an altered
enzyme with improved functionality in a nucleic acid cleavage assay comprising:
providing an enzyme and a nucleic acid test substrate; introducing a heterologous
30 functional domain into the enzyme to produce an altered enzyme; contacting the altered
enzyme with the nucleic acid test substrate to produce cleavage products; and detecting

the cleavage products. In some embodiments, the introduction of the heterologous functional domain comprises mutating one or more amino acids of the enzyme. In other embodiments, the introduction of the heterologous functional domain into the enzyme comprises adding a functional domain from a protein (*e.g.*, another enzyme) into the

5 enzyme (*e.g.*, substituting functional domains by removing a portion of the enzyme sequence prior to adding the functional domain of the protein). In preferred embodiments, the nucleic acid test substrate comprises a cleavage structure. In particularly preferred embodiment, the cleavage structure comprises an RNA target nucleic acid. In yet other preferred embodiments, the cleavage structure comprises an

10 invasive cleavage structure.

The present invention also provides nucleic acid treatment kits. One preferred embodiment is a kit comprising a composition comprising at least one improved 5' nuclease. Another preferred embodiment provides a kit comprising: a) a composition comprising at least one improved 5' nuclease; and b) an INVADER oligonucleotide and a

15 signal probe oligonucleotide. In some embodiments of the kits of the present invention, the improved 5' nuclease is derived from a DNA polymerase from a eubacterial species. In further embodiments, the eubacterial species is a thermophile. In still further embodiments, the thermophile is of the genus *Thermus*. In still further embodiments, the thermophile is selected from the group consisting of *Thermus aquaticus*, *Thermus flavus*,

20 *Thermus thermophilus*, *Thermus filiformis*, and *Thermus scotoductus*. In preferred embodiments, the improved 5' nuclease is encoded by DNA selected from the group comprising SEQ ID NOS: 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106,

25 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 340, 345, 347, 350, 352, 358, 364, 366, 368, 373, 375, 379, 383, 387, 391, 395, 399, 401, 405, 407, 409, 411, 415, 417, 419, 423, 426, 428, 431, 435, 439, 443, 445, 447, 449, 452, 454, 455, 459, 463, 467, 471, 475,

30 481, 484, 495, 497, 499, 501, 505, 509, 513, 517, 521, 525, 529, 533, 537, 541, 543, 549, 552, 559, 563, 565, 567, 571, 573, 575, 577, 579, 581, 583, 585, 587, and 589. In yet other preferred embodiments, the kits further comprise reagents for detecting a nucleic acid cleavage product. In further preferred embodiments, the reagents for detecting a

cleavage product comprise oligonucleotides for use in a subsequent invasive cleavage reaction (See e.g., U.S. Patent No. 5,994,069). In particularly preferred embodiments, the reagents for the subsequent invasive cleavage reaction comprise a probe labeled with moieties that produce a fluorescence resonance energy transfer (FRET) effect.

- 5 The present invention also provides methods for treating nucleic acid, comprising:
a) providing: a first structure-specific nuclease consisting of an endonuclease in a
solution containing manganese; and a nucleic acid substrate; b) treating the nucleic acid
substrate with increased temperature such that the substrate is substantially single-
stranded; c) reducing the temperature under conditions such that the single-stranded
10 substrate forms one or more cleavage structures; d) reacting the cleavage means with the
cleavage structures so that one or more cleavage products are produced; and e) detecting
the one or more cleavage products. In some embodiments of the methods, the
endonuclease includes, but is not limited to, CLEAVASE BN enzyme, *Thermus*
aquaticus DNA polymerase, *Thermus thermophilus* DNA polymerase, *Escherichia coli*
15 Exo III, and the *Saccharomyces cerevisiae* Rad1/Rad10 complex. In yet other preferred
embodiments, the nuclease is a 5' nuclease derived from a thermostable DNA polymerase
altered in amino acid sequence such that it exhibits reduced DNA synthetic activity from
that of the wild-type DNA polymerase but retains substantially the same 5' nuclease
activity of the wild-type DNA polymerase. In yet other embodiments, the nucleic acid is
20 selected from the group consisting of RNA and DNA. In further embodiments, the
nucleic acid of step (a) is double stranded.

- The present invention also provides nucleic acid treatment kits, comprising: a) a
composition comprising at least one purified FEN-1 endonuclease; and b) a solution
containing manganese. In some embodiments of the kits, the purified FEN-1
25 endonuclease is selected from the group consisting *Pyrococcus woesei* FEN-1
endonuclease, *Pyrococcus furiosus* FEN-1 endonuclease, *Methanococcus jannaschii*
FEN-1 endonuclease, *Methanobacterium thermoautotrophicum* FEN-1 endonuclease,
Archaeoglobus fulgidus FEN-1, *Sulfolobus solfataricus*, *Pyrobaculum aerophilum*,
Thermococcus litoralis, *Archaeaglobus veneficus*, *Archaeaglobus profundus*, *Acidianus*
30 *brierlyi*, *Acidianus ambivalens*, *Desulfurococcus amylolyticus*, *Desulfurococcus mobilis*,
Pyrodictium brockii, *Thermococcus gorgonarius*, *Thermococcus zilligii*, *Methanopyrus*

kandleri, *Methanococcus igneus*, *Pyrococcus horikoshii*, *Aeropyrum pernix*, and chimerical FEN-1 endonucleases. In other embodiments, the kits further comprise at least one second structure-specific nuclease. In some preferred embodiments, the second nuclease is a 5' nuclease derived from a thermostable DNA polymerase altered in amino acid sequence such that it exhibits reduced DNA synthetic activity from that of the wild-type DNA polymerase but retains substantially the same 5' nuclease activity of the wild-type DNA polymerase. In yet other embodiments of the kits, the portion of the amino acid sequence of the second nuclease is homologous to a portion of the amino acid sequence of a thermostable DNA polymerase derived from a eubacterial thermophile of the genus *Thermus*. In further embodiments, the thermophile is selected from the group consisting of *Thermus aquaticus*, *Thermus flavus* and *Thermus thermophilus*. In yet other preferred embodiments, the kits further comprise reagents for detecting the cleavage products.

The present invention further provides any of the compositions, mixtures, methods, and kits described herein, used in conjunction with endonucleases comprising *Sulfolobus solfataricus*, *Pyrobaculum aerophilum*, *Thermococcus litoralis*, *Archaeoglobus veneficus*, *Archaeoglobus profundus*, *Acidianus brieryi*, *Acidianus ambivalens*, *Desulfurococcus amylolyticus*, *Desulfurococcus mobilis*, *Pyrodictium brockii*, *Thermococcus gorgonarius*, *Thermococcus zilligii*, *Methanopyrus kandleri*, *Methanococcus igneus*, *Pyrococcus horikoshii*, and *Aeropyrum pernix* endonucleases. These include compositions comprising purified FEN-1 endonucleases from the organisms (including specific endonucleases described by sequences provided herein, as well as, variants and homologues), kits comprising these compositions, composition comprising chimerical endonucleases comprising at least a portion of the endonucleases from these organisms, kits comprising such compositions, compositions comprising nucleic acids encoding the endonucleases from these organisms (including vectors and host cells), kits comprising such compositions, antibodies generated to the endonucleases, mixtures comprising endonucleases from these organisms, methods of using the endonuclease in cleavage assays (e.g., invasive cleavage assays, CFLP, etc.), and kits containing components useful for such methods. Examples describing the generation, structure, use, and characterization of these endonucleases are provided herein.

The present invention also provides methods for improving the methods and enzymes disclosed herein. For example, the present invention provides methods of improving enzymes for any intended purpose (e.g., use in cleavage reactions, amplification reactions, binding reactions, or any other use) comprising the step of

- 5 providing an enzyme disclosed herein and modifying the enzyme (e.g., altering the amino acid sequence, adding or subtracting sequence, adding post-translational modifications, adding any other component whether biological or not, or any other modification). Likewise, the present invention provides methods for improving the methods disclosed herein comprising, conducting the method steps with one or more changes (e.g., change
10 in a composition provided in the method, change in the order of the steps, or addition or subtraction of steps).

The improved performance in a detection assay may arise from any one of, or a combination of several improved features. For example, in one embodiment, the enzyme of the present invention may have an improved rate of cleavage (k_{cat}) on a specific

- 15 targeted structure, such that a larger amount of a cleavage product may be produced in a given time span. In another embodiment, the enzyme of the present invention may have a reduced activity or rate in the cleavage of inappropriate or non-specific structures. For example, in certain embodiments of the present invention, one aspect of improvement is that the differential between the detectable amount of cleavage of a specific structure and the
20 detectable amount of cleavage of any alternative structures is increased. As such, it is within the scope of the present invention to provide an enzyme having a reduced rate of cleavage of a specific target structure compared to the rate of the native enzyme, and having a further reduced rate of cleavage of any alternative structures, such that the differential between the detectable amount of cleavage of the specific structure and the
25 detectable amount of cleavage of any alternative structures is increased. However, the present invention is not limited to enzymes that have an improved differential.

In some preferred embodiments, the present invention provides a composition comprising an enzyme, wherein the enzyme comprises a heterologous functional domain, wherein the heterologous functional domain provides altered (e.g., improved)

- 30 functionality in a nucleic acid cleavage assay. The present invention is not limited by the nature of the nucleic acid cleavage assay. For example, nucleic acid cleavage assays

include any assay in which a nucleic acid is cleaved, directly or indirectly, in the presence of the enzyme. In certain preferred embodiments, the nucleic acid cleavage assay is an invasive cleavage assay. In particularly preferred embodiments, the cleavage assay utilizes a cleavage structure having at least one RNA component. In another particularly preferred embodiment, the cleavage assay utilizes a cleavage structure having at least one RNA component, wherein a DNA member of the cleavage structure is cleaved.

5 The present invention is not limited by the nature of the altered functionality provided by the heterologous functional domain. Illustrative examples of alterations include, but are not limited to, enzymes where the heterologous functional domain
10 comprises an amino acid sequence (e.g., one or more amino acids) that provides an improved nuclease activity, an improved substrate binding activity and/or improved background specificity in a nucleic acid cleavage assay.

The present invention is not limited by the nature of the heterologous functional domain. For example, in some embodiments, the heterologous functional domain
15 comprises two or more amino acids from a polymerase domain of a polymerase (e.g., introduced into the enzyme by insertion of a chimerical functional domain or created by mutation). In certain preferred embodiment, at least one of the two or more amino acids is from a palm or thumb region of the polymerase domain. The present invention is not limited by the identity of the polymerase from which the two or more amino acids are
20 selected. In certain preferred embodiments, the polymerase comprises *Thermus thermophilus* polymerase. In particularly preferred embodiments, the two or more amino acids are from amino acids 300-650 of SEQ ID NO:1.

The novel enzymes of the invention may be employed for the detection of target
25 DNAs and RNAs including, but not limited to, target DNAs and RNAs comprising wild type and mutant alleles of genes, including, but not limited to, genes from humans, other animal, or plants that are or may be associated with disease or other conditions. In addition, the enzymes of the invention may be used for the detection of and/or identification of strains of microorganisms, including bacteria, fungi, protozoa, ciliates and viruses (and in particular for the detection and identification of viruses having RNA
30 genomes, such as the Hepatitis C and Human Immunodeficiency viruses). For example, the present invention provides methods for cleaving a nucleic acid comprising providing:

an enzyme of the present invention and a substrate nucleic acid; and exposing the substrate nucleic acid to the enzyme (e.g., to produce a cleavage product that may be detected). In some embodiments, the substrate nucleic acid is in a cell lysate sample.

- The present invention also provides a method for detecting the presence of a
- 5 target nucleic acid comprising: cleaving an invasive cleavage structure, said invasive cleavage structure comprising an RNA target nucleic acid; and detecting the cleavage of the invasive cleavage structure. Such an assay may comprise a multiplex assay, wherein multiple invasive cleavage structures are cleaved. Such structures include structures formed on different target nucleic acids, as well as, structures formed on different
- 10 locations of the sample target nucleic acid. In some embodiments, the target nucleic acid comprises a first region and a second region, said second region downstream of and contiguous to said first region. In some embodiments, the invasive cleavage structure comprises the target nucleic acid, a first oligonucleotide, and a second oligonucleotide, wherein at least a portion of the first oligonucleotide is completely complementary to the
- 15 first portion of the first target nucleic acid, and wherein the second oligonucleotide comprises a 3' portion and a 5' portion, wherein the 5' portion is completely complementary to said second portion of the target nucleic acid. In some embodiments, the 3' portion of the second oligonucleotide comprises a 3' terminal nucleotide not complementary to said target nucleic acid. In some embodiments, the 3' portion of the
- 20 second oligonucleotide consists of a single nucleotide not complementary to the target nucleic acid. In some embodiments, the method further comprises the steps of forming a second invasive cleavage structure comprising a non-target cleavage product and cleaving the second invasive cleavage structure. In some embodiments, the invasive cleavage structure or the second invasive cleavage comprises an oligonucleotide
- 25 comprising a sequence selected from the group consisting of SEQ ID NO:709-2640. In other embodiments, the invasive cleavage structure or the second invasive cleavage comprises an oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:169-211 and 619-706. In some preferred embodiments, the target nucleic acid comprises a cytochrome P450 RNA or a cytokine RNA. In some embodiments, the
- 30 first region or the second region of the target nucleic acid encompasses a splice junction, an exon (or a portion thereof), or an intron (or a portion thereof). In some embodiments,

the RNA target nucleic acid is provided in a cell lysate. In some embodiments, the first oligonucleotide is covalently attached to the second oligonucleotide. Such oligonucleotides find use, for example, in methods described in U.S. Patent Nos. 5,714,320 and 5,854,033, herein incorporated by reference in their entireties. The present invention also provides kits containing one or more of the components used in the above methods.

DEFINITIONS

To facilitate an understanding of the present invention, a number of terms and 10 phrases are defined below:

As used herein, the terms "complementary" or "complementarity" are used in reference to polynucleotides (*i.e.*, a sequence of nucleotides such as an oligonucleotide or a target nucleic acid) related by the base-pairing rules. For example, for the sequence "5'-A-G-T-3'," is complementary to the sequence "3'-T-C-A-5'." Complementarity may be 15 "partial," in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be "complete" or "total" complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection 20 methods that depend upon binding between nucleic acids. Either term may also be used in reference to individual nucleotides, especially within the context of polynucleotides. For example, a particular nucleotide within an oligonucleotide may be noted for its complementarity, or lack thereof, to a nucleotide within another nucleic acid strand, in contrast or comparison to the complementarity between the rest of the oligonucleotide 25 and the nucleic acid strand. Nucleotide analogs used to form non-standard base pairs, whether with another nucleotide analog (*e.g.*, an IsoC/IsoG base pair), or with a naturally occurring nucleotide (*e.g.*, as described in U.S. Patent 5,912,340, herein incorporated by reference in its entirety) are also considered to be complementary to a base pairing partner within the meaning this definition.

The term "homology" and "homologous" refers to a degree of identity. There may be partial homology or complete homology. A partially homologous sequence is one that is less than 100% identical to another sequence.

As used herein, the term "hybridization" is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (*i.e.*, the strength of the association between the nucleic acids) is influenced by such factors as the degree of complementary between the nucleic acids, stringency of the conditions involved, and the T_m of the formed hybrid. "Hybridization" methods involve the annealing of one nucleic acid to another, complementary nucleic acid, *i.e.*, a nucleic acid having a complementary nucleotide sequence. The ability of two polymers of nucleic acid containing complementary sequences to find each other and anneal through base pairing interaction is a well-recognized phenomenon. The initial observations of the "hybridization" process by Marmur and Lane, Proc. Natl. Acad. Sci. USA 46:453 (1960) and Doty et al., Proc. Natl. Acad. Sci. USA 46:461 (1960) have been followed by the refinement of this process into an essential tool of modern biology.

With regard to complementarity, it is important for some diagnostic applications to determine whether the hybridization represents complete or partial complementarity. For example, where it is desired to detect simply the presence or absence of pathogen DNA (such as from a virus, bacterium, fungi, mycoplasma, protozoan) it is only important that the hybridization method ensures hybridization when the relevant sequence is present; conditions can be selected where both partially complementary probes and completely complementary probes will hybridize. Other diagnostic applications, however, may require that the hybridization method distinguish between partial and complete complementarity. It may be of interest to detect genetic polymorphisms. For example, human hemoglobin is composed, in part, of four polypeptide chains. Two of these chains are identical chains of 141 amino acids (alpha chains) and two of these chains are identical chains of 146 amino acids (beta chains). The gene encoding the beta chain is known to exhibit polymorphism. The normal allele encodes a beta chain having glutamic acid at the sixth position. The mutant allele encodes a beta chain having valine at the sixth position. This difference in amino acids has a profound (most profound when the individual is homozygous for the mutant allele)

physiological impact known clinically as sickle cell anemia. It is well known that the genetic basis of the amino acid change involves a single base difference between the normal allele DNA sequence and the mutant allele DNA sequence.

- The complement of a nucleic acid sequence as used herein refers to an
5 oligonucleotide which, when aligned with the nucleic acid sequence such that the 5' end of one sequence is paired with the 3' end of the other, is in "antiparallel association." Certain bases not commonly found in natural nucleic acids may be included in the nucleic acids of the present invention and include, for example, inosine and 7-deazaguanine. Complementarity need not be perfect; stable duplexes may contain mismatched base
10 pairs or unmatched bases. Those skilled in the art of nucleic acid technology can determine duplex stability empirically considering a number of variables including, for example, the length of the oligonucleotide, base composition and sequence of the oligonucleotide, ionic strength and incidence of mismatched base pairs.

- As used herein, the term "T_m" is used in reference to the "melting temperature."
15 The melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands. Several equations for calculating the T_m of nucleic acids are well known in the art. As indicated by standard references, a simple estimate of the T_m value may be calculated by the equation: T_m = 81.5 + 0.41(% G + C), when a nucleic acid is in aqueous solution at 1 M NaCl (see
20 e.g., Anderson and Young, Quantitative Filter Hybridization, in Nucleic Acid Hybridization (1985). Other references (e.g., Alawi, H.T. & SantaLucia, J., Jr. Thermodynamics and NMR of internal G.T mismatches in DNA. Biochemistry 36, 10581-94 (1997) include more sophisticated computations which take structural and environmental, as well as sequence characteristics into account for the calculation of T_m.
25 As used herein the term "stringency" is used in reference to the conditions of temperature, ionic strength, and the presence of other compounds, under which nucleic acid hybridizations are conducted. With "high stringency" conditions, nucleic acid base pairing will occur only between nucleic acid fragments that have a high frequency of complementary base sequences. Thus, conditions of "weak" or "low" stringency are often required when it is desired that nucleic acids that are not completely
30 complementary to one another be hybridized or annealed together.

- "High stringency conditions" when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42 C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH₂PO₄ H₂O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5X Denhardt's reagent and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.1X SSPE, 1.0% SDS at 42 C when a probe of about 500 nucleotides in length is employed.
- 5 "Medium stringency conditions" when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42 C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH₂PO₄ H₂O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5X Denhardt's reagent and 100 µg/ml denatured salmon sperm DNA followed by washing in a solution comprising 1.0X SSPE, 1.0% SDS at 42 C when a probe of about 500 nucleotides in length is employed.
- 10 "Low stringency conditions" comprise conditions equivalent to binding or hybridization at 42 C in a solution consisting of 5X SSPE (43.8 g/l NaCl, 6.9 g/l NaH₂PO₄ H₂O and 1.85 g/l EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS, 5X Denhardt's reagent [50X Denhardt's contains per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 g/ml denatured salmon sperm DNA followed by washing in a solution comprising 5X SSPE, 0.1% SDS at 42 C when a probe of about 500 nucleotides in length is employed.
- 15 20 The term "gene" refers to a DNA sequence that comprises control and coding sequences necessary for the production of an RNA having a non-coding function (*e.g.*, a ribosomal or transfer RNA), a polypeptide or a precursor. The RNA or polypeptide can be encoded by a full-length coding sequence or by any portion of the coding sequence so long as the desired activity or function is retained.
- 25 The term "wild-type" refers to a gene or a gene product that has the characteristics of that gene or gene product when isolated from a naturally occurring source. A wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designated the "normal" or "wild-type" form of the gene. In contrast, the term "modified," "mutant," or "polymorphic" refers to a gene or gene product that displays modifications in sequence and/or functional properties (*i.e.*, altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring

mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.

The term "recombinant DNA vector" as used herein refers to DNA sequences containing a desired heterologous sequence. For example, although the term is not limited to the use of expressed sequences or sequences that encode an expression product, in some embodiments, the heterologous sequence is a coding sequence and appropriate DNA sequences necessary for either the replication of the coding sequence in a host organism, or the expression of the operably linked coding sequence in a particular host organism. DNA sequences necessary for expression in prokaryotes include a promoter, optionally an operator sequence, a ribosome-binding site and possibly other sequences. Eukaryotic cells are known to utilize promoters, polyadenylation signals and enhancers.

The term "LTR" as used herein refers to the long terminal repeat found at each end of a provirus (*i.e.*, the integrated form of a retrovirus). The LTR contains numerous regulatory signals including transcriptional control elements, polyadenylation signals and sequences needed for replication and integration of the viral genome. The viral LTR is divided into three regions called U3, R and U5.

The U3 region contains the enhancer and promoter elements. The U5 region contains the polyadenylation signals. The R (repeat) region separates the U3 and U5 regions and transcribed sequences of the R region appear at both the 5' and 3' ends of the viral RNA.

The term "oligonucleotide" as used herein is defined as a molecule comprising two or more deoxyribonucleotides or ribonucleotides, preferably at least 5 nucleotides, more preferably at least about 10-15 nucleotides and more preferably at least about 15 to 30 nucleotides. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. The oligonucleotide may be generated in any manner, including chemical synthesis, DNA replication, reverse transcription, PCR, or a combination thereof.

Because mononucleotides are reacted to make oligonucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is attached to the 3' oxygen of its neighbor in one direction via a phosphodiester linkage, an end of an oligonucleotide is referred to as the "5' end" if its 5' phosphate is not linked to the 3' oxygen of a

mononucleotide pentose ring and as the "3' end" if its 3' oxygen is not linked to a 5' phosphate of a subsequent mononucleotide pentose ring. As used herein, a nucleic acid sequence, even if internal to a larger oligonucleotide, also may be said to have 5' and 3' ends. A first region along a nucleic acid strand is said to be upstream of another region if 5 the 3' end of the first region is before the 5' end of the second region when moving along a strand of nucleic acid in a 5' to 3' direction.

When two different, non-overlapping oligonucleotides anneal to different regions of the same linear complementary nucleic acid sequence, and the 3' end of one oligonucleotide points towards the 5' end of the other, the former may be called the 10 "upstream" oligonucleotide and the latter the "downstream" oligonucleotide. Similarly, when two overlapping oligonucleotides are hybridized to the same linear complementary nucleic acid sequence, with the first oligonucleotide positioned such that its 5' end is upstream of the 5' end of the second oligonucleotide, and the 3' end of the first oligonucleotide is upstream of the 3' end of the second oligonucleotide, the first 15 oligonucleotide may be called the "upstream" oligonucleotide and the second oligonucleotide may be called the "downstream" oligonucleotide.

The term "primer" refers to an oligonucleotide that is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated. An oligonucleotide "primer" may occur naturally, as in a purified restriction 20 digest or may be produced synthetically.

A primer is selected to be "substantially" complementary to a strand of specific sequence of the template. A primer must be sufficiently complementary to hybridize with a template strand for primer elongation to occur. A primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide 25 fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being substantially complementary to the strand. Non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the template to hybridize and thereby form a template primer complex for synthesis of the extension product of the 30 primer.

The term "label" as used herein refers to any atom or molecule that can be used to provide a detectable (preferably quantifiable) effect, and that can be attached to a nucleic acid or protein. Labels include but are not limited to dyes; radiolabels such as ^{32}P ; binding moieties such as biotin; haptens such as digoxigenin; luminogenic,

- 5 phosphorescent or fluorogenic moieties; and fluorescent dyes alone or in combination with moieties that can suppress or shift emission spectra by fluorescence resonance energy transfer (FRET). Labels may provide signals detectable by fluorescence, radioactivity, colorimetry, gravimetry, X-ray diffraction or absorption, magnetism, enzymatic activity, and the like. A label may be a charged moiety (positive or negative
10 charge) or alternatively, may be charge neutral. Labels can include or consist of nucleic acid or protein sequence, so long as the sequence comprising the label is detectable.

The term "signal" as used herein refers to any detectable effect, such as would be caused or provided by a label or an assay reaction.

- As used herein, the term "detector" refers to a system or component of a system,
15 e.g., an instrument (e.g. a camera, fluorimeter, charge-coupled device, scintillation counter, etc.) or a reactive medium (X-ray or camera film, pH indicator, etc.), that can convey to a user or to another component of a system (e.g., a computer or controller) the presence of a signal or effect. A detector can be a photometric or spectrophotometric system, which can detect ultraviolet, visible or infrared light, including fluorescence or
20 chemiluminescence; a radiation detection system; a spectroscopic system such as nuclear magnetic resonance spectroscopy, mass spectrometry or surface enhanced Raman spectrometry; a system such as gel or capillary electrophoresis or gel exclusion chromatography; or other detection systems known in the art, or combinations thereof.

- The term "cleavage structure" as used herein, refers to a structure that is formed
25 by the interaction of at least one probe oligonucleotide and a target nucleic acid, forming a structure comprising a duplex, the resulting structure being cleavable by a cleavage agent, including but not limited to an enzyme. The cleavage structure is a substrate for specific cleavage by the cleavage means in contrast to a nucleic acid molecule that is a substrate for non-specific cleavage by agents such as phosphodiesterases that cleave
30 nucleic acid molecules without regard to secondary structure (*i.e.*, no formation of a duplexed structure is required).

The term "folded cleavage structure" as used herein, refers to a region of a single-stranded nucleic acid substrate containing secondary structure, the region being cleavable by an enzymatic cleavage means. The cleavage structure is a substrate for specific cleavage by the cleavage means in contrast to a nucleic acid molecule that is a substrate

- 5 for non-specific cleavage by agents such as phosphodiesterases that cleave nucleic acid molecules without regard to secondary structure (*i.e.*, no folding of the substrate is required).

As used herein, the term "folded target" refers to a nucleic acid strand that contains at least one region of secondary structure (*i.e.*, at least one double stranded 10 region and at least one single-stranded region within a single strand of the nucleic acid). A folded target may comprise regions of tertiary structure in addition to regions of secondary structure.

The term "cleavage means" or "cleavage agent" as used herein refers to any means that is capable of cleaving a cleavage structure, including but not limited to 15 enzymes. The cleavage means may include native DNAPs having 5' nuclease activity (*e.g.*, Taq DNA polymerase, *E. coli* DNA polymerase I) and, more specifically, modified DNAPs having 5' nuclease but lacking synthetic activity. "Structure-specific nucleases" or "structure-specific enzymes" are enzymes that recognize specific secondary structures in a nucleic acid molecule and cleave these structures. The cleavage means of the 20 invention cleave a nucleic acid molecule in response to the formation of cleavage structures; it is not necessary that the cleavage means cleave the cleavage structure at any particular location within the cleavage structure.

The cleavage means is not restricted to enzymes having solely 5' nuclease activity. The cleavage means may include nuclease activity provided from a variety of 25 sources including the CLEAVASE enzymes, the FEN-1 endonucleases (including RAD2 and XPG proteins), Taq DNA polymerase and *E. coli* DNA polymerase I.

The term "thermostable" when used in reference to an enzyme, such as a 5' nuclease, indicates that the enzyme is functional or active (*i.e.*, can perform catalysis) at an elevated temperature, *i.e.*, at about 55°C or higher.

The term "cleavage products" as used herein, refers to products generated by the reaction of a cleavage means with a cleavage structure (i.e., the treatment of a cleavage structure with a cleavage means).

5 The term "target nucleic acid" refers to a nucleic acid molecule containing a sequence that has at least partial complementarity with at least a probe oligonucleotide and may also have at least partial complementarity with an INVADER oligonucleotide. The target nucleic acid may comprise single- or double-stranded DNA or RNA, and may comprise nucleotide analogs, labels, and other modifications.

10 The term "probe oligonucleotide" refers to an oligonucleotide that interacts with a target nucleic acid to form a cleavage structure in the presence or absence of an INVADER oligonucleotide. When annealed to the target nucleic acid, the probe oligonucleotide and target form a cleavage structure and cleavage occurs within the probe oligonucleotide.

15 The term "non-target cleavage product" refers to a product of a cleavage reaction that is not derived from the target nucleic acid. As discussed above, in the methods of the present invention, cleavage of the cleavage structure generally occurs within the probe oligonucleotide. The fragments of the probe oligonucleotide generated by this target nucleic acid-dependent cleavage are "non-target cleavage products."

20 The term "INVADER oligonucleotide" refers to an oligonucleotide that hybridizes to a target nucleic acid at a location near the region of hybridization between a probe and the target nucleic acid, wherein the INVADER oligonucleotide comprises a portion (e.g., a chemical moiety, or nucleotide—whether complementary to that target or not) that overlaps with the region of hybridization between the probe and target. In some embodiments, the INVADER oligonucleotide contains sequences at its 3' end that are substantially the same as sequences located at the 5' end of a probe oligonucleotide.

25 The term "substantially single-stranded" when used in reference to a nucleic acid substrate means that the substrate molecule exists primarily as a single strand of nucleic acid in contrast to a double-stranded substrate which exists as two strands of nucleic acid which are held together by inter-strand base pairing interactions.

30 The term "sequence variation" as used herein refers to differences in nucleic acid sequence between two nucleic acids. For example, a wild-type structural gene and a

mutant form of this wild-type structural gene may vary in sequence by the presence of single base substitutions and/or deletions or insertions of one or more nucleotides. These two forms of the structural gene are said to vary in sequence from one another. A second mutant form of the structural gene may exist. This second mutant form is said to vary in sequence from both the wild-type gene and the first mutant form of the gene.

5 The term "liberating" as used herein refers to the release of a nucleic acid fragment from a larger nucleic acid fragment, such as an oligonucleotide, by the action of, for example, a 5' nuclease such that the released fragment is no longer covalently attached to the remainder of the oligonucleotide.

10 The term "K_m" as used herein refers to the Michaelis-Menten constant for an enzyme and is defined as the concentration of the specific substrate at which a given enzyme yields one-half its maximum velocity in an enzyme catalyzed reaction.

The term "nucleotide" as used herein includes, but is not limited to, naturally occurring and/or synthetic nucleotides, nucleotide analogs, and nucleotide derivatives.

- 15 For example, the term includes naturally occurring DNA or RNA monomers, nucleotides with backbone modifications such as peptide nucleic acid (PNA) (M. Egholm et al., Nature 365:566 [1993]), phosphorothioate DNA, phosphorodithioate DNA, phosphoramidate DNA, amine-linked DNA, MMI-linked DNA, 2'-O-methyl RNA, alpha-DNA and methylphosphonate DNA, nucleotides with sugar modifications such as
- 20 2'-O-methyl RNA, 2'-fluoro RNA, 2'-amino RNA, 2'-O-alkyl DNA, 2'-O-allyl DNA, 2'-O-alkynyl DNA, hexose DNA, pyranosyl RNA, and anhydrohexitol DNA, and nucleotides having base modifications such as C-5 substituted pyrimidines (substituents including fluoro-, bromo-, chloro-, iodo-, methyl-, ethyl-, vinyl-, formyl-, ethynyl-, propynyl-, alkynyl-, thiazoyl-, imidazolyl-, pyridyl-), 7-deazapurines with C-7
- 25 substituents including fluoro-, bromo-, chloro-, iodo-, methyl-, ethyl-, vinyl-, formyl-, alkynyl-, alkenyl-, thiazoyl-, imidazolyl-, pyridyl-), inosine and diaminopurine.

The term "base analog" as used herein refers to modified or non-naturally occurring bases such as 7-deaza purines (e.g., 7-deaza-adenine and 7-deaza-guanine); bases modified, for example, to provide altered interactions such as non-standard

- 30 basepairing, including, but not limited to: IsoC, Iso G, and other modified bases and nucleotides described in U.S. Patent Nos. 5,432,272; 6,001,983; 6,037,120; 6,140,496;

5,912,340; 6,127,121 and 6,143,877, each of which is incorporated herein by reference in their entireties; heterocyclic base analogs based no the purine or pyrimidine ring systems, and other heterocyclic bases. Nucleotide analogs include base analogs and comprise modified forms of deoxyribonucleotides as well as ribonucleotides.

5 The term "polymorphic locus" is a locus present in a population that shows variation between members of the population (*e.g.*, the most common allele has a frequency of less than 0.95). In contrast, a "monomorphic locus" is a genetic locus at little or no variations seen between members of the population (generally taken to be a locus at which the most common allele exceeds a frequency of 0.95 in the gene pool of 10 the population).

10 The term "microorganism" as used herein means an organism too small to be observed with the unaided eye and includes, but is not limited to bacteria, virus, protozoans, fungi, and ciliates.

15 The term "microbial gene sequences" refers to gene sequences derived from a microorganism.

16 The term "bacteria" refers to any bacterial species including eubacterial and archaeabacterial species.

20 The term "virus" refers to obligate, ultramicroscopic, intracellular parasites incapable of autonomous replication (*i.e.*, replication requires the use of the host cell's machinery).

25 The term "multi-drug resistant" or multiple-drug resistant" refers to a microorganism that is resistant to more than one of the antibiotics or antimicrobial agents used in the treatment of said microorganism.

30 The term "sample" in the present specification and claims is used in its broadest sense. On the one hand it is meant to include a specimen or culture (*e.g.*, microbiological cultures). On the other hand, it is meant to include both biological and environmental samples. A sample may include a specimen of synthetic origin.

35 Biological samples may be animal, including human, fluid, solid (*e.g.*, stool) or tissue, as well as liquid and solid food and feed products and ingredients such as dairy items, vegetables, meat and meat by-products, and waste. Biological samples may be obtained from all of the various families of domestic animals, as well as feral or wild

animals, including, but not limited to, such animals as ungulates, bear, fish, lagomorphs, rodents, etc.

Environmental samples include environmental material such as surface matter, soil, water and industrial samples, as well as samples obtained from food and dairy

- 5 processing instruments, apparatus, equipment, utensils, disposable and non-disposable items. These examples are not to be construed as limiting the sample types applicable to the present invention.

The term "source of target nucleic acid" refers to any sample that contains nucleic acids (RNA or DNA). Particularly preferred sources of target nucleic acids are biological samples including, but not limited to blood, saliva, cerebral spinal fluid, pleural fluid, milk, lymph, sputum and semen.

An oligonucleotide is said to be present in "excess" relative to another oligonucleotide (or target nucleic acid sequence) if that oligonucleotide is present at a higher molar concentration than the other oligonucleotide (or target nucleic acid

- 15 sequence). When an oligonucleotide such as a probe oligonucleotide is present in a cleavage reaction in excess relative to the concentration of the complementary target nucleic acid sequence, the reaction may be used to indicate the amount of the target nucleic acid present. Typically, when present in excess, the probe oligonucleotide will be present at least a 100-fold molar excess; typically at least 1 pmole of each probe
20 oligonucleotide would be used when the target nucleic acid sequence was present at about 10 fmoles or less.

A sample "suspected of containing" a first and a second target nucleic acid may contain either, both or neither target nucleic acid molecule.

- The term "charge-balanced" oligonucleotide refers to an oligonucleotide (the
25 input oligonucleotide in a reaction) that has been modified such that the modified oligonucleotide bears a charge, such that when the modified oligonucleotide is either cleaved (*i.e.*, shortened) or elongated, a resulting product bears a charge different from the input oligonucleotide (the "charge-unbalanced" oligonucleotide) thereby permitting separation of the input and reacted oligonucleotides on the basis of charge. The term
30 "charge-balanced" does not imply that the modified or balanced oligonucleotide has a net neutral charge (although this can be the case). Charge-balancing refers to the design and

modification of an oligonucleotide such that a specific reaction product generated from this input oligonucleotide can be separated on the basis of charge from the input oligonucleotide.

- For example, in an INVADER oligonucleotide-directed cleavage assay in which
- 5 the probe oligonucleotide bears the sequence: 5' TTCTTTCACCAAGCAGACGGG 3'
(*i.e.*, SEQ ID NO:136 without the modified bases) and cleavage of the probe occurs
between the second and third residues, one possible charge-balanced version of this
oligonucleotide would be: 5' Cy3-AminoT-Amino-TCTTTCACCAAGCAGAC GGG
3'. This modified oligonucleotide bears a net negative charge. After cleavage, the
10 following oligonucleotides are generated: 5' Cy3-AminoT-Amino-T 3' and 5'
CTTTCACCAAGCAGACGGG 3' (residues 3-22 of SEQ ID NO:136). 5' Cy3-
AminoT-Amino-T 3' bears a detectable moiety (the positively-charged Cy3 dye) and two
amino-modified bases. The amino-modified bases and the Cy3 dye contribute positive
charges in excess of the negative charges contributed by the phosphate groups and thus
15 the 5' Cy3-AminoT-Amino-T 3' oligonucleotide has a net positive charge. The other,
longer cleavage fragment, like the input probe, bears a net negative charge. Because the
5' Cy3-AminoT-Amino-T 3' fragment is separable on the basis of charge from the input
probe (the charge-balanced oligonucleotide), it is referred to as a charge-unbalanced
oligonucleotide. The longer cleavage product cannot be separated on the basis of charge
20 from the input oligonucleotide as both oligonucleotides bear a net negative charge; thus,
the longer cleavage product is not a charge-unbalanced oligonucleotide.

- The term "net neutral charge" when used in reference to an oligonucleotide,
including modified oligonucleotides, indicates that the sum of the charges present (*i.e.*, R-
NH3+ groups on thymidines, the N3 nitrogen of cytosine, presence or absence of
25 phosphate groups, etc.) under the desired reaction or separation conditions is essentially
zero. An oligonucleotide having a net neutral charge would not migrate in an electrical
field.

- The term "net positive charge" when used in reference to an oligonucleotide,
including modified oligonucleotides, indicates that the sum of the charges present (*i.e.*, R-
NH3+ groups on thymidines, the N3 nitrogen of cytosine, presence or absence of
30 phosphate groups, etc.) under the desired reaction conditions is +1 or greater. An

oligonucleotide having a net positive charge would migrate toward the negative electrode in an electrical field.

The term "net negative charge" when used in reference to an oligonucleotide, including modified oligonucleotides, indicates that the sum of the charges present (i.e., R-

- 5 NH₃⁺ groups on thymidines, the N₃ nitrogen of cytosine, presence or absence or phosphate groups, etc.) under the desired reaction conditions is -1 or lower. An oligonucleotide having a net negative charge would migrate toward the positive electrode in an electrical field.

- The term "polymerization means" or "polymerization agent" refers to any agent 10 capable of facilitating the addition of nucleoside triphosphates to an oligonucleotide. Preferred polymerization means comprise DNA and RNA polymerases.

The term "ligation means" or "ligation agent" refers to any agent capable of facilitating the ligation (i.e., the formation of a phosphodiester bond between a 3'-OH and a 5' P located at the termini of two strands of nucleic acid). Preferred ligation means 15 comprise DNA ligases and RNA ligases.

- The term "reactant" is used herein in its broadest sense. The reactant can comprise, for example, an enzymatic reactant, a chemical reactant or light (e.g., ultraviolet light, particularly short wavelength ultraviolet light is known to break oligonucleotide chains). Any agent capable of reacting with an oligonucleotide to either 20 shorten (i.e., cleave) or elongate the oligonucleotide is encompassed within the term "reactant."

- The term "adduct" is used herein in its broadest sense to indicate any compound or element that can be added to an oligonucleotide. An adduct may be charged (positively or negatively) or may be charge-neutral. An adduct may be added to the 25 oligonucleotide via covalent or non-covalent linkages. Examples of adducts include, but are not limited to, indodicarbocyanine dye amidites, amino-substituted nucleotides, ethidium bromide, ethidium homodimer, (1,3-propanediamino)propidium, (diethylenetriamino)propidium, thiazole orange, (N-N'-tetramethyl-1,3-propanediamino)propyl thiazole orange, (N-N'-tetramethyl-1,2-ethanediamino)propyl 30 thiazole orange, thiazole orange-thiazole orange homodimer (TOTO), thiazole orange-thiazole blue heterodimer (TOTAB), thiazole orange-ethidium heterodimer 1 (TOED1),

thiazole orange-ethidium heterodimer 2 (TOED2) and fluorescein-ethidium heterodimer (FED), psoralens, biotin, streptavidin, avidin, etc.

Where a first oligonucleotide is complementary to a region of a target nucleic acid and a second oligonucleotide has complementary to the same region (or a portion of this region) a "region of sequence overlap" exists along the target nucleic acid. The degree of overlap will vary depending upon the nature of the complementarity (see, e.g., region "X" in Figs. 29 and 67 and the accompanying discussions).

As used herein, the term "purified" or "to purify" refers to the removal of contaminants from a sample. For example, recombinant CLEAVASE nucleases are expressed in bacterial host cells and the nucleases are purified by the removal of host cell proteins; the percent of these recombinant nucleases is thereby increased in the sample.

The term "recombinant DNA molecule" as used herein refers to a DNA molecule that comprises of segments of DNA joined together by means of molecular biological techniques.

The term "recombinant protein" or "recombinant polypeptide" as used herein refers to a protein molecule that is expressed from a recombinant DNA molecule.

As used herein the term "portion" when in reference to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid (e.g., 4, 5, 6, . . . , n-1).

The term "nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin that may be single or double stranded, and represent the sense or antisense strand. Similarly, "amino acid sequence" as used herein refers to peptide or protein sequence.

The term "peptide nucleic acid" ("PNA") as used herein refers to a molecule comprising bases or base analogs such as would be found in natural nucleic acid, but attached to a peptide backbone rather than the sugar-phosphate backbone typical of nucleic acids. The attachment of the bases to the peptide is such as to allow the bases to base pair with complementary bases of nucleic acid in a manner similar to that of an oligonucleotide. These small molecules, also designated anti gene agents, stop transcript

elongation by binding to their complementary strand of nucleic acid (Nielsen, *et al.* Anticancer Drug Des. 8:53 63 [1993]).

As used herein, the terms "purified" or "substantially purified" refer to molecules, either nucleic or amino acid sequences, that are removed from their natural environment, 5 isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated. An "isolated polynucleotide" or "isolated oligonucleotide" is therefore a substantially purified polynucleotide.

As used herein, the term "fusion protein" refers to a chimeric protein 10 containing the protein of interest (e.g., CLEAVASE BN/thrombin nuclease and portions or fragments thereof) joined to an exogenous protein fragment (the fusion partner which consists of a non CLEAVASE BN/thrombin nuclease protein). The fusion partner may enhance solubility of recombinant chimeric protein (e.g., the CLEAVASE BN/thrombin nuclease) as expressed in a host cell, may provide an affinity tag (e.g., a his-tag) to allow 15 purification of the recombinant fusion protein from the host cell or culture supernatant, or both. If desired, the fusion protein may be removed from the protein of interest (e.g., CLEAVASE BN/thrombin nuclease or fragments thereof) by a variety of enzymatic or chemical means known to the art.

As used herein, the terms "chimeric protein" and "chimerical protein" refer to a 20 single protein molecule that comprises amino acid sequences portions derived from two or more parent proteins. These parent molecules may be from similar proteins from genetically distinct origins, different proteins from a single organism, or different proteins from different organisms. By way of example but not by way of limitation, a chimeric structure-specific nuclease of the present invention may contain a mixture of 25 amino acid sequences that have been derived from FEN-1 genes from two or more of the organisms having such genes, combined to form a non-naturally occurring nuclease. The term "chimerical" as used herein is not intended to convey any particular proportion of contribution from the naturally occurring genes, nor limit the manner in which the portions are combined. Any chimeric structure-specific nuclease constructs having 30 cleavage activity as determined by the testing methods described herein are improved cleavage agents within the scope of the present invention.

The term "continuous strand of nucleic acid" as used herein is means a strand of nucleic acid that has a continuous, covalently linked, backbone structure, without nicks or other disruptions. The disposition of the base portion of each nucleotide, whether base-paired, single-stranded or mismatched, is not an element in the definition of a

5 continuous strand. The backbone of the continuous strand is not limited to the ribose-phosphate or deoxyribose-phosphate compositions that are found in naturally occurring, unmodified nucleic acids. A nucleic acid of the present invention may comprise modifications in the structure of the backbone, including but not limited to phosphorothioate residues, phosphonate residues, 2' substituted ribose residues (e.g.,

10 2'-O-methyl ribose) and alternative sugar (e.g., arabinose) containing residues.

The term "continuous duplex" as used herein refers to a region of double stranded nucleic acid in which there is no disruption in the progression of basepairs within the duplex (*i.e.*, the base pairs along the duplex are not distorted to accommodate a gap, bulge or mismatch with the confines of the region of continuous duplex). As used herein

15 the term refers only to the arrangement of the basepairs within the duplex, without implication of continuity in the backbone portion of the nucleic acid strand. Duplex nucleic acids with uninterrupted basepairing, but with nicks in one or both strands are within the definition of a continuous duplex.

The term "duplex" refers to the state of nucleic acids in which the base portions of

20 the nucleotides on one strand are bound through hydrogen bonding the their complementary bases arrayed on a second strand. The condition of being in a duplex form reflects on the state of the bases of a nucleic acid. By virtue of base pairing, the strands of nucleic acid also generally assume the tertiary structure of a double helix, having a major and a minor groove. The assumption of the helical form is implicit in the

25 act of becoming duplexed.

The term "duplex dependent protein binding" refers to the binding of proteins to nucleic acid that is dependent on the nucleic acid being in a duplex, or helical form.

The term "duplex dependent protein binding sites or regions" as used herein refers to discrete regions or sequences within a nucleic acid that are bound with particular

30 affinity by specific duplex-dependent nucleic acid binding proteins. This is in contrast to the generalized duplex-dependent binding of proteins that are not site-specific, such as

the histone proteins that bind chromatin with little reference to specific sequences or sites.

The term "protein-binding region" as used herein refers to a nucleic acid region identified by a sequence or structure as binding to a particular protein or class of proteins.

- 5 It is within the scope of this definition to include those regions that contain sufficient genetic information to allow identifications of the region by comparison to known sequences, but which might not have the requisite structure for actual binding (e.g., a single strand of a duplex-dependent nucleic acid binding protein site). As used herein "protein binding region" excludes restriction endonuclease binding regions.
- 10 The term "complete double stranded protein binding region" as used herein refers to the minimum region of continuous duplex required to allow binding or other activity of a duplex-dependent protein. This definition is intended to encompass the observation that some duplex dependent nucleic acid binding proteins can interact with full activity with regions of duplex that may be shorter than a canonical protein binding region as
- 15 observed in one or the other of the two single strands. In other words, one or more nucleotides in the region may be allowed to remain unpaired without suppressing binding. As used here in, the term "complete double stranded binding region" refers to the minimum sequence that will accommodate the binding function. Because some such regions can tolerate non-duplex sequences in multiple places, although not necessarily
- 20 simultaneously, a single protein binding region might have several shorter sub-regions that, when duplexed, will be fully competent for protein binding.

- The term "template" refers to a strand of nucleic acid on which a complementary copy is built from nucleoside triphosphates through the activity of a template-dependent nucleic acid polymerase. Within a duplex the template strand is, by convention, depicted and described as the "bottom" strand. Similarly, the non-template strand is often depicted and described as the "top" strand.

- The term "template-dependent RNA polymerase" refers to a nucleic acid polymerase that creates new RNA strands through the copying of a template strand as described above and which does not synthesize RNA in the absence of a template. This is in contrast to the activity of the template-independent nucleic acid polymerases that

synthesize or extend nucleic acids without reference to a template, such as terminal deoxynucleotidyl transferase, or Poly A polymerase.

The term "ARRESTOR molecule" refers to an agent added to or included in an invasive cleavage reaction in order to stop one or more reaction components from

- 5 participating in a subsequent action or reaction. This may be done by sequestering or inactivating some reaction component (e.g., by binding or base-pairing a nucleic acid component, or by binding to a protein component). The term "ARRESTOR oligonucleotide" refers to an oligonucleotide included in an invasive cleavage reaction in order to stop or arrest one or more aspects of any reaction (e.g., the first reaction and/or 10 any subsequent reactions or actions; it is not intended that the ARRESTOR oligonucleotide be limited to any particular reaction or reaction step). This may be done by sequestering some reaction component (e.g., base-pairing to another nucleic acid, or binding to a protein component). However, it is not intended that the term be so limited as to just situations in which a reaction component is sequestered.

- 15 As used herein, the term "kit" refers to any delivery system for delivering materials. In the context of reaction assays, such delivery systems include systems that allow for the storage, transport, or delivery of reaction reagents (e.g., oligonucleotides, enzymes, etc. in the appropriate containers) and/or supporting materials (e.g., buffers, written instructions for performing the assay etc.) from one location to another. For 20 example, kits include one or more enclosures (e.g., boxes) containing the relevant reaction reagents and/or supporting materials. As used herein, the term "fragmented kit" refers to a delivery systems comprising two or more separate containers that each contain a subportion of the total kit components. The containers may be delivered to the intended recipient together or separately. For example, a first container may contain an enzyme 25 for use in an assay, while a second container contains oligonucleotides. The term "fragmented kit" is intended to encompass kits containing Analyte specific reagents (ASR's) regulated under section 520(e) of the Federal Food, Drug, and Cosmetic Act, but are not limited thereto. Indeed, any delivery system comprising two or more separate containers that each contains a subportion of the total kit components are included in the 30 term "fragmented kit." In contrast, a "combined kit" refers to a delivery system containing all of the components of a reaction assay in a single container (e.g., in a single

box housing each of the desired components). The term "kit" includes both fragmented and combined kits.

As used herein, the term "functional domain" refers to a region, or a part of a region, of a protein (e.g., an enzyme) that provides one or more functional characteristic 5 of the protein. For example, a functional domain of an enzyme may provide, directly or indirectly, one or more activities of the enzyme including, but not limited to, substrate binding capability and catalytic activity. A functional domain may be characterized through mutation of one or more amino acids within the functional domain, wherein mutation of the amino acid(s) alters the associated functionality (as measured empirically 10 in an assay) thereby indicating the presence of a functional domain.

As used herein, the term "heterologous functional domain" refers to a protein functional domain that is not in its natural environment. For example, a heterologous functional domain includes a functional domain from one enzyme introduced into another enzyme. A heterologous functional domain also includes a functional domain native to a 15 protein that has been altered in some way (e.g., mutated, added in multiple copies, etc.). A heterologous functional domain may comprise a plurality of contiguous amino acids or may include two or more distal amino acids or amino acids fragments (e.g., two or more amino acids or fragments with intervening, non-heterologous, sequence). Heterologous functional domains are distinguished from endogenous functional domains in that the 20 heterologous amino acid(s) are joined to or contain amino acid sequences that are not found naturally associated with the amino acid sequence in nature or are associated with a portion of a protein not found in nature.

As used herein, the term "altered functionality in a nucleic acid cleavage assay" refers to a characteristic of an enzyme that has been altered in some manner to differ from 25 its natural state (e.g., to differ from how it is found in nature). Alterations include, but are not limited to, addition of a heterologous functional domain (e.g., through mutation or through creation of chimerical proteins). In some embodiments, the altered characteristic of the enzyme may be one that improves the performance of an enzyme in a nucleic acid cleavage assay. Types of improvement include, but are not limited to, improved nuclease 30 activity (e.g., improved rate of reaction), improved substrate binding (e.g., increased or decreased binding of certain nucleic acid species [e.g., RNA or DNA] that produces a

desired outcome [e.g., greater specificity, improved substrate turnover, etc.]), and improved background specificity (e.g., less undesired product is produced). The present invention is not limited by the nucleic cleavage assay used to test improved functionality. However, in some preferred embodiments of the present invention, an invasive cleavage assay is used as the nucleic acid cleavage assay. In certain particularly preferred embodiments, an invasive cleavage assay utilizing an RNA target is used as the nucleic acid cleavage assay.

As used herein, the terms "N-terminal" and "C-terminal" in reference to polypeptide sequences refer to regions of polypeptides including portions of the N-terminal and C-terminal regions of the polypeptide, respectively. A sequence that includes a portion of the N-terminal region of polypeptide includes amino acids predominantly from the N-terminal half of the polypeptide chain, but is not limited to such sequences. For example, an N-terminal sequence may include an interior portion of the polypeptide sequence including bases from both the N-terminal and C-terminal halves of the polypeptide. The same applies to C-terminal regions. N-terminal and C-terminal regions may, but need not, include the amino acid defining the ultimate N-terminal and C-terminal ends of the polypeptide, respectively.

DESCRIPTION OF THE DRAWINGS

Figure 1 shows a schematic representation of sequential invasive cleavage reactions. In step A, an upstream INVADER oligonucleotide and a downstream probe combine with a target nucleic acid strand to form a cleavage structure. In step B, the portion of the cleaved signal probe from A combines with a second target nucleic acid strand and a labeled signal probe to form a second cleavage structure. In step C, cleavage of the labeled second cleavage structure yields a detectable signal.

Figure 2 shows schematic representations of several examples of invasive cleavage structures comprising RNA target strands (SEQ ID NO:141). Panel A depicts an INVADER oligonucleotide (SEQ ID NO:142) and probe (SEQ ID NO:143). Panel B depicts an INVADER oligonucleotide (SEQ ID NO:144) and probe (SEQ ID NO:143).

Panel C depicts an INVADER oligonucleotide (SEQ ID NO:145) and probe (SEQ ID

NO:145). Panel D depicts an INVADER oligonucleotide (SEQ ID NO:145) and probe (SEQ ID NO:146).

Figure 3 shows schematic representations of two examples of structures that are not invasive cleavage structures labelled SEQ ID NOS:147-152.

5 Figure 4 shows a schematic representation of a configuration of invasive cleavage that is useful for detection of target sequence variations. In A, an invasive cleavage structure having overlap between the two probes is formed, and the arrow indicates that it is cleavable by the enzymes of the present invention. In B, variation of the target sequence removes a region of complementarity to the downstream probe and eliminates 10 the overlap. The absence of an arrow in panel B indicates a reduced rate of cleavage of this structure compared to that diagrammed in panel A.

15 Figure 5 shows a diagram of the X-ray structure of a ternary complex of KlentaqI with primer/template DNA in the polymerizing mode determined by Li *et al.* (Li *et al.*, Protein Sci., 7:1116 [1998]). Without intending to represent precise borders between features of the physical form, the portions referred to in the text as the "fingers", "thumb" and "palm" regions are loosely indicated by the circle, rectangle, and oval, respectively.

20 Figure 6 shows a schematic diagram of the DNA polymerase gene from *Thermus aquaticus*. Restriction sites used in these studies are indicated above. The approximate regions encoding various structural or functional domains of the protein are indicated by double-headed arrows, below.

25 Figure 7 shows a schematic diagram of the chimeric constructs comprising portions of the TaqPol gene and the TthPol gene. Open and shaded boxes denote TaqPol and TthPol sequences, respectively. The numbers correspond to the amino acid sequence of TaqPol. The 5' nuclease and polymerase domains of TaqPol and the palm, thumb, and fingers regions of the polymerase domain are indicated. The abbreviations for the restrictions sites used for recombination are as follows: E, EcoRI; N, NotI; Bs, BstBI; D, NdeI; B, BamHI; and S, SalI.

30 Figure 8A-H shows a comparison of the nucleotide structure of the polymerase genes isolated from *Thermus aquaticus* (SEQ ID NO:153), *Thermus flavus* (SEQ ID NO:154) and *Thermus thermophilus* (SEQ ID NO:155); the consensus sequence (SEQ ID NO:156) is shown at the top of each row.

Figure 9A-C shows a comparison of the amino acid sequence of the polymerase isolated from *Thermus aquaticus* (SEQ ID NO:157), *Thermus flavus* (SEQ ID NO:158), and *Thermus thermophilus* (SEQ ID NO:1); the consensus sequence (SEQ ID NO:159) is shown at the top of each row.

5 Figure 10 shows the sequences and proposed structures of substrates for the invasive signal amplification reaction with human IL-6 RNA target strand (SEQ ID NO:160) and upstream probe (SEQ ID NO:161). The cleavage site of the downstream probe (SEQ ID NO:162) is indicated by an arrow. Sequence of the IL-6 DNA target strand (SEQ ID NO:163) is shown below.

10 Figure 11 shows the image generated by a fluorescence imager showing the products of invasive cleavage assays using the indicated enzymes, and the IL-6 substrate of Figure 10 having either a DNA target strand (A) or an RNA target strand (B).

Figure 12 compares the cycling cleavage activities of Taq DN RX HT, Tth DN RX HT, and Taq-Tth chimerical enzymes with IL-6 substrate having an RNA target strand.

15 Figure 13 shows a comparison of the amino acid sequences of the BstI-BamHI fragments of TaqPol (SEQ ID NO:164) and TthPol (SEQ ID NO:165). Pairs of similar amino acids are shaded with light gray. Aligned amino acids that have a charge difference are shaded with dark gray. The numbers correspond to the amino acid sequence of TaqPol. Amino acids of TaqPol changed to the corresponding amino acids of TthPol by site-directed mutagenesis are indicated by (+).

Figure 14 compares the cycling cleavage activities of Taq DN RX HT, Taq-Tth chimerical enzymes, and chimerical enzymes having the indicated additional amino acid modifications, with IL-6 substrate having an RNA target strand.

20 25 Figure 15 compares the cycling cleavage activities of Taq DN RX HT, Tth DN RX HT, and Taq DN RX HT having the indicated amino acid modifications, with IL-6 substrate having an RNA target strand.

Figure 16 compares polymerization activities of TaqPol, TthPol, and Taq-Tth chimerical enzymes, and TaqPol having the indicated amino acid modifications.

Figure 17 shows a diagram of the X-ray structure of a ternary complex of Klenetaq1 with primer/template DNA in the polymerizing mode determined by Li *et al.* (Li *et al.*, Protein Sci., 7:1116 [1998]). Amino acids G418 and E507 are indicated.

Figures 18 A-D show schematic diagrams of examples of substrates that may be used to measure various cleavage activities of enzymes. The substrates may be labeled, for example, with a fluorescent dye and a quenching moiety for FRET detection, as shown, to facilitate detection and measurement. The substrates of 18A and 18B are invasive cleavage structures having RNA and DNA target strands, respectively. 18C shows an example of an X-structure, and 18D shows an example of a hairpin structure, both of which may be used to assess the activity of enzymes on alternative structures that may be present in invasive cleavage reactions.

Figure 19 shows schematic diagrams of chimeric constructs comprising portions of the TaqPol gene and the TthPol gene. Open and shaded boxes denote TaqPol and TthPol sequences, respectively. The chimeras also include the DN, RX, and HT modifications. A table compares the cleavage activity of each protein on the indicated cleavage substrates.

Figure 20A shows a schematic diagram for an RNA containing invasive cleavage substrate. The 5' end of the target molecule (SEQ ID NO:166) is modified with biotin and blocked with streptavidin as described. The downstream probe (SEQ ID NO:167) with cleavage site is also shown. Panels B-D show analysis of the properties of the Taq DN RX HT G418K/E507Q mutant in cleavage of the shown substrate under conditions of varying reaction temperature, KCl concentration, and MgSO₄ concentration.

Figure 21 shows schematic diagrams for model substrates used to test enzymes for invasive cleavage activity. The molecule shown in 21A provides a DNA target strand (SEQ ID NO:168), while the model shown in 21B provides an RNA containing target strand (SEQ ID NO:167). Both 21A and B show downstream probe SEQ ID NO:166.

Figure 22 shows schematic diagrams for model substrates used to test enzymes for cleavage activity on alternative, non-invasive structures.

Figure 23 shows a schematic diagram for a model substrate used to test enzymes for invasive cleavage activity.

Figure 24 shows schematic diagrams for a model substrate used to test enzymes for invasive cleavage activity on RNA or DNA target strands.

Figure 25 compares the cycling cleavage activities of Tth DN RX HT, Taq 2M, TfIPol, Tsc Pol, and TfI and Tsc-derived mutant enzymes.

5 Figure 26 depicts structures that may be employed to determine the ability of an enzyme to cleave a probe in the presence and the absence of an upstream oligonucleotide. Fig. 26 displays the sequence of oligonucleotide 89-15-1 (SEQ ID NO:212), oligonucleotide 81-69-5 (SEQ ID NO:213), oligonucleotide 81-69-4 (SEQ ID NO:214), oligonucleotide 81-69-3 (SEQ ID NO:215), oligonucleotide 81-69-2 (SEQ ID NO:216) 10 and a portion of M13mp18 (SEQ ID NO:217).

Figure 27 shows the image generated by a fluorescence imager that shows the dependence of *Pfu* FEN-1 on the presence of an overlapping upstream oligonucleotide for specific cleavage of the probe.

15 Figure 28a shows the image generated by a fluorescence imager that compares the amount of product generated in a standard (*i.e.*, a non-sequential invasive cleavage reaction) and a sequential invasive cleavage reaction.

Figure 28b is a graph comparing the amount of product generated in a standard or basic (*i.e.*, a non-sequential invasive cleavage reaction) and a sequential invasive cleavage reaction ("INVADER sqrd") (y axis = fluorescence units; x axis = attomoles of 20 target).

Figure 29 shows the image generated by a fluorescence imager that shows that the products of a completed sequential invasive cleavage reaction cannot cross contaminant a subsequent similar reaction.

25 Figure 30 shows the sequence of the oligonucleotide employed in an invasive cleavage reaction for the detection of HCMV viral DNA; Fig. 30 shows the sequence of oligonucleotide 89-76 (SEQ ID NO:218), oligonucleotide 89-44 (SEQ ID NO:219) and nucleotides 3057-3110 of the HCMV genome (SEQ ID NO:220).

30 Figure 31 shows the image generated by a fluorescence imager that shows the sensitive detection of HCMV viral DNA in samples containing human genomic DNA using an invasive cleavage reaction.

Figure 32 is a schematic that illustrates one embodiment of the present invention, where the cut probe from an initial invasive cleavage reaction is employed as the INVADER oligonucleotide in a second invasive cleavage reaction, and where an ARRESTOR oligonucleotide prevents participation of remaining uncut first probe in the 5 cleavage of the second probe.

Figure 33 is a schematic that illustrates one embodiment of the present invention, where the cut probe from an initial invasive cleavage reaction is employed as an integrated INVADER-target complex in a second invasive cleavage reaction, and where an ARRESTOR oligonucleotide prevents participation of remaining uncut first probe in 10 the cleavage of the second probe.

Figure 34 shows three images generated by a fluorescence imager showing that two different lengths of 2' O-methyl, 3' terminal amine-modified ARRESTOR oligonucleotide both reduce non-specific background cleavage of the secondary probe when included in the second step of a reaction where the cut probe from an initial 15 invasive cleavage reaction is employed as an integrated INVADER-target complex in a second invasive cleavage reaction.

Figure 35A shows two images generated by a fluorescence imager showing the effects on nonspecific and specific cleavage signal of increasing concentrations of primary probe in the first step of a reaction where the cut probe from an initial invasive 20 cleavage reaction is employed as the INVADER oligonucleotide in a second invasive cleavage reaction.

Figure 35B shows two images generated by a fluorescence imager showing the effects on nonspecific and specific cleavage signal of increasing concentrations of primary probe in the first step of a reaction, and inclusion of a 2' O-methyl, 3' terminal 25 amine-modified ARRESTOR oligonucleotide in the second step of a reaction where the cut probe from an initial invasive cleavage reaction is employed as the INVADER oligonucleotide in a second invasive cleavage reaction.

Figure 35C shows a graph generated using the spreadsheet MICROSOFT EXCEL software, comparing the effects on nonspecific and specific cleavage signal of 30 increasing concentrations of primary probe in the first step of a reaction, in the presence or absence of a 2' O-methyl, 3' terminal amine-modified ARRESTOR oligonucleotide in

the second step of a reaction where the cut probe from an initial invasive cleavage reaction is employed as the INVADER oligonucleotide in a second invasive cleavage reaction.

Figure 36A shows two images generated by a fluorescence imager showing the effects on nonspecific and specific cleavage signal of including an unmodified ARRESTOR oligonucleotide in the second step of a reaction where the cut probe from an initial invasive cleavage reaction is employed as the INVADER oligonucleotide in a second invasive cleavage reaction.

Figure 36B shows two images generated by a fluorescence imager showing the effects on nonspecific and specific cleavage signal of including a 3' terminal amine modified ARRESTOR oligonucleotide, a partially 2' O-methyl substituted, 3' terminal amine modified ARRESTOR oligonucleotide, or an entirely 2' O-methyl, 3' terminal amine modified ARRESTOR oligonucleotide in the second step of a reaction where the cut probe from an initial invasive cleavage reaction is employed as the INVADER oligonucleotide in a second invasive cleavage reaction.

Figure 37A shows two images generated by a fluorescence imager comparing the effects on nonspecific and specific cleavage signal of including ARRESTOR oligonucleotides of different lengths in the second step of a reaction where the cut probe from an initial invasive cleavage reaction is employed as the INVADER oligonucleotide in a second invasive cleavage reaction.

Figure 37B shows two images generated by a fluorescence imager comparing the effects on nonspecific and specific cleavage signal of including an arrestor oligonucleotides of different lengths in the second step of a reaction where the cut probe from an initial invasive cleavage reaction is employed as the INVADER oligonucleotide in a second invasive cleavage reaction, and in which a longer variant of the secondary probe used in the reactions in Fig. 37A is tested.

Figure 37C shows a schematic diagram of a primary probe aligned with several ARRESTOR oligonucleotides of different lengths. The region of the primary probe that is complementary to the HBV target sequence is underlined. The ARRESTOR oligonucleotides are aligned with the probe by complementarity.

Figure 38 shows two images generated by a fluorescence imager comparing the effects on nonspecific and specific cleavage signal of including ARRESTOR oligonucleotides of different lengths in the second step of a reaction where the cut probe from an initial invasive cleavage reaction is employed as the INVADER oligonucleotide
5 in a second invasive cleavage reaction, using secondary probes of two different lengths.

Figure 39 shows a graph of the calculated running average of a ten nucleotide stretch of the hUbiquitin RNA (the Ave(10) Index) derived from the SS-count output of an mfold analysis, expressed as a percentage of the total number of structures found by mfold that include a particular base, plotted against the position of the base.

10 Figure 40 shows an example microplate layout for an RNA INVADER assay comprising 40 samples, 6 standards, and a No Target Control.

Figure 41 shows INVADER assay components for use in detecting human (h), mouse (m), or rat (r) RNAs of the indicated genes or transcripts.

15 Figure 42 shows a computer display of an INVADERCREATOR Order Entry screen.

Figure 43 shows a computer display of an INVADERCREATOR Multiple SNP Design Selection screen.

Figure 44 shows a computer display of an INVADERCREATOR Designer Worksheet screen.

20 Figure 45 shows a computer display of an INVADERCREATOR Output Page screen.

Figure 46 shows a computer display of an INVADERCREATOR Printer Ready Output screen.

25 Figure 47 shows INVADER assay components (SEQ ID NOs:709-2640) for use in detecting RNA target nucleic acids. Components are grouped per RNA analyte to be detected. Where multiple probes, INVADER oligonucleotides, stacker oligonucleotides, ARRESTOR oligonucleotides, or other components are provided, any of the multiple components may be used, unless indicated otherwise. Unless indicated otherwise, oligonucleotides are presented 5'-3' orientation.

30 Figure 48 shows a chart showing the Ave(10) Index against base pair position.

DESCRIPTION OF THE INVENTION**Introduction**

The present invention relates to methods and compositions for treating nucleic acid, and in particular, methods and compositions for detection and characterization of nucleic acid sequences and sequence changes.

In preferred embodiments, the present invention relates to means for cleaving a nucleic acid cleavage structure in a site-specific manner. While the present invention provides a variety of cleavage agents, in some embodiments, the present invention relates to a cleaving enzyme having 5' nuclease activity without interfering nucleic acid synthetic ability. In other embodiments, the present invention provides novel polymerases (*e.g.*, thermostable polymerases) possessing altered polymerase and/or nucleases activities.

For example, in some embodiments, the present invention provides 5' nucleases derived from thermostable DNA polymerases that exhibit altered DNA synthetic activity from that of native thermostable DNA polymerases. The 5' nuclease activity of the polymerase is retained while the synthetic activity is reduced or absent. Such 5' nucleases are capable of catalyzing the structure-specific cleavage of nucleic acids in the absence of interfering synthetic activity. The lack of synthetic activity during a cleavage reaction results in nucleic acid cleavage products of uniform size.

The novel properties of the nucleases of the invention form the basis of a method of detecting specific nucleic acid sequences. This method relies upon the amplification of the detection molecule rather than upon the amplification of the target sequence itself as do existing methods of detecting specific target sequences.

DNA polymerases (DNAPs), such as those isolated from *E. coli* or from thermophilic bacteria of the genus *Thermus* as well as other organisms, are enzymes that synthesize new DNA strands. Several of the known DNAPs contain associated nuclease activities in addition to the synthetic activity of the enzyme.

Some DNAPs are known to remove nucleotides from the 5' and 3' ends of DNA chains (Kornberg, DNA Replication, W.H. Freeman and Co., San Francisco, pp. 127-139 [1980]). These nuclease activities are usually referred to as 5' exonuclease and 3'

exonuclease activities, respectively. For example, the 5' exonuclease activity located in the N-terminal domain of several DNAPs participates in the removal of RNA primers during lagging strand synthesis during DNA replication and the removal of damaged nucleotides during repair. Some DNAPs, such as the *E. coli* DNA polymerase

- 5 (DNAPeC1), also have a 3' exonuclease activity responsible for proof-reading during DNA synthesis (Kornberg, *supra*).

A DNAP isolated from *Thermus aquaticus*, termed Taq DNA polymerase (DNAPTaq), has a 5' exonuclease activity, but lacks a functional 3' exonucleolytic domain (Tindall and Kunkell, *Biochem.*, 27:6008 [1988]). Derivatives of DNAPeC1 and 10 DNAPTaq, respectively called the Klenow and Stoffel fragments, lack 5' exonuclease domains as a result of enzymatic or genetic manipulations (Brutlag et al., *Biochem. Biophys. Res. Commun.*, 37:982 [1969]; Erlich et al., *Science* 252:1643 [1991]; Setlow and Kornberg, *J. Biol. Chem.*, 247:232 [1972]).

- The 5' exonuclease activity of DNAPTaq was reported to require concurrent 15 synthesis (Gelfand, *PCR Technology - Principles and Applications for DNA Amplification*, H.A. Erlich, [Ed.], Stockton Press, New York, p. 19 [1989]). Although mononucleotides predominate among the digestion products of the 5' exonucleases of DNAPTaq and DNAPeC1, short oligonucleotides (\leq 12 nucleotides) can also be observed implying that these so-called 5' exonucleases can function endonucleolytically (Setlow, 20 *supra*; Holland et al., *Proc. Natl. Acad. Sci. USA* 88:7276 [1991]).

In WO 92/06200, Gelfand et al. show that the preferred substrate of the 5' 25 exonuclease activity of the thermostable DNA polymerases is displaced single-stranded DNA. Hydrolysis of the phosphodiester bond occurs between the displaced single-stranded DNA and the double-helical DNA with the preferred exonuclease cleavage site being a phosphodiester bond in the double helical region. Thus, the 5' exonuclease activity usually associated with DNAPs is a structure-dependent single-stranded endonuclease and is more properly referred to as a 5' nuclease. Exonucleases are enzymes that cleave nucleotide molecules from the ends of the nucleic acid molecule. Endonucleases, on the other hand, are enzymes that cleave the nucleic acid molecule at 30 internal rather than terminal sites. The nuclease activity associated with some thermostable DNA polymerases cleaves endonucleolytically but this cleavage requires

contact with the 5' end of the molecule being cleaved. Therefore, these nucleases are referred to as 5' nucleases.

When a 5' nuclease activity is associated with a eubacterial Type A DNA polymerase, it is found in the one third N-terminal region of the protein as an independent 5 functional domain. The C-terminal two-thirds of the molecule constitute the polymerization domain that is responsible for the synthesis of DNA. Some Type A DNA polymerases also have a 3' exonuclease activity associated with the two-third C-terminal region of the molecule.

The 5' exonuclease activity and the polymerization activity of DNAPs can be 10 separated by proteolytic cleavage or genetic manipulation of the polymerase molecule. The Klenow or large proteolytic cleavage fragment of DNAPEc1 contains the polymerase and 3' exonuclease activity but lacks the 5' nuclease activity. The Stoffel fragment of DNAPTaq (DNAPSf) lacks the 5' nuclease activity due to a genetic manipulation that deleted the N-terminal 289 amino acids of the polymerase molecule 15 (Erlich et al., Science 252:1643 [1991]). WO 92/06200 describes a thermostable DNAP with an altered level of 5' to 3' exonuclease. U.S. Patent No. 5,108,892 describes a Thermus aquaticus DNAP without a 5' to 3' exonuclease. Thermostable DNA polymerases with lessened amounts of synthetic activity are available (Third Wave Technologies, Madison, WI) and are described in U.S. Pat. Nos. 5,541,311, 5,614,402, 20 5,795,763, 5,691,142, and 5,837,450, herein incorporated by reference in their entirities. The present invention provides 5' nucleases derived from thermostable Type A DNA polymerases that retain 5' nuclease activity but have reduced or absent synthetic activity. The ability to uncouple the synthetic activity of the enzyme from the 5' nuclease activity proves that the 5' nuclease activity does not require concurrent DNA synthesis as was 25 previously reported (Gelfand, PCR Technology, *supra*).

In addition to the 5'-exonuclease domains of the DNA polymerase I proteins of Eubacteria, described above, 5' nucleases have been found associated with bacteriophage, eukaryotes and archaeabacteria. Overall, all of the enzymes in this family display very similar substrate specificities, despite their limited level of sequence similarity. 30 Consequently, enzymes suitable for use in the methods of the present invention may be isolated or derived from a wide array of sources.

A mammalian enzyme with functional similarity to the 5'-exonuclease domain of E. coli Pol I was isolated nearly 30 years ago (Lindahl, *et al.*, Proc Natl Acad Sci U S A 62(2): 597-603 [1969]). Later, additional members of this group of enzymes called flap endonucleases (FEN1) from Eukarya and Archaea were shown to possess a nearly

- 5 identical structure specific activity (Harrington and Lieber, Embo J 13(5), 1235-46 [1994]; Murante *et al.*, J Biol Chem 269(2), 1191-6 [1994]; Robins, *et al.*, J Biol Chem 269(46), 28535-8 [1994]; Hosfield, *et al.*, J Biol Chem 273(42), 27154-61 [1998]), despite limited sequence similarity. The substrate specificities of the FEN1 enzymes, and the eubacterial and related bacteriophage enzymes have been examined and found to be
10 similar for all enzymes (Lyamichev, *et al.*, Science 260(5109), 778-83 [1993], Harrington and Lieber, *supra*, Murante, *et al.*, *supra*, Hosfield, *et al.*, *supra*, Rao, *et al.*, J Bacteriol 180(20), 5406-12 [1998], Bhagwat, *et al.*, J. Biol Chem 272(45), 28523-30 [1997], Garforth and Sayers, Nucleic Acids Res 25(19), 3801-7 [1997]).

Using preformed substrates, many of the studies cited above determined that these
15 nucleases leave a gap upon cleavage, leading the authors to speculate that DNA polymerase must then act to fill in that gap to generate a ligatable nick. A number of other 5' nucleases have been shown to leave a gap or overlap after cleavage of the same or similar flap substrates. It has since been determined that that all the structure-specific 5'-exonucleases leave a nick after cleavage if the substrate has an overlap between the upstream and downstream duplexes (Kaiser *et al.*, J. Biol .Chem. 274(30):21387-21394 [1999]). While duplexes having several bases of overlapping sequence can assume several different conformations through branch migration, it was determined that cleavage occurs in the conformation where the last nucleotide at the 3' end of the upstream strand is unpaired, with the cleavage rate being essentially the same whether the
20 end of the upstream primer is A, C, G, or T. It was determined to be positional overlap between the 3' end of the upstream primer and downstream duplex, rather than sequence overlap, that provides optimal cleavage. In addition to allowing these enzymes to leave a nick after cleavage, the single base of overlap causes the enzymes to cleave several orders of magnitude faster than when a substrate lacks overlap (Kaiser *et al.*, *supra*).
25

Any of the 5' nucleases described below may find application in one or more embodiments of the methods described herein. 5' nucleases of particular utility in the

methods of present invention include but are not limited to polymerases from a *Thermus* species including, but not limited to, *Thermus aquaticus*, *Thermus flavus*, *Thermus thermophilus*, *Thermus filiformis*, and *Thermus scotoductus*, and altered polymerases. Particularly preferred are altered polymerases exhibiting improved performance in

- 5 detection assays based on the cleavage of a DNA member of an invasive cleavage structure that comprises an RNA target strand.

Chimerical polymerases may find application in one or more embodiments of the present invention, including but not limited to chimerical polymerases comprising one or more portions of one or more FEN nucleases including but are not limited to those of

- 10 *Methanococcus jannaschii*, *Methanobacterium thermoautrophicum*, *Archaeoglobus veneficus*, *Sulfolobus solfataricus*, *Pyrobaculum aerophilum*, *Thermococcus littoralis*, *Archaeoglobus profundus*, *Acidianus brierlyi*, *Acidianus ambivalens*, *Desulfurococcus amylolyticus*, *Desulfurococcus mobilis*, *Pyrodictium brockii*, *Thermococcus gorgonarius*, *Thermococcus zilligii*, *Methanopyrus kandleri*, *Methanococcus igneus*, *Pyrococcus horikoshii*, and *Aeropyrum pernix*; particularly preferred FEN1 enzymes are chimerical *Archaeoglobus fulgidus* and *Pyrococcus furiosus*. Particularly preferred are altered polymerases exhibiting improved performance in detection assays based on the cleavage of a DNA member of an invasive cleavage structure that comprises an RNA target strand.
- 15

- 20 The detailed description of the invention is presented in the following sections:

- I. Detection of Specific Nucleic Acid Sequences Using 5' Nucleases in an INVADER Directed Cleavage Assay;
- II. Signal Enhancement By Incorporating The Products Of An Invasive Cleavage Reaction Into A Subsequent Invasive Cleavage Reaction;
- 25 III. Effect of ARRESTOR Oligonucleotides on Signal and Background in Sequential Invasive Cleavage Reactions.
- IV. Improved Enzymes For Use In INVADER Oligonucleotide-Directed Cleavage Reactions Comprising RNA Targets;
- 30 V. Reaction Design for INVADER Assay Detection of RNA Targets;
- VI. Kits for performing the RNA INVADER Assay; and

VII. The INVADER Assay for Direct Detection and Measurement of Specific RNA Analytes.

5 I. **Detection of Specific Nucleic Acid Sequences Using 5' Nucleases in an INVADER Directed Cleavage Assay**

1. **INVADER Assay Reaction design**

The present invention provides means for forming a nucleic acid cleavage structure that is dependent upon the presence of a target nucleic acid and cleaving the nucleic acid cleavage structure so as to release distinctive cleavage products. 5' nuclease activity, for example, is used to cleave the target-dependent cleavage structure and the resulting cleavage products are indicative of the presence of specific target nucleic acid sequences in the sample. When two strands of nucleic acid, or oligonucleotides, both hybridize to a target nucleic acid strand such that they form an overlapping invasive cleavage structure, as described below, invasive cleavage can occur. Through the interaction of a cleavage agent (e.g., a 5' nuclease) and the upstream oligonucleotide, the cleavage agent can be made to cleave the downstream oligonucleotides at an internal site in such a way that a distinctive fragment is produced. Such embodiments have been termed the INVADER assay (Third Wave Technologies) and are described in U.S. Patent Appl. Nos. 5,846,717, 5,985,557, 5,994,069, 6,001,567, and 6,090,543 and PCT Publications WO 97/27214 and WO 98/42873, herein incorporated by reference in their entireties.

The present invention further provides assays in which the target nucleic acid is reused or recycled during multiple rounds of hybridization with oligonucleotide probes and cleavage of the probes without the need to use temperature cycling (i.e., for periodic denaturation of target nucleic acid strands) or nucleic acid synthesis (i.e., for the polymerization-based displacement of target or probe nucleic acid strands). When a cleavage reaction is run under conditions in which the probes are continuously replaced on the target strand (e.g. through probe-probe displacement or through an equilibrium between probe/target association and disassociation, or through a combination

comprising these mechanisms, [Reynaldo et al., J. Mol. Biol. 97: 511 (2000)]) multiple probes can hybridize to the same target, allowing multiple cleavages, and the generation of multiple cleavage products.

- By the extent of its complementarity to a target nucleic acid strand, an
- 5 oligonucleotide may be said to define a specific region of the target. In an invasive cleavage structure, the two oligonucleotides define and hybridize to regions of the target that are adjacent to one another (*i.e.*, regions without any additional region of the target between them). Either or both oligonucleotides may comprise additional portions that are not complementary to the target strand. In addition to hybridizing adjacently, in order to
- 10 form an invasive cleavage structure, the 3' end of the upstream oligonucleotide must comprise an additional moiety. When both oligonucleotides are hybridized to a target strand to form a structure and such a 3' moiety is present on the upstream oligonucleotide within the structure, the oligonucleotides may be said to overlap, and the structure may be described as an overlapping, or invasive cleavage structure.
- 15 In one embodiment, the 3' moiety of the invasive cleavage structure is a single nucleotide. In this embodiment the 3' moiety may be any nucleotide (*i.e.*, it may be, but it need not be complementary to the target strand). In a preferred embodiment the 3' moiety is a single nucleotide that is not complementary to the target strand. In another embodiment, the 3' moiety is a nucleotide-like compound (*i.e.*, a moiety having chemical
- 20 features similar to a nucleotide, such as a nucleotide analog or an organic ring compound; *See e.g.*, U.S. Pat. No. 5,985,557). In yet another embodiment the 3' moiety is one or more nucleotides that duplicate in sequence one or more nucleotides present at the 5' end of the hybridized region of the downstream oligonucleotide. In a further embodiment, the duplicated sequence of nucleotides of the 3' moiety is followed by a single nucleotide
- 25 that is not further duplicative of the downstream oligonucleotide sequence, and that may be any other nucleotide. In yet another embodiment, the duplicated sequence of nucleotides of the 3' moiety is followed by a nucleotide-like compound, as described above.

- The downstream oligonucleotide may have, but need not have, additional moieties attached to either end of the region that hybridizes to the target nucleic acid strand. In a preferred embodiment, the downstream oligonucleotide comprises a moiety at its 5' end

(*i.e.*, a 5' moiety). In a particularly preferred embodiment, said 5' moiety is a 5' flap or arm comprising a sequence of nucleotides that is not complementary to the target nucleic acid strand.

- When an overlapping cleavage structure is formed, it can be recognized and
- 5 cleaved by a nuclease that is specific for this structure (*i.e.*, a nuclease that will cleave one or more of the nucleic acids in the overlapping structure based on recognition of this structure, rather than on recognition of a nucleotide sequence of any of the nucleic acids forming the structure). Such a nuclease may be termed a "structure-specific nuclease". In some embodiments, the structure-specific nuclease is a 5' nuclease. In a preferred
- 10 embodiment, the structure-specific nuclease is the 5' nuclease of a DNA polymerase. In another preferred embodiment, the DNA polymerase having the 5' nuclease is synthesis-deficient. In another preferred embodiment, the 5' nuclease is a FEN-1 endonuclease. In a particularly preferred embodiment, the 5' nuclease is thermostable.

In some embodiments, said structure-specific nuclease preferentially cleaves the

15 downstream oligonucleotide. In a preferred embodiment, the downstream oligonucleotide is cleaved one nucleotide into the 5' end of the region that is hybridized to the target within the overlapping structure. Cleavage of the overlapping structure at any location by a structure-specific nuclease produces one or more released portions or fragments of nucleic acid, termed "cleavage products."

- 20 In some embodiments, cleavage of an overlapping structure is performed under conditions wherein one or more of the nucleic acids in the structure can disassociate (*i.e.* un-hybridize, or melt) from the structure. In one embodiment, full or partial disassociation of a first cleavage structure allows the target nucleic acid to participate in the formation of one or more additional overlapping cleavage structures. In a preferred
- 25 embodiment, the first cleavage structure is partially disassociated. In a particularly preferred embodiment only the oligonucleotide that is cleaved disassociates from the first cleavage structure, such that it may be replaced by another copy of the same oligonucleotide. In some embodiments, said disassociation is induced by an increase in temperature, such that one or more oligonucleotides can no longer hybridize to the target
- 30 strand. In other embodiments, said disassociation occurs because cleavage of an oligonucleotide produces only cleavage products that cannot bind to the target strand

under the conditions of the reaction. In a preferred embodiment, conditions are selected wherein an oligonucleotide may associate with (*i.e.*, hybridize to) and disassociate from a target strand regardless of cleavage, and wherein the oligonucleotide may be cleaved when it is hybridized to the target as part of an overlapping cleavage structure. In a

- 5 particularly preferred embodiment, conditions are selected such that the number of copies of the oligonucleotide that can be cleaved when part of an overlapping structure exceeds the number of copies of the target nucleic acid strand by a sufficient amount that when the first cleavage structure disassociates, the probability that the target strand will associate with an intact copy of the oligonucleotide is greater than the probability that
- 10 that it will associate with a cleaved copy of the oligonucleotide.

In some embodiments, cleavage is performed by a structure-specific nuclease that can recognize and cleave structures that do not have an overlap. In a preferred embodiment, cleavage is performed by a structure-specific nuclease having a lower rate of cleavage of nucleic acid structures that do not comprise an overlap, compared to the

15 rate of cleavage of structures comprising an overlap. In a particularly preferred embodiment, cleavage is performed by a structure-specific nuclease having less than 1% of the rate of cleavage of nucleic acid structures that do not comprise an overlap, compared to the rate of cleavage of structures comprising an overlap.

- In some embodiments it is desirable to detect the cleavage of the overlapping
- 20 cleavage structure. Detection may be by analysis of cleavage products or by analysis of one or more of the remaining uncleaved nucleic acids. For convenience, the following discussion will refer to the analysis of cleavage products, but it will be appreciated by those skilled in the art that these methods may as easily be applied to analysis of the uncleaved nucleic acids in an invasive cleavage reaction. Any method known in the art
- 25 for analysis of nucleic acids, nucleic acid fragments or oligonucleotides may be applied to the detection of cleavage products.

- In one embodiment, the cleavage products may be identified by chemical content, e.g., the relative amounts of each atom, each particular type of reactive group or each nucleotide base (Chargaff et al., *J. Biol. Chem.* 177: 405 [1949]) they contain. In this way, a cleavage product may be distinguished from a longer nucleic acid from which it was released by cleavage, or from other nucleic acids.

In another embodiment, the cleavage products may be distinguished by a particular physical attribute, including but not limited to length, mass, charge, or charge-to-mass ratio. In yet another embodiment, the cleavage product may be distinguished by a behavior that is related to a physical attribute, including but not limited to rate of

- 5 rotation in solution, rate of migration during electrophoresis, coefficient of sedimentation in centrifugation, time of flight in MALDI-TOF mass spectrometry, migration rate or other behavior in chromatography, melting temperature from a complementary nucleic acid, or precipitability from solution.

Detection of the cleavage products may be through release of a label. Such labels
10 may include, but are not limited to one or more of any of dyes, radiolabels such as ^{32}P or ^{35}S , binding moieties such as biotin, mass tags, such as metal ions or chemical groups, charge tags, such as polyamines or charged dyes, haptens such as digoxigenin, luminogenic, phosphorescent or fluorogenic moieties, and fluorescent dyes, either alone or in combination with moieties that can suppress or shift emission spectra, such as by
15 fluorescence resonance energy transfer (FRET) or collisional fluorescence energy transfer.

In some embodiments, analysis of cleavage products may include physical resolution or separation, for example by electrophoresis, hybridization or by selective binding to a support, or by mass spectrometry methods such as MALDI-TOF. In other
20 embodiments, the analysis may be performed without any physical resolution or separation, such as by detection of cleavage-induced changes in fluorescence as in FRET-based analysis, or by cleavage-induced changes in the rotation rate of a nucleic acid in solution as in fluorescence polarization analysis.

Cleavage products can be used subsequently in any reaction or read-out method
25 that can make use of oligonucleotides. Such reactions include, but are not limited to, modification reactions, such as ligation, tailing with a template-independent nucleic acid polymerase and primer extension with a template-dependent nucleic acid polymerase. The modification of the cleavage products may be for purposes including, but not limited to, addition of one or more labels or binding moieties, alteration of mass, addition of
30 specific sequences, or for any other purpose that would facilitate analysis of either the

cleavage products or analysis of any other by-product, result or consequence of the cleavage reaction.

Analysis of the cleavage products may involve subsequent steps or reactions that do not modify the cleavage products themselves. For example, cleavage products may be

- 5 used to complete a functional structure, such as a competent promoter for *in vitro* transcription or another protein binding site. Analysis may include the step of using the completed structure for or to perform its function. One or more cleavage products may also be used to complete an overlapping cleavage structure, thereby enabling a subsequent cleavage reaction, the products of which may be detected or used by any of
10 the methods described herein, including the participation in further cleavage reactions.

Certain preferred embodiments of the invasive cleavage reactions are provided in the following descriptions. In some embodiments, the methods of the present invention employ at least a pair of oligonucleotides that interact with a target nucleic acid to form a cleavage structure for a structure-specific nuclease. In some embodiments, the cleavage

- 15 structure comprises i) a target nucleic acid that may be either single-stranded or double-stranded (when a double-stranded target nucleic acid is employed, it may be rendered single stranded, e.g., by heating); ii) a first oligonucleotide, termed the "probe," that defines a first region of the target nucleic acid sequence by being the complement of that region; iii) a second oligonucleotide, termed the "INVADER oligonucleotide," the 5' part
20 of which defines a second region of the same target nucleic acid sequence, adjacent to and downstream of the first target region, and the second part of which overlaps into the region defined by the first oligonucleotide.

It can be considered that the binding of these oligonucleotides in this embodiment divides the target nucleic acid into three distinct regions: one region that has

- 25 complementarity to only the probe; one region that has complementarity only to the INVADER oligonucleotide; and one region that has complementarity to both oligonucleotides. As discussed above, in some preferred embodiments of the present invention, the overlap may comprise moieties other than overlapping complementary bases. Thus, in some embodiments, there is a physical, but not sequence, overlap
30 between the INVADER and probe oligonucleotides, i.e., in these latter embodiments,

there is not a region of the target nucleic acid that has complementarity to both oligonucleotides.

a) Oligonucleotide design

Design of these oligonucleotides (i.e., the INVADER oligonucleotide and the probe) is accomplished using practices that are standard in the art. For example, sequences that have self-complementarity, such that the resulting oligonucleotides would either fold upon themselves, or hybridize to each other at the expense of binding to the target nucleic acid, are generally avoided.

One consideration in choosing a length for these oligonucleotides is the complexity of the sample containing the target nucleic acid. For example, the human genome is approximately 3×10^9 basepairs in length. Any 10-nucleotide sequence will appear with a frequency of $1:4^{10}$, or 1:1,048,576 in a random string of nucleotides, which would be approximately 2,861 times in 3 billion basepairs. Clearly, an oligonucleotide of this length would have a poor chance of binding uniquely to a 10-nucleotide region within a target having a sequence the size of the human genome. If the target sequence were within a 3 kb plasmid, however, such an oligonucleotide might have a very reasonable chance of binding uniquely. By this same calculation it can be seen that an oligonucleotide of 16 nucleotides (i.e., a 16-mer) is the minimum length of a sequence that is mathematically likely to appear once in 3×10^9 basepairs. This level of specificity may also be provided by two or more shorter oligonucleotides if they are configured to bind in a cooperative fashion (i.e., such that they can produce the intended complex only if both or all are bound to their intended target sequences), wherein the combination of the short oligonucleotides provides the desired specificity. In one such embodiment, the cooperativity between the shorter oligonucleotides is by a coaxial stacking effect that can occur when the oligonucleotides hybridize to adjacent sites on a target nucleic acid. In another embodiment, the shorter oligonucleotides are connected to one another, either directly, or by one or more spacer regions. The short oligonucleotides thus connected may bind to distal regions of the target and may be used to bridge across regions of secondary structure in a target. Examples of such bridging oligonucleotides are described in PCT Publication WO 98/50403, herein incorporated by reference in its entirety.

A second consideration in choosing oligonucleotide length is the temperature range in which the oligonucleotides will be expected to function. A 16-mer of average base content (50% G-C bases) will have a calculated T_m of about 41°C, depending on, among other things, the concentration of the oligonucleotide and its target, the salt

- 5 content of the reaction and the precise order of the nucleotides. As a practical matter, longer oligonucleotides are usually chosen to enhance the specificity of hybridization. Oligonucleotides 20 to 25 nucleotides in length are often used, as they are highly likely to be specific if used in reactions conducted at temperatures that are near their T_m s (within about 5 °C of the T_m). In addition, with calculated T_m s in the range of 50 to 70°C, such 10 oligonucleotides (i.e., 20 to 25-mers) are appropriately used in reactions catalyzed by thermostable enzymes, which often display optimal activity near this temperature range.

The maximum length of the oligonucleotide chosen is also based on the desired specificity. One should avoid choosing sequences that are so long that they are either at a high risk of binding stably to partial complements, or that they cannot easily be dislodged 15 when desired (e.g., failure to disassociate from the target once cleavage has occurred or failure to disassociate at a reaction temperature suitable for the enzymes and other materials in the reaction).

- The first step of design and selection of the oligonucleotides for the INVADER oligonucleotide-directed cleavage is in accordance with these sample general principles. 20 Considered as sequence-specific probes individually, each oligonucleotide may be selected according to the guidelines listed above. That is to say, each oligonucleotide will generally be long enough to be reasonably expected to hybridize only to the intended target sequence within a complex sample, usually in the 20 to 40 nucleotide range. Alternatively, because the INVADER oligonucleotide-directed cleavage assay depends 25 upon the concerted action of these oligonucleotides, the composite length of the 2 oligonucleotides which span/bind to the target may be selected to fall within this range, with each of the individual oligonucleotides being in approximately the 13 to 17 nucleotide range. Such a design might be employed if a non-thermostable cleavage means were employed in the reaction, requiring the reactions to be conducted at a lower 30 temperature than that used when thermostable cleavage means are employed. In some embodiments, it may be desirable to have these oligonucleotides bind multiple times

within a single target nucleic acid (e.g., to bind to multiple variants or multiple similar sequences within a target). It is not intended that the method of the present invention be limited to any particular size of the probe or INVADER oligonucleotide.

The second step of designing an oligonucleotide pair for this assay is to choose
5 the degree to which the upstream "INVADER" oligonucleotide sequence will overlap
into the downstream "probe" oligonucleotide sequence, and consequently, the sizes into
which the probe will be cleaved. In some preferred embodiments, the probe
oligonucleotide can be made to "turn over," that is to say probe can be made to depart to
allow the binding and cleavage of other copies of the probe molecule, without the
10 requirements of thermal denaturation or displacement by polymerization. While in one
embodiment of this assay probe turnover may be facilitated by an exonucleaseolytic
digestion by the cleavage agent, in some preferred embodiments of the present invention
turnover does not require this exonucleaseolytic activity. For example, in some
embodiments, a reaction temperature and reaction conditions are selected so as to create
15 an equilibrium wherein the probe hybridizes and disassociates from the target. In other
embodiments, temperature and reaction conditions are selected so that unbound probe can
initiate binding to the target strand and physically displace bound probe. In still other
embodiments, temperature and reaction conditions are selected such that either or both
mechanisms of probe replacement may occur in any proportion. The method of the
20 present invention is not limited to any particular mechanism of probe replacement. By
any mechanism, when the probe is bound to the target to form a cleavage structure,
cleavage can occur. The continuous cycling of the probe on and off of the target allows
multiple probes to bind and be cleaved for each copy of a target nucleic acid.

i) Non-sequence Overlaps

25 It has been determined that the relationship between the 3' end of the upstream
oligonucleotide and the desired site of cleavage on the probe should be carefully
designed. It is known that the preferred site of cleavage for the types of structure-specific
endonucleases employed herein is one basepair into a duplex (Lyamichev *et al., supra*).
It was previously believed that the presence of an upstream oligonucleotide or primer
30 allowed the cleavage site to be shifted away from this preferred site, into the single

stranded region of the 5' arm (Lyamichev *et al.*, *supra* and U.S. Patent No. 5,422,253). In contrast to this previously proposed mechanism, and while not limiting the present invention to any particular mechanism, it is believed that the nucleotide immediately 5', or upstream of the cleavage site on the probe (including miniprobe and mid-range probes)

- 5 should be able to basepair with the target for efficient cleavage to occur. In the case of the present invention, this would be the nucleotide in the probe sequence immediately upstream of the intended cleavage site. In addition, as described herein, it has been observed that in order to direct cleavage to that same site in the probe, the upstream oligonucleotide should have its 3' base (*i.e.*, nt) immediately upstream of the intended 10 cleavage site of the probe. In embodiments where the INVADER and probe oligonucleotides share a sequence overlap, this places the 3' terminal nucleotide of the upstream oligonucleotide and the base of the probe oligonucleotide 5' of the cleavage site in competition for pairing with the corresponding nucleotide of the target strand.

To examine the outcome of this competition (*i.e.* which base is paired during a 15 successful cleavage event), substitutions were made in the probe and INVADER oligonucleotides such that either the probe or the INVADER oligonucleotide were mismatched with the target sequence at this position. The effects of both arrangements on the rates of cleavage were examined. When the INVADER oligonucleotide is unpaired at the 3' end, the rate of cleavage was not reduced. If this base was removed, 20 however, the cleavage site was shifted upstream of the intended site. In contrast, if the probe oligonucleotide was not base-paired to the target just upstream of the site to which the INVADER oligonucleotide was directing cleavage, the rate of cleavage was dramatically reduced, suggesting that when a competition exists, the probe 25 oligonucleotide was the molecule to be base-paired in this position.

It appears that the 3' end of the upstream INVADER oligonucleotide is unpaired during cleavage, and yet is important for accurate positioning of the cleavage. To examine which part(s) of the 3' terminal nucleotide are required for the positioning of cleavage, INVADER oligonucleotides were designed that terminated on this end with nucleotides that were altered in a variety of ways. Sugars examined included 2' 30 deoxyribose with a 3' phosphate group, a dideoxyribose, 3' deoxyribose, 2' O-methyl ribose, arabinose and arabinose with a 3' phosphate. Abasic ribose, with and without 3'

phosphate were tested. Synthetic "universal" bases such at 3-nitropyrrole and 5-3 nitroindole on ribose sugars were tested. Finally, a base-like aromatic ring structure, acridine, linked to the 3' end the previous nucleotide without a sugar group was tested. The results obtained support the conclusion that the aromatic ring of the base (at the 3' 5 end of the INVADER oligonucleotide) is an important moiety for accomplishing the direction of cleavage to the desired site within the downstream probe. The 3' terminal moiety of the INVADER oligonucleotide need not be a base that is complementary to the target nucleic acid.

ii) Miniprobes And Mid-Range Probes;

10 As discussed above, the INVADER oligonucleotide-directed cleavage assay may be performed using INVADER and probe oligonucleotides that have a length of about 13-25 nucleotides (typically 20-25 nucleotides). It is also contemplated that the oligonucleotides may themselves be composed of shorter oligonucleotide sequences that align along a target strand but that are not covalently linked. This is to say that there is a 15 nick in the sugar-phosphate backbone of the composite oligonucleotide, but that there is no disruption in the progression of base-paired nucleotides in the resulting duplex. When short strands of nucleic acid align contiguously along a longer strand the hybridization of each is stabilized by the hybridization of the neighboring fragments because the basepairs can stack along the helix as though the backbone was in fact uninterrupted. This 20 cooperativity of binding can give each segment a stability of interaction in excess of what would be expected for the segment hybridizing to the longer nucleic acid alone. One application of this observation has been to assemble primers for DNA sequencing, typically about 18 nucleotides long, from sets of three hexamer oligonucleotides that are designed to hybridize in this way (Kotler *et al.* Proc. Natl. Acad. Sci. USA 90:4241 25 [1993]). The resulting doubly-nicked primer can be extended enzymatically in reactions performed at temperatures that might be expected to disrupt the hybridization of hexamers, but not of 18-mers.

The use of composite or split oligonucleotides is applied with success in the INVADER-directed cleavage assay. For example, the probe oligonucleotide may be split 30 into two oligonucleotides that anneal in a contiguous and adjacent manner along a target

oligonucleotide such that the downstream oligonucleotide (analogous to the probe) is assembled from two smaller pieces: a short segment of 6-10 nts (termed the "miniprobe"), that is to be cleaved in the course of the detection reaction, and an oligonucleotide that hybridizes immediately downstream of the miniprobe (termed the 5 "stacker"), that serves to stabilize the hybridization of the probe. To form the cleavage structure, an upstream oligonucleotide (the INVADER oligonucleotide) is provided to direct the cleavage activity to the desired region of the miniprobe. Assembly of the probe from non-linked pieces of nucleic acid (*i.e.*, the miniprobe and the stacker) allows regions of sequences to be changed without requiring the re-synthesis of the entire proven 10 sequence, thus improving the cost and flexibility of the detection system. In addition, the use of unlinked composite oligonucleotides makes the system more stringent in its requirement of perfectly matched hybridization to achieve signal generation, allowing this to be used as a sensitive means of detecting mutations or changes in the target nucleic acid sequences.

15 In one embodiment, the methods of the present invention employ at least three oligonucleotides that interact with a target nucleic acid to form a cleavage structure for a structure-specific nuclease. More specifically, the cleavage structure comprises i) a target nucleic acid that may be either single-stranded or double-stranded (when a double-stranded target nucleic acid is employed, it may be rendered single-stranded, *e.g.*, by heating); ii) a first oligonucleotide, termed the "stacker," that defines a first region of the target nucleic acid sequence by being the complement of that region.; iii) a second oligonucleotide, termed the "miniprobe," that defines a second region of the target nucleic acid sequence by being the complement of that region ; iv) a third oligonucleotide, termed the "INVADER oligonucleotide," the 5' part of which defines a 20 third region of the same target nucleic acid sequence, adjacent to and downstream of the second target region, and the second or 3' part of which overlaps into the region defined by the second oligonucleotide As described above for embodiments that do not employ a stacker, the overlap region can represent a region where there is a physical, but not sequence, overlap between the INVADER and probe oligonucleotides.

In addition to the benefits cited above, the use of a composite design for the oligonucleotides that form the cleavage structure allows more latitude in the design of the reaction conditions for performing the INVADER-directed cleavage assay. When a longer probe (*e.g.*, 16-25 nt), as described above, is used for detection in reactions that

- 5 are performed at temperatures below the T_m of that probe, the cleavage of the probe may play a significant role in destabilizing the duplex of which it is a part, thus allowing turnover and reuse of the recognition site on the target nucleic acid. In contrast, reaction temperatures that are at or above the T_m of the probe mean that the probe molecules are hybridizing and releasing from the target quite rapidly even without cleavage of the
10 probe. When an upstream INVADER oligonucleotide and a cleavage agent are provided the probe will be specifically cleaved, but the cleavage will not be necessary to the turnover of the probe. When a long probe (*e.g.*, 16-25 nt) is used in this way the temperatures required to achieve this state is high, around 65 to 70°C for a 25-mer of average base composition. Requiring the use of such elevated temperatures limits the
15 choice of cleavage agents to those that are very thermostable, and may contribute to background in the reactions, depending of the means of detection, through thermal degradation of the probe oligonucleotides. With miniprobes, this latter mechanism of probe replacement may be accomplished at a lower temperature. Thus, shorter probes are preferred for embodiments using lower reaction temperatures.

- 20 The miniprobe of the present invention may vary in size depending on the desired application. In one embodiment, the probe may be relatively short compared to a standard probe (*e.g.*, 16-25 nt), in the range of 6 to 10 nucleotides. When such a short probe is used, reaction conditions can be chosen that prevent hybridization of the miniprobe in the absence of the stacker oligonucleotide. In this way a short probe can be
25 made to assume the statistical specificity and selectivity of a longer sequence. In the event of a perturbation in the cooperative binding of the miniprobe and stacker nucleic acids, as might be caused by a mismatch within the short sequence that is otherwise complementary to the target nucleic acid or at the junction between the contiguous duplexes, this cooperativity can be lost, dramatically reducing the stability of the shorter duplex (*i.e.*, that of the miniprobe), and thus reducing the level of cleaved product in the
30 assay of the present invention.

It is also contemplated that probes of intermediate size may be used. Such probes, in the 11 to 15 nucleotide range, may blend some of the features associated with the longer probes as originally described, these features including the ability to hybridize and be cleaved absent the help of a stacker oligonucleotide. At temperatures below the expected T_m of such probes, the mechanisms of turnover may be as discussed above for probes in the 20 nt range, and be dependent on the removal of the sequence in the overlap region for destabilization and cycling.

- The mid-range probes may also be used at elevated temperatures, at or above their expected T_m , to allow melting rather than cleavage to promote probe turnover. In contrast to the longer probes described above, however, the temperatures required to allow the use of such a thermally driven turnover are much lower (about 40 to 60°C), thus preserving both the cleavage means and the nucleic acids in the reaction from thermal degradation. In this way, the mid-range probes may perform in some instances like the miniprobes described above. In a further similarity to the miniprobes, the accumulation of cleavage signal from a mid-range probe may be helped under some reaction conditions by the presence of a stacker.

- To summarize, a standard long probe usually does not benefit from the presence of a stacker oligonucleotide downstream (the exception being cases where such an oligonucleotide may also disrupt structures in the target nucleic acid that interfere with the probe binding), and it may be used in conditions requiring several nucleotides to be removed to allow the oligonucleotide to release from the target efficiently. If temperature of the reaction is used to drive exchange of the probes, standard probes may require use of a temperature at which nucleic acids and enzymes are at higher risk of thermal degradation.

- The miniprobe is very short and performs optimally in the presence of a downstream stacker oligonucleotide. The miniprobes are well suited to reactions conditions that use the temperature of the reaction to drive rapid exchange of the probes on the target regardless of whether any bases have been cleaved. In reactions with sufficient amount of the cleavage means, the probes that do bind will be rapidly cleaved before they melt off.

The mid-range or midiprobe combines features of these probes and can be used in reactions like those favored by long probes, with longer regions of overlap to drive probe turnover at lower temperature. In a preferred embodiment, the midrange probes are used at temperatures sufficiently high that the probes are hybridizing to the target and

- 5 releasing rapidly regardless of cleavage. The mid-range probe may have enhanced performance in the presence of a stacker under some circumstances.

The distinctions between the mini-, midi- (*i.e.*, mid-range) and long probes are not contemplated to be inflexible and based only on length. The performance of any given probe may vary with its specific sequence, the choice of solution conditions, the choice of 10 temperature and the selected cleavage means.

The assemblage of oligonucleotides that comprises the cleavage structure of the present invention is sensitive to mismatches between the probe and the target. It is also contemplated that a mismatch between the INVADER oligonucleotide and the target may be used to distinguish related target sequences. In the 3-oligonucleotide system,

- 15 comprising an INVADER, a probe and a stacker oligonucleotide, it is contemplated that mismatches may be located within any of the regions of duplex formed between these oligonucleotides and the target sequence. In a preferred embodiment, a mismatch to be detected is located in the probe. In a particularly preferred embodiment, the mismatch is in the probe, at the basepair immediately upstream (*i.e.*, 5') of the site that is cleaved 20 when the probe is not mismatched to the target.

In another preferred embodiment, a mismatch to be detected is located within the region defined by the hybridization of a miniprobe. In a particularly preferred embodiment, the mismatch is in the miniprobe, at the basepair immediately upstream (*i.e.*, 5') of the site that is cleaved when the miniprobe is not mismatched to the target.

25 iii) Software for Oligonucleotide Design for the INVADER assay

The present invention provides systems and methods for the design of oligonucleotides for use in detection assays. In particular, the present invention provides systems and methods for the design of oligonucleotides that successfully hybridize to appropriate regions of target nucleic acids (*e.g.*, regions of target nucleic acids that do not 30 contain secondary structure) under the desired reaction conditions (*e.g.*, temperature,

buffer conditions, etc.) for the detection assay. The systems and methods also allow for the design of multiple different oligonucleotides (e.g., oligonucleotides that hybridize to different portions of a target nucleic acid or that hybridize to two or more different target nucleic acids) that all function in the detection assay under the same or substantially the

- 5 same reaction conditions. These systems and methods may also be used to design control samples that work under the experimental reaction conditions.

While the systems and methods of the present invention are not limited to any particular detection assay, the following description illustrates the invention when used in conjunction with the INVADER assay (Third Wave Technologies, Madison WI; See e.g.,

- 10 U.S. Pat. Nos. 5,846,717, 5,985,557, 5,994,069, and 6,001,567 and PCT Publications WO 97/27214 and WO 98/42873, incorporated herein by reference in their entireties) to detect a SNP. One skilled in the art will appreciate that specific and general features of this illustrative example are generally applicable to other detection assays, and for use in designing INVADER assays for purposes other than SNP detection (e.g., for DNA or
- 15 RNA quantitation, for RNA splice junction detection, etc.). Further, it will be appreciated that all algorithms described herein can be applied as separate software elements, or calculations may be performed manually, for the design of any INVADER assay probe set without use of the INVADERCREATOR design system described below.

Oligonucleotide Design for the INVADER assay using the

20 INVADERCREATOR program

In some embodiments where an oligonucleotide is designed for use in the INVADER assay to detect a SNP, the sequence(s) of interest are entered into the INVADERCREATOR program (Third Wave Technologies, Madison, WI). As described above, sequences may be input for analysis from any number of sources, either directly

- 25 into the computer hosting the INVADERCREATOR program, or via a remote computer linked through a communication network (e.g., a LAN, Intranet or Internet network). The program designs probes for both the sense and antisense strand. Strand selection is generally based upon the ease of synthesis, minimization of secondary structure formation, and manufacturability. In some embodiments, the user chooses the strand for sequences to be designed for. In other embodiments, the software automatically selects the strand. By incorporating thermodynamic parameters for optimum probe cycling and

signal generation (Allawi and SantaLucia, *Biochemistry*, 36:10581 [1997]), oligonucleotide probes may be designed to operate at a pre-selected assay temperature (e.g., 63°C). Based on these criteria, a final probe set (e.g., primary probes for 2 alleles and an INVADER oligonucleotide) is selected.

- 5 In some embodiments, the INVADERCREATOR system is a web-based program with secure site access that contains a link to BLAST (available at the National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health web site) and that can be linked to RNAstructure (Mathews *et al.*, *RNA* 5:1458 [1999]), a software program that incorporates mfold (Zuker, *Science*, 244:48 [1989]).
- 10 RNAstructure tests the proposed oligonucleotide designs generated by INVADERCREATOR for potential uni- and bimolecular complex formation. INVADERCREATOR is open database connectivity (ODBC)-compliant and uses the Oracle database for export/integration. The INVADERCREATOR system was configured with Oracle to work well with UNIX systems, as most genome centers are
- 15 UNIX-based.

- In some embodiments, the INVADERCREATOR analysis is provided on a separate server (e.g., a Sun server) so it can handle analysis of large batch jobs. For example, a customer can submit up to 2,000 SNP sequences in one email. The server passes the batch of sequences on to the INVADERCREATOR software, and, when initiated, the program designs SNP sets. In some embodiments, probe set designs are returned to the user within 24 hours of receipt of the sequences.

- In some preferred embodiments, each INVADER assay reaction includes at least two target sequence-specific, unlabeled oligonucleotides for the primary reaction: an upstream INVADER oligonucleotide and a downstream Probe oligonucleotide. The 25 INVADER oligonucleotide is generally designed to bind stably at the reaction temperature, while the probe is designed to freely associate and disassociate with the target strand, with cleavage occurring only when an uncut probe hybridizes adjacent to an overlapping INVADER oligonucleotide. In some embodiments, the probe includes a 5' flap or "arm" that is not complementary to the target, and this flap is released from the probe when cleavage occurs. In some embodiments, the released flap participates as an 30 INVADER oligonucleotide in a secondary reaction.

The following discussion provides one example of how a user interface for an INVADERCREATOR program may be configured.

- The user opens a work screen (Figure 42), *e.g.*, by clicking on an icon on a desktop display of a computer (*e.g.*, a Windows desktop). The user enters information related to the target sequence for which an assay is to be designed. In some embodiments, the user enters a target sequence. In other embodiments, the user enters a code or number that causes retrieval of a sequence from a database. In still other embodiments, additional information may be provided, such as the user's name, an identifying number associated with a target sequence, and/or an order number. In preferred embodiments, the user indicates (*e.g.* via a check box or drop down menu) that the target nucleic acid is DNA or RNA. In other preferred embodiments, the user indicates the species from which the nucleic acid is derived. In particularly preferred embodiments, the user indicates whether the design is for monoplex (*i.e.*, one target sequence or allele per reaction) or multiplex (*i.e.*, multiple target sequences or alleles per reaction) detection. When the requisite choices and entries are complete, the user starts the analysis process. In one embodiment, the user clicks a "Go Design It" button to continue.

- In some embodiments, the software validates the field entries before proceeding. In some embodiments, the software verifies that any required fields are completed with the appropriate type of information. In other embodiments, the software verifies that the input sequence meets selected requirements (*e.g.*, minimum or maximum length, DNA or RNA content). If entries in any field are not found to be valid, an error message or dialog box may appear. In preferred embodiments, the error message indicates which field is incomplete and/or incorrect. Once a sequence entry is verified, the software proceeds with the assay design.

- In some embodiments, the information supplied in the order entry fields specifies what type of design will be created. In preferred embodiments, the target sequence and multiplex check box specify which type of design to create. Design options include but are not limited to SNP assay, Multiplexed SNP assay (*e.g.*, wherein probe sets for different alleles are to be combined in a single reaction), Multiple SNP assay (*e.g.*,

wherein an input sequence has multiple sites of variation for which probe sets are to be designed), and Multiple Probe Arm assays.

In some embodiments, the INVADERCREATOR software is started via a Web Order Entry (WebOE) process (*i.e.*, through an Intra/Internet browser interface) and these parameters are transferred from the WebOE via applet <param> tags, rather than entered through menus or check boxes.

5 In the case of Multiple SNP Designs, the user chooses two or more designs to work with. In some embodiments, this selection opens a new screen view (*e.g.*, a Multiple SNP Design Selection view Figure 43). In some embodiments, the software creates designs for each locus in the target sequence, scoring each, and presents them to the user in this screen view. The user can then choose any two designs to work with. In some embodiments, the user chooses a first and second design (*e.g.*, via a menu or buttons) and clicks a "Go Design It" button to continue.

10 To select a probe sequence that will perform optimally at a pre-selected reaction temperature, the melting temperature (T_m) of the SNP to be detected is calculated using the nearest-neighbor model and published parameters for DNA duplex formation (Allawi and SantaLucia, Biochemistry, 36:10581 [1997]). In embodiments wherein the target strand is RNA, parameters appropriate for RNA/DNA heteroduplex formation may be used. Because the assay's salt concentrations are often different than the solution 15 conditions in which the nearest-neighbor parameters were obtained (1M NaCl and no divalent metals), and because the presence and concentration of the enzyme influence optimal reaction temperature, an adjustment should be made to the calculated T_m to determine the optimal temperature at which to perform a reaction. One way of compensating for these factors is to vary the value provided for the salt concentration 20 within the melting temperature calculations. This adjustment is termed a 'salt correction'. As used herein, the term "salt correction" refers to a variation made in the value provided for a salt concentration for the purpose of reflecting the effect on a T_m calculation for a nucleic acid duplex of a non-salt parameter or condition affecting said duplex. Variation 25 of the values provided for the strand concentrations will also affect the outcome of these calculations. By using a value of 0.5 M NaCl (SantaLucia, Proc Natl Acad Sci U S A, 95:1460 [1998]) and strand concentrations of about 1 mM of the probe and 1 fM target,

the algorithm used for calculating probe-target melting temperature has been adapted for use in predicting optimal INVADER assay reaction temperature. For a set of 30 probes, the average deviation between optimal assay temperatures calculated by this method and those experimentally determined is about 1.5 °C.

- 5 The length of the downstream probe analyte-specific region (ASR) is defined by the temperature selected for running the reaction (e.g., 63°C). Starting from the position of the variant nucleotide on the target DNA (the target base that is paired to the probe nucleotide 5' of the intended cleavage site), and adding on the 3' end, an iterative procedure is used by which the length of the target-binding region of the probe is
- 10 increased by one base pair at a time until a calculated optimal reaction temperature (T_m plus salt correction to compensate for enzyme effect) matching the desired reaction temperature is reached. The non-complementary arm of the probe is preferably selected to allow the secondary reaction to cycle at the same reaction temperature. The entire probe oligonucleotide is screened using programs such as *mfold* (Zuker, Science, 244: 48
- 15 [1989]) or Oligo 5.0 (Rychlik and Rhoads, Nucleic Acids Res, 17: 8543 [1989]) for the possible formation of dimer complexes or secondary structures that could interfere with the reaction. The same principles are also followed for INVADER oligonucleotide design. Briefly, starting from the position N on the target DNA, the 3' end of the INVADER oligonucleotide is designed to have a nucleotide not complementary to either
- 20 allele suspected of being contained in the sample to be tested. The mismatch does not adversely affect cleavage (Lyamichev *et al.*, Nature Biotechnology, 17: 292 [1999]), and it can enhance probe cycling, presumably by minimizing coaxial stabilization effects between the two probes. Additional residues complementary to the target DNA starting from residue N-1 are then added in the 5' direction until the stability of the
- 25 INVADER oligonucleotide-target hybrid exceeds that of the probe (and therefore the planned assay reaction temperature), generally by 15-20 °C.

In some embodiments, the released cleavage fragment from a primary reaction is to be used in a secondary reaction. It is one aspect of the assay design that all of the probe sequences may be selected to allow the primary and secondary reactions to occur at the same optimal temperature, so that the reaction steps can run simultaneously. In an alternative embodiment, the probes may be designed to operate at different optimal

temperatures, so that the reaction steps are not simultaneously at their temperature optima.

- In some embodiments, the software provides the user an opportunity to change various aspects of the design including but not limited to: probe, target and INVADER 5 oligonucleotide temperature optima and concentrations; blocking groups; probe arms; dyes, capping groups and other adducts; individual bases of the probes and targets (e.g., adding or deleting bases from the end of targets and/or probes, or changing internal bases in the INVADER and/or probe and/or target oligonucleotides). In some embodiments, changes are made by selection from a menu. In other embodiments, changes are entered 10 into text or dialog boxes. In preferred embodiments, this option opens a new screen (e.g., a Designer Worksheet view, Figure 44).

- In some embodiments, the software provides a scoring system to indicate the quality (e.g., the likelihood of performance) of the assay designs. In one embodiment, the scoring system includes a starting score of points (e.g., 100 points) wherein the 15 starting score is indicative of an ideal design, and wherein design features known or suspected to have an adverse affect on assay performance are assigned penalty values. Penalty values may vary depending on assay parameters other than the sequences, including but not limited to the type of assay for which the design is intended (e.g., monoplex, multiplex) and the temperature at which the assay reaction will be performed. 20 The following example provides illustrative scoring criteria for use with some embodiments of the INVADER assay based on an intelligence defined by experimentation. Examples of design features that may incur score penalties include but are not limited to the following [penalty values are indicated in brackets, first number is for lower temperature assays (e.g., 62-64 °C), second is for higher temperature assays 25 (e.g., 65-66 °C)]:

1. [100:100] 3' end of INVADER oligonucleotide resembles the probe arm:

	ARM SEQUENCE:	PENALTY AWARDED IF INVADER
	OLIGONUCLEOTIDE ENDS IN:	
30	Arm 1: CGCGCCGAGG	5'...GAGGX or 5'...GAGGXX
	Arm 2: ATGACGTGGCAGAC	5'...CAGACX or 5'...CAGACXX

Arm 3: ACGGACGCGGAG

5'...GGAGX or 5'...GGAGXX

Arm 4: TCCGCCCGTCC

5'...GTCCX or 5'...GTCCXX

2. [70:70] a probe has 5-base stretch (*i.e.*, 5 of the same base in a row) containing the polymorphism;

- 5 3. [60:60] a probe has 5-base stretch adjacent to the polymorphism;
4. [50:50] a probe has 5-base stretch one base from the polymorphism;
5. [40:40] a probe has 5-base stretch two bases from the polymorphism;
6. [50:50] probe 5-base stretch is of Gs – additional penalty;
7. [100:100] a probe has 6-base stretch anywhere;
- 10 8. [90:90] a two or three base sequence repeats at least four times;
9. [100:100] a degenerate base occurs in a probe;
10. [60:90] probe hybridizing region is short (13 bases or less for designs 65-67°C; 12 bases or less for designs 62-64°C)
11. [40:90] probe hybridizing region is long (29 bases or more for designs 65-67°C, 28 bases or more for designs 62-64°C)
12. [5:5] probe hybridizing region length – per base additional penalty
13. [80:80] Ins/Del design with poor discrimination in first 3 bases after probe arm
14. [100:100] calculated INVADER oligonucleotide Tm within 7.5°C of probe target Tm (designs 65-67°C with INVADER oligonucleotide less than ≤ 70.5°C, designs 62-64°C with INVADER oligonucleotide ≤ 69.5°C)
- 20 15. [20:20] calculated probes Tms differ by more than 2.0°C
16. [100:100] a probe has calculated Tm 2°C less than its target Tm
17. [10:10] target of one strand 8 bases longer than that of other strand
18. [30:30] INVADER oligonucleotide has 6-base stretch anywhere – initial penalty
- 25 19. [70:70] INVADER oligonucleotide 6-base stretch is of Gs - additional penalty
20. [15:15] probe hybridizing region is 14, 15 or 24-28 bases long (65-67°C) or 13,14 or 26,27 bases long (62-64°C)
21. [15:15] a probe has a 4-base stretch of Gs containing the polymorphism

30 In particularly preferred embodiments, temperatures for each of the oligonucleotides in the designs are recomputed and scores are recomputed as changes are

made. In some embodiments, score descriptions can be seen by clicking a "descriptions" button. In some embodiments, a BLAST search option is provided. In preferred embodiments, a BLAST search is done by clicking a "BLAST Design" button. In some embodiments, this action brings up a dialog box describing the BLAST process. In

- 5 preferred embodiments, the BLAST search results are displayed as a highlighted design on a Designer Worksheet.

In some embodiments, a user accepts a design by clicking an "Accept" button. In other embodiments, the program approves a design without user intervention. In preferred embodiments, the program sends the approved design to a next process step

- 10 (e.g., into production; into a file or database). In some embodiments, the program provides a screen view (e.g., an Output Page, Figure 45), allowing review of the final designs created and allowing notes to be attached to the design. In preferred embodiments, the user can return to the Designer Worksheet (e.g., by clicking a "Go Back" button) or can save the design (e.g., by clicking a "Save It" button) and continue
15 (e.g., to submit the designed oligonucleotides for production).

In some embodiments, the program provides an option to create a screen view of a design optimized for printing (e.g., a text-only view) or other export (e.g., an Output view, Figure 46). In preferred embodiments, the Output view provides a description of the design particularly suitable for printing, or for exporting into another application (e.g.,
20 by copying and pasting into another application). In particularly preferred embodiments, the Output view opens in a separate window.

The present invention is not limited to the use of the INVADERCREATOR software. Indeed, a variety of software programs are contemplated and are commercially available, including, but not limited to GCG Wisconsin Package (Genetics computer
25 Group, Madison, WI) and Vector NTI (Informax, Rockville, Maryland).

b) **Design Of The Reaction Conditions**

Target nucleic acids (e.g., RNA and DNA) that may be analyzed using the methods of the present invention that employ a 5' nuclease or other appropriate cleavage agents. Such nucleic acids may be obtained using standard molecular biological techniques. For example, nucleic acids (RNA or DNA) may be isolated from a tissue
30

sample (e.g., a biopsy specimen), tissue culture cells, samples containing bacteria and/or viruses (including cultures of bacteria and/or viruses), etc. The target nucleic acid may also be transcribed *in vitro* from a DNA template or may be chemically synthesized or amplified by polymerase chain reaction. Furthermore, nucleic acids may be isolated
5 from an organism, either as genomic material or as a plasmid or similar extrachromosomal DNA, or they may be a fragment of such material generated by treatment with a restriction endonuclease or other cleavage agent, or a shearing force, or it may be synthetic.

Assembly of the target, probe, and INVADER oligonucleotide nucleic acids into
10 the cleavage reaction of the present invention uses principles commonly used in the design of oligonucleotide-based enzymatic assays, such as dideoxynucleotide sequencing and polymerase chain reaction (PCR). As is done in these assays, the oligonucleotides are provided in sufficient excess that the rate of hybridization to the target nucleic acid is very rapid. These assays are commonly performed with 50 fmols to 2 pmoles of each
15 oligonucleotide per microliter of reaction mixture, although they are not necessarily limited to this range. In the Examples described herein, amounts of oligonucleotides ranging from 250 fmols to 5 pmols per microliter of reaction volume were used. These values were chosen for the purpose of ease in demonstration and are not intended to limit the performance of the present invention to these concentrations. Other (e.g., lower)
20 oligonucleotide concentrations commonly used in other molecular biological reactions are also contemplated.

It is desirable that an INVADER oligonucleotide be immediately available to direct the cleavage of each probe oligonucleotide that hybridizes to a target nucleic acid. In some embodiments described herein, the INVADER oligonucleotide is provided in
25 excess over the probe oligonucleotide. While this is an effective means of making the INVADER oligonucleotide immediately available in such embodiments it is not intended that the practice of the present invention be limited to conditions wherein the INVADER oligonucleotide is in excess over the probe, or to any particular ratio of INVADER-to-probe (e.g., in some preferred embodiments described herein, the probe is provided in
30 excess over the INVADER oligonucleotide). Another means of assuring the presence of an INVADER oligonucleotide whenever a probe binds to a target nucleic acid is to

design the INVADER oligonucleotide to hybridize more stably to the target, *i.e.*, to have a higher T_m than the probe. This can be accomplished by any of the means of increasing nucleic acid duplex stability discussed herein (*e.g.*, by increasing the amount of complementarity to the target nucleic acid).

- 5 Buffer conditions should be chosen that are compatible with both the oligonucleotide/target hybridization and with the activity of the cleavage agent. The optimal buffer conditions for nucleic acid modification enzymes, and particularly DNA modification enzymes, generally included enough mono- and di-valent salts to allow association of nucleic acid strands by base-pairing. If the method of the present invention
10 is performed using an enzymatic cleavage agent other than those specifically described here, the reactions may generally be performed in any such buffer reported to be optimal for the nuclease function of the cleavage agent. In general, to test the utility of any cleavage agent in this method, test reactions are performed wherein the cleavage agent of interest is tested in the MOPS/MnCl₂/KCl buffer or Mg-containing buffers described
15 herein and in whatever buffer has been reported to be suitable for use with that agent, in a manufacturer's data sheet, a journal article, or in personal communication.

The products of the INVADER oligonucleotide-directed cleavage reaction are fragments generated by structure-specific cleavage of the input oligonucleotides. The resulting cleaved and/or uncleaved oligonucleotides may be analyzed and resolved by a number of methods including, but not limited to, electrophoresis (on a variety of supports including acrylamide or agarose gels, paper, etc.), chromatography, fluorescence polarization, mass spectrometry and chip hybridization. In some Examples the invention is illustrated using electrophoretic separation for the analysis of the products of the cleavage reactions. However, it is noted that the resolution of the cleavage products is not limited to electrophoresis. Electrophoresis is chosen to illustrate the method of the invention because electrophoresis is widely practiced in the art and is easily accessible to the average practitioner. In other Examples, the invention is illustrated without electrophoresis or any other resolution of the cleavage products.

The probe and INVADER oligonucleotides may contain a label to aid in their detection following the cleavage reaction. The label may be a radioisotope (*e.g.*, a ³²P or ³⁵S-labelled nucleotide) placed at either the 5' or 3' end of the oligonucleotide or

alternatively, the label may be distributed throughout the oligonucleotide (i.e., a uniformly labeled oligonucleotide). The label may be a nonisotopic detectable moiety, such as a fluorophore, that can be detected directly, or a reactive group that permits specific recognition by a secondary agent. For example, biotinylated oligonucleotides

- 5 may be detected by probing with a streptavidin molecule that is coupled to an indicator (e.g., alkaline phosphatase or a fluorophore) or a hapten such as dioxigenin may be detected using a specific antibody coupled to a similar indicator. The reactive group may also be a specific configuration or sequence of nucleotides that can bind or otherwise interact with a secondary agent, such as another nucleic acid, and enzyme, or an antibody.
- 10 In some embodiments, a probe is labeled with fluorescing moiety and a quenching moiety, wherein cleavage of the cleavage structure separates the fluorescing moiety from the quenching moiety, resulting in a detectable signal (e.g., FRET detection). In some embodiments, a change in quenching of signal from a donor fluorophor is detected, while in other embodiments, a change in emission from an acceptor fluorophore is detected. In
- 15 still other embodiments, the effect of FRET on both donor and acceptor emissions are detected.

In some embodiments of FRET detection, the fluorescence lifetime of the fluorescence emitter is measured (e.g., as in time-resolved fluorescence). While not limiting time-resolved fluorescence detection embodiments to any particular labeling systems,

- 20 examples of tags that are useful in time-resolved FRET measurements include europium chelate (Eu^{3+} ; Biosclair, *et al.*, J. Biomolecular Screening 5(5):319 [2000]), europium trisbipyridine cryptate (TBPEu $^{3+}$; Alpha-Bazin, *et al.*, Anal. Biochem. 286(1):17 [2000]), and ruthenium ligand complex {[Ru(bpy) $_2$ (phen-ITC) $^{2+}$; Youn, *et al.*, Anal. Biochem. 232(1):24 [1995]; Lakowicz, *et al.*, Anal. Biochem. 288:62 [2001]).

25 c) **Optimization Of Reaction Conditions**

The INVADER oligonucleotide-directed cleavage reaction is useful to detect the presence of specific nucleic acids. In addition to the considerations listed above for the selection and design of the INVADER and probe oligonucleotides, the conditions under which the reaction is to be performed may be optimized for detection of a specific target sequence.

One objective in optimizing the INVADER oligonucleotide-directed cleavage assay is to allow specific detection of the fewest copies of a target nucleic acid. To achieve this end, it is desirable that the combined elements of the reaction interact with the maximum efficiency, so that the rate of the reaction (e.g., the number of cleavage events per minute) is maximized. Elements contributing to the overall efficiency of the reaction include the rate of hybridization, the rate of cleavage, and the efficiency of the release of the cleaved probe.

- The rate of cleavage will be a function of the cleavage means chosen, and may be made optimal according to the manufacturer's instructions when using commercial preparations of enzymes or as described in the examples herein. The other elements (rate of hybridization, efficiency of release) depend upon the execution of the reaction, and optimization of these elements is discussed below.

- Three elements of the cleavage reaction that significantly affect the rate of nucleic acid hybridization are the concentration of the nucleic acids, the temperature at which the cleavage reaction is performed and the concentration of salts and/or other charge-shielding ions in the reaction solution.

- The concentrations at which oligonucleotide probes are used in assays of this type are well known in the art, and are discussed above. One example of a common approach to optimizing an oligonucleotide concentration is to choose a starting amount of oligonucleotide for pilot tests; 0.01 to 2 μ M is a concentration range used in many oligonucleotide-based assays. When initial cleavage reactions are performed, the following questions may be asked of the data: Is the reaction performed in the absence of the target nucleic acid substantially free of the cleavage product?; Is the site of cleavage specifically positioned in accordance with the design of the INVADER oligonucleotide?; Is the specific cleavage product easily detected in the presence of the uncleaved probe (or is the amount of uncut material overwhelming the chosen visualization method)?

- A negative answer to any of these questions would suggest that the probe concentration is too high, and that a set of reactions using serial dilutions of the probe should be performed until the appropriate amount is identified. Once identified for a given target nucleic acid in a give sample type (e.g., purified genomic DNA, body fluid extract, lysed bacterial extract), it should not need to be re-optimized. The sample type is

important because the complexity of the material present may influence the probe concentration optimum.

Conversely, if the chosen initial probe concentration is too low, the reaction may be slow, due to inefficient hybridization. Tests with increasing quantities of the probe

- 5 will identify the point at which the concentration exceeds the optimum (e.g., at which it produces an undesirable effect, such as background cleavage not dependent on the target sequence, or interference with detection of the cleaved products). Since the hybridization will be facilitated by excess of probe, it is desirable, but not required, that the reaction be performed using probe concentrations just below this point.

10 The concentration of INVADER oligonucleotide can be chosen based on the design considerations discussed above. In some embodiments, the INVADER oligonucleotide is in excess of the probe oligonucleotide. In a preferred embodiment, the probe oligonucleotide is in excess of the INVADER oligonucleotide.

Temperature is also an important factor in the hybridization of oligonucleotides.

15 The range of temperature tested will depend in large part on the design of the oligonucleotides, as discussed above. Where it is desired to have a reaction be run at a particular temperature (e.g., because of an enzyme requirement, for convenience, for compatibility with assay or detection apparatuses, etc.), the oligonucleotides that function in the reaction can be designed to optimally perform at the desired reaction temperature.

20 Each INVADER reaction includes at least two target sequence-specific oligonucleotides for the primary reaction: an upstream INVADER oligonucleotide and a downstream probe oligonucleotide. In some preferred embodiments, the INVADER oligonucleotide is designed to bind stably at the reaction temperature, while the probe is designed to freely associate and disassociate with the target strand, with cleavage occurring only

25 when an uncut probe hybridizes adjacent to an overlapping INVADER oligonucleotide. In preferred embodiments, the probe includes a 5' flap that is not complementary to the target, and this flap is released from the probe when cleavage occurs. The released flap can be detected directly or indirectly. In some preferred embodiments, as discussed in detail below, the released flap participate as in INVADER oligonucleotide in a secondary

- 30 reaction.

Optimum conditions for the INVADER assay are generally those that allow specific detection of the smallest amount of a target nucleic acid. Such conditions may be characterized as those that yield the highest target-dependent signal in a given timeframe, or for a given amount of target nucleic acid, or that allow the highest rate of probe cleavage (*i.e.*, probes cleaved per minute).

- As noted above, the concentration of the cleavage agent can affect the actual optimum temperature for a cleavage reaction. Additionally, different cleavage agents, even if used at identical concentrations, can affect reaction temperature optima differently (*e.g.*, the difference between the calculated probe T_m and the observed optimal reaction 10 temperature may be greater for one enzyme than for another). Determination of appropriate salt corrections for reactions using different enzymes or concentrations of enzymes, or for any other variation made in reaction conditions, involves a two step process of a) measuring reaction temperature optima under the new reaction conditions, and varying the salt concentration within the T_m algorithm to produce a calculated 15 temperature matching or closely approximating the observed optima. Measurement of an optimum reaction temperature generally involves performing reactions at a range of temperatures selected such that the range allows observation of an increase in performance as an optimal temperature is approached (either by increasing or decreasing temperatures), and a decrease in performance when an optimal temperature has been 20 passed, thereby allowing identification of the optimal temperature or temperature range (See *e.g.*, Lyamichev, et al., Biochemistry 39: 9523 [2000]).

In some embodiments, a secondary reaction is used where the released cleavage fragment from a primary reaction hybridizes to a synthetic cassette to form a secondary cleavage reaction. In some preferred embodiments, the cassette comprises a fluorescing 25 moiety and a quenching moiety, wherein cleavage of the secondary cleavage structure separates the fluorescing moiety from the quenching moiety, resulting in a detectable signal (*e.g.*, FRET detection). The secondary reaction can be configured a number of different ways. For example, in some embodiments, the synthetic cassette comprises two oligonucleotides: an oligonucleotide that contains the FRET moieties and a 30 FRET/INVADER oligonucleotide bridging oligonucleotide that allows the INVADER oligonucleotide (*i.e.*, the released flap from the primary reaction) and the FRET

oligonucleotide to hybridize thereto, such that a cleavage structure is formed. In some embodiments, the synthetic cassette is provided as a single oligonucleotide, comprising a hairpin structure (i.e., the FRET oligonucleotide is connected at its 3' end to the bridging oligonucleotide by a loop). The loop may be nucleic acid, or a non-nucleic acid spacer or

- 5 linker. The linked molecules may together be described as a FRET cassette. In the secondary reaction using a FRET cassette the released flap from the primary reaction, which acts as an INVADER oligonucleotide, should be able to associate and disassociate with the FRET cassette freely, so that one released flap can direct the cleavage of multiple FRET cassettes. It is one aspect of the assay design that all of the probe
10 sequences may be selected to allow the primary and secondary reactions to occur at the same optimal temperature, so that the reaction steps can run simultaneously. In an alternative embodiment, the probes may be designed to operate at different optimal temperatures, so that the reaction steps are not simultaneously at their temperature optima. As noted above, the same iterative process used to select the ASR of the probe
15 can be used in the design of the portion of the primary probe that participates in a secondary reaction.

Another determinant of hybridization efficiency is the salt concentration of the reaction. In large part, the choice of solution conditions will depend on the requirements of the cleavage agent, and for reagents obtained commercially, the manufacturer's

- 20 instructions are a resource for this information. When developing an assay utilizing any particular cleavage agent, the oligonucleotide and temperature optimizations described above should be performed in the buffer conditions best suited to that cleavage agent.

- In some embodiments, additional agents may be included in reaction mixtures to enhance assay performance. For example, charged compounds such as aminoglycosides
25 and other polyamines have been used to modulate DNA and RNA conformation and function (see, e.g., Earnshaw and Gait, Nucl. Acids Res. 26:5551 [1998]; Robinson and Wang, Nucl. Acids Res. 24:676 [1996]; Jerinie, J. Mol. Biol. 304(5):707 [2000]; Schroeder *et al.*, EMBO 19(1):1 [2000]). Inclusion of the aminoglycoside antibiotic neomycin sulfate (e.g., at 1 μ M in a primary reaction) can enhance assay performance by,
30 e.g., reducing background signal, and therefore reducing the limit of detection of a particular INVADER assay probe set. Compounds of this type that may find use in

INVADER assay reactions include, but are not limited to, aminoglycosides, oligomerized aminoglycosides, and aminoglycoside bioconjugates, and other polyanions including, but not limited to, spermine and hexaamine cobalt.

- A "no enzyme" control allows the assessment of the stability of the labeled oligonucleotides under particular reaction conditions, or in the presence of the sample to be tested e.g., in assessing the sample for contaminating nucleases). In this manner, the substrate and oligonucleotides are placed in a tube containing all reaction components, except the enzyme and treated the same as the enzyme-containing reactions. Other controls may also be included. For example, a reaction with all of the components except the target nucleic acid will serve to confirm the dependence of the cleavage on the presence of the target sequence.

d) Selection of a Cleavage Agent

- As demonstrated in a number of the Examples, some 5' nucleases do not require an upstream oligonucleotide to be active in a cleavage reaction. Although cleavage may be slower without the upstream oligonucleotide, it may still occur (Lyamichev et al., Science 260:778 [1993], Kaiser et al., J. Biol. Chem., 274:21387 [1999]). When a DNA strand is the template or target strand to which probe oligonucleotides are hybridized, the 5' nucleases derived from DNA polymerases and some flap endonucleases (FENs), such as that from *Methanococcus jannaschii*, can cleave quite well without an upstream oligonucleotide providing an overlap (Lyamichev et al., Science 260:778 [1993], Kaiser et al., J. Biol. Chem., 274:21387 [1999], and US Patent No. 5,843,669, herein incorporated by reference in its entirety). These nucleases may be selected for use in some embodiments of the INVADER assay, e.g., in embodiments wherein cleavage of the probe in the absence of an INVADER oligonucleotide gives a different cleavage product, which does not interfere with the intended analysis, or wherein both types of cleavage, INVADER oligonucleotide-directed and INVADER oligonucleotide-independent, are intended to occur.

In other embodiments it is preferred that cleavage of the probe be dependent on the presence of an upstream INVADER oligonucleotide, and enzyme having this requirement would be used. Other FENs, such as those from *Archaeoglobus fulgidus*

(Afu) and *Pyrococcus furiosus* (Pfu), cleave an overlapped structure on a DNA target at so much greater a rate than they do a non-overlapping structure (*i.e.*, either missing the upstream oligonucleotide or having a non-overlapping upstream oligonucleotide) that they can be viewed as having an essentially absolute requirement for the overlap

- 5 (Lyamichev et al., Nat. Biotechnol., 17:292 [1999], Kaiser et al., J. Biol. Chem., 274:21387 [1999]). When an RNA target is hybridized to DNA oligonucleotide probes to form a cleavage structure, many FENs cleave the downstream DNA probe poorly, regardless of the presence of an overlap. On such an RNA-containing structure, the 5' nucleases derived from DNA polymerases have a strong requirement for the overlap, and
10 are essentially inactive in its absence. The selection of enzymes for use in the detection of RNA targets is discussed in more detail below, in Section IV: Improved Enzymes For Use In INVADER Oligonucleotide-Directed Cleavage Reactions Comprising RNA Targets.

e) **Probing For Multiple Alleles**

- 15 The INVADER oligonucleotide-directed cleavage reaction is also useful in the detection and quantification of individual variants or alleles in a mixed sample population. By way of example, such a need exists in the analysis of tumor material for mutations in genes associated with cancers. Biopsy material from a tumor can have a significant complement of normal cells, so it is desirable to detect mutations even when
20 present in fewer than 5% of the copies of the target nucleic acid in a sample. In this case, it is also desirable to measure what fraction of the population carries the mutation. Similar analyses may also be done to examine allelic variation in other gene systems, and it is not intended that the method of the present invention be limited to the analysis of tumors.

- 25 As demonstrated below, in one embodiment, reactions can be performed under conditions that prevent the cleavage of probes bearing even a single-nucleotide difference mismatch, but that permit cleavage of a similar probe that is completely complementary to the target in this region. In a preferred embodiment, a mismatch is positioned at the

nucleotide in the probe that is 5' of the site where cleavage occurs in the absence of the mismatch.

In other embodiments, the INVADER assay may be performed under conditions that have a tight requirement for an overlap (e.g., using the Afu FEN for DNA target

- 5 detection or the 5' nuclease of DNA polymerase for RNA target detection, as described above), providing an alternative means of detecting single nucleotide or other sequence variations. In one embodiment, the probe is selected such that the target base suspected of varying is positioned at the 5' end of the target-complementary region of this probe. The upstream INVADER oligonucleotide is positioned to provide a single base of
10 overlap. If the target and the probe oligonucleotide are complementary at the base in question, the overlap forms and cleavage can occur. However, if the target does not complement the probe at this position, that base in the probe becomes part of a non-complementary 5' arm, no overlap between the INVADER oligonucleotide and probe oligonucleotide exists, and cleavage is suppressed.

- 15 It is also contemplated that different sequences may be detected in a single reaction. Probes specific for the different sequences may be differently labeled. For example, the probes may have different dyes or other detectable moieties, different lengths, or they may have differences in net charges of the products after cleavage. When differently labeled in one of these ways, the contribution of each specific target sequence
20 to final product can be tallied. This has application in detecting the quantities of different versions of a gene within a mixture. Different genes in a mixture to be detected and quantified may be wild type and mutant genes (e.g., as may be found in a tumor sample, such as a biopsy). In this embodiment, one might design the probes to precisely the same site, but one to match the wild-type sequence and one to match the mutant. Quantitative
25 detection of the products of cleavage from a reaction performed for a set amount of time will reveal the ratio of the two genes in the mixture. Such analysis may also be performed on unrelated genes in a mixture. This type of analysis is not intended to be limited to two genes. Many variants within a mixture may be similarly measured.

- Alternatively, different sites on a single gene may be monitored and quantified to
30 verify the measurement of that gene. In this embodiment, the signal from each probe would be expected to be the same.

It is also contemplated that multiple probes may be used that are not differently labeled, such that the aggregate signal is measured. This may be desirable when using many probes designed to detect a single gene to boost the signal from that gene. This configuration may also be used for detecting unrelated sequences within a mix. For 5 example, in blood banking it is desirable to know if any one of a host of infectious agents is present in a sample of blood. Because the blood is discarded regardless of which agent is present, different signals on the probes would not be required in such an application of the present invention, and may actually be undesirable for reasons of confidentiality.

Just as described for the two-oligonucleotide system, above, the specificity of the 10 detection reaction will be influenced by the aggregate length of the target nucleic acid sequences involved in the hybridization of the complete set of the detection oligonucleotides. For example, there may be applications in which it is desirable to detect a single region within a complex genome. In such a case the set of oligonucleotides may be chosen to require accurate recognition by hybridization of a 15 longer segment of a target nucleic acid, often in the range of 20 to 40 nucleotides. In other instances it may be desirable to have the set of oligonucleotides interact with multiple sites within a target sample. In these cases one approach would be to use a set of oligonucleotides that recognize a smaller, and thus statistically more common, segment of target nucleic acid sequence.

20 In one preferred embodiment, the INVADER and stacker oligonucleotides may be designed to be maximally stable, so that they will remain bound to the target sequence for extended periods during the reaction. This may be accomplished through any one of a number of measures well known to those skilled in the art, such as adding extra hybridizing sequences to the length of the oligonucleotide (up to about 50 nts in total 25 length), or by using residues with reduced negative charge, such as phosphorothioates or peptide-nucleic acid residues, so that the complementary strands do not repel each other to degree that natural strands do. Such modifications may also serve to make these flanking oligonucleotides resistant to contaminating nucleases, thus further ensuring their continued presence on the target strand during the course of the reaction. In addition, the 30 INVADER and stacker oligonucleotides may be covalently attached to the target (e.g., through the use of psoralen cross-linking).

f) Applications for pooled DNA and RNA samples

In some embodiments, the present invention provides methods and kits for assaying a pooled sample using INVADER detection reagents (e.g. primary probe, INVADER probe, and FRET cassette). In some preferred embodiments, the kit

- 5 comprises instructions on how to perform the INVADER assay and specifically how to apply the INVADER detection assay to pooled samples from many individuals, or to "pooled" samples from many cells (e.g. from a biopsy sample) from a single subject.

In particular embodiments, the present invention allows detection of polymorphisms in pooled samples combined from many individuals in a population (e.g.

- 10, 50, 100, or 500 individuals), or from a single subject where the nucleic acid sequences are from a large number of cells that are assayed at once. In this regard, the present invention allows the frequency of rare mutations in pooled samples to be detected and an allele frequency for the population established. In some embodiments, this allele frequency may then be used to statistically analyze the results of applying the INVADER
15 detection assay to an individual's frequency for the polymorphism (e.g. determined using the INVADER assay). In this regard, mutations that rely on a percent of mutants found (e.g. loss of heterozygosity mutations) may be analyzed, and the severity of disease or progression of a disease determined (See, e.g. US Patent 6,146,828 and 6,203,993 to Lapidus, hereby incorporated by reference for all purposes, where genetic testing and
20 statistical analysis are employed to find disease causing mutations or identify a patient sample as containing a disease causing mutations).

In some embodiments of the present invention, broad population screens are performed. In some preferred embodiments, pooling DNA from several hundred or a thousand individuals is optimal. In such a pool, for example, DNA from any one

- 25 individual would not be detectable, and any detectable signal would provide a measure of frequency of the detected allele in a broader population. The amount of DNA to be used, for example, would be set not by the number of individuals in a pool, but rather by the allele frequency to be detected. For example, in some embodiments, an assay gives ample signal from 20 to 40 ng of DNA in a 90 minute reaction. At this level of
30 sensitivity, analysis of 1 µg of DNA from a high-complexity pool would produce comparable signal from alleles present in only about 3-5% of the population.

g) Applications of RNA detection.

RNA quantitation is becoming increasingly important in basic, pharmaceutical, and clinical research. For example, quantitation of viral RNAs can predict disease progression and therapeutic efficacy. Likewise, gene expression analysis of diseased vs. normal, or untreated vs. treated, tissue can identify relevant biological responses or assess the effects of pharmacological agents. As the focus of the Human Genome Project moves toward gene expression analysis, the field will require a flexible RNA analysis technology that can quantitatively monitor multiple forms of alternatively transcribed and/or processed RNAs.

As described above for the detection of multiple alleles, multiplex formats of the RNA INVADER assay enable simultaneous expression analysis of two or more genes within the same sample. In a primary reaction, one-nucleotide overlap-substrates are generated by the hybridization of INVADER oligonucleotides and probe oligonucleotides 15 to their respective RNA targets. Each probe contains a specific, target-complementary region and a distinctive non-complementary 5' flap that is associated only with that specific mRNA in that assay. The distinctive flaps may be distinguished in any of the myriad ways disclosed herein (*e.g.*, with different labels, different secondary cleavage systems having different labels, specific antibodies, different sizes when resolved, 20 different sequences detected by hybridization in solution or on surfaces, etc.)

While the RNA invasive cleavage assay, like the method used for DNA detection described above, can use two invasive cleavage reactions in sequence (described below, in Section II of the Detailed Description of the Invention), its preference for the 5' nucleases derived from DNA polymerases (described in detail in Section IV of the 25 Detailed Description of the Invention) indicates that additional format changes are preferred. Unlike the FEN 5' nucleases generally used for detection of DNA targets, optimal signal amplification with the DNA Pol-related 5' nucleases occurs only when a probe turnover mechanism is employed in both the primary and secondary reactions (in contrast to an INVADER oligonucleotide turnover mechanism, wherein an INVADER 30 oligonucleotide cycles, *e.g.*, to direct the cleavage of multiple FRET cassettes, as

- described below, in Section II of this Detailed Description). Consequently, in preferred embodiments, RNA detection uses sequential operation of the two reactions, rather than simultaneous reaction performance. Because the reactions are performed truly sequentially, in these embodiments, the RNA INVADER assay signal accumulates
- 5 linearly in both a target- and time-dependent manner. In contrast, the primary and secondary reactions of the DNA INVADER assay, when run concurrently, amplify signal as a linear function of target level, but as a quadratic function of time. In the sequential embodiments, the RNA INVADER assay uses two separate oligonucleotides, a secondary probe (e.g., a FRET probe) and secondary target, for signal generation.
- 10 A key feature of the RNA invasive cleavage assay is its ability to discriminate highly homologous RNA sequences, such as those found in cytochrome P450 gene families. Like the DNA INVADER assay, the RNA INVADER assay can discriminate single-base changes. In some embodiments, the first 5' complementary base of each probe is positioned at a non-conserved site in its mRNA target, so that a mismatch
- 15 prevents formation of the overlap-structure, and thus prevents cleavage of the probe. Alternatively spliced mRNA variants can be specifically detected by positioning the cleavage site at a splice junction.
- 20 To monitor large changes in mRNA levels, the dynamic range of the assay can be extended using real-time analysis. However, since the assay generates signal linearly with time or target level, simply varying the amount of sample added per reaction and calculating the copies of mRNA per ng total RNA enables accurate quantitation with a single endpoint measurement on low-cost instrumentation. Further, in cases where absolute quantitation is not necessary, the assay's linear signal amplification mechanism and reproducibility also eliminate the need for a standard curve and enable simple and
- 25 precise relative quantitation of any one gene.
- The RNA INVADER assay is particularly suited for detecting alternatively spliced or edited RNA variants because even a single base change at the overlap site affects 5' nuclease cleavage. All areas requiring RNA quantitation, such as high-throughput screening in drug discovery research, monitoring drug metabolism and safety
- 30 in clinical trials, and clinical load monitoring of viral RNA can use this technology.

Splice variants can be monitored in at least two ways with the assay: 1) detection of an individual exon or 2) detection of a specific splice junction.

To examine an RNA population for variants having more or fewer exons after splicing, INVADER assay probe sets are designed for each of the exons of interest (or for

- 5 all exons in the mature RNA). Quantitation of exons, independent of how many mRNAs they reside in, may provide information about the number of splice variants for a given gene, as well as indicate the levels of expression for each exon. Mini *in vitro* transcripts containing only one or a few exons can be generated for each probe set so that absolute quantitation can be performed for each exon, thus enabling accurate comparisons of exon
10 levels. If it is known that a particular exon is present in all known variants, in some embodiments, a probe set is designed for that exon for use as an internal control to normalize across different samples. RNAs having a one copy of each exon (e.g., "normally spliced" RNA) should produce signal from the collection of probe sets in certain relative amounts (which should be essentially equal for all exons, corrected for
15 variations in the sensitivity of individual probe sets; see Section V). Alterations in splicing alter the relative amounts of the exons. For example, if all of the produced RNAs are missing one of the normal exons, the signal for that exon drops toward zero, while if half of the RNAs are missing that exon, the signal for that exon drops toward 50%. More complex combinations of splice variations and mixtures of differently
20 spliced mRNAs yield more complex and more informative profiles. Detection is not limited to exons. RNA populations may also be monitored for the presence of intron sequences that are usually removed by splicing. Such global exon screening provides biologically relevant or diagnostic information when comparing normal vs. diseased tissue or untreated vs. treated cells (e.g., in pharmacogenomic screening assays). An
25 array-based description of this type of measurement is referred to as alternative splicing detector arrays (D. Black, Cell 103:367 [2000]). It is contemplated that the mRNA INVADER assay gives similar results but with greater specificity and more accurate quantitation than the oligonucleotide array formats.

- In an alternative embodiment, alternatively spliced mRNAs is detected by
30 examination of specific splice junctions. The advantage of monitoring the splice sites, as

opposed to the exons themselves, is that even splice variants involving very small exons (e.g. < 10 nts) are accurately detected with the assay.

Additionally, in some embodiments, the mRNA INVADER assay is also used to monitor alternative start and stop sites in the mRNA, and is used to monitor lifetimes of

- 5 processed and unprocessed RNAs and RNA fragments (e.g., as used in timecourse studies following induction).

II. Signal Enhancement By Incorporating The Products Of An Invasive Cleavage Reaction Into A Subsequent Invasive Cleavage Reaction

10

As noted above, the oligonucleotide product released by the invasive cleavage can be used subsequently in any reaction or read-out method that uses oligonucleotides in the size range of a cleavage product. In addition to the reactions involving primer extension and transcription, described herein, another enzymatic reaction that makes use of

- 15 oligonucleotides is the invasive cleavage reaction. The present invention provides means of using the oligonucleotide released in a primary invasive cleavage reaction as a component to complete a cleavage structure to enable a secondary invasive cleavage reaction. It is not intended that the sequential use of the invasive cleavage product be limited to a single additional step. It is contemplated that many distinct invasive cleavage reactions may be performed in sequence.

The polymerase chain reaction uses a DNA replication method to create copies of a targeted segment of nucleic acid at a logarithmic rate of accumulation. This is made possible by the fact that when the strands of DNA are separated, each individual strand contains sufficient information to allow assembly of a new complementary strand. When 25 the new strands are synthesized the number of identical molecules has doubled. Within 20 iterations of this process, the original may be copied 1 million-fold, making very rare sequences easily detectable. The mathematical power of a doubling reaction has been incorporated into a number of amplification assays.

- By performing multiple, sequential invasive cleavage reactions the method of the 30 present invention captures an exponential mathematical advantage without producing additional copies of the target analyte. In a simple invasive cleavage reaction the yield,

Y, is simply the turnover rate, K, multiplied by the time of the reaction, t (*i.e.*, $Y = (K)(t)$). If Y is used to represent the yield of a simple reaction, then the yield of a compound (*i.e.*, a multiple, sequential reaction), assuming that each of the individual invasive cleavage steps has the same turnover rate, can be simply represented as Y^n ,

5 where n is the number of invasive cleavage reactions that have been performed in the series. If the yields of each step differ the ultimate yield can be represented as the product of the multiplication of the yields of each individual reaction in the series. For example, if a primary invasive cleavage reaction can produce one thousand products in 30 minutes, and each of those products can in turn participate in 1000 additional

10 reactions, there will be 1000^2 copies (1000×1000) of the ultimate product in a second reaction. If a third reaction is added to the series, then the theoretical yield will be 1000^3 ($1000 \times 1000 \times 1000$). In the methods of the present invention the exponent comes from the number of invasive cleavage reactions in the cascade. This can be contrasted to the amplification methods described above (*e.g.*, PCR) in which Y is limited to 2 by the

15 number of strands in duplex DNA, and the exponent n is the number of cycles performed, so that many iterations are necessary to accumulate large amounts of product.

To distinguish the exponential amplifications described above from those of the present invention, the former can be considered reciprocating reactions because the products the reaction feed back into the same reaction (*e.g.*, event one leads to some

20 number of events 2, and each event 2 leads back to some number of events 1). In contrast, the events in some embodiments of the present invention are sequential (*e.g.*, event 1 leads to some number of events 2; each event 2 leads to some number of events 3, etc., and no event can contribute to an event earlier in the chain).

The sensitivity of the reciprocating methods is also one of the greatest weaknesses

25 when these assays are used to determine if a target nucleic acid sequence is present or absent in a sample. Because the product of these reactions is detectable copies of the starting material, contamination of a new reaction with the products of an earlier reaction can lead to false positive results, (*i.e.*, the apparent detection of the target nucleic acid in samples that do not actually contain any of that target analyte). Furthermore, because the

30 concentration of the product in each positive reaction is so high, amounts of DNA sufficient to create a strong false positive signal can be communicated to new reactions

very easily either by contact with contaminated instruments or by aerosol. In contrast to the reciprocating methods, the most concentrated product of the sequential reaction (*i.e.*, the product released in the ultimate invasive cleavage event) is not capable of initiating a like reaction or cascade if carried over to a fresh test sample. This is a marked advantage
5 over the exponential amplification methods described above because the reactions of the present invention may be performed without the costly containment arrangements (*e.g.*, either by specialized instruments or by separate laboratory space) required by any reciprocating reaction. While the products of a penultimate event may be inadvertently transferred to produce a background of the ultimate product in the absence of the a target
10 analyte, the contamination would need to be of much greater volume to give an equivalent risk of a false positive result.

When the term sequential is used it is not intended to limit the invention to configurations in which that one invasive cleavage reaction or assay must be completed before the initiation of a subsequent reaction for invasive cleavage of a different probe.
15 Rather, the term refers to the order of events as would occur if only single copies of each of the oligonucleotide species were used in an assay. The primary invasive cleavage reaction refers to that which occurs first, in response to the formation of the cleavage structure on the target nucleic acid. Subsequent reactions may be referred to as secondary, tertiary and so forth, and may involve artificial "target" strands that serve only
20 to support assembly of a cleavage structure, and which are unrelated to the nucleic acid analyte of interest. While the complete assay may, if desired, be configured with each step of invasive cleavage separated either in space (*e.g.*, in different reaction vessels) or in time (*e.g.*, using a shift in reaction conditions, such as temperature, enzyme identity or solution condition, to enable the later cleavage events), it is also contemplated that all of
25 the reaction components may be mixed so that secondary reactions may be initiated as soon as product from a primary cleavage becomes available. In such a format, primary, secondary and subsequent cleavage events involving different copies of the cleavage structures may take place simultaneously.

Several levels of this sort of linear amplification can be envisioned, in which each
30 successive round of cleavage produces an oligonucleotide that can participate in the cleavage of a different probe in subsequent rounds. The primary reaction would be

specific for the analyte of interest with secondary (and tertiary, etc.) reactions being used to generate signal while still being dependent on the primary reaction for initiation.

The released product may perform in several capacities in the subsequent reactions. For example, the product of one invasive cleavage reaction becomes the
5 INVADER oligonucleotide to direct the specific cleavage of another probe in a second reaction. In such an example, the first invasive cleavage structure is formed by the annealing of the INVADER oligonucleotide and the probe oligonucleotide (Probe 1) to the first target nucleic acid (Target 1). The target nucleic acid is divided into three regions based upon which portions of the INVADER and probe oligonucleotides are
10 capable of hybridizing to the target. Region 1 of the target has complementarity to only the INVADER oligonucleotide; region 3 of the target has complementarity to only the probe; and region 2 of the target has an overlap between the INVADER and probe oligonucleotides.

Cleavage of Probe 1 releases the "Cut Probe 1". The released Probe 1 is then
15 used as the INVADER oligonucleotide in second cleavage. The second cleavage structure is formed by the annealing of the Cut Probe 1, a second probe oligonucleotide ("Probe 2") and a second target nucleic acid ("Target 2"). In some embodiments, Probe 2 and the second target nucleic acid are covalently connected, preferably at their 3' and 5'
ends, respectively, thus forming a hairpin stem and loop, termed herein a "cassette". The
20 loop may be nucleic acid or a non-nucleic acid spacer or linker. Inclusion of an excess of the cassette molecule allows each Cut Probe 1 to serve as an INVADER to direct the cleavage of multiple copies of the cassette.

Probe 2 may be labeled and detection of cleavage of the second cleavage structure may be accomplished by detecting the labeled cut Probe 2; the label may a radioisotope
25 (e.g., ³²P, ³⁵S), a fluorophore (e.g., fluorescein), a reactive group capable of detection by a secondary agent (e.g., biotin/streptavidin), a positively charged adduct which permits detection by selective charge reversal (as discussed in Section IV above), etc.
Alternatively, the cut Probe 2 may be used in a tailing reaction, or to complete or activate a protein-binding site, or may be detected or used by any of the means for detecting or
30 using an oligonucleotide described herein.

- In other embodiments, probe oligonucleotides that are cleaved in the primary reaction can be designed to fold back on themselves (*i.e.*, they contain a region of self-complementarity) to create a molecule that can serve as both the INVADER and target oligonucleotide (termed here an "IT" complex). The IT complex then enables cleavage 5 of a different probe present in the secondary reaction. Inclusion of an excess of the secondary probe molecule ("Probe 2"), allows each IT molecule to serve as the platform for the generation of multiple copies of cleaved secondary probe. The target nucleic acid is divided into three regions based upon which portions of the INVADER and probe 10 oligonucleotides are capable of hybridizing to the target (as discussed above and it is noted that the target may be divided into four regions if a stacker oligonucleotide is employed). The second cleavage structure is formed by the annealing of the second probe ("Probe 2") to the fragment of Probe 1 ("Cut Probe 1") that was released by cleavage of the first cleavage structure. The Cut Probe 1 forms a hairpin or stem/loop 15 structure near its 3' terminus by virtue of the annealing of the regions of self-complementarity contained within Cut Probe 1 (this self-annealed Cut Probe 1 forms the IT complex). The IT complex (Cut Probe 1) is divided into three regions. Region 1 of the IT complex has complementarity to the 3' portion of Probe 2; region 2 has complementarity to both the 3' end of Cut Probe 1 and to the 5' portion of Probe 2; and region 3 contains the region of self-complementarity (*i.e.*, region 3 is complementary to 20 the 3' portion of the Cut Probe 1). Note that with regard to the IT complex (*i.e.*, Cut Probe 1), region 1 is located upstream of region 2 and region 2 is located upstream of region 3. As for other embodiments of invasive cleavage, region "2" can represent a region where there is a physical, but not sequence, overlap between the INVADER 25 oligonucleotide portion of the Cut Probe 1 and the Probe 2 oligonucleotide.
- The cleavage products of the secondary invasive cleavage reaction (*i.e.*, Cut Probe 2) can either be detected, or can in turn be designed to constitute yet another integrated INVADER-target complex to be used with a third probe molecule, again unrelated to the preceding targets.

It is envisioned that the oligonucleotide product of a primary cleavage reaction 30 may fill the role of any of the oligonucleotides described herein (*e.g.*, it may serve as a target strand without an attached INVADER oligonucleotide-like sequence, or it may

serve as a stacker oligonucleotide, as described above), to enhance the turnover rate seen in the secondary reaction by stabilizing the probe hybridization through coaxial stacking.

Secondary cleavage reactions in some preferred embodiments of the present invention include the use of FRET cassettes. Such molecules provide both a secondary target and a FRET labeled cleavable sequence, allowing homogeneous detection (*i.e.*, without product separation or other manipulation after the reaction) of the sequential invasive cleavage reaction. Other preferred embodiments use a secondary reaction system in which the FRET probe and synthetic target are provided as separate oligonucleotides.

10 In a preferred embodiment, each subsequent reaction is facilitated by (*i.e.*, is dependent upon) the product of the previous cleavage, so that the presence of the ultimate product may serve as an indicator of the presence of the target analyte. However, cleavage in the second reaction need not be dependent upon the presence of the product of the primary cleavage reaction; the product of the primary cleavage reaction may merely measurably enhance the rate of the second cleavage reaction.

15 In summary, the INVADER assay cascade (*i.e.*, sequential invasive cleavage reactions) of the present invention is a combination of two or more linear assays that allows the accumulation of the ultimate product at an exponential rate, but without significant risk of carryover contamination. It is important to note that background that 20 does not arise from sequential cleavage, such as thermal breakage of the secondary probe, generally increases linearly with time. In contrast, signal generation from a 2-step sequential reaction follows quadratic kinetics. Thus, collection of data as a time course, either by taking time points or through the use of an instrument that allows real-time detection during the INVADER assay reaction incubations, provides the attractive 25 capability of discriminating between the true signal and any background solely on the basis of quadratic versus linear increases in signal over time. For example, when viewed graphically, the real signal will appear as a quadratic curve, while any accumulating background will be linear, and thus easy to distinguish, even if the absolute level of the background signal (*e.g.*, fluorescence in a FRET detection format) is substantial.

30 The sequential invasive cleavage amplification of the present invention can be used as an intermediate boost to any of the detection methods (*e.g.*, gel based analysis by

either standard or by charge reversal), polymerase tailing, and incorporation into a protein binding region, described herein. When used in such combinations the increased production of a specific cleavage product in the invasive cleavage assay reduces the burdens of sensitivity and specificity on the read-out systems, thus facilitating their use.

5 In addition to enabling a variety of detection platforms, the cascade strategy is suitable for multiplex analysis of individual analytes (*i.e.*, individual target nucleic acids) in a single reaction. The multiplex format can be categorized into two types. In one case, it is desirable to know the identity (and amount) of each of the analytes that can be present in a clinical sample, or the identity of each of the analytes as well as an internal
10 control. To identify the presence of multiple individual analytes in a single sample, several distinct secondary amplification systems may be included. Each probe cleaved in response to the presence of a particular target sequence (or internal control) can be designed to trigger a different cascade coupled to different detectable moieties, such as different sequences to be extended by DNA polymerase or different dyes in an FRET
15 format. The contribution of each specific target sequence to final product can thereby be tallied, allowing quantitative detection of different genes or alleles in a sample containing a mixture of genes or alleles.

In the second configuration, it is desirable to determine if any of several analytes are present in a sample, but the exact identity of each does not need to be known. For
20 example, in blood banking it is desirable to know if any one of a host of infectious agents is present in a sample of blood. Because the blood is discarded regardless of which agent is present, different signals on the probes would not be required in such an application of the present invention, and may actually be undesirable for reasons of confidentiality. In this case, the 5' arms (*i.e.*, the 5' portion that will be released upon cleavage) of the
25 different analyte-specific probes would be identical and would therefore trigger the same secondary signal cascade. A similar configuration would permit multiple probes complementary to a single gene to be used to boost the signal from that gene or to ensure inclusivity when there are numerous alleles of a gene to be detected.

In the primary INVADER assay reaction, there are two potential sources of
30 background. The first is from INVADER oligonucleotide-independent cleavage of probe annealed to the target, to itself, or to one of the other oligonucleotides present in the

reaction. The use of an enzyme that cannot efficiently cleave a structure that lacks a primer is preferred for this reason. The enzyme *Pfu* FEN-1 gives no detectable cleavage in the absence of the upstream oligonucleotide or even in the presence of an upstream oligonucleotide that fails to invade the probe-target complex. This indicates that the *Pfu*

- 5 FEN-1 endonuclease is a suitable enzyme for use in the methods of the present invention.

Other structure-specific nucleases may be suitable as well. As discussed in the first example, some 5' nucleases can be used in conditions that significantly reduce this primer-independent cleavage. For example, it has been shown that when the 5' nuclease of DNAPATaq is used to cleave hairpins the primer-independent cleavage is markedly 10 reduced by the inclusion of a monovalent salt in the reaction (Lyamichev, *et al.*, [1993], *supra*).

III. Effect of ARRESTOR Molecules on Signal and Background in Sequential Invasive Cleavage Reactions.

15 As described above, the concentration of the probe that is cleaved can be used to increase the rate of signal accumulation, with higher concentrations of probe yielding higher final signal. However, the presence of large amounts of residual uncleaved probe can present problems for subsequent use of the cleaved products for detection or for further amplification. If the subsequent step is a simple detection (*e.g.*, by gel 20 resolution), the excess uncut material may cause background by streaking or scattering of signal, or by overwhelming a detector (*e.g.*, over-exposing a film in the case of radioactivity, or exceeding the quantitative detection limits of a fluorescence imager). This can be overcome by partitioning the product from the uncut probe. In more complex 25 detection methods, the cleaved product may be intended to interact with another entity to indicate cleavage. As noted above, the cleaved product can be used in any reaction that makes use of oligonucleotides, such as hybridization, primer extension, ligation, or the direction of invasive cleavage. In each of these cases, the fate of the residual uncut probe should be considered in the design of the reaction. In a primer extension reaction, the uncut probe can hybridize to a template for extension. If cleavage is required to reveal 30 the correct 3' end for extension, the hybridized uncut probe will not be extended. It may, however, compete with the cleaved product for the template. If the template is in excess

of the combination of cleaved and uncleaved probe, then both of the latter should be able to find a copy of template for binding. If, however, the template is limiting, any competition may reduce the portion of the cleaved probe that can find successfully bind to the available template. If a vast excess of probe was used to drive the initial reaction,

- 5 the remainder may also be in vast excess over the cleavage product, and thus may provide a very effective competitor, thereby reducing the amount of the final reaction (*e.g.*, extension) product for ultimate detection.

The participation of the uncut probe material in a secondary reaction can also contribute to background in these reactions. While the presentation of a cleaved probe
10 for a subsequent reaction may represent an ideal substrate for the enzyme to be used in the next step, some enzymes may also be able to act, albeit inefficiently, on the uncut probe as well. It was shown during the development of the present invention that transcription can be promoted from a nicked promoter even when one side of the nick has additional unpaired nucleotides. Similarly, when the subsequent reaction is to be an

- 15 invasive cleavage, the uncleaved probe may bind to the elements intended to form the second cleavage structure with the cleaved probe. In experiments conducted during the development of the present invention, it was found that some of the 5' nucleases described herein can catalyze some measure of cleavage of defective structures. Even at a low level, this aberrant cleavage can be misinterpreted as positive target-specific
20 cleavage signal.

With these negative effects of the surfeit of uncut probe considered, there is clearly a need for some method of preventing these interactions. As noted above, it is possible to partition the cleaved product from the uncut probe after the primary reaction by traditional methods. However, these methods are often time consuming, may be
25 expensive (*e.g.*, disposable columns, gels, etc.), and may increase the risk for sample mishandling or contamination. It is far preferable to configure the sequential reactions such that the original sample need not be removed to a new vessel for subsequent reaction.

- The present invention provides a method for reducing interactions between the
30 primary probe and other reactants. This method provides a means of specifically diverting the uncleaved probes from participation in the subsequent reactions. The

diversion is accomplished by the inclusion in the next reaction step an agent designed to specifically interact with the uncleaved primary probe. While the primary probe in an invasive cleavage reaction is discussed for reasons of convenience, it is contemplated that the ARRESTOR molecules may be used at any reaction step within a chain of invasive cleavage steps, as needed or desired for the design of an assay. It is not intended that the ARRESTOR molecules of the present invention be limited to any particular step.

The method of diverting the residual uncut probes from a primary reaction makes use of agents that can be specifically designed or selected to bind to the uncleaved probe molecules with greater affinity than to the cleaved probes, thereby allowing the cleaved probe species to effectively compete for the elements of the subsequent reaction, even when the uncut probe is present in vast excess. These agents have been termed "ARRESTOR molecules," due to their function of stopping or arresting the primary probe from participation in the later reaction. In various Examples below, an oligonucleotide is provided as an ARRESTOR molecule in an invasive cleavage assay. It can be appreciated that any molecule or chemical that can discriminate between the full-length uncut probe and the cleaved probe, and that can bind or otherwise disable the uncleaved probe preferentially may be configured to act as ARRESTOR molecules within the meaning of the present invention. For example, antibodies can be derived with such specificity, as can the "aptamers" that can be selected through multiple steps of *in vitro* amplification (e.g., "SELEX," U.S. Patent Nos. 5,270,163 and 5,567,588; herein incorporated by reference) and specific rounds of capture or other selection means.

In one embodiment, the ARRESTOR molecule is an oligonucleotide. In another embodiment the ARRESTOR oligonucleotides is a composite oligonucleotide, comprising two or more short oligonucleotides that are not covalently linked, but that bind cooperatively and are stabilized by co-axial stacking. In a preferred embodiment, the oligonucleotide is modified to reduce interactions with the cleavage agents of the present invention. When an oligonucleotide is used as an ARRESTOR oligonucleotide, it is intended that it not participate in the subsequent reactive step. The binding of the ARRESTOR oligonucleotide to the primary probe may, either with the participation of the secondary target, or without such participation, create a bifurcated structure that is a substrate for cleavage by the 5' nucleases used in some embodiments of the methods of

the present invention. Formation of such structures would lead to some level of unintended cleavage that could contribute to background, reduce specific signal or compete for the enzyme. It is preferable to provide ARRESTOR oligonucleotides that will not create such cleavage structures. One method of doing this is to add to the

- 5 ARRESTOR oligonucleotides such modifications as have been found to reduce the activity of INVADER oligonucleotides, as the INVADER oligonucleotides occupy a similar position within a cleavage structure (*i.e.*, the 3' end of the INVADER oligonucleotide positions the site of cleavage of an unpaired 5' arm). Modification of the 3' end of the INVADER oligonucleotides was examined for the effects on cleavage in the
10 Example section below; a number of the modifications tested were found to be significantly debilitating to the function of the INVADER oligonucleotide. Other modifications not described herein may be easily characterized by performing such a test using the cleavage enzyme to be used in the reaction for which the ARRESTOR oligonucleotide is intended.

- 15 In a preferred embodiment, the backbone of an ARRESTOR oligonucleotide is modified. This may be done to increase the resistance to degradation by nucleases or temperature, or to provide duplex structure that is a less favorable substrate for the enzyme to be used (*e.g.*, A-form duplex vs. B-form duplex). In particularly preferred embodiment, the backbone-modified oligonucleotide further comprises a 3' terminal modification. In a preferred embodiment, the modifications comprise 2' O-methyl substitution of the nucleic acid backbone, while in a particularly preferred embodiment, the 2' O-methyl modified oligonucleotide further comprises a 3' terminal amine group.
20

- 25 The purpose of the ARRESTOR oligonucleotide is to allow the minority population of cleaved probe to effectively compete with the uncleaved probe for binding whatever elements are to be used in the next step. While an ARRESTOR oligonucleotide that can discriminate between the two probe species absolutely (*i.e.*, binding only to uncut and never to cut) may be of the greatest benefit in some embodiments, it is envisioned that in many applications, including the sequential INVADER assays described herein, the ARRESTOR oligonucleotide of the present invention may perform
30 the intended function with only partial discrimination. When the ARRESTOR oligonucleotide has some interaction with the cleaved probe, it may prevent detection of

some portion of these cleavage products, thereby reducing the absolute level of signal generated from a given amount of target material. If this same ARRESTOR oligonucleotide has the simultaneous effect of reducing the background of the reaction (*i.e.*, from non-target specific cleavage) by a factor that is greater than the factor of

- 5 reduction in the specific signal, then the significance of the signal (*i.e.*, the ratio of signal to background), is increased, even with the lower amount of absolute signal. Any potential ARRESTOR molecule design may be tested in a simple fashion by comparing the levels of background and specific signals from reactions that lack ARRESTOR molecules to the levels of background and specific signal from similar reactions that
10 include ARRESTOR oligonucleotides. What constitutes an acceptable level of tradeoff of absolute signal for specificity will vary for different applications (*e.g.*, target levels, read-out sensitivity, etc.), and can be determined by any individual user using the methods of the present invention.

15 **IV. Improved Enzymes For Use In INVADER Oligonucleotide-Directed Cleavage Reactions Comprising RNA Targets;**

A cleavage structure is defined herein as a structure that is formed by the interaction of a probe oligonucleotide and a target nucleic acid to form a duplex, the
20 resulting structure being cleavable by a cleavage agent, including but not limited to an enzyme. The cleavage structure is further defined as a substrate for specific cleavage by the cleavage means in contrast to a nucleic acid molecule that is a substrate for nonspecific cleavage by agents such as phosphodiesterases. In considering improvements to enzymatic cleavage agents, one may consider the action of said
25 enzymes on any structures that fall within the definition of a cleavage structure. Specific cleavage at any site within such a structure is contemplated.

Improvements in an enzyme may be an increased or decreased rate of cleavage of one or more types of structures. Improvements may also result in more or fewer sites of cleavage on one or more of said cleavage structures. In developing a library of new
30 structure-specific nucleases for use in nucleic acid cleavage assays, improvements may

have many different embodiments, each related to the specific substrate structure used in a particular assay.

As an example, one embodiment of the INVADER oligonucleotide-directed cleavage assay of the present invention may be considered. In the INVADER

5 oligonucleotide-directed cleavage assay, the accumulation of cleaved material is influenced by several features of the enzyme behavior. Not surprisingly, the turnover rate, or the number of structures that can be cleaved by a single enzyme molecule in a set amount of time, is very important in determining the amount of material processed during the course of an assay reaction. If an enzyme takes a long time to recognize a substrate
10 (e.g., if it is presented with a less-than-optimal structure), or if it takes a long time to execute cleavage, the rate of product accumulation is lower than if these steps proceeded quickly. If these steps are quick, yet the enzyme "holds on" to the cleaved structure, and does not immediately proceed to another uncut structure, the rate will be negatively affected.

15 Enzyme turnover is not the only way in which enzyme behavior can negatively affect the rate of accumulation of product. When the means used to visualize or measure product is specific for a precisely defined product, products that deviate from that definition may escape detection, and thus the rate of product accumulation may appear to be lower than it is. For example, if one had a sensitive detector for trinucleotides that
20 could not see di- or tetranucleotides, or any sized oligonucleotide other than 3 residues, in the INVADER-directed cleavage assay of the present invention any errant cleavage would reduce the detectable signal proportionally. It can be seen from the cleavage data presented here that, while there is usually one site within a probe that is favored for cleavage, there are often products that arise from cleavage one or more nucleotides away
25 from the primary cleavage site. These are products that are target-dependent, and are thus not non-specific background. Nevertheless, if a subsequent visualization system can detect only the primary product, these represent a loss of signal. One example of such a selective visualization system is the charge reversal readout presented herein, in which the balance of positive and negative charges determines the behavior of the products. In
30 such a system the presence of an extra nucleotide or the absence of an expected nucleotide can exclude a legitimate cleavage product from ultimate detection by leaving

that product with the wrong balance of charge. It can be easily seen that any assay that can sensitively distinguish the nucleotide content of an oligonucleotide, such as standard stringent hybridization, suffers in sensitivity when some fraction of the legitimate product is not eligible for successful detection by that assay.

- 5 These discussions suggest two highly desirable traits in any enzyme to be used in the method of the present invention. First, the more rapidly the enzyme executes an entire cleavage reaction, including recognition, cleavage and release, the more signal it may potentially created in the INVADER oligonucleotide-directed cleavage assay. Second, the more successful an enzyme is at focusing on a single cleavage site within a
10 structure, the more of the cleavage product can be successfully detected in a selective read-out.

- The rationale cited above for making improvements in enzymes to be used in the INVADER oligonucleotide-directed cleavage assay are meant to serve as an example of one direction in which improvements might be sought, but not as a limit on either the
15 nature or the applications of improved enzyme activities. As another direction of activity change that would be appropriately considered improvement, the DNAP-associated 5' nucleases may be used as an example. In creating some of the polymerase-deficient 5' nucleases described herein it was found that those that were created by deletion of substantial portions of the polymerase domain, assumed activities that were weak or
20 absent in the parent proteins. These activities included the ability to cleave non-forked structures, a greatly enhanced ability to exonucleolytically remove nucleotides from the 5' ends of duplexed strands, and a nascent ability to cleave circular molecules without benefit of a free 5' end.

- In addition to the 5' nucleases derived from DNA polymerases, the present
25 invention also contemplates the use of structure-specific nucleases that are not derived from DNA polymerases. For example, a class of eukaryotic and archaeabacterial endonucleases have been identified which have a similar substrate specificity to 5' nucleases of Pol I-type DNA polymerases. These are the FEN1 (Flap EndoNuclease), RAD2, and XPG (Xeroderma Pigmentosa-complementation group G) proteins. These
30 proteins are involved in DNA repair, and have been shown to favor the cleavage of structures that resemble a 5' arm that has been displaced by an extending primer during

polymerization. Similar DNA repair enzymes have been isolated from single cell and higher eukaryotes and from archaea, and there are related DNA repair proteins in eubacteria. Similar 5' nucleases have also been associated with bacteriophage such as T5 and T7.

5 Recently, the 3-dimensional structures of DNAPTaq and T5 phage 5'-exonuclease were determined by X-ray diffraction (Kim *et al.*, *Nature* 376:612 [1995]; and Ceska *et al.*, *Nature* 382:90 [1995]). The two enzymes have very similar 3-dimensional structures despite limited amino acid sequence similarity. The most striking feature of the T5 5'-exonuclease structure is the existence of a triangular hole formed by the active site of 10 the protein and two alpha helices. This same region of DNAPTaq is disordered in the crystal structure, indicating that this region is flexible, and thus is not shown in the published 3-dimensional structure. However, the 5' nuclease domain of DNAPTaq is likely to have the same structure, based its overall 3-dimensional similarity to T5 5'-exonuclease, and that the amino acids in the disordered region of the DNAPTaq 15 protein are those associated with alpha helix formation. The existence of such a hole or groove in the 5' nuclease domain of DNAPTaq was predicted based on its substrate specificity (Lyamichev *et al.*, *supra*).

It has been suggested that the 5' arm of a cleavage structure must thread through the helical arch described above to position said structure correctly for cleavage (Ceska *et 20 al.*, *supra*). One of the modifications of 5' nucleases described herein opened up the helical arch portion of the protein to allow improved cleavage of structures that cut poorly or not at all (e.g., structures on circular DNA targets that would preclude such threading of a 5' arm). The gene construct that was chosen as a model to test this approach was the one called CLEAVASE BN, which was derived from DNAPTaq but 25 does not contain the polymerase domain. It comprises the entire 5' nuclease domain of DNAP Taq, and thus should be very close in structure to the T5 5' exonuclease. This 5' nuclease was chosen to demonstrate the principle of such a physical modification on proteins of this type. The arch-opening modification of the present invention is not intended to be limited to the 5' nuclease domains of DNA polymerases, and is 30 contemplated for use on any structure-specific nuclease that includes such an aperture as a limitation on cleavage activity. The present invention contemplates the insertion of a

thrombin cleavage site into the helical arch of DNAPs derived from the genus *Thermus* as well as 5' nucleases derived from DNAPs derived from the genus *Thermus*. The specific example shown herein using the CLEAVASE BN/thrombin nuclease merely illustrates the concept of opening the helical arch located within a nuclease domain. As the amino acid sequence of DNAPs derived from the genus *Thermus* are highly conserved, the teachings of the present invention enable the insertion of a thrombin site into the helical arch present in these DNAPs and 5' nucleases derived from these DNAPs.

The opening of the helical arch was accomplished by insertion of a protease site in the arch. This allowed post-translational digestion of the expressed protein with the appropriate protease to open the arch at its apex. Proteases of this type recognize short stretches of specific amino acid sequence. Such proteases include thrombin and factor Xa. Cleavage of a protein with such a protease depends on both the presence of that site in the amino acid sequence of the protein and the accessibility of that site on the folded intact protein. Even with a crystal structure it can be difficult to predict the susceptibility of any particular region of a protein to protease cleavage. Absent a crystal structure it must be determined empirically.

In selecting a protease for a site-specific cleavage of a protein that has been modified to contain a protease cleavage site, a first step is to test the unmodified protein for cleavage at alternative sites. For example, DNAPTaq and CLEAVASE BN nuclease were both incubated under protease cleavage conditions with factor Xa and thrombin proteases. Both nuclease proteins were cut with factor Xa within the 5' nuclease domain, but neither nuclease was digested with large amounts of thrombin. Thus, thrombin was chosen for initial tests on opening the arch of the CLEAVASE BN enzyme.

In the protease/ CLEAVASE modifications described herein the factor Xa protease cleaved strongly in an unacceptable position in the unmodified nuclease protein, in a region likely to compromise the activity of the end product. Other unmodified nucleases contemplated herein may not be sensitive to the factor Xa, but may be sensitive to thrombin or other such proteases. Alternatively, they may be sensitive to these or other such proteases at sites that are immaterial to the function of the nuclease sought to be modified. In approaching any protein for modification by addition of a protease cleavage site, the unmodified protein should be tested with the proteases under

consideration to determine which proteases give acceptable levels of cleavage in other regions.

Working with the cloned segment of DNAPTaq from which the CLEAVASE BN protein is expressed, nucleotides encoding a thrombin cleavage site were introduced 5 in-frame near the sequence encoding amino acid 90 of the nuclease gene. This position was determined to be at or near the apex of the helical arch by reference to both the 3-dimensional structure of DNAPTaq, and the structure of T5 5' exonuclease. The encoded amino acid sequence, LVPGRS, was inserted into the apex of the helical arch by site-directed mutagenesis of the nuclease gene. The proline (P) in the thrombin cleavage 10 site was positioned to replace a proline normally in this position in CLEAVASE BN because proline is an alpha helix-breaking amino acid, and may be important for the 3-dimensional structure of this arch. This construct was expressed, purified and then digested with thrombin. The digested enzyme was tested for its ability to cleave a target 15 nucleic acid, bacteriophage M13 genomic DNA, that does not provide free 5' ends to facilitate cleavage by the threading model.

While the helical arch in this nuclease was opened by protease cleavage, it is contemplated that a number of other techniques could be used to achieve the same end. For example, the nucleotide sequence could be rearranged such that, upon expression, the resulting protein would be configured so that the top of the helical arch (amino acid 90) 20 would be at the amino terminus of the protein, the natural carboxyl and amino termini of the protein sequence would be joined, and the new carboxyl terminus would lie at natural amino acid 89. This approach has the benefit that no foreign sequences are introduced and the enzyme is a single amino acid chain, and thus may be more stable than the cleaved 5' nuclease. In the crystal structure of DNAPTaq, the amino and carboxyl 25 termini of the 5'-exonuclease domain lie in close proximity to each other, which suggests that the ends may be directly joined without the use of a flexible linker peptide sequence as is sometimes necessary. Such a rearrangement of the gene, with subsequent cloning and expression could be accomplished by standard PCR recombination and cloning techniques known to those skilled in the art.

30 The INVADER invasive cleavage reaction has been shown to be useful in the detection of RNA target strands (*See e.g.*, U.S. Patent 6,001,567, incorporated herein by

reference in its entirety). As with the INVADER assay for the detection of DNA (Lyamichev *et al.*, Nat. Biotechnol., 17:292 [1999]), the reactions may be run under conditions that permit the cleavage of many copies of a probe for each copy of the target RNA present in the reaction. In one embodiment, the reaction may be performed at a 5 temperature close to the melting temperature (T_m) of the probe that is cleaved, such that the cleaved and uncleaved probes readily cycle on and off the target strand without temperature cycling. Each time a full-length probe binds to the target in the presence of the INVADER oligonucleotide, it may be cleaved by a 5' nuclease enzyme, resulting in an accumulation of cleavage product. The accumulation is highly specific for the 10 sequence being detected, and may be configured to be proportional to both time and target concentration of the reaction. In another embodiment, the temperature of the reaction may be shifted (*i.e.*, it may be raised to a temperature that will cause the probe to dissociate) then lowered to a temperature at which a new copy of the probe hybridizes to the target and is cleaved by the enzyme. In a further embodiment, the process of raising 15 and lowering the temperature is repeated many times, or cycled, as it is in PCR (Mullis and Faloona, Methods in Enzymology, 155:335 [1987], Saiki *et al.*, Science 230:1350 [1985]).

As noted above, 5' nucleases of Pol A type DNA polymerases are preferred for 20 cleavage of an invasive cleavage structure that comprises an RNA target strand. The present invention provides enzymes having improved performance in detection assays based on the cleavage of a structure comprising RNA. In particular, the altered 25 polymerases of the present invention exhibit improved performance in detection assays based on the cleavage of a DNA member of an invasive cleavage structure that comprises an RNA target strand.

The 5' nucleases of the present invention may be derived from Pol A type DNA 30 polymerases. The terminology used in describing the alterations made in this class of 5' nucleases relates to the descriptions of DNA polymerase structures known in the art. The Klenow fragment of the Pol A polymerase from *E. coli* (the C-terminal two thirds, which has the DNA synthesizing activity but lacks the 5' nuclease activity) has been described as having a physical form resembling a right hand, having an open region called the "palm", and a cleft that holds the primer/template duplex defined on one side by a

"fingers" domain and on the other by a "thumb" domain (Joyce and Steitz, Trends in Biochemical Science 12:288 [1987]). This is shown schematically in Figure 5. Because this physical form has proved to be common to all Pol A DNA polymerases and to a number of additional template-dependent polymerizing enzymes such as reverse

- 5 transcriptases, the hand terminology has become known in the art, and the sites of activity in these enzymes are often described by reference to their position on the hand. For reference, and not intended as a limitation on the present invention, the palm is created from roughly the first 200 amino acids of the polymerase domain, the thumb from the middle 140, and the fingers by the next 160, with the base of the cleft formed from the
10 remaining regions (Figures 6). Although some enzymes may deviate from these structural descriptions, the equivalent domains and sequences corresponding to such domains may be identified by sequence homology to known enzyme sequences, by comparison of enzyme crystal structures, and other like methods.

In creating the improved enzymes of the present invention, several approaches
15 have been taken, although the present invention is not limited to any particular approach. First two DNA polymerases, Taq and Tth, that have different rates of DNA strand cleavage activity on RNA targets were compared. To identify domains related to the differences in activity, a series of chimerical constructs was created and the activities were measured. This process identified two regions of the Tth polymerase that could, if
20 transferred into the Taq polymerase, confer on the TaqPol an RNA-dependent cleavage activity equivalent to that of the native Tth protein. Once these regions were identified, the particular amino acids involved in the activity were examined. Since the two proteins are about 87 percent identical in amino acid sequence overall, the identified regions had only a small number of amino acid differences. By altering these amino acids singly and
25 in combinations, a pair of amino acids were identified in TthPol that, if introduced into the TaqPol protein, increased the rate of cleavage up to that of the native TthPol.

These data demonstrate two important aspects of the present invention. First, specific amino acids can be changed to confer TthPol-like RNA-dependent cleavage activity on a polymerase having a lesser activity. More broadly, however, these results
30 provide regions of these polymerases that are involved in the recognition of the RNA-containing cleavage structure. Identification of these important regions, combined

with published information on the relationships of other amino acids to the various functions of these DNA polymerases and computer-assisted molecular modeling during the development of the present invention have allowed a rational design approach to create additional improved 5' nucleases. The information also allowed a focused random

- 5 mutagenesis approach coupled with a rapid screening procedure to quickly create and identify enzymes having improved properties. Using these methods of the present invention, a wide array of improved polymerases are provided.

The methods used in creating and selecting the improved 5' nucleases of the present invention are described in detail below and in the experimental examples. A
10 general procedure for screening and characterizing the cleavage activity of any 5'
nuclease is included in the experimental examples. The methods discussions are divided
into the following sections: I) Creation and selection of chimerical constructs; II)
Site-specific mutagenesis based on information from chimerical constructs; III)
Site-specific mutagenesis based on molecular modeling and published physical studies;
15 and IV) focused random mutagenesis.

1) Creation and selection of chimerical constructs

The PolA-type DNA polymerases, including but not limited to DNA polymerase enzymes from *Thermus* species, comprise two distinctive domains, the 5' nuclease and
20 the polymerase domains, shown schematically in Figure 6. The polymerase domains reside in the C-terminal two-thirds of the proteins and are responsible for both DNA-dependent and RNA-dependent DNA polymerase activities. The N-terminal one-third portions contain the 5' nuclease domains. In the genus *Thermus* Pol A polymerase, the palm region consists of, roughly, amino acids 300-500, the thumb region
25 includes amino acids 500-650, while the fingers region is formed by the remaining amino acids from 650 to 830 (Figure 6).

The derivatives, Taq DN RX HT and Tth DN RX HT, of Taq and TthPol used in many of the experiments of the present invention, and described herein, are modified to reduce synthetic activity and to facilitate chimera construction, but have 5' nuclease
30 activity essentially identical to unmodified TaqPol and TthPol. Unless otherwise

specified, the TaqPol and TthPol enzymes of the following discussion refer to the DN RX HT derivative.

TthPol has a 4-fold higher cleavage rate with the IL-6 RNA template (shown in Figure 10) than TaqPol (shown in Figures 11 and 12), although the Taq and TthPols show 5 similarities of cleavage in DNA target structures (Figure 10). Since the amino acid sequences of TaqPol and TthPol (Figures 8 and 9) share about 87% identity and greater than 92% similarity, the high degree of homology between the enzymes allowed creation of a series of chimeric enzymes between TthPol and TaqPol. The activity of the chimeric enzymes was used as a parameter to identify the region(s) of these proteins affecting 10 RNA dependent 5' nuclease activity.

The chimeric constructs between TthPol and TaqPol genes shown schematically in Figures 7 and 19 were created by swapping DNA fragments defined by the restriction endonuclease sites, EcoRI and BamHI, common for both genes, the cloning vector site Sall and the new sites, NotI, BstBI and NdeI, created at the homologous positions of both 15 genes by site directed mutagenesis. The restriction enzymes have been abbreviated as follows: EcoRI is E; NotI is N; BstBI is Bs; NdeI is D, BamHI is B, and Sall is S.

The activity of each chimeric enzyme was evaluated using the invasive signal amplification assay with the IL-6 RNA target (Figure 10), and the cycling cleavage rates shown in Figure 12 were determined as described in the Experimental Examples. 20 Comparison of the cleavage rates of the first two chimeras, TaqTth(N) and TthTaq(N), created by swapping the polymerase and 5' nuclease domains at the NotI site (Figure 7), shows that TaqTth(N) has the same activity as TthPol, whereas its counterpart TthTaq(N) retains the activity of TaqPol (Figure 12). This result indicates that the higher cleavage rate of TthPol is associated with its polymerase domain and suggests an important role of 25 the polymerase domain in the 5' nuclease activity.

The next step was to identify a minimal region of TthPol polymerase that would give rise to the TthPol-like RNA dependent 5' nuclease activity when substituted for the corresponding region of the TaqPol sequence. To this end, the TaqTth(N) chimera was selected to generate a series of new constructs by replacing its TthPol sequence with 30 homologous regions of TaqPol. First, the N-terminal and C-terminal parts of the TaqPol polymerase domain were substituted for the corresponding regions of TaqTth(N) using

the common BamHI site as a breaking point to create TaqTth(N-B) and TaqTth(B-S) chimeras, respectively (Figure 7). TaqTth(N-B) which has the TthPol sequence between amino acids 328 and 593, is approximately 3 times more active than the TaqTth(B-S) and 40% more active than TthPol (Figure 12). This result establishes that the NdeI-BamHI portion of the TthPol polymerase domain determines superior RNA-dependent 5' nuclease activity of TthPol.

From these data it was determined that a central portion of the TthPol, when used to replace the homologous portion of TaqPol (TaqTth(N-B) construct) could confer superior RNA recognition on the chimerical protein composed primarily of Taq protein.

In fact, the cycling rate of this chimerical protein exceeded that of the parent TthPol. Comparison of chimeras that included sub-portions of the activity-improving region of TthPol, approximately 50% of the region in each case (*See*, TaqTth(N-D) and TaqTth(D-B), Figures 7 and 12) showed no significant improvement in RNA dependent activity as compared to the parent TaqPol. This result indicates that aspects of each half of the region are required for this activity. A construct having an only slightly smaller portion of the Tth insert portion (TaqTth(Bs-B)) showed activity that was close to that of the parent TthPol protein, but which was less than that of the TaqTth(N-B) construct.

2) Site-specific mutagenesis based on information from chimerical constructs

Comparison of the TthPol and TaqPol amino acid sequences between the BstBI and BamHI sites reveals only 25 differences (Figure 13). Among those, there are 12 conservative changes and 13 substitutions resulting in a change in charge. Since the analysis of the chimeric enzymes has suggested that some critical amino acid changes are located in both BstBI-NdeI and NdeI-BamHI regions of TthPol, site directed mutagenesis was used to introduce the TthPol specific amino acids into the BstBI-NdeI and NdeI-BamHI regions of the TaqTth(D-B) and TaqTth (N-D) chimeras, respectively. Six TthPol-specific substitutions were generated in the BstBI-NdeI region of the TaqTth(D-B) by single or double amino acid mutagenesis and only one double mutation, W417L/G418K, was able to restore the TthPol activity with the IL-6 RNA target (*See e.g.*, Figure 14). Similarly, 12 TthPol specific amino acids were introduced at the

homologous positions of the NdeI-BamHI region of the TaqTth(N-D) and only one of them, E507Q, increased the cleavage rate to the TthPol level (*See e.g.*, Figure 14).

To confirm that the W417L, G418K and E507Q substitutions are sufficient to increase the TaqPol activity to the TthPol level, TaqPol variants carrying these mutations were created and their cleavage rates with the IL-6 RNA substrate were compared with that of TthPol. Figure 15 shows that the TaqPol W417L/G418K/E507Q and TaqPol G418K/E507Q mutants have 1.4 times higher activity than TthPol and more than 4 fold higher activity than TaqPol, whereas the TaqPol W417L/E507Q mutant has the same activity as TthPol, which is about 3 fold higher than TaqPol. These results demonstrate that K418 and Q507 of TthPol are important amino acids in defining its superior RNA dependent 5' nuclease activity compared to TaqPol.

The ability of these amino acids to improve the RNA dependent 5' nuclease activity of a DNA polymerase was tested by introducing the corresponding mutations into the polymerase A genes of two additional organisms: *Thermus filiformis* and *Thermus scotoductus*. TaqPol showed improved RNA dependent activity when it was modified to contain the W417L and E507Q mutations, which made it more similar at these residues to the corresponding residues of TthPol (K418 and Q507). The TfIPol was modified to have P420K and E507Q, creating TfIDN 2M, while the TscPol was modified to have E416K and E505Q, to create TscDN 2M. The activity of these enzymes for cleaving various DNA and RNA containing structures was determined as described in Example 1, using the IdT2, IrT3, hairpin and X-structures diagrammed in Figures 21 and 22, with the results shown in both Figure 25 and Table 8. Both enzymes have much less RNA-dependent cleavage activity than either the TthPol or the Taq 2M enzymes. However, introduction of the mutations cited above into these polymerases increased the RNA dependent cleavage activity over 2 fold compared to the unmodified enzymes (Figure 25). These results demonstrate that transferability of improved RNA dependent cleavage activity into a wide range of polymerases using the methods of the present invention.

3) Site-specific mutagenesis based on molecular modeling and published physical studies

The positions of the G418H and E507Q mutations in the crystal structure of a complex of the large fragment of TaqPol (Klenetaq1) with a primer/template DNA 5 determined by Li *et al.* (Li *et al.*, Protein Sci., 7:1116 [1998]) are shown in Figure 17. The E507Q mutation is located at the tip of the thumb subdomain at a nearest distance of 3.8 Å and 18 Å from the backbone phosphates of the primer and template strands, respectively. The interaction between the thumb and the minor groove of the DNA primer/template was previously suggested by the co-crystal structures of Klenow 10 fragment DNA polymerase I (Breese *et al.*, Science 260:352 [1993]) and TaqPol (Eom *et al.*, Nature 382:278 [1996]). Deletion of a 24 amino acid portion of the tip of the thumb in Klenow fragment, corresponding to amino acids 494-518 of TaqPol, reduces the DNA binding affinity by more than 100-fold (Minnick *et al.*, J. Biol. Chem., 271:24954 15 [1996]). These observations are consistent with the hypothesis that the thumb region, which includes the E507 residue, is involved in interactions with the upstream substrate duplex.

The W417L and the G418K mutations in the palm region of TaqPol (Figure 17) are located approximately 25 Å from the nearest phosphates of the template and upstream strands, according to the co-crystal structures of TaqPol with duplex DNA bound in the 20 polymerizing mode (Li *et al.*, Protein Sci., 7:1116 [1998], Eom *et al.*, Nature 382:278 [1996]). The same distance was observed between the analogous W513 and P514 amino acids of Klenow fragment and the template strand of DNA bound in the editing mode (Breese *et al.*, Science 260:352 [1993]). Thus, no interactions between TaqPol and the overlapping substrate can be suggested from the available co-crystal studies for this 25 region.

Although an understanding of the mechanism of action of the enzymes is not necessary for the practice of the present invention and the present invention is not limited to any mechanism of action, it is proposed that the amino acids at positions 417 and 418 in the palm region of TaqPol interact with the upstream substrate duplex only when the 30 enzyme functions as a 5' nuclease, but no interaction with these amino acids occurs when TaqPol switches into polymerizing mode. This hypothesis suggests a novel mode of

substrate binding by DNA polymerases called here the "5' nuclease mode." Several lines of evidence support this hypothesis. The study of the chimeric enzymes described here clearly separates regions of the polymerase domain involved in the 5' nuclease and polymerase activities. Accordingly, the W417L and G418K mutations, together with the 5 E507Q mutation, affect the 5' nuclease activity of TaqPol on substrates having an RNA target strand (Figure 15), but have no effect on either RNA-dependent or DNA-dependent DNA polymerase activities (Figure 16). On the other hand, mutations in the active site of TaqPol, such as R573A, R587A, E615A, R746A, N750A and D785N, which correspond to substitutions in Klenow fragment of *E.coli* DNA Pol I that affect both polymerase 10 activity and substrate binding affinity in the polymerizing mode (Polesky *et al.*, *J. Biol. Chem.*, 265:14579 [1990], Polesky *et al.*, *J. Biol. Chem.*, 267:8417 [1992], Pandey *et al.*, *Eur. J. Biochem.*, 214:59 [1993]) were shown to have little or no effect on the 5' nuclease activity. Superposition of the polymerase domains of TaqPol (Eom *et al.*, *Nature* 382:278 [1996]), *E.coli* Pol I and *Bacillus stearothermophilus* Pol I (Kiefer *et al.*, *Nature* 391:304 [1998]) using the programs DALI (Holm and Sander, *J. Mol. Biol.*, 233:123 15 [1993], Holm and Sander, *Science* 273:595 [1996]) and Insight II (Molecular Simulation Inc., Naperville, IL) shows that the palm region of TaqPol between amino acids 402-451, including W417 and G418, is structurally highly conserved between the three 20 polymerases, although there is no structural similarity between the rest of the palm subdomains. This observation suggests an important role for this region in eubacterial DNA polymerases.

The 5' nuclease and polymerase activities should be precisely synchronized to create a nicked structure rather than a gap or an overhang that could cause a deletion or an insertion during Okazaki fragment processing or DNA repair, if ligase joins the ends 25 inappropriately. According to the previously proposed model (Kaiser *et al.*, *J. Biol. Chem.*, 274:21387 [1999]), the 3' terminal nucleotide of the upstream strand is sequestered by the 5' nuclease domain to prevent its extension, thus halting synthesis. The interaction with the 3' nucleotide apparently activates the 5' nuclease that 30 endonucleolitically removes the displaced 5' arm of the downstream strand. This cleavage occurs by the precise incision at the site defined by the 3' nucleotide, thus creating the nick. This model requires a substantial rearrangement of the

substrate-enzyme complex, which may include a translocation of the complex to the 5' nuclease mode to separate the primer/template from the polymerase active site.

It is possible that a relocation of the substrate away from the polymerase active site could be induced by the interaction between the duplex formed between the template and incoming strands and the crevice formed by the finger and thumb subdomains. Such an interaction could force conformational transitions in the thumb that would bring the template/primer duplex into close contact with the W417 and G418 amino acids.

Significant flexibility of the thumb has been previously reported that might explain such changes (Beese *et al.*, *Science* 260:352 [1993], Eom *et al.*, *Nature* 382:278 [1996], Ollis *et al.*, *Nature* 313:762 [1985], Kim *et al.*, *Nature* 376:612 [1995], Korolev *et al.*, *Proc. Natl. Acad. Sci.*, 92:9264 [1995], Li *et al.*, *EMBO J.*, 17:7514 [1998]). Additional conformational changes of the fingers domain that might help to open the crevice, such as the transition from the 'closed' to the 'open' structure described by Li *et al.* (Li *et al.*, *EMBO J.*, 17:7514 [1998]), are consistent with this model. It may be that the 5' nuclease binding mode was not observed in any of the published co-crystal structures of a DNA Pol I because the majority of the structures were solved for the polymerase domain only, with a template/primer substrate rather than with an overlapping 5' nuclease substrate.

K_m values of 200-300 nM have been determined for TaqPol, TthPol and TaqPol G418K/E507Q for the RNA containing substrate. These values are much higher than the 20 K_m value of <1 nM estimated for TthPol with an all-DNA overlapping substrate suggesting that the RNA template adversely affects substrate binding. The low affinity could be explained by the unfavorable interaction between the enzyme and either the A-form duplex adopted by the substrate with an RNA target, or the ribose 2' hydroxyls of the RNA strand. Between these two factors, the latter seems more likely, since the 25 5' nucleases of eubacterial DNA polymerases can efficiently cleave substrates with an RNA downstream probe (Lyamichev *et al.*, *Science* 260:778 [1993]), which would presumably have an A-form. Further, the co-crystal studies suggest that the template/primer duplex partially adopts a conformation close to A-form in its complex with DNA polymerase (Eom *et al.*, *Nature* 382:278 [1996], Kiefer *et al.*, *Nature* 391:304 [1998], Li *et al.*, *EMBO J.*, 17:7514 [1998]). The G418K/E507Q mutations increase the k_{cat} of TaqPol 30 more than two fold, but have little effect on K_m . Such an effect would be expected if the

mutations position the substrate in an orientation more appropriate for cleavage rather than simply increasing the binding constant.

In addition to the mutational analysis described above, another approach to studying specific regions of enzymes, enzyme structure-function relationships, and 5 enzyme-substrate interaction is to investigate the actual, physical structure of the molecule.

With the advances in crystallographic, NMR, and computer and software technology, study of molecular structure has become a viable tool for those interested in the configuration, organization, and dynamics of biomolecules. Molecular modeling has 10 increased the understanding of the nature of the interactions that underlie the structure of proteins and how proteins interact functionally with substrate. Numerous publications describing the structures of various polymerases or polymerase protein portions, HIV reverse transcriptase, and other nucleic acid binding proteins have provided mechanistic insights into protein conformation, changes in conformation, and molecular interactions 15 necessary for function.

As an example, the report by Doublet *et al.* (Doublet *et al.*, *Nature* 391:251 [1998]) discloses the crystal structure of T7 DNA polymerase and provides information about which amino acid regions are likely to have an affect on substrate binding, which are required to contact the substrate for polymerization, and which amino acids bind 20 cofactors, such as metal ions. It is noted in this paper and others that many of the polymerases share not only sequence similarity, but structural homology as well. When certain structural domains of different polymerases are superimposed (for example, T7 polymerase, Klenow fragment editing complex, the unliganded Taq DNA polymerase and the Taq Polymerase-DNA complex) conserved motifs are clearly discernable.

25 Specifically, combining the information from all of these different structural sources and references, a model of the protein interacting with DNA, RNA, or heteroduplex can be made. The model can then be examined to identify amino acids that may be involved in substrate recognition or substrate contact. Changes in amino acids can be made based on these observations, and the effects on the various activities of the 5' 30 nuclease proteins are assessed using screening methods such as those of the present invention, described in the experimental examples.

- The domain swapping analysis discussed previously demonstrated that sequences of TthDN that are important in RNA-dependent 5' nuclease activity lie in the polymerase domain of the protein. Therefore, study of structural data of the polymerase domain with respect to nucleic acid recognition provides one method of locating amino acids that,
- 5 when altered, alter RNA recognition in a 5' nuclease reaction. For example, analysis conducted during the development of the present invention examined published analyses relating to primer/template binding by the polymerase domain of *E. coli* Pol 1, the Klenow fragment. Table 2 shows a sampling of kinetic constants determined for the Klenow fragment, and shows the effects a number of mutations on these measurements.
- 10 The corresponding or similarly positioned amino acids in the TaqPol are indicated in the right hand column. It was postulated that mutations having a noticeable impact on the interactions of the Klenow fragment with the DNA template or the primer/template duplex, as indicated by changes in K_d and Relative DNA affinity values, might also have effects when made at the corresponding sites in TaqPol and related chimerical or mutant derivatives. A selection of the mutations that produced a higher K_d value or a lower
- 15 Relative DNA affinity value when introduced into the Klenow fragment were created and examined in TaqPol. These Taq derivatives include, but are not limited to, those indicated by asterisks in the right hand column of Table 2.

For some Klenow variants, such as the R682 mutants, selection for testing was not made based on the DNA affinity measurements, but because molecular modeling suggested interaction between some aspect of the template/primer duplex and that amino acid. Similarly, additional regions of Taq polymerase (or Taq derivatives) were targeted for mutagenesis based on structural data and information from molecular modeling. Based on modeling, the thumb region was postulated to contact an RNA template. Thus, amino acids in the thumb region were looked for that, if altered, might alter that contact. For example, Figures 6 and 17 show that amino acids 502, 504, and 507 are located at the tip of the thumb. It was postulated that altering these amino acids might have an affect on the enzyme-substrate interaction. Using the activity screening methods described in Example 1, mutations that produced beneficial effects were identified. This approach was used to create a number of improved enzymes. For example, TaqPol position H784, corresponding to Klenow amino acid H881, is an amino acid in the fingers region and, as

such, may be involved in primer/template substrate binding. When the H881 amino acid in the Klenow enzyme is replaced by alanine, the change decreases the affinity of the enzyme for DNA to only 30 to 40% of the wild type level. An analogous substitution was tested in a TaqPol-derived enzyme. Starting with the Taq derivative

- 5 W417L/G418K/E507Q, amino acid 784 was changed from Histidine (H) to Alanine (A) to yield the W417L/G418K/E507Q/H784A mutant, termed Taq 4M. This variant showed improved 5' nuclease activity on the RNA test IrT1 (Figure 24) test substrate (data in Table 3). Amino acid R587 is in the thumb region, and was selected for mutation based on its close proximity to the primer/template duplex in computer models. When an
10 R587A mutation was added to the Taq 4M variant, the activity on the test IrT1 test substrate was still further improved. In addition, the reduction, relative to the 4M variant, in cleavage of the X structure shown in Figure 22 constitutes an additional improvement in this enzyme's function.

Not all amino acid changes that reduce DNA binding in the polymerization affect
15 the 5' nuclease activity. For example, mutations E615A, R677A, affecting amino acid that are also in the thumb and fingers domains, respectively, have either adverse effect, or no effect on the 5' nuclease activities, respectively, as measured using the test substrates in Figures 21 and 22, and compared to the parent variants that lacked these changes. The R677A mutation was added to, and compared with the TaqSS variant, while the E615A
20 mutation was added to and compared with the Taq 4M variant. The test methods described herein provide a convenient means of analyzing any variant for the alterations in the cleavage activity of both invasive and noninvasive substrates, for both DNA and RNA containing structures. Thus, the present invention provides methods for identifying all suitable improved enzymes.

25 Alterations that might increase the affinity of the enzymes for the nucleic acid targets were also examined. Many of the mutations described above were selected because they caused the Klenow fragment enzyme to have decreased affinity for DNA, with the goal of creating enzymes more accepting of structures containing non-DNA strands. In general, the native DNA polymerases show a lower affinity for RNA/DNA
30 duplexes, compared to their affinity for DNA/DNA duplexes. During the development of the present invention, it was sought to increase the general affinity of the proteins of the

present invention for a nucleic acid substrate without restoring or increasing any preference for structures having DNA rather than RNA target strands. The substitution of amino acids having different charges was examined as a means of altering the interaction between the proteins and the nucleic acid substrates. For example, it was postulated that
5 addition of positively charged amino acid residues, such as lysine (K), might increase the affinity of a protein for a negatively charged nucleic acid.

As noted above, alterations in the thumb region could affect the interactions of the protein with the nucleic acid substrate. In one example, the mutation G504K (tip of the thumb) was introduced in Taq4M and caused an enhancement of nuclease activity by
10 15% on an RNA target. Additional positively charged mutations (A502K and E507K) further improve the RNA target dependent activity by 50% compared to the parent Taq4M enzyme.

The use of data from published studies and molecular modeling, in combination with results accrued during the development of the present invention allowed the
15 identification of regions of the proteins in which changes of amino acids would be likely to cause observable differences in at least one aspect of cleavage function. While regions could be targeted in this way, it was observed that changes in different amino acids, even if near or immediate neighbors in the protein, could have different effects. For example, while the A502K substitution created a marked increase in the RNA-dependent cleavage
20 activity of Taq 4M, changing amino acid 499 from G to a K, only 3 amino acids away from 502, gave minimal improvement. As can be seen in the Experimental Examples, the approach of the present invention was to change several amino acids in a candidate region, either alone or in combination, then use the screening method provided in Example 1 to rapidly assess the effects of the changes. In this way, the rational design
25 approach is easily applied to the task of protein engineering.

In addition to the thumb, palm, and hand regions found in the polymerase domain of these proteins, regions that are specific to 5' nucleases and nuclease domains were examined. Comparative studies on a variety of 5' nucleases have shown that, though the amino acid sequences vary dramatically from enzyme to enzyme, there are structural
30 features common to most. Two of these features are the helix-hairpin-helix motif (H-h-H) and the arch or loop structure. The H-h-H motif is believed to mediate

non-sequence specific DNA binding. It has been found in at least 14 families of proteins, including nucleases, N-glycosylases, ligases, helicases, topoisomerases, and polymerases (Doherty *et al.*, *Nucl. Acid. Res.*, 24:2488 [1996]). The crystallographic structure of rat DNA polymerase pol β bound to a DNA template-primer shows non-specific hydrogen bonds between the backbone nitrogens of the pol β HhH motif and the phosphate oxygens of the primer of the DNA duplex (Pelletier *et al.*, *Science* 264:1891 [1994]). Because the HhH domain of 5' nuclease domains of Taq and Tth polymerases may function in a similar manner, it is contemplated that mutations in the HhH region of the enzyme alter activity. Mutations may be introduced to alter the shape and structure of the motif, or to change the charge of the motif to cause increased or decreased affinity for substrate.

Another structure common to many 5' nucleases from diverse sources such as eukaryotes, eubacteria, archaea and phage, is the arch or loop domain. The crystal structure of the 5' exonuclease of bacteriophage T5 showed a distinct arch formed by two helices, one positively charged and one containing hydrophobic residues (Ceska *et al.*, *Nature* 382:90 [1996]). Interestingly, three residues that are conserved between T5 and Taq, Lys 83, Arg 86 and Tyr 82 are all in the arch. These correspond to amino acids Lys 83, Arg 86, and Tyr 82 in Taq DNA polymerase. The crystal structure for Taq (5' nuclease) has also been determined (Kim *et al.*, *Nature* 376:612 [1995]).

The crystal structure from the flap endonuclease-1 from *Methanococcus jannaschii* also shows such a loop motif (Hwang *et al.*, *Nat. Struct. Biol.*, 5:707 [1998]). The backbone crystal structure of Mja FEN-1 molecules may be superimposed on T5 exonuclease, Taq 5'-exonuclease and T4 RNase H. An interesting feature common to all of these is the long loop. The loop of FEN-1 consists of a number of positively charged and aromatic residues and forms a hole with dimensions large enough to accommodate a single-stranded DNA molecule. The corresponding region in T5 exonuclease consists of three helices forming a helical arch. The size of the hole formed by the helical arch in T5 exonuclease is less than half that formed by the L1 loop in Mj FEN-1. In T4 RNase H or Taq 5' exonuclease, this region is disordered. Some regions of the arch bind metals, while other regions of the arch contact nucleic acid substrate. Alignment of the amino-acid sequences of six 5' nuclease domains from DNA polymerases in the pol I

family show six highly conserved sequence motifs containing ten conserved acidic residues (Kim *et al.*, *Nature* 376 [1995]).

The effects of alterations in the arch region were examined. In Taq polymerase the arch region is formed by amino acids 80-95 and 96-109. Site directed mutagenesis was performed on the arch region. Alignment of amino acid sequences of the FEN and polymerase 5' nucleases suggested the design of 3 amino acid substitution mutations, P88E, P90E and G80E. These substitutions were made on the Taq4M polymerase mutant as a parent enzyme. Results indicated that although the background activity on the HP and X substrates shown in Figure 22 are tremendously suppressed in all mutants, the desirable 5' nuclease activity on proper substrates (IdT and IrT, Figure 24) is also reduced. Despite the sequence homology between Taq and Tth polymerases, they have very different activity on HP and X substrates. The alignment of the Taq and Tth polymerase arch regions also demonstrates regions of extensive sequence homology as well as minor differences. These differences led to the design of mutations L109F and A110T using Taq4M to generate Taq4M L109F/A110T, and the mutant Taq 4M A502K/G504K/E507K/T514S to generate Taq 4M L109F/A110T/A502K/G504K/E507K/T514S mutant. These two mutations have drastically converted Taq4M enzyme to become more like Tth enzyme in terms of the background substrate specificity while the 5' nuclease activities on both DNA and RNA substrates are almost unchanged.

4) Focused random mutagenesis

As described above, physical studies and molecular modeling may be used alone or in combination to identify regions of the enzymes in which changes of amino acids are likely to cause observable differences in at least one aspect of cleavage function. In the section above, use of this information was described to select and change specific amino acids or combinations of amino acids. Another method of generating an enzyme with altered function is to introduce mutations randomly. Such mutations can be introduced by a number of methods known in the art, including but not limited to, PCR amplification under conditions that favor nucleotide misincorporation (REF), amplification using primers having regions of degeneracy (*i.e.*, base positions in which different individual,

but otherwise similar oligonucleotides in a reaction may have different bases), and chemical synthesis. Many methods of random mutagenesis are known in the art (Del Rio *et al.*, Biotechniques 17:1132 [1994]), and may be incorporated into the production of the enzymes of the present invention. The discussions of any particular means of

- 5 mutagenesis contained herein are presented solely by way of example and not intended as a limitation. When random mutagenesis is performed such that only a particular region of an entire protein is varied, it can be described as "focused random mutagenesis." As described in the Experimental Examples, a focused random mutagenesis approach was applied to vary the HhH and the thumb domains some of the enzyme variants previously
10 created. These domains were chosen to provide examples of this approach, and it is not intended that the random mutagenesis approach be limited to any particular domain, or to a single domain. It may be applied to any domain, or to any entire protein. Proteins thus modified were tested for cleavage activity in the screening reactions described in Example 1, using the test substrates diagrammed in Figures 22 and 24, with the results
15 described in Tables 6 and 7.

Random mutagenesis was performed on the HhH region with the parent TaqSS or TthDN H785A mutants. None of the 8 mutants generated showed an improvement in activity compared to the parent enzyme (Table 6). In fact, mutations of the region between residues 198-205 have about 2-5 fold lower activity on both DNA and RNA
20 substrates, suggesting that this region is essential for substrate recognition. Mutagenesis in the thumb region resulted in new mutations that improved 5' nuclease activity by 20-100% on a DNA target and about 10% on an RNA target (Table 7).

Numerous amino acids in each of the distinct subdomains play roles in substrate contact. Mutagenesis of these may alter substrate specificity by altering substrate
25 binding. Moreover, mutations introduced in amino acids that do not directly contact the substrate may also alter substrate specificity through longer range or general conformation altering effects. These mutations may be introduced by any of several methods known in the art, including, but not limited to random mutagenesis, site directed mutagenesis, and generation of chimeric proteins.

30 As noted above, numerous methods of random mutagenesis are known in the art. The methods applied in the focused random mutagenesis described herein may be applied

to whole genes. It is also contemplated that additional useful chimerical constructs may be created through the use of molecular breeding (*See e.g.*, U.S. Pat. No. 5,837,458 and PCT Publications WO 00/18906, WO 99/65927, WO 98/31837, and WO 98/27230, herein incorporated by reference in their entireties). Regardless of the mutagenesis method chosen, the rapid screening method described herein provides a fast and effective means of identifying beneficial changes within a large collection of recombinant molecules. This makes the random mutagenesis procedure a manageable and practical tool for creating a large collection of altered 5' nucleases having beneficial improvements. The cloning and mutagenesis strategies employed for the enzymes used as examples are applicable to other thermostable and non-thermostable Type A polymerases, since DNA sequence similarity among these enzymes is very high. Those skilled in the art would understand that differences in sequence would necessitate differences in cloning strategies, for example, the use of different restriction endonucleases may be required to generate chimeras. Selection of existing alternative sites, or introduction via mutagenesis of alternative sites are well established processes and are known to one skilled in the art.

Enzyme expression and purification can be accomplished by a variety of molecular biology methods. The examples described below teach one such method, though it is to be understood that the present invention is not to be limited by the method of cloning, protein expression, or purification. The present invention contemplates that the nucleic acid construct be capable of expression in a suitable host. Numerous methods are available for attaching various promoters and 3' sequences to a gene structure to achieve efficient expression.

5) Site-Specific mutagenesis

In some embodiments of the present invention, any suitable technique (*e.g.*, including, but not limited to, one or more of the techniques described above) are used to generate improved cleavage enzymes (*e.g.*, SEQ ID NO:221) with heterologous domains. Accordingly, in some embodiments, site-specific mutagenesis (*e.g.*, primer-directed mutagenesis using a commercially available kit such as the Transformer Site Directed mutagenesis kit (Clontech)) is used to make a plurality of changes throughout a nucleic acid sequence in order to generate nucleic acid encoding a cleavage enzyme of the

present invention. In some embodiments, a plurality of primer-directed mutagenesis steps are carried out in tandem to produce a nucleic acid encoding a cleavage enzyme of the present invention.

- In some embodiments, a plurality of primer directed mutagenesis steps are
- 5 directed to a selected portion of a nucleic acid sequence, to produce changes in a selected portion of a cleavage enzyme of the present invention. In other embodiments, a nucleic acid having changes in one selected portion is recombined with a nucleic acid having mutations in a different selected portion (e.g., through cloning, molecular breeding, or any of the other recombination methods known in the art), thereby creating a nucleic acid
- 10 having mutations in a plurality of selected portions, and encoding a cleavage enzyme of the present invention. The mutations in each selected portion may be introduced by any of the methods described above, or any combination of said methods, including but not limited to methods of random mutagenesis and site-directed mutagenesis.

For example, in one illustrative embodiment of the present invention, the nucleic acid sequence of SEQ ID NO:222 (a nucleic acid sequence encoding the cleavage enzyme of SEQ ID NO:221) is generated by making a plurality of primer-directed mutations to the nucleic acid sequence of SEQ ID NO: 104 (see Example 7 for the construction of SEQ ID NO:104). In some embodiments, each mutation is introduced using a separate mutagenesis reaction. Reactions are carried out sequentially such that

15 the resulting nucleic acid (SEQ ID NO: 222) contains all of the mutations. In another illustrative embodiment of the present invention, the nucleic acid sequence of SEQ ID NO:222 is generated by making a plurality of primer-directed mutations, as described above, in the nuclease portion (e.g., as diagrammed in Figure 6) of SEQ ID NO:111. The mutant nuclease portion is then combined with the "polymerase" portion of SEQ ID

20 NO:104 at the Not I site, using the recombination methods described in Example 4, thereby creating a single nucleic acid having SEQ ID NO:222, and encoding the cleavage enzyme of SEQ ID NO:221. Following mutagenesis, the resulting altered polypeptide is produced and tested for cleavage activity using any suitable assay (e.g., including, but not limited to, those described in Examples 1 and 6). In some embodiments, the nucleic acid

25 sequence encoding the cleavage enzyme of SEQ ID NO:221 (e.g., SEQ ID NO:222) is further modified using any suitable method.

V. Reaction Design for INVADER Assay Detection of RNA Targets;

Approaches to designing INVADER assays for the detection of RNA targets can vary depending on the needs of a particular assay. For example, in some embodiments, 5 an RNA to be detected or analyzed may be present in a test sample at low levels, so a high level of sensitivity (*i.e.*, a low limit of detection, or LOD) may be desirable; in other embodiments, an RNA may abundant, and may not require an especially sensitive assay for detection. In some embodiments, an RNA to be detected may be similar to other RNAs in a sample that are not intended to be detected, so that a high level of selectivity 10 in an assay is desirable, while in other embodiments, it may be desired that multiple similar RNAs be detected in a single reaction, so an assay may be provided that is not selective with respect to the differences among these similar RNAs.

In some embodiments it is especially desirable to avoid detection of any DNA molecules related to the target RNA molecules in a reaction. In some embodiments, this 15 is accomplished by designing INVADER assay probe sets to RNA splice junctions, such that only the properly spliced mRNAs provide the selected target sites for detection. In other embodiments, samples are handled such that DNA remains double stranded (*e.g.*, the nucleic acids are not heated or otherwise subjected to denaturing conditions), and is thus not available to serve as target in an INVADER assay reaction. In other 20 embodiments, cells are lysed under conditions that leave nuclei intact, thereby containing and preventing detection of the genomic DNA, while releasing the cytosolic mRNAs into the lysate solution for detection by the assay.

In some embodiments, the INVADER assay is to be used for detection or quantitation of an entire RNA having a particular variation of a sequence (*e.g.*, a mutation 25 a SNP, a particular spliced junction); in such embodiments, the location of the base or sequence to be detected is a determining factor in the selection of a site for the INVADER assay probe set to hybridize. In other embodiments, any portion of an RNA target may be used to indicate the presence or the amount of the entire RNA (*e.g.*, as in gene expression analysis). In this case, the probe sets may be directed toward a portion 30 of the RNA selected for optimal performance (*e.g.*, sites determined to be particularly accessible for probe hybridization) as a target in the INVADER assay.

The discussion of INVADER assay probe design is divided into the following sections:

- i. Target site selection based on accessibility
- ii. Target site selection based on selectivity
- 5 iii. Oligonucleotide design
 - a. Target-specific regions: length and melting temperature
 - b. Non-complementary regions
 - c. Folding and dimer analysis
- iv. Assay performance evaluation
- 10 v. Design and assay optimization

i. **Target site selection based on accessibility**

One consideration in the selection of sites for detection is the availability of the target site for hybridization of the assay probe set. To simply use randomly selected

- 15 complementary oligonucleotides for a given RNA target without prior knowledge of regions of the RNA that allow efficient hybridization can be an ineffective approach. For example, it is estimated that targeting RNA with antisense oligonucleotides based on random design results in one out of 18-20 tested oligonucleotides showing significant inhibition of gene expression (Sczakiel, *Frontiers in Biosciences* 5:194 [2000]; Patzel *et al.*, *Nucleic Acids Res.*, 27:4328 [1999]; Peyman *et al.*, *Biol. Chem. Hoppe-Seyler* 367:195 [1995]; Monia *et al.*, *Nature Med.*, 2:668 [1996]). Secondary and tertiary structures of RNA are thought to be the major reasons that influence the ability of an oligonucleotide to bind targeted regions of the RNA (Vickers *et al.*, *Nucleic Acids Res.*, 28:1340 [2000]; Lima *et al.*, *Biochemistry* 31:12055 [1992]; Uhlenbeck, *J. Mol. Biol.*, 25: 65:25 [1972]; Freier and Tinoco, *Biochemistry* 14:3310 [1975]). This is due to the hybridization kinetics and thermodynamics of destroying any structural motifs of the RNA and, in return, hybridizing the complementary DNA oligonucleotide (Patzel *et al.*, *Nucleic Acids Res.*, 27:4328 [1999]; Mathews *et al.*, *RNA* 5:1458 [1999]). Thus, the ability to identify regions of RNA that are "accessible" for hybridization is important for 25 design and selection of effective oligonucleotides.

- There are several experimental and theoretical methods available for identifying accessible regions in RNA. These include the use of RNase-H footprinting (Ho *et al.*, *Nature Biotechnology* 16:59 [1998]; Mateeva *et al.*, *Nucleic Acids Res.*, 25:5010 [1997]; Mateeva *et al.*, *Nature Biotechnology* 16:1374 [1998]), complementary arrays of
- 5 oligonucleotide libraries (Southern *et al.*, *Nucleic Acids Res.*, 22:1368 [1994]; Mir and Southern, *Nature Biotechnology* 17:788 [1999]), ribozyme libraries with random hexamer internal guide sequences (Campbell and Cech, *RNA* 1:598 [1995]; Lan *et al.*, *Science* 280:1593 [1998]), and RNA and DNA structure prediction computer programs (Szczakiel, *Frontiers in Biosciences* 5:194 [2000]; Patzel *et al.*, *Nucleic Acids Res.*,
- 10 27:4328 [1999]; Zuker, *Science* 244:48 [1989]; Walton *et al.*, *Biotechnol. Bioeng.*, 65:1 [1999]). Recently, new methods have been developed that use primer extension to identify sites in RNAs that are accessible for hybridization. Target nucleic acids (*e.g.*, mRNA target nucleic acids) are contacted with a plurality of primers containing a 3' a region of degenerate sequence and primer extension reactions are conducted. Where the
- 15 target nucleic acid is an RNA molecule, preferred enzymes for use in the extension reactions are reverse transcriptases, which produce a DNA copy of the RNA template. Folded structures present in the target nucleic acid affect the initiation and/or efficiency of the extension reaction. The extension products of the primers are analyzed to provide a map of the accessible sites. For example, certain extension products are not generated
- 20 where the primer is complementary to a sequence that is involved in a folded structure. Regions of the target nucleic acid that do not allow hybridization of the primer and do not result in the production of an extension product are considered inaccessible sites. In contrast, the presence of an extension product indicates that the primer was able to bind to an accessible region of the target nucleic acid. Such methods are referred to herein as
- 25 "reverse transcription with random oligonucleotide libraries" or "RT-ROL" (HT Allawi, *et al.*, *RNA* 7(2):314-27 [2001]). The use of a physical measurement such as RT-ROL or array hybridization provides the most direct evidence of the accessibility of a site on an RNA strand. In general, INVADER assays directed toward accessible regions produce stronger signals for a given amount of RNA than assays directed toward less accessible
- 30 regions of an RNA strand. For the detection of rare RNAs (*e.g.*, fewer than about 5,000 to 10,000 copies per INVADER assay reaction), or in any assay wherein it is desirable to

have the best (*i.e.*, lowest) limit of detection possible, it may be beneficial to start the assay design by analyzing the RNA structure using RT-ROL or another method of physical analysis.

- In other embodiments, ease of assay design may be more important than creation
- 5 of an assay with a particularly low LOD. Structure prediction software can simplify the task of determining which parts of an RNA are likely to be single stranded, and thus be more accessible for probe hybridization. As first step, the sequence of an RNA to be detected is entered into an electronic file. It may be entered manually or imported from a file (*e.g.*, a sequence data file, or a word processing file). In some embodiments, the
- 10 sequence is downloaded from a database, such as GenBank or EMBL. The RNA sequence can then be analyzed using a program such as *mfold* (Zucker, Science 244:48 [1989]), OligoWalk (Mathews *et al.*, RNA 5:1458 [1999]), and variations of both (Szakiel, Frontiers in Biosciences 5:194 [2000]; Patzel *et al.*, Nucleic Acids Res., 27:4328 [1999]; Walton *et al.*, Biotechnol. Bioeng., 65:1 [1999]).

15 ***Mfold* Analysis for target RNA structure prediction.**

- The output of *mfold* analysis can be used in several ways to assist in identifying accessible regions of an RNA target molecule. In one embodiment, the *mfold* program is used to generate an "ss count" file for identifying regions least likely to be involved in intra-strand basepairing. In another embodiment, the *mfold* program is used to generate a
- 20 ".ct" file, a file used as input information for use with RNA Structure 3.5 to perform an OligoWalk analysis. In preferred embodiments, for either use, the sequence to be detected is entered into *mfold*. In a preferred embodiment, the settings used in the *mfold* analysis include:
- Folding Temperature: 37°C (Even though the INVADER reaction may not be

25 conducted at this temperature.)

 - % Suboptimality: 5
 - # foldings: 50
 - Window Parameter: Default
 - Maximum distance between paired bases: No Limit

30 • Select BATCH folding

- Enter:an e mail address where the results are to be sent when ready
 - Image Resolution: High
 - Structure Format: Bases
 - Base Number Frequency:Default
- 5 • Structure Rotation Angle: 0
- Structure Annotation: SS-Count
 - 1M NaCl (Australian *mfold* Internet site only)

When results are ready, an e mail message is sent containing the Web address of
10 the results. The only file that is necessary for subsequent INVADER assay probe design analysis is the SS-Count file, which is then downloaded from the Results page. An exemplary *mfold* analysis using a GenBank entry for Human Ubiquitin (#4506712) is shown below:

SS-Count analysis for accessible sites identification.

15 The SS-Count file is then imported into an Excel spreadsheet file and the following options are chosen: Data Type = Delimited <press Next>; Delimited = Select (x) Spaces; (x) Treat multiple delimiters as one <press Next>; Column for data format = General. Selecting these options results in the import into Excel of three columns of data (Figure 39). The first line in the first column is the total number of stable structures
20 *mfold* found under the parameters used in the folding. With the Ubiquitin example, there were 12 structures found.

 The rest of the first column is the RNA nucleotide position numbered from 1. The second column is the raw SS-Count number and represents the number of times the corresponding base was NOT base-paired as part of some secondary structure. The third column is the sequence of the RNA analyzed, identifying the base at each numbered position. By looking for bases that are involved in fewer structures (*i.e.*, bases listed in column 3 corresponding to the higher numbers in column 2), it is possible to identify regions of the mRNA (identified by position number in column 1) that are more likely to be free of intra-strand base-pairing, and thus are more likely to be available for detection
25 30 using the INVADER assay.

One way of viewing the data is to calculate the running average SS-count for a ten nucleotide stretch of the RNA (the Ave(10) Index) and chart the Ave(10) Index against the base pair position (See e.g., Figure 48).

An alternative plot is to graph the nucleotide position against the Ave(10) Index
5 expressed as a percentage of the total number of structures found by *mfold* (Fig 39). As with the raw SS-count table, regions of the RNA corresponding to higher numbers in the Ave(10) Index are involved in fewer predicted folded structures. Viewing the Ave(10) Index in either a chart or graph format reduces the complexity of the data, and can reveal longer stretches of the RNA that are more likely to be structure-free. For example, from
10 the graph of the running average, a user can pick out all of the major peak areas as likely regions for INVADER assay probe design. This creates an SS-Count Candidate List. In the Human ubiquitin example, there is one major peak and about 6 other peaks (Fig. 39)

The next step is to refer back to the raw (*i.e.*, not the running average) SS-Count data from within each of the peak areas, and identify the residue where the running
15 average is changing in magnitude, this is a local "turn" and is generally a good candidate residue to be positioned at the INVADER assay probe set cleavage site. For example, in Human Ubiquitin, residue G119 is found at a minor local turn within a globally accessible region (Fig. 40). The INVADER assay probe set with the cleavage site at this location is a good performer in detection of this RNA. Placing the cleavage site at G114
20 did not result in better detection even though it had a higher %Ave(10) value. While not limiting the present invention to any particular mechanism, and an understanding of the mechanism is not necessary to practice the invention, this is likely to be because this area was less accessible to the Probe or INVADER oligonucleotides than was position G119.

OligoWalk Structure prediction with RNA Structure 3.5 for accessible sites

25 identification

In some embodiments, the program OligoWalk, a module of the software "RNAStructure" (Mathews *et al.*, RNA 5:1458 [1999]) is used in the selection of sites that are more likely to be accessible for oligonucleotide binding. OligoWalk uses sets of thermodynamic parameters for both RNA and DNA, and their hybrids (Allawi and

30 SantaLucia, Biochemistry 36:10581 [1997]; Mathews *et al.*, J. Mol. Biol., 288:911

[1999]; Sugimoto *et al.*, Biochemistry 34:11211 [1995]) in an algorithm that relies on *mfold* for RNA secondary structure prediction (Zucker, Science 244:48 [1989]).

OligoWalk is designed to predict the most favorable regions of an RNA target for designing antisense oligonucleotides by estimating the overall thermodynamics of

- 5 hybridizing an antisense oligomer to the RNA by taking into account the thermodynamics of destroying any structural motifs in the RNA target or the antisense oligonucleotide. The affinity of the oligomer to its target is expressed as an overall Gibbs free energy change of a self-structured oligomer, and of a target associating into an oligomer-target complex. This free energy is usually a negative number, indicating favorable binding,
- 10 and is expressed in 'kcal/mol' units. OligoWalk analysis is performed with 8 to 15 base oligonucleotide size to resemble the average length of the analyte specific region of the Signal Probe. Plotting the total binding energy against the length of the RNA generates a graph of peaks and valleys. The lowest negative values generally indicate the most favorable sites for oligonucleotides to bind. The most inaccessible regions have positive
- 15 binding energy values, and generally are a poor sites for assay probe design

In a preferred embodiment, the OligoWalk module of RNA Structure 3.5 is used to determine binding energies by performing an 8-base OligoWalk using the following settings:

- 20 □ Break Local Structure
- Include suboptimal structures
- Oligo Length: 8nt
- Oligo Concentration: 100 nM
- Oligo Type: DNA
- Walk entire Target RNA

25

When these parameters have been set, the sequence file to be folded (the ".ct" output file from *mfold*) can be selected and opened. Once the sequence has been folded, a report can be created using the Output menu. The report is imported into Excel and the data generated above is plotted. In a preferred embodiment, the OligoWalk data is

- 30 graphed with the SS-Count data. The regions displaying the lowest free energy values (*i.e.*, the largest negative numbers) are generally the most likely to be accessible for

- hybridization. In preferred embodiments, the 3' end and the majority of the target-binding region of the probe oligonucleotide complement an accessible region of the target RNA. In particularly preferred embodiments, the majority of the binding site for the corresponding INVADER oligonucleotide falls within the same accessible region.
- 5 another preferred embodiment, the binding site for an INVADER oligonucleotide falls within a nearby accessible region.

An INVADER oligonucleotide can generally be positioned to bind to a less accessible site. While not limiting the present invention to any particular mechanism, it is observed that the INVADER oligonucleotides are generally longer than probe
10 oligonucleotides used in the INVADER assay reactions and, because they are generally designed to remain bound to the target at the reaction temperature, they will be selected to have a T_m s about 12 to 15 °C higher than that of a corresponding probe. Consequently, INVADER oligonucleotides may more readily break the local target structure, and thus may be less dependent on the accessibility of the target-binding site.
15 In selecting among accessible sites for the design of INVADER assay oligonucleotides, the base composition of the site is also considered. It has been observed that stretches of more than 4 or 5 of the same nucleotide in a row (e.g., ...AAAA... or ...CCCC...) in any portion of the binding site for the assay oligonucleotides may reduce the performance of the probe set in the assay (e.g., by
20 increasing background or decreasing specificity). Thus, in preferred embodiments, any stretches comprising four or more repeated bases are generally avoided. Another consideration is the effect of base composition on lengths of the oligonucleotides in the probe set. In many cases, targeting A-T rich sequences requires the use of longer oligonucleotides for a reaction performed at a given temperature, compared to the length
25 of oligonucleotides targeted to sequences having a more even distribution of A-T and G-C bases. Longer oligonucleotides can be more prone to formation of intrastrand structures and dimer structures. Thus, it is preferred that the distribution of A-T bases and G-C bases within a target region be as close to even (*i.e.*, about 50% G-C content) as the region to be detected permits. In particularly preferred embodiments, the distribution
30 of A-T and G-C positions is evenly distributed across the binding sites (e.g., not having all A-T positions in one half, with all G-C positions in the other).

ii. Target site selection based on selectivity

In some embodiments, probe sets are designed to examine highly homologous, or closely related RNA targets (*i.e.*, targets that are very similar in sequence). In such 5 embodiments, the RNA or homologous cDNA sequences are compared, *e.g.*, using an alignment program such as MEGALIGN (DNAsstar Madison, WI).

In some embodiments, selectivity is provided by designing probe sets to detect splice junctions. Splice junctions can be identified by aligning the cDNA and gene sequences using an alignment program (*e.g.* MEGALIGN) or under the BLAST menu at 10 the NCBI website (BLAST 2 sequences). Splice junctions are also often listed in the GenBank report (intron/exon sites). INVADER assay oligonucleotide sets are designed such that the probe and INVADER oligonucleotides are complementary to the coding strand (mRNA), generally with the cleavage site being as close to the splice junction as possible. In some embodiments, different splice junctions within an mRNA are analyzed 15 for accessibility, as described above. In preferred embodiments, probe sets are designed to detect one or more splice junctions showing greater accessibility compared to the accessibility of other splice junctions within the same RNA target.

In some embodiments designed to exclude detection of RNAs related to the target RNA, sequences are examined to identify bases that are unique to the target RNA when 20 compared to the other similar sequences from which the target is distinguished. Generally, the unique base is positioned to hybridize to the 5' end of the target-specific region of the probe oligonucleotide. In some embodiments, two adjacent bases are unique to the target compared to the related RNA. If two adjacent unique bases are available in an appropriately accessible portion of the target RNA, it is preferred that 25 these bases be used as the site around which the probe and INVADER oligonucleotides sets are designed. In some embodiments, the two unique bases are positioned such that the site of cleavage of the probe is between the two base-pairs they form with the probe. In other embodiments, one of the unique bases is in the last position of the hybridization site of the INVADER oligonucleotide (*i.e.*, it is positioned to base-pair to the penultimate 30 residue on the 3' end of the INVADER oligonucleotide).

In some embodiments, the assay is designed to include detection of RNAs that are similar, but not identical, to the target RNA. If the assay is being designed for inclusive detection, the compared sequences are examined to identify sites having complete homology. Such designs can be created to detect homologous sequences in the same species or between species. Generally, the most homologous regions are selected as hybridization targets for probe oligonucleotides. Generally, some variation can be tolerated, for example, if it is not at the base that would hybridize to the 5' end of the target-specific region of a probe. In some embodiments, variation is accommodated by the use of degenerate bases in the INVADER assay oligonucleotides (e.g., mixtures of bases are used at positions within the synthesized probe, INVADER and/or stacker oligonucleotides, said mixtures selected to complement the mixture of specific bases present in the collection of related target RNAs).

iii. Oligonucleotide design

15 a. Target-specific regions: length and melting temperature

As described above in Section I (a) concerning the oligonucleotide design, in some embodiments, the length of the analyte-specific regions are defined by the temperature selected for running the reaction. Starting from the desired position (e.g., a variant position or splice junction in a target RNA, or a site corresponding to a low free energy value in an OligoWalk analysis) an iterative procedure is used by which the length of the ASR is increased by one base pair until a calculated optimal reaction temperature (T_m plus salt correction to compensate for enzyme and any other reaction conditions effects) matching the desired reaction temperature is reached. In general probes are selected to have an ASR with a calculated T_m of about 60 °C if a stacking oligonucleotide is not used, and a T_m of about 50 to 55 °C if a stacking oligonucleotide is used (a stacking oligonucleotide typically raises the T_m of a flanking probe oligonucleotide by about 5 to 15 °C). If the position of variation or a splice junction is a starting position, then the additions are made to the 3' end of the probe. Alternatively, if the 3' end of the probe is to be positioned at the most accessible site, the additions are in the 5' direction. In some embodiments, wherein a stacker oligonucleotide is to be used, it is preferred that the

probe be designed to have a 3' base that has stable stacking interaction interface with the 5' base of the stacker oligonucleotide. The stability of coaxial stacking is highly dependent on the identity of the stacking bases. Overall, the stability trend of coaxial stacking in decreasing order is purine:purine > purine:pyrimidine ≈ pyrimidine:purine > 5 pyrimidine:pyrimidine. In other embodiments employing a stacker, a less stable stacking interaction is preferred; in such cases the probe 3' base and/or the stacker 5' base are selected to provide a less stable stacking interaction. In some embodiments, the probe 3' base and/or the stacker 5' base are selected to have a mismatch with respect to the target strand, to reduce the strength of the stacking interaction.

10 The same principles are also followed for INVADER oligonucleotide design. Briefly, starting from the position N, additional residues complementary to the target RNA starting from residue N-1 are then added in the upstream direction until the stability of the INVADER-target hybrid exceeds that of the probe (and therefore the planned assay reaction temperature). In preferred embodiments, the stability of the INVADER-target hybrid exceeds that of the probe by 12-15 °C. In general, INVADER oligonucleotides are selected to have a T_m near 75 °C. Software applications, such as INVADERCREATOR (Third Wave Technologies, Madison, WI) or Oligonucleotide 5.0 may be used to assist in such calculations.

If a stacking oligonucleotide is to be used, similar design principles are applied.

20 The stacking oligonucleotide is generally designed to hybridize at the site adjacent to the 3' end of the probe oligonucleotide, such that the stacker/target helix formed can coaxially stack with the probe/target helix. The sequence is selected to have a calculated T_m of about 60 to 65 °C, with the calculation based on the use of natural bases. However, stacking oligonucleotides are generally synthesized using only 2'-O-methyl nucleotides, and consequently, have actual T_m s that are higher than calculated by about 0.8°C per base, for actual T_m s close to 75 °C.

In some embodiments, ARRESTOR oligonucleotides are included in a secondary reaction. ARRESTOR oligonucleotides are provided in a secondary reaction to sequester any remaining uncleaved probe from the primary reaction, to preclude interactions 30 between the primary probe and the secondary target strand. ARRESTOR oligonucleotides are generally 2'-O-methylated, and comprise a portion that is

complementary to essentially all of their respective probe's target-specific region, and a portion that is complementary to at least a portion of the probe's flap regions (e.g., six nucleotides, counted from the +1 base towards the 5' end of the arm).

b. Non-complementary regions

5 Probe 5' Arm selection

The non-complementary arm of the probe, if present, is preferably selected (by an iterative process as described above) to allow the secondary reaction to be performed at a particular reaction temperature. In the secondary reaction, the secondary probe is generally cycling, and the cleaved 5' arm (serving as an INVADER oligonucleotide) 10 should stably bind to the secondary target strand.

INVADER oligonucleotide 3' terminal mismatch selection

In preferred embodiments, the 3' base of the INVADER oligonucleotide is not complementary to the target strand, and is selected in the following order of preference

15 (listed as INVADER oligonucleotide 3' base/target base):

C in target:	C/C > A/C > T/C > G/C
A in target:	A/A > C/A > G/A > T/A
G in target:	A/G > G/G > T/G > C/G
U in target:	C/U > A/U > T/U > G/U

20

c. Folding and dimer analysis

In some embodiments, the oligonucleotides proposed for use in the INVADER assay are examined for possible inter- and intra-molecular structure formation in the absence of the target RNA. In general, it is desirable for assay probes to have fewer 25 predicted inter- or intra molecular interactions. In some embodiments, the program OLIGO (e.g., OLIGO 5.0, Molecular Biology Insights, Inc., Cascade, CO) is used for such analysis. In other embodiments, the program *mfold* is used for the analysis. In yet other embodiments, the RNAStructure program can be used for dimer analysis. The

following sections provide stepwise instructions for the use of these programs for analysis of INVADER assay oligonucleotides.

OLIGO 5.0 analysis for Probe structure and interaction prediction.

5 Analysis of INVADER oligonucleotides using OLIGO 5.0 comprises the following steps. All menu choices are shown in UPPER CASE type.

1. Launch OLIGO 5.0 and open a sequence file for each mRNA to be analyzed. This is done by using a menu to select the following

- 10 • Choose FILE->NEW
 • Paste in longest available sequence
 • Choose ACCEPT & QUIT (F6)

2. Set Program settings to default

Choose FILE->RESET->ORIGINAL DEFAULTS

15 3. Identify Probe Oligonucleotide

- Select OLIGO LENGTH to be around 16 nucleotides (open the menu for this option by using ctrl-L keystrokes).
• Move the cursor indicating the 5' end of the Current Oligo until the 3' end is located at the candidate cleavage site residue.
20 • Choose ANALYSE->DUPLEX FORMATION->CURRENT OLIGO (ctrl-D) for a rough determination of the extent of dimer and hairpin formation.
• Confirm length of analyte region corresponds with desired reaction temperature [e.g., through the use of T_m calculation as described in the Optimization of Reaction Conditions, I (c) of the Detailed Description of the Invention]
25 • Select the "LOWER" button in OLIGO 5.0 to copy the anti-sense sequence (this will be the analyte-specific region of the actual probe oligonucleotide and is anti-sense to the RNA strand.)
• Import into a database file.

- Save to computer memory.

4. Identify INVADER Oligonucleotide

- Choose sequence adjacent to the probe oligonucleotide identified from step 3.
- Select OLIGO LENGTH to ~24 nucleotides
- 5 • Confirm length of analyte region corresponds with desired reaction temperature [e.g., through the use of T_m calculation as described in the Optimization of Reaction Conditions, I (c) of the Detailed Description of the Invention, about 75 °C for INVADER oligonucleotides]. Select the "LOWER" button in OLIGO 5.0 to copy the corresponding anti-sense sequence (this will be the analyte-specific region of the actual INVADER oligonucleotide.)
- 10 • Import into a database file.
- Save to computer memory.

5. Addition of Cleaved Arm Sequence and INVADER Oligonucleotide Mismatch Sequence.

- 15 • Export the Probe oligonucleotide as Upper Primer.
- Export the INVADER oligonucleotide as Lower Primer.
- EDIT UPPER PRIMER to add in a candidate arm sequence (selected, for example, as described above).
- 20 • Check that the arm sequence does not create new secondary structures (analysis performed as described above).
- EDIT LOWER PRIMER to add in the 3' mismatched nucleotide that will overlap into the cleavage site (selected according to the guidelines for this mismatched bases, provided above).
- Select all Upper and Lower Primer boxes in the "Print/Save Options"
- 25 • PRINT ANALYSIS of Upper (Probe) and Lower (INVADER) oligonucleotides and check for lack of stable secondary structures.
- Save both mRNA sequence and oligonucleotide sequence database files before quitting the program.

Generally, oligonucleotides having detected intra-molecular formations with stabilities of less than $-6 \Delta G$ are preferred. Less stable structures represent poor substrates for CLEAVASE enzymes, and thus cleavage of such structures is less likely to contribute to background signal. Probe and INVADER oligonucleotides having less affinity for each other are more available to bind to the target, ensuring the best cycling rates.

- The T_m of dimerized probes (*i.e.*, probes wherein one probe molecule is hybridized to another probe molecule) should ideally be lower than the T_m for the probe hybridized to the target, to ensure that the probes preferentially hybridize to the target sequence at the elevated temperatures at which INVADER assay reactions are generally conducted. Similarly, the T_m for the INVADER oligonucleotide hybridized either to itself or to a probe molecule should be lower than the INVADER oligonucleotide/target T_m . It is preferred that dimer T_m s (*i.e.*, Probe/Probe and Probe/INVADER oligonucleotide) be 25°C or less to ensure that they will be unlikely to form at the planned reaction temperature.

The melting temperatures for each of these complexes can be determined as described above in Optimization of Reaction Conditions, I (c) of the Detailed Description of the Invention, or by using the OLIGO software. Once RNAs sites and several candidate INVADER assay oligonucleotide sets are selected according to the process outlined above, the candidate oligonucleotide sets can be ranked according to the degree to which they comply with preferred selection rules, *e.g.*, their location on the SS-Count average plot (peak, valley, neither), and the energetic predictions of probe and INVADER oligonucleotide interactions. In some embodiments, the ranked probe sets are tested in order of rank to identify one or more sets having suitable performance in an RNA INVADER assay. In other embodiments, several of the top ranked sets (*e.g.*, two, three or more) are selected for testing, to rapidly identify one or more sets having suitable or desirable performance.

Mfold analysis for probe structure and interaction prediction

- Analysis of probe and INVADER oligonucleotide interactions may be performed using *mfold* for DNA provided by Michael Zuker, available through Rensselaer

Polytechnic Institute at bioinfo.math.rpi.edu/~mfold/dna/form1.cgi. The analysis is performed without changing the default ionic conditions, and with a selected temperature of 37 °C and with % suboptimality set to 75. Each sequence (e.g., probe, INVADER oligonucleotide, stacker, etc.) is folded using the program to check for any unimolecular structure formation (e.g., hairpins). The energies provided by *mfold* gives for unimolecular structures can be used as provided, without further calculations.

- 5 Bimolecular structure formation for a given oligonucleotide is assessed by typing in the oligonucleotide sequence (5' to 3') followed by the sequence of a small, stable hairpin forming sequence (e.g., CCCCCCTTTGGGGG [SEQ ID NO:707]), followed by
10 the same oligonucleotide sequence, again listed 5' to 3'. Constraints are entered to require that these Ts remain single-stranded and the strings of Cs and Gs in this spacer are basepaired. The command "F" is used to force basepairing, while the command "P" is used to prohibit basepairing, and the positions of the forced or prohibited basepairs are counted from the 5' end. For example, if the sequence of interest is a 20-mer, then the
15 following is entered:

F 21 0 5 [this forces the C's, C21 to C25, to base pair]
P 26 0 4 [this forces the T's, T26 to T29, to be single stranded]
F 30 0 5 [this forces the G's, G30 to G34, to base pair]

- On examination of the resulting structures, the stability of each can be estimated
20 by subtracting the stability (*i.e.*, the thermodynamic measures) of the central spacer hairpin from the total result (*i.e.*, Thermodynamics of possible structure = *mfold* structure thermodynamics – core hairpin thermodynamics). For convenience, in some embodiments, any nearest neighbor interactions between the central hairpin and dimers formed by the test sequence are ignored for this calculation; a more accurate analysis
25 would require consideration of this interaction. The core hairpin formed by CCCCCCTTTGGGGG (SEQ ID NO:707) has the following thermodynamics: $\Delta G = -5.3$; $\Delta H = -37.8$; $\Delta S = -104.8$.

- The process can be demonstrated using the following probe sequence: 5'-
CCCTATCTTAAAGTTTAAAAAGTTGA-3' (SEQ ID NO:708). The
30 oligonucleotide sequence is examined by *mfold* analysis for bimolecular structures using the following steps.

1- In *mfold* sequence box type:

CCCTATCTTAAAGTTTAAAAAGTTGACCCCTTTGGGGCCC
TATCTTAAAGTTTAAAAAGTTGA (SEQ ID NO:137)

5 2- In the constraint box type:

P 36 0 4

F 31 0 5

F 40 0 5

10 Results (showing one):

Structure 1
 $\Delta G = -14.2 \quad \Delta H = -150.5 \quad \Delta S = -439.5 \quad T_m = 69.3$
 CCCTATCTT | G G ----- T
 AAA TTTTTAAAAA TTGGA CCCCCC T
 TTT AAAAATTTTT AATT GGGGG T
 ----- AG ^G G TCTATCCC T
 15

To evaluate the stability of the duplex:

20 CCCTATCTT | G G
 AAA TTTTTAAAAA TTGGA
 TTT AAAAATTTTT AATT
 ----- AG ^G G TCTATCCC

the thermodynamic values for the hairpin alone are subtracted from the values for the
 25 complete structure:

$$\Delta G = -14.2 - (-5.3) = -8.9,$$

$$\Delta H = -150.5 - (-37.8) = -112.7,$$

$$\Delta S = -439.5 - (-104.8) = -334.7,$$

Using a calculation wherein $T_m (\text{ }^{\circ}\text{C}) = \{\Delta H / [\Delta S + R \ln (CT/4)]\} - 273.15$, wherein R is
 30 the gas constant 1.987 (cal/K.mol), ln is the natural log, and CT is the total single strand
 concentration in Molar, this results in a calculated T_m of 46.1 $^{\circ}\text{C}$ for the non-hairpin
 portion of the structure.

The above method is not limited to the use of the core hairpin sequence
 CCCCTTTGGGG but rather any stable hairpin sequences can be used. For
 35 example, CGCGCGGAACGCGCG (SEQ ID NO:138) or CCCGGGTTTCCCGGG

(SEQ ID NO:139). However, if a different hairpin sequence is used, one needs to calculate its stability using *mfold* and use its thermodynamics in the subsequent calculations.

5 RNAStructure for oligonucleotide interaction prediction

Dimer formation can also be evaluated using the RNAStructure program. Unlike *mfold*, RNAStructure allows the calculation of all possible oligonucleotide-oligonucleotide interactions and provides an output .ct file. One can then view the structures using any .ct viewing program such as RNAStructure or RNAAvis (1997, P.

- 10 Rijk, University of Antwerp (UIA), available on the Internet at rna.uia.ac.be/rnavis) and evaluate the stability of any dimer formation using the nearest-neighbor model (Borer et al., 1974) and DNA nearest-neighbor parameters (Allawi & SantaLucia, 1997).

For example, to evaluate the propensity of the sequence 5'

- AGGCGCACCAATTGGTGTT 3' (SEQ ID NO:140) for dimer formation using the
15 DNA Fold Intermolecular module of RNAStructure, the sequence is saved into a file (e.g., probe.seq) and the following parameters are set:

Sequence file 1: probe.seq

Sequence file 2: probe.seq

CT file: dimer.ct

- 20 Max % Energy difference: 50

Max number of structures: 20

Window size: do not change

- After the calculation is done, one can view the resulting .ct file using the "view" module
25 of RNAStructure. Generally, there will be several structures within the .ct file. The view module is used to view them individually. One of the dimers that the test sequence, above, can form according to RNAStructure is:

AGGCG	TT
CACCAATTTGGTG	
GTTGGTTAACAC	
TT	GCGGA

5

According to the nearest-neighbor model (*i.e.*, using DNA nearest-neighbor and mismatch parameters [Allawi & SantaLucia, 1997]), the stability of this duplex in 1M NaCl and at a probe concentration of 100 μ M is:

$$\Delta G^\circ_{37} = -10.7$$

10 $\Delta H = -87.6$

$\Delta S = -250.1$

$T_m = 50.1 \text{ } ^\circ\text{C}$

- By changing the identities of Sequence Files 1 & 2, RNAStructure can be used to
15 evaluate the possibility of any dimer formation between pairs of all of the DNA oligonucleotides present in an INVADER assay reaction.

iv. Assay performance evaluation

- Probe sets selected according to the guidelines provided above can be tested in the
20 INVADER assay to evaluate performance. While the oligonucleotides are designed to perform at or near a particular desired reaction temperature, the best performance for a given design may not be precisely at the intended temperature. Thus, in evaluating any new INVADER assay probe set, it can be helpful to examine the performance in the INVADER assay conducted at several different reaction temperatures, over a range of
25 about 10 to 15 $^{\circ}\text{C}$, centered around the designed temperature. For convenience, temperature optimization can be performed on a temperature gradient thermocycler with a fixed amount of RNA (*e.g.*, 2.5 amoles of an *in vitro* transcript per reaction), and for a fixed amount of time (*e.g.*, 1 hour each for Primary and Secondary reactions). The temperature gradient test will reveal the temperature at which the designed probe set
30 produces the best performance (*e.g.*, the highest level of target-specific signal compared

to background signal, generally expressed as a multiple of the zero-target background signal, or "fold over zero").

- The results can be examined to see how close the measured temperature optimum is to the intended temperature of operation. In some embodiments, it is desirable to have
- 5 probe sets that operate at or near a pre-selected temperature. If the measured temperature optimum is higher than the desired reaction temperature, a probe design can be altered in ways that tend to reduce the probe/target T_m (e.g., shortened by one or more bases, or altered to contain one or more mismatched bases). In some embodiments, wherein a stacker oligonucleotide is not used, wherein the reaction temperature is more than 7 °C
- 10 above the desired reaction temperature, and wherein the performance (e.g., the fold over zero) is acceptable, use of a 3' mismatch on the probe oligonucleotide is likely to lower the reaction temperature without otherwise altering the assay performance.

- An LOD determination can be made by performing reactions on varying amounts of target RNA (e.g., an *in vitro* transcript control RNA of known concentration). In
- 15 preferred embodiments, a designed assay has an LOD of less than 0.05 attomole. In particularly preferred embodiments, a designed assay has an LOD of less than 0.01 attomole. It is contemplated that the same guideline provided above for reducing the LOD of a designed assay may be used for the purpose of raising the LOD of a designed assay, *i.e.*, to make it LESS sensitive to the presence of a target RNA. For example, it
- 20 may be desirable to detect an abundant RNA and a rare RNA in the same reaction. In such a reaction, it may be desirable to attenuate the signal generated for the abundant RNA so that it does not overwhelm the signal from the rarer species. In some embodiments this may be done by designing probe sets for reduced signal generation, e.g., an LOD of at least (not less than) 0.5 attomoles. In some embodiments, a single step
- 25 INVADER assay may be used for detection of abundant targets in a sample, while sequential INVADER reactions to amplify signal, as described in Section II, may be used for less abundant analytes in the same sample. In preferred embodiments, the single step and the sequential INVADER assay reactions for the different analytes are performed in a single reaction.

- 30 In some embodiments, time course reactions are run, wherein the accumulation of signal for a known amount of target is measured for reactions run for different lengths of

time. This measurement will establish the linear ranges, *i.e.*, the ranges in which accurate quantitative measurements can be made using a given assay design, with respect to time and starting target RNA level.

5 v. Design and assay optimization

Some designed assays may not meet the preferred performance criteria described above. A number of variations on the performance of INVADER assay reactions have been described herein. In optimizing performance of the INVADER assay for the detection of RNA targets, these variations may be used alone or in combination. For 10 example, in some embodiments, a stacker oligonucleotide is employed. While not limiting the present invention to any particular mechanism of action, in some embodiments, a stacker oligonucleotide may enhance performance of an assay by altering the hybridization characteristics (*e.g.*, T_m) of a probe or an INVADER oligonucleotide. In some embodiments, a stacker oligonucleotide may increase performance by enabling 15 the use of a shorter probe. In other embodiments, a stacker oligonucleotide may enhance performance by altering the folded structure of the target nucleic acid. In yet other embodiments, the enhancing activity of the stacker oligonucleotide may involve these and other mechanisms in combination.

In other embodiments, the target site may be shifted. In some embodiments, 20 reactions are optimized by testing multiple probe sets that shift along a suspected accessible site. In preferred embodiments, such probe sets shift along the accessible site in one to two base increments. In embodiments wherein accessible sites have previously been predicted only by computer analysis, physical detection of the accessible sites may be employed to optimize a probe set design. In preferred embodiments, the RT-ROL 25 method of detecting accessible sites is employed. In some embodiments, optimization of a probe set design may require shifting of the target site to a newly identified accessible site.

In some embodiments, *e.g.*, wherein an accessible site has been identified yet probe set performance is low, a change in the design of a probe 5' arm may improve 30 assay performance without altering the site targeted. In other embodiments, altering the length of an ARRESTOR oligonucleotide (*e.g.*, increasing the length of the portion that is

complementary to the 5' arm region of the probe) may reduce background signal, thus increasing the probe set performance.

Other variations on oligonucleotide design may be employed to alter performance in an assay. Some modifications may be employed to shift the ideal operating

- 5 temperature of a probe set design into a preferred temperature range. For example, the use of shorter oligonucleotides and the incorporation of mismatches generally act to reduce the T_m s, and thus reduce the ideal operating temperatures, of designed oligonucleotides. Conversely, the use of longer oligonucleotides and the employment of stacking oligonucleotides generally act to increase the T_m s, and thus increase the ideal
10 operating temperatures of the designed oligonucleotides.

Other modifications may be employed to alter other aspects of oligonucleotide performance in an assay. For example, the use of base analogs or modified bases can alter enzyme recognition of the oligonucleotide. In some embodiments, such modified bases are used to protect a region of an oligonucleotide from nuclease cleavage. In other

- 15 embodiments, modified bases are used to affect the ability of an oligonucleotide to participate as a member of a cleavage structure that is not in a position to be cleaved (e.g., to serve as an INVADER oligonucleotide to enable cleavage of a probe). These modified bases may be referred to as "blocker" or "blocking" modifications. In some embodiments, assay oligonucleotides incorporate 2'-O-methyl modifications. In other
20 embodiments, assay oligonucleotides incorporate 3' terminal modifications (e.g., NH₂, 3' hexanol, 3' phosphate, 3' biotin).

In yet other embodiments, the components of the reaction may be altered to affect assay performance. For example, oligonucleotide concentrations may be varied.

- Oligonucleotide concentrations can affect multiple aspects of the reaction. Since melting
25 temperatures of complexes are partly a function of the concentrations of the components of the complex, variation of the concentrations of the oligonucleotide components can be used as one facet of reaction optimization. In the methods of the present invention, ARRESTOR oligonucleotides may be used to modulate the availability of the primary probe oligonucleotides in an INVADER assay reaction. In some embodiments, an
30 ARRESTOR oligonucleotide may be excluded. Other reaction components may also be varied, including enzyme concentration, salt and divalent ion concentration and identity.

VI. Kits for performing the RNA INVADER Assay

In some embodiments, the present invention provides kits comprising one or more of the components necessary for practicing the present invention. For example, the present invention provides kits for storing or delivering the enzymes of the present invention and/or the reaction components necessary to practice a cleavage assay (e.g., the INVADER assay). The kit may include any and all components necessary or desired for the enzymes or assays including, but not limited to, the reagents themselves, buffers, control reagents (e.g., tissue samples, positive and negative control target oligonucleotides, etc.), solid supports, labels, written and/or pictorial instructions and product information, inhibitors, labeling and/or detection reagents, package environmental controls (e.g., ice, desiccants, etc.), and the like. In some embodiments, the kits provide a sub-set of the required components, wherein it is expected that the user will supply the remaining components. In some embodiments, the kits comprise two or more separate containers wherein each container houses a subset of the components to be delivered. For example, a first container (e.g., box) may contain an enzyme (e.g., structure specific cleavage enzyme in a suitable storage buffer and container), while a second box may contain oligonucleotides (e.g., INVADER oligonucleotides, probe oligonucleotides, control target oligonucleotides, etc.). In some embodiments one or more of the reaction components may be provided in a predisposed format (*i.e.*, premeasured for use in a step of the procedure without re-measurement or re-dispensing). In some embodiments, selected reaction components are mixed and predisposed together. In preferred embodiments, predisposed reaction components are predisposed and are provided in a reaction vessel (including but not limited to a reaction tube or a well, as in, *e.g.*, a microtiter plate). In particularly preferred embodiments, predisposed reaction components are dried down (*e.g.*, desiccated or lyophilized) in a reaction vessel.

Additionally, in some embodiments, the present invention provides methods of delivering kits or reagents to customers for use in the methods of the present invention. The methods of the present invention are not limited to a particular group of customers. Indeed, the methods of the present invention find use in the providing of kits or reagents

to customers in many sectors of the biological and medical community, including, but not limited to customers in academic research labs, customers in the biotechnology and medical industries, and customers in governmental labs. The methods of the present invention provide for all aspects of providing the kits or reagents to the customers, 5 including, but not limited to, marketing, sales, delivery, and technical support.

In some embodiments of the present invention, quality control (QC) and/or quality assurance (QA) experiments are conducted prior to delivery of the kits or reagents to customers. Such QC and QA techniques typically involve testing the reagents in experiments similar to the intended commercial uses (e.g., using assays similar to those 10 described herein). Testing may include experiments to determine shelf life of products and their ability to withstand a wide range of solution and/or reaction conditions (e.g., temperature, pH, light, etc.).

In some embodiments of the present invention, the compositions and/or methods of the present invention are disclosed and/or demonstrated to customers prior to sale (e.g., 15 through printed or web-based advertising, demonstrations, etc.) indicating the use or functionality of the present invention or components of the present invention. However, in some embodiments, customers are not informed of the presence or use of one or more components in the product being sold. In such embodiments, sales are developed, for example, through the improved and/or desired function of the product (e.g., kit) rather 20 than through knowledge of why or how it works (*i.e.*, the user need not know the components of kits or reaction mixtures). Thus, the present invention contemplates making kits, reagents, or assays available to users, whether or not the user has knowledge of the components or workings of the system.

Accordingly, in some embodiments, sales and marketing efforts present 25 information about the novel and/or improved properties of the methods and compositions of the present invention. In other embodiments, such mechanistic information is withheld from marketing materials. In some embodiments, customers are surveyed to obtain information about the type of assay components or delivery systems that most suits their needs. Such information is useful in the design of the components of the kit and the 30 design of marketing efforts.

VII. The INVADER Assay for Direct Detection and Measurement of Specific RNA Analytes.

The following section provides a few illustrative examples of mRNAs that may be
5 detected or measured using the methods, compositions and systems of the present
invention.

HOUSEKEEPING CONTROLS

10 RNAs that are generally present in predictable or invariant amounts in test samples provide useful control targets for detection assays. These controls can be useful in several ways, including but not limited to providing confirmation of the proper function of an assay, and as a standard against which a test result for another RNA can be compared or measured to aid in interpretation of a result. mRNAs for the following genes find particular use in the methods of the present invention.

15 **Human Ubiquitin and Mouse/Rat Ubiquitin**

The ubiquitin system is a major pathway for selective protein degradation. Degradation by this system is instrumental in a variety of cellular functions such as DNA repair, cell cycle progression, signal transduction, transcription, and antigen presentation. The ubiquitin pathway also eliminates proteins that are misfolded, misplaced, or that are
20 in other ways abnormal. This pathway requires the covalent attachment of ubiquitin (E1), a highly conserved 76 amino acid protein, to defined lysine residues of substrate proteins.

Human, rat and mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH)

25 GAPDH is an important enzyme in the glycolysis and gluconeogenesis pathways. This homotetrameric enzyme catalyzes the oxidative phosphorylation of D-glyceraldehyde-3-phosphate to 1,3-diphosphoglycerate in the presence of cofactor and inorganic phosphate. A variety of diverse biological properties of GAPDH have been reported. These include functions in endocytosis, mRNA regulation, tRNA export, DNA
30 replication, DNA repair, and neuronal apoptosis.

CYTOKINES

A growing family of regulatory proteins that deliver signals between cells of the immune system has been identified. Called cytokines, these proteins have been found to control the growth and development, and bioactivities, of cells of the hematopoietic and 5 immune systems. Cytokines exhibit a wide range of biological activities with target cells from bone marrow, peripheral blood, fetal liver, and other lymphoid or hematopoietic organs. The present invention describes methods for the detection of expression of cytokines, including but not limited to of the exemplary members of the cytokine family listed below.

10

Human Oncostatin M

Oncostatin M is a secreted single-chain polypeptide cytokine that regulates the growth of certain tumor-derived and normal cell lines. A number of cell types have been found to bind the oncostatin M protein. While it has been shown to inhibit proliferation 15 of a number of tumor cell types, it has also been implicated in stimulating proliferation of Kaposi's sarcoma cells.

Human transforming growth factor-beta (TGF- β)

Transforming growth factor-beta (TGF-beta) is a member of a family of 20 structurally-related cytokines that elicit a variety of responses, including growth, differentiation, and morphogenesis, in many different cell types. In vertebrates, at least five different forms of TGF-beta, termed TGF-beta1 to TGF-beta5, have been identified; they all share a high degree (60%-80%) of amino-acid sequence identity. While TGF-beta1 was initially characterized by its ability to induce anchorage-independent growth of 25 normal rat kidney cells, its effects on most cell types are anti-mitogenic. It is strongly growth-inhibitory for many types of cells, including both normal and transformed epithelial, endothelial, fibroblast, neuronal, lymphoid, and hematopoietic cells. In addition, TGF-beta plays a central role in regulating the formation of extracellular matrix and cell-matrix adhesion processes.

30

Human monocyte chemoattractant protein-1 (MCP-1)

Within this family of cytokines, an emerging group of chemotactic cytokines, also called chemokines or intercrines, has been identified. Two subfamilies of chemokines have been recognized, alpha and beta, based on chromosomal location and the arrangement of the cysteine residues.

- 5 The human genes encoding the beta subfamily proteins are located on chromosome 17 (their mouse counterparts are clustered on mouse chromosome 11, which is the counterpart of human chromosome 17). Homology in the beta subfamily ranges from 28-45% intraspecies, from 25-55% interspecies. An exemplary member is the
10 human protein MCP-1 (monocyte chemoattractant protein-1). MCP-1 exerts several effects specifically on monocytes. It is a potent chemoattractant for human monocytes *in vitro* and can stimulate an increase in cytosolic free calcium and the respiratory burst in monocytes. MCP-1 has been reported to activate monocyte-mediated tumorstatic activity, as well as to induce tumoricidal activity. MCP-1 has been implicated as an
15 important factor in mediating monocytic infiltration of tissues inflammatory processes such as rheumatoid arthritis and alveolitis. The factor may also play a fundamental role in the recruitment of monocyte-macrophages into developing atherosclerotic lesions.

Human tumor necrosis factor alpha (TNF- α)

- 20 Tumor necrosis factor alpha (TNF-alpha also cachectin) is an important cytokine that plays a role in host defense. The cytokine is produced primarily in macrophages and monocytes in response to infection, invasion, injury, or inflammation. Some examples of inducers of TNF-alpha include bacterial endotoxins, bacteria, viruses, lipopolysaccharide (LPS) and cytokines including GM-CSF, IL-1, IL-2 and IFN-gamma.
25 Despite the protective effects of the cytokine, overexpression of TNF-alpha often results in disease states, particularly in infectious, inflammatory and autoimmune diseases. This process may involve the apoptotic pathways. High levels of plasma TNF-alpha have been found in infectious diseases such as sepsis syndrome, bacterial meningitis, cerebral malaria, and AIDS; autoimmune diseases such as rheumatoid
30 arthritis, inflammatory bowel disease (including Crohn's disease), sarcoidosis, multiple sclerosis, Kawasaki syndrome, graft-versus-host disease and transplant (allograft)

rejection; and organ failure conditions such as adult respiratory distress syndrome, congestive heart failure, acute liver failure and myocardial infarction. Other diseases in which TNF-alpha is involved include asthma, brain injury following ischemia, non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus, hepatitis, atopic dermatitis, and pancreatitis. Further, inhibitors of TNF-alpha have been suggested to be useful for cancer prevention. Elevated TNF-alpha expression may also play a role in obesity. TNF-alpha was found to be expressed in human adipocytes and increased expression, in general, correlated with obesity.

10 **Human interleukin-6 (IL-6)**

IL-6 is the standardized name of a cytokine called B lymphocyte differentiating factor, interferon beta2, 26 Kd protein, hybridoma/plasmacytoma growth factor, hepatocyte stimulating factor, etc.

IL-6 induces activated B cells to be differentiated into antibody forming cells.
15 For T cells, IL-6 induces T cells stimulated by mitogens to produce IL-2 and induces the expression of IL-2 receptor on a certain T cell line or thymocytes. For blood forming cells, IL-6 induces the growth of blood forming stem cells synergistically in the presence of IL-3. Furthermore, recently, it was reported that IL-6 acted like thrombopoietin.

IL-6 is produced by various cells. It is produced by lymphocytes and is also
20 produced by human fibroblasts stimulated by Poly (I)-Poly (C) and cycloheximide. Murine IL-6 is produced in mouse cells, which are stimulated by Poly (A)-Poly (U). Inducers for stimulation are diverse, and include known cytokines such as IL-1, TNF and IFN-beta, growth factors such as PDGF and TGF-beta, LPS, PMA, PHA, cholera toxin, etc. Moreover, it is reported that human vascular endothelial cells, macrophages, human
25 glioblastomas, etc. also produce IL-6. Furthermore, it is also known that the productivity can be further enhanced by stimulating cells using an inducer and subsequently treating the cells by a metabolic inhibitor such as verapamil, cycloheximide or actinomycin D, etc.

Human interleukin 1beta (IL-1 β)

Interleukin-1 (IL-1) is important to the activation of T and B lymphocytes and mediates many inflammatory processes. Two distinct forms of IL-1 have been isolated and expressed; termed IL-1beta and IL-1alpha. IL-1beta is the predominant form

- 5 produced by human monocytes both at the mRNA and protein level. The two forms of human IL-1 share only 26% amino acid homology. Despite their distinct polypeptide sequences, the two forms of IL-1 have structural similarities, in that the amino acid homology is confined to discrete regions of the IL-1 molecule. The two forms of IL-1 also possess identical biological properties, including induction of fever, slow wave
10 sleep, and neutrophilia, T- and B-lymphocyte activation, fibroblast proliferation, cytotoxicity for certain cells, induction of collagenases, synthesis of hepatic acute phase proteins, and increased production of colony stimulating factors and collagen. IL-1 also activates endothelial cells, resulting in increased leukocyte adhesiveness, PG_I2 and PGE₂ (prostaglandins) release, and synthesis of platelet activating factor, procoagulant activity,
15 and a plasminogen activator inhibitor. Clearly, IL-1 plays a central role in local and systemic host responses. Because many of the biological effects of IL-1 are produced at picomolar (pg) concentrations *in vivo*, IL-1 production is likely a fundamental characteristic of host defense mechanisms.

20 **Human interleukin 2 (IL-2)**

Interleukin-2 (IL-2) is the main growth factor of T lymphocytes. By regulating T helper lymphocyte activity IL-2 increases the humoral and cellular immune responses. By stimulating cytotoxic CD8 T cells and NK cells, this cytokine participates in the defense mechanisms against tumors and viral infections. IL-2 is used in therapy against
25 metastatic melanoma and renal adenocarcinoma. IL-2 is used in clinical trials in many forms of cancer. It is also used in HIV infected patients and leads to a significant increase in CD4 counts. Human IL-2 is a protein of 133 amino acids (aa) composed of four alpha helices connected by loops of various length, its tridimensional structure has been established. IL-2R is composed of three chains alpha, beta and gamma. IL2R α controls the affinity of the receptor IL-2R β and IL-2R γ are responsible for IL-2 signal transduction. The different molecular areas of IL-2 interacting with the three

chains of the IL-2 R have been defined. More specifically it has been determined that a helix A as well as the NH₂ terminal area of IL-2 (residues 1 to 30) control the interactions IL-2/IL-2Rbeta.

5 **Human interleukin 8 (IL-8)**

Human IL-8 is a cytokine that has variously been called neutrophil-activating protein, neutrophil chemotactic factor (NCF) and T-cell chemotactic factor. IL-8 can be secreted by several types of cells upon appropriate stimulation. IL-8 is secreted by activated monocytes and macrophages as well as by embryonic fibroblasts.

- 10 IL-8 is known to induce neutrophil migration and to activate functions of neutrophils such as degranulation, release of superoxide anion and adhesion to the endothelial cell monolayer. There are a number of conditions that are known to involve leukocyte infiltration into lesions. These include pulmonary diseases such as pulmonary cystic fibrosis, idiopathic pulmonary fibrosis, adult respiratory distress syndrome, sarcoidosis and empyema; dermal diseases such as psoriasis, rheumatoid arthritis; and inflammatory bowel disease (Crohn's Disease).
- 15

The amino acid sequence characterizing human IL-8 was described by Matsushima, et al. in PCT application WO89/08665. More recently, it was shown that monocyte-derived IL-8 was evidently variably processed at the N-terminus and that the 20 IL-8 originally disclosed by Matsushima et al. was accompanied by two forms of the factor which had seven or five additional amino acids at the N-terminus (Yoshimura, *et al.*, Mol Immunol 26:87 [1989]). The longest form accounted for about 8%, the next longest form for about 47%, and the shortest form for about 45% of the total IL-8 derived from monocytes.

25

Human interleukin 10 (IL-10)

- Interleukin-10 (IL-10), a recently discovered lymphokine, was originally described as an inhibitor of interferon-gamma synthesis and is postulated as a major mediator of the humoral class of immune response. Two classes of often mutually 30 exclusive immune responses are the humoral (antibody-mediated) and the delayed-type hypersensitivity.

It is postulated that these two differing immune responses may arise from two types of helper T-cell clones, namely Th1 and Th2 helper T-cells, which demonstrate distinct cytokine secretion patterns. Mouse Th1 cell clones secrete interferon-gamma, and IL-2 and preferentially induce the delayed-type hypersensitivity response while Th-2

- 5 cell clones secrete IL-4, IL-5 and IL-10 and provide support for the humoral responses. The contrast in immune response could result because interferon-gamma secreted by the Th1 cell clones inhibits Th2 clone proliferation in vitro, while IL-10 secreted by the Th2 cell clones inhibits cytokine secretion by the Th1 cell clones. Thus the two T-helper cell types may be mutually inhibitory and may provide the underpinning for the two
10 dissimilar immune responses.

IL-10 has been cloned and sequenced from both murine and human T cells. Both sequences contain an open reading frame encoding a polypeptide of 178 amino acids with an N-terminal hydrophobic leader sequence of 18 amino acids, and have an amino acid sequence homology of 73%.

15

Human interleukin 4 (IL-4)

Interleukin-4 (IL-4, also known as B cell stimulating factor, or BSF-1) was originally characterized by its ability to stimulate the proliferation of B cells in response to low concentrations of antibodies directed to surface immunoglobulin. More recently,

- 20 IL-4 has been shown to possess a far broader spectrum of biological activities, including growth co-stimulation of T cells, mast cells, granulocytes, megakaryocytes, and erythrocytes. In addition, IL-4 stimulates the proliferation of several IL-2- and IL-3-dependent cell lines, induces the expression of class II major histocompatibility complex molecules on resting B cells, and enhances the secretion of IgE and IgG1 isotypes by
25 stimulated B cells. Both murine and human IL-4 have been definitively characterized by recombinant DNA technology and by purification to homogeneity of the natural murine protein.

The biological activities of IL-4 are mediated by specific cell surface receptors for IL-4 that are expressed on primary cells and in vitro cell lines of mammalian origin. IL-4

- 30 binds to the receptor, which then transduces a biological signal to various immune effector cells.

Human interferon gamma (IFN- γ)

Like the interleukins, interferons belong to the class of the cytokines and are listed in various classes: interferon-alpha, interferon-beta, interferon-gamma, interferon-omega

- 5 and interferon-tau. Interferon-gamma is a glycoprotein, the amino acid sequence of which has been known since 1982. In the mature condition the interferon-gamma has 143 amino acids and a molecular weight of 63 to 73 kilodaltons.

The tertiary and quaternary structure of the non-glycosylated protein was clarified in 1991. According to this, interferon-gamma exists as a homodimer, the monomers 10 being orientated in contrary directions in such a way that the C-terminal end of one monomer is located in the vicinity of the N-terminal end of the other monomer. Each of these monomers in all has six alpha-helices. Interferon-gamma is also called immunointerferon, as it has non-specific antiviral, antiproliferative and in particular immunomodulatory effects. Its production in T-helper-lymphocytes is stimulated by 15 mitogens and antigens. The effect of the expressed interferon-gamma has not yet been precisely clarified, but is subject to intensive research. In particular, interferon-gamma leads to the activation of macrophages and to the synthesis of histocompatibility antigens of the class 2. *In vitro*, the activity of interferon-gamma is normally determined as a reduction in the virus-induced cytopathic effect, which arises from treatment with 20 interferon-gamma. Due to its antigen-non-specific antiviral, antiproliferative and immunomodulatory activity it is suitable as a human therapeutic agent, for example of kidney tumours and chronic granulomatosis.

CYTOCHROME P450s

- 25 The term cytochrome P-450 refers to a family of enzymes (located on the endoplasmic reticulum, with high concentrations of the proteins in the cells of the liver and small intestine) that are primarily responsible for the metabolism of xenobiotics such as drugs, carcinogens and environmental chemicals, as well as several classes of endobiotics such as steroids and prostaglandins. Members of the cytochrome P450 30 family are present in varying levels and their expression and activities are controlled by variables such as chemical environment, sex, developmental stage, nutrition and age.

More than 200 cytochrome P450 genes have been identified. There are multiple forms of these P450 genes and each of the individual forms exhibit degrees of specificity towards individual chemicals in the above classes of compounds. In some cases, a substrate, whether it be drug or carcinogen, is metabolized by more than one of the 5 cytochromes P450. Genetic polymorphisms of cytochromes P450 result in phenotypically-distinct subpopulations that differ in their ability to perform biotransformations of particular drugs and other chemical compounds.

The present invention provides methods for the detection cytochrome P450 mRNAs, including but not limited to, Human CYP 1A1, Human CYP 1A2, Human CYP 10 2B1, Human CYP 2B2, Human CYP 2B6, Human CYP 2C19, Human CYP 2C9, Human CYP 2D6, Human CYP 3A4, Human CYP 3A5, Human CYP 3A7, Rat CYP 2E1, Rat CYP 3A1, Rat CYP 3A2, Rat CYP 4A1, Rat CYP 4A2 and Rat CYP 4A3.

EXAMPLES

The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

- 5 In the disclosure which follows, the following abbreviations apply: Afu (*Archaeoglobus fulgidus*); Mth (*Methanobacterium thermoautotrophicum*); Mja (*Methanococcus jannaschii*); Pfu (*Pyrococcus furiosus*); Pwo (*Pyrococcus woesei*); Taq (*Thermus aquaticus*); Taq DNAP, DNAP_{Taq}, and Taq Pol I (*T. aquaticus* DNA polymerase I); DNAPStf (the Stoffel fragment of DNAP_{Taq}); DNAPEc1 (*E. coli* DNA polymerase I); Tth (*Thermus thermophilus*); Ex. (Example); Fig. (Figure); °C (degrees Centigrade); g (gravitational field); hr (hour); min (minute); olio (oligonucleotide); rxn (reaction); vol (volume); w/v (weight to volume); v/v (volume to volume); BSA (bovine serum albumin); CTAB (cetyltrimethylammonium bromide); HPLC (high pressure liquid chromatography); DNA (deoxyribonucleic acid); p (plasmid); µl (microliters); ml (milliliters); µg (micrograms); mg (milligrams); M (molar); mM (millimolar); µM (microMolar); pmoles (picomoles); amoles (attomoles); zmoles (zeptomoles); nm (nanometers); kdal (kilodaltons); OD (optical density); EDTA (ethylene diamine tetra-acetic acid); FITC (fluorescein isothiocyanate); SDS (sodium dodecyl sulfate); NaPO₄ (sodium phosphate); NP-40 (Nonidet P-40); Tris (tris(hydroxymethyl)-aminomethane); PMSF (phenylmethylsulfonylfluoride); TBE (Tris-Borate-EDTA, i.e., Tris buffer titrated with boric acid rather than HCl and containing EDTA); PBS (phosphate buffered saline); PPBS (phosphate buffered saline containing 1 mM PMSF); PAGE (polyacrylamide gel electrophoresis); Tween (polyoxyethylene-sorbitan); ATCC (American Type Culture Collection, Rockville, MD); Coriell (Coriell Cell Repositories, Camden, NJ); DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany); Ambion (Ambion, Inc., Austin, TX); Boehringer (Boehringer Mannheim Biochemical, Indianapolis, IN); MJ Research (MJ Research, Watertown, MA; Sigma (Sigma Chemical Company, St. Louis, MO); Dynal (Dynal A.S., Oslo, Norway); Gull (Gull Laboratories, Salt Lake City, UT); Epicentre (Epicentre Technologies, Madison, WI); Lampire (Biological Labs., Inc., Coopersberg, PA); MJ Research (MJ Research, Watertown, MA); National Biosciences (National Biosciences,

Plymouth, MN); NEB (New England Biolabs, Beverly, MA); Novagen (Novagen, Inc., Madison, WI); Promega (Promega, Corp., Madison, WI); Stratagene (Stratagene Cloning Systems, La Jolla, CA); Clonetech (Clonetech, Palo Alto, CA) Pharmacia (Pharmacia, Piscataway, NJ); Milton Roy (Milton Roy, Rochester, NY); Amersham 5 (Amersham International, Chicago, IL); and USB (U.S. Biochemical, Cleveland, OH). Glen Research (Glen Research, Sterling, VA); Coriell (Coriell Cell Repositories, Camden, NJ); Gentra (Gentra, Minneapolis, MN); Third Wave Technologies (Third Wave Technologies, Madison, WI); PerSeptive Biosystems (PerSeptive Biosystems, Framingham, MA); Microsoft (Microsoft, Redmond, WA); Qiagen (Qiagen, Valencia, 10 CA); Molecular Probes (Molecular Probes, Eugene, OR); VWR (VWR Scientific,); Advanced Biotechnologies (Advanced Biotechnologies, INC., Columbia, MD); and Perkin Elmer (also known as PE Biosystems and Applied Biosystems, Foster City, CA).

EXAMPLE 1

15 Rapid screening of colonies for 5' nuclease activity

The native 5' nucleases and the enzymes of the present invention can be tested directly for a variety of functions. These include, but are not limited to, 5' nuclease activity on RNA or DNA targets and background specificity using alternative substrates 20 representing structures that may be present in a target detection reaction. Examples of nucleic acid molecules having suitable test structures are shown schematically in Figures 18A-D and Figures 21-24. The screening techniques described below were developed to quickly and efficiently characterize 5' nucleases and to determine whether the new 5' nucleases have any improved or desired activities. Enzymes that show improved cycling 25 rates on RNA or DNA targets, or that result in reduced target-independent cleavage merit more thorough investigation. In general, the modified proteins developed by random mutagenesis were tested by rapid colony screen on the substrates shown in Figures 18A and 18B. A rapid protein extraction was then done, and a test of activity on alternative structures, (e.g., as shown in Figures 18C-D) was performed using the protein extract. 30 Either the initial screen, or further screening and characterization of enzymes for improved activity may be performed using other cleavage complexes, such as those

diagrammed in Figures 21-24. It is not intended that the scope of the invention be limited by the particular sequences used to form such test cleavage structures. One skilled in the art would understand how to design and create comparable nucleic acids to form analogous structures for rapid screening.

5 This order of testing may be chosen to reduce the number of tests overall, to save time and reagents. The order of testing for enzyme function is not intended to be a limitation on the present invention. Those mutants that showed reasonable cycling rates with the RNA or DNA targets may then be cultured overnight, and a rapid protein extraction done. Alternatively, any subset or all of the cleavage tests may be done at the
10 same time.

For convenience, each type of rapid screen may be done on a separate microtiter plate. For example, one plate may be set up to test RNA INVADER activity, one plate set up to test for DNA INVADER activity. As many as 90 different colonies may be screened on one plate. The colonies screened can be from a variety of sources, such as
15 clones of unaltered (native) 5' nucleases, from one mutagenesis reaction (*e.g.*, many colonies from a single plate) or from a variety of reactions (colonies selected from multiple plates).

Ideally, positive and negative controls should be run on the same plate as the mutants, using the same preparation of reagents. One example of a good positive control
20 is a colony containing the unmodified enzyme, or a previously modified enzyme whose activity is to be compared to new mutants. For example, if a mutagenesis reaction is performed on the Taq DN RX HT construct (described below), the unmodified Taq DN RX HT construct would be chosen as the standard for comparing the effects of mutagenesis on enzymatic activity. Additional control enzymes may also be incorporated
25 into the rapid screening test. For example, Tth DN RX HT (described below; unless otherwise specified, the TaqPol and TthPol enzymes of the following discussion refer to the DN RX HT derivative) may also be included as a standard for enzymatic activity along with the Taq DN RX HT. This would allow a comparison of any altered enzymes to two known enzymes having different activities. A negative control should also be run
30 to determine the background reaction levels (*i.e.*, cleavage or probe degradation due to sources other than the nucleases being compared). A good negative control colony would

be one containing only the vector used in the cloning and mutagenesis, for example, colonies containing only the pTrc99A vector.

Two factors that may influence the number of colonies chosen from a specific mutagenesis reaction for the initial rapid screen are 1) total number of colonies obtained from the mutagenesis reaction, and 2) whether the mutagenesis reaction was site-specific or randomly distributed across a whole gene or a region of a gene. For example, if only 5-10 colonies are present on the plate, all colonies can easily be tested. If hundreds of colonies are present, a subset of these may be analyzed. Generally 10-20 colonies are tested from a site-specific mutagenesis reaction, while 80 to 100 or more colonies are routinely tested from a single random mutagenesis reaction.

Where indicated, the altered 5' nucleases described in these experimental examples were tested as detailed below.

A. Rapid screen: INVADER activity on RNA target (Figure 18A)

15 A 2X substrate mix was prepared, comprising 20 mM MOPS, pH 7.5, 10 mM MgSO₄, 200 mM KCl, 2 µM FRET-probe oligo SEQ ID NO:223 (5'-Fl-CGCT-cy3-TCTCGCTCGC-3'), 1 µM INVADER oligo SEQ ID NO:224 (5'-ACGGAACGAGCGTCTTG-3'), and 4 nM RNA target SEQ ID NO:225 (5'-GCG AGC GAGA CAG CGA AAG ACG CUC GUU CCG U-3'). Five µl of the 2X substrate mix were dispensed into each sample well of a 96 well microtiter plate (Low Profile MULTIPLATE 96, M.J. Research, Inc.).

Cell suspensions were prepared by picking single colonies (mutants, positive control, and negative control colonies) and suspending each one in 20µl of water. This can be done conveniently in a 96 well microtiter plate format, using one well per colony.

25 Five µl of the cell suspension was added to the appropriate test well such that the final reaction conditions were 10 mM MOPS, pH 7.5, 5 mM MgSO₄, 100 mM KCl, 1 µM FRET-probe oligo, 0.5 µM INVADER oligo, and 2 nM RNA target. The wells were covered with 10 µl of Clear CHILLOUT 14 (M.J. Research, Inc.) liquid wax, and the samples were heated at 85°C for 3 minutes, then incubated at 59°C for 1 hour. After the 30 incubation, the plates were read on a Cytofluor fluorescense plate reader using the following parameters: excitation 485/20, emission 530/30.

B. Rapid screen: INVADER activity on DNA target (Figure 18B)

A 2X substrate mix was prepared, comprising 20 mM MOPS, pH 7.5, 10 mM MgSO₄, 200 mM KCl, 2 µM FRET-probe oligo SEQ ID NO:223

- 5 (5'-Fl-CGCT-Cy3-TCTCGCTCGC-3'), 1 µM INVADER oligo SEQ ID NO:224
(5'-ACGGAACGAGCGTCTTG-3'), 1 nM DNA target SEQ ID NO:226 (5'-GCG
AGC GAGA CAG CGA AAG ACC CTC GTT CCG T-3'). Five µl of the 2X substrate
mix was dispensed into each sample well of a 96 well microtiter plate (MJ Low Profile).

Cell suspensions were prepared by picking single colonies (mutants, positive
10 control and negative control colonies) and suspending them in 20 µl of water, generally
in a 96 well microtiter plate format.

5 µl of the cell suspension were added to the appropriate test well such that the
final reaction conditions were 10 mM MOPS, pH 7.5, 5 mM MgSO₄, 100 mM KCl, 1 µM
FRET-probe oligo, 0.5 µM INVADER oligo, and 0.5 nM DNA target. Wells were
15 covered with 10µl of Clear CHILLOUT 14 (M.J. Research, Inc.) liquid wax, and the
reactions were heated at 85°C for 3 minutes, then incubated at 59°C for 1 hour. After the
hour incubation, the plate were read on a Cytofluor flourescan plate reader using the
following parameters: excitation 485/20, emission 530/30, gain 40, reads per well 10.

20 **C. Rapid protein extraction (crude cell lysate)**

Those mutants that gave a positive or an unexpected result in either the RNA or
DNA INVADER assay were further analyzed, specifically for background activity on the
X-structure or the hairpin substrate (Figure 18C and D, respectively). A rapid colony
screen format can be employed, as described above. By simply changing the substrate,
25 tests for background or aberrant enzymatic activity can be done. Another approach
would be to do a rapid protein extraction from a small overnight culture of positive
clones, and then test this crude cell lysate for additional protein function. One possible
rapid protein extraction procedure is detailed below. Two to five ml of LB (containing
the appropriate antibiotic for plasmid selection; *See e.g.*, Maniatis, books 1,2 and 3) were
30 inoculated with the remaining volume of the 20 µl water-cell suspension and incubated at
37°C overnight. About 1.4 ml of the culture were transferred to a 1.5 ml microcentrifuge

tube, and microcentrifuged at top speed (e.g., 14,000 rpm in an Eppendorf 5417 table top microcentrifuge), at room temperature for 3-5 minutes to pellet the cells. The supernatant was removed, and the cell pellet was suspended in 100 µl of TES buffer pH 7.5 (Sigma).
5 Lysozyme (Promega) was added to a final concentration of 0.5µg/µl and samples were incubated at room temperature for 30 minutes. Samples were then heated at 70°C for 10 minutes to inactivate the lysozyme, and the cell debris was pelleted by microcentrifugation at top speed for 5 minutes. The supernatant was removed and this crude cell lysate was used in the following enzymatic activity assays.

10 D. **Rapid screen: background specificity X structure substrate (Figure 18C)**

Reactions were performed under conditions as detailed above. One µl of crude cell lysate was added to 9 µl of reaction components for a final volume of 10 µl and final concentrations of 10 mM MOPS, pH 7.5, 5 mM MgSO₄, 100 mM KCl, 1 µM FRET-probe oligo (SEQ ID NO:223), 0.5µM X-structure INVADER oligo SEQ ID NO:227 (5'-ACGGAACGAGCGTCTTCATCTGTCAATC-3'), and 0.5 nM DNA target (SEQ ID NO:226). Wells were covered with 10 µl of Clear CHILLOUT 14 (M.J. Research, Inc.) liquid wax, and the reactions were heated at 85°C for 3 minutes, then incubated at 59°C for 1 hour. After the incubation, the plates were read on a Cytofluor fluorescence plate reader using the following parameters: excitation 485/20, emission 20 530/30, gain 40, reads per well 10.

E. **Rapid screen: background specificity hairpin substrate (Figure 18D)**

Reactions were performed under conditions as detailed above. One µl of crude cell lysate was added to 9 µl of reaction components for a final volume of 10 µl and final concentrations of 10 mM MOPS, pH 7.5, 5 mM MgSO₄, 100 mM KCl, 1 µM FRET-probe oligonucleotide (SEQ ID NO:223), and 0.5 nM DNA target (SEQ ID NO:226). Wells were covered with 10 µl of Clear CHILLOUT 14 (M.J. Research, Inc.) liquid wax, and the reactions were heated at 85°C for 3 minutes, then incubated at 59°C for 1 hour. After the hour incubation, the plate were read on a Cytofluor plate reader

using the following parameters: excitation 485/20, emission 530/30, gain 40, reads per well 10.

F. Activity assays with IrT1 and IdT targets (Figures 24)

The 5' nuclease activities assays were carried out in 10 μ l of a reaction containing 10 mM MOPS, pH 7.5, 0.05% Tween 20, 0.05% Nonidet P-40, 10 μ g/ml tRNA, 100 mM KCl and 5 mM MgSO₄. The probe concentration (SEQ ID NO: 167) was 2 mM. The substrates (IrT1 (SEQ ID NO: 228) or IdT (SEQ ID NO: 229) at 10 or 1 nM final concentration respectively) and approximately 20 ng of an enzyme, prepared as in Example 3, were mixed with the above reaction buffer and overlaid with CHILLOUT (MJ Research) liquid wax. Reactions were brought up to reaction temperature 57 °C, started by addition of MgSO₄, and incubated for 10 min. Reactions were then stopped by the addition of 10 μ l of 95% formamide containing 10 mM EDTA and 0.02% methyl violet (Sigma). Samples were heated to 90°C for 1 minute immediately before electrophoresis through a 20% denaturing acrylamide gel (19:1 cross-linked), with 7 M urea, and in a buffer of 45 mM Tris-borate, pH 8.3, 1.4 mM EDTA. Unless otherwise indicated, 1 μ l of each stopped reaction was loaded per lane. Gels were then scanned on an FMBIO-100 fluorescent gel scanner (Hitachi) using a 505 nm filter. The fraction of cleaved product was determined from intensities of bands corresponding to uncut and cut substrate with FMBIO Analysis software (version 6.0, Hitachi). The fraction of cleavage product did not exceed 20% to ensure that measurements approximated initial cleavage rates. The turnover rate was defined as the number of cleaved signal probes generated per target molecule per minute under these reaction conditions (1/min).

G. Activity assays with X structure (X) and hairpin (HP) targets (Figures 22)

The 5' nuclease activity assays were carried out in 10 μ l of a reaction containing 10 mM MOPS, pH 7.5, 0.05% Tween 20, 0.05% Nonidet P-40, 10 μ g/ml tRNA, 100 mM KCl and 5 mM MgSO₄. Each oligo for formation of either the hairpin structure assembly (22A, SEQ ID NOS: 230 and 231) assembly or the X structure assembly (22B, SEQ ID NOS: 230-232) was added to a final concentration of 1 μ M, and approximately 20 ng of test enzyme prepared as described in Example 3, were mixed with the above reaction

buffer and overlaid with CHILLOUT (MJ Research) liquid wax. Reactions were brought up to reaction temperature 60 °C, started by addition of MgSO₄, and incubated for 10 min. Reactions were then stopped by the addition of 10 µl of 95% formamide containing 10 mM EDTA and 0.02% methyl violet (Sigma). Samples were heated to 90°C for 1 minute immediately before electrophoresis through a 20% denaturing acrylamide gel (19:1 cross-linked), with 7 M urea, and in a buffer of 45 mM Tris-borate, pH 8.3, 1.4 mM EDTA. Unless otherwise indicated, 1 µl of each stopped reaction was loaded per lane. Gels were then scanned on an FMBIO-100 fluorescent gel scanner (Hitachi) using a 505 nm filter. The fraction of cleaved product was determined from intensities of bands corresponding to uncut and cut substrate with FMBIO Analysis software (version 6.0, Hitachi). The fraction of cleavage product did not exceed 20% to ensure that measurements approximated initial cleavage rates. The turnover rate was defined as the number of cleaved signal probes generated per target molecule per minute under these reaction conditions (1/min).

15

H. Activity assays with human IL-6 target (Figure 10)

The 5' nuclease activities assays were carried out in 10 µl reactions containing 10 mM MOPS, pH 7.5, 0.05% Tween 20, 0.05% Nonidet P-40, 10 µg/ml tRNA, 100 mM KCl and 5 mM MgSO₄. Reactions comprising the DNA IL-6 substrate contained 0.05 nM IL-6 DNA target (SEQ ID NO: 163) and 1 µM of each probe (SEQ ID NO: 162) and INVADER (SEQ ID NO: 161) oligonucleotides, and were carried out at 60°C for 30 min. Reactions comprising the IL-6 RNA target (SEQ ID NO: 160) were performed under the same conditions, except that the IL-6 RNA target concentration was 1 nM and the reactions were performed at 57°C for 60 min. Each reaction contained approximately 20 ng of test enzyme, prepared as described in Example 3.

I. Activity assays with synthetic r25mer target (Figure 23)

Reactions comprising the synthetic r25mer target (SEQ ID NO: 233) were carried out under the same reaction conditions (10 mM MOPS, pH 7.5, 0.05% Tween 20, 0.05% Nonidet P-40, 10 µg/ml tRNA, 100 mM KCl and 5 mM MgSO₄) and 1 µM of each probe (SEQ ID NO: 234) and INVADER (SEQ ID NO: 235) oligonucleotides, except that the

r25mer target concentration was 5 nM and the reactions were performed at 58°C for 60 min. Approximately 20 ng of each test enzyme was added to the reactions. Enzymes were prepared as described in Example 3.

- 5 Any of the tests described above can be modified to derive the optimal conditions for enzymatic activity. For example, enzyme titrations can be done to determine the optimal enzyme concentration for maximum cleavage activity, and lowest background signal. By way of example, but not by way of limitation, many of the mutant enzymes were tested at 10, 20 and 40 ng amounts. Similarly, a temperature titration can also be
10 incorporated into the tests. Since modifying the structure of a protein can alter its temperature requirements, a range of temperatures can be tested to identify the condition best suited for the mutant in question.

Examples of the results from such screens (using approximately 20 ng of the mutant enzyme) are shown in Tables 3-8, and Figures 12, 14, 15, 19, and 25.

15

EXAMPLE 2

Cloning and Expression of 5' nucleases of DNA polymerases and mutant polymerases

20 A. DNA polymerases of *Thermus aquaticus* and *Thermus thermophilus*

1. Cloning of TaqPol and TthPol

Type A DNA polymerases from eubacteria of the genus *Thermus* share extensive protein sequence identity (90% in the polymerization domain, using the Lipman-Pearson method in the DNA analysis software from DNASTar, WI) and behave similarly in both polymerization and nuclease assays. Therefore, the genes for the DNA polymerase of *Thermus aquaticus* (TaqPol), *Thermus thermophilus* (TthPol) and *Thermus scotoductus* were used as representatives of this class. Polymerase genes from other eubacterial organisms, including, but not limited to, *Escherichia coli*, *Streptococcus pneumoniae*,
25 *Mycobacterium smegmatis*, *Thermus thermophilus*, *Thermus sp.*, *Thermotoga maritima*, *Thermosipho africanus*, and *Bacillus stearothermophilus* are equally suitable.

a. **Initial TaqPol Isolation: mutant TaqA/G**

- The *Taq* DNA polymerase gene was amplified by polymerase chain reaction from genomic DNA from *Thermus aquaticus*, strain YT-1 (Lawyer *et al.*, *supra*), using as primers the oligonucleotides described in SEQ ID NOS:236 and 237. The resulting fragment of DNA has a recognition sequence for the restriction endonuclease *Eco*RI at the 5' end of the coding sequence and a *Bgl*II sequence at the 3' end of the coding strand. Cleavage with *Bgl*II leaves a 5' overhang or "sticky end" that is compatible with the end generated by *Bam*HI. The PCR-amplified DNA was digested with *Eco*RI and *Bam*HI. The 2512 bp fragment containing the coding region for the polymerase gene was gel purified and then ligated into a plasmid that contains an inducible promoter.

In one embodiment of the invention, the pITQ18 vector, which contains the hybrid *trp-lac* (*tac*) promoter, was used (M.J.R. Stark, *Gene* 5:255 [1987]). The *tac* promoter is under the control of the *E. coli lac* repressor protein. Repression allows the synthesis of the gene product to be suppressed until the desired level of bacterial growth has been achieved, at which point repression is removed by addition of a specific inducer, isopropyl- β -D-thiogalactopyranoside (IPTG). Such a system allows the controlled expression of foreign proteins that may slow or prevent growth of transformants.

Particularly strong bacterial promoters, such as the synthetic *Ptac*, may not be adequately suppressed when present on a multiple copy plasmid. If a highly toxic protein is placed under control of such a promoter, the small amount of expression leaking through, even in the absence of an inducer, can be harmful to the bacteria. In another embodiment of the invention, another option for repressing synthesis of a cloned gene product is contemplated. A non-bacterial promoter from bacteriophage T7, found in the plasmid vector series pET-3, was used to express the cloned mutant *Taq* polymerase genes (Studier and Moffatt, *J. Mol. Biol.*, 189:113 [1986]). This promoter initiates transcription only by T7 RNA polymerase. In a suitable strain, such as BL21(DE3)pLYS, the gene for the phage T7 RNA polymerase is carried on the bacterial genome under control of the *lac* operator. This arrangement has the advantage that expression of the multiple copy gene (on the plasmid) is completely dependent on the

expression of T7 RNA polymerase, which is easily suppressed because it is present in a single copy.

These are just two examples of vectors having suitable inducible promoters. Others are well known to those skilled in the art, and it is not intended that the improved nucleases of the present invention be limited by the choice of expression system.

For ligation into the pTTQ18 vector, the PCR product DNA containing the *Taq* polymerase coding region (termed *mutTaq* for reasons discussed below, SEQ ID NO:238) was digested with EcoRI and BgIII and this fragment was ligated under standard "sticky end" conditions (Sambrook *et al. Molecular Cloning*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp. 1.63-1.69 [1989]) into the EcoRI and *Bam*HI sites of the plasmid vector pTTQ18. Expression of this construct yields a translational fusion product in which the first two residues of the native protein (Met-Arg) are replaced by three from the vector (Met-Asn-Ser), but the remainder of the PCR product's protein sequence is not changed (SEQ ID NO:239). The construct was transformed into the JM109 strain of *E. coli*, and the transformants were plated under incompletely repressing conditions that do not permit growth of bacteria expressing the native protein. These plating conditions allow the isolation of genes containing pre-existing mutations, such as those that result from the infidelity of *Taq* polymerase during the amplification process.

Using this amplification/selection protocol, a clone was isolated containing a mutated *Taq* polymerase gene (*mutTaq*). The mutant was first detected by its phenotype, in which temperature-stable 5' nuclease activity in a crude cell extract was normal, but polymerization activity was almost absent (approximately less than 1% of wild type *Taq* polymerase activity). Polymerase activity was determined by primer extension reactions. The reactions were carried out in 10 μ l of buffer containing 10 mM MOPS, pH 7.5, 5 mM MgSO₄, 100 mM KCl. In each reaction, 40 ng of enzyme were used to extend 10 μ M (dT)₂₅₋₃₀ primer in the presence of either 10 μ M poly (A)₂₈₆ or 1 μ M poly (dA)₂₇₃ template, 45 μ M dTTP and 5 μ M Fl-dUTP at 60°C for 30 minutes. Reactions were stopped with 10 μ l of stop solution (95% formamide, 10 mM EDTA, 0.02% methyl violet dye). Samples (3 μ l) were fractionated on a 15% denaturing acrylamide gel (19:1

crossed-linked) and the fraction of incorporated Fl-dUTP was quantitated using an FMBIO-100 fluorescence gel scanner (Hitachi) equipped with a 505 nm emission filter.

DNA sequence analysis of the recombinant gene showed that it had changes in the polymerase domain resulting in two amino acid substitutions: an A to G change at 5 nucleotide position 1394, which causes a Glu to Gly change at amino acid position 465 (numbered according to the natural nucleic and amino acid sequences, SEQ ID NOS:153 and 157), and another A to G change at nucleotide position 2260, which causes a Gln to Arg change at amino acid position 754. Because the Gln to Gly mutation is at a nonconserved position and because the Glu to Arg mutation alters an amino acid that is 10 conserved in virtually all of the known Type A polymerases, the latter mutation is most likely the one responsible for curtailing the synthesis activity of this protein. The nucleotide sequence for the construct is given in SEQ ID NO:39. The enzyme encoded by this sequence is referred to as Taq A/G.

15 **b. Initial TthPol Isolation**

The DNA polymerase enzyme from the bacterial species *Thermus thermophilus* (Tth) was produced by cloning the gene for this protein into an expression vector and overproducing it in *E. coli* cells. Genomic DNA was prepared from 1 vial of dried *Thermus thermophilus* strain HB-8 from ATCC (ATCC #27634). The DNA polymerase 20 gene was amplified by PCR using the following primers:
5'-CACGAATTCCGAGGCGATGCTTCGGCTC-3' (SEQ ID NO:240) and
5'-TCGACGTCGACTAACCCCTGGCGGAAAGCC-3' (SEQ ID NO:241). The resulting PCR product was digested with *Eco*RI and *Sal*I restriction endonucleases and inserted into *Eco*RI/*Sal*I digested plasmid vector pTrc99G (described in Example 2C1) 25 to create the plasmid pTrcTth-1. This *Tth* polymerase construct is missing a single nucleotide that was inadvertently omitted from the 5' oligonucleotide, resulting in the polymerase gene being out of frame. This mistake was corrected by site specific mutagenesis of pTrcTth-1 as described in Examples 4 and 5 using the following oligonucleotide: 5'-GCATCGCCTCGGAATTCATGGTC-3' (SEQ ID NO:242), to create 30 the plasmid pTrcTth-2. The protein and the nucleic acid sequence encoding the protein are referred to as TthPol, and are listed as SEQ ID NOS:243 and 244 respectively.

c. Large Scale preparation of recombinant proteins

The recombinant proteins were purified by the following technique which is derived from a *Taq* DNA polymerase preparation protocol (Engelke *et al.*, *Anal.*

- 5 Biochem.
- 191:396 [1990]) as follows. *E. coli* cells (strain JM109) containing either pTrc99A TaqPol, pTrc99GTthPol were inoculated into 3 ml of LB containing 100 mg/ml ampicillin and grown for 16 hrs at 37°C. The entire overnight culture was inoculated into 200 ml or 350 ml of LB containing 100 mg/ml ampicillin and grown at 37°C with vigorous shaking to an A_{600} of 0.8. IPTG (1 M stock solution) was added to a final 10 concentration of 1 mM and growth was continued for 16 hrs at 37°C.

The induced cells were pelleted and the cell pellet was weighed. An equal volume of 2X DG buffer (100 mM Tris-HCl, pH 7.6, 0.1 mM EDTA) was added and the pellet was suspended by agitation. Fifty mg/ml lysozyme (Sigma) were added to 1 mg/ml final concentration and the cells incubated at room temperature for 15 min.

- 15 Deoxycholic acid (10% solution) was added dropwise to a final concentration of 0.2 % while vortexing. One volume of H₂O and 1 volume of 2X DG buffer were added, and the resulting mixture was sonicated for 2 minutes on ice to reduce the viscosity of the mixture. After sonication, 3 M (NH₄)₂SO₄ was added to a final concentration of 0.2 M, and the lysate was centrifuged at 14000 x g for 20 min at 4°C. The supernatant was 20 removed and incubated at 70°C for 60 min at which time 10% polyethylimine (PEI) was added to 0.25%. After incubation on ice for 30 min., the mixture was centrifuged at 14,000 x g for 20 min at 4°C. At this point, the supernatant was removed and the protein precipitated by the addition of (NH₄)₂SO₄ as follows.

- 25 Two volumes of 3 M (NH₄)₂SO₄ were added to precipitate the protein. The mixture was incubated overnight at room temperature for 16 hrs centrifuged at 14,000 x g for 20 min at 4°C. The protein pellet was suspended in 0.5 ml of Q buffer (50 mM Tris-HCl, pH 8.0, 0.1 mM EDTA, 0.1% Tween 20). For the *Mja* FEN-1 preparation, solid (NH₄)₂SO₄ was added to a final concentration of 3 M (~75% saturated), the mixture was incubated on ice for 30 min, and the protein was spun down and suspended as 30 described above.

The suspended protein preparations were quantitated by determination of the A₂₇₉ dialyzed and stored in 50% glycerol, 20 mM Tris HCl, pH 8.0, 50 mM KCl, 0.5% Tween 20, 0.5% Nonidet P-40, with 100 µg/ml BSA.

5 B. DNA polymerases of *Thermus filiformis* and *Thermus scotoductus*

1 1. Cloning of *Thermus filiformis* and *Thermus scotoductus*

One vial of lyophilized *Thermus filiformis* (Tfi) obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany, strain #4687) was rehydrated in 1 ml of Castenholz medium (DSMZ medium 86) and
10 inoculated into 500 ml of Castenholz medium preheated to 50°C. The culture was incubated at 70°C with vigorous shaking for 48 hours. After growth, the cells were harvested by centrifugation at 8000 x g for 10 minutes, the cell pellet was suspended in 10 ml of TE (10 mM TrisHCl, pH 8.0, 1 mM EDTA), and the cells were frozen at -20°C in 1 ml aliquots. A 1 ml aliquot was thawed, lysozyme was added to 1 mg/ml, and the
15 cells were incubated at 23°C for 30 minutes. A solution of 20% SDS (sodium dodecyl sulfate) was added to a final concentration of 0.5% followed by extraction with buffered phenol. The aqueous phase was further extracted with 1:1 phenol:chloroform, and extracted a final time with chloroform. One-tenth volume of 3 M sodium acetate, pH 5.0 and 2.5 volumes of ethanol were added to the aqueous phase and mixed. The DNA was
20 pelleted by centrifugation at 20,000 x g for 5 minutes. The DNA pellet was washed with 70% ethanol, air dried and resuspended in 200 µl of TE and used directly for amplification. *Thermus scotoductus* (Tsc, ATCC # 51532) was grown and genomic DNA was prepared as described above for *Thermus filiformis*.

The DNA polymerase I gene from *Tfi* (GenBank accession #AF030320) could not
25 be amplified as a single fragment. Therefore, it was cloned in 2 separate fragments into the expression vector pTrc99a. The 2 fragments overlap and share a *Not I* site which was created by introducing a silent mutation at position 1308 of the *Tfi* DNA polymerase open reading frame (ORF) in the PCR oligonucleotides. The 3' half of the gene was amplified using the Advantage cDNA PCR kit (Clonetech) with the following oligonucleotides;
30 5'-ATAGCCATGGTGGAGCGGCCGCTCTCCGG (SEQ ID NO:245) and
5'-AAGCGTCGACTCAATCCTGCTCGCCTCCAGCC (SEQ ID NO:246). The PCR

product from this reaction was approximately 1200 base pairs in length. It was cut with the restriction enzymes Not I and Sal I, and the resulting DNA was ligated into pTrc99a cut with NotI and SalI to create pTrc99a-Tfi3'. The 5' half of the gene was amplified as described above using the following two primers;

- 5 5'AATCGAATTCACCCCACTTTGACCTGGAGG (SEQ ID NO:247) and
5'-CCGGGAGAGCCGCCGCTCCAC (SEQ ID NO:248). The resulting 1300 base pair fragment was cut with restriction enzymes Eco RI and Not I and ligated into pTrc99a-Tfi3' cut with NotI and EcoRI to produce pTrc99a-TfiPol, SEQ ID NO:249 (the corresponding amino acid sequence is listed in SEQ ID NO:250).
- 10 The DNA polymerase I gene from *Thermus scotoductus* was amplified using the Advantage eDNA PCR kit (Clontech) using the following two primers;
5'-ACTGGAATTCTGCCCTTGTAGGCCAAG (SEQ ID NO:251) and
5'-AACAGTCGACCTAGGCCTTGGCGGAAAGCC (SEQ ID NO:252). The PCR product was cut with restriction enzymes Eco RI and Sal I and ligated into Eco RI, Sal I
15 cut pTrc99a to create pTrc99a-TscPol SEQ ID NO:253 (the corresponding amino acid sequence is listed in SEQ ID NO:254).

2. Expression and purification of *Thermus filiformis* and *Thermus scotoductus*

- 20 Plasmids were transformed into protease deficient *E. coli* strain BL21 (Novagen) or strain JM109 (Promega Corp., Madison, WI) for protein expression. Flasks containing 200 ml of LB containing 100 µg/ml ampicillin were inoculated with either a single colony from an LB plate or from a frozen stock of the appropriate strain. After several hours of growth at 37°C with vigorous shaking, cultures was induced by the addition of
25 200 µl of 1 M isothiopropyl-galatoside (IPTG). Growth at 37°C was continued for 16 hours prior to harvest. Cells were pelleted by centrifugation at 8000 x g for 15 minutes followed by suspension of the cell pellet in 5 ml of TEN (10 mM TrisHCl, pH 8.0, 1 mM EDTA, 100 mM NaCl). 100 µl of 50 mg/ml lysozyme were added and the cells incubated at room temperature for 15 minutes. Deoxycholic acid (10%) was added to a
30 final concentration of 0.2%. After thorough mixing, the cell lysates were sonicated for 2 minutes on ice to reduce the viscosity of the mixture. Cellular debris was pelleted by

centrifugation at 4°C for 15 minutes at 20,000 x g. The supernatant was removed and incubated at 70°C for 30 min after which 10% polyethylimine (PEI) was added to 0.25%. After incubation on ice for 30 minutes, the mixture was centrifuged at 20,000 x g for 20 min at 4°C. At this point, the supernatant containing the enzyme was removed, and the 5 protein was precipitated by the addition of 1.2 g of ammonium sulfate and incubation at 4°C for 1 hour. The protein was pelleted by centrifugation at 4°C for 10 minutes at 20,000 x g. The pellet was resuspended in 4 ml of HPLC Buffer A (50 mM TrisHCl, pH 8.0, 1 mM EDTA). The protein was further purified by affinity chromatography using an Econo-Pac heparin cartridge (Bio-Rad) and a Dionex DX 500 HPLC instrument. Briefly, 10 the cartridge was equilibrated with HPLC Buffer A, and the enzyme extract was loaded on the column and eluted with a linear gradient of NaCl (0-2 M) in the same buffer. Pure protein elutes between 0.5 and 1 M NaCl. The enzyme peak was collected and dialyzed in 50% glycerol, 20 mM Tris HCl, pH 8, 50 mM KCl, 0.5% Tween 20, 0.5% Nonidet P40, 100 mg/ml BSA.

15

C. Generation of polymerase mutants with reduced polymerase activity but unaltered 5' nuclease activity

All mutants generated in section C were expressed and purified as described in Example 2A1C.

20

1. Modified TaqPol Genes: TaqDN

A polymerization deficient mutant of *Taq* DNA polymerase called TaqDN was constructed. TaqDN nuclease contains an asparagine residue in place of the wild-type aspartic acid residue at position 785 (D785N).

25

DNA encoding the TaqDN nuclease was constructed from the gene encoding the *Taq* A/G in two rounds of site-directed mutagenesis. First, the G at position 1397 and the G at position 2264 of the *Taq* A/G gene (SEQ ID NO:238) were changed to A at each position to recreate a wild-type TaqPol gene. In a second round of mutagenesis, the wild type TaqPol gene was converted to the Taq DN gene by changing the G at position 2356 30 to A. These manipulations were performed as follows.

DNA encoding the Taq A/G nuclease was recloned from pTTQ18 plasmid into the pTrc99A plasmid (Pharmacia) in a two-step procedure. First, the pTrc99A vector was modified by removing the G at position 270 of the pTrc99A map, creating the pTrc99G cloning vector. To this end, pTrc99A plasmid DNA was cut with *Nco*I and the recessive 3' ends were filled-in using the Klenow fragment of *E.coli* polymerase I in the presence of all four dNTPs at 37°C for 15 min. After inactivation of the Klenow fragment by incubation at 65°C for 10 min, the plasmid DNA was cut with *Eco*RI and the ends were again filled-in using the Klenow fragment in the presence of all four dNTPs at 37°C for 15 min. The Klenow fragment was then inactivated by incubation at 65°C for 10 min. The plasmid DNA was ethanol precipitated, recircularized by ligation, and used to transform *E.coli* JM109 cells (Promega). Plasmid DNA was isolated from single colonies, and deletion of the G at position 270 of the pTrc99A map was confirmed by DNA sequencing.

In a second step, DNA encoding the Taq A/G nuclease was removed from the pTTQ18 plasmid using *Eco*RI and *Sal*I and the DNA fragment carrying the Taq A/G nuclease gene was separated on a 1% agarose gel and isolated with Geneclean II Kit (Bio 101, Vista, CA). The purified fragment was ligated into the pTrc99G vector that had been cut with *Eco*RI and *Sal*I. The ligation mixture was used to transform competent *E.coli* JM109 cells (Promega). Plasmid DNA was isolated from single colonies and insertion of the Taq A/G nuclease gene was confirmed by restriction analysis using *Eco*RI and *Sal*I.

Plasmid DNA pTrcAG carrying the Taq A/G nuclease gene cloned into the pTrc99A vector was purified from 200 ml of JM109 overnight culture using QIAGEN Plasmid Maxi kit (QIAGEN, Chatsworth, CA) according to manufacturer's protocol. pTrcAG plasmid DNA was mutagenized using two mutagenic primers, E465 (SEQ ID NO:255) (Integrated DNA Technologies, Iowa) and R754Q (SEQ ID NO:256) (Integrated DNA Technologies), and the selection primer Trans Oligonucleotide AlwNI/*Spe*I (Clontech, Palo Alto, CA, catalog #6488-1) according to TRANSFORMER Site-Directed Mutagenesis Kit protocol (Clontech, Palo Alto, CA) to produce a restored wild-type TaqPol gene (pTrcWT).

pTrcWT plasmid DNA carrying the wild-type TaqPol gene cloned into the pTrc99A vector was purified from 200 ml of JM109 overnight culture using QIAGEN Plasmid Maxi kit (QIAGEN, Chatsworth, CA) according to manufacturer's protocol. pTrcWT was then mutagenized using the mutagenic primer D785N (SEQ ID NO:257) 5 (Integrated DNA Technologies) and the selection primer Switch Oligonucleotide Spel/AlwNI (Clontech, Palo Alto, CA, catalog #6373-1) according to TRANSFORMER Site-Directed Mutagenesis Kit protocol (Clontech, Palo Alto, CA) to create a plasmid containing DNA encoding the Taq DN nuclease. The DNA sequence encoding the Taq DN nuclease is provided in SEQ ID NO:258; the amino acid sequence of Taq DN 10 nuclease is provided in SEO ID NO:259.

2. Modified TthPol Gene: Tth DN

The *Tth* DN construct was created by mutating the *Tth*Pol described above. The sequence encoding an aspartic acid at position 787 was changed by site-specific mutagenesis as described above to a sequence encoding asparagine. Mutagenesis of pTrcTth-2 with the following oligonucleotide: 5'-CAGGAGGAGCTCGTTGGACCTGGA-3' (SEQ ID NO:260) was performed to create the plasmid pTrcTthDN. The mutant protein and protein coding nucleic acid sequence is termed TthDN SEQ ID NOS:261 and 262 respectively.

3. Tag DN HT and Tth DN HT

Six amino acid histidine tags (his-tags) were added onto the carboxy termini of Taq DN and Tth DN. The site-directed mutagenesis was performed using the TRANSFORMER Site Directed Mutagenesis Kit (Clontech) according to the manufacturer's instructions. The mutagenic oligonucleotides used on the plasmids pTaq DN and pTh DN were sequence 117-067-03,
25 5'-TCTAGAGGATCTATCAGTGGTGGTGGTGGTGGTGGTGGCAGACG-
3' (SEQ ID NO:263) and
5'-TGCTCGAGGTGACGCTAGCTAGTGGTGGTGGTGGTGGTGGCAGACG-
30 3' (SEQ ID NO:264), sequence 136-037-05. The selection primer Trans Oligo AlwNI/SpeI (Clontech, catalog # 6488-1) was used for both mutagenesis reactions.

The resulting mutant genes were termed Taq DN HT (SEQ ID NO:265, nucleic acid sequence; SEQ ID NO:266, amino acid sequence) and Tth DN HT (SEQ ID NO:267, nucleic acid sequence; SEQ ID NO:268, amino acid sequence).

5 **4. Purification of Taq DN HT and Tth DN HT**

Both Taq DN HT and Tth DN HT proteins were expressed in *E. coli* strain JM109 as described in Example 2B2. After ammonium sulfate precipitation and centrifugation, the protein pellet was suspended in 0.5 ml of Q buffer (50 mM Tris-HCl, pH 8.0, 0.1 mM EDTA 0.1% Tween 20). The protein was further purified by affinity chromatography 10 using His-Bind Resin and Buffer Kit (Novagen) according to the manufacturer's instructions. 1 ml of His-Bind resin was transferred into a column, washed with 3 column volumes of sterile water, charged with 5 volumes of 1X Charge Buffer, and equilibrated with 3 volumes of 1X Binding Buffer. Four ml of 1X Binding Buffer was added to the protein sample and the sample solution was loaded onto the column. After 15 washing with 3 ml of 1X Binding Buffer and 3 ml of 1X Wash Buffer, the bound His-Tag protein was eluted with 1 ml of 1X Elute Buffer. The pure enzyme was then dialyzed in 50% glycerol, 20 mM Tris-HCl, pH 8.0, 50 mM KCl, 0.5% Tween 20, 0.5% Nonidet P40, and 100 µg.ml BSA. Enzyme concentrations were determined by measuring absorption at 279 nm.

20

EXAMPLE 3

RNA-dependent 5' nuclease activity of TthPol can be conferred on TaqPol by transfer of the N-terminal portion of the DNA polymerase domain

25

A. Preparation and purification of substrate structures having either a DNA or an RNA target strand

The downstream (SEQ ID NO:162) and upstream probes (SEQ ID NO:161) and the IL-6 DNA (SEQ ID NO:163) (Figure 10) target strand were synthesized on a

30 PerSeptive Biosystems instrument using standard phosphoramidite chemistry (Glen Research). The synthetic RNA-DNA chimeric IrT target labeled with biotin at the 5'-end

(Figure 20A) was synthesized utilizing 2'-ACE RNA chemistry (Dharmacon Research). The 2'-protecting groups were removed by acid-catalyzed hydrolysis according to the manufacturer's instructions. The downstream probes labeled with 5'-fluorescein (FL) or 5'-tetrachloro-fluorescein (TET) at their 5' ends were purified by reverse phase HPLC
5 using a Resource Q column (Amersham-Pharmacia Biotech). The 648-nucleotide IL-6 RNA target (SEQ ID NO:160) (Figure 10) was synthesized by T7 RNA polymerase runoff-transcription of the cloned fragment of human IL-6 cDNA (nucleotides 64-691 of the sequence published in May *et al.*, Proc. Natl. Acad. Sci., 83:8957 [1986]) using a Megascript Kit (Ambion). All oligonucleotides were finally purified by separation on a
10 20% denaturing polyacrylamide gel followed by excision and elution of the major band. Oligonucleotide concentration was determined by measuring absorption at 260 nm. The biotin labeled IrT target was incubated with a 5-fold excess of streptavidin (Promega) in a buffer containing 10 mM MOPS, pH 7.5, 0.05% Tween 20, 0.05% NP-40 and 10 µg/ml tRNA at room temperature for 10 min.
15

B. Introduction of restriction sites to make chimeras

The restriction sites used for formation of chimerical proteins, described below, were chosen for convenience. The restriction sites in the following example have been strategically placed to surround regions shown by crystal structure and other analysis to
20 be functional domains (*See*, Figures 6, 7, and 19). Different sites, either naturally occurring or created via directed mutagenesis can be used to make similar constructs with other Type A polymerase genes from related organisms. It is desirable that the mutations all be silent with respect to protein function. By studying the nucleic acid sequence and the amino acid sequence of the protein, one can introduce changes in the nucleic acid
25 sequence that have no effect on the corresponding amino acid sequence. If the nucleic acid change required affects an amino acid, one can make the alteration such that the new amino acid has the same or similar characteristics of the one replaced. If neither of these options is possible, one can test the mutant enzyme for function to determine if the nucleic acid alteration caused a change in protein activity, specificity or function. It is
30 not intended that the invention be limited by the particular restriction sites selected or introduced for the creation of the improved enzymes of the present invention.

C. Generation of Tth DN RX HT and Taq DN RX HT

Mutagenesis was performed to introduce 3 additional, unique restriction sites into the polymerase domain of both the Taq DN HT and Tth DN HT enzymes. Site-specific mutagenesis was performed using the Transformer Site-Directed Mutagenesis Kit from 5 Clonetech according to manufacturer's instructions. One of two different selection primers, Trans Oligo AlwNI/SpeI or Switch Oligo SpeI/AlwNI (Clontech, Palo Alto CA catalog #6488-1 or catalog #6373-1) was used for all mutagenesis reactions described. The selection oligo used in a given reaction is dependent on the selection restriction site 10 present in the vector. All mutagenic primers were synthesized by standard synthetic chemistry. Resultant colonies were expressed in *E.coli* strain JM109.

The Not I sites (amino acid position 328) were created using the mutagenic primers 5'-ggccgcaggggccggccgtccacggcc (SEQ ID NO:269) and 5'-gcgtcaggggccggccgtgcacccggca (SEQ ID NO:270) corresponding to the sense 15 strands of the Taq DN HT and the Tth DN HT genes, respectively. The BstI (amino acid position 382) and NdeI (amino acid position 443) sites were introduced into both genes using sense strand mutagenic primes 5'-ctccctggacccttgaacacccaccc (SEQ ID NO:271) and 5'-gtccctggccatatggaggccac (SEQ ID NO:272). The mutant plasmids were over-expressed and purified using Qiagen QiaPrep Spin Mini Prep Kit (cat. # 27106). 20 The vectors were tested for the presence of the restriction sites by DNA sequencing and restriction mapping. These constructs are termed Tth DN RX HT (DNA sequence SEQ ID NO:273; amino acid sequence SEQ ID NO:274) and Taq DN RX HT (DNA sequence SEQ ID NO:275; amino acid sequence SEQ ID NO:276).

25 D. Chimeras

The chimeric constructs shown in Figure 19 were created by exchanging homologous DNA fragments defined by the restriction endonuclease sites EcoRI (E) and BamHI (B), common for both genes, the cloning vector site SalI (S) and the new sites, 30 NotI (N), BstBI (Bs), NdeI (D) created at the homologous positions of both genes by site directed mutagenesis. In generating these chimeric enzymes, two different pieces of DNA are ligated together to yield the final construct. The larger piece of DNA that

contains the plasmid vector as well as part of the Taq or Tth (or parts of both) sequence will be termed the "vector." The smaller piece of DNA that contains sequences of either the Taq or Tth (or parts of both) polymerase will be termed the "insert."

All restriction enzymes were from New England Biolabs or Promega and used in reactions with the accompanying buffer, according to the manufacturer's instructions. Reactions were done in 20 µl volume with about 500 ng of DNA per reaction, at the optimal temperature for the specified enzyme. More than one enzyme was used in a single reaction (double digest) if the enzymes were compatible with respect to reaction buffer conditions and reaction temperature. If the enzymes in question were not compatible with respect to buffer conditions, the enzyme requiring the lowest salt condition was used first. After the completion of that reaction, buffer conditions were changed to be optimal or better suited to the second enzyme, and the second reaction was performed. These are common restriction enzyme digest strategies, well known to those in the art of basic molecular biology (Maniatis, *supra*).

The digested restriction fragments were gel isolated for optimal ligation efficiency. Two µl of 10X loading dye (50% glycerol, 1X TAE, 0.5% bromophenol blue) were added to the 20 µl reaction. The entire volume was loaded and run on a 1%, 1X TAE agarose gel containing 1 µl of a 1% ethidium bromide solution per 100 ml of agarose gel solution. The digested fragments were visualized under UV light, and the appropriate fragments (as determined by size) were excised from the gel. These fragments were then purified using the Qiagen Gel Extractio Kit, (cat # 28706) according to the manufacturer's instructions.

Ligations were performed in a 10 µl volume, using 400 units per reaction of T4 DNA Ligase enzyme from New England Biolabs (catalog #202L), with the accompanying reaction buffer. Ligation reactions were done at room temperature for 1 hour, with 1 µl of each of the Qiagen-purified fragments (approximately 20-50 ng of each DNA, depending on recovery from the gel isolation). Ligation products were then transformed into *E. coli* strain JM 109 and plated onto an appropriate growth and selection medium, such as LB with 100µg/ml of ampicillin to select for transformants.

For each ligation reaction, six transformants were tested to determine if the desired construct was present. Plasmid DNA was purified and isolated using the QiaPrep

Spin Mini Prep Kit, according to manufacturer's instructions. The constructs were verified by DNA sequencing and by restriction mapping.

Expression and purification of the chimeric enzymes was done as follows.

Plasmids were transformed into *E. coli* strain JM109 (Promega). Log phase cultures (200

- 5 ml) of JM109 were induced with 0.5 mM IPTG (Promega) and grown for an additional 16 hours prior to harvest. Crude extracts containing soluble proteins were prepared by lysis of pelleted cells in 5 ml of 10 mM Tris-HCl, pH 8.3, 1mM EDTA, 0.5mg/ml lysozyme during incubation at room temperature for 15 minutes. The lysate was mixed with 5 ml of 10 mM Tris-HCl pH 7.8, 50 mM KCl, 1 mM EDTA, 0.5% Tween 20, 0.5% Nonidet P-40, heated at 72°C for 30 minutes, and cell debris was removed by centrifugation at 12,000x g for 5 minutes. Final purification of the protein was done by affinity chromatography using an Econo-Pac heparin cartridge (Bio-Rad) and Dionex DX 500 HPLC instrument. Briefly, the cartridge was equilibrated with 50mM Tris-HCl pH 8, 1 mM EDTA, and an enzyme extract dialyzed against the same buffer was loaded on the column and eluted with a linear gradient of NaCl (0-2 M) in the same buffer. The HPLC-purified protein was dialyzed and stored in 50% (vol/vol) glycerol, 20 mM Tris-HCl pH 8.0, 50 mM KCl, 0.5% Tween 20, 0.5% Nonidet P-40, and 100µg/m BSA. The enzymes were purified to homogeneity according to SDS-PAGE, and the enzyme concentrations were determined by measuring absorption at 279 nm.

20

1. Construction of TaqTth(N) and TthTaq(N)

The first exchange that was performed involved the polymerase domains of the two enzymes. Separation of the nuclease domain (the N-terminal end of the protein) from the polymerase domain (the C-terminal portion of the protein) was accomplished by cutting both genes with the restriction endonucleases EcoRI and NotI. The approximately 900 base pair fragment from the Tth DN RX HT gene was cloned into the homologous sites of the Taq DN RX HT gene, and the approximately 900 base pair fragment from the Taq DN RX HT gene was cloned into the homologous sites of the Tth DN RX HT gene, yielding two chimeras, TaqTth(N) (DNA sequence SEQ ID NO:69; amino acid sequence SEQ ID NO:2) which has the Taq DN RX HT 5' nuclease domain and the Tth DN RX HT polymerase domain, and TthTaq(N) (DNA sequence SEQ ID

NO:70; amino acid sequence SEQ ID NO:3) which is made up of the Tth DN RX HT 5' nuclease domain and the Taq DN RX HT polymerase domain.

2. Construction of TaqTth(N-B)

5 The Taq DN RX HT construct was cut with the enzymes NdeI and BamHI and the larger, vector fragment was gel isolated as detailed above. The Tth DN RX HT construct was also cut with NdeI and BamHI and the smaller (approximately 795 base pairs) Tth fragment was gel isolated and purified. The Tth NdeI-BamHI insert was ligated into the Taq NdeI-BamHI vector as detailed above to generate the TaqTth(N-B)
10 (DNA sequence SEQ ID NO:71; amino acid sequence SEQ ID NO:4).

3. Construction of TaqTth(B-S)

The Taq DN RX HT construct was cut with the enzymes BamHI and Sall and the larger vector fragment was gel isolated as detailed above. The Tth DN RX HT construct
15 was also cut with BamHI and Sall and the smaller (approximately 741 base pairs) Tth fragment was gel isolated and purified. The Tth BamHI-Sall insert was ligated into the Taq BamHI-Sall vector as detailed above to generate the TaqTth(B-S) (DNA sequence SEQ ID NO:72; amino acid sequence SEQ ID NO:5).

20 4. Construction of TaqTth(N-D)

The Taq DN RX HT construct was cut with the enzymes NotI and NdeI and the larger vector fragment was isolated as detailed above. The Tth DN RX HT construct was also cut with NotI and NdeI and the smaller (approximately 345 base pairs) Tth fragment was gel isolated and purified. The Tth NotI-NdeI insert was ligated into the Taq
25 NotI-NdeI vector as detailed above to generate the TaqTth(N-D) (DNA sequence SEQ ID NO:73; amino acid sequence SEQ ID NO:6).

5. Construction of TaqTth(D-B)

The Taq DN RX HT construct was cut with the enzymes NdeI and BamHI and the larger vector fragment was isolated as detailed above. The Tth DN RX HT construct
30 was also cut with NdeI and BamHI and the smaller (approximately 450 base pairs) Tth

fragment was gel isolated and purified. The Tth NdeI-BamHI insert was ligated into the Taq NdeI-BamHI vector as detailed above to generate the TaqTth(D-B) (DNA sequence SEQ ID NO:74; amino acid sequence SEQ ID NO:7).

5 **6. Construction of TaqTth(Bs-B)**

The Taq DN RX HT construct was cut with the enzymes BstBI and BamHI and the larger vector fragment was isolated as detailed above. The Tth DN RX HT construct was also cut with BstBI and BamHI and the smaller (approximately 633 base pairs) Tth fragment was gel isolated and purified. The Tth NdeI-BamHI insert was ligated into the 10 Taq NdeI-BamHI vector as detailed above to generate TaqTth(Bs-B) (DNA sequence SEQ ID NO:75; amino acid sequence SEQ ID NO:8).

7. **Construction of TaqTth(N-Bs)**

The Taq DN RX HT construct was cut with the enzymes NotI and BstBI and the 15 larger vector fragment was isolated as detailed above. The Tth DN RX HT construct was also cut with NotI and BstBI and the smaller (approximately 162 base pairs) Tth fragment was gel isolated and purified. The Tth NotI-BstBI insert was ligated into the Taq NotI-BstBI vector as detailed above to generate TaqTth(N-Bs) (DNA sequence SEQ ID NO:76; amino acid sequence SEQ ID NO:9).

20

8. **Construction of TthTaq(B-S)**

The Tth DN RX HT construct was cut with the enzymes BamHI and SalI and the larger vector fragment was isolated as detailed above. The Taq DN RX HT construct was also cut with BamHI and SalI and the smaller (approximately 741 base pairs) Tth 25 fragment was gel isolated and purified. The Taq BamHI-SalI insert was ligated into the Tth BamHI-SalI vector as detailed above to generate the TthTaq(B-S) (DNA sequence SEQ ID NO:77; amino acid sequence SEQ ID NO:10).

30

9. **Construction of Tth Taq(N-B)**

The Tth DN RX HT construct was cut with the enzymes NotI and BamHI and the larger vector fragment was isolated as detailed above. The Taq DN RX HT construct was

also cut with NotI and BamHI and the smaller (approximately 795 base pairs) Tth fragment was gel isolated and purified. The Taq NotI-BamHI insert was ligated into the Tth NotI-BamHI vector as detailed above to generate the TthTaq(N-B) (DNA sequence SEQ ID NO:78; amino acid sequence SEQ ID NO:11).

5

The cleavage activities of these chimerical proteins were characterized as described in Example 1, part A, and a comparison of the cleavage cycling rates on an RNA target is shown in Figure 12. As further discussed in the Description of the Invention, these data show that elements found in the central third of the TthPol protein are important in conferring the TthPol-like RNA-dependent cleavage activity on the chimerical proteins comprising portions of TaqPol.

10

EXAMPLE 4

Alterations influencing RNA-dependent 5' nuclease activity do not necessarily
15 influence RNA-dependent DNA polymerase activity

TthPol is known to have a more active RNA template dependent DNA polymerase than does the TaqPol (Myers and Gelfand, Biochemistry 30:7661 [1991]). To determine whether the RNA template dependent 5' nuclease activity of the Thermus 20 DNA Pol I enzymes is related to their RNA-dependent polymerase activity, the D785N and D787N mutations used to create the polymerase-deficient versions of TaqPol and TthPol, respectively were reversed. Polymerase activity was similarly restored to the TaqTth (N) (DNA sequence SEQ ID NO:79; amino acid sequence SEQ ID NO:12), TaqTth(N-B) (DNA sequence SEQ ID NO:80; amino acid sequence SEQ ID NO:13), 25 TaqTth(B-S) (DNA sequence SEQ ID NO:81; amino acid sequence SEQ ID NO:14) chimeras, and the TaqPol(W417L/G418K/ E507Q) (DNA sequence SEQ ID NO:82; amino acid sequence SEQ ID NO:15) mutant proteins.

Polymerase function was restored in all the above mentioned enzyme mutants by inserting the BamHI to SalI fragment of the native, non-DN sequence into the selected 30 chimera or mutant enzyme. For example, the mutant construct TaqTth(N-B) was cut with the restriction enzyme BamHI (approximate amino acid position 593) and the

restriction enzyme Sall (approximate amino acid position 840). The larger vector fragment was gel purified as described in Example 3D. The native TaqPol construct was also cut with the restriction endonucleases BamHI and Sall, and the smaller insert fragment containing the native amino acid sequence was also gel purified. The insert 5 fragment was then ligated into the vector as detailed in Experimental Example 3D.

The polymerase activities of these proteins were evaluated by extension of the dT₂₅₋₃₅-oligonucleotide primer with fluorescein-labeled dUTP in the presence of either poly(dA) or poly(A) template. Primer extension reactions were carried out in 10 µl buffer containing 10 mM MOPS, pH7.5, 5 mM MgSO₄, 100 mM KCl. Forty ng of 10 enzyme were used to extend 10 µM (dT)₂₅₋₃₀ primer in the presence of either 10 µM poly(A)₂₈₅ or 1 µM poly(dA)₂₇₃ template, 45 µM dTTP and 5 µM Fl-dUTP at 60°C for 30 min. Reactions were stopped with 10 µl of stop solution (95% formamide, 10 mM EDTA, 0.02% methyl violet dye). Samples (3 µl) were fractionated on a 15% denaturing 15 acrylamide gel and the fraction of incorporated Fl-dUTP was quantitated using an FMBIO-100 fluorescent gel scanner (Hitachi) equipped with a 505 nm filter as described above.

As shown in Figure 16, the DNA-dependent polymerase activities are very similar for all constructs used in this experiment, whereas the RNA-dependent polymerase 20 activities of TthPol, TaqTth(N) and TaqTth(B-S) are at least 6-fold higher than the activities of TaqPol, TaqTth(N-B) and the TaqPol W417L/G418K/E507Q mutant. From the analysis of these results, it can be concluded that the high RNA-dependent DNA polymerase activity of TthPol is determined by the C-terminal half of the polymerase domain (roughly, amino acids 593-830) and that the RNA-dependent 5' nuclease and polymerase activities are not related to each other, and are controlled by different regions.

25

EXAMPLE 5

Specific point mutants in Taq DN RX HT developed from information from the chimeric studies

30 The chimeric studies (Example 3, above) suggest that the part of the TthPol sequence determining its high RNA-dependent 5' nuclease activity comprises the

BstBI-BamHI region located approximately between amino acid 382 and 593.

Comparison of the amino acid sequences between the BstBI and BamHI regions of Tth DN RX HT and Taq DN RX HT (SEQ ID NOS:165 and 164, respectively) revealed only 25 differences (Figure 13). Among these, 12 amino acid changes were conservative

5 while 13 of the differences resulted in changes in charge. Since the analysis of the chimeric enzymes suggested that the critical mutations are located in both the BstBI-NdeI and the NdeI-BamHI regions of Tth DN RX HT, site specific mutagenesis was used to introduce the Tth DN RX HT specific amino acids into the BstBI-NdeI and NdeI-BamHI regions of the TaqTth(D-B) and the TaqTth(N-D) respectively.

10 Six Tth DN RX HT specific substitutions were generated in the BstBI-NdeI region of the TaqTth(D-B) by single or double amino acid mutagenesis. Similarly, 12 Tth DN RX HT specific amino acid changes were introduced at the homologous position of the NdeI-BamHI region of the TaqTth(N-D).

Plasmid DNA was purified from 200 ml of JM109 overnight culture using
15 QIAGEN Plasmid Maxi Kit (QIAGEN, Chatsworth, CA) according to the manufacturer's protocol to obtain enough starting material for all mutagenesis reactions. All site specific mutations were introduced using the Transformer Site Directed mutagenesis Kit (Clontech) according to the manufacturer's protocol; specific sequence information for the mutagenic primers used for each site is provided below. One of two different
20 selection primers, Trans Oligo AlwNI/SpeI or Switch Oligo SpeI/AlwNI (Clontech, Palo Alto, CA catalog #6488-1 or catalog #6373-1) was used for all mutagenesis reactions described. The selection oligo used in a given reaction is dependent on the restriction site present in the vector. All mutagenic primers were synthesized by standard synthetic chemistry. Resultant colonies were *E.coli* strain JM109.

25

1. **Construction of TaqTth(D-B) E404H (DNA sequence SEQ ID NO:83; amino acid sequence SEQ ID NO:16)**

Site specific mutagenesis was performed on pTrc99A TaqTth(D-B) DNA using the mutagenic primer 240-60-01 5'-gag gag gcg ggg cac cgg gcc gcc ctt-3' (SEQ ID

30 NO:277) to introduce the E404H mutation.

2. **Construction of TaqTth(D-B) F413H/A414R (DNA sequence SEQ ID NO:84; amino acid sequence SEQ ID NO:17)**

Site specific mutagenesis was performed on pTrc99A TaqTth(D-B) DNA using the mutagenic primer 240-60-02 5'-ctt tcc gag agg ctc cat cgg aac ctg tgg ggg agg-3' (SEQ ID NO:278) to introduce the F413H and the A414R mutations.

3. **Construction of TaqTth(D-B) W417L/G418K (DNA sequence SEQ ID NO:85; amino acid sequence SEQ ID NO:18)**

Site specific mutagenesis was performed on pTrc99A TaqTth(D-B) DNA using the mutagenic primer 240-60-03 5'-ctc ttc gcc aac ctg ctt aag agg ctt gag ggg gag-3' (SEQ ID NO:279) to introduce the W417L and the G418K mutations.

4. **Construction of TaqTth(D-B) A439R (DNA sequence SEQ ID NO:86; amino acid sequence SEQ ID NO:19)**

Site specific mutagenesis was performed on pTrc99A TaqTth(ND-B) DNA using the mutagenic primer 240-60-04 5'-agg ccc ctt tcc cgg gtc ctg gcc cat-3' (SEQ ID NO:280) to introduce the A439R mutation.

5. **Construction of TaqTth(N-D) L451R (DNA sequence SEQ ID NO:87; amino acid sequence SEQ ID NO:20)**

Site specific mutagenesis was performed on pTrc99AtaqTth(N-D) DNA using the mutagenic primer 240-60-05 5'-acg ggg gtg cgc cgg gac gtc gcc tat-3' (SEQ ID NO:281) to introduce the L451Q mutation.

25 6. **Construction of TaqTth(N-D) R457Q (DNA sequence SEQ ID NO:88; amino acid sequence SEQ ID NO:21)**

Site specific mutagenesis was performed on pTrc99AtaqTth(N-D) DNA using the mutagenic primer 240-60-06 5'-gtg gcc tat ctc cag gcc tgg tcc ctg-3' (SEQ ID NO:282) to introduce the L451Q mutation.

7. **Construction of TaqTth(N-D) V463L (DNA sequence SEQ ID NO:89; amino acid sequence SEQ ID NO:22)**

Site specific mutagenesis was performed on pTrc99AtaqTth(N-D) DNA using the mutagenic primer 240-60-07 5'-tgt tcc ctg gag ctt gcc gag gag atc-3' (SEQ ID NO:283)
5 to introduce the V463L mutation.

8. **Construction of TaqTth(N-D) A468R (DNA sequence SEQ ID NO:90; amino acid sequence SEQ ID NO:23)**

Site specific mutagenesis was performed on pTrc99AtaqTth(N-D) DNA using the mutagenic primer 240-60-08 5'-gcc gag gag atc cgc cgc ctc gag gcc-3' (SEQ ID NO:284)
10 to introduce the A468R mutation.

9. **Construction of TaqTth(N-D) A472E (DNA sequence SEQ ID NO:91; amino acid sequence SEQ ID NO:24)**

15 Site specific mutagenesis was performed on pTrc99AtaqTth(N-D) DNA using the mutagenic primer 240-60-09 5'-gcc cgc ctc gag gag gtc ttc cgc-3' (SEQ ID NO:285)
to introduce the A472E mutation.

10. **Construction of TaqTth(N-D) G499R (DNA sequence SEQ ID NO:92; amino acid sequence SEQ ID NO:25)**

Site specific mutagenesis was performed on pTrc99AtaqTth(N-D) DNA using the mutagenic primer 240-60-10 5'-ttt gac gag cta agg ctt ccc gcc atc-3' (SEQ ID NO:286) to
introduce the G499R mutation.

25 11. **Construction of TaqTth(N-D) E507Q (DNA sequence SEQ ID NO:93; amino acid sequence SEQ ID NO:26)**

Site specific mutagenesis was performed on pTrc99AtaqTth(N-D) DNA using the mutagenic primer 276-046-04 5'-atc gcc aag acg caa aag acc ggc aag-3' (SEQ ID NO:287) to introduce the E507Q mutation.

12. Construction of TaqTth(N-D) Y535H (DNA sequence SEQ ID NO:94; amino acid sequence SEQ ID NO:27)

Site specific mutagenesis was performed on pTrc99A^{taq}Tth(N-D) DNA using the mutagenic primer 240-60-11 5'-aag atc ctg cag cac egg gag ctc acc-3' (SEQ ID NO:288) 5 to introduce the Y535H mutation.

13. Construction of TaqTth(N-D) S543N (DNA sequence SEQ ID NO:95; amino acid sequence SEQ ID NO:28)

Site specific mutagenesis was performed on pTrc99A^{taq}Tth(N-D) DNA using the 10 mutagenic primer 240-60-12 5'-acc aag ctg aag aac acc tac att gac-3' (SEQ ID NO:289) to introduce the S543N mutation.

14. Construction of TaqTth(N-D) I546V (DNA sequence SEQ ID NO:96; amino acid sequence SEQ ID NO:29)

15 Site specific mutagenesis was performed on pTrc99A^{taq}Tth(N-D) DNA using the mutagenic primer 240-60-13 5'-aag agc acc tac gtg gac ccc ttg ccg-3' (SEQ ID NO:290) to introduce the I546V mutation.

15. Construction of TaqTth(N-D) D551S/I553V (DNA sequence SEQ ID NO:97; amino acid sequence SEQ ID NO:30)

Site specific mutagenesis was performed on pTrc99A^{taq}Tth(N-D) DNA using the 20 mutagenic primer 240-60-14 5'-att gac ccc ttg ccg agc ctc gtc cac ccc agg acg ggc-3' (SEQ ID NO:291) to introduce the D551S and the I553V mutations.

25 16. Construction of TaqDN RX HT W417L/G418K/E507Q (DNA sequence SEQ ID NO:98; amino acid sequence SEQ ID NO:31)

The TaqDN RX HT W417L/G418K/E507Q triple mutant was made by combining the TaqTth(D-B)W417L/G418K with the TaqTth(N-D) E507Q.

TaqTth(D-B)W417L/G418K was cut with the restriction enzymes NdeI and BamHI, and 30 the larger, vector fragment was isolated as detailed in Example 3. The TaqTth(N-D) E507Q construct was also cut with NdeI and BamHI and the smaller (approximately 795

base pairs) fragment was gel isolated and purified as detailed in Example 3. The NdeI-BamHI insert was ligated into the gel purified vector, as detailed in Example 3.

17. **Construction of TaqDN RX HT W417L/E507Q (DNA sequence SEQ
5 ID NO:99; amino acid sequence SEQ ID NO:32)**

Starting with TaqDN RX HT W417L/G418K/E507Q described above, mutagenic primer 337-01-02: 5'-TTC GCC AAC CTG CTT GGG AGG CTT GAG GGG GAG -3' (SEQ ID NO:292) was used in a site specific mutagenesis reaction to change the K at amino acid position 418 back to the wild-type amino acid, G. Site specific mutagenesis was done using the Transformer Site Directed Mutagenesis Kit (Clonetech) according to the manufacturer's instructions, and as described in Experimental Example 4.

18. **Construction of TaqDN RX HT G418K/E507Q (DNA sequence SEQ
15 ID NO:100; amino acid sequence SEQ ID NO:33)**

Starting with TaqDN RX HT W417L/G418K/E507Q described above, mutagenic primer 337-01-01: 5'-CTC TTC GCC AAC CTG TGG AAG AGG CTT GAG GGG -3' (SEQ ID NO:293) was used in a site specific mutagenesis reaction to change the L at amino acid position 417 back to the wild-type amino acid, W. Site specific mutagenesis was done using the Transformer Site Directed Mutagenesis Kit (Clonetech) according to the manufacturer's instructions, and as described in Experimental Example 4.

Expression and purification of mutant proteins was done as detailed in Example 3, and the cleavage activities of these proteins were characterized as described in Example 1, part A. A comparison of the cleavage cycling rates of a selection of these mutant proteins on an RNA target is shown in Figure 14. As further discussed in the Description of the Invention, these data show that amino acids in the regions 417/418 and amino acid 507 are important in the conferring the TthPol-like RNA-dependent cleavage activity on the chimerical proteins comprising portions of TaqPol in combination with portions of TthPol that are not independently capable of providing enhanced RNA dependent activity (*i.e.*, the D-B and N-D portions of Tth). As described in the Description of the Invention, Taq DN RX HT variant carrying only the W417L, G418K and E507Q substitutions were created. By comparing their cleavage rates to that of Tth DN RX HT on the IL-6 RNA

substrate as described in Example 1, these mutations were determined to be sufficient to increase the Taq DN RX HT activity to the Tth DN RX HT level. Figure 15 shows that the Taq DN RX HT W417L/G418K/E507Q and Taq DN RX HT G418K/E507Q mutants have 1.4 times higher activity than Tth DN RX HT and more than 4 fold higher activity
5 than Taq DN RX HT, whereas the Taq DN RX HT W417L/E507Q mutant has the same activity as the enzyme, which is about 3 fold higher than Taq DN RX HT. These results demonstrate that K418 and Q507 of TthPol are particularly important amino acids in providing RNA dependent 5' nuclease activity that is enhanced compared to TaqPol.

10

EXAMPLE 6

RNA-dependent 5' nuclease properties of the Taq DN RX HT G418K/E507Q 5' nuclease are similar to Tth DN RX HT with respect to salt and temperature optima

15

To determine if the G418K/E507Q mutations caused any significant changes in the properties of the Taq DN RX HT mutant in addition to the increased cleavage rate with the RNA target, the Taq DN RX HT G418K/E507Q (SEQ ID NO:33), Taq DN RX HT (SEQ ID NO:276), and Tth DN RX HT (SEQ ID NO:274) enzymes were compared in the RNA template dependent 5' nuclease assay under conditions where temperature and the concentrations of salt and divalent ions were varied. The upstream DNA and the
20 template RNA strands of the substrate used in this study were linked into a single IrT molecule (SEQ ID NO:166) as shown in Figure 20A, and the labeled downstream probe (SEQ ID NO:167) was present in large excess. The 5' end of the target RNA strand was blocked with a biotin-streptavidin complex to prevent any non-specific degradation by the enzyme during the reaction (Lyamichev *et al.*, Science 260:778 [1993], Johnson *et
25 al.*, Science 269:238 [1995]). The cleavage rates for Taq DN RX HT G418K/E507Q, Taq DN RX HT, and Tth DN RX HT are plotted as functions of temperature in Figure 20B. The closed circles represent enzyme Taq DN RX HT, the open circles represent enzyme Tth DN RX HT, and the Xs represent enzyme Taq DN RX HT G418K/E507Q. The difference in the activities of Tth and Taq DN RX HT enzymes with the IrT substrate
30 is even greater than the difference found with the IL-6 RNA substrate when tested in a cleavage assay as described in Example 1. The G418K/E507Q mutations increase the

activity of the Taq enzyme more than tenfold and by 25% compared with the Tth enzyme. All three enzymes show a typical temperature profile of the invasive signal amplification reaction and have the same optimal temperature. No significant effect of G418K/E507Q mutations on DNA dependent 5' nuclease activity of Taq DN RX HT with the all-DNA substrate analogous to IrT (SEQ ID NO:168) under the same conditions was found.

The effects of KCl and MgSO₄ concentrations on the 5' nuclease activity of Taq DN RX HT G418K/E507Q, Taq DN RX HT, and Tth DN RX HT with the IrT substrate are shown in Figure 20C and D. The activities of all enzymes have similar salt dependencies with an optimal KCl concentration of 100 mM for Taq DN RX HT G418K/E507Q and Tth DN RX HT and 50 mM for Taq DN RX HT. The optimal MgSO₄ concentration for all enzymes is approximately 8 mM. The analysis of the data presented in Figure 20 suggests that the properties of Taq DN RX HT G418K/E507Q are much closer to those of Tth DN RX HT rather than Taq DN RX HT confirming the key role of the G418K/E507Q mutations in the recognition of the substrate with an RNA target.

To understand the mechanism of the reduction of the 5' nuclease activity in the presence of an RNA versus a DNA target, the Michaelis constant (K_m) and the maximal catalytic rate (k_{cat}) of all three enzymes were determined, using an excess of the IrT substrate (SEQ ID NO:166) and the downstream probe (SEQ ID NO:167) and a limiting enzyme concentration. For these measurements, ten- μ l reactions were assembled containing 10 mM MOPS, pH 7.5, 0.05% Tween 20, 0.05% Nonidet P-40, 10 μ g/ml tRNA, 4 mM MgCl₂, 1 nM of enzyme (Taq DN RX HT, Tth DN RX HT, or Taq DN RX HT G418K/E507Q) and different concentrations (0.125, 0.25, 0.5 or 1 μ M) of an equimolar mixture of the IrT target and the downstream probe. The cleavage kinetics for each enzyme and each substrate concentration were measured at 46°C. Reactions were stopped by the addition of 10 μ l of 95% formamide containing 10 mM EDTA and 0.02% methyl violet (Sigma). One μ l of each stopped reaction digest was fractionated on a 20% denaturing acrylamide gel (19:1 cross-linked), with 7M urea, and in a buffer of 45 mM Tris-borate, pH 8.3, 1.4mM EDTA. Gels were scanned on an FMBIO-100 fluorescent gel scanner (Hitachi) using a 585 nm filter. The fraction of cleaved product (determined

from intensities of bands corresponding to uncut and cut substrate with FMBIO Analysis software, version 6.0, Hitachi) was plotted as a function of reaction time. The initial cleavage rates were determined from the slopes of linear part of the cleavage kinetics and were defined as the concentration of cut product divided by the enzyme concentration
5 and the time of the reaction (in minutes). The Michaelis constant K_m and the maximal catalytic rate k_{cat} of each enzyme with IrT substrate were determined from the plots of the initial cleavage rate as functions of the substrate concentration.

It was found that all three enzymes have similar K_m values (in the range of 200-300 nM) and k_{cat} values of approximately 4 min⁻¹ for Taq DN RX HT and Tth DN
10 RX HT and of 9 min⁻¹ for Taq DN RX HT G418K/E507Q. That the G418K/E507Q mutations increase the k_{cat} of Taq DN RX HT more than two fold, but have little effect on K_m suggest that the mutations position the substrate in an orientation more appropriate for cleavage, rather than simply increase the binding constant.

15

EXAMPLE 7

Use of molecular modeling to further improve RNA-dependent 5' nuclease activity

A. Point mutants

To develop enzymes with altered function, sequence changes were introduced by site-specific mutagenesis in predetermined locations or by random mutagenesis.
20 Locations for site-specific mutagenesis were chosen based on evidence from chimeric studies, relevant published literature, and molecular modeling. Seven additional mutant enzymes were developed from the Tth DN RX HT enzyme, and twenty additional mutant enzymes were developed from the Taq DN RX HT enzyme, both discussed previously.
25 Some of the mutant enzymes are the result of multiple mutagenesis reactions, that is, more than one change has been introduced to obtain the final product. Mutation reactions were done using the Tth DN RX HT construct (SEQ ID NO:273) described in Example 2C2, or the Taq DN RX HT construct (SEQ ID NO:275), described in Example 2C1 unless otherwise stated. Plasmid DNA was purified from 200 ml of JM109 overnight culture using QIAGEN Plasmid Maxi Kit (QIAGEN, Chatsworth, CA) according to the manufacturer's protocol to obtain enough starting material for all mutagenesis reactions.
30

All site-specific mutations were introduced using the Transformer Site Directed mutagenesis Kit (Clontech) according to the manufacturer's protocol. One of two different selection primers, Trans Oligo AlwNI/SpeI or Switch Oligo SpeI/AlwNI (Clontech, Palo Alto CA catalog #6488-1 or catalog #6373-1) was used for all

5 mutagenesis reactions described. The selection oligo used in a given reaction is dependent on the restriction site present in the vector. All mutagenic primers for both the site-specific mutagenesis and the random mutagenesis were synthesized by standard synthetic chemistry. Resultant colonies for both types of reactions were *E. coli* strain JM109. Random mutagenesis methods are described below.

10 Mutants were tested via the rapid screening protocol detailed in Example 1. Then, if more detailed analysis was desired, or if a larger protein preparation was required, expression and purification of mutant proteins was done as detailed in Example 3.

15 **1. Construction of Tth DN RX HT H641A, Tth DN RX HT H748A, Tth DN RX HT H786A**

Site specific mutagenesis was performed on pTrc99A Tth DN RX HT DNA using the mutagenic primer 583-001-02: 5'-gct tgc ggt ctg ggt ggc gat gtc ctt ccc ctc-3' (SEQ ID NO:294) to introduce the H641A mutation (DNA sequence SEQ ID NO:101; amino acid sequence SEQ ID NO:34), or the mutagenic primer 583-001-03: 5' cat gtt gaa ggc cat ggc ctc cgc ggc ctc cct-3' (SEQ ID NO:295) to generate the H748A mutant (DNA sequence SEQ ID NO:102; amino acid sequence SEQ ID NO:35), or the mutagenic primer 583-001-04: 5'-cag gag gag ctc gtt ggc gac ctg gag gag-3' (SEQ ID NO:296) to generate the H786A mutant enzyme (DNA sequence SEQ ID NO:103; amino acid sequence SEQ ID NO:36).

20 **2. Construction of Tth DN RX HT (H786A/G506K/Q509K)**

Starting with the mutant Tth DN RX HT H786A, generated above, site specific mutagenesis was done using the mutagenic primer 604-022-02: 5'-gga gcg ctt gcc tgt ctt ctt cgt ctt cta gca ggc ggg agg cct-3' (SEQ ID NO:297) to generate this variant termed 30 "TthAKK", (DNA sequence SEQ ID NO:104; amino acid sequence SEQ ID NO:37).

35 **3. Construction of Taq DN RX HT (W417L/G418K/E507Q/H784A)**

Mutagenic oligonucleotide 158-029-02: 5'-gag gac cag ctc gtt ggc gac ctg aag gag cat-3' (SEQ ID NO:298) was used in a site specific mutagenesis reaction to introduce the H784A mutation and generate this construct termed "Taq4M" (DNA sequence SEQ ID NO:105; amino acid sequence SEQ ID NO:38).

5 **4. Construction of Taq4M H639A, Taq4M R587A, Taq4M G504K and
Taq4M G80E**

Site specific mutagenesis was done on the Taq4M mutant, using primer 473-010-11: 5'-gagggccggacatcgccacggagacggcagg-3' (SEQ ID NO:299) to generate the Taq 4M H639A mutant (DNA sequence SEQ ID NO:106; amino acid sequence SEQ ID NO:39), primer 473-010-10: 5'-cag aac ate ecc gtc gcc acc ccg ctt ggg cag-3' (SEQ ID NO:300) to generate Taq 4M R587A (DNA sequence SEQ ID NO:107; amino acid sequence SEQ ID NO:40), primer 300-081-06: 5'-ggg ctt ccc gcc atc aag aag acg gag aag acc-3' (SEQ ID NO:301) to generate Taq 4M G504K (DNA sequence SEQ ID NO:108; amino acid sequence SEQ ID NO:41), and primer 330-088-04: 5'-cta ggg ctt ccc gcc atc aag aag acg caa aag acc ggc-3' (SEQ ID NO:302) to generate the Taq 4M G80E mutant (DNA sequence SEQ ID NO:109; amino acid sequence SEQ ID NO:42).

10 **5. Construction of Taq 4M P88E/P90E and Taq 4M L109F/A110T**

Starting with Taq 4M described above, site specific mutagenesis was done using primer 473-087-03: 5'-ccg ggg aaa gtc ctc ctc cgt ctc gcc cgg gcc ccc ctt-3' (SEQ ID NO:303) to generate the P88E/P90E mutations (DNA sequence SEQ ID NO:110; amino acid sequence SEQ ID NO:43), or primer 473-087-05: 5'-cgg gac ctc gag ggg cgt gaa ccc gag gag gtc cac-3' (SEQ ID NO:304) to generate the L109F/A110T mutations (DNA sequence SEQ ID NO:111; amino acid sequence SEQ ID NO:44).

15 **6. Construction of Taq DN RX HT**

20 **(W417L/G418K/G499R/A502K/I503L /G504K/ E507K/H784A)**

Two PCR reactions were performed, first using construct Taq4M (Taq W417L/G418K/G504K/E507Q/H784A) as a template. Using primers 158-84-01 5'-CTCCTCCACGAGTTGGC-3' (SEQ ID NO:305) and 535-33-02 5'-ACC GGT CTT CTT CGT CTT CAA CTT GGG AAG CCT GAG CTC GTC AAA-3' (SEQ ID NO:306) a 620 base pair PCR fragment was generated. Another 510 base pair PCR product was generated using primer 535-33-01 5'-AAG ACG AAG AAG ACC GGT

AAG CGC TCC ACC AGC-3' (SEQ ID NO:307) and 330-06-03 5'-GTC GAC TCT AGA TCA GTG GTG GTG GTG GTG CTT GGC CGC CCG GCG CAT C-3' (SEQ ID NO:308). The two PCR products overlap such that a final recombinant PCR amplification was done using the outside primers 158-84-01 and 330-06-03 to yield the

- 5 1182 base pair product. The recombinant PCR product was digested with the restriction enzymes NotI and BamHI according to the manufacturer's instructions to yield a 793 base pair fragment. The parent plasmid Taq4M was also digested with the same enzymes and used as the vector for ligation. All DNA fragments were TAE agarose gel purified prior to ligation. The fragment was ligated into the vector, and transformed into JM109
10 cells, thus incorporating the mutations G499R, A502K, I503L, and E507K as well as the restriction endonuclease site, AgeI. This construct is termed "Taq 8M" (DNA sequence SEQ ID NO:112; amino acid sequence SEQ ID NO:45).

B. Random Mutagenesis

- 15 Numerous enzymes with altered function were generated via random mutagenesis. The regions of the protein targeted for random mutagenesis were chosen based on molecular modeling data and from information in the literature. Different mutagenic primers were used to introduce mutations into different regions of the protein. Random mutagenesis was performed on the Taq variant Taq 4M G504K (Taq DN RX
20 HT W417L/G418K/G504K/E507Q/H784A/) (SEQ ID NO:108) described above and mutant PCR fragments generated in the mutagenesis reaction were exchanged for homologous regions in Tag8M (SEQ ID NO:112) unless otherwise stated.

Random mutagenesis was also performed on the Tth DN RX HT H786A (SEQ ID NO:103) described above. Mutant PCR fragments generated with the Tth DN RX HT
25 H786A template were exchanged for homologous regions in the unaltered Tth DN RX HT H786A.

1. Random mutants in amino acid residues 500-507 or 513-520

- The first mutagenic oligonucleotide, 535-054-01: 5'-gga gcg ctt acc ggt ctt (ttg
30 cgt ctt ctt gat ctt ggg aag) cct tag ctc gtc aaa gag-3' (SEQ ID NO:309) was used in conjunction with 158-84-01: 5'-CTC CTC CAC GAG TTC GGC-3' (SEQ ID NO:310) to

install random residues from amino acid position 500 to 507 of Taq polymerase variant 5 Taq DN RX HT W417L/G418K/G504K/E507Q/H784A (SEQ ID NO:108). This was accomplished by synthesizing the primer 535-054-01 such that only 91% of the bases within the parenthesis are unaltered while the remaining 9% of the bases are an equal mixture of the other 3 nucleotides. The initial, unaltered sequence of this oligo includes the G499R, A502K and the Q507K changes.

To generate mutations in the region 500-507, primer 535-054-01 and primer 158-84-01 were used in a PCR reaction, using the Advantage cDNA PCR kit (Clontech) and Taq variant described above, as the target. This PCR fragments was then run on a 10 1% TAE agarose gel, excised and purified with QIAquick Gel Extraction Kit (Qiagen, Valencia CA, catalog # 28706). The purified fragment was cut with NotI and AgeI and ligated into pTaq8M that had been linearized with NotI and AgeI. JM109 *E.coli* cells (Promega) were transformed with the ligated products. Clones were tested as described below.

15 The second mutagenic oligonucleotide (used in a separate reaction) 535-054-02: 5'-caa aag acc ggt aag cgc (tcc acc agc gcc gcc gtc ctg gag) gcc ctc cgc gag gcc cac-3' (SEQ ID NO:311) was used in conjunction with 330-06-03: 5'-GTC GAC TCT AGA TCA GTG GTG GTG GTG GTG CTT GGC CGC CCG GCG CAT C-3' (SEQ ID NO:312) to install random residues from amino acid 513-520. The bases within the 20 parenthesis of primer 535-054-02 are also 91% wild-type and 3% each of the other 3 nucleotides.

To generate mutations in the region 513-520, primer 535-054-02 and primer 535-054-02 were used in a PCR reaction with Taq DN RX HT W417L/G418K/G504K/E507Q/H784A (SEQ ID NO:108) as template, as described above. The resulting PCR 25 fragment was purified as above and cut with the restriction enzymes AgeI and BamHI. The cut fragment was then ligated into the Taq8M construct, also linearized with AgeI and BamHI. JM109 *E.coli* cells were transformed with the ligated products. Clones were tested as described Example 1. Mutants developed from these include:

30 Taq DN RX HT W417L/G418K/G499R/A502K/K504N/E507K/H784A (M1-13) (DNA sequence SEQ ID NO:113; amino acid sequence SEQ ID NO:46).

Taq DN RX HT W417L/G418K/G499R/L500I/A502K/G504K/Q507H/H784A (M1-36)

(DNA sequence SEQ ID NO:114; amino acid sequence SEQ ID NO:47).

Taq DN RX HT W417L/G418K/G499R/A502K/I503L/G504K/E507K/T514S/H784A.

(M2-24) (DNA sequence SEQ ID NO:115; amino acid sequence SEQ ID NO:48).

- 5 Taq DN RX HT W417L/G418K/G499R/A502K/I503L/G504K/E507K/ V518L/H784A
(M2-06) (DNA sequence SEQ ID NO:116; amino acid sequence SEQ ID NO:49).

2. TthDN RX HT H786A random mutagenesis

To generate mutants in the helix-hairpin-helix region of the TthDN RX HT H786A (SEQ ID NO:36) enzyme, two different PCR reactions were performed using the 10 H786A (SEQ ID NO:103) mutant as a template. The two PCR products overlap such that a recombinant PCR reaction can be performed (Higuchi, in PCR Technology, H. A. Erlich, ed., Stockton Press, New York. pp61-70 [1989]). This final PCR product is then exchanged with the homologous region of the TthDN H786A mutant by using restriction enzyme sites located on the ends of the fragment and within the TthDN H786A sequence.

15 Starting with TthDN H786A discussed above, and using primer 604-08-06: 5'-gtc gga ggg gtc ccc cac gag-3' (SEQ ID NO:313) and primer 390-76-08: 5'-tgt gga att gtg agc gg (SEQ ID NO:314), a 620 base pair PCR fragment was generated. PCR reactions were performed using the Advantage cDNA PCR kit (Clontech) according to manufacturer's instructions. This PCR product includes amino acids 1-194. No 20 mutations were introduced via this reaction, however the restriction enzyme site EcoRI is present at the 5' end.

Starting with TthDN RX HT H786A discussed above, and using mutagenic primer 604-08-05: 5'-ctc gtg ggg gac ccc tcc gac aac ctc (ccc ggg gtc aag ggc atc ggg gag aag acc gcc) ctc aag ctt ctc aag-3' (SEQ ID NO:315) and primer 209-74-02: 5'-gtg 25 gcc tcc ata tgg gcc agg ac-3' (SEQ ID NO:316) a 787 base pair PCR fragment was generated. PCR reactions were done as above. This fragment does contain random mutations, due to the presence of the mutagenic primer, 604-08-05. The bases within the parenthesis of this primer were synthesized such that 91% of the sequence is wild-type, while the additional 9% is evenly divided between the remaining 3 bases.

30 The two PCR fragments overlap, and were combined in a recombinant PCR reaction. Primers 390-76-08 and 209-74-02 were added, and the Advantage cDNA PCR

kit (Clontech) was again used according to manufacturer's instructions. A 1380 base pair product was generated from this reaction.

The recombinant PCR product was cut with the restriction enzymes EcoRI and NotI according to the manufacturer's instructions to yield a 986 base pair fragment.

- 5 TthDN RX HT H786A was prepared by cutting with the same enzymes. The fragment was then ligated into the vector, and transformed into JM109 cells. New mutants developed from this set of reactions include:

10 TthDN RX HT H786A/P197R/K200R (DNA sequence SEQ ID NO:117; amino acid sequence SEQ ID NO:50).

TthDN RX HT H786A/K205Y (DNA sequence SEQ ID NO:118; amino acid sequence SEQ ID NO:51).

TthDN RX HT H786A/G203R (DNA sequence SEQ ID NO:119; amino acid sequence SEQ ID NO:52).

15 **3. Construction of Taq DN RX HT W417L/G418K/H784A
L109F/A110T/G499R/A502K/I503L/G504K/E507K/T514S (Taq SS)**

Starting with Taq DN RX HT

W417L/G418K/G499R/A502K/I503L/G504K/E507K/T514S/H784A (SEQ ID NO:115) mutant described above, primer 473-087-05: 5'-ccg gac ctc gag gcg cgt gaa ccc cag gag gtc cac-3' (SEQ ID NO:317) was used in conjunction with the appropriate selection primer in a site specific mutagenesis reaction to incorporate the L109F and A110T mutations to generate this enzyme, termed "TaqSS" (DNA sequence SEQ ID NO:120; amino acid sequence SEQ ID NO:53).

20 **4. Construction of Taq DN RX HT W417L/G418L/H784A
P88E/P90E/G499R/A502K/I503L/G504K/E507K/T514S**

Starting with Taq DN RX HT

W417L/G418K/G499R/A502K/I503L/G504K/E507K/T514S/H784A (SEQ ID NO:115) mutant described above, primer 473-087-03: 5'-ccg ggg aaa gtc ctc ctc cgt ctc ggc cgg gcc cgc ctt-3' (SEQ ID NO:318) was used in conjunction with the appropriate selection primer in a site specific mutagenesis reaction to incorporate the P88E and P90E

mutations to generate this enzyme (DNA sequence SEQ ID NO:121; amino acid sequence SEQ ID NO:54).

5. TaqSS random mutagenesis

Random mutagenesis was used to introduce additional changes in the

- 5 helix-hairpin-helix domain of the TaqSS mutant (SEQ ID NO:120). The mutagenesis was done as described in example 9 above. In the first step, two different but overlapping PCR products were generated. One of the PCR products, generated with oligos 390-76-08 (SEQ ID NO:314), and 604-08-04: 5'-gtc gga ctc gtc acc ggt cag ggc-3' (SEQ ID NO:319) incorporates the EcoRI site into the fragment, but does not incorporate any 10 mutations. The second PCR product utilizes mutagenic primer 604-08-03: 5'-ctg acc ggt gag ctc gac aac ctt (ccc ggg gtc aag ggc atc ggg gag aag acg gcg) agg aat ctt ctg gag-3' (SEQ ID NO:320) and primer 209-74-02 (SEQ ID NO:316). This fragment contains random point mutations, and when combined via recombinant PCR with the first fragment, can be cut with the restriction enzymes EcoRI and NotI, and ligated into the 15 TaqSS construct, also cut with EcoRI and NotI. The ligated construct was then transformed into JM109. Colonies were screened as described below. Enzymes developed from this mutagenesis include:

- TaqSS K198N (DNA sequence SEQ ID NO:112; amino acid sequence SEQ ID NO:55).
20 TaqSS A205Q (DNA sequence SEQ ID NO:123; amino acid sequence SEQ ID NO:56).
TaqSS I200M/A205G (DNA sequence SEQ ID NO:124; amino acid sequence SEQ ID NO:57).
TaqSS K203N (DNA sequence SEQ ID NO:125; amino acid sequence SEQ ID NO:58).
TaqSS T204P (DNA sequence SEQ ID NO:126; amino acid sequence SEQ ID NO:59).

25 6. Construction of TaqSS R677A

- To generate enzymes with sequence changes in both the arch region and in the polymerase region, additional specific point mutations were generated in TaqSS. Site specific mutagenesis was performed as described above using the oligo 473-060-10: 5'-tag ctc ctg gga gag ggc gtg ggc cga cat gcc-3' (SEQ ID NO:321) to generate the 30 TaqSS R677A mutant (DNA sequence SEQ ID NO:127; amino acid sequence SEQ ID NO:60).

7. Construction of TaqTthAKK (DNA sequence SEQ ID NO:128; amino acid sequence SEQ ID NO:61) and TthTaq5M (DNA sequence SEQ ID NO:129; amino acid sequence SEQ ID NO:62)

Chimeric mutant TaqTthAKK and TthTaq5M were generated by cutting Tth DN
5 RX HT (H786A/G506K/Q509K) (SEQ ID NO:104; here abbreviated TthAKK) or Taq
4M G504 (SEQ ID NO:108; here abbreviated Taq 5M) with the restriction endonucleases
EcoRI and NotI. The smaller insert fragments as well as the larger vector fragments were
gel purified as detailed in Example 3D, and the insert fragments were exchanged between
the two mutants and ligated as described in Example 3D. Screening and verification of
10 the construct sequence was also done as in Example 3D.

EXAMPLE 8

Improvement of RNA-dependent 5' nuclease activity in other polymerases

15 Information gained from the TaqPol/TthPol recombinations, mutagenesis and modeling, was used to make comparable mutations in additional DNA polymerases and examined the effects on the cleavage activities of these enzymes. The DNA polymerases of *Thermus filiformis* (TfiPol) and *Thermus scotoductus* (TscPol) were cloned and purified as described in Example 2. The mutagenesis of these two proteins is described
20 below.

A. Construction of TfiPolDN2M

Mutagenesis of pTrc99a-TfiPol (SEQ ID NO:249) was done using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's protocol. The P420K mutation was made with the following two oligonucleotides;
25 5'-CTTCCAGAACCTCTTAAACGGCTTCGAGAAG (SEQ ID NO:322) and 5'-CTTCTCGAAAGCCGTITAAAGAGGTTCTGGAAG (SEQ ID NO:323). The E507Q mutation was made with the following two oligonucleotides;
5'-CCGGTGGGCCGGACGCAGAAGACGGCAAGC (SEQ ID NO:324) and 5'-GCTTGCCCCGTCTCTCGCTCCGCCACCGG (SEQ ID NO:325). The D785N
30 mutation was made with the following two oligonucleotides;
5'-CTCCTCCAAGTGCACAAACGAGCTGGTCTGG (SEQ ID NO:326) and

5'-CCAGGACCAGCTCGTTGCACTTGGAGGAG (SEQ ID NO:327). The plasmid containing all three mutations is called pTrc99a-TfiPolDN2M, (DNA sequence SEQ ID NO:130; amino acid sequence SEQ ID NO:63).

B. Construction of TscPolDN2M

- 5 Mutagenesis of pTrc99a-TscPol (SEQ ID NO:253) was done with the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's protocol. The E416K mutation was made with the following two oligonucleotides; 5'-GCCGCCCTCCTGAAGCGGGCTTAAGGG (SEQ ID NO:328) and 5'-CCCTTAAGCCGCTTCAGGAGGGCGGC (SEQ ID NO:329). The E505Q mutation was made with the following two oligonucleotides; 10 5'-ATCGGCAAGACGCAGAACGCGCAAGC (SEQ ID NO:330) and 5'-GCTTGCCCGTCTCTCGGTCTTGCCTGCGAT (SEQ ID NO:331). The D783N mutation was made with the following two oligonucleotides; 5'-TTGCAGGTGCACAACGAACGGTCCTC (SEQ ID NO:332) and 15 5'-GAGGACCAGTCGTTGTGCACCTGCAA (SEQ ID NO:333). The plasmid containing all three mutations is called pTrc99a-TscPolDN2M, (DNA sequence SEQ ID NO:131; amino acid sequence SEQ ID NO:64).

C. Chimerics of Tsc, Tfi, Tth and Taq mutants

- 20 1. Construction of TfiTth AKK (DNA sequence SEQ ID NO:132; amino acid sequence SEQ ID NO:65), TscTthAKK (DNA sequence SEQ ID NO:133; amino acid sequence SEQ ID NO:66), TfiTaq5M (DNA sequence SEQ ID NO:134; amino acid sequence SEQ ID NO:67) and TscTaq5M (DNA sequence SEQ ID NO:135; amino acid sequence SEQ ID NO:68)
- 25 To generate chimeric enzymes between Tth DN RX HT (H86A/G506K/Q509K) (here abbreviated TthAKK, SEQ ID NO:104) or Taq 4M G504 (here abbreviated Taq 5M, SEQ ID NO:108), and Tfi DN 2M (SEQ ID NO:130), or Tsc DN 2M (SEQ ID NO:131), additional restriction endonuclease sites were introduced by site specific mutagenesis into the named Tfi and Tsc mutants. Mutagenic primers 700-011-01 5'-cag acc atg aat tcc acc cca ctt ttt gac ctg gag-3' (SEQ ID NO:334) and 700-011-02 5'-gtg gac 30 gcg gcc gcc cga ggc cgc cag ggc cag-3' (SEQ ID NO:335) were used to introduce an

EcoRI site at amino acid position 1 and a NotI site at amino acid position 331 in Tfi DN 2M. Mutagenic primers 700-011-03 5'-cag acc atg aat tcc ctg ccc ctc ttg gag ccc aag-3' (SEQ ID NO:336) and 700-011-04 5'-gtt aac acg cgc gcc cca ggc ggc gca gaa ggc gtt-3' (SEQ ID NO:337) were used to introduce an EcoRI site at amino acid position 1 and a 5 NotI site at amino acid position 327 in Tsc DN 2M. PCR reactions were done using the Advance cDNA PCR kit (Clonetech) according to manufacturer's instructions and either Tfi DN 2M or Tsc DN 2M as target, with their corresponding primers. The 1017 base pair PCR products were cut with both EcoRI and NotI to yield 993 base pair insert fragments that were gel purified as described in Example 3D. The mutants Taq4M 10 G504K (SEQ ID NO:108) and Tth DN RX HT (H786A/G506K/Q509K) (SEQ ID NO:104) were also cut with EcoRI and NotI, and the larger, vector fragment was gel isolated as above. Ligations were performed as detailed in Example 3D, as was the screening and verification of the new constructs.

15 **EXAMPLE 9**

Additional Enzymes having Improved RNA-dependent 5' nuclease activity

Generation of Tfi DN 2M(ΔN)

20 To facilitate later cloning steps, an endogenous restriction enzyme site (Not I) was removed from the polymerase region of the TfiPolDN2M gene (SEQ ID NO: 130 described in Example 8A), and a unique Not I site was inserted in a more advantageous position.

The endogenous Not I site was removed as follows. The QUIKCHANGE 25 Site-Directed Mutagenesis Kit from (Stratagene) was used according to manufacturer's instructions with the mutagenic primers 5'-gag-gtg-gag-cgg-ccc-ctc-tcc-cgg-gtc-ttg (SEQ ID NO: 338) and 5'-caa-gac-ccg-gga-gag-ggg-ccg-ctc-cac-ctc (SEQ ID NO: 339). The new construct was named Tfi DN 2M(ΔN) (DNA sequence SEQ ID NO: 340; amino acid sequence SEQ ID NO: 341).

30

Generation of Tfi DN 2M(N), Tsc DN 2M(N)

To install a unique NotI site (at amino acid position 328) in Tfi DN 2M(ΔN) (SEQ ID NO: 340), primers 886-088-07 (SEQ ID NO: 342) 5'-tgg-cgg-cgg-cct-cgg-gcg-gcc-gcg-tcc-acc-ggg-caa-ca-3' and 700-010-03 5'-ctt-ctc-tca-tcc-gcc-aaa-aca-gcc (SEQ ID NO: 343) were used in a PCR reaction with Tfi DN 2M(ΔN) (SEQ ID NO: 340) as template. The resulting PCR fragment was purified and cut with the restriction enzymes NotI and SalI. The cut fragment was then ligated into the TfiTthAKK (SEQ ID NO: 132, described in example 8,C) construct which was also digested with NotI and SalI. The new construct was termed Tfi DN 2M(N) (DNA sequence SEQ ID NO: 345; amino acid sequence SEQ ID NO: 346).

To introduce a Not I restriction endonuclease site into mutant TscPol DN 2M (previously described in Example 8B above), PCR was performed with primers: 886-088-05 (SEQ ID NO: 344) 5'-tgg-cgg-cgg-cct-ggg-gcg-gcc-gcg-ttt-acc-ggg-cgg-ag-3' and 15 700-010-03 (SEQ ID NO: 343) 5'-ctt-ctc-tca-tcc-gcc-aaa-aca-gcc-3' using TscPolDN2M (SEQ ID NO: 131) as template. The NotI-SalI digested fragment of the PCR product was then sub-cloned into NotI and SalI digested TscTthAKK vector (SEQ ID NO: 133). The resulting construct was termed Tsc DN 2M(N) (DNA sequence SEQ ID NO:347; amino acid sequence SEQ ID NO:348).

20 Generation of Tfi DN 2M(N)AKK and Tsc DN2M(N)AKK

To generate the “AKK” set of mutations (G504K/E507K/H784A/D785N), site specific mutagenesis was done on the Tfi DN 2M(N) mutant (DNA sequence SEQ ID NO: 345), using primers 959-022-01 to -04: 5'-ggc-ctc-acc-ccg-gtg-aag-cgg-acg-aag-acg-ggc-aag-cgc-3', 5'-gcg-ctt-gcc-cgt-ctt-cgt-cgg-ctt-cac-cgg-ggt-gag-gcc-3', 5'-ctc-25 ctc-ctc-caa-gtg-gcc-aac-gag-ctg-gtc-ctg-3', 5'-cag-gac-cag-ctc-gtg-ggc-cac-ttg-gag-gag-gag-3' (SEQ ID NO: 354-357) to generate the Tfi 2M(N)AKK mutant (DNA sequence SEQ ID NO: 358; amino acid sequence SEQ ID NO: 359). This construct is termed “TfiAKK”.

30 To install the “AKK” set of mutations (G502K/E505K/H782A/D783N), into the TscDN 2M (N) construct, (DNA sequence SEQ ID NO: 347) primers 959-022-05 to -08:

5'-ggg-ctt-ccc-gcc-atc-aag-aag-acg-aag-acg-ggc-aag-cgc-3', 5'-gcg-ctt-gcc-cgt-ctt-
ctt-egt-ctt-ctt-gat-ggc-ggg-aag-ccc-3', 5'-atg-ctt-ttg-cag-gtg-gcc-aac-gaa-ctg-gtc-ctc-3',
5'-gag-gac-cag-ttc-gtt-ggc-cac-ctg-caa-aag-cat-3' (SEQ ID NO: 360-363) were used to
generate Tsc2M(N)AKK (DNA sequence SEQ ID NO: 364; amino acid sequence SEQ
5 ID NO: 365). This construct is termed "Tsc AKK".

Construction of point mutants by recombinant PCR

Construction of TthAKK(P195A) and TthAKK(P195K)

To introduce mutations at amino acid position 195 (either a P195A or P195K) in
10 the nuclelease domain of TthAKK construct, mutagenic primer 785-073-01 (P195A) 5'-
ccc-tcc-gac-aac-ctc-gcc-ggg-gtc-aag-ggc-atc-3' (SEQ ID NO: 370) or 785-073-02
(P195K) 5'-ccc-tcc-gac-aac-ctc-aag-ggg-gtc-aag-ggc-atc-3' (SEQ ID NO: 371) and
primer 209-074-02: 5'-gtg-gcc-tcc-ata-tgg-gcc-agg-ac-3' (SEQ ID NO: 316) were used in
a PCR reaction to generate a 787 base pair fragment. Another PCR fragment was
15 obtained by using the primers: 390-076-08 5'-tgt-gga-att-gtg-ago-gg-3' (SEQ ID
NO: 314) and 785-073-03 5'-gag-gtt-gtc-gga-ggg-gtc-3' (SEQ ID NO: 372) in a reaction
with the same template.

The two PCR fragments overlap and were combined in a recombinant PCR
reaction. The outside primers 390-076-08 and 209-074-02 were added, and the
20 Advantage cDNA PCR kit (Clontech) was used according to manufacturer's instructions.
A 1380 base pair product was generated from this reaction.

The recombinant PCR product was cut with the restriction enzymes EcoRI and
NotI to yield a 986 base pair fragment. The TthAKK construct was prepared by cutting
with the same enzymes. The fragment was then ligated into the vector, and transformed
25 into JM109 cells. New mutants developed from this set of reactions include:
TthAKK(P195A) (DNA sequence SEQ ID NO: 373; amino acid sequence SEQ ID NO:
374) and TthAKK(P195K) (DNA sequence SEQ ID NO: 375; amino acid sequence SEQ
ID NO: 376).

Construction of TthAKK(N417K/L418K)

30 The same approach was used to construct TthAKK(N417K/L418K). Two
overlapping PCR fragments were generated by mutagenic primers: 785-73-07 5'-gag-

agg-ctc-caf-cgg-aag-aag-ctt-aag-cgc-ctc-gag-3' (SEQ ID NO: 377) and 700-10-03 5'-ctt-ctc-tca-tcc-gcc-aaa-aca-gcc-3' (SEQ ID NO:343), and primers 158-084-01 5'-ctc-ctc-cac-gag-ttc-ggc-3' (SEQ ID NO:310) and 785-73-08 5'-ccg-atg-gag-ctt-ctc-cga-3' (SEQ ID NO: 378). The two products were combined and amplified with outside primers 700-10-03 and 158-084-01. The recombinant PCR product was cut with the restriction enzymes NotI and BamHI and ligated into the NotI/BamHI pre-cut TthAKK construct. This mutant was termed TthAKK(N417K/L418K) (DNA sequence SEQ ID NO: 379; amino acid sequence SEQ ID NO: 380).

10 **Construction of additional TthAKK point mutants by site-directed mutagenesis**
Construction of TthAKK(P255L)

Site specific mutagenesis was performed on the TthAKK construct using the mutagenic primer 886-049-05 and 886-049-06: 5'-gtg-cgc-acc-gac-ctc-ctc-ctg-gag-gtg-gac-ctc-3' (SEQ ID NO: 381), 5'-gag-gtc-cac-ctc-cag-gag-gag-gtc-ggt-gcg-eac-3' (SEQ ID NO: 382) to generate TthAKK(P255L) (DNA sequence SEQ ID NO: 383; amino acid sequence SEQ ID NO: 384).

Construction of TthAKK(F311Y)

Site specific mutagenesis was performed on the TthAKK construct using the mutagenic primer 886-049-09 and 886-049-10: 5'-ggg-gcc-ttc-gtg-ggc-tac-gtc-ctc-tcc-cgc-ccc-3' (SEQ ID NO: P385), 5'-ggg-gcg-gga-gag-gac-gta-gcc-cac-gaa-ggc-ccc-3' (SEQ ID NO: 386) to generate TthAKK(F311Y) (DNA sequence SEQ ID NO: 387; amino acid sequence SEQ ID NO: 388).

25 **Construction of TthAKK(N221H/R224Q)**

Site specific mutagenesis was performed on the TthAKK construct using the mutagenic primer 886-049-01 and 886-049-02: 5'-gaa-aac-ctc-ctc-aag-cac-ctg-gac-cag-gta-aag-cca-gaa-aac-3' (SEQ ID NO: 389), 5'-gtt-ttc-tgg-ctt-tac-ctg-gtc-cag-gtg-ctt-gag-gag-gtt-ttc-3' (SEQ ID NO: 390) to generate TthAKK(N221H/R224Q) (DNA sequence SEQ ID NO: 391; amino acid sequence SEQ ID NO: 392).

Construction of TthAKK(R251H)

Site specific mutagenesis was performed on TthAKK construct using the mutagenic primer 886-049-03 and 886-049-04: 5'-gag-ctc-tcc-cgg-gtg-cac-acc-gac-ctc-ccc-ctg-3' (SEQ ID NO: 393), 5'-cag-ggg-gag-gtc-ggt-gtg-cac-ccg-gga-gag-ctc-3' (SEQ 5 ID NO: 394) to generate TthAKK(R251H) (DNA sequence SEQ ID NO: 395; amino acid sequence SEQ ID NO: 396).

Construction of TthAKK(P255L/R251H)

Site specific mutagenesis was performed on the TthAKK(P255L) construct using 10 the mutagenic primer 886-088-01 and 886-088-02: 5'-gag-ctc-tcc-cgg-gtg-cac-acc-gac-ctc-ctc-ctg-3' (SEQ ID NO: 397), 5'-cag-gag-gag-gtc-ggt-gtg-cac-ccg-gga-gag-ctc-3' (SEQ ID NO: 398) to generate TthAKK(P255L/R251H) (DNA sequence SEQ ID NO: 399; amino acid sequence SEQ ID NO: 400).

15 **Construction of Tth AKK L429V (DNA sequence SEQ ID NO: 401; amino acid sequence SEQ ID NO: 402)**

Palm region randomization mutagenesis was performed on the Tth AKK construct using the mutagenic primer 680-79-02 5'-ctc cat cgg aac ctc ctt [aag cgc ctc gag ggg gag gag aag ctc ctt tgg] ctc tac cac gag gtg-3' (SEQ ID NO: 403) and reverse primer 680-79-04 5'-AAG GAG GTT CCG ATG GAG-3' (SEQ ID NO: 404) to introduce the random mutations in the Palm region. Brackets indicate a synthesis of 91% base shown and 3% all other bases.

20 **Construction of Tth AKK E425V (DNA sequence SEQ ID NO: 405; amino acid sequence SEQ ID NO: 406)**

25 Palm region randomization mutagenesis was performed on the Tth AKK construct using the mutagenic primer 680-79-02 5'-ctc cat cgg aac ctc ctt [aag cgc ctc gag ggg gag gag aag ctc ctt tgg] ctc tac cac gag gtg-3' (SEQ ID NO: 403) and reverse primer 680-79-04 5'-AAG GAG GTT CCG ATG GAG-3' (SEQ ID NO: 404) to introduce the random mutations in the Palm region. Brackets indicate a synthesis of 91% base shown and 3% 30 all other bases.

Construction of Tth AKK L422N/E425K (DNA sequence SEQ ID NO: 407; amino acid sequence SEQ ID NO: 408)

Palm region randomization mutagenesis was performed on the Tth AKK construct using the mutagenic primer 680-79-02 5'-ctc cat cgg aac ctc ctt [aag cgc ctc gag ggg gag 5 gag aag ctc ctt tgg] ctc tac cac gag gtg-3' (SEQ ID NO: 403) and reverse primer 680-79-04 5'-AAG GAG GTT CCG ATG GAG-3' (SEQ ID NO: 404) to introduce the random mutations in the Palm region. Brackets indicate a synthesis of 91% base shown and 3% all other bases.

10 **Construction of Tth AKK L422F/W430C (DNA sequence SEQ ID NO: 409; amino acid sequence SEQ ID NO: 410)**

Palm region randomization mutagenesis was performed on Tth AKK DNA using the mutagenic primer 680-79-02 5'-ctc cat cgg aac ctc ctt [aag cgc ctc gag ggg gag gag 15 aag ctc ctt tgg] ctc tac cac gag gtg-3' (SEQ ID NO: 403) and reverse primer 680-79-04 5'-AAG GAG GTT CCG ATG GAG-3' (SEQ ID NO: 404) to introduce the random mutations in the Palm region. Brackets indicate a synthesis of 91% base shown and 3% all other bases.

20 **Construction of Tth AKK A504F (DNA sequence SEQ ID NO: 411; amino acid sequence SEQ ID NO: 412)**

Site saturation mutagenesis was performed on Tth AKK construct using the mutagenic primer 680-80-03 5'-cag gag ctt agg ctt ccc mnn ttg aag aag acg aag aac-3' (SEQ ID NO: 413) and reverse primer 680-80-06 5'-cct aag ctc gtc aaa gag-3' (SEQ ID NO: 414) to introduce the random mutations in the A504 amino acid.

25 **Construction of Tth AKK A504V (DNA sequence SEQ ID NO: 415; amino acid sequence SEQ ID NO: 416)**

Site saturation mutagenesis was performed on Tth AKK construct using the mutagenic primer 680-80-03 5'-cag gag ctt agg ctt ccc mnn ttg aag aag acg aag aac-3' 30 (SEQ ID NO: 413) and reverse primer 680-80-06 5'-cct aag ctc gtc aaa gag-3' (SEQ ID NO: 414) to introduce the random mutations in the A504 amino acid.

Construction of Tth AKK A504S (DNA sequence SEQ ID NO: 417; amino acid sequence SEQ ID NO: 418)

Site saturation mutagenesis was performed on Tth AKK construct using the
5 mutagenic primer 680-80-03 5'-cag gag ctt agg ctt ccc nnn ttg aag aag acg aag aac-3' (SEQ ID NO: 413) and reverse primer 680-80-06 5'-ctt aag ctc gtc aaa gag-3' (SEQ ID NO: 414) to introduce the random mutations in the A504 amino acid.

Construction of Tth AKK S517G (DNA sequence SEQ ID NO: 419; amino acid sequence SEQ ID NO: 420)

Site saturation mutagenesis was performed on Tth AKK construct using the
mutagenic primer 680-80-07 5'-GGC AAG CGC TCC ACC NNN GCC GCG GTG CTG
GAG GCC CTA CGG-3' (SEQ ID NO: 421) and reverse primer 680-80-10 5'-GGT
GGA GCG CTT GCC-3' (SEQ ID NO: 422) to introduce the random mutations in the
15 S517 amino acid.

Construction of Tth AKK A518L (DNA sequence SEQ ID NO: 423; amino acid sequence SEQ ID NO: 424)

Site saturation mutagenesis was performed on Tth AKK construct using the
20 mutagenic primer 680-80-07 5'-GGC AAG CGC TCC ACC AGC NNN GCG GTG CTG
GAG GCC CTA CGG-3' (SEQ ID NO: 425) and reverse primer 680-80-10 5'-GGT
GGA GCG CTT GCC-3' (SEQ ID NO:422) to introduce the random mutations in the
A518 amino acid.

25 Construction of Tth AKK A518R (DNA sequence SEQ ID NO: 426; amino acid sequence SEQ ID NO: 427)

Site saturation mutagenesis was performed on Tth AKK construct using the
mutagenic primer 680-80-07 5'-GGC AAG CGC TCC ACC AGC NNN GCG GTG CTG
GAG GCC CTA CGG-3' (SEQ ID NO: 425) and reverse primer 680-80-10 5'-ggg gga
30 geg ctt gcc-3' (SEQ ID NO: 422) to introduce the random mutations in the A518 amino acid.

Construction of Taq5M L451R (DNA sequence SEQ ID NO: 428; amino acid sequence SEQ ID NO: 429)

Site directed mutagenesis was performed on the Taq 5M construct using the 5 mutagenic primer 240-60-05 5'-acg-ggg-gtg-cgc-cgg-gac-gtg-gcc-tat 3' (SEQ ID NO: 430) to introduce the L451R mutation in the Taq 5M enzyme.

Construction of Tth AKK A504K (DNA sequence SEQ ID NO: 431; amino acid sequence SEQ ID NO: 432)

10 Site directed mutagenesis was performed on the Tth AKK construct using the mutagenic primer 680-69-04 5'-ctt agg ctt ccc aag ttg aag aag acg aag aag aca-3' (SEQ ID NO: 433) and reverse primer 680-69-05 5'-tgt ctt ctt cgt ctt ctt ctt ctt ggg aag cct aag-3' (SEQ ID NO: 434) to introduce the A504K mutation in the Tth AKK enzyme.

15 **Construction of Tth AKK H641A (DNA sequence SEQ ID NO: 435; amino acid sequence SEQ ID NO: 436)**

Site directed mutagenesis was performed on Tth AKK construct using the mutagenic primer 680-69-08 5'-gag ggg aag gac atc gcc acc cag acc gca agc-3' (SEQ ID NO: 437) and reverse primer 583-01-02 5'-gtc tgc ggt ctg ggt ggc gat gtc ctt ccc ctc- 3' 20 (SEQ ID NO: 438) to introduce the H641A mutation in the Tth AKK enzyme.

Construction of Tth AKK T508P (DNA sequence SEQ ID NO: 439; amino acid sequence SEQ ID NO: 440)

Site directed mutagenesis was performed on TthAKK construct using the 25 mutagenic primer 680-70-01 5'-ccc-gcc ttg aag aag ccg aag aag aca ggc aag-3' (SEQ ID NO: 441) and reverse primer 680-70-02 5'-ctt gcc tgt ctt ctt cgg ctt ctt caa ggc ggg-3' (SEQ ID NO: 442) to introduce the T508P mutation in the Tth AKK enzyme.

Chimeras and mutations in chimeras.

30 **Fusion between TthAKK enzyme and alpha-peptide**

A TthAKK-lacZ-alpha-peptide chimeric fusion was constructed to allow detection of mutations (including frame-shifts, deletions, insertions, etc.) which cause the inability of expression of the full-length fusion protein based on the colony blue-white screening (Wu et al., Nucleic Acids Research, 24:1710 [1996]).

5 Site specific mutagenesis was performed on TthAKK DNA using the mutagenic primers 959-041-03, 5'-cac-cac-cac-cac-cac-gtc-gac-tag-tgc-tag-cgt-cga-ctt-gct-gca-ggc-atg-caa-gct-tgg-c-3' (SEQ ID NO: 477) and 959-041-04, 5'-gcc-aag-ctt-gca-tgc-ctg-cag-ctt-gtc-gac-gct-agg-act-agg-cgt-ggt-ggt-ggt-g-3' (SEQ ID NO: 478) to generate pTthAKK-L with SalI site following the 6xHis tag at the C-terminus of TthAKK
10 for the insertion of lacZ alpha peptide. The alpha peptide (of 201 amino acids) was first PCR amplified from the pCRII-TOPO vector (Invitrogen) with primers 959-041-01, 5'-cag-gaa-gcg-gcc-gcg-tcg-aca-tga-cca-tga-ata-cgc-caa-gc-3' (SEQ ID NO: 479) and 959-093-01, 5'-ggg-ccc-gcc-agg-gtc-gac-tca-agg-cgt-tgg-ccc-act-acg-tga-3' (SEQ ID NO:
15 480). The PCR product was then digested with restriction enzyme SalI and ligated into the pTthAKK-L vector, which was also cut with the same enzyme to generate the chimeric construct TthAKK-alpha peptide (DNA sequence SEQ ID NO: 481; amino acid sequence SEQ ID NO: 482). The orientation of the insert was confirmed by sequencing.

Construction of TthTscAKK and TthTfiAKK enzymes

20 The TthAKK construct was cut with the enzymes EcoRI and NotI and the smaller insert fragment was gel isolated. The TscAKK or TfiAKK constructs were also cut with EcoRI and NotI and the larger fragment was gel isolated and purified. The Tth insert (nuclease domain) was ligated into the TscAKK and TfiAKK vectors (polymerase domain) to generate TthTscAKK (DNA sequence SEQ ID NO: 447; amino acid sequence SEQ ID NO: 448) and TthTfiAKK (DNA sequence SEQ ID NO: 449; amino acid sequence SEQ ID NO: 450) chimeric constructs.
25

FT mutations of Tth polymerase to improve substrate specificity

Construction of Taq(FT)TthAKK

30 Site specific mutagenesis was performed on the TaqTthAKK construct using the mutagenic primer 473-087-05: 5'-cgg-gac-ctc-gag-gcg-cgt-gaa-ccc-cag-gag-gtc-cac-3'

(SEQ ID NO: 483) to introduce the L107F/A108T mutations and generate Taq(FT)TthAKK (DNA sequence SEQ ID NO: 484; amino acid sequence SEQ ID NO: 485).

Construction of Tfi(FT)TthAKK

Site specific mutagenesis was performed on the TfiTthAKK construct using the mutagenic primers 785-096-01: 5'-gtg-gac-ctt-ctg-ggc-ttt-acc-cgc-ctc-gag-gcc-ccg-3' (SEQ ID NO: 486) and 785-096-02: 5'-cggt-ggc-ctc-gag-gcg-ggt-aaa-gcc-cag-aag-gtc-cac-3' (SEQ ID NO: 487) to introduce the L107F/V108T mutations and generate Tfi(FT)TthAKK (DNA sequence SEQ ID NO: 349; amino acid sequence SEQ ID NO: 488).

Tfi(FT) DN 2M(N) and Tsc(FT) DN 2M(N) mutants

The L107F/V108T mutations were introduced by isolating the NotI and Sall fragment of the Tfi DN 2M(N) mutant (DNA sequence SEQ ID NO: 345) and inserting it into a NotI-Sall pre-digested Tfi(FT)TthAKK (DNA sequence SEQ ID NO: 349; amino acid sequence SEQ ID NO: 488) to yield the Tfi(FT) DN 2M(N) mutant (DNA sequence SEQ ID NO: 350, amino acid sequence SEQ ID NO: 351). To add the L107F or the E108T mutations into this Tsc-based construct, an identical procedure was done. The NotI and Sall cut fragment of Tsc DN 2M(N) mutant (DNA sequence SEQ ID NO: 348) was inserted into NotI-Sall pre-digested Tsc(FT)TthAKK (DNA sequence SEQ ID NO: 491) vector to yield Tsc(FT) DN 2M(N) mutant (DNA sequence SEQ ID NO: 352, amino acid sequence SEQ ID NO: 353).

Construction of Tfi(FT) AKK and Tsc(FT) AKK

Starting with the Tfi(FT)DN2M(N) construct described previously (DNA sequence SEQ ID NO: 350), primers (959-022-01 to -04: 5'-ggc-ctc-acc-ccg-gtg-aagg-cgg-acg-aag-acg-ggc-aag-cgc-3', 5'-gctt-gcc-cgt-ctt-ctt-cgt-ccg-ctt-cac-cgg-ggt-gag-gcc-3', 5'-ctc-clc-ctc-caa-gtg-gcc-aac-gag-cgt-gtc-ctg-3', 5'-cag-gac-cag-clc-gtt-ggc-cac-ttg-gag-gag-gag-3' (SEQ ID NO: 354-357) were used to introduce the "AKK" set of mutations (H784A, G504K and E507K) by site specific mutagenesis. The resulting

mutant construct is termed Tfi(FT)AKK (DNA sequence SEQ ID NO:366; amino acid sequence SEQ ID NO:367).

Likewise, primers 959-022-05 to -08: 5'-ggg-ctt-ccc-gcc-atc-aag-aag-acg-aag-aag-acg-ggc-aag-cgc-3'; 5'-ggg-ctt-gcc-cgt-ctt-ctt-cgt-ctt-gat-ggc-aaa-ccc-3'; 5'-atg-ctt-itg-cag-gtg-gcc-aac-ctg-gtc-ctc-3'; 5'-gag-gac-cag-ttc-gtt-ggc-cac-ctg-caa-aag-cat-3' (SEQ ID NO: 360-363) were used in a site specific mutagenesis reaction, with the Tsc(FT)DN2M(N) mutant (DNA sequence SEQ ID NO: 352) as template to generate the Tsc(FT)AKK mutant (DNA sequence SEQ ID NO: 368; amino acid sequence SEQ ID NO: 369).

10 **Construction of Tsc(FT)TthAKK**

Site specific mutagenesis was performed on the TscTthAKK construct using the mutagenic primers 785-008-03 5'-ttt-acc-cgc-ctc-gag-gtg-cgg-ggc-3' (SEQ ID NO: 489) and reverse primer 680-21-03 5'-cgg cac ctc gag gcg ggt aaa gcc caa aag gtc cac-3' (SEQ ID NO: 490) to introduce the L107F/E108T mutations and generate Tsc(FT)TthAKK (DNA sequence SEQ ID NO: 454; amino acid sequence SEQ ID NO: 491).

15 **Construction of Taq(FT)TscAKK and Taq(FT)TfiAKK enzymes**

The Taq(FT)TthAKK construct was cut with the enzymes EcoRI and NotI and the smaller insert fragment was gel isolated. The TscAKK or TfiAKK constructs were also cut with EcoRI and NotI and the larger fragment was gel isolated and purified. The 20 Taq(FT) insert (nuclease domain) was ligated into the TscAKK and TfiAKK vectors (polymerase domain) to generate the Taq(FT)TscAKK (DNA sequence SEQ ID NO: 443; amino acid sequence SEQ ID NO: 444) and Taq(FT)TfiAKK (DNA sequence SEQ ID NO: 445; amino acid sequence SEQ ID NO: 446) chimeric constructs.

25 **Construction of TaqEFT-Tth(AKK) (DNA sequence SEQ ID NO:501; amino acid sequence SEQ ID NO: 502)**

Site specific mutagenesis was performed on Taq(FT)-Tth(AKK) DNA (SEQ ID NO: 484) using the mutagenic primers 436-013-08: 5'-atc-gtg-gtc-ttt-gac-gcc-gag-gcc-ccc-cc-cc-3' (SEQ ID NO:503) and 436-013-09 5'-gga-agg-agg-ggg-cct-cgg-cgt-caa-agc-cca-cgg-t-3' (SEQ ID NO:504) to introduce the K70E mutation.

30

Additional mutations to improve enzyme activity of Taq(EFT)TthAKK

Construction of TaqEFT-Tth(AKK)-A/M1 (DNA sequence SEQ ID NO:505; amino acid sequence SEQ ID NO: 506)

- Site specific mutagenesis was performed on Taq(EFT)-Tth(AKK) DNA (SEQ ID NO: 501) using the mutagenic primers 1044-038-01: 5'-cag-acc-atg-aat-tcg-gag-gcg-atg-ctg-ccc-ctc-ttt-3' (SEQ ID NO:507) and 1044-038-02: (SEQ ID NO: 508) 5'-aaa-gag-ggg-cag-cat-cgc-ctc-cga-att-cat-ggt-ctg-3' to introduce the G4EA mutation.

Construction of TaqEFT-Tth(AKK)-B/M2 (DNA sequence SEQ ID NO:509; amino acid sequence SEQ ID NO: 510)

- Site specific mutagenesis was performed on Taq(EFT)-Tth(AKK) DNA (SEQ ID NO: 501) using the mutagenic primers 1044-038-03: 5'-gcc-tac-cgc-acc-ttc-ttt-gcc-ctg-aag-ggc-ctc-3 and 1044-038-04: 5'-gag-gcc-ctt-cag-ggc-aaa-gaa-ggt-gcg-gta-ggc-3' (SEQ ID NO: 511 and 512, respectively) to introduce the H29F mutation.

15 Construction of TaqEFT-Tth(AKK)-C/M3 (DNA sequence SEQ ID NO:513; amino acid sequence SEQ ID NO: 514)

- Site specific mutagenesis was performed on Taq(EFT)-Tth(AKK) DNA (SEQ ID NO: 501) using the mutagenic primers 1044-038-05: 5'-ctc-ctc-aag-gcc-ctc-agc-gag-gac-ggg-gac-gcg-3' and 1044-038-06: 5'-cgc-gtc-ccc-gtc-ctc-lct-gag-ggc-ctt-gag-gag-3' (SEQ ID NO: 515 and 516, respectively) to introduce the K57R mutation.

20 Construction of TaqEFT-Tth(AKK)-D/M5 (DNA sequence SEQ ID NO:517; amino acid sequence SEQ ID NO:518)

- Site specific mutagenesis was performed on Taq(EFT)-Tth(AKK) DNA (SEQ ID NO: 501) using the mutagenic primers 1044-038-09: 5'-gac-gac-gtc-ctg-gcc-acc-ctg-gcc-aag-aag-gcg-3' and 1044-038-10: 5'-cgc-ctt-ctt-ggc-cag-ggt-ggc-cag-gac-gtc-gtc-3' (SEQ ID NO: 519 and 520, respectively) to introduce the S125T mutation.

25 Construction of TaqEFT-Tth(AKK)-E/M6 (DNA sequence SEQ ID NO:521; amino acid sequence SEQ ID NO: 522)

- Site specific mutagenesis was performed on Taq(EFT)-Tth(AKK) DNA (SEQ ID NO: 501) using the mutagenic primers 1044-038-11: 5'-ggg-gag-aag-acg-gcg-ctc-aag-ctt-

ctg-gag-gag-3' and 1044-038-12: 5'-ctc-ctc-cag-aag-ctt-gag-cgc-cgt-ctt-ctc-ccc-3' (SEQ ID NO: 523 and 524, respectively) to introduce the R206L mutation.

Construction of TaqEFT-Tth(AKK)-F/M7 (DNA sequence SEQ ID NO:525; amino acid sequence SEQ ID NO: 526)

Site specific mutagenesis was performed on Taq(EFT)-Tth(AKK) DNA (SEQ ID NO: 501) using the mutagenic primers 1044-038-13: 5'-gag-ccc-gac-cgg-gag-ggg-ctt-aag-gcc-ttt-ctg-gag-agg-3' and 1044-038-14: 5'-ctt-ctc-cag-aaa-ggc-ctt-aag-ccc-ctc-ccg-gtc-ggg-ctc-3' (SEQ ID NO: 527 and 528, respectively) to introduce the R269G and

10 R271K mutations.

Construction of TaqEFT-Tth(AKK)-G/M8 (DNA sequence SEQ ID NO:529; amino acid sequence SEQ ID NO: 530)

Site specific mutagenesis was performed on Taq(EFT)-Tth(AKK) DNA (SEQ ID NO: 501) using the mutagenic primers 1044-038-15: 5'-cac-gag-ttc-ggc-ctt-ctg-gga-ggg-15 gag-aag-ccc-cgg-gag-gag-gcc-ccc-tgg-ccc-3' and 1044-038-16: 5'-ggg-cca-ggg-ggc-ctc-ctc-ccg-ggg-ctt-ctc-ccc-tcc-cag-aag-gcc-gaa-ctc-gtg-3' (SEQ ID NO: 531 and 532, respectively) to introduce the E290G, S291G, P292E, A294P, and L295R mutations.

Construction of TaqEFT-Tth(AKK)-H/M9 (DNA sequence SEQ ID NO:533; amino acid sequence SEQ ID NO: 534)

Site specific mutagenesis was performed on Taq(EFT)-Tth(AKK) DNA (SEQ ID NO: 501) using the mutagenic primers 1044-038-17: 5'-ctg-gcc-ctg-gcc-gcc-tgc-agg-ggc-ggc-cgc-gtg-3' and 1044-038-18: 5'-cac-gcg-gcc-gcc-cct-gca-ggc-ggc-cag-ggc-cag-3' (SEQ ID NO: 535 and 536, respectively) to introduce the A328C mutation.

25

Construction of TaqEFT-Tth(AKK)-I/M10 (DNA sequence SEQ ID NO:537; amino acid sequence SEQ ID NO: 538)

Site specific mutagenesis was performed on Taq(EFT)-Tth(AKK) DNA (SEQ ID NO: 501) using the mutagenic primers 1080-015-01 (SEQ ID NO:539) 5'-ggg gag aag 30 acg gcg agg aag ctt ctg aag gag tgg ggg agc-3' and 1080-015-02 (SEQ ID NO: 540) 5'-gct ccc cca ctc ctt cag aag ctt cct cgc cgt ctt ctc ccc-3' to introduce the E210K mutation.

Construction of TaqEFT-Tth(AKK)-M1-9 (DNA sequence SEQ ID NO:541; amino acid sequence SEQ ID NO: 542)

Seven independent PCR reactions were performed, using construct TaqEFT-
5 Tth(AKK) (SEQ ID: 501) as a template, with the following pairs of mutagenic primers:
PCR Reaction 1; 1044-038-01 5'-cag-acc-atg-aat-tcg-gag-gcg-atg-ctg-ccc-ctc-ttt-3' (SEQ
ID NO:507) and 1044-038-04 5'-gag-gcc-ctt-cag-ggc-aaa-gaa-ggt-gcg-gta-ggc-3' (SEQ
ID NO:512) to yield a 108 base pair fragment, PCR Reaction 2; 1044-038-03 5'-gcc-tac-
cgc-acc-ctc-ttt-gcc-ctg-aag-ggc-ctc-3' (SEQ ID NO: 511) and 1044-038-06 5'-cgc-gtc-
10 ccc-gtc-ctc-tct-gag-ggc-ctt-gag-gag-3' (SEQ ID NO: 516) to yield a 117 base pair
fragment, PCR Reaction 3; 1044-038-05 5'-ctc-ctc-aag-gcc-ctc-aga-gag-gac-ggg-gac-
gag-3' (SEQ ID NO: 515) and 1044-038-10 5'-cgc-ctt-ctt-ggc-cag-ggt-ggc-cag-gac-gtc-
gtc-3' (SEQ ID NO: 520) to yield a 237 base pair fragment, PCR Reaction 4; 1044-038-
09 5'-gac-gac-gtc-ctg-gcc-acc-ctg-gcc-aag-aag-gcg-3' (SEQ ID NO: 519) and 1044-038-
15 12 5'-ctc-ctc-cag-aag-ctt-gag-cgc-cgt-ctt-ctc-ccc-3' (SEQ ID NO: 524) to yield a 276 base
pair fragment, PCR Reaction 5; 1044-038-11 5'-ggg-gag-aag-acg-gcg-ctc-aag-ctt-ctg-
gag-gag-3' (SEQ ID NO: 523) and 1044-038-14 5'-cct-ctc-cag-aaa-ggc-ctt-aag-ccc-ctc-
cog-gtc-ggg-ctc-3' (SEQ ID NO: 528) to yield a 228 base pair fragment, PCR Reaction 6;
1044-038-13 5'-gag-ccc-gac-cgg-gag-ggg-ctt-aag-gcc-itt-ctg-gag-agg-3' (SEQ ID NO:
20 527) and 1044-038-16 5'-ggg-cca-ggg-ggc-ctc-ctc-ccg-ggg-ctt-ctc-ccc-tcc-cag-aag-gcc-
gaa-ctc-gtg-3' (SEQ ID NO: 532) to yield a 113 base pair fragment, PCR Reaction 7;
1044-038-15 5'-cac-gag-ttc-ggc-ctt-ctg-gga-ggg-gag-aag-ccc-cgg-gag-gag-gcc-ccc-tgg-
ccc-3' (SEQ ID NO: 531) and 1044-038-18 5'-cac-gcg-gcc-gcc-ctt-gca-ggc-ggc-cag-ggc-
cag-3' (SEQ ID NO: 536) to yield a 157 base pair fragment. The seven PCR products
25 overlap such that PCR amplification in the absence of primers yielded the appropriate
1005 base pair product to introduce the K70E, G4EA, H29F, K57R, S125T, R206L,
R269G, R271K, E290G, S291G, P292E, A294P, L295R, and A328C mutations. The
product was further amplified using the outside primers: 1044-038-1 (SEQ ID NO: 507)
and 1044-038-18 (SEQ ID NO: 536) and cloned into pPCR-Script-Amp. From this
30 construct, the nuclease domain was again amplified using primers: 1044-038-1 (SEQ ID
NO: 507) and 1044-038-18 (SEQ ID NO: 536) and digested with EcoRI and NotI. The

digested PCR product was ligated into an EcoRI and NotI digested TaqEFT-Tth(AKK) construct and transformed into JM109 for protein expression and screening.

Construction of TaqEFT-Tth(AKK)-M1-10 (DNA sequence SEQ ID NO:543; amino acid sequence SEQ ID NO: 544)

5 Seven independent PCR reactions were performed, using construct TaqEFT-Tth(AKK) (SEQ ID: 501) as a template, with the following pairs of mutagenic primers:
PCR Reaction 1; 1044-038-01 5'-cag-acc-atg-aat-tcg-gag-gcg-atg-ctg-ccc-ctc-ttt-3' (SEQ ID NO:507) and 1044-038-04 5'-gag-gcc-ctt-cag-ggc-aaa-gaa-ggt-gcg-gta-ggc-3' (SEQ ID NO:512) to yield a 108 base pair fragment, PCR Reaction 2; 1044-038-03 5'-gcc-tac-cgc-acc-ttt-ttt-gcc-ctg-aag-ggc-ctc-3' (SEQ ID NO: 511) and 1044-038-06 5'-cgc-gtc-ccc-gtc-ctc-lct-gag-ggc-ctt-gag-gag-3' (SEQ ID NO: 516) to yield a 117 base pair
10 fragment, PCR Reaction 3; 1044-038-05 5'-ctc-ctc-aag-gcc-ctc-aga-gag-gac-ggg-gac-gcg-3' (SEQ ID NO: 515) and 1044-038-10 5'-cgc-ctt-ctt-ggc-cag-ggt-ggc-cag-gac-gtc-
15 gtc-3' (SEQ ID NO: 520) to yield a 237 base pair fragment, PCR Reaction 4; 1044-038-09 5'-gac-gac-gtc-ctg-gcc-acc-ctg-gcc-aag-aag-gcg-3' (SEQ ID NO: 519) and 1080-42-02 5'-gc-ttc cag gtc ccc cca ctc ctt cag aag ctt gag cgc cgt ctt ctc ccc-3' (SEQ ID NO: 546) to yield a 299 base pair fragment, PCR Reaction 5; 1080-42-01 5'-ggg gag aag acg gog ctc
20 agg ctt ctg aag gag tgg ggg agc ctg gaa gc-3' (SEQ ID NO: 545) and 1044-038-14 5'-cct-ctc-cag-aaa-ggc-ctt-aag-ccc-ctc-ccg-gtc-ggg-ctc-3' (SEQ ID NO: 528) to yield a 228 base pair fragment, PCR Reaction 6; 1044-038-13 5'-gag-ccc-gac-egg-gag-ggg-ctt-aag-gcc-ttt-ctg-gag-agg-3' (SEQ ID NO: 527) and 1044-038-16 5'-ggg-cca-ggg-ggc-ctc-ctc-cgg-ggg-
25 ctt-ctc-ccc-tcc-cag-aag-gcc-gaa-ctc-gtg-3' (SEQ ID NO: 532) to yield a 113 base pair fragment, PCR Reaction 7; 1044-038-15 5'-cac-gag-ttc-ggc-ctt-ctg-gga-ggg-gag-aag-ccc-cgg-gag-gag-gcc-ccc-igg-ccc-3' (SEQ ID NO: 531) and 1044-038-18 5'-cac-gcg-gcc-gcc-cct-gca-ggc-ggc-cag-ggc-cag-3' (SEQ ID NO: 536) to yield a 157 base pair fragment.
The seven PCR products overlap such that PCR amplification in the absence of primers yielded the appropriate 1005 base pair product to introduce the K70E, G4EA, H29F,
K57R, S125T, R206L, E210K, R269G, R271K, E290G, S291G, P292E, A294P, L295R,
30 and A328C mutations. The product was further amplified using the outside primers:
1044-038-1 (SEQ ID NO: 507) and 1044-038-18 (SEQ ID NO: 536) and cloned into

pPCR-Script-Amp. From this construct, the nuclease domain was again amplified using primers: 1044-038-1 (SEQ ID NO: 507) and 1044-038-18 (SEQ ID NO: 536) and digested with EcoRI and NotI. The digested PCR product was ligated into an EcoRI and NotI digested TaqEFT-Tth(ACK) construct and transformed into JM109 for enzyme expression and screening.

5

K69E Mutation of FEN enzymes to further improve substrate specificity

Construction of Tth(K69E)AKK, Taq(K69E)TthAKK, TfI(K69E)TthAKK and

10 Tsc(K69E)TthAKK and mutants

Site specific mutagenesis was performed on TthAKK, TaqTthAKK, TfITthAKK and TscTthAKK DNAs using the mutagenic primers 5'-atc-gtg-gtc-ttt-gac-gcc-gag-gcc-ccc-tcc-ttc-c-3' (SEQ ID NO: 492) and 5'-gga-agg-agg-ggg-cct-cgg-cgt-caa-aga-cca-cga-t-3' (SEQ ID NO: 493) to introduce the K69E mutation and to generate Tth(K69E)AKK (DNA sequence SEQ ID NO: 452; amino acid sequence SEQ ID NO: 494), Taq(K69E)ThAKK, (DNA sequence SEQ ID NO: 495; amino acid sequence SEQ ID NO: 496), TfI(K69E)TthAKK (DNA sequence SEQ ID NO: 497; amino acid sequence SEQ ID NO: 498) and Tsc(K69E)TthAKK (DNA sequence SEQ ID NO: 499; amino acid sequence SEQ ID NO: 500) mutant enzymes.

20

Construction of Tsc(167-334)TthAKK

Two overlapping PCR fragments were generated by primers 390-76-08: 5'-tgt-gga-att-gtg-agc-gg-3' (SEQ ID NO:314) and 1044-041-01: 5'-ctt-ctc-tca-tcc-gcc-aaa-aca-gcc-3' (SEQ ID NO: 451) with template Tth(K69E)AKK, (DNA sequence SEQ ID NO: 452), and primers 1044-041-02: 5'-ctc-ctc-cac-gag-ttc-ggc-3' (SEQ ID NO: 453) and 209-074-02: 5'-tgt-gcc-tcc-ata-tgg-gcc-agg-ac-3' (SEQ ID NO:316) with template Tsc(K69E)TthAKK, (DNA sequence SEQ ID NO: 454). Two products were combined and amplified with outside primers 390-76-08 and 209-074-02. The recombinant PCR product was cut with the restriction enzymes EcoRI and NotI and ligated into the vector TthAKK which was prepared by cutting with the same enzymes to yield Tsc(167-

30

333)TthAKK construct (DNA sequence SEQ ID NO: 455; amino acid sequence SEQ ID NO: 456).

Construction of Tsc(222-334)TthAKK

5 Two overlapping PCR fragments were generated by primers 390-76-08: 5'-tgt-gga-att-gtg-agc-gg-3' (SEQ ID NO:314) and 1044-041-03: 5'-ttc-cag-gtg-ctt-gag-gag-gtt-
ttc-cag-3' (SEQ ID NO: 457) with template Tth(K69E)AKK (DNA sequence SEQ ID NO: 452), and primers 1044-041-04: 5'-ctc-ctc-aag-cac-ctg-gaa-cag-gtg-aaa-3' (SEQ ID NO: 458) and 209-074-02: 5'-gtg-gcc-tcc-ata-tgg-gcc-agg-ac-3' (SEQ ID NO:316) with
10 template Tsc(K69E)TthAKK, (DNA sequence SEQ ID NO: 454). Two products were combined and amplified with outside primers 390-76-08 and 209-074-02. The recombinant PCR product was cut with the restriction enzymes EcoRI and NotI and ligated into the vector TthAKK which was prepared by cutting with the same enzymes to yield Tsc(222-334)TthAKK construct (DNA sequence SEQ ID NO: 459; amino acid
15 sequence SEQ ID NO: 460).

Construction of Tf1(222-334)TthAKK

Two overlapping PCR fragments were generated by primers 390-76-08: 5'-tgt-gga-att-gtg-agc-gg-3' (SEQ ID NO:314) and 1044-058-05: 5'-gtc-cag-gtt-ctt-gag-gag-gtt-
20 ttc-cag-3' (SEQ ID NO: 461) with template Tth(K69E)AKK (DNA sequence SEQ ID NO: 452), and primers 1044-058-06: 5'-ctc-ctc-aag-aac-ctg-gac-cgg-gta-aag-3' (SEQ ID NO: 462) and 209-074-02: 5'-gtg-gcc-tcc-ata-tgg-gcc-agg-ac-3' (SEQ ID NO:316) with template Tf1(K69E)TthAKK (DNA sequence SEQ ID NO: 497). Two products were combined and amplified with outside primers 390-76-08 and 209-074-02. The
25 recombinant PCR product was cut with the restriction enzymes EcoRI and NotI and ligated into the vector TthAKK which was prepared by cutting with the same enzymes to yield Tf1(222-334)TthAKK construct (DNA sequence SEQ ID NO: 463; amino acid sequence SEQ ID NO: 464).

Construction of TfI(167-334)TthAKK

Two overlapping PCR fragments were generated by primers 390-76-08 5'-tgt-gga-att-gtg-agc-gg-3' (SEQ ID NO:314) and 1044-058-07 5'-gac-gtc-ctt-cgg-ggt-gat-gag-gtg-gcc-3' (SEQ ID NO: 465) with template Tth(K69E)AKK, (DNA sequence SEQ 5 ID NO: 452), and primers 1044-058-08 5'-atc-acc-ccg-aag-gac-gtc-cag-gag-aag-3' (SEQ ID NO: 466) and 209-074-02 5'-gtg-gcc-tcc-ata-tgg-gcc-agg-ac-3' (SEQ ID NO:316) with template TfI(K69E)TthAKK, (DNA sequence SEQ ID NO: 498). Two products were combined and amplified with outside primers 390-76-08 and 209-074-02. The recombinant PCR product was cut with the restriction enzymes EcoRI and NotI and 10 ligated into the vector TthAKK which was prepared by cutting with the same enzymes to yield TfI(167-333)TthAKK construct (DNA sequence SEQ ID NO: 467; amino acid sequence SEQ ID NO: 468).

Construction of Tsc(111-334)TthAKK

15 Two overlapping PCR fragments were generated by primers 390-76-08 5'-tgt-gga-att-gtg-agc-gg-3' (SEQ ID NO:314) and 1044-058-01 5'-ctc-gag-gcg-ggt-aaa-ccc-cag-gag-gtc-3' (SEQ ID NO: 469) with template Tth(K69E)AKK (DNA sequence SEQ ID NO: 452), and primers 1044-058-02 5'-ggg-ttt-acc-cgc-ctc-gag-gtg-ccc-ggc-3' (SEQ ID NO: 470) and 209-074-02 5'-gtg-gcc-tcc-ata-tgg-gcc-agg-ac-3' (SEQ ID NO:316) 20 with template Tsc(K69E)TthAKK (DNA sequence SEQ ID NO: 499). Two products were combined and amplified with outside primers 390-76-08 and 209-074-02. The recombinant PCR product was cut with the restriction enzymes EcoRI and NotI and ligated into the vector TthAKK which was prepared by cutting with the same enzymes to yield Tsc(167-333)TthAKK construct (DNA sequence SEQ ID NO: 471; amino acid 25 sequence SEQ ID NO: 472).

Construction of Tsc(1-167)TthAKK

Two overlapping PCR fragments were generated by primers 390-76-08 5'-tgt-gga-att-gtg-agc-gg-3' (SEQ ID NO:314) and 1044-058-03 5'-aag-cca-ctc-cgg-ggt-gat-gag-gta-acc-3' (SEQ ID NO: 473) with template Tsc(K69E)TthAKK (DNA sequence 30 SEQ ID NO: 499), and primers 1044-058-04 5'-atc-acc-ccg-gag-tgg-ctt-tgg-gag-aag-3'

(SEQ ID NO: 474) and 209-074-02 5'-gtg-gcc-tcc-ata-tgg-gcc-agg-ac-3' (SEQ ID NO:316) with template Tth(K69E)AKK (DNA sequence SEQ ID NO: 452). Two products were combined and amplified with outside primers 390-76-08 and 209-074-02. The recombinant PCR product was cut with the restriction enzymes EcoRI and NotI and 5 ligated into the vector TthAKK which was prepared by cutting with the same enzymes to yield Tsc(1-167)TthAKK construct (DNA sequence SEQ ID NO: 475; amino acid sequence SEQ ID NO: 476).

Modification of AfuFEN enzymes

10

Construction of pAfuFEN

Plasmid pAfuFEN1 was prepared as described [U.S. Patent application Ser. No. 09/684,938, WO 98/23774, each incorporated herein by reference in their entireties]. Briefly, genomic DNA was prepared from one vial (approximately 5 ml of culture) of 15 live *A. fulgidus* bacteria from DSMZ (DSMZ #4304) with the DNA XTRAX kit (Gull Laboratories, Salt Lake City, UT) according to the manufacturer's protocol. The final DNA pellet was resuspended in 100 µl of TE (10 mM Tris HCl, pH 8.0, 1 mM EDTA). One microliter of the DNA solution was employed in a PCR using the ADVANTAGE cDNA PCR kit (Clonetech); the PCR was conducted according to manufacturer's 20 recommendations.

The 5' end primer is complementary to the 5' end of the Afu FEN-1 gene except it has a 1 base pair substitution to create an *Nco* I site. The 3' end primer is complementary to the 3' end of the Afu FEN-1 gene downstream from the FEN-1 ORF except it contains a 2 base substitution to create a *Sal* I site. The sequences of the 5' and 3' end primers are 25 5'-CCGTCAACATTACCATGGGTGCGGA-3' (SEQ ID NO:617) and 5'-CCGCCACCTCGTAGTCGACATCCTTTCTGTG (SEQ ID NO:618), respectively. Cloning of the resulting fragment was as described for the PfuFEN1 gene, U.S. Patent application Ser. No. 5,994,069, incorporated herein in its entirety for all purposes, to 30 create the plasmid pTrc99-AFFEN1. For expression, the pTrcAfuHis plasmid was constructed by modifying pTrc99-AFFEN1, by adding a histidine tail to facilitate purification. To add this histidine tail, standard PCR primer-directed mutagenesis

methods were used to insert the coding sequence for six histidine residues between the last amino acid codon of the pTrc99-AFFEN1 coding region and the stop codon. The resulting plasmid was termed pTrcAfuHis. The protein was then expressed as described and purified by binding to a Ni⁺⁺ affinity column.

5

Construction of Afu(Y236A), A46-5

Two overlapping PCR fragments were generated from template AfuFEN (SEQ ID NO:556) with primers: 785-73-04 5'-ctg-gtc-ggg-acg-gac-gcc-aat-gag-ggt-gtg-aag-3' (SEQ ID NO: 547) and 700-10-03 5'-ctt-ctc-tca-tcc-gcc-aaa-aca-gcc-3' (SEQ ID NO:343), and primers: 390-076-08 5'-tgt-gga-att-gtg-agc-gg-3' (SEQ ID NO:314) and 785-73-06 5'-gtc-cgt-ccc-gac-cag-aat-3' (SEQ ID NO: 548). The two products were combined and amplified with outside primers 700-10-03 and 390-076-08. The recombinant PCR product was cut with the restriction enzymes NcoI and SalI and ligated into the AfuFEN construct which was prepared by cutting with the same enzymes to yield 10 the Afu(Y236A) construct (DNA sequence SEQ ID NO: 549; amino acid sequence SEQ ID NO: 550).

15

Construction of Afu(Y236R), A56-9

Two overlapping PCR fragments were generated using the template AfuFEN with 20 primers: 785-73-05 5'-ctg-gtc-ggg-acg-gac-agg-aat-gag-ggt-gtg-aag-3' (SEQ ID NO: 551) and 700-10-03 5'-ctt-ctc-tca-tcc-gcc-aaa-aca-gcc-3' (SEQ ID NO:343), and primers: 390-076-08 5'-tgt-gga-att-gtg-agc-gg-3' (SEQ ID NO:314) and 785-73-06 5'-gtc-cgt-ccc-gac-cag-aat-3' (SEQ ID NO: 548). The two products were combined and amplified with outside primers 700-10-03 and 390-076-08. The recombinant PCR product was cut with 25 the restriction enzymes NcoI and SalI and ligated into the AfuFEN construct which was prepared by cutting with the same enzymes to yield Afu(Y236R) construct (DNA sequence SEQ ID NO: 552; amino acid sequence SEQ ID NO: 553).

2. Chimeras of FEN enzymes and *Thermus* Polymerase derivatives

The following enzyme constructs combine portions of the AfuFEN enzyme polymerase domain and the polymerase domain of *Thermus* ploymerases. These combinations were designed based on information generated by molecular modeling.

5

Construction of Afu336-Tth296(AKK), AT1-1

Two overlapping PCR fragments were generated. The first fragment was made using the AfuFEN construct (SEQ ID NO:556) as template with the primers: 390-076-08 5'-tgt-gga-att-gtg-ago-gg-3' (SEQ ID NO:314) and 390-065-05 5'-gaa-cca-cct-ctc-aag-10 cgt-gg-3' (SEQ ID NO: 554). The second fragment was made using TthAKK (SEQ ID NO:558) as template and the primers: 700-049-01 5'-acg-ctt-gag-agg-tgg-itc-ctg-gag-gag-gcc-ccc-tgg-3' (SEQ ID NO: 555) and 390-076-09 5'-taa-tct-gta-tca-ggc-tg-3' (SEQ ID NO:557). The two products contain a region of sequence overlap, and were combined and amplified with outside primers 390-076-08 and 390-076-09 in a recombinant PCR reaction. The recombinant PCR product was cut with the restriction enzymes BspEI and Sall and ligated into the AfuFEN construct which was prepared by cutting with the same enzymes to yield Afu336-Tth296(AKK) construct (DNA sequence SEQ ID NO: 559; amino acid sequence SEQ ID NO: 560).

15

Construction of Afu328-Tth296(AKK), AT2-3

Two overlapping PCR fragments were generated, the first by primers: 390-076-08 5'-tgt-gga-att-gtg-ago-gg-3' (SEQ ID NO:314) and 700-049-02 5'-ggt-tga-ctt-cag-ago-itt-20 gag-3' (SEQ ID NO: 561) with template AfuFEN (DNA sequence SEQ ID NO:556), and the second by primers: 700-049-03 5'-aaa-gct-ctg-aag-tca-acc-ctg-gag-gag-gcc-ccc-tgg-3' (SEQ ID NO: 562) and 390-076-09 5'-taa-tct-gta-tca-ggc-tg-3' (SEQ ID NO:557) with 25 template TthAKK (DNA sequence SEQ ID NO:558). The two products were combined and amplified with outside primers 390-076-08 and 390-076-09. The recombinant PCR product was cut with the restriction enzymes BspEI and Sall and ligated into the vector pAfuFEN which was prepared by cutting with the same enzymes to yield Afu336-Tth296(AKK) construct (DNA sequence SEQ ID NO: 563; amino acid sequence SEQ ID NO: 564).

Construction of Afu336-Taq5M

The Taq5M construct (SEQ ID NO:41) was cut with the enzymes NotI and SalI and the smaller insert fragment was gel isolated. The Afu336-Tth296(ACK) construct (DNA sequence SEQ ID NO: 559) was also cut with the same restriction enzymes and
5 the larger vector fragment was purified. The insert (Taq5M polymerase domain) was then ligated into the vector to generate the Afu336-Taq5M construct (DNA sequence SEQ ID NO: 565; amino acid sequence SEQ ID NO: 566).

Construction of Afu336-TaqDN

10 The TaqDNHT construct was cut with the enzymes NotI and SalI and the smaller insert fragment was gel isolated. The Afu336-Tth296(ACK) construct (DNA sequence SEQ ID NO: 559) was also cut with the same restriction enzymes and the larger vector fragment was purified. The insert (TaqDN polymerase domain) was then ligated into the vector to generate the Afu336-Taq5M construct (DNA sequence SEQ ID NO: 567; amino
15 acid sequence SEQ ID NO: 568).

Random Chimerization of *Thermus* Polymerases

Numerous enzymes with altered functions were generated via random
chimerization of *Thermus* polymerases based on the principal of DNA shuffling (Volkov
20 and Arnold, *Methods in Enzymology* 328:456 [2000]). The procedure below was used to develop the following chimeras.

The genes of interest for random chimerization were PCR amplified with primers:
390-076-08 5'-tgt-gga-att-gtg-agc-gg-3' (SEQ ID NO:314) and 209-074-02: 5'-gtg-gcc-
tcc-ata-tgg-gcc-agg-ac-3' (SEQ ID NO:316) to generate the approximately 1.4 kbp
25 templates. About 2 µg of the DNA templates were mixed in equal proportion, and then digested with DNase I (0.33 U) in a 30 µl reaction at 15° C for approximately 1 minute to generate fragments 50-200 bp in size. DNA fragments were purified in a 4 % agarose gel and extracted by QIAEXII gel extraction kit (QIAGEN) according to manufacturer's instructions. The purified fragments (10 µl) were added to 10 µl of 2X PCR pre-mix (5-
30 fold diluted, cloned Pfu buffer, 0.4 mM each dNTP, 0.06 U/µl cloned Pfu DNA polymerase, STRATAGENE Cat.# 600153, with accompanying buffer) for the fragment

reassembly reaction (PCR program: 3 min 94 °C followed by 40 cycles of 30 sec 94 °C, 1 min 52 °C, 2 min + 5 s/cycle 72 °C, followed by 4 min at 72 °C). The reassembled products (1 µl of a 10-fold dilution) were then PCR amplified with a pair of nested primers: 072-090-01 5'-gag-cgg-ata-aca-att-tca-cac-agg-3' (SEQ ID NO: 569) and 189-
5 082-01 5'-tgc-ccg-gtg-cac-gcg-gcc-cct-gca-ggc-3' (SEQ ID NO: 570) using the CLONTECH GC melt cDNA PCR kit (Cat.# K1907-Y) according to the manufacturer's instructions. The purified PCR products were digested with restriction enzymes EcoRI and NotI and then ligated into the TthAKK construct that was prepared by cutting with the same enzymes. The ligation mixture was transformed into JM109 competent cells
10 and colonies were screened for enzyme activity.

1. Generation of Random Chimeras S26 and S36

The templates used to develop these chimeric enzymes were the nuclease domains from TthAKK, TaqTthAKK, TscTthAKK and the TfTthAKK constructs. Two clones were found to show improvement of activity based on primary activity screening. Random chimeras S26 (DNA sequence SEQ ID NO: 571; amino acid sequence SEQ ID NO: 572) and S36 (DNA sequence SEQ ID NO: 573; amino acid sequence SEQ ID NO: 574) were then sequenced and isolated.
15

20

2. Introduction of L107F/E108T, L109F/V110T and K69E mutations in S26 and S36 to improve substrate specificity

Construction of S26(FT)

Site specific mutagenesis was performed on pS26 DNA using the mutagenic primers: 785-008-03 5'-ttt-acc-cgt-ctc-gag-gtg-cgg-ggc-3' (SEQ ID NO: 489) and 680-21-03 5'-cggtt-acc-cgt-ctc-gag-gcg-ggt-aaa-gcc-caa-aag-gtc-cac-3' (SEQ ID NO: 490) to introduce the L107F/E108T mutations and generate S26(FT) (DNA sequence SEQ ID NO: 575; amino acid sequence SEQ ID NO: 576).

Construction of S36(FT)

Site specific mutagenesis was performed on pS36 DNA using the mutagenic primers: 785-096-01: 5'-gtt-gac-ctt-ctg-ggc-ttt-acc-cgt-ctc-gag-gcc-cgg-3' (SEQ ID NO:
30

486) and 785-096-02: 5'-cgg-ggc-ctc-gag-gcg-ggt-aaa-gcc-cag-aag-gtc-cac-3' (SEQ ID NO: 487) to introduce the L109F/V110T mutations and generate S36(FT) (DNA sequence SEQ ID NO: 577; amino acid sequence SEQ ID NO: 578).

Construction of S26(K69E)

5 Site specific mutagenesis was performed on S26 DNA using the mutagenic primers: 5'-atc-gtg-gtc-ttt-gac-gcc-gag-gcc-ccc-tcc-itc-c-3' (SEQ ID NO: 492) and 5'-gga-agg-agg-ggg-cct-cgg-cgt-caa-aga-cca-cga-t-3' (SEQ ID NO: 493) to introduce the K69E mutation and to generate S26(K69E) (DNA sequence SEQ ID NO: 579; amino acid sequence SEQ ID NO: 580).

Construction of S26(FT/K69E)

10 Site specific mutagenesis was performed on S26(FT) DNAs using the mutagenic primers: 5'-atc-gtg-gtc-ttt-gac-gcc-gag-gcc-ccc-tcc-itc-c-3' (SEQ ID NO: 492) and 5'-gga-agg-agg-ggg-cct-cgg-cgt-caa-aga-cca-cga-t-3' (SEQ ID NO: 493) to introduce the K69E mutation and to generate S26(FT/K69E) (DNA sequence SEQ ID NO: 581; amino acid sequence SEQ ID NO: 582).

3. More random chimeras, N3D7, N1A12 N1C4, and N2C3

The templates used to generate these chimerics were the nuclease domains of Tth(K69E)AKK, Taq(K69E)TthAKK, Tsc(K69E)TthAKK and TfI(K69E)TthAKK constructs. Four clones were shown to have improved activity based on the primary activity screening. Random chimeras N3D7 (DNA sequence SEQ ID NO: 583; amino acid sequence SEQ ID NO: 584), N1A12 (DNA sequence SEQ ID NO: 585; amino acid sequence SEQ ID NO: 586), N1C4 (DNA sequence SEQ ID NO: 587; amino acid sequence SEQ ID NO: 588) and N2C3 (DNA sequence SEQ ID NO: 589; amino acid sequence SEQ ID NO: 590) were then sequenced and isolated respectively.

EXAMPLE 10

**Test For The Dependence Of An Enzyme On
The Presence Of An Upstream Oligonucleotide**

30 When choosing a structure-specific nuclease for use in a sequential invasive cleavage reaction it is preferable that the enzyme have little ability to cleave a probe 1) in the absence of an upstream oligonucleotide, and 2) in the absence of overlap between the

upstream oligonucleotide and the downstream probe oligonucleotide. Figs. 26a-e depicts several structures that can be used to examine the activity of an enzyme is confronted with each of these types of structures. The structure **a** (Fig. 26a) shows the alignment of a probe oligonucleotide with a target site on bacteriophage M13 DNA (M13 sequences shown in Fig. 26 are provided in SEQ ID NO:217) in the absence of an upstream oligonucleotide. Structure **b** (Fig. 26b) is provided with an upstream oligonucleotide that does not contain a region of overlap with the labeled probe (the label is indicated by the star). In structures **c**, **d** and **e** (Figs. 26c-e) the upstream oligonucleotides have overlaps of 1, 3 or 5 nucleotides, respectively, with the downstream probe oligonucleotide and each of these structures represents a suitable invasive cleavage structure. The enzyme *Pfu* FEN-1 was tested for activity on each of these structures and all reactions were performed in duplicate.

Each reaction comprised 1 μ M 5' TET labeled probe oligonucleotide 89-15-1 (SEQ ID NO:212), 50 nM upstream oligonucleotide (either oligo 81-69-2 [SEQ ID NO:216], oligo 81-69-3 [SEQ ID NO:215], oligo 81-69-4 [SEQ ID NO:214], oligo 81-69-5 [SEQ ID NO:213], or no upstream oligonucleotide), 1 fmol M13 target DNA, 10 mg/ml tRNA and 10 ng of *Pfu* FEN-1 in 10 μ l of 10 mM MOPS (pH 7.5), 7.5 mM MgCl₂ with 0.05% each of Tween 20 and Nonidet P-40.

All of the components except the enzyme and the MgCl₂ were assembled in a final volume of 8 μ l and were overlaid with 10 μ l of CHILLOUT liquid wax. The samples were heated to the reaction temperature of 69°C. The reactions were started by the addition of the *Pfu* FEN-1 and MgCl₂, in a 2 μ l volume. After incubation at 69°C for 30 minutes, the reactions were stopped with 10 μ l of 95% formamide, 10 mM EDTA, 0.02% methyl violet. Samples were heated to 90°C for 1 min immediately before electrophoresis through a 20% denaturing acrylamide gel (19:1 cross-linked), with 7 M urea, in a buffer of 45 mM Tris-Borate, pH 8.3, 1.4 mM EDTA. Gels were then analyzed with a FMBIO-100 Hitachi FMBIO fluorescence imager. The resulting image is displayed in Fig. 27.

In Fig. 27, lanes labeled "a" contain the products generated from reactions conducted without an upstream oligonucleotide (structure **a**), lanes labeled "b" contain an upstream oligonucleotide that does not invade the probe/target duplex (structure **b**).

Lanes labeled "c", "d" and "e" contain the products generated from reactions conducted using an upstream oligonucleotide that invades the probe/target duplex by 1, 3 or 5 bases, respectively. The size (in nucleotides) of the uncleaved probe and the cleavage products is indicated to the left of the image in Fig. 27. Cleavage of the probe was not detectable 5 when structures **a** and **b** were utilized. In contrast, cleavage products were generated when invasive cleavage structures were utilized (structures **c-e**). These data show that the *Pfu* FEN-1 enzyme requires an overlapping upstream oligonucleotide for specific cleavage of the probe.

Any enzyme may be examined for its suitability for use in a sequential invasive 10 cleavage reaction by examining the ability of the test enzyme to cleave structures **a-e** (it is understood by those in the art that the specific oligonucleotide sequences shown in Figs. 26a-e need not be employed in the test reactions; these structures are merely illustrative of suitable test structures). Desirable enzymes display little or no cleavage of structures **a** and **b** and display specific cleavage of structures **c-e** (*i.e.*, they generate 15 cleavage products of the size expected from the degree of overlap between the two oligonucleotides employed to form the invasive cleavage structure).

EXAMPLE 11

Use Of The Products Of A First Invasive Cleavage Reaction To Enable A Second 20 Invasive Cleavage Reaction With A Net Gain In Sensitivity

As discussed in the Description of The Invention above, the detection sensitivity of the invasive cleavage reaction can be increased by performing a second round of invasive cleavage using the products of the first reaction to complete the cleavage structure in the second reaction. In this Example, the use of a probe that, when cleaved in 25 a first invasive cleavage reaction, forms an integrated INVADER oligonucleotide and target molecule for use in a second invasive cleavage reaction, is illustrated.

A first probe was designed to contain some internal complementarity so that when cleaved in a first invasive cleavage reaction the product ("Cut Probe 1") could form a target strand comprising an integral INVADER oligonucleotide. A second probe was 30 provided in the reaction that would be cleaved at the intended site when hybridized to the newly formed target/INVADER molecule. To demonstrate the gain in signal due to the

performance of sequential invasive cleavages, a standard invasive cleavage assay, as described above, was performed in parallel.

All reactions were performed in duplicate. Each standard (*i.e.*, non-sequential) invasive cleavage reaction comprised 1 μ M 5' fluorescein-labeled probe oligo 073-182 (5'
5' FI-AGAAAGGAAGGGAAGAAAGCGAA-3'; SEQ ID NO:591), 10 nM upstream oligo
81-69-4 (5'-CTTGACGGGAAAGCCGGCGAACGTGGCGA-3'; SEQ ID NO:214), 10
to 100 attomoles of M13 target DNA, 10 mg/ml tRNA and 10 ng of *Pfu* FEN-1 in 10 μ l
of 10 mM MOPS (pH 7.5), 8 mM MgCl₂ with 0.05% each of Tween 20 and Nonidet
P-40. All of the components except the enzyme and the MgCl₂ were assembled in a
10 volume of 7 μ l and were overlaid with 10 μ l of CHILLOUT liquid wax. The samples
were heated to the reaction temperature of 62°C. The reactions were started by the
addition of the *Pfu* FEN-1 and MgCl₂, in a 2 μ l volume. After incubation at 62°C for 30
minutes, the reactions were stopped with 10 μ l of 95% formamide, 10 mM EDTA, 0.02%
methyl violet.

15 Each sequential invasive cleavage reaction comprised 1 μ M 5' fluorescein-labeled
oligonucleotide 073-191 (the first probe or "Probe 1", 5' FI-TGGAGGTCAAAACATCG
ATAAGTCGAAGAAAGGAAGGGAAAGAAAT-3'; SEQ ID NO:592), 10 nM upstream
oligonucleotide 81-69-4 (5'- CTTGACGGGAAA GCCGGCGAACGTGGCGA-3';
SEQ ID NO:214), 1 μ M of 5' fluorescein labeled oligonucleotide 106-32 (the second
20 probe or "Probe 2", 5' FI-TGTTITGACCT CCA-3'; SEQ ID NO:593), 1 to 100 amol of
M13 target DNA, 10 mg/ml tRNA and 10 ng of *Pfu* FEN-1 in 10 μ l of 10 mM MOPS
(pH 7.5), 8 mM MgCl₂ with 0.05% each of Tween 20 and Nonidet P-40. All of the
components except the enzyme and the MgCl₂ were assembled in a volume of 8 μ l and
were overlaid with 10 μ l of CHILLOUT liquid wax. The samples were heated to the
25 reaction temperature of 62°C (this temperature is the optimum temperature for annealing
of Probe 1 to the first target). The reactions were started by the addition of *Pfu* FEN-1
and MgCl₂, in a 2 μ l volume. After incubation at 62°C for 15 minutes, the temperature
was lowered to 58°C (this temperature is the optimum temperature for annealing of Probe
2 to the second target) and the samples were incubated for another 15 min. Reactions

were stopped by the addition of 10 μ l of 95% formamide, 20 mM EDTA, 0.02% methyl violet.

Samples from both the standard and the sequential invasive cleavage reactions were heated to 90° C for 1 min immediately before electrophoresis through a 20%

- 5 denaturing acrylamide gel (19:1 cross-linked), with 7 M urea, in a buffer of 45 mM Tris-Borate, pH 8.3, 1.4 mM EDTA. The gel was then analyzed with a Molecular Dynamics FluorImager 595. The resulting image is displayed in Fig. 28a. A graph showing measure of fluorescence intensity for each of the product bands is shown in Fig. 28b.

- 10 In Fig. 28a, lanes 1-5 contain the products generated in standard invasive cleavage reactions that contained either no target (lane 1), 10 amol of target (lanes 2 and 3) or with 100 amol of target (lanes 4 and 5). The uncleaved probe is seen as a dark band in each lane about half way down the panel and the cleavage products appear as a smaller black band near the bottom of the panel, the position of the cleavage product is indicated by an arrow head to the left of Fig. 28a. The gray ladder of bands seen in lanes 1-5 is due to the 15 thermal degradation of the probe and is not related to the presence or absence of the target DNA. The remaining lanes display products generated in sequential invasive cleavage reactions that contained 1 amol of target (lanes 6 and 7), 10 amol of target (lanes 8 and 9) and 100 amol of target (lanes 10 and 11). The uncleaved first probe 20 (Probe 1; labeled "1 uncut") is seen near the top of the panel, while the cleaved first probe is indicated as "1: cut". Similarly, the uncleaved and cleaved second probe are indicated as "2: uncut" and "2: cut," respectively.

- The graph shown in Fig. 28b compares the amount of product generated from the 25 standard reaction ("Series 1") to the amount of product generated from the second step of the sequential reaction ("Series 2"). The level of background fluorescence measured from a reaction that lacked target DNA was subtracted from each measurement. It can be seen from the table located below the graph that the signal from the standard invasive cleavage assay that contained 100 attomoles of target DNA was nearly identical to the signal from the sequential invasive cleavage assay in which 1 attomole of target was 30 present, indicating that the inclusion of a second cleavage structure increases the sensitivity of the assay 100 to 200-fold. This boost in signal allows easy detection of

target nucleic acids at the sub attomole level using the sequential invasive cleavage assay, while the standard assay, when performed using this enzyme for only 30 minutes, does not generate detectable product in the presence of 10 attomoles of target.

When the amount of target was decreased by 10 or 100 fold in the sequential invasive cleavage assay, the intensity of the signal was decreased by the same proportion. 5 This indicates that the quantitative capability of the invasive cleavage assay is retained even when reactions are performed in series, thus providing a nucleic acid detection method that is both sensitive and quantitative.

While in this Example, the two probes used had different optimal hybridization 10 temperatures (*i.e.*, the temperature empirically determined to give the greatest turnover rate in the given reaction conditions), the probes may also be selected (*i.e.*, designed) to have the same optimal hybridization temperature so that a temperature shift during incubation is not necessary.

15

EXAMPLE 12

The Products Of A Completed Sequential Invasive Cleavage Reaction Cannot Cross Contaminate Subsequent Similar Reactions

As discussed in the Description of the Invention, the serial nature of the multiple invasive cleavage events that occur in the sequential invasive cleavage reaction, in contrast to the reciprocating nature of the polymerase chain reaction and similar doubling assays, means that the sequential invasive cleavage reaction is not subject to 20 contamination by the products of like reactions because the products of the first cleavage reaction do not participate in the generation of new signal in the second cleavage reaction. If a large amount of a completed reaction were to be added to a newly assembled reaction, the background that would be produced would come from the amount of target that was also carried in, combined with the amount of already-cleaved probe that was carried in. In this Example, it is demonstrated that a very large portion of 25 a primary reaction must be introduced into the secondary reaction to create significant signal.

30

A first or primary sequential invasive cleavage reaction was performed as described above using 100 amol of target DNA. A second set of 5 reactions were

assembled as described in Ex. 11 with the exception that portions of the first reaction were introduced and no additional target DNA was included. These secondary reactions were initiated and incubated as described above, and included 0, 0.01, 0.1, 1, or 10% of the first reaction material. A control reaction including 100 amol of target was included
5 in the second set also. The reactions were stopped, resolved by electrophoresis and visualized as described above, and the resulting image is displayed in Fig. 29. The primary probe, uncut second probe and the cut 2nd probe are indicated on the left as "1: cut", 2: uncut" and 2: cut", respectively.

In Fig. 29, lane 1 shows the results of the first reaction with the accumulated
10 product at the bottom of the panel, and lane 2 show a 1:10 dilution of the same reaction, to demonstrate the level of signal that could be expected from that level of contamination, without further amplification. Lanes 3 through 7 show the results of the secondary cleavage reactions that contained 0, 10, 1, 0.1 or 0.01% of the first reaction material added as contaminant, respectively and lane 8 shows a control reaction that had 100 amol
15 of target DNA added to verify the activity of the system in the secondary reaction. The signal level in lane 4 is as would be expected when 10% of the pre-cleaved material is transferred (as in lane 2) and 10% of the transferred target material from the lane 1 reaction is allowed to further amplify. At all levels of further dilution the signal is not readily distinguished from background. These data demonstrate that while a large-scale
20 transfer from one reaction to another may be detectable, cross contamination by the minute quantities that would be expected from aerosol or from equipment contamination would not be easily mistaken for a false positive result. These data also demonstrate that when the products of one reaction are deliberately carried over into a fresh sample, these products do not participate in the new reaction, and thus do not affect the level of target-dependent signal that may be generated in that reaction.
25

EXAMPLE 13**Detection of Human Cytomegalovirus Viral DNA by Invasive Cleavage**

The previous Example demonstrates the ability of the invasive cleavage reaction

- 5 to detect minute quantities of viral DNA in the presence of human genomic DNA. In this Example, the probe and INVADER oligonucleotides were designed to target the 3104-3061 region of the major immediate early gene of human cytomegalovirus (HCMV) as shown in Fig. 30. In Fig. 30, the INVADER oligo (89-44; SEQ ID NO:219) and the fluorescein (F1)-labeled probe oligo (89-76; SEQ ID NO:218) are shown annealed 10 along a region of the HCMV genome corresponding to nucleotides 3057-3110 of the viral DNA (SEQ ID NO:220). The probe used in this Example is a poly-pyrimidine probe and as shown herein the use of a poly-pyrimidine probe reduces background signal generated by the thermal breakage of probe oligos.

- The genomic viral DNA was purchased from Advanced Biotechnologies, 15 Incorporated (Columbia, MD). The DNA was estimated (but not certified) by personnel at Advanced Biotechnologies to be at a concentration of 170 amol (1×10^8 copies) per microliter. The reactions were performed in quadruplicate. Each reaction comprised 1 μ M 5' fluorescein labeled probe oligonucleotide 89-76 (SEQ ID NO:218), 100 nM INVADER oligonucleotide 89-44 (SEQ ID NO:219), 1 ng/ml human genomic DNA, and 20 one of five concentrations of target HCMV DNA in the amounts indicated above each lane in Fig. 31, and 10 ng of *Pfu* FEN-1 in 10 μ l of 10 mM MOPS (pH 7.5), 6 mM MgCl₂ with 0.05% each of Tween 20 and Nonidet P-40. All of the components except the labeled probe, enzyme and MgCl₂ were assembled in a final volume of 7 μ l and were overlaid with 10 μ l of CHILLOUT liquid wax. The samples were heated to 95°C for 5 25 min, then reduced to 62°C. The reactions were started by the addition of probe, *Pfu* FEN-1 and MgCl₂, in a 3 μ l volume. After incubation at 62°C for 60 minutes, the reactions were stopped with 10 μ l of 95% formamide, 10 mM EDTA, 0.02% methyl violet. Samples were heated to 90° C for 1 min immediately before electrophoresis 30 through a 20% acrylamide gel (19:1 cross-linked), with 7 M urea, in a buffer of 45 mM Tris-Borate, pH 8.3, 1.4 mM EDTA. Gels were then analyzed with a Molecular Dynamics FluorImager 595.

The resulting image is displayed in Fig. 31. The replicate reactions were run in groups of four lanes with the target HCMV DNA content of the reactions indicated above each set of lanes (0-170 amol). The uncleaved probe is seen in the upper third of the panel ("Uncut 89-76") while the cleavage products are seen in the lower two-thirds of the panel ("Cut 89-76"). It can be seen that the intensity of the accumulated cleavage product is proportional to the amount of the target DNA in the reaction. Furthermore, it can be clearly seen in reactions that did not contain target DNA ("no target") that the probe is not cleaved, even in a background of human genomic DNA. While 10 ng of human genomic DNA was included in each of the reactions shown in Fig. 31, inclusion of 10 genomic DNA up to 200 ng has slight impact on the amount of product accumulated. The data did not suggest that 200 ng per 10 μ l of reaction mixture represented the maximum amount of genomic DNA that could be tolerated without a significant reduction in signal accumulation. For reference, this amount of DNA exceeds what might be found in 0.2 ml of urine (a commonly tested amount for HCMV in neonates) 15 and is equivalent to the amount that would be found in about 5 μ l of whole blood.

These results demonstrate that the standard (*i.e.*, non-sequential) invasive cleavage reaction is a sensitive, specific and reproducible means of detecting viral DNA. Detection of 1.7 amol of target is roughly equivalent to detection of 10^6 copies of the virus. This is equivalent to the number of viral genomes that might be found in 0.2 mls 20 of urine from a congenitally infected neonate (10^2 to 10^6 genome equivalents per 0.2 mls; Stagno *et al.*, J. Infect. Dis., 132:568 [1975]). Use of the sequential invasive cleavage assay would permit detection of even fewer viral DNA molecules, facilitating detection in blood (10^1 to 10^5 viral particles per ml; Pector *et al.*, J. Clin. Microbiol., 30:2359 [1992]), which carries a much larger amount of heterologous DNA.

25 From the above it is clear that the invention provides reagents and methods to permit the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. The INVADER-directed cleavage reaction and the sequential INVADER-directed cleavage reaction of the present invention provide ideal direct detection methods that combine the advantages of the direct detection assays (*e.g.*, easy quantification and minimal risk of carry-over contamination) with the specificity 30 provided by a dual or tri oligonucleotide hybridization assay.

As indicated in the Description of the Invention, the use of sequential invasive cleavage reactions can present the problem of residual uncut first, or primary, probe interacting with the secondary target, and either competing with the cut probe for binding, or creating background through low level cleavage of the resulting structure.

- 5 This is shown diagrammatically in Figs. 32 and 33. In Fig. 32, the reaction depicted makes use of the cleavage product from the first cleavage structure to form an INVADER oligonucleotide for a second cleavage reaction. The structure formed between the secondary target, the secondary probe and the uncut primary probe is depicted in Fig. 32, as the right hand structure shown in step 2a. This structure is recognized and cleaved by
10 the 5' nucleases, albeit very inefficiently (*i.e.*, at less than about 1% in most reaction conditions). Nonetheless, the resulting product is indistinguishable from the specific product, and thus may lead to a false positive result. The same effect can occur when the cleaved primary probe creates an integrated INVADER/target (IT) molecule, as described in Example 11; the formation of the undesirable complex is depicted
15 schematically in Fig. 33, as the right hand structure shown in step 2a.

The improvements provided by the inclusion of ARRESTOR oligonucleotides of various compositions in each of these types of sequential INVADER assays are demonstrated in the following Examples. These ARRESTOR oligonucleotides are configured to bind the residual uncut probe from the first cleavage reaction in the series, 20 thereby increasing the efficacy of and reducing the non-specific background in the subsequent reaction(s).

EXAMPLE 14

"ARRESTOR" Oligonucleotides Improve Sensitivity of Multiple Sequential 25 Invasive Cleavage Assays

In this Example, the effect of including an ARRESTOR oligonucleotide on the generation of signal using the IT probe system 33 is demonstrated. The ARRESTOR oligonucleotide hybridizes to the primary probe, mainly in the portion that recognizes the target nucleic acid during the first cleavage reaction. In addition to examining the effects
30 of adding an ARRESTOR oligonucleotide, the effects of using ARRESTOR oligonucleotides that extended in complementarity different distances into the region of

the primary probe that composes the secondary IT structure were also investigated. These effects were compared in reactions that included the target DNA over a range of concentrations, or that lacked target DNA, in order to demonstrate the level of nonspecific (*i.e.*, not related to target nucleic acid) background in each set of reaction

5 conditions.

The target DNA for these reactions was a fragment that comprised the full length of the hepatitis B genome from strain of serotype adw. This material was created using the polymerase chain reaction from plasmid pAM6 (ATCC #45020D). The PCRs were conducted using a vector-based forward primer, oligo # 156-022-001 (5'-

10 ggcgaccacacccgtctgt-3'; SEQ ID NO:594) and a reverse primer, oligo #156-022-02 (5'-ccacatgcgtccggcgtag-3'; SEQ ID NO:595) to amplify the full length of the HBV insert, an amplicon of about 3.2kb. The cycling conditions included a denaturation of the plasmid at 95°C for 5 minutes, followed by 30 cycles of 95°C, 30 seconds; 60°C, 40 seconds; and 72°C, 4 minutes. This was followed by a final extension at 72°C for 10 minutes. The resulting amplicon, termed pAM6#2, was adjusted to 2 M NH₄OAc, and collected by precipitation with isopropanol. After drying *in vacuo*, DNA was dissolved in 10 mM Tris pH .0, 0.1 mM EDTA. The concentration was determined by OD₂₆₀ measurement, and by INVADER assay with comparison to a standard of known concentration.

20 The INVADER reactions were conducted as follows. Five master mixes, termed "A," "B," "C," "D," and "E," were assembled; all mixes contained 12.5 mM MOPS, pH 7.5, 500 fmoles primary INVADER oligo #218-55-05 (SEQ ID NO:596), 10 ng human genomic DNA (Novagen) and 30 ng AfuFEN1 enzyme, for every 8 µl of mix. Mix A contained no added HBV genomic amplicon DNA; mix B contained 600 molecules of 25 HBV genomic amplicon DNA pAM6 #2; mix C contained 6,000 molecules pAM6 #2; mix D contained 60,000 molecules pAM6 #2; and mix E contained 600,000 molecules pAM6 #2. The mixes were aliquotted to the reaction tubes, 8 µl/tube: mix A to tubes 1, 2, 11, 12, 21 and 22; mix B to tubes 3, 4, 13, 14, 23 and 24; mix C to tubes 5, 6, 15, 16, 25 and 26; mix D to tubes 7, 8, 17, 18, 27 and 28; and mix E to tubes 9, 10, 19, 20, 29 30 and 30. The samples were incubated at 95°C for 4 minutes to denature the HBV genomic amplicon DNA. The reactions were then cooled to 67°C, and 2 µl of a mix containing

37.5 mM MgCl₂ and 2.5 pmoles 218-95-06 (SEQ ID NO:597) for every 2 µl, was added to each sample. The samples were incubated at 67°C for 60 minutes. Three secondary reaction master mixes were prepared, all mixes contained 10 pmoles of secondary probe oligonucleotide #228-48-04 (SEQ ID NO:598) for every 2 µl of mix. Mix 2A contained
5 no additional oligonucleotide, mix 2B contained 5pmoles “ARRESTOR” oligo # 218-95-03 (SEQ ID NO:599) and mix 2C contained 5 pmoles of “ARRESTOR” oligo # 218-95-01 (SEQ ID NO:600). After the 60 minute incubation at 67°C (the primary reaction described above), 2 µl of the secondary reaction mix was added to each sample: Mix 2A was added to samples #1-10; Mix 2B was added to samples #11-20; and Mix 2C was
10 added to samples #21-30. The temperature was adjusted to 52°C and the samples were incubated for 30 minutes at 52°C. The reactions were then stopped by the addition of 10 µl of a solution of 95% formamide, 5 mM EDTA and 0.02% crystal violet. All samples were heated to 95°C for 2 minutes, and 4 µl of each sample were resolved by
electrophoresis through 20% denaturing acrylamide gel (19:1 cross-linked) with 7 M
15 urea, in a buffer containing 45 mM Tris-Borate (pH8.3) and 1.4 mM EDTA. The results were imaged using the Molecular Dynamics Fluoroimager 595, excitation 488, emission 530. The resulting images are shown in Fig. 34.

In Fig. 34, Panel A shows the results of the target titration when no ARRESTOR oligonucleotide was included in the secondary reaction; Panel B shows the results of the
20 same target titration using an ARRESTOR oligonucleotide that extended 2 nt into the non-target complementary region of the primary probe; and Panel C shows the results of the same target titration using an ARRESTOR oligonucleotide that extended 4 nt into the non-target complementary region of the primary probe. The product of the secondary cleavage reaction is seen as a band near the bottom of each panel. The first two lanes of
25 each panel (*i.e.*, 1 and 2, 11 and 12, 21 and 22) lacked target DNA, and the signal that co-migrates with the product band represents the nonspecific background under each set of conditions.

It can be seen by visual inspection of these panels that the background signal is both reduced, and made more predictable, by the inclusion of either species of
30 ARRESTOR oligonucleotide. In addition to reducing the background in the no-target control lanes, the background reduction in the reactions that had the more dilute amounts

of target included is reduced, leading to a signal that is a more accurate reflection of the target contained within the reaction, thus improving the quantitative range of the multiple, sequential invasive cleavage reaction.

- To quantify the impact of including the ARRESTOR oligonucleotide in the
- 5 secondary cleavage reaction under these conditions, the average product band signal from the reactions having the largest amount of target (*i.e.*, averages of the signals from lanes 9 and 10, lanes 19 and 20, and lanes 29 and 30), were compared to the averaged signal from the no-target control lanes for each panel, determine the "fold over background," the factor of signal amplification over background, under each set of conditions. For the
- 10 reactions without the ARRESTOR oligonucleotide, Panel A, the fold over background was 5.3; for Panel B, the fold over background was 12.7; and for Panel C, the fold over background was 13.4, indicating that in this system inclusion of any ARRESTOR oligonucleotide at least doubled the specificity of the signal over the ARRESTOR oligonucleotide -less reactions, and that the ARRESTOR oligonucleotide that extended
- 15 slightly farther into the non-target complementary region may be slightly more effective, at least in this embodiment of the system. This clearly shows the benefits of using an ARRESTOR oligonucleotide to enhance the specificity of these reactions, an advantage that is of particular benefit at low levels of target nucleic acid.

20

EXAMPLE 15

"ARRESTOR" Oligonucleotides Allow use of Higher Concentrations of Primary Probe Without Increasing Background Signal

- Increasing the concentration of the probe in the invasive cleavage reaction can dramatically increase the amount of signal generated for a given amount of target DNA.
- 25 While not intending to limit the explanation to any specific mechanism, this is believed to be caused by the fact that increased concentration of probe increases the rate at which the cleaved probe is supplanted by an uncleaved copy, thereby increasing the apparent turnover rate of the cleavage reaction. Unfortunately, this effect could not heretofore be applied in the primary cleavage reaction of a multiple sequential INVADER assay
- 30 because the residual uncleaved primary probe can hybridize to the secondary target, in competition with the cleaved molecules, thereby reducing the efficacy of the secondary

reaction. Elevated concentrations of primary probe exacerbate this problem. Further, the resulting complexes, as described above, can be cleaved at a low level, contributing to background. Therefore, increasing the primary probe can have the double negative effect of both slowing the secondary reaction and increasing the level of this form of non target-specific background. The use of an ARRESTOR oligonucleotide to sequester or neutralize the residual primary probe allows this concentration-enhancing effect to be applied to these sequential reactions.

To demonstrate this effect, two sets of reactions were conducted. In the first set of reactions, the reactions were conducted using a range of primary probe concentrations, but no ARRESTOR oligonucleotide was supplied in the secondary reaction. In the second set of reactions, the same probe concentrations were used, but an ARRESTOR oligonucleotide was added for the secondary reactions.

All reactions were performed in duplicate. Primary INVADER reactions were done in a final volume of 10 μ l and contained: 10 mM MOPS, pH 7.5, 7.5 mM MgCl₂, 500 fm of primary INVADER (218-55-05; SEQ ID NO:596), 30 ng of AfuFEN1 enzyme and 10 ng of human genomic DNA. 100 zeptomoles of HBV pAM6 #2 amplicon was included in all even numbered reactions (by reference to Figs. 35A and B). Reactions included 10 pmoles, 20 pmoles, 50 pmoles, 100 pmoles or 150 pmoles of primary probe (218-55-02; SEQ ID NO:601). MOPS, target and INVADER oligonucleotides were combined to a final volume of 7 μ l. Samples were heat denatured at 95°C for 5 minutes, then cooled to 67°C. During the 5 minute denaturation, MgCl₂, probe and enzyme were combined. The primary INVADER reactions were initiated by the addition of 3 μ l of MgCl₂, probe and enzyme mix, to the final concentrations indicated above. Reactions were incubated for 30 minutes at 67°C. The reactions were then cooled to 52°C, and each primary INVADER reaction received the following secondary reaction components in a total volume of 4 μ l: 2.5 pmoles secondary target (oligo number 218-95-04; SEQ ID NO:602); 10 pmoles secondary probe (oligo number 228-48-04; SEQ ID NO:598). The reactions that included the ARRESTOR oligonucleotide had either 40 pmoles, 80 pmoles, 200 pmoles, 400 pmoles or 600 pmoles of ARRESTOR oligonucleotide (oligo number 218-95-01; SEQ ID NO:600), added at a 4-fold molar excess over the primary probe amount for each reaction, with this mix. Reactions were then incubated at 52°C for 30

minutes.* The reactions were stopped by the addition of 10 μ l of a solution of 95% formamide, 10 mM EDTA and 0.02% crystal violet. All samples were heated to 95°C for 1 minute, and 4 μ l of each sample were resolved by electrophoresis through 20% denaturing acrylamide gel (19:1 cross-linked) with 7 M urea, in a buffer containing 45 5 mM Tris-Borate (pH8.3) and 1.4 mM EDTA. The results were imaged using the Molecular Dynamics Fluoroimager 595, excitation 488, emission 530. The resulting images for the reactions either without or with an ARRESTOR oligonucleotide are shown in Figs. 35A and 35B, respectively. The products of cleavage of the secondary probe are seen as a band near the bottom of each panel.

- 10 In Fig. 35A, lane sets 1 and 2 show results with 10 pmoles of primary probe; 3 and 4 had 20 pmoles; 5 and 6 had 50 pmoles; 7 and 8 had 100 pmoles; and 9 and 10 had 150 pmoles. It can be seen by visual examination, that the increases in the amount of primary probe have the combined effect of slightly increasing the background in the no-target lanes (odd numbers) while reducing the specific signal in the presence of target 15 (even numbered lanes), and therefore the reducing the specificity of the reaction if viewed as the measure of "fold over background," demonstrating that the approach of increasing signal by increasing probe cannot be applied in these sequential reactions.

- In Fig. 35B, lane sets 1 and 2 show results with 10 pmoles of primary probe; while 3 and 4 had 20 pmoles; 5 and 6 had 50 pmoles; 7 and 8 had 100 pmoles; and 9 and 20 10 had 150 pmoles. In addition, each reaction included 4-fold molar excess of the ARRESTOR oligonucleotide added before the secondary cleavage reaction. It can be seen by visual examination that the background in the no-target lanes (odd numbers) is lower in all cases, while the specific signal in the presence of target (even numbered lanes) increases with increased amounts of primary probe, leading to a greater "fold over 25 background" sensitivity at this target level.

To quantitatively compare these effects, the fluorescence signal from the products of both non-specific and specific cleavage were measured. The results are depicted graphically in Fig. 35C, graphed as a measure of the percentage of the secondary probe cleaved during the reaction, compared to the amount of primary probe used.

- 30 Examination of the plots from the no-target reactions confirms that the background in the absence of the ARRESTOR oligonucleotide is, in general, roughly two-fold higher, and

that both increase slightly with the increasing probe amounts. The specific signals however, diverge between the two sets of reaction more dramatically. While the signal in the no-ARRESTOR oligonucleotide reactions decreases steadily as primary probe was increased, the signal in the ARRESTOR oligonucleotide reactions continued to increase.

- 5 At the highest primary probe concentrations tested, the no-ARRESTOR oligonucleotide reactions had specific signal that was only 1.7 fold over background, while the ARRESTOR oligonucleotide reactions detected the 100 zmoles (60,000 copies) of target with a signal 6.5 fold over background, thus demonstrating the improvement in the sequential invasive cleavage reaction when an ARRESTOR oligonucleotide is included.

10

EXAMPLE 16

Modified Backbones Improve Performance of ARRESTOR Oligonucleotides All Natural "ARRESTOR" Oligo With No 3'-Amine

- The reactions described in the previous two Examples used ARRESTOR oligonucleotides that were constructed using 2' O-methyl ribose backbone, and that included a positively charged amine group on the 3' terminal nucleotide. The modifications were made specifically to reduce enzyme interaction with the primary probe/ARRESTOR oligonucleotide complex. During the development of the present invention, it was determined that the 2' O-methyl modified oligonucleotides are somewhat resistant to cleavage by the 5' nucleases, just as they are slowly degraded by nucleases when used in antisense applications (See e.g., Kawasaki *et al.*, J. Med. Chem., 36:831 [1993]).

- 20 The presence of an amino group on the 3' end of an oligonucleotide reduces its ability to direct invasive cleavage. To reduce the possibility that the ARRESTOR oligonucleotide would form a cleavage structure in this way, an amino group was included in the design of the experiments described in this and other Examples.

- 25 Initial designs of the ARRESTOR oligonucleotides (sometimes referred to as "blockers") did not include these modifications, and these molecules were found to provide no benefit in reducing background cleavage in the sequential invasive cleavage assay and, in fact, sometimes contributed to background by inducing cleavage at an unanticipated site, presumably by providing some element to an alternative cleavage

structure. The effects of natural and modified ARRESTOR oligonucleotides on the background noise in these reactions are examined in this Example.

The efficacy of an "all-natural ARRESTOR oligonucleotide (*i.e.*, an ARRESTOR oligonucleotide that did not contain any base analogs or modifications) was examined by

- 5 comparison to an identical reactions that lacked ARRESTOR oligonucleotide. All reactions were performed in duplicate, and were conducted as follows. Two master mixes were assembled, each containing 12.5 mM MOPS, pH 7.5, 500 fmoles primary INVADER oligonucleotide #218-55-05 (SEQ ID NO:596), 10 ng human genomic DNA (Novagen) and 30 ng AfuFEN1 enzyme for every 8 μ l of mix. Mix A contained no
10 added HBV genomic amplicon DNA, mix B contained 600,000 molecules of HBV genomic amplicon DNA, pAM6 #2. The mixes were distributed to the reaction tubes, in aliquots of 8 μ l/tube as follows: mix A to tubes 1, 2, 5 and 6; and mix B to tubes 3, 4, 7 and 8. The samples were incubated at 95°C for 4 minutes to denature the HBV genomic amplicon DNA. The reactions were then cooled to 67°C and 2 μ l of a mix containing 37.5
15 mM MgCl₂ and 10 pmoles 218-55-02B (SEQ ID NO:603) for every 2 μ l, was added to each sample. The samples were then incubated at 67°C for 30 minutes. Two secondary reaction master mixes were prepared, each containing 10 pmole of secondary probe
oligo #228-48-04N (SEQ ID NO:604) and 2.5 pmole of secondary target oligonucleotide
#218-95-04 (SEQ ID NO:602) for every 3 μ l of mix. Mix 2A contained no additional
20 oligonucleotide, while mix 2B contained 50 pmole of the natural "ARRESTOR"
oligonucleotide #241-62-02 (SEQ ID NO:605). After the initial 30 minute incubation at
67°C, the temperature was adjusted to 52°C, and 3 μ l of a secondary reaction mix was
added to each sample, as follows: Mix 2A was added to samples #1-4; and Mix 2B was
added to samples #5-8. The samples were then incubated for 30 minutes at 52°C. The
25 reactions were then stopped by the addition of 10 μ l of a solution of 95% formamide, 10
mM EDTA and 0.02% crystal violet.

All of the samples were heated to 95°C for 2 minutes, and 4 μ l of each sample were resolved by electrophoresis through a 20% denaturing acrylamide gel (19:1 cross-linked) with 7 M urea, in a buffer containing 45 mM Tris-Borate (pH 8.3) and 1.4 mM

EDTA. The results were imaged using the Molecular Dynamics Fluoroimager 595, excitation 488, emission 530. The resulting image is shown in Fig. 36A.

To compare the effects of the various modifications made to the ARRESTOR oligonucleotides, reactions were performed using ARRESTOR oligonucleotides having 5 all natural bases, but including a 3' terminal amine; ARRESTOR oligonucleotides having a 3' portion composed of 2' O-methyl nucleotides, plus the 3' terminal amine; and ARRESTOR oligonucleotides composed entirely of 2' O-methyl nucleotides, plus the 3' terminal amine. These were compared to reactions performed without an ARRESTOR oligonucleotide. The reactions were conducted as follows. Two master mixes were 10 assembled, all mixes contained 14.3 mM MOPS, pH 7.5, 500 fmoles primary INVADER oligo #218-55-05 (SEQ ID NO:596) and 10 ng human genomic DNA (Novagen) for every 7 µl of mix. Mix A contained no added HBV genomic amplicon DNA, mix B contained 600,000 molecules of HBV genomic amplicon DNA, pAM6 #2. The mixes were distributed to the reaction tubes, at 7 µl/tube: mix A to tubes 1, 2, 5, 6, 9, 10, 13 and 15 14; and mix B to tubes 3, 4, 7, 8, 11, 12, 15 and 16. The samples were warmed to 95°C for 4 minutes to denature the HBV DNA. The reactions were then cooled to 67°C and 3 µl of a mix containing 25 mM MgCl₂, 25 pmoles 218-55-02B (SEQ ID NO:603) and 30 ng AfuFEN1 enzyme per 3 µl, were added to each sample. The samples were then incubated at 67°C for 30 minutes. Four secondary reaction master mixes were prepared; 20 all mixes contained 10 pmoles of secondary probe oligonucleotide #228-48-04B (SEQ ID NO:606) and 2.5 pmole of secondary target oligonucleotide #218-95-04 (SEQ ID NO:602) for every 3 µl of mix. Mix 2A contained no additional oligonucleotide, while mix 2B contained 100 pmoles of the natural+amine ARRESTOR oligonucleotide # 241-62-01 (SEQ ID NO:607), mix 2C contained 100 pmoles of partially O-methyl+amine 25 oligonucleotide # 241-62-03 (SEQ ID NO:608) and mix 2D contained 100 pmoles of all O-methyl+amine oligonucleotide # 241-64-01 (SEQ ID NO:609). After the initial 30 minute incubation at 67°C, the temperature was adjusted to 52°C and 3 µl of a secondary reaction mix was added to each sample, as follows: mix 2A was added to samples #1-4; mix 2B was added to samples #5-8; mix 2C was added to samples #9-12; and mix 2D 30 was added to samples #13-16. The samples were incubated for 30 minutes at 52°C, then

stopped by the addition of 10 μ l of a solution of 95% formamide, 10 mM NaEDTA, and 0.2% crystal violet.

All samples were heated to 95°C for 2 minutes, and 4 μ l of each sample were resolved by electrophoresis through a 20% denaturing acrylamide gel (19:1 cross-linked) 5 with 7 M urea, in a buffer containing 45 mM Tris-Borate (pH8.3) and 1.4 mM EDTA. The results were imaged using the Molecular Dynamics Fluoroimager 595, excitation 488, emission 530. The resulting image is shown in Fig. 36B.

In Fig. 36A, the left-hand panel shows the reactions that lacked an ARRESTOR oligonucleotide, while the right hand panel shows the data from reactions that included 10 the all natural ARRESTOR oligonucleotide. The first two lanes of each panel are from no-target controls, the second set of lanes contained target. The products of cleavage are visible in the bottom one/fourth of each panel. The position at which the specific reaction products should run is indicated by arrows on left and right.

It can be seen by examination of these data, that the reactions run in the absence 15 of ARRESTOR oligonucleotide show reproducible quality between the replicates, and show significant cleavage only when target is present. In contrast, the addition of another unmodified oligonucleotide into the reactions causes great variation between the replicate lanes (*e.g.*, lanes 5 and 6 were provided with the same reactants, but produced markedly different results). The introduction of the all-natural ARRESTOR oligonucleotide 20 produced, rather than reduced, background in these no-target lanes, and increased cleavage at other sites (*i.e.*, the bands other than those indicated by the arrows flanking the panels). For these reasons the modifications that are described above, the effects of which are shown on Fig. 36B, were incorporated.

The first 4 lanes of Fig. 36B show the products of duplicate reactions without an 25 ARRESTOR oligonucleotide, plus or minus the HBV target (lanes 1, 2, and lanes 3, 4, respectively); The next 4 lanes, 5, 6 and 7, 8 used a natural ARRESTOR oligonucleotide having a 3' terminal amine; lanes 9, 10 and 11, 12 used the ARRESTOR oligonucleotide with a 3' portion composed of 2' O-methyl nucleotides, and having a 3' terminal amine; lanes 13, 14 and 15, 16 used the ARRESTOR oligonucleotide composed entirely of 2' O- 30 methyl nucleotides and having a 3' terminal amine. The products of cleavage of the secondary probe are visible in the lower one third of each panel.

Visual inspection of these data shows that the addition of the 3' terminal amine to the natural ARRESTOR oligonucleotide suppresses the aberrant cleavage seen in Fig. 36A, but this ARRESTOR oligonucleotide does not improve the performance of the reaction, as compared to the no-ARRESTOR oligonucleotide controls. In contrast, the 5 use of the 2' O-methyl nucleotides in the body of the ARRESTOR oligonucleotide does reduce background, whether partially or completely substituted. To quantify the relative effects of these modifications, the fluorescence from each of the co-migrating product bands was measured, the signals from the duplicate lanes were averaged and the "fold over background" was calculated for each reaction containing target nucleic acid.

10 When ARRESTOR oligonucleotide was omitted, the target-specific signal (lanes 3, 4) was 27-fold over the no target background; the natural ARRESTOR oligonucleotide +amine gave a signal of 17-fold over background; the partial 2' O-methyl+ amine gave a signal of 47-fold over background; and the completely 2' O-methyl+ amine gave a signal of 33 fold over background.

15 These Figures show that both modifications can have a beneficial effect on the specificity of the multiple, sequential invasive cleavage assay. They also show that the use of the 2' O-methyl substituted backbone, either partial or entire, markedly improves the specificity of these reactions. It is intended that, in various embodiments of the present invention, any number of modifications that make either the ARRESTOR 20 oligonucleotide or the complex it forms with the primary target resistant to nucleases will provide similar enhancement.

EXAMPLE 17

Effect of ARRESTOR Oligonucleotide Length on Signal Enhancement in Multiple Sequential Invasive Cleavage Assays

25 As noted in the Description of the Invention, the optimal length for an ARRESTOR oligonucleotide depends upon the design of the other nucleic acid elements of the INVADER reaction, particularly on the design of the primary probe. In this Example, the effects of varying the length of the ARRESTOR oligonucleotide were explored in systems using two different secondary probes. A schematic diagram showing 30 these ARRESTOR oligonucleotides aligned as they would hybridize to the primary probe

oligonucleotide is provided in Fig. 37C. In this Figure, the region of the primary probe that recognizes the target nucleic acid is shown underlined; the non-underlined portion, plus the first underlined base is the portion that is released by the first cleavage, and goes on to participate in the second or subsequent cleavage structure.

- 5 All reactions were performed in duplicate. The INVADER reactions were done in a final volume of 10 μ l final volume containing 10 mM MOPS, pH 7.5, mM MgCl₂, 500 fmoles of primary INVADER 241-95-01, (SEQ ID NO:610), 25 pmoles of primary probe 241-95-02 (SEQ ID NO:611), 30 ng of AfuFEN1 enzyme, and 10 ng of human genomic DNA, and if included, 1 amoles of HBV amplicon pAM 6 #2. MOPS, target 10 DNA, and INVADER oligonucleotides were combined to a final volume of 7 μ l.
- Samples were heat denatured at 95°C for 5 minutes, then cooled to 67°C. During the 5 minute denaturation, MgCl₂, probe and enzyme were combined. The primary INVADER reactions were initiated by the addition of 3 μ l of MgCl₂, probe and enzyme mix, to the final concentrations indicated above. Reactions were incubated for 30 minutes at 67°C.
- 15 The reaction were then cooled to 52°C, and each primary INVADER reaction received the following secondary reaction components in a total volume of 3 μ l: 2.5 pmoles secondary target 241-95-07 (SEQ ID NO:612), 10 pmoles of either secondary probe 228-48-04 (SEQ ID NO:598), or 228-48-04N (SEQ ID NO:604) and 100 pmoles of an ARRESTOR oligonucleotide, either 241-95-03 (SEQ ID NO:613), 241-95-04 (SEQ ID 20 NO:614), 241-95-05 (SEQ ID NO:615) or 241-95-06 (SEQ ID NO:616). The ARRESTOR oligonucleotides were omitted from some reactions as controls for ARRESTOR oligonucleotide effects.

- The reactions were incubated at 52°C for 34 minutes, and were then stopped by the addition of 10 μ l of 95% formamide, 10 mM EDTA, and 0.02% crystal violet. All 25 samples were heated to 95°C for 1 minute, and 4 μ l of each sample were resolved by electrophoresis through 20% denaturing acrylamide gel (19:1 cross-linked) with 7 M urea, in a buffer containing 45 mM Tris-Borate (pH8.3) and 1.4 mM EDTA. The results were imaged using the Molecular Dynamics Fluorimager 595, excitation 488, emission 530. The resulting images for the reactions with the shorter and longer secondary probes 30 are shown in Figs. 37A and 37B, respectively.

In each Figure, the products of cleavage are visible as bands in the bottom half of each lane. The first 4 lanes of each Figure show the products of duplicate reactions without an ARRESTOR oligonucleotide, plus or minus the HBV target (lanes sets 1 and 2 respectively); in the next 4 lanes, sets 3 and 4 used the shortest ARRESTOR 241-95-03 (SEQ ID NO:613); lanes 5 and 6 used 241-95-04 (SEQ ID NO:614); lanes 7 and 8 used 241-95-05 (SEQ ID NO:615); and lanes 9 and 10 used 241-95-06 (SEQ ID NO:616).

The principal background of concern is the band that appears in the "no target" control lanes (odd numbers; this band co-migrates with the target-specific signal near the bottom of each gel panel). Visual inspection shows that the shortest ARRESTOR oligonucleotide was the least effective at suppressing this background, and that the efficacy was increased when the ARRESTOR oligonucleotide extended further into the portion that participates in the subsequent cleavage reaction. Even with this difference in effect, it can be seen from these data that there is much latitude in the design of the ARRESTOR oligonucleotide. The choice of lengths will be influenced by the temperature at which the reaction making use of the ARRESTOR oligonucleotide is performed, the lengths of the duplexes formed between the primary probe and the target, the primary probe and the secondary target, and the relative concentrations of the different nucleic acid species in the reactions.

20

EXAMPLE 18

Effect of ARRESTOR Oligonucleotide Concentration on Signal Enhancement in Multiple Sequential Invasive Cleavage Assays

In examining the effects of including ARRESTOR oligonucleotides in these cleavage reactions, it was of interest to determine if the concentration of the ARRESTOR oligonucleotide in excess of the primary probe concentration would have an effect on yields of either non-specific or specific signal, and if the length of the ARRESTOR oligonucleotide would be a factor. These two variables were investigated in the following Example.

All reactions were performed in duplicate. The primary INVADER reactions were done in a final volume of 10 μ l and contained 10 mM MOPS, pH 7.5; 7.5 mM MgCl₂, 500 fmoles of primary INVADER 241-95-01 (SEQ ID NO:610), 25 pmoles of

primary probe 241-95-02 (SEQ ID NO:611), 30 ng of AfuFEN1 enzyme, and 10 ng of human genomic DNA. Where included, the target DNA was 1 amole of HBV amplicon pAM 6 #2, as described above. MOPS, target and INVADER were combined to a final volume of 7 μ l. The samples were heat denatured at 95°C for 5 minutes, then cooled to 5 67°C. During the 5 minute denaturation, MgCl₂, probe and enzyme were combined. The primary INVADER reactions were initiated by the addition of 3 μ l of MgCl₂, probe and enzyme mix. The reactions were incubated for 30 minutes at 67°C. The reactions were then cooled to 52°C and each primary INVADER reaction received the following secondary reaction components: 2.5 pmoles secondary target 241-95-07 (SEQ ID 10 NO:612), 10 pmoles secondary probe 228-48-04 (SEQ ID NO:598); and, if included, 50, 100 or 200 pmoles of either ARRESTOR oligonucleotide 241-95-03 (SEQ ID NO:613) or 241-95-05 (SEQ ID NO:615), in a total volume of 3 μ l. Reactions were then 15 incubated at 52°C for 35 minutes. Reactions were stopped by the addition of 10 μ l of 95% formamide, 10 mM EDTA, and 0.02% crystal violet. All of the samples were heated to 95°C for 1 minute, and 4 μ l of each sample were resolved by electrophoresis 20 through 20% denaturing acrylamide gel (19:1 cross-linked) with 7 M urea, in a buffer containing 45 mM Tris-Borate (pH8.3), and 1.4 mM EDTA. The results were imaged using the Molecular Dynamics Fluorimager 595, excitation 488, emission 530. The resulting images are shown as a composite image in Fig. 38.

25 Each of the duplicate reactions were loaded on the gel in adjacent lanes and are labeled with a single lane number. All odd numbered lanes were no-target controls. Lanes 1 and 2 had no ARRESTOR oligonucleotide added; lanes 3-8 show results from reactions containing the shorter ARRESTOR oligonucleotide, 241-95-03 (SEQ ID NO:613); lanes 9-14 show results from reactions containing the longer ARRESTOR oligonucleotide, 241-95-05 (SEQ ID NO:615). The products of cleavage from the 20 secondary reaction are visible in the bottom one third of each panel. Visual inspection of these data (*i.e.*, comparison of the specific products to the background bands) shows that both ARRESTOR oligonucleotides have some beneficial effect at all concentration.

To quantify the relative effects of ARRESTOR oligonucleotide length and 25 concentration, the fluorescence from each of the co-migrating product bands was measured, the signals from the duplicate lanes were averaged and the "fold over

- background" (signal+target/signal-target) was calculated for each reaction containing target nucleic acid. The reaction lacking an ARRESTOR oligonucleotide yielded a signal approximately 27-fold over background. Inclusion of the shorter ARRESTOR oligonucleotide at 50, 100 or 200 pmoles produced products at 42, 51 and 60-fold over background, respectively. This shows that while the short ARRESTOR at the lowest concentration seems to be less effective than the longer ARRESTOR oligonucleotides (See, e.g., previous Example) this can be compensated for by increasing the concentration of ARRESTOR oligonucleotide, and thereby the ARRESTOR oligonucleotide:primary probe ratio.
- 10 In contrast, inclusion of the longer ARRESTOR oligonucleotide at 50, 100 or 200 pmoles produced products at 60, 32 and 24 fold over background, respectively. At the lowest concentration, the efficacy of this longer ARRESTOR oligonucleotide relative to the shorter ARRESTOR oligonucleotide is consistent with the previous Example. Increasing the concentration, however, decreased the yield of specific product, suggesting
- 15 a competition effect with some element of the secondary cleavage reaction.

These data show that the ARRESTOR oligonucleotides can be used to advantage in a number of specific reaction designs. The choice of concentration will be influenced by the temperature at which the reaction making use of the ARRESTOR oligonucleotide is performed, the lengths of the duplexes formed between the primary probe and the target, the primary probe and the secondary target, and between the primary probe and the ARRESTOR oligonucleotide.

Selection of oligonucleotides for target nucleic acids other than the HBV shown here, (e.g., oligonucleotide composition and length), and the optimization of cleavage reaction conditions in accord with the models provided here follow routine methods and common practice well known to those skilled in the methods of molecular biology.

Example 10 demonstrated that some enzymes require an overlap between an upstream INVADER oligonucleotide and a downstream probe oligonucleotide to create a cleavage structure (Figure 27). It has also been determined that the 3' terminal nucleotide of the INVADER oligonucleotide need not be complementary to the target strand, even if it is the only overlapping base in the INVADER oligonucleotide (e.g., as with the HCMV probes shown in Figure 30). The requirement for an overlap can serve as a convenient

basis for detecting single base polymorphisms (SNPs) or mutations in a nucleic acid sample.

For detection of single base variations, at least two oligonucleotides (e.g., a probe and an INVADER oligonucleotide) hybridize in tandem to the target nucleic acid

- 5 to form the overlapping structure recognized by the CLEAVASE enzyme to be used in the reaction. An unpaired "flap" is included on the 5' end of the probe. The enzyme recognizes the overlap and cleaves off the unpaired flap, releasing it as a target-specific product. Enzymes that have a strong preference for an overlapping structure, i.e., that cleave the overlapping structure at a much greater rate than they cleave a non-
10 overlapping structure include the FEN-1 enzymes from *Archaeoglobus fulgidus* and *Pyrococcus furiosus* and such enzymes are particularly preferred in the detection of mutations and SNPs. .

EXAMPLE 19

15 Kits for performing the mRNA INVADER Assay

In some embodiments, the present invention provides kits comprising one or more of the components necessary for practicing the present invention. For example, the present invention provides kits for storing or delivering the enzymes of the present invention and/or the reaction components necessary to practice a cleavage assay (e.g., the
20 INVADER assay). By way of example, and not intending to limit the kits of the present invention to any particular configuration or combination of components, the following section describes one embodiment of a kit for practicing the present invention:

In some embodiments, the kits of the present invention provide the following reagents:

25

CLEAVASE enzyme (e.g., TthAKK)	Primary Oligos
RNA Primary Buffer 1	Secondary Oligos
RNA Secondary Buffer 1	RNA Standard [100amol/ μ l]
tRNA Carrier [20 ng/ μ l]	10X Cell Lysis Buffer 1
T ₁₀ E _{0.1} Buffer [10mM Tris•HCl, pH 8, 0.1mM EDTA]	

Examples of Primary Oligonucleotides and Secondary Oligonucleotides suitable for use with the methods of the present invention are provided in Figure 41. While the oligonucleotides shown therein may find use in a number of the methods, and variations of the methods, of the present invention, these INVADER assay oligonucleotide sets find

- 5 particular use with kits of the present invention. The oligonucleotide sets shown in Figure 41 may be used as individual sets to detect individual target RNAs, or may be combined in biplex or multiplex reactions for the detection of two or more analytes or controls in a single reaction. It is contemplated that the designs of these probe sets (e.g., the oligonucleotides and/or their sequences) may be adapted for use in DNA detection assays, using the guidelines for reaction design and optimization provided herein.
- 10 Additional oligonucleotides that find use in detection assays and kits of the present invention are provided in Figure 47.

In some embodiments, a kit of the present invention provides a list of additional components (e.g., reagents, supplies, and/or equipment) to be supplied by a user in order 15 to perform the methods of the invention. For example, and without intending to limit such additional components lists to any particular components, one embodiment of such a list comprises the following:

- 20
- RNase-free (e.g., DEPC-treated) H₂O
 - Clear CHILLOUT-14 liquid wax (MJ Research) or RNase-free, optical grade mineral oil (Sigma, Cat. No. M-5904)
 - Phosphate-buffered saline (no MgCl₂, no CaCl₂)
 - 96-well polypropylene microplate (MJ Research, Cat. No. MSP-9601)
 - 0.2-ml thin-wall tubes
 - Thermaseal well tape (e.g., GeneMate, Cat. No. T-2417-5)
 - 25 ▪ Multichannel pipets (0.5–10μl, 2.5–20μl, 20–200μl)
 - Thermal cycler or other heat source (e.g., lab oven or heating block).
 - Fluorescence microplate reader (a preferred plate reader is top-reading, equipped with light filters have the following characteristics:

Excitation (Wavelength/Bandwidth)	Emission (Wavelength/Bandwidth)
485 nm/20 nm	530 nm/25 nm
560 nm/20 nm	620 nm/40 nm

- In some embodiments, a kit of the present invention provides a list of optional components (e.g., reagents, supplies, and/or equipment) to be supplied by a user to facilitate performance of the methods of the invention. For example, and without
- 5 intending to limit such optional components lists to any particular components, one embodiment of such a list comprises the following:
- tRNA Solution, 20ng/ μ l (Sigma, R-5636)
 - 1X Stop Solution (10mM Tris-HCl, pH 8, 10mM EDTA)
 - Black opaque, 96-well microplate (e.g., COSTAR, Cat. No. 3915)
 - 10 ▪ Electronic repeat pipet (250 μ l)

In some embodiments of a kit, detailed protocols are provided. In preferred embodiments, protocols for the assembly of INVADER assay reactions (e.g., formulations and preferred procedures for making reaction mixtures) are provided. In

15 particularly preferred embodiments, protocols for assembly of reaction mixtures include computational or graphical aids to reduce risk of error in the performance of the methods of the present invention (e.g., tables to facilitate calculation of volumes of reagents needed for multiple reactions, and plate-layout guides to assist in configuring multi-well assay plates to contain numerous assay reactions). By way of example, and without

20 intending to limit such protocols to any particular content or format, kits of the present invention may comprise the following protocol:

- I. DETAILED mRNA INVADER ASSAY PROTOCOL**
1. Plan the microplate layout for each experimental run. An example microplate layout
- 25 for 40 samples, 6 standards, and a No Target Control is shown in Fig. 40. Inclusion of a No Target Control (tRNA Carrier or 1X Cell Lysis Buffer 1) and quantitation

standards are required for absolute quantitation.

2. Prepare the Primary Reaction Mix for either the single or bplex assay format. To calculate the volumes of reaction components needed for the assay (X Volume), multiply the number of reactions (for both samples and controls) by 1.25 [X Volume (μ l) = # reactions x 1.25]. Vortex the Primary Reaction Mix briefly after the last reagent addition to mix thoroughly. Aliquot 5 μ l of the Primary Reaction Mix per microplate well (an electronic repeat pipet is recommended for this step).

Primary Reaction Mix

10 Single Assay Format

Reaction Components	1X Volume	X Volume
RNA Primary Buffer 1	4.0 μ l	
Primary Oligos	0.25 μ l	
T ₁₀ e _{0.1} Buffer	0.25 μ l	
CLEAVASE enz. enzyme	0.5 μ l	
Total Mix Volume (1X)	5.0 μ l	

Bplex Assay Format

Reaction Components	1X Volume	X Volume
RNA Primary Buffer 1	4.0 μ l	
Primary Oligos	0.25 μ l	
Housekeeping Primary Oligos	0.25 μ l	
CLEAVASE enzyme	0.5 μ l	
Total Mix Volume (1X)	5.0 μ l	

- 15 3. Add 5 μ l of each No Target Control, standard, or sample (total RNA or cell lysate) to the appropriate well and mix by pipetting up and down 1–2 times. Overlay each reaction with 10 μ l of clear CHILLOUT or mineral oil. Seal microplate with Thermaseal well tape.
4. Incubate reactions for 90 minutes at 60°C in a thermal cycler or oven.
- 20 5. While the primary reaction is incubating, prepare the Secondary FRET Reaction Mix for the single or bplex format. Calculate the component volumes required (X Volume) by multiplying the number of reactions (for both samples and controls) by

1.25 [X Volume (μ l)] = # reactions x 1.25 (μ l). Aliquot the Secondary FRET Reaction Mix into multiple 0.2-ml thin-wall tubes or an 8-well strip (70 μ l/tube is sufficient for a row of 12 reactions).

5 **Secondary FRET Reaction Mix**

Single Assay Format

Reaction Components	1X Volume	X Volume
RNA Secondary Buffer 1	2.0 μ l	
Secondary Oligos	1.5 μ l	
T ₁₀ e _{0.1} Buffer	1.5 μ l	
Total Mix Volume (1X)	5.0μl	

Biplex Assay Format

Reaction Components	1X Volume	X Volume
RNA Secondary Buffer 1	2.0 μ l	
Secondary Oligos	1.5 μ l	
Housekeeping Secondary	1.5 μ l	
Total Mix Volume (1X)	5.0μl	

10

6. After the primary reaction incubation is completed, remove the microplate seal, and add 5 μ l Secondary FRET Reaction Mix per well using a multichannel pipet. Mix by pipetting up and down 1–2 times. Reseal the microplate with the well tape and incubate the microplate at 60°C for 60 or 90 minutes, as indicated in each Product Information Sheet. The secondary reaction incubation time can be varied. See sections 2 of the **PROCEDURAL NOTES FOR OPERATION OF THE mRNA INVADER ASSAY** for details.

7. Reactions can be read using one of two procedures: Direct Read or Stop and Transfer.

NOTE: Remove the microplate seal before reading the microplate.

Direct Read Procedure

- This procedure enables collection of multiple data sets to extend the assay's dynamic range. During the secondary INVADER reaction, read the microplate directly in a top-reading fluorescence microplate reader.
- Recommended settings for a PerSeptive Biosystem Cytofluor 4000 instrument are as follows:

Specific Gene Signal:		Housekeeping Gene Signal:	
Excitation:	485/20nm	Excitation:	560/20nm
Emission:	530/25nm	Emission:	620/40nm
Reads/Well:	10	Reads/Well:	10
Gain:	40	Gain:	45
Temperature:	25°C	Temperature:	25°C

NOTE: Because the optimal gain setting can vary between instruments, adjust the gain as needed to give the best signal/background ratio (sample raw signal divided by the No Target Control signal) or No Target Control sample readings of ~100 RFUs. Fluorescence microplate readers that use a xenon lamp source generally produce higher RFUs. For directly reading the microplates, the probe height of, and how the plate is positioned in, the fluorescence microplate reader may need to be adjusted according to the manufacturer's recommendations.

Stop and Transfer Procedure

1. Prepare 1X Stop Solution (10mM Tris-HCl, pH 8, 10mM EDTA) with RNase-free H₂O. Add 100µl per well with a multichannel pipet.
2. Transfer 100µl of the diluted reactions to a black microplate (*e.g.*, COSTAR (Corning), Cat. No. 3915).
3. Read the microplate using the same parameters as the Direct Read Procedure, but adjust the gain to give No Target Control sample readings of ~100 RFUs (see NOTE above).

In some embodiments, supplementary documentation, such as protocols for ancillary procedures, *e.g.*, for the preparation of additional reagents, or for preparation of

samples for use in the methods of the present invention, are provided. In preferred embodiments, supplementary documentation includes guidelines and lists of precautions provided to facilitate successful use of the methods and kits by unskilled or inexperienced users. In particularly preferred embodiments, supplementary documentation includes a troubleshooting guide, e.g., a guide describing possible problems that may be encountered by users, and providing suggested solutions or corrections to intended to aid the user in resolving or avoiding such problems.

For example, and without intending to limit such supplementary documentation to any particular content, kits of the present invention may comprise any of the following procedures and guidelines:

II. AVOIDANCE OF RNase CONTAMINATION

To avoid RNase contamination during sample preparation and testing, in one embodiment, the user is cautioned to observe the following precautions:

- 15 • Wear disposable gloves at all times to avoid contact with samples and reagents.
- Use certified RNase-free disposables, including thin-wall polypropylene tubes and aerosol-barrier pipet tips, for preparing samples and assay reagents, to avoid cross-contamination.
- Use RNase-free (DEPC-treated) H₂O for diluting samples and/or reagents.
- 20 • Keep RNA samples and controls on ice during assay setup.

III. SAMPLE AND CONTROL PREPARATION

NOTE: Dilute both standards and samples to concentrations that correspond to a 5-μl addition per reaction.

25 **Example 1:** The concentration of a 5-attomole standard is 1amol/μl. 1amol = 10¹⁸ mole = 602,000 molecules.

Example 2: The concentration of a 100-ng sample should be 20ng/μl.

A. Control Preparation**No Target Control:**

Total RNA Format: tRNA Carrier (20ng/ μ l)

Cell Lysate Format: 1X Cell Lysis Buffer 1 (dilute 10X Cell Lysis Buffer 1 to 1X
5 with RNase-free H₂O)

Positive Control: RNA Standard (Std) (100amol/ μ l *in vitro* transcript)

1. Prepare RNA standards by diluting the positive controls with tRNA Carrier (when running total RNA samples) or with 1X Cell Lysis Buffer 1 [10X Cell Lysis Buffer 1 diluted with RNase-free H₂O] (when running cell lysate samples). The Product Information Sheet included in each kit indicates the recommended standard test levels and preparation methods.
2. Using a fresh set of standards for each run is recommended. Store the standards on ice during reaction setup.

15

B. Total RNA Sample Preparation

1. Prepare total RNA from cells or tissue according to manufacturer's instructions for the selected preparation method. Recommended methods include TRIZOL (Life Technologies, Rockville, MD), RNEASY (Qiagen, Valencia, CA), and RNA WIZ (Ambion, Austin, TX).
2. Dilute total RNA samples with RNase-free H₂O to the appropriate concentration.

C. Cell Lysate Sample Preparation – 96-well microplate format

NOTE: This cell lysate detection format is used for adherent cells cultured in 96-well tissue culture microplates. Cells are typically seeded at 10,000–40,000 cells per well. Different seeding densities may be required depending on cell type and/or mRNA expression levels. See Procedural Notes for more details. For cells exhibiting high expression, the following methods can be used to attenuate the signal from the cell lysates:

- plate fewer cells per well;
 - dilute the cell lysates with 1X Cell Lysis Buffer 1 before addition to the reaction (e.g., 2.5µl lysate + 2.5µl 1X Cell Lysis Buffer 1);
 - read the reaction microplate 15–30 minutes after addition of the Secondary FRET Reaction Mix instead of the recommended 60–90 minutes;
- 5
1. Dilute 10X Cell Lysis Buffer 1 to a 1X concentration with RNase-free H₂O.
 2. Using a multichannel pipet, carefully remove the culture medium from the wells of 10 adherent cells without disturbing the cell monolayer.
 3. Wash the cells once with 200µl PBS (no MgCl₂, no CaCl₂) and carefully remove the residual PBS with the multichannel pipet.
 4. Add 40µl 1X Cell Lysis Buffer 1 per well. Lyse cells at room temperature for 3–5 minutes.
 15. 5. Using a multichannel pipet, carefully transfer 25µl of each lysate sample into a 96-well microplate. Avoid transferring cellular material from the bottom of the well.
 6. Overlay each lysate sample with 10µl clear CHILLOUT or mineral oil (overlaying is not necessary if using a heated-lid thermal cycler).
 7. Seal microplate with Thermaseal well tape. Immediately heat lysates at 75–80°C for 20 15 minutes in a thermal cycler or oven to inactivate cellular nucleases.
 8. During the heating step, proceed with the reaction setup. See DETAILED mRNA INVADER ASSAY PROTOCOL (above) for instructions.
 9. After the heat inactivation step, add the lysate samples immediately to the reaction microplate. Alternatively, the lysate samples can be quickly transferred to a –70°C 25 freezer for later testing (long-term stability has not been established and may differ for each cell type).

IV. PROCEDURAL NOTES FOR OPERATION OF THE mRNA INVADER ASSAY

1. RNA sample types and optimization of RNA sample amount.

The assay is optimized for performance with total RNA samples prepared from either tissue or cells. Several total RNA preparation methods/kits have been validated for performance in the mRNA INVADER assay:

- TRIZOL (Life Technologies, Rockville, MD)
- RNeasy (Qiagen, Valencia, CA)
- RNA WIZ (Ambion, Austin, TX)

It is important to use a method or kit that minimizes the level of genomic DNA, which can inhibit signal generation. Performance of a preliminary experiment is recommended to determine the amount of total RNA sample (typically 1–200ng, depending on the gene's expression level) that provides the best limit of detection and dynamic range.

The assay has also been validated with lysate samples from a number of cell types. Recommended cell densities in a 96-well tissue culture microplate are 10,000–40,000 cells per well depending on cell type and expression level of the gene of interest. Performance of a preliminary experiment is recommended for any given cell line and/or gene being monitored. Such an experiment should include different cell density levels and/or dilution of the lysate samples with 1X Cell Lysis Buffer 1 (e.g. a 1µl test level is prepared by mixing 1µl lysate sample + 4µl 1X Cell Lysis Buffer 1 for a 5µl sample addition).

2. Dynamic range modulation: variable secondary reaction incubation times.

The length of the secondary reaction incubation time listed in the protocol is sufficient for most analytes. However, the linear detection range (Signal/Background < 15–25) can be adjusted by reading the reaction microplate at variable times after addition of the secondary FRET reagents. For example,

high expression samples can often be detected in 15–30 minutes. The Direct Read method (DETAILED mRNA INVADER ASSAY PROTOCOL, step 7) enables simple optimization of the secondary reaction time as the reaction microplate can be incubated further if an early time read does not provide enough signal from the samples being tested.

Monitoring the secondary reaction fluorescence signal with time can also extend the dynamic range of the assay. The Direct Read method at multiple time points can be applied using low-cost instrumentation. Alternatively, real-time fluorescence instrumentation can be used to achieve comparable dynamic ranges exhibited by other mRNA quantitation methods.

3. Dynamic range modulation: variable sample levels.

While the FRET detection method greatly simplifies the assay, the dynamic range is typically limited to 2–3 logs when using an endpoint read method. However, since mRNA INVADER assay signal is generated linearly with both target level and time, the easiest method for extending the dynamic range beyond 3 logs (as may be required, *e.g.*, for highly induced genes) is to adjust total RNA sample levels. Fold changes in gene expression (treated sample signal divided by untreated sample signal) can be reliably calculated using normalized sample signals. This is accomplished by testing sample levels that give signal within the linear detection range defined by the standard curve. For example, the fold induction for a highly induced sample can be calculated as follows:

25 $\text{Fold induction} = (\text{Net Signal for 1 ng treated sample} \times 100) / \text{Net Signal}$
for 100 ng untreated sample

V. TROUBLESHOOTING GUIDE

Problem	Possible Solution
No signal	<ul style="list-style-type: none"> Check that the fluorescence microplate reader has been set up correctly and that the appropriate excitation and emission filters are in place. Perform mRNA INVADER assay with the provided standard as a positive control. Potential RNase contamination of the samples and reagents. Discard suspect reagents. Use only reagents and oligonucleotides supplied in the kit. Do not mix reagents or oligonucleotides between kits.
High variation between replicates	<ul style="list-style-type: none"> Always work with master primary and secondary reaction mixes. Thoroughly mix all master mixes and samples. Pipet in a similar manner across all the controls and samples. Calibrate pipets frequently.
Lack of low target level detection	<ul style="list-style-type: none"> Calibrate thermal cycler or heat block. Minimize assay variability (see above), i.e. CVs are less than 5% for the sample replicates. This is particularly important for detecting low target levels.
Lack of discrimination between high signal samples	<ul style="list-style-type: none"> Decrease secondary reaction incubation time to achieve detection within the linear range of the assay. Use less total RNA per reaction. Attenuate cell lysate sample signal (see NOTE, Sample and Control Preparation, Part C).
Signal inhibition	<ul style="list-style-type: none"> Run samples on an agarose gel to check for presence of genomic DNA. Alter the RNA sample isolation method to minimize genomic DNA or presence of other inhibitors. The same isolation procedure should be used throughout an experiment. If using the cell lysate format, residual PBS can be inhibitory. Be sure to remove residual PBS from the tissue culture microplate. Do not use PBS that contains MgCl₂ or CaCl₂, which inhibits the assay.

APPENDIX A:

mRNA INVADER SINGLE ASSAY WORKSHEET

mRNA INVADER ASSAY PROCEDURE

- Prepare samples and controls.
- 5 ▪ Prepare Primary Reaction Mix. Vortex briefly and aliquot 5µl per well.
- Add 5µl sample or control per well and pipet up and down 1-2 times.
- Add 10µl CHILLOUT or mineral oil per well.
- Incubate primary reaction at 60°C for 90 minutes.
- Prepare Secondary FRET Reaction Mix, vortex briefly.
- 10 ▪ Using a multichannel pipet, aliquot 5µl per well and pipet up and down 1-2 times.
- Incubate secondary reaction at 60°C for 60 or 90 minutes.
- Read microplate in fluorescence microplate reader (FAM Dye: Ex. 485 nm/Em. 530 nm).

15 PRIMARY REACTION MIX

Reaction Components	1X Volume	X Volume (No. of reactions x 1.25)
RNA Primary Buffer 1	4.0µl	
Primary Oligos	0.25µl	
T ₁₀ c _{0.1} Buffer	0.25µl	
CLEAVASEenzyme	0.5µl	
Total Mix Volume (1X)	5.0µl	

SECONDARY FRET REACTION MIX

Reaction Components	1X Volume	X Volume (No. of reactions x 1.25)
RNA Secondary Buffer 1	2.0µl	
Secondary Oligos	1.5µl	
T ₁₀ c _{0.1} Buffer	1.5µl	
Total Mix Volume (1X)	5.0µl	

APPENDIX B:**mRNA INVADER BIPLEX ASSAY WORKSHEET****mRNA INVADER ASSAY PROCEDURE**

- 5 ▪ Prepare samples and controls.
- Prepare Primary Reaction Mix. Vortex briefly and aliquot 5 μ l per well.
- Add 5 μ l sample or control per well and pipet up and down 1–2 times.
- Add 10 μ l CHILLOUT or mineral oil per well.
- Incubate primary reaction at 60°C for 90 minutes.
- 10 ▪ Prepare Secondary FRET Reaction Mix, vortex briefly.
- Using a multichannel pipet, aliquot 5 μ l per well and pipet up and down 1–2 times.
- Incubate secondary reaction at 60°C for 60 or 90 minutes.
- Read microplate in fluorescence microplate reader (FAM Dye: Ex. 485 nm/Em. 530 nm and red dye: Ex. 560nm/Em. 620nm).

15

PRIMARY REACTION MIX

Reaction Components	1X Volume	<u> X Volume</u> <u>(# reactions x 1.25)</u>
RNA Primary Buffer 1	4.0 μ l	
Primary Oligos	0.25 μ l	
Housekeeping Primary Oligos	0.25 μ l	
CLEAVASE IX enzyme	0.5 μ l	
Total Mix Volume (1X)	5.0μl	

SECONDARY FRET REACTION MIX

Reaction Components	1X Volume	<u> X Volume</u> <u>(# reactions x 1.25)</u>
RNA Secondary Buffer 1	2.0 μ l	
Secondary Oligos	1.5 μ l	
Housekeeping Secondary Oligos	1.5 μ l	
Total Mix Volume (1X)	5.0μl	

20

TABLE 2

5

<u>Klenow</u>	<u>Kcat (s⁻¹)</u>	<u>Km(dNTP) (μM)</u>	<u>Kd (nM)</u>	<u>Relative DNA affinity</u>	<u>Reference</u>	<u>Taq Pol</u>
Wild-Type	2.4	2.8	8	1	2	Wild-Type
S610A	n. d.	-	n. d.	-	5	S515
R668A	0.006	6.5	140, 150	0.06, 0.05	1,2	R573*
N678A	n. d.	-	n. d.	-	5	N583
E710A	0.1	15	250	0.03	2	E615*
E710D	1.7	7.7	110	0.07	2	E615*
K758A	0.131	15.6	-	0.63	4	K663
K758R	2.0	2.1	-	1.125	4	K663
Y766S	0.8	6.4	13	0.4, 0.6	1,2	Y671
R841A	0.3	9.8	40, 53	0.2	1,2	R746*
N845A	1.0	23	8, 5	1.0, 1.7	1,2	N750*
N845Q	0.03	1.7	80, 55	0.1, 0.2	1,2	N750*
Q849A	0.02	3.8	100, 160	0.08, 0.05	1,2	Q754
Q849E	0.001	n. d.	90, 91	0.09	1,2	Q754
H881A	0.3	3.3	20, 28	0.4, 0.3	1,2	H784*
D882N	<0.0001	n. d.	30	0.6	2	D785
D882S	0.001	7.5	0.9	9	2	D785

References:

- JBC (1990) 265:14579-14591
- JBC (1992) 267:8417-8428
- Eur. J. Biochem (1993) 214:59-65
- JBC (1994) 269:13259-13265
- Nature (1996) 382:278-281

15 TABLE 3: Rational mutations in the polymerase region

A. DNA activity table

	<u>IdT</u>	<u>%Tth</u>	<u>%Taq4M</u>	<u>HP</u>	<u>X</u>
<u>Tth DN RX HT</u>	<u>31.91</u>	<u>100%</u>	<u>83%</u>	<u>3.81</u>	<u>101.9</u>
Tth DN RX HT H641A	23.61	74%	62%	5.32	221.24
Tth DN RX HT R748A	22.1	69%	58%	4.39	88.17
Tth DN RX HT H786A	34.31	108%	90%	7.75	185.35
Tth DN RX HT	32.1	101%	84%	5.7	332.8

H786A/G506K/ Q509K (AKK)					
Taq DN RX HT W417L/G418K/ E507Q/H784A (Taq 4M)	38.23	120%	100%	68.21	1100.18
Taq 4M G504K	36.04	113%	94%	31.76	417.40
Taq 4M H639A	42.95	135%	112%	91.46	2249.67
Taq 4M R587A	44.78	140%	117%	143.0	252.69
Taq DN RX HT W417L/G418K/ G499R/A502K/ I503L/K504N/ E07K/H784A (Taq8M)	43.95	138%	115%	122.53	346.56
TaqSS R677A	32.3	101%	84%	206.9	2450.0

B. RNA activity table

	IrT1	%Tth	%Taq4M
Tth DN RX HT	0.89	100%	34%
Tth DN RX HT H641A	1.18	133%	45%
Tth DN RX HT R748A	1.34	151%	51%
Tth DN RX HT H786A	1.31	147%	49%
Tth DN RX HT H786A/G506K/ Q509K (AKK)	1.59	179%	60%
Taq DN RX HT W417L/G418K/ E507Q/H784A (Taq 4M)	2.65	298%	100%
Taq 4M G504K	2.76	310%	114%
Taq 4M H639A	3.89	437%	147%
Taq 4M R587A	3.13	352%	118%
Taq DN RX HT W417L/G418K/ G499R/A502K/ I503L/K504N/ E07K/H784A (Taq8M)	4.00	450%	151%
TaqSS R677A	2.22	249%	84%

TABLE 4: Rational arch mutations**DNA activity table**

	IdT	%Tth	%Taq4M	HP	X
Taq 4M P88E/P90E	10.20	32%	27%	2.00	97.00
Taq 4M G80E	26.30	82%	69%	103.6	2900
Taq 4M L109F/A110T	36.45	114%	95%	19.71	749.69

5

RNA activity table

IrT1	IdT	%Tth	%Taq4M		
Taq 4M P88E/P90E	Taq 4M P88E/P90E		0.10	11%	4%
Taq 4M G80E	Taq 4M G80E		3.11	349%	117%
Taq 4M L109F/A110T	Taq 4M L109F/A110T		2.45	275%	92%

10

TABLE 5: Arch/thumb combinations**DNA activity table**

	IdT	%Tth	%Taq4M	HP	X
Taq W417L/ G418K/E507K/ H784A/L109F/ A110T/G499R/ A502K/I503L/ G504K/E507K/ T514S (Taq SS)	63.33	198%	166%	177.05	202.32
Taq P88E/P90E/ W417L/G418K/ G499R/A502K/ I503L/G504K/ E507K/T514S/ H784A	36.48	114%	95%	9.44	70.35

15

RNA activity table

	IdT1	%Tth	%Taq4M
Taq W417L/ G418K/E507K/ H784A/L109F/ A110T/G499R/ A502K/I503L/ G504K/E507K/ T514S (Taq SS)	3.16	355%	119%
Taq P88E/P90E/ W417L/G418K/ G499R/A502K/ I503L/G504K/ E507K/T514S/ H784A	0.22	25%	8%

5

TABLE 6: Helix-hairpin-helix random mutagenesis**DNA activity table**

	IdT	%Tth	%Taq4M	HP	X
TaqSS K198N	23.4	73%	61%	25.7	1233.1
TaqSS A205Q	25.6	80%	67%	13.4	699.1
TaqSS T204P	11.2	35%	29%	1.9	209.4
TaqSS I200M/A205G	16.8	53%	44%	7.8	597.2
TaqSS K203N	25.9	81%	68%	36.6	1429.8
Tth DN RX HT H786A/P197R/K200R	10.7	33%	28%	3.2	66.3
Tth DN RX HT H786A/K205Y	11.5	36%	30%	6.1	327.5
Tth DN RX HT H786A/G203R	18.3	57%	48%	2.1	98.8

10

15

RNA activity table

	IdT1	%Tth	%Taq4M
TaqSS K198N	1.22	137%	46%
TaqSS A205Q	0.62	70%	23%
TaqSS T204P	0.36	40%	14%
TaqSS I200M/A205G	0.77	87%	29%
TaqSS K203N	2.09	235%	79%
Tth DN RX HT H786A/P197R/K200R	0.47	52%	18%
Tth DN RX HT H786A/K205Y	0.68	77%	26%
Tth DN RX HT H786A/G203R	1.61	180%	61%

5 TABLE 7: Random thumb mutations
DNA activity table

	IdT	%Tth	%Taq4M	HP	X
Taq DN RX HT W417L/G418K/ E507K/H784A/G499R/ A502K/K504N (M1-13)	59.96	188%	157%	133.65	907.41
Taq DN RX HT W417L/G418K/ H784A/L500I/Q507H A502K/G504K (M1-36)	46.74	146%	122%	123.11	822.61
Taq DN RX HT W417L/G418K/G499R/ A502K/G504K/E507K/ H784A/T514S (M2-24)	85.7	269%	224%	369.96	3752.12
Taq DN RX HT W417L/G418K/G499R/ A502K/G504K/E507K/ H784A/V518L (M2-06)	76.7	240%	201%	355.87	2038.19

RNA activity table

	IrT1	%Tth	%Taq4M
Taq DN RX HT W417L/G418K/ E507K/H784A/G499R/ A502K/K504N/ (M1-13)	2.55	287%	96%
Taq DN RX HT W417L/G418K/ H784A/L500I/Q507H A502K/G504K (M1-36)	2.71	304%	102%
Taq DN RX HT W417L/G418K/G499R/ A502K/G504K/E507K/ H784A/T514S (M2-24)	4.43	498%	167%
Taq DN RX HT W417L/G418K/G499R/ A502K/G504K/E507K/ H784A/V518L (M2-06)	3.56	400%	134%

5 **TABLE 8: Chimeric mutants****A. DNA activity table**

	IdT2	%TthAKK	HP	X
TthAKK	34.18	100%	5	393
Taq 4M G504K	40.19	105%	28	1991
Tfi DN 2M	36.60	106%	289	1326
Tsc DN 2M	25.49	75%	283	2573
TaqTthAKK	63.89	187%	32	1658
TthTaq 4M G504K	25.03	73%	8	627
TthTthAKK	34.13	100%	15	459
TscTthAKK	35.23	103%	29	2703
TthTaq 4M G504K	35.69	104%	37	872
TscTaq 4M G504K	30.04	88%	25	2008

10

B. RNA activity table

	IrT3	%TthAKK
TthAKK	2.27	100%
Taq 4M G504K	2.31	102%
Tfi DN 2M	0.20	9%
Tsc DN 2M	0.29	13%

TaqTthAKK	6.81	300%
TthTaq 4M G504K	1.09	48%
TfITthAKK	1.24	55%
TscTthAKK	9.65	4.25%
TfITaq 4M G504K	1.05	46%
TscTaq 4M G504K	2.95	130%

- All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described
5 methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention
10 which are obvious to those skilled in the relevant fields are intended to be within the scope of the following claims.

CLAIMS

We claim:

- 5 1. A composition comprising an enzyme, wherein said enzyme comprises a heterologous functional domain, wherein said heterologous functional domain provides altered functionality in a nucleic acid cleavage assay.
- 10 2. The composition of Claim 1, wherein said enzyme comprises a 5' nuclease.
- 15 3. The composition of Claim 2, wherein said 5' nuclease comprises a thermostable 5' nuclease.
- 20 4. The composition of Claim 1, wherein said enzyme comprises a polymerase.
- 25 5. The composition of Claim 4, wherein said polymerase is altered in sequence relative to a naturally occurring sequence of a polymerase such that it exhibits reduced DNA synthetic activity from that of the naturally occurring polymerase.
- 30 6. The composition of Claim 4, wherein said polymerase comprises a thermostable polymerase.
- 25 7. The composition of Claim 6, wherein said thermostable polymerase comprises a polymerase from a *Thermus* species.
- 30 8. The composition of Claim 7, wherein said *Thermus* species is selected from *Thermus aquaticus*, *Thermus flavus*, *Thermus thermophilus*, *Thermus filiformis*, and *Thermus scotoductus*.

9. The composition of Claim 1, wherein said heterologous functional domain comprises an amino acid sequence that provides an improved nuclease activity in said nucleic acid cleavage assay.

5 10. The composition of Claim 1, wherein said heterologous functional domain comprises an amino acid sequence that provides an improved substrate binding activity in said nucleic acid cleavage assay.

10 11. The composition of Claim 1, wherein said heterologous functional domain comprises an amino acid sequence that provides improved background specificity in said nucleic acid cleavage assay.

12. The composition of Claim 1, wherein said heterologous functional domain comprises two or more amino acids from a polymerase domain of a polymerase.

15 13. The composition of Claim 12, wherein at least one of said two or more amino acids is from a palm region of said polymerase domain.

20 14. The composition of Claim 12, wherein at least one of said two or more amino acids is from a thumb region of said polymerase domain.

15. The composition of Claim 12, wherein said polymerase comprises *Thermus thermophilus* polymerase.

25 16. The composition of Claim 12, wherein said two or more amino acids from said polymerase domain comprise two or more amino acids from amino acids 300-650 of SEQ ID NO:1.

30 17. The composition of Claim 1, wherein said enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:2-68, 341, 346, 348, 351, 353, 359, 365, 367, 369, 374, 376, 380, 384, 388, 392, 396, 400, 402, 406, 408, 410,

412, 416, 418, 420, 424, 427, 429, 432, 436, 440, 444, 446, 448, 450, 456, 460, 464, 468,
472, 476, 482, 485, 488, 491, 494, 496, 498, 500, 502, 506, 510, 514, 518, 522, 526, 530,
534, 538, 542, 544, 550, 553, 560, 564, 566, 568, 572, 574, 576, 578, 580, 582, 584, 586,
588, and 590.

5

18. The composition of Claim 1, wherein said nucleic acid cleavage assay
comprises cleavage of a DNA member of a substrate containing at least one RNA
component.

10

19. The composition of Claim 1, wherein said nucleic acid cleavage assay
comprises an invasive cleavage assay.

15

20. A composition comprising a nucleic acid encoding the enzyme of Claim 1.
21. The composition of Claim 20, wherein said nucleic acid is selected from
the group consisting of SEQ ID NOs:69-135, 340, 345, 347, 350, 352, 358, 364, 366,
368, 373, 375, 379, 383, 387, 391, 395, 399, 401, 405, 407, 409, 411, 415, 417, 419, 423,
426, 428, 431, 435, 439, 443, 445, 447, 449, 452, 454, 455, 459, 463, 467, 471, 475, 481,
484, 495, 497, 499, 501, 505, 509, 513, 517, 521, 525, 529, 533, 537, 541, 543, 549, 552,
559, 563, 565, 567, 571, 573, 575, 577, 579, 581, 583, 585, 587, and 589.

22. The composition comprising an expression vector, said expression vector
comprising said nucleic acid of Claim 20.

25

23. A composition comprising a host cell containing the expression vector of
Claim 22.

24. A method for producing an altered enzyme with improved functionality in
a nucleic acid cleavage assay comprising:

30

a) providing an enzyme and a nucleic acid test substrate;

- 5 b) introducing a heterologous functional domain into said enzyme to produce an altered enzyme;
- c) contacting said altered enzyme with said nucleic acid test substrate to produce cleavage products; and
- d) detecting said cleavage products.

25. The method of Claim 24, wherein said introducing a heterologous functional domain comprises mutating one or more amino acids of said enzyme.

10 26. The method of Claim 24, wherein said introducing a heterologous functional domain into said enzyme comprises adding a functional domain from a protein into said enzyme.

15 27. The method of Claim 26, wherein said adding a functional domain from a protein into said enzyme comprising removing a portion of said enzyme sequence prior to adding said functional domain of said protein.

20 28. The method of Claim 24, wherein said nucleic acid test substrate comprises a cleavage structure.

29. The method of Claim 28, wherein said cleavage structure comprises an RNA target nucleic acid.

30 30. The method of Claim 28, wherein said cleavage structure comprises an invasive cleavage structure.

31. The method of Claim 24, wherein said enzyme comprises a 5' nuclease.

32. The method of Claim 31, wherein said 5' nuclease comprises a
30 thermostable 5' nuclease.

33. The method of Claim 24, wherein said enzyme comprises a polymerase.
34. The method of Claim 33, wherein said polymerase is altered in sequence relative to a naturally occurring sequence of a polymerase such that it exhibits reduced
5 DNA synthetic activity from that of the naturally occurring polymerase.
35. The method of Claim 24, wherein said polymerase comprises a thermostable polymerase.
- 10 36. The method of Claim 35, wherein said thermostable polymerase comprises a polymerase from a *Thermus* species.
- 15 37. The method of Claim 36, wherein said *Thermus* species is selected from *Thermus aquaticus*, *Thermus flavus*, *Thermus thermophilus*, *Thermus filiformis*, and
Thermus scotoductus.
38. The method of Claim 24, wherein said heterologous functional domain comprises an amino acid sequence that provides an improved nuclease activity in said nucleic acid cleavage assay.
20
39. The method of Claim 24, wherein said heterologous functional domain comprises an amino acid sequence that provides an improved substrate binding activity in said nucleic acid cleavage assay.
25
40. The method of Claim 24, wherein said heterologous functional domain comprises an amino acid sequence that provides improved background specificity in said nucleic acid cleavage assay.
41. The method of Claim 24, wherein said heterologous functional domain
30 comprises two or more amino acids from a polymerase domain of a polymerase.

42. The method of Claim 41, wherein at least one of said two or more amino acids is from a palm region of said polymerase domain.

43. The method of Claim 41, wherein at least one of said two or more amino acids is from a thumb region of said polymerase domain.
5

44. The method of Claim 41, wherein said polymerase domain comprises a polymerase domain of a *Thermus thermophilus* polymerase.

10 45. The method of Claim 41, wherein said two or amino acids from said polymerase domain comprise two or more amino acids from amino acids 300-650 of SEQ ID NO:1.

15 46. The method of Claim 24, wherein said enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:2-68, 341, 346, 348, 351, 353, 359, 365, 367, 369, 374, 376, 380, 384, 388, 392, 396, 400, 402, 406, 408, 410, 412, 416, 418, 420, 424, 427, 429, 432, 436, 440, 444, 446, 448, 450, 456, 460, 464, 468, 472, 476, 482, 485, 488, 491, 494, 496, 498, 500, 502, 506, 510, 514, 518, 522, 526, 530, 534, 538, 542, 544, 550, 553, 560, 564, 566, 568, 572, 574, 576, 578, 580, 582, 584, 586, 588, 20 and 590.

47. The method of Claim 24, wherein said altered enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:69-135, 340, 345, 347, 350, 352, 358, 364, 366, 368, 373, 375, 379, 383, 387, 391, 395, 399, 401, 405, 407, 409, 25 411, 415, 417, 419, 423, 426, 428, 431, 435, 439, 443, 445, 447, 449, 452, 454, 455, 459, 463, 467, 471, 475, 481, 484, 495, 497, 499, 501, 505, 509, 513, 517, 521, 525, 529, 533, 537, 541, 543, 549, 552, 559, 563, 565, 567, 571, 573, 575, 577, 579, 581, 583, 585, 587, and 589.

30 48. An altered enzyme produced by the method of Claim 24.

49. A kit comprising the altered enzyme of Claim 48.
50. A kit comprising the composition of Claim 1.
- 5 51. The kit of Claim 50, further comprising at least one nucleic acid cleavage substrate.
52. The kit of Claim 51, further comprising at least one RNA capable of hybridizing to said nucleic acid cleavage substrate.
- 10 53. The kit of Claim 50, further comprising a labeled oligonucleotide.
54. The kit of Claim 50, further comprising an invasive oligonucleotide.
- 15 55. A method for cleaving a nucleic acid comprising:
 - a) providing:
 - i) the enzyme of Claim 1; and
 - ii) a sample comprising substrate nucleic acid; and
 - b) exposing said substrate nucleic acid to said enzyme.
- 20 56. The method of Claim 55, wherein said exposing said substrate nucleic acid to said enzyme produces at least one cleavage product.
57. The method of Claim 56, further comprising the step of c) detecting said cleavage product.
- 25 58. The method of Claim 55, wherein said sample comprising substrate nucleic acid comprises a cell lysate.
- 30 59. A method for detecting the presence of a target nucleic acid comprising:

- a) cleaving an invasive cleavage structure, said invasive cleavage structure comprising an RNA target nucleic acid; and
- b) detecting the cleavage of said invasive cleavage structure.

5

60. The method of Claim 59, wherein cleaving is carried out by a cleavage agent.

61. The method of Claim 59, wherein said target nucleic acid comprises a first 10 region and a second region, said second region downstream of and contiguous to said first region.

62. The method of Claim 61, wherein said invasive cleavage structure comprises said target nucleic acid, a first oligonucleotide, and a second oligonucleotide, 15 wherein at least a portion of said first oligonucleotide is completely complementary to said first region of said first target nucleic acid, and wherein said second oligonucleotide comprises a 3' portion and a 5' portion, wherein said 5' portion is completely complementary to said second region of said target nucleic acid.

63. The method of Claim 62, wherein at least said portion of said first oligonucleotide is annealed to said first region of said target nucleic acid and wherein at least said 20 5' portion of said second oligonucleotide is annealed to said second region of said target nucleic.

64. The method of Claim 59, wherein said cleaving generates a non-target 25 cleavage product.

65. The method of Claim 64, wherein said detecting the cleavage of said invasive cleavage structure comprises detecting said non-target cleavage product.

30

66. The method of Claim 62, wherein said 3' portion of said second oligonucleotide comprises a 3' terminal nucleotide not complementary to said target nucleic acid.

5 67. The method of Claim 62, wherein said 3' portion of said second oligonucleotide consists of a single nucleotide not complementary to said target nucleic acid.

10 68. The method of Claim 59, wherein said detecting the cleavage of said invasive cleavage structure comprises detection of fluorescence.

69. The method of Claim 59, wherein said detecting the cleavage of said invasive cleavage structure comprises detection of mass.

15 70. The method of Claim 59, wherein said detecting the cleavage of said invasive cleavage structure comprises detection of fluorescence energy transfer.

20 71. The method of Claim 59, wherein said detecting the cleavage of said cleavage structure comprises detection selected from the group consisting of detection of radioactivity, luminescence, phosphorescence, fluorescence polarization, and charge.

72. The method of Claim 62, wherein said first oligonucleotide is attached to a solid support.

25 73. The method of Claim 62, wherein said second oligonucleotide is attached to a solid support.

74. The method of Claim 60, wherein said cleavage agent comprises a structure-specific nuclease.

75. The method of Claim 74, wherein said structure-specific nuclease comprises a thermostable structure-specific nuclease.

76. The method of Claim 60, wherein said cleavage agent comprises an enzyme, wherein said enzyme comprises a heterologous functional domain, wherein said heterologous functional domain provides altered functionality in a nucleic acid cleavage assay.

77. The method of Claim 76, wherein said enzyme comprises a 5' nuclease.

78. The method of Claim 77, wherein said 5' nuclease comprises a thermostable 5' nuclease.

79. The method of Claim 76, wherein said enzyme comprises a polymerase.

80. The method of Claim 79, wherein said polymerase is altered in sequence relative to a naturally occurring sequence of a polymerase such that it exhibits reduced DNA synthetic activity from that of the naturally occurring polymerase.

81. The method of Claim 79, wherein said polymerase comprises a thermostable polymerase.

82. The method of Claim 81, wherein said thermostable polymerase comprises a polymerase from a *Thermus* species.

83. The method of Claim 82, wherein said *Thermus* species is selected from *Thermus aquaticus*, *Thermus flavus*, *Thermus thermophilus*, *Thermus filiformis*, and *Thermus scotoductus*.

84. The method of Claim 76, wherein said heterologous functional domain comprises an amino acid sequence that provides an improved nuclease activity in said nucleic acid cleavage assay.

5 85. The method of Claim 76, wherein said heterologous functional domain comprises an amino acid sequence that provides an improved substrate binding activity in said nucleic acid cleavage assay.

10 86. The method of Claim 76, wherein said heterologous functional domain comprises an amino acid sequence that provides improved background specificity in said nucleic acid cleavage assay.

87. The method of Claim 76, wherein said heterologous functional domain comprises two or more amino acids from a polymerase domain of a polymerase.

15 88. The method of Claim 87, wherein at least one of said two or more amino acids is from a palm region of said polymerase domain.

20 89. The method of Claim 87, wherein at least one of said two or more amino acids is from a thumb region of said polymerase domain.

90. The method of Claim 87, wherein said polymerase domain comprises a polymerase domain of a *Thermus thermophilus* polymerase.

25 91. The method of Claim 87, wherein said two or more amino acids from said polymerase domain comprise two or more amino acids from amino acids 300-650 of SEQ ID NO:1.

30 92. The method of Claim 76, wherein said enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID Nos:2-68, 341, 346, 348, 351, 353, 359, 365, 367, 369, 374, 376, 380, 384, 388, 392, 396, 400, 402, 406, 408, 410, 412,

416, 418, 420, 424, 427, 429, 432, 436, 440, 444, 446, 448, 450, 456, 460, 464, 468, 472,
476, 482, 485, 488, 491, 494, 496, 498, 500, 502, 506, 510, 514, 518, 522, 526, 530, 534,
538, 542, 544, 550, 553, 560, 564, 566, 568, 572, 574, 576, 578, 580, 582, 584, 586, 588,
and 590.

5

93. The method of Claim 76, wherein said enzyme is encoded by a nucleic acid selected from the group consisting of SEQ ID NOs:69-135, 340, 345, 347, 350, 352, 358, 364, 366, 368, 373, 375, 379, 383, 387, 391, 395, 399, 401, 405, 407, 409, 411, 415, 417, 419, 423, 426, 428, 431, 435, 439, 443, 445, 447, 449, 452, 454, 455, 459, 463, 467, 471, 475, 481, 484, 495, 497, 499, 501, 505, 509, 513, 517, 521, 525, 529, 533, 537, 541, 543, 549, 552, 559, 563, 565, 567, 571, 573, 575, 577, 579, 581, 583, 585, 587, and 589.

10

94. The method of Claim 64, further comprising the steps of forming a second invasive cleavage structure comprising said non-target cleavage product and cleaving
15 said second invasive cleavage structure.

95. The method of Claim 94, wherein said invasive cleavage structure or said second invasive cleavage structure comprises an oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:709-2640.

20

96. The method of Claim 94, wherein said invasive cleavage structure or said second invasive cleavage structure comprises an oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:169-211 and 619-706.

25

97. The method of Claim 59, wherein said RNA target nucleic acid comprises a cytochrome P450 RNA.

98. The method of Claim 59, wherein said RNA target nucleic acid comprises a cytokine RNA.

30

99. The method of Claim 61, wherein a portion of said target nucleic acid consisting of said first region and said second region of said target nucleic acid comprises a splice junction.

5 100. The method of Claim 61, wherein said first region or said second region of said target nucleic acid comprises an exon.

101. The method of Claim 61, wherein said first region or said second region of said target nucleic acid comprises an intron.

10

102. The method of Claim 59, wherein said RNA target nucleic acid is provided in a cell lysate.

15 103. The method of Claim 62, wherein said first oligonucleotide is covalently attached to said second oligonucleotide.

104. A kit for performing an invasive cleavage assay comprising a probe oligonucleotide and an invasive oligonucleotide configured to form an invasive cleavage structure in the presence of an RNA target nucleic acid.

20

105. The kit of Claim 104, wherein said kit comprises an oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:709-2640.

25 106. The kit of Claim 104, wherein said kit comprises an oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO:169-211 and 619-706.

107. A method for detecting the presence of two or more target nucleic acid sequences comprising:

30 a) cleaving two or more invasive cleavage structures, each of said two or more invasive cleavage structures comprising an RNA target nucleic

acid having a target sequence, wherein each of said invasive cleavage structures comprises a different RNA target sequence; and

b) detecting the cleavage of said invasive cleavage structures.





FIGURE 1

FIGURE 2






FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7

FIGURE 8A

FIGURE 8B

FIGURE 8C

ποτανη

FIGURE 8E

MAJORITY	[SEQ ID NO:156]	GGAGATCCGGGGCTGGAGGAGGCTTGCGGTGGGGTGGGGCTGAGCTAAGTCGGAC	1464
DNAPTAQ	[SEQ ID NO:153]GC.....GC.....	1465
DNAPTEL	[SEQ ID NO:154]	G.G.....AG.G.....	1466
DNAPTH	[SEQ ID NO:155]T.....G.....	1470
MAJORITY	GAGCTGAAAGGGTGGCTTGAGGAGCTGGGCTTGCGGAAGCGCATGGCAAGAGCAGXGGAGG		
DNAPTAQC.....	A.....	1534
DNAPTEL	GG.....	G.C.G.T.....	1531
DNAPTH	TA.....T.G.G.....	1540
MAJORITY	GCTCACAGGGCCGCGCTGGAGGCCCTXGGXAGGGCCACCCATGTGGAAAGATCTTGCTA		
DNAPTAQC.....	C.....	1604
DNAPTEL	T.....	G.A.....	1607
DNAPTHG.....	A.G.....	1610
MAJORITY	CGGGAGCTCACAAAGCTAACCTAACCTAACATXGACCCCCCTGCCXGCTCGTCAAGGACGGGC		
DNAPTAQG.....	T.....T.....	1674
DNAPTEL	A.....C.C.G.....	1677
DNAPTH	G.G.....C.AAG.....	1680
MAJORITY	CGCCTCACACCGCGCTAACCGAACGGGACCGGACCGGAGGCTTAGCTCCGACCCAACTGG		
DNAPTAQ	A.....T.....	1744
DNAPTEL	G.....	T.G.C.....	1741
DNAPTH	G.....	1750

FIGURE 8K

FIGURE 8G

MAJORITY	[SEQ ID NO:156]	AGCTTCCCAGGTGGATTGAGAACCCGGAGGGACGGGAGGCTGGTACGTGGAGA	
DNAPTAQ	[SEQ ID NO:153]
DNAPTEL	[SEQ ID NO:154]
DNAPTH	[SEQ ID NO:155]
MAJORITY	GGGTCTTGGGGGGGGCTACGGCGGAGCTAACGCCCGGGTAAAGGGGGCGGGGG		
DNAPTAQ	G.....A.....AG.....G.....C.....G.....A.....G.....	2234
DNAPTEL	T.....A.....G.....G.....C.....A.....G.....	2231
DNAPTH	AA.....AA.....	2240
MAJORITY	GGGATGGCTCACATGGCGGTGGGGGACCGGGCGCCGCCCCATGAAGCTGCCATGGGAAGGTC		
DNAPTAQ
DNAPTEL
DNAPTH
MAJORITY	TTCGGGGCTXCGGAATGGGGCGAGGATGGCTXCGGGTCCAGACGGCTGGGCTCGAGGGCG		
DNAPTAQ	A.....GG.....C.....G.....TT.....G.....G.....G.....	2304
DNAPTEL	T.....G.....G.....G.....G.....G.....G.....	2301
DNAPTH	C.....C.....G.....G.....G.....G.....G.....	2310
MAJORITY	CCAAAAGAGCGGGCTAGGXGGTGGCGCTTGGCAAGGGCATGGAGGGCTATGCCCTGGCGGT		
DNAPTAQ	A.....A.....CC.....GGGC.....	2444
DNAPTEL	G.....G.....AG.....A.....	2441
DNAPTH	C.....C.....G.....A.....G.....	2450

MAJORITY [SEQ ID NO:156] GGCGGTGGAGGTGGATGGGGAGACTGGCTCAGGCAGGAGTAG
DNAPTAQ [SEQ ID NO:153].....A.....A.....GA.....
DNAPTEI [SEQ ID NO:154].....CC.....T.....GT.....
DNAPTRH [SEQ ID NO:155].....T.....GT.....

2499
2496
2505

FIGURE 9A

MAJORITY	[SEQ ID NO:159]	RAAMPLFEPKGRLIVLUDGHHLAYRIFTALKGIIITSRGEPVQAVYGFAKSLLKALKEDG-DAUVVFDAK	69
TAO PRO	[SEQ ID NO:157]	R.G.....H.....	68
TFL PRO	[SEQ ID NO:158]	68
TTH PRO	[SEQ ID NO:1]	E.....	70
MAJORITY	APSFRAYEAYKAAGRATPDEPRLALIKELWOLLGIXRLEIPGYEADVLATLAKKAEEGVFVRIL		
TAO PRO	GG.....	A.....S.....	133
TFL PRO	V.....F.....	133
TTH PRO	F.....	140
MAJORITY	TADRDYOLLSRDIAVLHPEGYLITPAWLWEKYGLRPEQWDRALXGDPSDNLPGUKGIGEKTAAXLLX		
TAO PRO	...K.....H.....	D..A....T..E.....	209
TFL PRO	...E.....I.....	A.....I.....	208
TTH PRO	...V.....H.....	F.....V.....	210
MAJORITY	EWGSLENLKNLDRKWP-XXREKUAXAHMEDIKLSSXXLSXURDPLEUDFXRREPREGRAFLERLF		
TAO PRO	...A.....L.....AI.....L.....	K.....R.....	278
TFL PRO	...FOH.....SI.....I.O.G.....A.A.RK.....Q.H.....	GR.....T.NL.....	277
TTH PROENV.....K.L.....R.I.F.E.R.....	L.QG.....	280
MAJORITY	GSLIHEFGLEXPKALEERPWPPPPGAFVGULSRPEPMWAELLAAAARYSRVHRAXDPLXGLRDLKEV		
TAO PRO	S.....	PE.YKA.....G.....	348
TFL PRO	G.....A.....	G.WE.L.....Q.....R.....	347
TTH PRO	A.AP.....	K.....C.D.....A.K.....	350

FIGURE 9B

MAJORITY [SEQ ID NO:159] RGLLAVIALREGDLXPDDPM LAYLDPSNTPEGUARRYGEWEDEDAGERALSERLFNXLXX			
TAO PRO [SEQ ID NO:157] S G . P		E A A	WG 418
TFL PRO [SEQ ID NO:158] . I F . E		A A D	KE 417
TTH PRO [SEQ ID NO:1] S U		AH HR	LK 420
MAJORITY RLEGERBLWLYXEVKPLSRULAHMEATGURDUAYLOALSELEVAFIRRLLEEVFRAGHPFNLNSRD			
TAO PROR...R...A.....R.....	R.....A.....	483
TFL PROK.....E.....R.....	EA.V.Q.....	487
TTH PROR.....H.....	L.....	490
MAJORITY QLERVLIFDELGLPAIGKTETKGKRSTSRAVLEALREAHPIVEKULQYRELTKLKNTYIDPLPXIWHPRTG		S.....D.....I.....	558
TAO PRO	DR.....	
TFL PROR.....L.....Q.....	H.....V.....S.....	K.....
TTH PRO		
MAJORITY RLHTRNQTTATGRSSSDPHLQNPURTPIGORIRRRAFAAEQWXLVALDYSSQELRVLAHLSGDENL			
TAO PRO	I.....L.....	628
TFL PRO	V.....V.....	
TTH PRO	A.....A.....	630
MAJORITY IRUFQFGDHTQTASWMGPPEANDPLMRRAAKTINFGVLYGMSAHLSQELAPIYEAVAFIERYFO			
TAO PROE.....R.....	0.....G.....	698
TFL PROS.....G.....	G.....S.....	697
TTH PROK.....	V.....	700

FIGURE 9C

MAJORITY [SEQ ID NO:159]	SFPKVRAWI EKILEFGRRRSYUETLGRRYVPOLNARVKSUREAERMAFNNPUDGTAADI MKLAMNUKL
TAO PRO	[SEQ ID NO:157].....E.....
TEL PRO	[SEQ ID NO:158].....G.....
TH PRO	[SEQ ID NO:1].....K.....
MAJORITY	FPRIXEMGARM LQVHDELVLEAPKXRAEXUAALAKEVME GUYPLAUPLEUEUGXGEDWL SAKEX
TAO PROE.....
TEL PROQ. L.....
TH PROR.
	768
	767
	770
	633
	831
	635




FIGURE 10




FIGURE 11




FIGURE 12

		BstBI (382)		NdeI (445)	
1	TagPol	390	400	410	420
2	TthPol	DFSNNTTGGTAYRYGGENTEAGTAA DFSNNTTGGTAYRYGGENTEDAA	+ +	430	440
1	TagPol	LEVAEEVRLLEEVPLAAGHFNLNNSDQLE	4.80	4.90	5.00
2	TthPol	LELAEEVRLLEEVPLAAGHFNLNNSDQLE	+ +	+ +	+ +
1	TagPol	550	560	570	580
2	TthPol	LKSTYIIPDPLIHPRTGRLTRENPQATATRLLSSSPNQNPVRTPLGORI LKSTYIIPDPLIHPRTGRLTRENPQATATRGLSSSDENQNIPVRTPLGORI	+ +	+ +	+ +

FIGURE 13




FIGURE 14




FIGURE 15

	Nuclease Domain	Polymerase Domain	Polymerase Activity Assays	
			% Fl-labeled dUTP incorporated RNA, p(A) or DNA, p(dA) Template	
Tth			5.8 (1.00)	14.8 (1.00)
Taq			0.8 (0.14)	15.0 (1.01)
TaqTth(N)			4.88 (0.84)	12.9 (0.87)
TaqTth(N-B)			0.58 (0.10)	13.3 (0.90)
TaqTth(B-S)			6.60 (1.14)	14.9 (1.01)
Taq(W417L/G418K/E507Q)			0.42 (0.07)	12.6 (0.85)

FIGURE 16



FIGURE 17




FIGURE 18A




FIGURE 18B




FIGURE 18C




FIGURE 18D




FIGURE 19




FIGURE 20

FIGURE 21

A


5'-tet-TTT CAACTGCCGTGA
A CGAGGCGCACG
G GCTCCGCGTGGTTGACGGCACT

B

5'-tet-TTT CAACTGCCGTGA
A CGAGGCGCACG
A GCUCCCGCGUGGUUGACGGCACU-BiotinSA-5'

FIGURE 22

A



B




FIGURE 23




FIGURE 24




FIGURE 25




FIGURE 26







FIGURE 27

FIGURE 28

a



b



attomoles/target	basic invader	invader sqrd
1		8386
10		133185
100	8512	1862211

FIGURE 29

FIGURE 30




FIGURE 31





FIGURE 32

FIGURE 33





FIGURE 34

FIGURE 35A




FIGURE 35B




FIGURE 35C





FIGURE 36A

FIGURE 36B





FIGURE 37A






FIGURE 37B

FIGURE 37C




FIGURE 38





Figure 39

FIGURE 40

	1	2	3	4	5	6	7	8	9	10	11	12
A	Negative Control	No Target Control	Sample 1	Sample 9	Sample 17	Sample 25	Sample 2	Sample 25	Sample 33	Sample 33		
	No Target Control	No Target Control	Sample 2	Sample 10	Sample 18	Sample 13	Sample 26	Sample 26	Sample 34	Sample 34		
B	Standard 1	Standard 1	Sample 3	Sample 11	Sample 19	Sample 19	Sample 27	Sample 27	Sample 35	Sample 35		
	Standard 2	Standard 2	Sample 4	Sample 12	Sample 12	Sample 20	Sample 28	Sample 28	Sample 36	Sample 36		
C	Standard 3	Standard 3	Sample 5	Sample 13	Sample 13	Sample 21	Sample 29	Sample 29	Sample 37	Sample 37		
	Standard 4	Standard 4	Sample 6	Sample 14	Sample 14	Sample 22	Sample 30	Sample 30	Sample 38	Sample 38		
D	Standard 5	Standard 5	Sample 7	Sample 15	Sample 15	Sample 23	Sample 31	Sample 31	Sample 39	Sample 39		
	Standard 6	Standard 6	Sample 8	Sample 8	Sample 16	Sample 24	Sample 32	Sample 32	Sample 40	Sample 40		

FIGURE 41

hUbiquitin					
Primary probe	5'-CGC CGA GAT CAC CCT TAC ATT TTC TAT CGT 1 NH2-3'	(SEQ ID NO:169)			
INVADER oligonucleotide	5'-CCT TCC TTA TCC ATG TTG GCA -3'	(SEQ ID NO:170)			
ARRESTOR oligonucleotide	5'-AACG ATA GAA AAT GTA AAG GTG ATC-3'	(SEQ ID NO:171)			
FRET Probe	5'-RED-CTC (Z28) TTC TCA GTG CG-3'	(SEQ ID NO:172)			
Secondary target	5'-CGC AGT GAG AAT GAG GTG ATC TCG GCG GT-3'	(SEQ ID NO:173)			
m/r Ubiquitin, mouse (288C, 516C, 744C, 972C), rat (247C, 475C, 703C, 931C)					
Primary probe	5'-CCG CGG AGA TCA CGG ATG TTG TAA TCA GAG A-NH2-3'	(SEQ ID NO:174)			
INVADER oligonucleotide 1	5'-GTG CAG GGT TGA CTC CTT CTC-3'	(SEQ ID NO:175)			
INVADER oligonucleotide 2	5'-GTC CAG GGT TGA CTC CTT CTC-3'	(SEQ ID NO:176)			
INVADER oligonucleotide 3	5'-GTG CAG GGT TGA CTC CTT CTC-3'	(SEQ ID NO:177)			
ARRESTOR oligonucleotide	5'-TCT CTG ATT ACA ACA TCC GTG ATC T-3'	(SEQ ID NO:178)			
FRET Probe	5'-RED-CTC (Z28) TTC TCA GTG CG-3'	(SEQ ID NO:172)			
Secondary target	5'-CGC AGT GAG AAT GAG GTG ATC TCG GCG GT-3'	(SEQ ID NO:173)			
r/m GAPDH, rat (150C), mouse (166C)					
Primary probe	5'-CGC CGA GAT CAC GTA GTT GAG GTC AAT GA-NH2-3'	(SEQ ID NO:179)			
INVADER oligonucleotide	5'-GAA TCA TAC TGG AAC ATG TAG ACC ATC-3'	(SEQ ID NO:180)			
ARRESTOR oligonucleotide	5'-TCA TTG ACC TCA ACT ACG TGA TCT-3'	(SEQ ID NO:181)			
FRET Probe	5'-RED-CTC (Z28) TTC TCA GTG CG-3'	(SEQ ID NO:172)			
Secondary target	5'-CGC AGT GAG AAT GAG GTG ATC TCG GCG GT-3'	(SEQ ID NO:173)			
hGAPDH, 516C					
Primary probe	5'-CCG CGG AGA TCA CGA TGA TCT TGA GGC T-NH2-3'	(SEQ ID NO:182)			
INVADER oligonucleotide	5'-TGG TGC AGG AGG CAT TGC TC-3'	(SEQ ID NO:183)			
ARRESTOR oligonucleotide	5'-CAG CCT CAA GAT TAC CGT GAT CT-3'	(SEQ ID NO:184)			
FRET Probe	5'-RED-CTC (Z28) TTC TCA GTG CG-3'	(SEQ ID NO:172)			
Secondary target	5'-CGC AGT GAG AAT GAG GTG ATC TCG GCG GT-3'	(SEQ ID NO:173)			

hTGF-β		(SEQ ID NO:185) 5'-CCG TCA CGC CTC CTC CAC GGC TC-3' 5'-AGG CGA AAG CCC TCA ATT TCC CA-3' 5'-AAC CAC TGC CTC ACA-3' 5'-GAG CGG TGG AGG AGG CG-3' 5'-FL-CAC-(Z28)-TGC TTC GTG G-3' 5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'	(SEQ ID NO:186) 5'-GGG TTG TGG AGT GAG TGT TCA AGT A-3' NC STACKER 5'-GGG AAA-CTC-CGA-AGG- AGG-CG-3' 5'-FL-CAC-Z28-TGC TTC GTG G-3' 5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'	(SEQ ID NO:187) 5'-GAG CGA AAG CCC TCA ATT TCC CA-3' 5'-AAC CAC TGC CTC ACA-3' 5'-GAG CGG TGG AGG AGG CG-3' 5'-FL-CAC-(Z28)-TGC TTC GTG G-3' 5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'	(SEQ ID NO:188) 5'-GAG CGA AAG CCC TCA ATT TCC CA-3' 5'-AAC CAC TGC CTC ACA-3' 5'-GAG CGG TGG AGG AGG CG-3' 5'-FL-CAC-(Z28)-TGC TTC GTG G-3' 5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'	(SEQ ID NO:189) 5'-GAG CGA AAG CCC TCA ATT TCC CA-3' 5'-AAC CAC TGC CTC ACA-3' 5'-GAG CGG TGG AGG AGG CG-3' 5'-FL-CAC-(Z28)-TGC TTC GTG G-3' 5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'
hMCP-1						
Primary probe		5'-CCG TCA CGC CTC TCT GAC TGC CA NH2-3'	5'-TTG TCA CTC GGG GTT CGA GAA GAT GAA-3'	5'-GGG CGA GAG GG-3'	5'-AGG CAG TCA GAG AGG CG-3'	5'-CCG TCA CGC CTC TCT GAC TGC CA NH2-3'
INVADER oligonucleotide		(SEQ ID NO:190)	(SEQ ID NO:191)	(SEQ ID NO:192)	(SEQ ID NO:193)	(SEQ ID NO:194)
Stacker		NC STACKER	NC STACKER	NC STACKER	NC STACKER	NC STACKER
ARRESTOR oligonucleotide						
FRET Probe						
Secondary target						
hTNF-α						
Primary probe		5'-CCG TCA CGC CTC TCT GAC TGC CA NH2-3'	5'-TTG TCA CTC GGG GTT CGA GAA GAT GAA-3'	5'-GGG CGA GAG GG-3'	5'-AGG CAG TCA GAG AGG CG-3'	5'-CCG TCA CGC CTC CTC CTC ATT GAA TTNH2-3'
INVADER oligonucleotide		(SEQ ID NO:195)	(SEQ ID NO:196)	(SEQ ID NO:197)	(SEQ ID NO:198)	(SEQ ID NO:199)
Stacker		NC STACKER	NC STACKER	NC STACKER	NC STACKER	NC STACKER
ARRESTOR oligonucleotide						
FRET Probe						
Secondary target						
hIL-6						
Primary probe		5'-CGG TCA CGC CTC CTC ATT GAA TTNH2-3'	5'-OCA AAA GTC CAG TGA ATT TCA CCA GGC AAG TA -3'	5'-GAG ATT GGA GAC ATT CAT CT-3'	5'-GATTCA ATG AGG AGG AGG CG-3'	5'-CGG TCA CGC CTC CTC ATT GAA TTNH2-3'
INVADER oligonucleotide		(SEQ ID NO:196)	(SEQ ID NO:200)	(SEQ ID NO:201)	(SEQ ID NO:199)	(SEQ ID NO:198)
Stacker		NC STACKER	NC STACKER	NC STACKER	NC STACKER	NC STACKER
ARRESTOR oligonucleotide						
FRET Probe						
Secondary target						

hIL-1 β

Primary probe
INVADER oligonucleotide
Stacker
ARRESTOR oligonucleotide
FRET Probe
Secondary target

5'-CCG TCA CGC CTC CAT CTG TTT AGG NH2-3'
5'-CAG GTC CTC GAA GGA GCA CCTT A-3'
5'-GCC ATC AGC TTC TTT GTT CTC ATTC-3'
5'-GCC CTA AAC AGA TGG AGG CG-3'
5'-FL-CAC-(Z28)-TGC TTC GTG G-3'
5'-CCA GGA AGC AAG TGC AGG CGT GAC GGT-3'

hIL-2

Primary probe
INVADER oligonucleotide
Stacker
ARRESTOR oligonucleotide
FRET Probe
Secondary target

5'-CCG TCA CGC CTC CTC CAG TTG TAG NH2-3'
5'-AAA ATC ATC TGT AAA TCC AGC AGT AAA TGA-3'
5'-CTG TGT TTT CTT TGT AGA AC-3'
5'-CTA CAA CTC GAG GAG GC-3'
5'-FL-CAC-(Z28)-TGC TTC GTG G-3'
5'-CCA GGA AGC AAG TGC AGG CGT GAC GGT-3'

hIL-8

Primary probe
INVADER oligonucleotide
Stacker
ARRESTOR oligonucleotide
FRET Probe
Secondary target

5'-CCG TCA CGC CTC CTC TCA GTT CT-NH2-3'
5'-GTG TGG TCC ACT CTC AAT OAA-3'
5'-TTG ATA AAT TTG GGG TGG AAA GGT TTG GA-3'
5'-AGA ACT GAG AGG AGG CG-3'
5'-FL-CAC-(Z28)-TGC TTC GTG G-3'
5'-CCA GGA AGC AAG TGC AGG CGT GAC GGT-3'

hIL-10

Primary probe
INVADER oligonucleotide
Stacker
ARRESTOR oligonucleotide
FRET Probe
Secondary target

5'-AAC GAG GCG CAC CAA ACT CAC TCA T-NH2-3'
5'-GTC ATG TAG GCT TCT ATG TAG TTG ATG AGT ATG TA-3'
5'-GGC TTT GAT GCC TTT CTC TTG GA-3'
5'-ATG AGT GAG TTT GGT GCG-3'
5'-FL-CAC-(Z28)-TGC TTC GTG G-3'
5'-CCA GGA AGC AAG TGC AGG CGT GAC GGT-3'

hIL-4

Primary probe
INVADER oligonucleotide
Stacker
ARRESTOR oligonucleotide
FRET Probe
Secondary target

5'-AAC GAG GCG CAC CTT GGA GGC A-NH2-3'
 5'-AAC GTT TCC TTC TCA GTT GTG TTA-3'
 5'-GAA AAG ATG TCT GTT ACG GTC AAC TCA-3'
 5'-TSC CTC CAA GGT GCG C-3'
 5'-FL-CAC (Z28)-TGC TTC GTG G-3'
 5'-CCA GGA AGC AAG TGG TGC GGC TCG TTT-3'

hIFN γ

Primary probe
INVADER oligonucleotide
Stacker
ARRESTOR oligonucleotide
FRET Probe
Secondary target

(SEQ ID NO:626)
 (SEQ ID NO:627)
 (SEQ ID NO:628)
 (SEQ ID NO:629)
 (SEQ ID NO:189)
 (SEQ ID NO:625)
 (SEQ ID NO:630)
 (SEQ ID NO:631)
 (SEQ ID NO:632)
 (SEQ ID NO:633)
 (SEQ ID NO:189)
 (SEQ ID NO:625)

5'-AAC GAG GCG CAC CTT CAA AAT GCC TAA-NH2-3'
 5'-TGT CAC TCT CCT CTT TCC AAT TA-3'
 5'-GAA AAG AGT TCC ATT ATC GGC TAC ATC TG-3'
 5'-TTA GGC ATT TTG AAG GTG CGC-3'
 5'-FL-CAC (Z28)-TGC TTC GTG G-3'
 5'-CCA GGA AGC AAG TGG TGC GCC TCG TTT-3'

hCYP 1A2, 1193G
 Primary probe
 INVADER oligonucleotide
 Slackier
 ARRESTOR oligonucleotide
 FRET Probe
 Secondary target

5'-AAC GAG GCG CAC CGT TGT GTC CC-NH2-3'
 5'-GGG ATG TAG AAG CCA TTC AGA-3'
 5'-TTG TTG TGC TGT GGG GGA TG-3'
 5'-GGG ACA CAA CGG TGC GG-3'
 5'-FL-CAC (Z28) TGC TTC GTG G-3'
 5'-CCA GGA AGC AAG TGG TGC GCC TCG TTT-3'

hCYP 2B6, 343G

Primary probe
 INVADER oligonucleotide
 Slackier
 ARRESTOR oligonucleotide
 FRET Probe
 Secondary target

5'-CCG TCA CGC CTC CAC CAT ATC CC-NH2-3'
 5'-CCA GCG GTT TCC ATT GGC AAA GAT CAA-3'
 5'-GGG AAG AAT GGG TCG ACC ATG-3'
 5'-GGG ATA (Z28) TGC TGG AGG CG-3'
 5'-FL-CAC (Z28) TGC TTC GTG G-3'
 5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'

hCYP 2C19, 223G

Primary probe
 INVADER oligonucleotide
 Slackier
 ARRESTOR oligonucleotide
 FRET Probe
 Secondary target

5'-AAC GAG GCG CAC CGT TCC AGG C-NH2-3'
 5'-CAT ATC CAT GCA GCA CCA CCA TGA-3'
 5'-CAA AAT ACA GAG TGA ACA CAG GGC C-3'
 5'-GCC TGG AAC GGT GCG C-3'
 5'-FL-CAC (Z28) TGC TIC GTG G-3'
 5'-CCA GGA AGC AAG TGG TGC GCC TCG TTT-3'

hCYP 2C9, 1554T

Primary probe
 INVADER oligonucleotide
 Slackier
 ARRESTOR oligonucleotide
 FRET Probe
 Secondary target

5'-CCG TCA CGC CTC ATG GAT ATT GCC C-NH2-3'
 5'-CAG GTG AGA AAA GGC ATT ACA GAT AGT GAA AGC-3'
 5'-CAG AGG AAA GAG AGC TGC AGG G-3'
 5'-GGG CAT TAT CCA TGA GGC G-3'
 5'-FL-CAC (Z28) TGC TTC GTG G-3'
 5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'

hCYP 2D6, 1316G		
Primary probe	5'-CCG TCA CGC CTC CCT GCT GAG AAA-NH2-3'	(SEQ ID NO:650)
INVADER oligonucleotide	5'-CCG GCA TGC ACG GCG GA-3'	(SEQ ID NO:651)
Slacker	5'-GGC AGG AAG Sec CTC-3'	(SEQ ID NO:652)
ARRESTOR oligonucleotide	5'-TTT CTC AGC AGG GAG GCG-3'	(SEQ ID NO:653)
FRET Probe	5'-FL-CAC (Z28) TGC TTC GTG G-3'	(SEQ ID NO:189)
Secondary target	5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'	(SEQ ID NO:190)
hCYP 3A4, 309C		
Primary probe	5'-CCG TCA CGC CTC GCC CCA CA-NH2-3'	(SEQ ID NO:654)
INVADER oligonucleotide	5'-CAG CAC AGG CTG TTG ACC ATC ATA AAA C-3'	(SEQ ID NO:655)
Slacker	5'-GTT TCC CAT ACT TTT TAT GAC ATT C-3'	(SEQ ID NO:656)
ARRESTOR oligonucleotide	5'-TGT GGG GCG AGG CG-3'	(SEQ ID NO:657)
FRET Probe	5'-FL-CAC (Z28) TGC TTC GTC G-3'	(SEQ ID NO:189)
Secondary target	5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'	(SEQ ID NO:190)
hCYP 3A5 v2, 323T		
Primary probe	5'-AAC GAG GCG CAC AGT TGA CCT TC-NH2-3'	(SEQ ID NO:668)
INVADER oligonucleotide	5'-CTG ATG GCC AGC ACA GGG C-3'	(SEQ ID NO:669)
Slacker	5'-ATA CGT TCC CCA CAT TTT TC-3'	(SEQ ID NO:660)
ARRESTOR oligonucleotide	5'-TGA AGG TGA ACT GTG CGC-3'	(SEQ ID NO:661)
FRET Probe	5'-FL-CAC (Z28) TGC TTC GTG G-3'	(SEQ ID NO:189)
Secondary target	5'-CCA GGA AGC AAG TGG AGG CGC TCG TTT-3'	(SEQ ID NO:625)
hCYP 3A7, 231C		
Primary probe	5'-AAC GAG GCG CAC GTG ATA ATT ACC CC-NH2-3'	(SEQ ID NO:662)
INVADER oligonucleotide	5'-GCC AGC ATA GGC TGT TGA CAC-3'	(SEQ ID NO:663)
Slacker	5'-AGA CTT TTC TAT ACT TTT TAT AAC ATT C-3'	(SEQ ID NO:664)
ARRESTOR oligonucleotide	5'-GGG GTA TTT ATG ACG TGC G-3'	(SEQ ID NO:665)
FRET Probe	5'-FL-CAC (Z28) TGC TTC GTG G-3'	(SEQ ID NO:189)
Secondary target	5'-CCA GGA AGC AAG TGG TGC GCC TCG TTT-3'	(SEQ ID NO:625)

h/rCYP 1A1 (human: 937, rat 863G)	
Primary probe	5'-CCG TCA CGC CTC CTG TCT GTG AT-NH2-3'
INVADER oligonucleotide (h)	(SEQ ID NO:666)
INVADER oligonucleotide (r)	(SEQ ID NO:667)
Slacker	(SEQ ID NO:668)
ARRESTOR oligonucleotide	(SEQ ID NO:669)
FRET Probe	(SEQ ID NO:670)
Secondary target	(SEQ ID NO:189)
	(SEQ ID NO:190)
h/rCYP 1A2 (813C/819C)	
Primary probe	5'-AAC GAG GCG CAC GGA CTG TTT TCT GC-NH2-3'
INVADER oligonucleotide (h)	(SEQ ID NO:671)
INVADER oligonucleotide (r)	(SEQ ID NO:672)
ARRESTOR oligonucleotide	(SEQ ID NO:673)
FRET Probe	(SEQ ID NO:674)
Secondary target	(SEQ ID NO:189)
	(SEQ ID NO:225)
rCYP 2B1, 1017T	
Primary probe	5'-CCG TCA CGC CTC ACT GCG GTC AAT-NH2-3'
INVADER oligonucleotide	(SEQ ID NO:675)
Slacker	(SEQ ID NO:676)
ARRESTOR oligonucleotide	(SEQ ID NO:677)
FRET Probe	(SEQ ID NO:678)
Secondary target	(SEQ ID NO:189)
	(SEQ ID NO:190)
rCYP 2B2, 162T	
Primary probe	5'-CCG TCA CGC CTC AGA GCC AAT CAC-NH2-3'
INVADER oligonucleotide	(SEQ ID NO:679)
Slacker	(SEQ ID NO:680)
ARRESTOR oligonucleotide	(SEQ ID NO:681)
FRET Probe	(SEQ ID NO:682)
Secondary target	(SEQ ID NO:189)
	(SEQ ID NO:190)

rCYP 2E1, 969G							
Primary probe	5'-CCG TCA CGC CTC CTC TTC AAT TIC TG-NH2-3'	(SEQ ID NO:683)					
INVADER oligonucleotide	5'-CGG TGT CAA TT CTT CAT GAA GTT TA-3'	(SEQ ID NO:684)					
Stacker	5'-GGT ATT TCA TGA GGA TCA GGA GC-3''	(SEQ ID NO:685)					
ARRESTOR oligonucleotide	5'-CAG AAA TTG AAG AGG CG-3'	(SEQ ID NO:686)					
FRET Probe	5'-FL-CAC (Z28) TGC TIC GTG G-3'	(SEQ ID NO:189)					
Secondary target	5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'	(SEQ ID NO:190)					
rCYP 3A1, 164G							
Primary probe	5'-AAC GAG GCG CAC CGG GTC CCA-NH2-3'	(SEQ ID NO:587)					
INVADER oligonucleotide	5'-TCC CCT GTT TCT TGA AAA GTC CAT GTG TGA-3'	(SEQ ID NO:588)					
Stacker	5'-AAT CCG TAG AGG ACC AGG-3'	(SEQ ID NO:589)					
ARRESTOR oligonucleotide	5'-TGG GAC CGC GTG CGC-3'	(SEQ ID NO:590)					
FRET Probe	5'-FL-CAC (Z28) TGC TIC GTG G-3'	(SEQ ID NO:189)					
Secondary target	5'-CCA GGA AGC AAG TGG TGC GCC TCG TGT GAC GGT-3'	(SEQ ID NO:525)					
rCYP 3A2, 1091G							
Primary probe	5'-CCG TCA CGC CTC CTC GGC AGG-NH2-3'	(SEQ ID NO:591)					
INVADER oligonucleotide	5'-CAC AAT ATC GTA GGT AGG AGG TGC CTT AA-3'	(SEQ ID NO:592)					
Stacker	5'-GCC CCA TCG ATC TCC TCC-3'	(SEQ ID NO:593)					
ARRESTOR oligonucleotide	5'-CCT GCG GAG GAG GCG-3'	(SEQ ID NO:594)					
FRET Probe	5'-FL-CAC (Z28) TGC TIC GTG G-3'	(SEQ ID NO:189)					
Secondary target	5'-CCA GGA AGC AAG TGG AGG CGT GAC GGT-3'	(SEQ ID NO:190)					
rCYP 4A1, 296A							
Primary probe	5'-AAC GAG GCG CAC TAG GCT TTG CT-NH2-3'	(SEQ ID NO:595)					
INVADER oligonucleotide	5'-TTC ATG TAG TCA GGG TCA TAG ACA ATT AAG A-3'	(SEQ ID NO:596)					
Stacker	5'-TCC CCA GAA CCA TCG AGG AAA GG-3''	(SEQ ID NO:597)					
ARRESTOR oligonucleotide	5'-AGC AAA GGC TAG TGC GC-3'	(SEQ ID NO:598)					
FRET Probe	5'-FL-CAC (Z28) TGC TIC GTG G-3'	(SEQ ID NO:189)					
Secondary target	5'-CCA GGA AGC AAG TGG TGC GCC TCG TGT TTT-3'	(SEQ ID NO:525)					

rCYP 4A2

Primary probe

INVADER oligonucleotide

Stacker

ARRESTOR oligonucleotide

FRET Probe

Secondary target

5'-AAC GAG GCG CAC AGA AGG CCC CCT-NH2-3'

(SEQ ID NO:699)

(SEQ ID NO:700)

(SEQ ID NO:701)

(SEQ ID NO:702)

(SEQ ID NO:189)

(SEQ ID NO:625)

rCYP 4A3, 1235C

Primary probe

INVADER oligonucleotide

Stacker

ARRESTOR oligonucleotide

FRET Probe

Secondary target

5'-AAC GAG GCG CAC GTT GTG ATA CCT-T-NH2-3'

(SEQ ID NO:703)

(SEQ ID NO:704)

(SEQ ID NO:705)

(SEQ ID NO:706)

(SEQ ID NO:189)

(SEQ ID NO:625)

5'-GAT GAA GGC CAT AAA TTA AAA TTG TGC-3'

5'-TGG GTA TGG AAC GTC C-3'

5'-AAG GTA ATCA CAA CGT GCG C-3'

5'-FL-CAC (228) TGC TTC GTG G-3'

5'-CCA GGA AGC AAG TGG TGC GCC TCG TTT-3'


Figure 42

Figure 43




Figure 44




Figure 45




Figure 46




FIGURE 47
 Oligo sequence descriptions: 5' to 3' direction, 2'-Ome nts are bolded and underlined, internal modifications defined in (1)

Oligo Type	Oligo Sequence (5' to 3')	Modification	SEQ ID NO
I ⁿ TNF- α			
probe	cgg cgg aca tca ctc tga ctc cgt cct NH2	3' Amine	709
invader	tg tea ctc ggg gtt cgt gaa gat gaa	all 2'One bases	710
stacker	<u>ggg cca</u> gag <u>ggc</u> tga <u>tta</u> <u>q</u>	all 2'One bases	711
stacker	ggg cca gag <u>ggc</u> tga <u>tta</u> <u>at</u>	all 2'One bases	712
stacker	ggg cca gag <u>ggc</u> tga <u>tq</u> <u>at</u>	all 2'One bases	713
stacker	ggg cca gag <u>ggc</u> tga <u>tg</u> <u>at</u>	all 2'One bases	714
stacker	ggg cca gag <u>ggc</u> tga <u>tg</u> <u>tg</u>	all 2'One bases	715
stacker	ggg cca gag <u>ggc</u> tga <u>tg</u> <u>tg</u>	all 2'One bases	716
arrestor	agg ctc tca gag tga <u>tct</u> <u>c</u>	all 2'One bases	717
arrestor	agg ctc tca gag tga <u>tct</u> <u>c</u>	all 2'One bases	718
SRT	cgaaaggaa <u>gcgttgg</u> at <u>tcgtcg</u> gcggNH2	3' Amine	
FRET probe	Fc-ac(Cy3)gcgttcacccg		
probe	cgg tca cgc ctc tct gag lgc ct NH2	3' Amine	720
invader	tg tea ctc ggg gtt cgt gaa gat gaa	all 2'One bases	721
stacker	<u>ggg cca</u> gag <u>ggc</u> tga <u>tta</u> <u>q</u>	all 2'One bases	722
arrestor	agg ctc tca gag <u>agg</u> <u>cg</u>	3base 2'One, 3'Amine	723
SRT	cggaaaggaa <u>gcgttgg</u> at <u>tcgtcg</u> gcggNH2	3base 2'One, 3'Amine	724
FRET probe	Fc-ac(Cy3)gcgttcacccg		725
probe	cgg tca cgc ctc tct gag lgc ct NH2	3' Amine	726
invader	tg tea ctc ggg gtt cgt gaa gat gaa	all 2'One bases	727
arrestor	<u>cca</u> <u>ggc</u> <u>atc</u> <u>tca</u> <u>aga</u> <u>ggc</u> <u>q</u>	3base 2'One, 3'Amine	728
SRT	cggaaaggaa <u>gcgttgg</u> at <u>tcgtcg</u> gcggNH2	3base 2'One, 3'Amine	729
FRET probe	Fc-ac(Cy3)gcgttcacccg		730
probe	cgg cgg aca tca ctc tga ctc cgt cc NH2	3' Amine	731
invader	tg tea ctc ggg gtt cgt gaa gat gaa	all 2'One bases	732
stacker	<u>ggg cca</u> <u>ggg</u> cgt <u>att</u> <u>a</u>	all 2'One bases	733
arrestor	agg ctc tca gag <u>tta</u> <u>tc</u>	3' Amine	734
SRT	cggaaaggaa <u>gcgttgg</u> at <u>tcgtcg</u> gcggNH2	3' Amine	735
FRET probe	Fc-ac(Cy3)gcgttcacccg		736
probe	cgg cgg aca tca ctc tga ctc cgt c NH2	3' Amine	737
invader	cit gtc act cgg ggt tcg aga a <u>aga</u> <u>c</u>		738

stacker	cct ggg .c.c.a.gaa.ggc.tga.tt.	739
arrestor	cag tca .gtt cgt cgt tcc ..	740
SRT	cggaaagcacatgttgttgtttcgccggNH2	741
FRET probe	Fcac(Cy3)gttttcctccgg	742
probe	cgg tca ccg ctc tct gtc ggc tca NH2	743
probe	cgg tca ccg ctc tct tgc tgc tgc ct NH2	744
probe	cgg tca ccg ctc tct tgc tgc tgc ct NH2	745
invader	tgg tca ccg tct gtt cgt a ga gat gaa	746
stacker	ggg cca gag gg	747
arrestor	agg cgtta gag agg cg	748
arrestor	agg cctt taa gag agg cg	749
arrestor	agg ctgt taa gag agg cg	750
arrestor	cggaaagcacatgttgttgtttcgccggNH2	751
SRT	Fcac(Cy3)gttttcctccgg	752
FRET probe	cgg cgg aca ctc tct tgc tgg ctg gg NH2	753
probe	cit gtc act cgg ggt tgg aaga tgg a tgg a	754
invader	cac.c.agg caa tca gaa ttc ttc NH2	755
arrestor	cggaaagcacatgttgttgtttcgccggNH2	756
SRT	Fcac(Cy3)gttttcctccgg	757
FRET probe	cgg cgg aca ctc tct tgc tgg ctg gg NH2	758
hll-1 β		759
probe	cgg tca ccg ctc cat ctg ttt agg g NH2	760
invader	cag gtc ctg gaa gaa gaa cta a	761
stacker	cra .tea .gtt tct ttt ttc tca .tc ..	762
arrestor	gcc .cta aac aca tgg agg cgg	763
SRT	cggaaagcacatgttgttgtttcgccggNH2	764
FRET probe	Fcac(Cy3)gttttcctccgg	764
probe	cgg tca ccg ctc cat ctg ttt agg g NH2	765
invader	cag gtc ctg gaa gaa gaa cta a	766
stacker	cra .ctt .ctt ttt tct ttt .cat .cc ..	767
arrestor	gcc .cta aac aca tgg agg cgg	768
SRT	cggaaagcacatgttgttgtttcgccggNH2	769
FRET probe	Fcac(Cy3)gttttcctccgg	770
probe	cgg tca ccg ctc cat ctg ttt agg g NH2	771

probe		aec gag ggc ccc ctt cgg agt ttg gg NH2	3' Amine	870
invader		ggg ttg tgg agt ggg lgt tca egt a	all 2'One bases	871
arrestor		ccc.aaa.ccc.cca.agg.tgg.g	3' last 5 bases 2'One, 3' Amine	872
SRT		cggaaatggatgttggggccgttgttaalNH2		873
FRET probe		Fcaco(Cy3)gcitcccg		874
probe		ccg tca cgc ctc ctt cgg aat ttg g NH2	3' Amine	875
invader		ggg ttg tgg agt ggg lgt tca egt a	all 2'One bases	876
stacker		gtt ttt ctt ctc. cag. gtt. g	all 2'One bases	877
arrestor		cca. aac. tcc. gca. gaa. gtc. g	all 2'One bases	878
SRT		cggaaatggatgttggggccgttgttaalNH2	3'base 2'One, 3'Amine	879
FRET probe		Fcaco(Cy3)gcitcccg		880
probe		ccg tca cgc ctc ctt cgg aat ttg g NH2	3' Amine	881
invader		ggg ttg tgg agt ggg lgt tca egt a	all 2'One bases	882
stacker		gtt ttt ctt ctc. cag. gtt. g	all 2'One bases	883
arrestor		cca. aac. tcc. gca. gaa. gtc. g	all 2'One bases	884
SRT		cggaaatggatgttggggccgttgttaalNH2	3'base 2'One, 3'Amine	885
FRET probe		Fcaco(Cy3)gcitcccg		886
probe		ccg tca cgc ctc ctt cgg aat ttg g NH2	3' Amine	887
invader		ggg ttg tgg agt ggg lgt tca egt a	all 2'One bases	888
stacker		gtt ttt ctt ctc. cag. gtt. g	all 2'One bases	889
arrestor		cca. aac. tcc. gca. gaa. gtc. g	all 2'One bases	890
SRT		cggaaatggatgttggggccgttgttaalNH2	3'base 2'One, 3'Amine	891
FRET probe		Fcaco(Cy3)gcitcccg		892
probe		cgcacgcgcgcggatgttggggNH2	3' Amine	893
invader		gtt tgg gag gaa gtt ttc aag tat ta	all 2'One bases	894
stacker		ttt gct ttt cca ggt ggt cca g	all 2'One bases	895
arrestor		ccc.aaa.ccc.cca.agg.tgg.g	all 2'One bases	896
SRT		cggaaatggatgttggggccgttgttaalNH2	3'base 2'One, 3'Amine	897
FRET probe		Fcaco(Cy3)gcitcccg		898
probe		cac cgt gat cac cgg aat ttg gg NH2	3' Amine	899
invader		gtt tgg gag tgg ttc aag tat ta	all 2'One bases	900
stacker		ttt gct ttt cca ggt ggt cca g	all 2'One bases	901
arrestor		cta. gtt. gtc. tea. aac. cc	all 2'One bases	902
SRT		cggaaatggatgttggggccgttgttaalNH2	3' Amine	903
FRET probe		Fcaco(Cy3)gcitcccg		904

hsA4 probe	gtg gcg tat cac aga caa tga gag	1190					
hsA4 invader	cct cct tta tat tcc caa gta taa cac tct aa	1191					
Capture Sequence							
Set 2/ Set 3							
hsA4 probe	AAC GAG GCG CAC CAC AGA CAA TGA GAG	1192					
hsA4 arrestor	CCT CTC ATG TGT CTG TG GCG -NH2	1193					
hsA4 invader	cct cct tta tat tcc caa gta taa cac tct aa	1194					
hsA4 stacking oligo	agtcacatgcgtacatgcgtacatcccg	1195					
hsA4 stacking oligo	agtcacatgcgtacatgcgtacatcccg	1196					
SRT							
FRET Oligo							
Set 4							
hsA4 probe	aac gag gcg cac aga caa tga gag agc-NH2	1197					
hsA4 arrestor	cic tct cat ttt ctg ttg tgc gtc -NH2	1198					
hsA4 invader	cct cct tta tat tcc caa gta taa cac tct aa	1199					
hsA4 stacking oligo	ctt aat gca ttt tca gta tcc tcg gtt	1200					
SRT							
FRET Oligo							
Set 5							
hsA4 probe	aac gag gcg cac aga caa tga gag agc-NH2	1201					
hsA4 arrestor	agc tct ctc att gtc tot gtt gtc -NH2	1202					
hsA4 invader	cct cct tta tat tcc caa gta taa cac tct aa	1203					
SRT							
FRET probe	Fl-caa-c(y)3)g-cit-cct-cgg	1204					
Set 6							
hsA4 probe	aac gag gcg cac aga caa tga gag agc-NH2	1205					
hsA4 arrestor	gtt ctc tot ttg ttt gtc -NH2	1206					
hsA4 invader	cct cct tta tat tcc caa gta taa cac tct aa	1207					
SRT							
FRET probe	Fl-caa-c(y)3)g-cit-cct-cgg	1208					
Set 7/ Set 8							
hsA4 probe	aac gag gcg cac aga caa tga gag a-NH2	1209					
hsA4 probe	aac gag gcg cac aga caa tga gag a	1210					
hsA4 arrestor	tct ctc att gtc tot gtt gtc -NH2	1211					
hsA4 stacking oligo	gtt caa tgc atg lac aga atc ccc ggt t	1212					

h3A4 invader	cc t cc itt itt tcc caa gta ita cac tct aa	1213
SRT		
FRET Oligo		
Set 9		
h3A4 probe	aac gag gag cac cac aga caa tga gg-NH2	1214
h3A4 arrestor	tct cat tgc tg tag ttc gr-NH2	1215
h3A4 invader	cc t cc itt itt tcc caa gta ita cac tct aa	1216
h3A4 stacking oligo	ggc ctc aat gca tgc acg gaa tcc ccg	1217
SRT		
FRET Oligo		
Set 1/ Set 2		
h3A4 probe	AACGAGGGCACCTCTTATCAGAGCTC	1218
h3A4 probe	AACGAGGGCACCTCTTATCAGAGCTC-NH2	1219
h3A4 invader	tgt tag aata ita itg aya aai git gat ta	1220
h3A4 arrestor	GAGCTCGATAAGAGGGGCC-NH2	1221
SRT		
Set 1 / Set 2 / Set 3		
h3A4 probe	ccg tca cgc ctc goc cca ca - NH2	1222
h3A4 arrestor	tat tgg ggg agg cg	1223
h3A4 invader	cgt cac agg ctt tgg acc aic ataa aaaa c	1224
h3A4 stacking oligo	cau-ucu-uu-uu-uu-uu-uu-uu-uu-uc	1225
h3A4 stacking oligo	ctt ttc cag act ttt tat gag	1226
h3A4 stacking oligo	ctt ttc cag act ttt tat gag	1227
SRT		
FRET		
Set 4 / Set 5		
h3A4 probe	ccg tca cgc ctc gcc cca ca - HEX	1228
h3A4 probe	ccg tca cgc ctc gcc cca ca - HEX	1229
h3A4 invader	cgt cac agg ctt tgg acc aic ataa aaaa c	1230
h3A4 stacking oligo	cau-ucu-uu-uu-uu-uu-uu-uu-uc	1231
SRT		
FRET		
Set 6 / Set 7 / Set 8		
h3A4 probe	ccg tca cgc ctc goc cca cc - NH2	1232

	h3A4 probe	ccg lca cpc ctc ggc cca cg - NH2	1233
	h3A4 probe	ccg lca cpc ctc ggc cca ct - NH2	1234
	h3A4 arrestor	tgt ggg gca agg cg	1235
	h3A4 invader	cag ctc agg ctg tgg acc atc ata aata c	1236
	h3A4 stacking oligo	cau-uuu-ccu-acc-uuu-uuu-uuu-gac-auu-c-	1237
SRT	FRET		
Set 1			
	h3A4 probe	ccg lca cpc ctc ala aaaa gcc c -NH2	1238
	h3A4 arrestor	ggg ttta tga tca ggc g	1239
	h3A4 invader	cag ctc agg ctg tgg acc c	1240
	h3A4 stacking oligo	cac act ttu cca ttc ttu ttu tg	1241
SRT	FRET		
Set 2			
	h3A4 probe	aac ggg gca cca ttg gat gaa g - NH2	1242
	h3A4 arrestor	ctt ttat cca atg gtt gca g	1243
	h3A4 invader	gtt cag aat ccc ttg ttg aat gat ta	1244
	h3A4 stacking oligo	cccc atc ttu tca ttu ttu tg	1245
SRT	FRET		
Set 1			
	h3A5 probe	gtt gcg tat cgt gtc taa tt caa g	1246
	h3A5 invader	aat 999 ttu ttg ttg aat gat ttg ttg a	1247
	Capture Sequence		
Set 2/ Set 3			
	h3A5 probe	AACGAGGCCACCGTGTCTAATTTCAG	1248
	h3A5 arrestor	AACGAGGCCACCCGTGTCTAATTCAAGCG-P <i>i</i>	1249
	h3A5 invader	CITGAAATTAGACACGTCG-G-NH2	1250
SRT	FRET		
Set 4			
	h3A5 probe	AACGAGGCCACCGTGTCTAATTTCAG	1252
	h3A5 arrestor	CITGAAATTAGACACGTCG-G-NH2	1253

h3A5 invader	aat 9gg ttt ttc tgg ttg aag aag tcc ttgt a		1254
h3A5 stacking oligo	9gg atc ttg gtt tct ttta caa gtt		1255
SRT			
FRET			
Set 5			
h3A5 probe	AACGAGGGCGCACCCGTGCTTAATTTCAAAGGG-NH2		1256
h3A5 arrestor	ctt gaa att tga eac gtt tct ttt		1257
h3A5 invader	gtt tti tct tgg tga aag agt cct tga		1258
h3A5 stacking oligo	ggg atc ttg tct ttt		1259
SRT			
FRET			
Set 6			
h3A5 probe	AACGAGGGCGCACCCGTGCTTAATTTCAAAGGG-NH2		1260
h3A5 arrestor	CCCTTGAAATTAGACACGGTSGC-NH2		1261
h3A5 invader	aat 9gg ttt ttc tgg ttg aag aag tcc ttgt a		1262
SRT			
FRET probe	FL-caa-c(cy3)g-att-cdt-cgg		1263
Set 7/ Set 8			
h3A5 probe	aac gag ggg cac cgt gtc taa ttt caa gg-NH2		1264
h3A5 probe	aac gag ggg catc cgt gtc taa ttt caa gg		1265
h3A5 probe	cct tga aat tag aca cgg tgg tgc gtc-NH2		1266
h3A5 arrestor	sct tga aat tag aca cgg tgg tgc gg		1267
h3A5 invader	aat 9gg ttt ttc tgg ttg aag aag tcc ttgt a		1268
h3A5 stacking oligo	ggg ttg ttt ctg tac aag gtt tga aag ag		1269
SRT			
FRET			
Set 9			
h3A5 probe	aac gag ggg cac cgt gtc taa ttt caa-NH2		1270
h3A5 arrestor	ttt aaa ttg aac acg ttg cgt cgt-NH2		1271
h3A5 invader	aat 9gg ttt ttc tgg ttg aag aag tcc ttgt a		1272
h3A5 stacking oligo	ggg gat cgt ttt tttt aca aag		1273
SRT			
FRET			
Set 10			
h3A5 probe	aac gag ggg cac cgt gtc taa ttt caa - NH2		1274

h3A5 arrestor
h3A5 invader
h3A5 stacking oligo
SRT
FRET

Set 1
h3A5 probe
h3A5 invader
Capture Sequence

Set 1
h3A5 probe
h3A5 invader
Capture Sequence

Set 2/ Set 3
h3A5 probe
h3A5 arrestor
h3A5 invader
h3A5 stacking oligo
SRT
FRET

h3A5 probe
h3A5 invader
h3A5 stacking oligo
SRT
FRET

Set 1
h3A5 probe
h3A5 arrestor
h3A5 invader
h3A5 stacking oligo
SRT
FRET

h3A5 probe	ccg tca cgc ctg ttc ala cgt tcc -NH2	1294
h3A5 arrestor	sgg acg tat gaa cag ggg	1295
h3A5 invader	cca gca cgg gga gtt gac c	1296
h3A5 stacking oligo	cca cat ttcc ataa cttt	1297
SRT		
FRET		
Set 1-Set 4		
h3A5 probe	aac gag ggg cac agt tga cct tca	1298
h3A5 probe	aac gag ggg cac agt tga cct tca	1299
h3A5 probe	aac gag ggg cac agt tga cct tca - HEX	1300
h3A5 arrestor	tta aatg tca act gtt cgc	1301
h3A5 invader	gtg atg ggg aca ggg c	1302
h3A5 stacking oligo	tac gtt ccc cat att ttc	1303
h3A5 stacking oligo	tac gtt ccc cat att ttc	1304
SRT		
FRET		
Set 5		
h3A5 probe	ccg tca cgc ctc agt tga oct tca	1305
h3A5 arrestor	tga aatg tca tac gag ggg	1306
h3A5 invader	gtg atg ggg aca ggg c	1307
h3A5 stacking oligo	tac gtt ccc cat att ttc	1308
SRT		
FRET		
Set 6		
h3A5 probe	aac gag ggg cac tcc tct caa gt -NH2	1309
h3A5 arrestor	act tta gaa taa ttc tcc tcc	1310
h3A5 invader	cca ttt att tca aca tcc ttc ttt	1311
h3A5 stacking oligo	cta att gca act ggg aat aat ttc	1312
SRT		
FRET		
Set 7		
h3A5 probe	ccg tca cgc ctc tcc tct caa gtt - NH2	1313
h3A5 arrestor	act ttt ggg ggg agg ccg	1314
h3A5 invader	cca ttt att tca aca tcc ttc ttt	1315
h3A5 stacking oligo	cta att gca act ggg aat aat ttc	1316

FRET				
Set 8				
h345 probe	aac gag ggg cac aeg tga cct tc - NH2	1317		
h345 arrester	tga agg tca aet gtt cgg	1318		
h345 invader	gtt aig gcc aeg aca 999 c	1319		
h345 stacking oligo	ata cgt tcc cca cat tt tc	1320		
SRT				
FRET				
Set 1				
h347 Probe	tgg cgt atc tgg att aaaa tct taa aag	1321		
h347 Invader	gac ttt lat tgg aeg aac gaa tgg atc taa a	1322		
Capture Oligo				
Set 2				
h347 Primary Probe	AACGAGGGCACACTGGATTAAATCTTAAAAAG	1323		
h347 Invader	gac ttt lat tgg aac gaa tgg aic taa a	1324		
h347 Arrestor	C T T T A A G G A T T T A A T C C A G T G C G - N H 2	1325		
SRT				
FRET				
Set 3				
h347 Primary Probe	AACGAGGGCACACTGGATTAAATCTTAAAAAG	1326		
h347 Invader	gac ttt lat tgg aac gaa tgg aic taa a	1327		
h347 Arrestor	C T T T A A G G A T T T A A T C C A G T G C G - N H 2	1328		
h347 Stacking Oligo	sit ctt ggt gtt ttc ca	1329		
SRT				
FRET				
Set 4				
h347 Probe	agg agc cac tca loc cit gac t	1330		
h347 Invader oligo	cit agg gaa atc egg ctc cac tta cgg ta	1331		
Capture Oligo				
Set 5/ Set 6				
h347 Primary Probe	AACGAGGGCACCTCATCCCTTGACT	1332		
h347 Primary Probe	AACGAGGGCACCTCATCCCTTGACT - NH2	1333		
h347 Arrestor	AGTCAGGGATGGATGGGTGGG - NH2	1334		
h347 Invader oligo	cit agg gaa atc agg cit cac tta cgg ta	1335		

SRT							
FRET							
Set 7 - Set 10							
hsA7 Primary Probe	aac gag gcg cac ctc atc cct tga c-NH2	1336					
hsA7 Invader oligo	gtc aag ggg tga ggt tgc c-NH2	1337					
hsA7 Stacking Oligo	cit agg gaa atc aeg ctc caactt ccg ta	1338					
hsA7 Stacking Oligo	tca gcc tt aag aca aag ggt tt tc t gt ag3'	1339					
hsA7 Stacking Oligo	tcg aca tt tca aca atg gtt tt tc t g	1340					
hsA7 Stacking Oligo	cic adc ct tag aac aat ggg tt ttc t	1341					
hsA7 Stacking Oligo	etc agc ct tag sac aat ggg tt ttc t	1342					
SRT							
FRET							
Set 11							
hsA7 Primary Probe	aac gag gcg cac ctc atc cct tga c-NH2	1343					
hsA7 Primary Probe	aac gag ggg ctc atc ctc tga c	1344					
hsA7 Arrestor	tca aag gat ggg gta ctc c-NH2	1345					
hsA7 Invader oligo	ctt agg gaa atc aeg ctc caactt ccg ta	1346					
hsA7 Stacking Oligo	cic agc ct tag aac aat ggg tt ttc t gg3'	1347					
SRT							
FRET							
Set 1							
hsA7 Probe	ata cgg ttg gta aeg taa ttg ggt	1348					
hsA7 Invader	gaa gcc cgt ctt cat ttc agg git cta tt c	1349					
Capture Sequence							
Set 2							
hsA7 Primary Probe	AACGAGGGC/CACGTAAAGTAATTGGAGGT	1350					
hsA7 Invader	gaa gcc cgt ctt cat ttc agg git cta tt c	1351					
hsA7 Arrestor	ACCTCAAATTACTTTAACGTGCG-NH2	1352					
SRT							
FRET							
Set 3							
hsA7 Primary Probe	AACGAGGGC/CACGTAAAGTAATTGGAGGT	1353					
hsA7 Invader	gaa gcc cgt ctt cat ttc agg git cta tt c	1354					
hsA7 Arrestor	ACCTCAAATTACTTTAACGTGCG-NH2	1355					
hsA7 Stacking Oligo	etc tgg ttg tct ggg	1356					

SRT				
FRET				
Set 1				
h3A7 probe	ccg tca cgc ctc gtc ata aat acc cc - NH2	1357		
h3A7 arrestor	ggg gtc ttg atg acg agg cg	1358		
h3A7 invader	gcc ggc aia sgc tgc lga cac	1359		
h3A7 stacking oligo	aga ctt ttc fal act tt tat sac att c	1360		
SRT				
FRET				
Set 2 - Set 4				
h3A7 probe	aac gag gag eac gtc ala aat acc cc -NH2	1361		
h3A7 probe	aac gag gag cac gtc ala aat acc cc	1362		
h3A7 probe	aac gag gag cac gtc ala aat acc cc - HEX	1363		
h3A7 arrestor	ggg gta ttg atg acg tgc gg	1364		
h3A7 invader	gcc ggc aia sgc tgc lga cac	1365		
h3A7 stacking oligo	aga ctt ttc fal act tt tat sac att c	1366		
SRT				
FRET				
Set 1				
h3A7 probe	ccg tca cgc ctc gat itaa alc taa aat gct t - NH2	1367		
h3A7 arrestor	aag ctt tta aga tt aat cgt ggc g	1368		
h3A7 invader	gac tt taa tgg aac gas tgg atc laa tgc	1369		
h3A7 stacking oligo	cit ggt gtt ttc eac aaa g	1370		
SRT				
FRET				
Set 2				
h3A7 probe	aac gag gag cac gat taa alc tta aaa gct t -NH2	1371		
h3A7 arrestor	aag ctt tta aga tt aat cgt qcd c	1372		
h3A7 invader	gac tt taa tgg aac gas tgg alc laa tgc	1373		
h3A7 stacking oligo	cit ggt gtt ttc eac aaa g	1374		
SRT				
FRET				
Set 1				
h3A7 probe	ccg tca cgc ctc gtc cit g - NH2	1375		
h3A7 arrestor	caa ggg atg cac ggc g	1376		

hsA7 invader	sga aat cag gel cca ctt acg gtc a						
hsA7 stacking oligo	act cag cct tta gaa caa tg						
SRT							
FRET							
Set 1							
hsA7 probe	ccg lca cgc ctc taa agt aat tgg agg tc -NH2						
hsA7 arrestor	gac ctc aaa tta ctt tgg agc tg						
hsA7 invader	cgf ctt cat ttc aeg gtt cta ttt gaa						
hsA7 stacking oligo	tct ggt gtt ctg gg						
SRT							
FRET							
Set 2							
hsA7 probe	aac gag gtc cac taa aeg eal tgg aeg tc -NH2						
hsA7 arrestor	gac ctc aaa gga ctt tag tgc gg						
hsA7 invader	cgt ctt cat ttc aeg gtt cta ttt gaa						
hsA7 stacking oligo	tct ggt gtt ctg gg						
SRT							
FRET							
Set 1							
rAA1 Probe	tgg-tgt-aatc-ttg-gct-ttg-ttttcc						
rAA1 Invader	ttc atg tag tca ggg tca tag aca att aeg a						
Capture Sequence							
Set 2							
rAA1 Primary Probe	AACGAGGCCCACTAGGCCTTGCCTTC						
rAA1 Arrestor	GGAAAGCAAAGGCCTAGTGCAG-NH2						
rAA1 Invader	sga aat cca ggc tgg tgc gg-NH2						
FRET Probe 1	ttc atg tag tca ggg tca tag aca att aeg a						
Set 3							
rAA1 Primary Probe	aac gag gtc cac tag gct tgg ctt ccc-NH2						
rAA1 Arrestor	sgg aat cca aeg ctt atg tgg tgc gg-NH2						
rAA1 Invader	ttc atg tag tca ggg tca tag aca att aeg a						
SRT							
FRET Probe 1							

Set 4	r4A1 Primary Probe	aac gag gag cac tag gct tgg ctg c-NH2	1396
	r4A1 Arrestor	qaa gca aatg cct aatg ggc c	1397
	r4A1 Slacker	ccc sga acc atc gag gaa egg c	1398
	r4A1 Invader	tcc atg tag tca ggg tca tag aata att aag a	1399
SRT	FRET Probe 1		
Set 5	r4A1 Primary Probe	aac gag gag cac tag gct tgg ctg c-NH2	1400
	r4A1 Arrestor	aatg cca aatg cct aatg ggc c	1401
	r4A1 Invader	ttc atg tag tca ggg tca tag aata att aag a	1402
	r4A1 Slacker	ccc cag eac cat cga tga aag g	1403
	r4A1 Slacker	ccc cag eac cat cgt gta aag g	1404
SRT	FRET Probe 1		
Set 6	r4A1 Primary Probe	aac gag gag cac tag gct tgg ctg c-NH2	1405
	r4A1 Arrestor	aatg cca aatg cct aatg ggc c	1406
	r4A1 Invader	ttc atg tag tca ggg tca tag aata att aag a	1407
	r4A1 Slacker	ccc cag eac cat cgt gta aag g	1408
	r4A1 Slacker	ccc cag eac cat cgt gta aag g	1409
SRT	FRET Probe 1		
Set 7	r4A1 Primary Probe	aac gag gag cac tag gct tgg ctg c-NH2	1410
	r4A1 Primary Probe	aatg cca aatg cct aatg ggc c	1411
	r4A1 Probe	egg agat tat gtt gaa aata ttg aac	1412
	r4A1 Arrestor	tcc cca gaa tca tgg aag gaa gg	
	r4A1 Invader	tcc cca gaa tca tgg aag gaa gg	
	r4A1 Slacker		
	r4A1 Slacker		
SRT	FRET Probe 1		
Set 8	r4A1 Probe	ata egg tgg gtc tgg ccc	1413
	r4A1 Invader	egg agat tat gtt gaa aata ttg aac	1414
Capture Sequence			
Set 12	r4A1 Primary Probe	AACGAGGGCAAGCTCTGAACCTGCC	1415
	r4A1 Invader	GGGAGGGCAAGCTGGAGGAGG	1416
	r4A1 Invader	agg aata ttg gaa aata ttg aac	1417

SRT							
FRET Probe 1							
Set 3							
raA1 Primary Probe	AACGAGGCCACGTCTTGACCTGC-Pi						
raA1 Arrestor	GGAGGGTAAAGACGTGCG-NH2						
raA1 Invader	agg ega lat gtt gaa aqa itt cta tag agg ac						
SRT							
FRET Probe 1							
Set 1							
raA1 Probe	tgg cgt atc ita dat ggg gla agg a						
raA1 Invader	att cct cat eat tca aaa ggg act tag tag gt						
Set 2							
raA1 Primary Probe	AACGAGGCCACTTAGATGGAGTAAGGGA						
raA1 Arrestor	TGCTTACTCCATCTAAGTGGC-NH2						
SRT							
FRET Probe 1							
Set 1							
raA1 Primary Probe	aac gag ggc eac lgg ala occ ttg gg-NH2						
raA1 Arrestor	ccc aag ggt atc eac tgc gtc-NH2						
raA1 Invader	ggg gaa gac cat aaa tgg aag gtc tga cta						
SRT							
FRET Probe 1							
Set 1							
raA2 Probe	aac gag ggc eac agg lgt ctg gag taa aag-NH2						
raA2 Arrestor	ctt tta ctc cag aca cct gtg cgc-NH2						
raA2 Invader	gtc cac gca cta gct ggg ac						
SRT							
FRET Probe 1							
Set 1							
raA2 Probe	aac gag ggc eac agg ooc cit-NH2						
raA2 Arrestor	aag ggg ccc tct dtg cgc-NH2						
raA2 Invader	cct tga aca gca gaa ata gac tga gca c						
raA2 stacking oligo	ggg aga acc eac aga cac cat cc						
SRT							

Set 2	cgg tca cgc ctc aca agg ccc ctt g-NH2 aag sgg cct ttg tgc sgg c-NH2 ccc tga atca gca cca gca ataa gac tga gca c	1435 1436 1437				
r442 Probe						
r442 Arrestor						
r442 Invader						
SRT						
FRET Probe 1						
Set 3	aac gag gog caac aga agg ccc ctt g-NH2 aaa sgg gca ttc ttt tgc sgg c-NH2 ccc tga atca gca cca gca ataa gac tga gca c	1438 1439 1440				
r442 Probe						
r442 Arrestor						
r442 Invader						
SRT						
FRET Probe 1						
Set 4	aac gag gog caac aga agg ccc ctt g-NH2 aac gag gog caac aga agg ccc ctt aac gag gog caac aga agg ccc ctt - HEX cca aag gca ctt ttt tgc sgg c-NH2 aag sgg cct ttg tgg sgg ccc tga atca gca cca gca ataa gac tga gca c	1441 1442 1443 1444 1445 1446				
r442 Probe						
r442 Arrestor						
r442 Invader						
SRT						
FRET Probe 1						
Set 1	aac gag gog caac ttt tgc aca gag tcc gg-NH2 ggc gca ttt tgc aag tgc ttt gca tta taa	1447 1448 1449				
r443 Probe						
r443 Arrestor						
r443 Invader						
SRT						
FRET Probe 1						
Set 2	aac gag gog caac ttt tgc aca gag tcc gg-NH2 ggc act ctt tca ttt tgc sgg c-NH2 gtt tct ccc att ttt tca gca tta taa cca tgg ttt tga cat agg gtg tga gca tg	1450 1451 1452 1453				
r443 Probe						
r443 Arrestor						
r443 Invader						
r443 stacking oligo						
SRT						
FRET Probe 1						

Set 3	aac gag gag cac ttg aca gag tcc-NH2 aac gag gag cac ttg aca gag tcc aac gag gag cac ttg aca gag tcc - HEX ggc ctc tct caa gtt cgc ccc-NH2 ggc ctc tct caa gtt ccc gtt tct ccc att tct cta gca ita taa gtt tct ccc att tct cta gca ita taa gcc atg att ttg aca tag ggt tag agg atg SRT	1454 1455 1455 1456 1457 1458 1459 1460
FRET Probe 1		
Set 1		
r2B1 probe r2B1 invader Capture Sequence	cgg agc ctc lgc ggt cat caa: g tgg ata act gca tea gtg tat ggc att tta a	1461 1462
Set 2 / Set 3		
r2B1 probe r2B1 invader Capture Sequence	gtg-gcg-tat-cdg-cgg-lca-lca-ag gtg-gcg-tat-cdg-cgg-lca-lca-a tgt ata act gca tea gtg tat ggc att tta a	1463 1464 1465
Set 4		
r2B1 probe r2B1 invader Capture Sequence	tgg agt act gca tea gtg tat ggc att tta a	1466 1467
Set 5 - Set 7		
r2B1 probe r2B1 invader r2B1 invader r2B1 invader SRT FRET	acc-gag-gcg-cac-cdg-cgg-lca-lca-a ttt-atg-acc-gca-gtg-lcc-lcc-NH2 ttt-atg-acc-gca-gtg-gcg-lcc-Pi ttt-atg-acc-gca-gtg-gcg-lcc-OH tgt ata act gca tea gtg tat ggc att tta a	1468 1469 1470 1471 1472
Set 8		
r2B1 probe	aaa-gag-gcg-cac-dig-cgg-lca-lca-a	1473

ttg-atg-acc-gca-tgt-gcc-cc-Pi tgg ataa acg tca gtt ttt gtc att tt ggg ttt gtt gtc ttt gtt agc cgt ttt SRT FRET	1474 1475 1476
	1477 1478 1479
	1480 1481 1482
	1483 1484 1485
	1486 1487 1488
	1489 1490 1491
Set 9 (2B1) arrestor (2B1) invader (2B1) stacker SRT FRET	
aac-gtg-gcg-eac-cgt-agg-tca-tca-a-NH2 ttg-atg-acc-gca-tgt-gcc-NH2 ttg ataa acg tca gtt ttt gtc att tt ggg ataa acg tca gtt ttt gtc att tt SRT FRET	
Set 10 (2B1) probe (2B1) arrestor (2B1) invader SRT FRET	
gcg-eac-gtg-tca-cac-cgt-cgt-agg-tca-tca-ag-Pi ttg-atg-acc-gca-tgt-gcc-cc-Pi ttg ataa acg tca gtt ttt gtc att tt ggg ataa acg tca gtt ttt gtc att tt SRT FRET	
Set 11 (2B1) probe (2B1) arrestor (2B1) invader SRT FRET	
aac ggg ccc ctt ctt ctt ttt ttt ctt gat gag ccc agg tgc c-NH2 ttg ataa acg tca gtt ttt gtc att tt ggg ataa acg tca gtt ttt gtc att tt SRT FRET	
Set 12 (2B1) probe (2B1) arrestor (2B1) invader SRT FRET	
aac ggg ggg ccc ctt ctt ctt ttt ttt ccc ttt ttt ttt ttt ttt ttt ttt ttt gat gag ccc agg tgc c-NH2 ttg ataa acg tca gtt ttt gtc att tt ggg ataa acg tca gtt ttt gtc att tt SRT FRET	
Set 13 (2B1) probe (2B1) arrestor (2B1) invader SRT FRET	
atg acg tga cag acc ttt ttt ttt ttt gat gag ccc agg tgc c-NH2 ttg ataa acg tca gtt ttt gtc att tt ggg ataa acg tca gtt ttt gtc att tt SRT FRET	

Set 14	aac gag gac cac ctg agg tca tca a-NH2 ttg atg acc tca cgt lgcg-NH2 tgg aha acr gca tca gtg tat gcc att tt a SRT FRET	1492 1493 1494
Set 15	cag tca cgt ctg ctg ctg tca aag-NH2 ctt gat gac ctc agg atg atg cg-NH2 tgt atc act gca tca gtg tat gcc att tt a SRT FRET	1495 1496 1497
Set 16	cag tca cgt ctg act gcg gtc atc aag-NH2 gtt gat gac tgc atc agt gta tgg cat tt c ctt gat gac ctc agg atg atg aag-NH2 SRT FRET	1498 1499 1500
Set 17	cag tca cgt ctg act gcg gtc atc aag-NH2 ttg atg acc gca gtg atg atg cg-NH2 tgt gat aac tgc atc agt gta tgg cat tt c gtt tgg tgg gca tgg tgg agc cta t SRT FRET	1501 1502 1503 1504
Set 18	cag tca cgt ctg act gcg gtc atc aag-NH2 ttg tga cgg cag tga gac q-NH2 gtt gat aac tgc atc agt gta tgg cat tt c agg gtt ggt ggg atg ctg tgg tgg occ a SRT FRET	1505 1506 1507 1508
Set 19	cag tca cgt ctg act gcg gtc atc aag-NH2	1509

1510
1511
1512

1513 1514 1515 1516

1521
1522
1523
1524

1530

ctt gat gac cgc agt gag acg -NH₂
 ggg gat aac tgc atc agt gta tgg cat tt c
 gct tgg tag cct qtq tga qcc qat c

```

cag tca cgt ctc act gcg gtc at-NH2
atg acc gca gtc gtg aga cg-NH2
gtg gat aac tgc atc agt gla lgg cat ttt c
caa ggg ttg gta gca gtc lgt glg agc c

```

ccg ica cgc ctc act gcg gtc atc-NH₂
gat_gac cgc agt gag gcg-NH₂
gig gat aac tgc atc agt gta tgg cat tt c
aag ggt tgg tag cgg gtg tg.

alg glg lct llg glg act clg lgt ggt aca

r2B1 arrestor
r2B1 invader
r2B1 stacker

r2B1 probe
r2B1 arrestor
r2B1 invader
r2B1 stacker

r2B1 probe
r2B1 arrestor
r2B1 invader
r2B1 stacker

Set 1

r2B1 arrester	cit-gtc-ctt-att-gga-tgtg-ccgc-c		1532
SRT			
FRET			
Set 1			
r2B1 probe	ggg fac tgc egg cgt tgg gac c	1533	
r2B1 invader	cat tt act gcg glc atc aag tgt tgg tc	1534	
Capture Sequence			
r2B1 probe	tgg cct atg aac cgg tgt cgg c	1535	
r2B1 invader	cat tt act gcg glc atc aeg ggt tgg tc	1536	
Capture Sequence			
Set 1			
r2B2 invader	ggg tga cgt cat cag lgt atg gca ttt tgc	1537	
r2B2 probe	aac-ggg-ggg-cac-gta-cgt-aac-ccgc-c-NH2	1538	
r2B2 arrester		1539	
SRT			
FRET			
Set 1			
r2B2 invader	atg gtg tct tttt ggt act ctg tgt ggt aac	1540	
r2B2 probe	tgg cct atg acc aat tgg ggc aa	1541	
r2B2 stacker	gtt tgg cact atc tct gtta tct gt gta tg	1542	
r2B2 invader stacker	tct tgg aga gca ggt acc ctc tgg ac	1543	
Set 2			
r2B2 probe	tgg cct atg acc aat tgg ggc aag	1544	
r2B2 invader	atg gtg tct tgg ggt act ctg tgt ggt aac	1545	
r2B2 stacker	atc tgg aact tct tct ctt gtt gat gaa	1546	
r2B2 invader stacker	tct tgg aga gca ggt acc ctc tgg ac	1547	
Set 3			
r2B2 probe	aac-geg-geg-cac-accc-aat-tgg-3ac-c-aatg	1548	
r2B2 probe	aac gag gac cac acc aat tgg ggc aag	1549	
r2B2 arrester	ttt-gtc-cca-att-tgt-tgt-3ccgc-c-NH2	1550	
r2B2 invader	atg gtg tct tgg act ctg tgt ggt aac	1551	
SRT			
FRET			

Set 4	aac-gag-gcc-acc-aat-tgt-tgg-c-aag-Pi	1552	cit-gcc-ccr-att-tgt-ttg-cgc-c-Pi	1553	aln gtt tct tgg act ctc tgg ttt aac	1554		
r2B2 probe								
r2B2 arrestor								
r2B2 invader								
SRT								
FRET								
Set 5	cit gcc cca att ggt gtt cgt ca-NH2	1555	aac-gag-gcc-acc-aat-tgt-tgg-c-aag-NH2	1556	aln gtt tct tgg act ctc tgg ttt aac	1557	aln tgc aaa tct tgg aat ctc gtt gtt ga	1558
r2B2 arrestor								
r2B2 probe								
r2B2 invader								
r2B2 stalker								
SRT								
FRET								
Set 6	ggc-aac-agg-gcc-cac-cca-thg-ggg-csa-q	1559	ctt-gcc-ccr-att-tgt-tgg-cgc-c-NH2	1560	aln gtt tct tgg act ctc tgg ttt aac	1561		
r2B2 probe								
r2B2 arrestor								
r2B2 invader								
SRT								
FRET								
Set 7	aac gag ggc acc aat tgg ggc aag atc-NH2	1562	gtt ctt gcc cca att ggt gtt cgt ca-NH2	1563	aln gtt tct tgg act ctc tgg ttt aac	1564		
r2B2 probe								
r2B2 arrestor								
r2B2 invader								
SRT								
FRET								
Set 8	aac gag ggc acc aat tgg ggc aag-NH2	1565	cit-gcc-cca-att-ggt-gtt-cgt-ca-NH2	1566	aln gtt tct tgg act ctc tgg ttt aac	1567	aln tgc aaa tct tgg aat ctc gtt gtt ga	1568
r2B2 probe								
r2B2 arrestor								
r2B2 invader								
r2B2 stalker								
SRT								
FRET								
Set 9	cag tca cgt ctc atg gtt gtt gcc ttt g-NH2	1569						
r2B2 probe								

r2B2 invader	gtt tgg cat ttg ggt aeg atc aat gag 9gc	1570
r2B2 arrestor	cac agg cca cca tga gag g-NH2	1571
SRT		
FRET		
Set 10		
r2B2 probe	cag tca tgg ctc agia goc aat cac ctg-NH2	1572
r2B2 invader	cga tca tca aag aat ggt ggc ctg tgc	1573
r2B2 arrestor	sag-gtg aat ggc tct gag acg-NH2	1574
r2B2 slacker	ata aat ctc ctt tg gac ttt ctc tgc g	1575
SRT		
FRET		
Set 11		
r2B2 probe	cag tca tgg ctc agia goc aat cac ct-NH2	1576
r2B2 invader	cga tca tca aag aat ggt ggc ctg tgc	1577
r2B2 arrestor	agg tga ttg acti ctg agia sg-NH2	1578
r2B2 slacker	gtt cac ta cct ttg gaa ctt tct tgc c	1579
SRT		
FRET		
Set 12		
r2B2 probe	FAM-cag tca cgt ctc agia goc aat cac ct-NH2	1580
Set 13 / Set 14		
r2B2 probe	cag tca ogl ctc agia goc aat cac c-NH2	1581
r2B2 invader	sgt gatggc ctc tgc gag g-NH2	1582
r2B2 arrestor	cga tca tca aag aat ggt ggc ctg tgc	1583
r2B2 slacker	gtt cac tct oct ttg gaa ctt tct tgc c	1584
r2B2 slacker	tga tca atc tcc ttg aat ttc tct tgc	1585
SRT		
FRET		
Set 15		
r2B2 probe	cag tca ogl ctc agia goc aat cac-NH2	1586
r2B2 arrestor	gtt atl gag tet gag acg-NH2	1587
r2B2 slacker	ctg atl aat ctc ctt tgg gac ttt cac tgc g	1588
r2B2 invader	cga tca tca aag gag ggt ggc ctg tgc	1589
SRT		
FRET		

		1590
	r2b2 probe	1591
	r2b2 arrester	1592
	r2b2 invader	1593
	r2b2 stacker	
	SRT	
	FRET	
Set 16		
r2b2 probe	cgc tca cgc ctc aga ggc aat cac ct-NH2	1594
r2b2 arrester	agg tga ttg ctc ctg aga gcc-NH2	1595
r2b2 invader	cga tca tca aat gat ggt gcc ctg tgc	1596
r2b2 stacker	gat caa tct cct ttt gga ctt tct ctg c	1597
SRT		
FRET		
Set 17		
r2b2 probe	cgc tca cgc ctc aga ggc aat cac ctg-NH2	1598
r2b2 arrester	cag dtg att cc tct gaa atcg-NH2	1599
r2b2 invader	cga tca tca agg gag gat ggt gcc ctg lgc	1600
r2b2 stacker	atc aat ctc ctt tgg gac ttt ctg ctc g	1601
SRT		
FRET		
Set 18		
r2b2 probe	cgc tca cgc ctc aga ggc aat cac ct-NH2	1602
r2b2 arrester	agg tga ttg ctc ctg agc gcc-NH2	1603
r2b2 invader	cga tca tca agg gag gat ggt gcc ctg lgc	1604
r2b2 stacker	gat caa tct cct ttt gga ctt tct ctg c	1605
SRT		
FRET		
Set 19		
r2b2 probe	cgc tca cgc ctc aga ggc aat cac c-NH2	1606
r2b2 arrester	gtt gat tgg ctc tga gcc g-NH2	1607
r2b2 invader	cga tca tca aat gat ggt gcc ctg lgc	1608
r2b2 stacker	tga tca atc tcc ttt tgg act ttc tct gc	1609
SRT		
FRET		
Set 20-21		
r2b2 probe	cgc tca cgc ctc aga ggc aat cac-NH2	1610
r2b2 probe	cgc tca cgc ctc aga ggc aat cac	1611
r2b2 arrester	dtg att cc tct gaa atcg-NH2	1612
r2b2 invader	cga tca tca agg gag gat ggt gcc ctg lgc	1613
r2b2 stacker	ctg aat ctc ctt tgg gac ttt ctg g	1614
SRT		
FRET		

Set 22				
R2B2 probe	cac tca cgt ctc aat gtc aaaa qta ctg tgg tg-NH2	1611		
R2B2 invader	gga aqj gct cag tga aqg tgt ctg gc	1612		
R2B2 invader	cca cag tac ttt gac cat gag acg-NH2	1613		
SRT				
FRET				
Set 23				
R2B2 probe	acc ggg ggc cac atg gtc aaaa qta ctg tgg tg-NH2	1614		
R2B2 invader	cca gag tac ttg cat gtt tg-NH2	1615		
R2B2 invader	gga aqj gct cag tga aqg tgt ctg gc	1616		
SRT	cca cag tac ttt gac cat gag acg-NH2	1617		
FRET		1618		
R2B2 probe	cat acg gtt ggg octt ggt aga gc	1619		
R2B2 invader	cat ttg aqj acg atc alc aeg gga tgg tc	1620		
R3A1 probe	agg egg cac egg lcc cca alic	1621		
R3A1	FL-egg acc cac egg lcc cca alic	1622		
R3A1 invader	tcc cat gtt ttg lga aaaa gtc cat ggj tqa	1623		
R3A1 probe	F-tgg octt aqj tgg gtc oca aat c	1624		
R3A1	cat-ctt-egg-ggaa-ccc-agg-tgt-cc-act-c	1625		
R3A1 invader	gat-ltg-ggaa-ccc-agg-tgt-cc-act-c-NH2	1626		
R3A1 probe	acc-agg-ggg-cac-cgg-agg-ccc-aaa-act-c-NH2	1627		
R3A1 invader	cat-ctt-egg-ggaa-ccc-agg-tgt-cc-act-c-NH2	1628		
R3A1 probe	ggg ttg ggg aac-egg tgg cgg cgg - NH2	1629		
R3A1 invader	ggg ttg ggg acc-egg tgg cgg cgg - NH2	1630		
R3A1 invader	ggg ttg ggg acc-ccc-actt-egg cgg - NH2	1631		
R3A1 invader	gat-ltg-ggaa-ccc-agg-tgt-cc-act-c-NH2	1632		
R3A1 invader	gat-ltg-ggaa-ccc-agg-tgt-cc-act-c-NH2	1633		
R3A1 invader	gat-ltg-ggaa-ccc-agg-tgt-cc-act-c-NH2	1634		
R3A1 invader	gat-ltg-ggaa-ccc-agg-tgt-cc-act-c-NH2	1635		
R3A1 probe	acc gag agg cac cgg gtc cca bat c-PtI	1636		
R3A1 probe				
R3A1 probe				

r3A1 invader	tcc cct gtt tct tga aaa gtc cat gtg lga	1637
r3A1 probe	aac gag gag cac cog gtc cca aat c-NH2	1638
r3A1 arrester	gtt ttt gta gca ccc agt ggg-NH2	1639
r3A1 probe	aac gag gag cac cog gtc cca aat c-NH2	1640
r3A1 arrester	gga ttt ggg acc ccc tgc agt gtt-NH2	1641
r3A1 probe	aac gag gag cac cog gtc cca aat c-NH2	1642
r3A1 arrester	att tgg gac ccc tgg cgg-NH2	1643
r3A1 probe	cgg tag agg acc aag agg	1644
r3A1 arrester	aac gag gag cac cog gtc cca aat c-NH2	1645
r3A1 probe	ttt ggg acc ccc tgg tgc ac-NH2	1646
r3A1 arrester	lcc tga gag gag cac cog ga	1647
r3A1 probe	cgg tca cgg ccc gtc cca aat c-NH2	1648
r3A1 arrester	ttt ggg acc ccc tgg aca cgg-NH2	1649
r3A1 probe	lcc tgg gag tgg gag ccc gtc cca aat c-NH2	1650
r3A1 arrester	cgg tca cgg ccc gtc cca aat c-NH2	1651
r3A1 probe	ttt ggg acc ccc tgg acg ccc-NH2	1652
r3A1 arrester	lcc tgg gag tgg gag ccc gtc cca aat c-NH2	1653
r3A1 probe	cgg tca cgg ccc gtc cca aat c-NH2	1654
r3A1 arrester	ttt ggg acc ccc tgg aca cgg-NH2	1655
r3A1 probe	lcc tgg gag tgg gag ccc gtc cca aat c-NH2	1656
r3A1 arrester	cgg tca cgg ccc gtc cca aat c-NH2	1657
r3A1 probe	ttt ggg acc ccc tgg acg ccc-NH2	1658
r3A1 arrester	lcc tgg gag tgg gag ccc gtc cca aat c-NH2	1659
r3A1 probe	cgg tca cgg ccc gtc cca aat c-NH2	1660
r3A1 invader	ttc ctt gtt tct taa aata ttc cat qtc taa	1661
r3A2 invader	att tt tgg aac ttc ttt tta tag cac tcc alc	1662
r3A2 probe	tgg cgt atc tgg gtt cca agt c	1663
r3A2 probe	aac gag gcg ccc gtc gaa tct ccc taa	1664
r3A2 probe	aac-gag-gcg-acc-tgg-gtt-cca-agg-c	1665
r3A2 arrester	tta tgg aca ttt gac gtt cgc c - NH2	1666
r3A2 arrester	gac-ttg-aaa-cooc-ccgc-ccgc-cc-NH2	1667
r3A2 probe	aac gag gcg ccc gtc gaa tct ccc taa	1668
r3A2 probe	aac-gag-gcg-acc-tgg-gtt-cca-agg-c-Pi	1669
r3A2 arrester	gac ttt gaa ccc act cccg-NH2	1670
r3A2 probe	aac gag ggg cac tgg gtt cca agt cg-NH2	1671
r3A2 arrester	cgg ctt ggg aac accg tgc gtc-NH2	1672
r3A2 probe	aac gag ggg cac acc cat cca gtt cta ta-NH2	1673

r3A2 invader	ggc atc ctc act act gag cct ttt ggt ata aec ac	1674
r3A2 stalker	tct ttt caa gag act ctc tea atg cta ita cc	1675
r3A2 arrestor	fat aag act taa tgg ttg tac gtc sic-NH2	1676
r3A2 probe	aat gag gag cac aac cat caa gtl cta-NH2	1677
r3A2 stalker	tat ctt ttt lac sign ctc tea gtc tat tac c	1678
r3A2 arrestor	tag aac ttt atg gtt sign sgc-NH2	1679
r3A2 probe	cag tca tgg ctc cic ggc sign gg-NH2	1680
r3A2 invader	cac sat ate gta ggt agg tgc ctt aat	1681
r3A2 arrestor	gcc.ctg.cgg.agg.aga.cg-NH2	1682
r3A2 stalker	cag tca tgg ctc ggc sign gg-NH2	1683
r3A2 invader	cac sat ate gta ggt agg tgc ctt aat	1684
r3A2 probe	ccc.tgc.tga.sign.gac.g-NH2	1685
r3A2 stalker	cag tca tgg ctc ggc sign gg-NH2	1686
r3A2 arrestor	goc oca tgg atc tcc toc	1687
r3A2 probe	ccc.tgc.tgg.gag.acg.acg-NH2	1688
r3A2 stalker	cag tca tgg ctc ggc sign gg-NH2	1689
r3A2 arrestor	ggc oca tgg atc tcc toc	1690
r3A2 stalker	cta cgg agg.aga.cg-NH2	1691
r3A2 invader	cgg tea oca cic ctc ggc sign gg-NH2	1692
r3A2 probe	scf.gcc.gag.gag.gag-NH2	1693
r3A2 arrestor	gicc oca tgg ate toc toc	1694
r3A2 stalker	ccg tea oca cic ctc ggc sign gg-NH2	1695
r3A2 probe		
hICAM-1 probe	ccg tea oga ctc ggc ttt ggt tgg-NH2	1696
hICAM-1 invader	cca.aac.caat.ggc.gtg.gcg	1697
hICAM-1 stalker	ggt.ttc.att.ggg.gtc.cct	1698
hICAM-1 arrestor	gaa.cac.aaa.agc.cga.ggc.g	1699
hICAM-1 probe	ccg tea oga ctc ggc ttt ggt tgg-NH2	1700
hICAM-1 invader	cca.aac.caat.ggc.gtg.gcg	1701
hICAM-1 stalker	ggt.ttc.att.ggg.gtc.cat.c	1702
hICAM-1 probe	ccg tea oga ctc ggc ttt ggt tgg-NH2	1703
hICAM-1 invader	cca.aac.caat.ggc.gtg.gcg	1704
hICAM-1 stalker	ggt.ttc.att.ggg.gtc.tea.tc	1705
hGAPDH probe	aaac gag gag ctc get ocd gga aga tg-NH2	1707
hGAPDH invader	cat ett caa qda oca tcc tcc-NH2	1708

1709

Secondary system oligos

Capture Oligo	aaa agt gac tcc t-(biotin)c	1710
Capture Oligo	aaa aga ggc tcc gct-(biotin)c	1711
Capture Oligo	aaa atg tac gcc gtc-(biotin)c	1712
Capture Oligo	aaa aga tcc gtc aca gct-(biotin)c	1713
Capture Oligo	aaa acc bac tgg aag aac t-(biotin)c	1714
Capture Oligo	aaa atc ata cgc cac t-(biotin)c	1715
	cgg-agg-aag-cag-ttg-ttg-cgt-gcc-ttt-NH2	1716
SRT	cgg agg aag cag ttg ttg ccc ctc gtt aa-NH2	1717
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-NH2	1718
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-NH2	1719
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-NH2	1720
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-	1721
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-	1722
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-	1723
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-	1724
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-	1725
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-	1726
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-	1727
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-	1728
SRT	cgg aag aeg cag ttg ccc ctc gtt aa-	1729
	Fl-caa ctc(3)gc ttc ctc	1730
	Fl-caa ctc(3)gc ttcc ctc c	1731
	Fl-caa ctc(3)gc ttcc ctc c	1732
	Fl-caa-ctc(3)gc-ctt-ctt-cgt-uu	1733
	Fl-caa-ctc(3)gc-ctt-ctt-cgt-uu	1734
	Fl-caa-ctc(3)gc-ctt-ctt-cgt-NH2	1735

Human GAPDH Probe	TTCATACGGTTGGCTCTGGAAAGAATG CACTTGAATTGGAGGGAACTICA	1769 1770
Human GAPDH Invader	TTCATACGGTTGGCTCTGGAAAGAATG AGAACATCATCTGGAACTAGAACATC	1771 1772
Mouse/rat GAPDH Probe	FITGGCGTATCACTGAGCTGAGCTGA	1773
Mouse/rat GAPDH Invader	TGGCGTATCACTGAGCTGAGCTGA	1774
Mouse GAPDH Probe	GGACTCATACTGGACATGTAGACC	1775
Mouse GAPDH Invader	TGGCGTATCACTGAGCTGAGCTGA	1776
Mouse GAPDH Probe	AGTCAACTGGAAACATGTAGACCA	1777
Mouse GAPDH Invader	GGACTCATACTGGACATGTAGACCA	1778
<hr/>		
MOUSE IL-6		
Mouse IL-6 Probe	FL-TGGCGTATC1'CT1'CT1'CT1'II	1779
Mouse IL-6 Invader	TGGCGTATC1'CT1'CT1'CT1'II	1780
Mouse Oncostatin M Probe	ACATACAGAAATGGCCATGTGACAAACA	1781
Mouse Oncostatin M Invader	FL-GAAAGCAGAGGGACGCGTGGGGC GAAGGAGAGGAAACGCGTGGGGC	1782 1783
Mouse Oncostatin M Probe	AAAGACATCCTGGTTGATGTA	1784
Mouse Oncostatin M Invader	FL-TGGCGTATC1'CT1'CT1'CT1'II	1785
Mouse Oncostatin M Probe	TGGCGTATC1'CT1'CT1'CT1'II	1786
Mouse Oncostatin M Invader	CACTGAGCGCGATGAAAGCGATGGTAA	1787
Mouse Oncostatin M Probe	FL-TGGCGTATC1'CT1'CT1'CT1'II	1788
Mouse Oncostatin M Invader	TGGCGTATC1'CT1'CT1'CT1'II	1789
Mouse Oncostatin M Probe	GTGTTAGGTTGGGGCGGATAA	1790
Mouse Oncostatin M Invader	FL-TGGCGTATC1'CT1'CT1'CT1'II	1791
Mouse Oncostatin M Probe	TGGCGTATC1'CT1'CT1'CT1'II	1792
Mouse Oncostatin M Invader	GTGTTAGGTTGGGGCGGATAA	1793
FRET Probe	FLATTIC(CY3)TCTCAAGA-3'NH2	1794
FRET Probe	FLATTIC(CY3)TCTCAAGA-3'NH2	1795
SRT	FLATTIC(CY3)TCTCAAGA-3'NH2	1796
Mouse Oncostatin M Arrestor	CAGTCCTAGATGATGATACGCCAGG-3'NH2	1797
Mouse Oncostatin M Arrestor	CTGGAGCCCTAGAT-3'NH2	1798
Mouse Oncostatin M Arrestor	CTGGAGCCCTAGAT-3'NH2	1799
Mouse Oncostatin M Probe	CTGGCGTATCTAGGCTTCCA	1800
Mouse Oncostatin M Invader	GTGTTAGGTTGGGGCGGATAA	1802
SRT	CAGTCCTAGATGATACGCCAGG-3'NH2	1803
Arrestor	CTGGAGCCCTAGAT-3'NH2	1804
Mouse Oncostatin M Probe	FL-C1'CTGCTCTAGGCTCCA	1805

Mouse Oncostatin M Probe	CTCTCTCGTCTCTAGGGCTCCA	1807
Mouse Oncostatin M Invader	GTGTTAGGTTTGGAGGGGATAA	1808
SRT	CAGTCGCTCTGAATGAGACGAGAA GT-NH2	1809
Mouse Oncostatin M Arrestor	CTTGGAGCCCTAGAAG-GAGAGA GT-NH2	1810
Mouse Oncostatin M Probe	Fl-TGGGATATCIAAGGGCTCCA	1811
Mouse Oncostatin M Probe	TGGCGTATGAGGGCTCCA	1812
Mouse Oncostatin M Invader	GTGTTAGGTTTGGAGGGATAA	1813
Mouse Oncostatin M Probe	TGGCGTATCCTCCAGAGAAA	1814
Mouse Oncostatin M Probe	TGGCGTATCCTCCAGAGAGA	1815
Mouse Oncostatin M Invader	CACTGAGCCATGAGGTGTAAG	1816
Mouse Oncostatin M Probe	TGGCGTATCCTATAGGGCIC	1817
Mouse Oncostatin M Invader	GTTGTTAGGTGAGGGGCAA	1818
Mouse Oncostatin M Probe	CTCTCTCGTCTCTCAGGTTTG	1819
Mouse Oncostatin M Invader	GGCAGCTCTAGSTAGTGTGTA	1820
Mouse Oncostatin M Invader	AGGCAGCTCTAGGTGGTGTGA	1821
Mouse Oncostatin M Invader	CAGTCTGAGTGAATGAGACGAGAA GT-NH2	1822
SRT	F-ATTG(C3)TCTCGAAC-3'NH2	1823
FRET Probe	CAAACCTGAAAGAA-3'NH2	1824
Mouse Oncostatin M Arrestor	CAAAACCTGAAAGAGAC-3'NH2	1825
Mouse Oncostatin M Arrestor	CAAACACCTGAAAGAGAC-3'NH2	1826
Mouse Oncostatin M Probe	Fl-CTCTCTCGTCTCTAGGTTTTG	1827
Mouse Oncostatin M Probe	CTCTCTCGTCTCTCAGGTTTG-NH2	1828
Mouse Oncostatin M Invader	GGGAGCTCTAGGTGAGGTGTGA	1829
Mouse Oncostatin M Invader	GAGGCCGATATAGGGCT-Biotin TEG	1830
Human Oncostatin M Slacker	<u>.....</u>	
Human Oncostatin M Probe	CTCTCTCGTCTCTAAGGACTIA	1831
Human Oncostatin M Probe	CTCTCTCGTCTCTAAGGACTIAC	1832
Human Oncostatin M Invader	GAAACAGGAGCTCAAGGACAGACA	1833
Human Oncostatin M Probe	TCACGCTCTCTAGGIIIG	1834
Human Oncostatin M Probe	GTCACGCTCTCTAGGIIIG	1835
Human Oncostatin M Probe	AGTCAGGCTCTCTICAAGGTTTG	1836
Human Oncostatin M Probe	CAGTCAGCTCTAGGTGAGGTGTA	1837
Human Oncostatin M Invader	AGGCAGCTCTAGGTGAGGTGTA	1838
Fret Probe 1	Fl-CAAC(C3)GCTCTCG	1839
SRT	CGGAGGAAAGCAGTGTGAGACTGTGG-NH2	1840
SRT with mismatch	CGGAGGAAAGCAGTGTGAGACTGTGG-NH2	1841
SRT with mismatch	CGGAGGAAAGCAGTGTGAGACTGTGG-NH2	1842

bold indicates 2' o-methyl bases

Oligo Type	Oligo Sequence	Oligo #	SEQ ID NO
SECONDARY SYSTEM:			
SET 1 FRET probe 1 secondary target	5'-F-OAAC(CY3)GCCTCCCTCG-3' 5'-CGGAAAGAAGCAGTTGGTGGCCCTCGTAA-NH2	DB04001F6 649-10-01	1843 1844
SET 2 FRET probe 1 secondary target	5'-F-CAAC(CY3)GCCTCCCTCG-3' 5'-OGGARGARACGAGTTGGAGSGGTGACGGT-NH2-3'	DB04001F6 641-80-03	1845 1846
h2C19 designs 2			
probe	5'-AACGAGGCCACAGATGCCATCGA-NH2-3'	971-26-09	1847
slackster	5'-TCCTGGTGTCTTTACTTCTG-3'	971-26-12	1848
invader	5'-GCAATCAATAAGTCCGAGGGTTGTT	971-26-11	1849
arrestor	5'-TCGATGGACATCGTCGCG-3'	971-26-10	1850
h2D6 p450 designs			
probe	5'-CGGTCA CGCCCTCTCACCCATCT-NH2-3'	971-11-01	1851
slackster	5'-CTGGTCGCCGCACCT-3'	971-11-04	1852
invader	5'-TGAGGGCATGTGAGGCTTGGA-3'	971-11-03	1853
arrestor	5'-AGATGGAGAGGGCG-3'	971-11-02	1854
SET 1			
probe	5'-CGGTCA CGCCCTCTCACCCATCT-NH2-3'	971-11-05	1855
slackster	5'-ACTTCGATGTCAGGGGATGTCATATGG-3'	971-11-08	1856
invader	5'-GAGTGTGTTCCCTTAAGGAATGCGC-3'	971-11-06	1857
arrestor	5'-ACAGGGCTCGAGGGCG-3'	971-11-08	1858
SET 2			
probe	5'-CGGTCA CGCCCTCTCACCCATCT-NH2-3'	971-11-09	1859
slackster	5'-GCAGGAAAGGCTCG-3'	971-11-12	1860
invader	5'-CCCGAGGATGCAOGGGCGA-3'	971-11-11	1861
arrestor	5'-CTTCTCAGCAGGAGGGCG-3'	971-11-10	1862

h 206 shooter designs								
probe	5'-CCGTCACGCCCTCGTGAGAAA-HEX-3'	1051-12-06						
probe	5'-CCGTCACGCCCTCGTGAGAAA-3'	1051-12-05						
probe	5'-CCGTCACGCCCTCGTGAGAAA-NH2-3'	1051-12-05						
invader	5'-CCCGAGGCATGCAAGGGCGAA-3'	971-38-01						
slackster	5'-GGCAAGGAAGGCGCTCC-3'	971-11-11						
arrestor	5'-TTCTCAGCAGCGGAGGGCG-3'	971-38-03						
SET 1		971-38-02						
probe	5'-CCGTCACGCCCTCCCTCGTGAGAA-NH2-3'	1051-12-06						
invader	5'-AAGGAGGGAGGGCTCTG-3'	971-11-11						
slackster	5'-TCTCAGCAGGGAGGGCG-3'	971-38-09						
arrestor		971-38-08						
SET 2								
probe	5'-CCGTCACGCCCTCCCTCGTGAGAA-NH2-3'	1051-12-06						
invader	5'-AGGAGGGAGGGCTCTG-3'	971-11-11						
slackster	5'-TCTCAGCAGGGAGGGCG-3'	971-38-06						
arrestor		971-38-05						
SET 2								
probe	5'-CCGTCACGCCCTCCCTCGTGAGAA-NH2-3'	1051-12-06						
invader	5'-GAGGAGGGCTCCG-3'	971-11-11						
slackster	5'-CTTCTCAGCAGGGAGGGCG-3'	971-11-12						
arrestor		971-11-10						
SET 2								
h 2B6 p450 alt: Splice designs								
probe	5'-AACGAGGGCCACCAATATCCC-NH2-3'	1051-12-02						
invader	5'-CCAGGGTTCCATTGGCAAAGATCAA-3'	971-01-03						
slackster	5'-CGGAAATGGTGACCCATG-3'	971-01-04						
arrestor	5'-GGATATGGTGCG-3'	1051-12-02						
SET 1								
probe	5'-CCGTCACGCCCTCCATATCCC-HEX-3'	1051-12-02						
probe	5'-CCGTCACGCCCTCCATATCCC-3'	1051-12-01						
probe	5'-CCGTCACGCCCTCCATATCCC-NH2-3'	971-01-01						
invader	5'-GGATATGGTGCG-3'	971-01-03						
slackster	5'-GGATATGGTGCG-3'	971-01-04						
arrestor	5'-GGATATGGTGCG-3'	971-01-02						

	1886	5'-AACGAGGCCACCAAGAGCTGATGAG-NH2-3'	1051-48-03
probe	1887	5'-GAGAAGGCTCAAACAGCTGGCCGAATA-3'	971-01-10
invader	1888	5'-GAAAAAAAGTCTGTAGAACAGTCAGTCAGE-3'	971-01-11
stacker	1889	5'-CTCATAGCTCTGGTGCGC-3'	1051-48-04
SET 1			
probe	1890	5'-COSTCACGGCTCCAGAGCTGATGAG-NH2-3'	971-01-08
probe	1891	5'-CTCATAGCTCTGGAGGC-3'	971-01-09
SET 2			
n 2B6 p450 alt splice designs	1892	5'-AACGAGGCCACCCCTGGATTTC-NH2-3'	1051-48-05
p	1893	5'-CTGTGAACTTCCCCTGTAGACTCTCTA-3'	1051-48-10
	1894	5'-CGAAAGCTCTCTATCAG-3'	1051-48-09
s	1895	5'-GAATAATCCAAGGGTGGCC-3'	1051-48-06
a			
SET 1			
p	1896	5'-CCGTCACGCTCCCTGGATTTC-NH2-3'	1051-48-07
	1897	5'-GAATCCAAGGGAGGCG-3'	1051-48-10
s	1898	5'-AACGAGGCCACTGAGGCC-NH2-3'	1051-48-11
a	1899	5'-CCGTCACGCTCTGGGGCC-NH2-3'	1051-48-16
a	1900	5'-CCGTGAACTTCCGAAG-3'	1051-48-15
a	1901	5'-GGCCCTCAAGGCC-3'	1051-48-12
SET 2			
n 2B6 p450 alt Splice designs	1902	5'-CCGTCACGCTCTGGGCC-NH2-3'	1051-48-13
p	1903	5'-GCCCTCAAGGGCG-3'	1051-48-16
s			
a			
SET 2			
n 2B6 p450 alt Splice designs	1904	5'-GCCCTCAAGGGCG-3'	1051-48-14

probe	5'-AACGAGGGC/CACAAATACAGAGCTG-NH2-3'	1051-48-17		
invader	5'-GAGAGACTCAAAACAGCTGCCGC-3'	1051-48-22		
stacker	5'-ATGASTGAAAGTCGTAGAAC-3'	1051-48-21		
arrestor	5'-CAGCTCTATTGTGCGC-3'	1051-48-18		
SET 1				
probe	5'-CGGTCACGCCCTCAATACAGAGCTG-NH2-3'	1051-48-19		
invader		1051-48-22		
stacker		1051-48-21		
arrestor		1051-48-20		
SET 1				
probe	5'-AACGAGGGC/CACGGTTAGGTTCTG-NH2-3'	1051-48-23		
invader	5'-CAGCAAGAAGAGCGAGAGCTGTTGAC-3'	1051-48-28		
stacker	5'-GTGGCTGAATTCTACTGTG-3'	1051-48-27		
arrestor	5'-CAGAACCTOAAACGTCGCGC-3'	1051-48-24		
SET 1				
probe	5'-CGGTCACGCCCTGGTTGAGGTTCTG-NH2-3'	1051-48-25		
invader		1051-48-28		
stacker		1051-48-27		
arrestor		1051-48-26		
SET 1				
probe	5'-CAGAACCTOAAACGGGGGG-3'	1051-48-26		
invader				
stacker				
arrestor				
SET 2				
h2B6 p450 designs				
probe	5'-CCGTCACGCCCTCCACCATATCCCG-NH2-3'	971-01-06		
invader	5'-CCGTCACGCCCTCCACCATATCCC-NH2-3'	971-01-03		
stacker	5'-CGGAGAAATGGTGCAC-3'	971-01-06		
arrestor	5'-CGGAGAAATGGTGGAGGCG-3'	971-01-04		
SET 2				
probe	5'-CCAGGGTTTCATTGGCAAAGATCAA-3'	971-01-01		
invader		971-01-03		
stacker		971-01-07		
arrestor				
SET 2				
probe	5'-CCGTCACGCCCTCCAGAGCTGATGAG-NH2-3'	971-01-08		
invader	5'-GAGAGACTCAAAACAGCTGCCGAAATAA-3'	971-01-10		
stacker	5'-GAAAAAGACTCTAGAACAGTCAGC-3'	971-01-11		

arrestor	5'-CTCATAGCTCTGGAGGG-3'	971-01-09	1926
SET 2			
h2b6p450 designs 2			
probe	5'-CCGTCACGCCCTCAGATGACTGCC-NH2-3'	971-01-12	1927
invader	5'-GGAGAAGGTGGAAAATCT(GAACTCATC-3'	971-01-13	1928
stacker	5'-TCTGTGATGGATTTCATCTGG-3'	971-01-14	1929
arrestor	5'-GGCACTCATCTGAGGC-3'	971-01-15	1930
SET 2			
h2C19 designs 1			
probe	5'-CGGTGACGGCTCCATCTTAAATATCTAT-NH2-3'	971-26-01	1931
invader	5'-GAGGATTTGTTAAGGATTGCTGAA-3'	971-26-03	1932
stacker	5'-CTGTAGGATATTCCAATGACTGGG-3'	971-26-04	1933
arrestor	5'-ATAATTAAGATGGAGGGCG-3'	971-26-02	1934
SET 2			
h2C19 shorter site 2 designs			
probe	5'-AACGAGGGGCCACCGTTCCAGGG-NH2-3'	971-26-05	1935
invader	5'-CATATCCATGAGCACACATGAA-3'	971-26-07	1936
stacker	5'-CAAAATAATAGAGTGAAACAGGGCC-3'	971-26-08	1937
arrestor	5'-GCCTGGAAACGCTGGC-3'	971-26-06	1938
SET 1			
h2C19 site 1 bs.			
probe	5'-AACGAGGGGCCACCGTTCCAGGG-NH2-3'	971-68-01	1939
probe	5'-AACGAGGGGCCACCGTTCCAGGG-NH2-3'	971-26-07	1940
probe	5'-AACGAGGGGCCACCGTTCCAGGG-NH2-3'	971-68-03	1941
invader	5'-CAAAATAATAGAGTGAAACAGGGCC-3'	971-68-02	1942
stacker	5'-GCCTGGAAACGCTGGC-3'		
arrestor			
SET 1			
rat 1A1, rat 1A2			
probe	5'-AACGAGGGGCCACCGTTCCAGGG-NH2-3'	971-26-05	1943
probe	5'-AACGAGGGGCCACCGTTCCAGGG-NH2-3'	1051-12-03	1944
probe	5'-AACGAGGGGCCACCGTTCCAGGG-NH2-3'	1051-12-04	1945
invader	5'-CAAAATAATAGAGTGAAACAGGGCC-3'	971-26-07	1946
stacker	5'-GCCTGGAAACGCTGGC-3'	971-68-04	1947
arrestor			
SET 1			
Rat 1A1 site 1 bs.			
5'-CCGTCACGCCCTCAGATTGACTATGCTG-NH2-3'	500-58-01	1948	

invader	5'-CAGTAACCTCCAAAACCTAATGCCCTC-3'	1949	500-58-03
slacker	5'-AGGACTCTCTGTCATCGT-3'	1950	500-58-04
arrestor	5'-CAGCATAGCAATCTGGCG-3'	1951	500-58-02
SET 2			
rat 1A2	Rat 1A2 site 1 bs. 674-725	1952	500-58-05
probe	5'-AACGAGGCCACTGGCTGACACA-NH2-3'	1953	500-58-07
invader	5'-GTCACAGCAATTCCGTAGGA-3'	1954	500-58-08
slacker	5'-AAGTCCTTGCTCTTC-3'	1955	500-53-06
arrestor	5'-GTGGAAATGTCAGTGGC-3'		
SET 1			
rat 2B1-2B2	Rat 2B1-2B2 patient	1956	500-49-05
probe	5'-AACGAGGCCACTGGCTGACACA-NH2-3'	1957	500-49-03
invader	5'-GTCGAATGCTGGAGCAA-3'	1958	12B1, 2B2, 500-49-07
slacker	5'-GAGAAGTTCTGGAGGATGGTGG-3'	1959	500-49-08
arrestor	5'-TGTTCAAGCCAATGGCC-3'		
SET 1			
probe	5'-AACGAGGCCACTGGCTGACACA-NH2-3'	1960	500-49-01
invader	5'-AGAAGTTCTGGAGGATGGTGG-3'	1961	500-49-03
slacker	5'-CTGTGTCAGGCCAGTGGC-3'	1962	12B1, 2B2, 500-49-04
arrestor	5'-GGGGCAATGCTCTCGTGC-3'		500-49-02
SET 1			
rat 2B1-2B2	PROBE SET 2 (r2B1 bs 1299-1353, r2B2 bs. 474-528)	1963	500-49-12
site 4	5'-GTTCTGGAGATGGTGTGAAAGAC-3'	1964	500-49-10
probe	5'-GGGGCAATGCTCTCGTGC-3'	1965	500-49-14
invader	5'-AATGAATTGTTCTCTCGTGC-3'	1966	500-49-13
slacker	5'-AACGAGGCCACTGGCTGACACA-NH2-3'	1967	500-49-08
arrestor	5'-GGGCAATGCTCTCGTGC-3'	1968	500-49-11
SET 2	5'-GAAATGAATTGTTCTCTCGTGC-3'	1969	500-49-09
probe	5'-AACGAGGCCACTGGCTGACACA-NH2-3'	1970	500-49-15
invader			
slacker			
arrestor			
SET 1			
rat 2B1-2B2 , 5 patient			
	5'-AACGAGGCCACTGGCTGACACA-NH2-3'		

invader	5'-GCCCTAGCGGGATCACGGC-3'	1971
invader	5'-GCCCTAGCCGATCACGGC-3'	1972
slacker	5'-ATCTGGTACGGAGGTATT-3'	1973
slacker	5'-ATCTGGTACGGAGGTATT-3'	1974
arrestor	5'-CTGCCTCTCACGCTGCSC-3'	1975
NOTE: all 3 invader/probe sets are designed to detect both 2B1 and 2B2		
SET 1		
rat 2E1 p450 (af061442) 500-73	Rat 2E1 PROBE SET (570C)	
p	5'-CCGTCAGGCTCTGGAAACGTTGTT-NH2-	1976
	5'-CCTGACACTCTCTGTCATTGTA-C-3'	1977
s	5'-GAAGGAGGATATCGAAATGACATTCG-3'	1978
a	5'-AACAAAACGTTCGACGAGGGCG-3'	1979
SET 2		
p	5'-CCGTCAGGCTCTGGAAACGTTGTTGAAAG-NH2-3'	1980
	5'-CCGTCAGGCTCTGGAAACGTTGTTGAAAG-NH2-3'	1980
s	5'-CTTCACAAACAGTTCTGACGAGGGCG-3'	1981
a	5'-CTTCACAAACAGTTCTGACGAGGGCG-3'	1981
SET 2		
rat 2E1 p450 (af061442) 500-73	Rat 2E1 PROBE SET (822G) (designed over splice junction #5)	
p	5'-CCGTCAGGCTCTGGAAACGTTGTTGTTCTATG-NH2-3'	1982
	5'-GTTCTGGCTGCTCTCTCTTCTTA-C-3'	1983
s	5'-AGGAGACAGTCAGTCACATC-C-3'	1984
a	5'-CATAGAGATGGAGGGCG-3'	1985
SET 2		
p	5'-CCGTCAGGCTCTGGAAACGTTGTTGAAAG-NH2-3'	1986
	5'-CCGTCAGGCTCTGGAAACGTTGTTGAAAG-NH2-3'	1986
s	5'-CTCATAGAGATGGAGGGCG-3'	1987
a	5'-CTCATAGAGATGGAGGGCG-3'	1987
SET 2		
rat 2E1 PROBE SET (969G)	Designed over splice junction #6	
probe	5'-CCGTCAGGCTCTGGAAACGTTGTTGTTCTG-HEX-3'	1988
invader	5'-CCGTCAGGCTCTGGAAACGTTGTTCTG-HEX-3'	1989
slacker	5'-GGTATTCTGAGGATCAGGAGGC-3'	1990
arrestor	5'-CCGAGAAAATTGAGGAGGGCG-3'	1991
SET 2		

probe	5'-CCGTCAGCCTCTCTCAATTCTG-3'	1982	
probe	5'-CCGTCAGCCTCTCTCAATTCTG-NH2-3'	1983	
probe	5'-CCGTCAGCCTCTCTCAATTCTG-NH2-3'	1984	
invader		500-40-13	
slacker		500-40-14	
arrestor		500-40-17	
SET 2	5'-CAGAAATTGAAAGAGGGGGG-3'	500-40-18	1985
Rat 2E1 PROBE SET (969G)	Designed over splice junction #6	1996	
probe	5'-CCGTCAGCCTCTCTCAATTCTG-3'	500-73-01	
invader	5'-CCGTCAGCCTCTCTCAATTCTGAGTTTA-3'	500-40-14	1987
slacker	5'-GGGTATTCATGAGGATCAGGGAG-3'	500-73-03	1988
arrestor	5'-AGAATTGAAAGAGGGGG-3'	500-73-02	1989
SET 2			
Rat 3A's design 2			
probe	5'-CCGTCAGCCTCTGTTCCCTGGGT-NH2-3'	500-43-15	2000
invader	5'-GAGCAAACCTCATGCCAATGCCAC-3'	r3A1, 3A18	500-43-23
invader	5'-GAGCAAACCTCATGCCAATGCCAC-3'	r3A2	500-43-24
invader	5'-GAGCAAACCTCATGCCAATGCCAC-3'	r3A2	500-43-24
slacker	5'-CCATTCCAAAGGGCAG-3'	short r3A1, 3A2	500-43-19
slacker	5'-CCATTCCAAAGGGCAG-3'	short r3A9	500-43-20
arrestor	5'-ACCCAGGAACGAGGGG-3'	500-43-16	
SET 2			
probe	5'-CCGTCAGGCTGTTCTGGGT-NH2-3'	500-43-13	2007
invader	5'-GACCCAGGAACGAGGGG-3'	r3A1, 3A18	500-43-23
invader	5'-GACCCAGGAACGAGGGG-3'	r3A2	500-43-24
arrestor		500-43-14	
SET 2			
Rat 3A's desing 3			
probe	5'-CCGTCAGCCTCTGAGAGCAAACCT-NH2-3'	500-43-29	2009
invader	5'-AGACCGAGTTTCCATATTCAA-3'	r3A1, 3A2	500-43-35
invader	5'-AGACCGAGTTTCCATATTCAA-3'	r3A9	500-43-36
invader	5'-AGACCGAGTTTCCATATTCAA-3'	r3A18	500-43-37
slacker	5'-CATGCCAATGCAAGTTCCTG-3'	r3A1, 3A18	500-43-31
slacker	5'-CATGCCAATGCAAGTTCCTG-3'	r3A2	500-43-32
arrestor	5'-CATGCCAATGCAAGTTCCTG-3'	r3A9	500-43-33
SET 2			

arrestor SET 2	5'-AGGTTTGCTCTCCGAGGGC-3'	500-43-30	2016
probe invader invader invader arrestor SET 2	5'-CCGTCAGGCCCTGAGAGCAACCTCA-NH2-3' 5'-TGGGTTGGCTCTCAGAGGGC-3'	500-43-27 (3A1, 3A2 500-43-35 (3A9 500-43-36 (3A18 500-43-37 500-43-28	2017
rat 3A's designs probe invader Invader Invader s s a SET 2	5'-CCGTCAGGCCCTGAGACATCTCCCTTGA-NH2-3' 5'-TGTCCTCCATACTGTCAATGTGGC-3' 5'-TATCTGTTATACGTGTTAAATGTGGC-3' 5'-TGGTCTCATGTCTCATGGGC-3' 5'-TGAGCTCCCACTGGTG-3' 5'-TGAGTTGCACTGGTG-3' a 500-43-03 (3A1, 3A2 500-43-09 (3A9 500-43-10 (3A18 500-43-11 (3A1, 3A2 500-43-05 (3A9 500-43-06 (3A18 500-43-07	2019 2020 2021 2022 2023 2024 2025	
probe invader invader invader arrestor SET 2	5'-CCGTCAGGCCCTGGAAACATCTCCCTTGA-NH2-3' 5'-TCAAGGAGATGTTGGAGGGCG-3'	500-43-01 (3A1, 3A2 500-43-09 (3A9 500-43-10 (3A18 500-43-11 500-43-02	2026
rat 3A's design 2b probe invader Invader Invader stacker stacker arrestor SET 2	5'-CCGTCAGGCCCTGTTCTGG-NH2-3' 5'-GAGCAAACCTCATGCCAATGAC-3' 5'-GAGCAAACCTCATGCAATGAC-3' 5'-GAGCAAACCTCATGCCAATACAC-3' 5'-TCCATTTCACAAAGGGCAG-3' 5'-TCCATTTCACAAAGGGCAG-3' 5'-CCGAGGAGAGGAGCGC-3'	991-39-01 (3A1, 3A18 500-43-23 (3A2 500-43-24 (3A9 500-43-25 (3A1, 3A2, 3A18 991-39-03 (3A9 991-39-04 991-39-02	2028 2029 2030 2031 2032 2033 2034
rat or human 1A1 shorter site 2 probe probe	5'-CCGTCAGGCCCTGCTGTGAT-HEX-3' 5'-CCGTCAGGCCCTGCTGTGAT-1073-19-02 1073-19-01		2035

probe	5'-CGGTACCGCCCTCGTGTGAT-NH2-3'	991-12-04	2037
invader	5'-TCCTGACAAATGCTCAATGAGA-3'	r 1A1 500-53-11	2038
invader	5'-TCC TGACAGCTCAATCAGGA-3'	h 1A1 500-53-12	2039
stacker	5'-GTCGGGATGTGGCC-3'	rat/human 1A1 991-12-06	2040
arrestor	5'-ACATCACAGACAGGGCG-3'	500-53-10	2041
SET 2			
probe	5'-CGGTACCGCCCTCGTGTGATG-NH2-3'	991-12-01	2042
invader	5'-TCCTGACAAATGCTCAATGAGA-3'	r 1A1 500-53-11	2043
invader	5'-TCC TGACAGCTCAATCAGGA-3'	h 1A1 500-53-12	2044
stacker	5'-GTCGGGATGTGGCC-3'	rat/human 1A1 991-12-03	2045
arrestor	5'-CATCACAGACAGGGCG-3'	991-12-02	2046
SET 2			
probe	5'-CGGTACCGCCCTCGTGTGAT-NH2-3'	500-53-09	2047
invader	5'-TCCTGACAAATGCTCAATGAGA-3'	r 1A1 500-53-11	2048
invader	5'-TCC TGACAGCTCAATCAGGA-3'	h 1A1 500-53-12	2049
stacker	5'-GTCGGGATGTGGCC-3'	rat/human 1A1 991-12-06	2050
arrestor	5'-ATCACAGACAGGGCG-3'	500-53-07	2051
SET 2			
rat or human 1A1 site 1			
probe	5'-CGGTACCGCCCTCGGCCCTCTGC-NH2-3'	500-53-04	2052
invader	5'-CTGTCGTGATGCCGGATGTA-3'	500-53-03	2053
stacker	5'-TCAAATGTTCTGTAGTSGCTC-3'	rat 1A1 500-53-06	2054
stacker	5'-TCAAAGTTTTAGTSGCTC-3'	human 1A1 500-53-07	2055
arrestor	5'-GAA GGCCAGAGGGCG-3'	500-53-05	2056
SET 2			
probe	5'-CGGTACCGCCCTCGGCCAGAGGGCG-3'	500-53-01	2057
invader	5'-GAGAAAGGGCCAGAGGGCG-3'	500-53-03	2058
arrestor	5'-GAGAAAGGGCCAGAGGGCG-3'	500-53-02	2059
SET 2			
Rat/Human 1A1 site 2			
probe	5'-CGGTACCGCCCTCGTGTGATG-NH2-3'	500-53-09	2060
invader	5'-TCCTGACAAATGCTCAATGAGA-3'	r 1A1 500-53-11	2061
invader	5'-TCC TGACAGCTCAATCAGGA-3'	h 1A1 500-53-12	2062
stacker	5'-GTCGGGATGTGGCC-3'	rat/human 1A1 500-53-14	2063
arrestor	5'-ACATCACAGACAGGGCG-3'	500-53-10	2064

	SET 2	
rat or human 1A2 sites		
probe	5'-AACGAGGGGCCACGGACTGTTCTGC-HEX-3'	1073-19-04
probe	5'-AACGAGGGGCCACGGACTGTTCTGC-3'	1073-19-03
probe	5'-AACGAGGGGCCACGGACTGTTCTGC-NH2-3'	500-53-15
invader	5'-CTTGTGAAAGTCCTGATACTGTCCTC-3'	rat 1A2 500-53-17
invader	5'-CTTGTGAAAGTCCTGATACTGTCCTC-3'	human 1A2 500-53-18
arrestor	5'-CGAGAAAAAGTCGGTGCGC-3'	500-53-16
SET 1		500-53-16
shorter h2C19 design site 3		
probe	5'-AACGAGGGGCCACGGATGTCATCG-NH2-3'	971-48-01
invader	5'-SCATCATATAAGTCCCGAGGGTTGTT-3'	971-26-11
stacker	5'-ATTCTGGTGTCTTTACTTCTC-3'	971-48-03
arrestor	5'-CGATGGACATGTCGC-3'	971-48-02
SET 1		

Human LL-10

Human IL-6

Secondary Cassettes

Oligo sequence descriptions: 5' to 3' direction, 2'-Ome nts are bolded and underlined, internal modifications defined in (1)

FRET Oligo/SRT Combinations

SEQ ID NO.	Position	Notes
SEQ ID NO.	Oligo #	Oligo Sequence
Srt 1		
FRET Oligo	SRT	
187-46-01	041-40-02	
187-46-01	059-42-03	
307-70-02	339-42-03	
303-18-05	343-25-07	
303-18-05	343-25-11	
187-46-01	048-10-01	
187-46-01	277-04-01	
187-46-01	744-02-01	
187-46-01	833-16-01	
767-28-03	773-17-10	
767-28-02	858-19-01	
1067-20-01	858-20-01	
307-70-02	988-20-01	
307-70-02	1017-20-04	
491-01-01	494-02-04	
187-46-01	655-84-01	
187-46-01	187-46-01	
Srt 2		
Srt 3		
Srt 4		
Srt 5		
Srt 6		
Srt 7		
Srt 8		
Srt 9		
Srt 10		
Srt 11		
Srt 12		
Srt 13		
Srt 14		
Srt 15		
Srt 16		
Srt 17		
Srt 18		
Srt 19		
Srt 20		
Srt 21		
Srt 22		
Srt 23		
Srt 24		
Srt 25		
Srt 26		
Srt 27		
Srt 28		
Srt 29		
Srt 30		
Srt 31		
Srt 32		
Srt 33		
Srt 34		
Srt 35		
Srt 36		
Srt 37		
Srt 38		
Srt 39		
Srt 40		
Srt 41		
Srt 42		
Srt 43		
Srt 44		
Srt 45		
Srt 46		
Srt 47		
Srt 48		
Srt 49		
Srt 50		
Srt 51		
Srt 52		
Srt 53		
Srt 54		
Srt 55		
Srt 56		
Srt 57		
Srt 58		
Srt 59		
Srt 60		
Srt 61		
Srt 62		
Srt 63		
Srt 64		
Srt 65		
Srt 66		
Srt 67		
Srt 68		
Srt 69		
Srt 70		
Srt 71		
Srt 72		
Srt 73		
Srt 74		
Srt 75		
Srt 76		
Srt 77		
Srt 78		
Srt 79		
Srt 80		
Srt 81		
Srt 82		
Srt 83		
Srt 84		
Srt 85		
Srt 86		
Srt 87		
Srt 88		
Srt 89		
Srt 90		
Srt 91		
Srt 92		
Srt 93		
Srt 94		
Srt 95		
Srt 96		
Srt 97		
Srt 98		
Srt 99		
Srt 100		
Srt 101		
Srt 102		
Srt 103		
Srt 104		
Srt 105		
Srt 106		
Srt 107		
Srt 108		
Srt 109		
Srt 110		
Srt 111		
Srt 112		
Srt 113		
Srt 114		
Srt 115		
Srt 116		
Srt 117		
Srt 118		
Srt 119		
Srt 120		
Srt 121		
Srt 122		
Srt 123		
Srt 124		
Srt 125		
Srt 126		
Srt 127		
Srt 128		
Srt 129		
Srt 130		
Srt 131		
Srt 132		
Srt 133		
Srt 134		
Srt 135		
Srt 136		
Srt 137		
Srt 138		
Srt 139		
Srt 140		
Srt 141		
Srt 142		
Srt 143		
Srt 144		
Srt 145		
Srt 146		
Srt 147		
Srt 148		
Srt 149		
Srt 150		
Srt 151		
Srt 152		
Srt 153		
Srt 154		
Srt 155		
Srt 156		
Srt 157		
Srt 158		
Srt 159		
Srt 160		
Srt 161		
Srt 162		
Srt 163		
Srt 164		
Srt 165		
Srt 166		
Srt 167		
Srt 168		
Srt 169		
Srt 170		
Srt 171		
Srt 172		
Srt 173		
Srt 174		
Srt 175		
Srt 176		
Srt 177		
Srt 178		
Srt 179		
Srt 180		
Srt 181		
Srt 182		
Srt 183		
Srt 184		
Srt 185		
Srt 186		
Srt 187		
Srt 188		
Srt 189		
Srt 190		
Srt 191		
Srt 192		
Srt 193		
Srt 194		
Srt 195		
Srt 196		
Srt 197		
Srt 198		
Srt 199		
Srt 200		
Srt 201		
Srt 202		
Srt 203		
Srt 204		
Srt 205		
Srt 206		
Srt 207		
Srt 208		
Srt 209		
Srt 210		
Srt 211		
Srt 212		
Srt 213		
Srt 214		
Srt 215		
Srt 216		
Srt 217		
Srt 218		
Srt 219		
Srt 220		
Srt 221		
Srt 222		
Srt 223		
Srt 224		
Srt 225		
Srt 226		
Srt 227		
Srt 228		
Srt 229		
Srt 230		
Srt 231		
Srt 232		
Srt 233		
Srt 234		
Srt 235		
Srt 236		
Srt 237		
Srt 238		
Srt 239		
Srt 240		
Srt 241		
Srt 242		
Srt 243		
Srt 244		
Srt 245		
Srt 246		
Srt 247		
Srt 248		
Srt 249		
Srt 250		
Srt 251		
Srt 252		
Srt 253		
Srt 254		
Srt 255		
Srt 256		
Srt 257		
Srt 258		
Srt 259		
Srt 260		
Srt 261		
Srt 262		
Srt 263		
Srt 264		
Srt 265		
Srt 266		
Srt 267		
Srt 268		
Srt 269		
Srt 270		
Srt 271		
Srt 272		
Srt 273		
Srt 274		
Srt 275		
Srt 276		
Srt 277		
Srt 278		
Srt 279		
Srt 280		
Srt 281		
Srt 282		
Srt 283		
Srt 284		
Srt 285		
Srt 286		
Srt 287		
Srt 288		
Srt 289		
Srt 290		
Srt 291		
Srt 292		
Srt 293		
Srt 294		
Srt 295		
Srt 296		
Srt 297		
Srt 298		
Srt 299		
Srt 300		
Srt 301		
Srt 302		
Srt 303		
Srt 304		
Srt 305		
Srt 306		
Srt 307		
Srt 308		
Srt 309		
Srt 310		
Srt 311		
Srt 312		
Srt 313		
Srt 314		
Srt 315		
Srt 316		
Srt 317		
Srt 318		
Srt 319		
Srt 320		
Srt 321		
Srt 322		
Srt 323		
Srt 324		
Srt 325		
Srt 326		
Srt 327		
Srt 328		
Srt 329		
Srt 330		
Srt 331		
Srt 332		
Srt 333		
Srt 334		
Srt 335		
Srt 336		
Srt 337		
Srt 338		
Srt 339		
Srt 340		
Srt 341		
Srt 342		
Srt 343		
Srt 344		
Srt 345		
Srt 346		
Srt 347		
Srt 348		
Srt 349		
Srt 350		
Srt 351		
Srt 352		
Srt 353		
Srt 354		
Srt 355		
Srt 356		
Srt 357		
Srt 358		
Srt 359		
Srt 360		
Srt 361		
Srt 362		
Srt 363		
Srt 364		
Srt 365		
Srt 366		
Srt 367		
Srt 368		
Srt 369		
Srt 370		
Srt 371		
Srt 372		
Srt 373		
Srt 374		
Srt 375		
Srt 376		
Srt 377		
Srt 378		
Srt 379		
Srt 380		
Srt 381		
Srt 382		
Srt 383		
Srt 384		
Srt 385		
Srt 386		
Srt 387		
Srt 388		
Srt 389		
Srt 390		
Srt 391		
Srt 392		
Srt 393		
Srt 394		
Srt 395		
Srt 396		
Srt 397		
Srt 398		
Srt 399		
Srt 400		
Srt 401		
Srt 402		
Srt 403		
Srt 404		
Srt 405		
Srt 406		
Srt 407		
Srt 408		
Srt 409		
Srt 410		
Srt 411		
Srt 412		
Srt 413		
Srt 414		
Srt 415		
Srt 416		
Srt 417		
Srt 418		
Srt 419		
Srt 420		
Srt 421		
Srt 422		
Srt 423		
Srt 424		
Srt 425		
Srt 426		
Srt 427		
Srt 428		
Srt 429		
Srt 430		
Srt 431		
Srt 432		
Srt 433		
Srt 434		
Srt 435		
Srt 436		
Srt 437		
Srt 438		
Srt 439		
Srt 440		
Srt 441		
Srt 442		
Srt 443		
Srt 444		
Srt 445		
Srt 446		
Srt 447		
Srt 448		
Srt 449		
Srt 450		
Srt 451		
Srt 452		
Srt 453		
Srt 454		
Srt 455		
Srt 456		
Srt 457		
Srt 458		
Srt 459		
Srt 460		
Srt 461		
Srt 462		
Srt 463		
Srt 464		
Srt 465		
Srt 466		
Srt 467		
Srt 468		
Srt 469		
Srt 470		
Srt 471		
Srt 472		
Srt 473		
Srt 474		
Srt 475		
Srt 476		
Srt 477		
Srt 478		
Srt 479		
Srt 480		
Srt 481		
Srt 482		
Srt 483		
Srt 484		
Srt 485		
Srt 486		
Srt 487		
Srt 488		
Srt 489		
Srt 490		
Srt 491		
Srt 492		
Srt 493		
Srt 494		
Srt 495		
Srt 496		
Srt 497		
Srt 498		
Srt 499		
Srt 500		
Srt 501		
Srt 502		
Srt 503		
Srt 504		
Srt 505		
Srt 506		
Srt 507		
Srt 508		
Srt 509		
Srt 510		
Srt 511		
Srt 512		
Srt 513		
Srt 514		
Srt 515		
Srt 516		
Srt 517		
Srt 518		
Srt 519		
Srt 520		
Srt 521		
Srt 522		
Srt 523		
Srt 524		

Amster							
Secondary Cassette							
Probe	425-87-05	CCTCAGAGAGAGAGCG					2286
Invader	425-87-03	Set 3	Same as 425-61-01 without Fluorescent				2270
Amster	425-81-02	CCTCTGCTCTCACAGGAGATG					2271
Secondary Cassette	425-87-06	GCTTGACGTTATTCATTCGA					2272
Probe		Salt 3					
Invader	425-23-01	A TACCTCAAGACCTCTGGAGAT					
Amster	425-23-02	A TAGCTTGACACTCTTGGAGATG					
Secondary Cassette	425-23-04	ATGAGTCAGAGACCTCTGGAGAT					
Probe	425-23-02	CATTGATATTAGTGAGCTGGAGAT					
Invader	425-23-05	ATTCCTCAGAGAGAGCTCTGGAGA					
Amster		Salt 5					
Secondary Cassette							
Probe	425-87-04	CAGTCAGTCCTCTCAAGTTTG					2280
Invader	365-45-07	AGGAGAGCTTAAGTAGTGTTGA					2281
Secondary Reaction Template	624-51-01	FICCTGTTCTTCAGTACAGG					2282
Secondary Reaction Template	624-51-02	CCCTAATGAGAAAGAGACGTGCTTA-NH2					2283
Probe	425-87-04	CCCTAATGAGAAAGAGACGTGCTTA-NH2					2284
Invader	365-45-07	CACTGAGCTCTCTCAAGTTTG					2285
FRET Probe - Secondary Reaction	524-43-102	AGGAGACTCTCAAGTGTGAA					2286
Secondary Reaction Template	524-43-105	FICCTGTTCTTCAGTACAGG					2287
Probe	524-43-105	TGCTGACTATAGATGAGAGAGACTGACTGATA-NH2					2288
Secondary Reaction Template	524-43-106	TGCTGACTATAGATGAGAGAGACTGACTGATA-NH2					2289
Human Ubiquitin							
Probe	768-72-01	AAACAGGGCCACCTTACATTTCTATGTTATCC					119
Invader	428-81-02	CCTTCCTATCTGTGATCTTGCA					2280
Amster	760-72-02	GGATACATGATAAAATGAAAGTGCG					2281
Secondary Cassette		Salt 6					2282
Probe	760-72-03	AAACAGGGCCACCTTACATTTCTATGTTATCC					2283
Invader	428-81-02	CCTTCCTATCTGTGATCTTGCA					2284
Amster	760-72-04	GGATACATGATAAAATGAAAGTGCG					2285
Secondary Cassette		Salt 6					
Probe	680-35-01	AAACAGGGCCACCTTACATTTCTATG					2286
Invader	680-35-02	GGATACATGATAAAATGAAAGTGCG					2287
Amster	680-35-03	Salt 7					2288
Secondary Cassette		AAACAGGGCCACCTTACATTTCTATGTTATCC					2289
Probe	680-35-01	GGATACATGATAAAATGAAAGTGCG					2300
Invader	680-35-02	AAACAGGGCCACCTTACATTTCTATG					2301
Amster	680-35-03	Salt 8					2302
Secondary Cassette		AAACAGGGCCACCTTACATTTCTATGTTATCC					2303
Probe	820-88-04	GGATACATGATAAAATGAAAGTGCG					2304
Invader	428-81-02	Salt 7					2305
Amster	820-85-13	GGCAGAGGCACCTTACATTTCTATGTTATCC					
Secondary Cassette		GGCTTCATCTTCAGTACATTTCTATGTTATCC					2306
Probe	847-85-01	AGGATAGAAATGAAAGCGCG					2307
Invader	428-81-02	AAACAGGGCCACCTTACATTTCTATG					2308
Amster	847-85-02	AGGATAGAAATGAAAGCGCG					2309
Secondary Cassette	847-85-03	Salt 8					
Probe	038-11-01	AAACAGGGCCACCTTACATTTCTATGTTATCC					2310
Invader	428-81-02	GGCTTCATCTTCAGTACATTTCTATGTTATCC					2311
			Same as 425-87-01 without Biotin blocking group				

Amplor				2312
Secondary Cassette				
Monocyte Chemoattract Protein 1 (MCP-1)	938-61-02	CGGATACGATAGAAATGTAAAGTGCGC Seq 7		
Probe	939-08-01	CGCTTACGGCTCTTCGGATTTGG GGTTGGGGATGGATGAGTGAAGTA	Same as 728-87-01 without the amine	2313
Invader	935-76-01	CGATGGCAAAACAGCTGCAAGAAG GAGATCACAGGAGAATAG	Same as 728-87-01 without the amine	2314
Amplor	920-49-02	AACAGAGCACACACGGCTGG CGAACGGCTGG	Same as 728-87-01 without the amine	2315
Secondary Cassette				
MAGE-3	1091-01-01	FATTTCGGAGGCTTCTCT CGATGGCAAAACAGCTGCAAGAAG GAGATCACAGGAGAATAG	Same analyte specific Region as 671-48-02.	2316
Probe	971-18-01	AACAGAGCACACACGGCTGG CGAACGGCTGG	Same analyte specific Region as 671-48-02.	2317
Invader	971-18-01	CGACGGCTCTGGACT AACAGAGCACACACGGCTGG	Same analyte specific Region as 671-48-02.	2318
Stuffer	1138-50-01	1138-50-01	Same analyte specific Region as 671-48-02.	2319
Probe	1138-50-03	1138-50-03	Same analyte specific Region as 671-48-02.	2320
Stuffer	1138-50-03	1138-50-03	Same analyte specific Region as 671-48-02.	2321
Probe	1138-50-04	1138-50-04	Same analyte specific Region as 671-48-02.	2322
Invader	1138-50-05	1138-50-05	Same analyte specific Region as 671-48-02.	2323
Amplor	1138-50-06	1138-50-06	Same analyte specific Region as 671-48-02.	2324
Secondary Cassette				
Sazier	1138-51-01	ACCTCTGGGATC AACGAGGCACACTGGTGAGC	Same analyte specific Region as 671-48-02.	2325
Probe	1138-51-02	1138-51-02	Same analyte specific Region as 671-48-02.	2326
Stuffer	1138-51-03	1138-51-03	Same analyte specific Region as 671-48-02.	2327
Probe	1138-51-04	1138-51-04	Same analyte specific Region as 671-48-02.	2328
Invader	1138-51-05	1138-51-05	Same analyte specific Region as 671-48-02.	2329
Amplor	1138-51-06	1138-51-06	Same analyte specific Region as 671-48-02.	2330
Secondary Cassette				
Stuffer	1138-67-01	1138-67-01	Same analyte specific Region as 671-48-02.	2331
Probe	1138-67-02	1138-67-02	Same analyte specific Region as 671-48-02.	2332
Invader	1138-67-03	1138-67-03	Same analyte specific Region as 671-48-02.	2333
Amplor	1138-67-04	1138-67-04	Same analyte specific Region as 671-48-02.	2334
Secondary Cassette				
Stuffer	1138-67-05	1138-67-05	Same analyte specific Region as 671-48-02.	2335
Probe	1138-67-06	1138-67-06	Same analyte specific Region as 671-48-02.	2336
Invader	1138-67-07	1138-67-07	Same analyte specific Region as 671-48-02.	2337
Amplor	1138-67-08	1138-67-08	Same analyte specific Region as 671-48-02.	2338
Secondary Cassette				
Human Oncostatin M				
Probe	338-30-02	CCTGGCTATCTAGGCTCAA GTTGCGATTTGGCGCGATA	Same as 435-07-04 with 3' Amines	2339
Invader	261-42-03	CTTGGACCGTAAATGAAATC-NH2		2340
Amplor	374-32-01	CTTGGACCGTAAATGAAATC-NH2		2341
Amplor	374-32-02	CTTGGACCGTAAATGAAATC-NH2		2342
Secondary Cassette				
Stuffer	692-58-01	CAGTCACCTCTCTGGTTTTC-NH2 AACGAGCCACGAGCTGATGAA	Same as 435-07-04 with 3' Amines	2344
Probe	365-05-07	GGAAAGGGAAAGGGGGAA GAAAGGGGGAAAGGGGGAA		2345
Stuffer	365-05-07	GGAAAGGGAAAGGGGGAA		2346
Secondary Cassette				
Stuffer	941-13-01	GGAAAGGGAAAGGGGGAA		2347
Probe	1088-74-01	AACAGGGCCACACCTCTGTTG CACACAGAGGGCTGCTG-NH2		2348
Amplor	1088-74-02	AACAGGGCCACACCTCTGTTG CACACAGAGGGCTGCTG-NH2		2349
Probe	1088-74-03	AACAGGGCCACACCTCTGTTG CACACAGAGGGCTGCTG-NH2		2350
Amplor	1088-74-04	AACAGGGCCACACCTCTGTTG CACACAGAGGGCTGCTG-NH2		2351
Invader	1088-75-03	AACAGGGCCACACCTCTGTTG CACACAGAGGGCTGCTG-NH2		2352

HEX = Hexanediol

SEQ ID NO

ELISA Format Kits

Leukocyte-associated molecule-1 alpha subunit, human (h-LFA1)

Ga731 Probe Set

P**I****C**

5'-CTCTCTCGTCAGGGGCTGCTGG-P04-3'
 5'-CTGTCACACGTCGTCGCTGA-3'
 5'-AAAAAGGAGACGAGAAGATG-3'

for the remainder of the oligo sets on this list, the fret/target secondary sets are one of the following 1':

FRET/TARGET SETS**FRET****TARGET**

set 1	307-70-03	502-93-01
set 2	307-70-03	502-93-02
set 3	187-46-01	641-60-02
set 4	187-46-01	277-68-05
set 5	187-46-01	685-56-01
set 6	187-46-01	641-60-03
set 7	187-46-01	649-10-01
set 8	680-17-02	782-70-02
set 9	187-46-01	277-68-06
set 10	187-46-01	491-02-02
set 11	307-70-03	761-40-02

FRETS

307-70-03	5-CAGTCTGAGATGATAGAGAAGACT-NH2-3'
187-46-01	5'-Fam-CAAC (C ^Y 3)GCTTCCTCCG-3'
680-17-02	5'-Fam-CGCT (C ^Y 3)TCGCTGC-3'

TARGET'S

502-93-01	5-CAGTCTGAGATGATAGAGAAGACT-NH2-3'
502-93-02	5'-CAGTCTGAGATGATAGAGCAGAGGT-NH2-3'
641-60-02	5'-GGGAGAAAGCAGTGGAGGCCGTCGCTGACGCT-NH2-3'
277-68-05	5'-CGGAGGAAGCAGTGGAGGCCGTCGCTGACGCT-NH2-3'
685-56-01	5'-GCGGAGGAAGCAGTGGAGGCCGTCGCTGACGCT-NH2-3'
641-60-03	5'-GGGAGAAAGCAGTGGAGGCCGTCGCTGACGCT-NH2-3'
649-10-01	5'-CGGAGGAAGCAGTGGAGGCCAAGCTGCCGTC-3'
782-70-02	5'-GGGAGAAAGCAGTGGAGGCCAAGCTGCCGTC-3'
277-68-06	5'-GGGAGAAAGCAGTGGAGGCCAAGCTGCCGTC-3'
491-02-02	5'-GGGAGAAAGCAGTGGAGGCCAAGCTGCCGTC-3'

761-40-02		5-GGAGTGAAGCAGCAAAAGACTGCCGTCT-3'	2405
Cell Lysate Kits			
adipocyte lipid binding protein, mouse (m- <i>aP2</i>)			
C289 Probe Set			
	p	FRET/TARGET SET 1	2406
	p	5'-CGGCATCATAGGGTATGATGCTA-	2407
	a	5'-CTCTCTGCTTCACCTCTGTCG-NH2-3'	2408
	a	3'-PO4-AGCAAGGAAAGTGGAAAGCACG-5'	2409
	a	3'-NH2-AAGCAGAGAAAGTGGAAAGCACG-5'	2410
	a	3'-PO4-AGAGAGAGAAAGTGGAAAGCACG-5'	2411
	p	5'-AACGAGCAGCACCCTCACCTCTGTCG-Biotin-3'	2412
	p	3'-PO4-CGGCTGGAAAGTGGAAAGCACG-5'	2413
	a	5'-CATCTTCGGGACTCTACCTCTGTCG-NH2	2414
	a	3'-PO4-GCCCTGAAGTGGAAAGCACG-5'	2415
	p	5'-CTTGCTGCCATGCTTACCTCTGTCG-NH2	2416
	p	5'-CTTGCTCCCGTGCTTACCTCTGTCG-NH2	2417
	p	3'-PO4-GGGCACGAAAGTGGAAAGCACG-5'	2418
	p	3'-PO4-AGGGGCCAGGAAGTGGAAAGCACG-5'	2419
	a		2420
	a		2421
G392 Probe Set			
	p	FRET/TARGET SET 1	2422
	p	5'-CTCTCTGCTCACATTCACCCACCA-G-NH2-3'	2423
		5'-TTGTGTAAGTCAGCCTTCTCAATAT-3'	
rev-ErBa, mouse (m-revErBa)			
C155 Probe Set			
	p	FRET/TARGET SET 4	2424
	p	5'-AACGAGCAGCAGAAAGCAGGTAATGAAATCT-NH2-3'	2425
		5'-CCACTCTGAAGGCTCCCACTC-3'	
Cardiolipin palmitoyltransferase, mouse (m-CPT-1)			
T352 Probe Set			
	p	FRET/TARGET SET 2	2426
	p	5'-CTCTCTGCTCACATGCTGCC-NH2-3'	2427
		5'-GCTTCAAGGGTTGTCGAAGAACAC-3'	
C551 Probe Set			
	p	FRET/TARGET SET 2	2428
	p	5'-CTCTCTGCTGCTTGGGGATACAT-NH2-3'	2429
		5'-CAGCTGATCTCACAGGTCAC-3'	
Carnitine palmitoyltransferase, human (h-CPT-1)			

U744 Probe Set								
P	I							
I								
A								
S								
A456 Probe Set								
P	P	I						
I								
A								
S								
C759 Probe Set								
P	P	I						
I								
A								
S								
G329 Probe Set								
P	P	I						
I								
A								
S								
C1763 Probe Set								
P	P	I						
I								
A								
Phosphatidylinositol-3-phosphate p110 → human (h-PI3Kp110.)								
G1045 Probe Set (FV Arm)								
P	P	I						
I								
A								
C1521 Probe Set								
P	P	I						
I								
A								
C2667 Probe Set								
P	P	I						

a	3'NH2-AGCAGAGCAACATAAGAAAATTGGTC-5'	2455
	FRET/TARGET SET 2	
p	5'-CTCTCTGTTCTCCCTGGTGGATATGTTG-NH2-3'	2456
	5'-CTAAGTTTCAGGGATGGATGGTCA-TGC-3'	2457
a	3'NH2-AGCAGAGGAACACCTATAAAC-5'	2458
	FRET/TARGET SET 2	
p	5'-CTCTCTGCTCAACTGTGGGC-NH2-3'	2459
	5'-TTAGATCTGTAGTCCTCCGAAC-3'	2460
a	3'NH2-AGCAGAGTCACACCCG-5'	2461
	FRET/TARGET SET 1	
A831 Probe Set	5'-CGGTCACGCCCTCTGCTCC-(biotin)-3'	2462
p	5'-AGCCCTCAACTTCAAGCTGT-3'	2463
	5'-GGGAGGCCAACAGGAAGGCG-(biotin)-3'	2464
a		
	FRET/TARGET SET 1	
Cartilage-derived morphogenic protein 1, human (h-CMP1)	5'-CGGAGAGATCTGAGAGAGATGCTGATGG-(biotin)-3'	2465
A1691 Probe Set	5'-ACACCACTGTTGECAGAGTCAAAG-3'	2466
p	5'-CCATCAGCATCTCTCACTGATCTCGG-(biotin)-3'	2467
a		
	FRET/TARGET SET 5	
C1671 Probe Set (longer)	5'-CGGTCACGCCCTGCTTAGGGTCA-NH2-3'	2468
p	5'-TCTGGTGTCATCTTTCACGGGTGA-3'	2469
	5'-GCGGGCGGAAATGCCAAGT-5'	2470
a	5'-GAGGGGGCTCGGTGAGC-3'	2471
s		
	FRET/TARGET SET 5	
b-actin, rat (r-bACT)	5'-CGGAGATCGAGGTTGCTGCTTC-(biotin)-3'	2472
C1671 Probe Set (longer)	5'-CGGGGGAGATCGAGGTTGCTGCTTC-(biotin)-3'	2473
p	5'-TTCACACAGCTTTCCTGGTATCTCC-3'	2474
	3'-(biotin)-CTAGTGTCAAGAAGGGAAAG-5'	2475
a		
	FRET/TARGET SET 2	
Bile Salt port Pump, rat (r-BSEP)	5'-CTCTCTGCTCCAGGAAAGGCCAGT-(biotin)-3'	2476
p	5'-TCTTACATCTAGGACAAGTGTGAAACCAA-3'	2477
	5'-ACTGGCCCTCTGGGAAGC-(biotin)-3'	2478
a		
	FRET/TARGET SET 2	
G1288 Probe Set	5'-CGGAGATCGAGGTTGCTGCTTC-(biotin)-3'	2479
p	5'-TTCACACAGCTTTCCTGGTATCTCC-3'	2480
	3'-(biotin)-CTAGTGTCAAGAAGGGAAAG-5'	2481
a		

A780 Probe Set	FRET/TARGET SET 6	5'-CGGTACAGGCCCTTTCCTCATCTCCGACTCTGGATTAATC-3'	2479
		5'-CCCAATTCCATCTTATTCGAAAGTAAATC-3'	2480
a		5'-AGGAAATGAGAAAAGAGGGG-(biotin)-3'	2481
A5418 Probe Set	FRET/TARGET SET 6	5'-CGGTACAGGCCCTTTCCTGC-(biotin)-3'	2482
		5'-GCTGACCGCCACCC-3'	2483
p		5'-GCGAAGAAAGACAGAGCG-(biotin)-3'	2484
Nitric Oxide Synthase 2A, human (h-NOS2)	FRET/TARGET SET 6	5'-AACGAGGGGCACTCTCTTATTCCTGG-3'	2485
		5'-AACGAGGGGCACTCTTATTCCTGG-NH2-3'	2486
p		5'-GTCCTAAAGTCCACCAAGCTGTC-3'	2487
		5'-CAGGAGATAAAGAAAGTGCGC-(biotin)-3'	2488
s			
A1221 Probe Set	FRET/TARGET SET 7	5'-CGGTACAGGCCCTCTCTTATTCCTGG-3'	2489
		5'-GCTGACGGGCACTCTTATTCCTGG-3'	2490
p		5'-GTCCTAAAGTCCACCAAGCTGTC-3'	2491
		5'-CAGGAGATAAAGAAAGTGCGC-(biotin)-3'	2492
a			2493
s			
C1309 Probe Set	FRET/TARGET SET 6	5'-GAACGGAGGTGGCAGCTTGGATT-NH2-3'	2494
		5'-CAGGTAGCGTAGCTGCTGTA-3'	2495
p		3'-NH2-CGTCAAACGGTGAACCGTAA-5'	2496
		5'-GGCTCTGTGCTGGCTA-NH2-3'	2497
a			
s			
G1480 Probe Set	FRET/TARGET SET 6	5'-CGGTACAGGCCCTCGGACTCTGGATT-(biotin)-3'	2498
		5'-CGGTACAGGCCCTCGGACTCTGGATT-(biotin)-3'	2499
p		5'-AGACGGAGTCGGAGG-(biotin)-3'	2500
a			
Peroxisomal Proliferator Activator Protein Receptor alpha, human (h-PPAR _α)	FRET/TARGET SET 8	5'-CGGTACAGGCCCTCGGACTCTGGATT-(biotin)-3'	2501
		5'-CGGTACAGGCCCTCGGACTCTGGATT-(biotin)-3'	2502
a		5'-AGAACGATCAAGTGACAGGGCG-(biotin)-3'	2503
A1044 Probe Set	FRET/TARGET SET 6	5'-CGGTACAGGCCCTCGTACCTGATCGTTCT-(biotin)-3'	2504
		5'-TGGCTCTATAAAACTCGTATTAGCAAG-3'	2505
p		5'-AGAACGATCAAGTGACAGGGCG-(biotin)-3'	2506
a			

C 1311 Probe Set	FRET/TARGET SET 6	2504
p	5'-CGGCCGAGATCACGGTCCCTACGTITAGAACG-(biotin)-3'	2505
i	5'-CACAGTGAAATTACCCCTCCCTGATTTCATAATC-3'	2506
a	5'-CTCTAAACGTAGAACAGCACGTSATCTCGG-(biotin)-3'	
Peroxisomal Proliferation Activator Protein Receptor beta, human (hPPAR_β)		
A595 Probe Set	FRET/TARGET SET 6	
6B. Designed truncated probe and slackers to reduce temperature		
p	5'-CCGTCAGGCCCTCTCTGAATCTTG-3'	2507
	5'-CTGGCACTTTGGCGGTTCTA-3'	
a	3'-NH2-GCGGAGAGAACGTTAGAACG-5'	2508
s	5'-AGCTGGCTCACACTCTCGT-3'	2510
FRET/TARGET SET 6		
6C. Design for new INVADER assay with 50% 2'-Me.		
p	5'-CCGTCAGGCCCTCTCTGAATCTTG-NH2-3'	2511
	5'-CTGGCACTTTGGCGGTTCTA-3'	2512
a	3'-NH2-GCGGAGAGAACGTTAGAAC-5'	2513
s	5'-CAGGTGGCTCACACTCTCGT-NH2-3'	2514
FRET/TARGET SET 6		
6D. Truncate probe.		
p	5'-CCGTCAGGCCCTCTCTGAATCTTG-NH2-3'	2515
	5'-CTGTGGCACTTTGGGGTTCTA-3'	2516
a	5'-GGAGCTGGCTCACACTCTCGT-NH2-3'	2517
s		
FRET/TARGET SET 7		
C891 Probe Set		
p	5'-AACGAGGGCACGGTAGGCATTGTAGA-3'	2518
	5'-CCCTCTTTTGCTCATGGTAAGTTTTCAC-3'	2519
a	3'-CGGTGGCATCGTAACACT-5'	2520
s	5'-TGTGGCTGGAGAACGGCTTCA-3'	2521
Substance P, rat (r-SubP)		
C344 Probe Set	FRET/TARGET SET 6	
p	5'-CCGTCAGGCCCTCTCTGAATCTTG-NH2-3'	2522
	5'-CCATGCCATAAAAGAGCTTAAACAGGA-3'	2523
a	3'-NH2-GCGGAGGGTGAACAAAAAGT-5'	2524
s	NO STACKER	
FRET/TARGET SET 6		
A396 Probe Set		
p	5'-CCGTCAGGCCCTCTCTGAATCTTG-NH2-3'	2525

G-protein coupled receptor 2, rat (r-ETBR-LP2)

A1629 Probe set

P			
a			
s			

5'-GAACGGCAGGTTGTCAAGCAGAACCGC-NH2-3'
 5'-GAGGGCAGAAATGAGAACCATGTGAAAGAAA-3'
 3'-NH2-CGTCAAACGATGTTGCGG-5'
 5'-CATGATGCCATGCC-NC-3'

i kappa b alpha, human (h-MADS)

C542 Probe Set

P			
a			

5'-AACGAGCCACGGTGTAGGGGG-(biotin)-3'
 5'-GCCCTGTCAGAGGCAAT-2'
 5'-CCGCCTACACCGTGCGC-(biotin)-3'

C363 Probe Set

P			
A			

5'-CGCTAAGCCCTGCAACTTCATG
 5'-CACCTGGGGATCACTTCATG
 5'-GAAAGGCACTGAGAGGGC-(biotin)-3'

G553 Probe Set

P			
A			

5'-CGCTACGGCTCCCTCATCCTCACT-(biotin)-3'
 5'-ACTCTGACTCTGTTGATAGCTCTT
 5'-AGTGAGGATGAGGAAGCG-(biotin)-3'

C523 Probe Set

P			
A			

5'-AACGAGGGCAGGGTTCTAGTGTC-A-NH2-3'
 5'-CTCACTCTGCAAGCATCTGAAT
 3'-NH2-CGCGTCCAAGATACTACAGT-5'
 5'-GCTGGCCAGCTGC-NH2-3'

Lecithin cholesterol acyltransferase, human (h-LCAT)

C821 Probe Set (truncated Probe Design)

P			
a			
s			

5'-CGCCGAGATCACGGTTATGCGCTG-NH2-3'
 5'-CCAGGGGGAGGTGGTC-3'
 3'-NH2-1CTAGTGCCAATACGCGACG-5'
 5'-CTCTCTTCACTGATGCTGG-NH2-3'

C827 Probe Design

P			
a			

5'-GAACGGCAGGTTGGGTGGTGTATGCG-NH2-3'
 5'-AGAGGAAACATCCAGGGGAG-3'
 3'-NH2-CGTCANACCCACCAATACGC-5'

FRET/TARGET SET 8			
5'-GAACGGCAGGTTGTCAAGCAGAACCGC-NH2-3'	2552	2553	
5'-GAGGGCAGAAATGAGAACCATGTGAAAGAAA-3'	2554	2555	
3'-NH2-CGTCAAACGATGTTGCGG-5'			
5'-CATGATGCCATGCC-NC-3'			
FRET/TARGET SET 7			
5'-AACGAGCCACGGTGTAGGGGG-(biotin)-3'	2556		
5'-GCCCTGTCAGAGGCAAT-2'	2557		
5'-CCGCCTACACCGTGCGC-(biotin)-3'	2558		
FRET/TARGET SET 6			
5'-CGCTAAGCCCTGCAACTTCATG	2559		
5'-CACCTGGGGATCACTTCATG	2560		
5'-GAAAGGCACTGAGAGGGC-(biotin)-3'	2561		
FRET/TARGET SET 5			
5'-CGCTACGGCTCCCTCATCCTCACT-(biotin)-3'	2562		
5'-ACTCTGACTCTGTTGATAGCTCTT	2563		
5'-AGTGAGGATGAGGAAGCG-(biotin)-3'	2564		
FRET/TARGET SET 7			
5'-AACGAGGGCAGGGTTCTAGTGTC-A-NH2-3'	2565		
5'-CTCACTCTGCAAGCATCTGAAT	2566		
3'-NH2-CGCGTCCAAGATACTACAGT-5'	2567		
5'-GCTGGCCAGCTGC-NH2-3'	2568		
FRET/TARGET SET 5			
5'-CGCCGAGATCACGGTTATGCGCTG-NH2-3'	2569		
5'-CCAGGGGGAGGTGGTC-3'	2570		
3'-NH2-1CTAGTGCCAATACGCGACG-5'	2571		
5'-CTCTCTTCACTGATGCTGG-NH2-3'	2572		
FRET/TARGET SET 8			
5'-GAACGGCAGGTTGGGTGGTGTATGCG-NH2-3'	2573		
5'-AGAGGAAACATCCAGGGGAG-3'	2574		
3'-NH2-CGTCANACCCACCAATACGC-5'	2575		

C1217 Probe Design								
p								
a								
A177 Probe Set								
p								
s								
Apolipoprotein A-1, human (h-ApoA1)								
A227 Probe Set (in vitro length of 2'-O-Me in Invader)								
p								
a								
A								
s								
G350 Probe Set								
p								
a								
s								
G233 Probe Set								
p								
a								
s								
Metabotropic Glutamate Receptor 1, rat (r-mGluR1)								
T934 Probe Set								
p								
a								
s								
Ubiquilin, human (h-UBIQ)								
FRET/TARGET SET 5								
5'-CGGCCAGATCAGGATGTCATCCG-NH2-3'	2576							
5'-GGTCAAGTGTGCTGAAGACCA(GTTG-3'	2577							
3'-NH2-TCTAGTGCTCATCACATAGGG-5'	2578							
FRET/TARGET SET 6								
5'-CGGTACGCCCTCTGAGCACATCCACAG-NH2-3'	2579							
5'-ACATATCTCTCGCGCTGCTTA-3'	2580							
5'-NH2-GGGAGACTCTGTAAGTGC-5'	2581							
5'-TACACAAGTGGCCAGTCCT-NH2-3'	2582							
FRET/TARGET SET 8								
5'-GAACGCCAGGTTGCCAACAGGCCG-NH2-3'	2583							
5'-GTCAGGAGGCTTAGTTAGCTGTTTA-3'	2584							
5'-GTCAGGATCTCTAGGTTAGCTGTTTA-3'	2585							
5'-GTCAGGATCTAGGTTAGCTGTTTA-3'	2586							
3'-NH2-GTCCAAACGGGTTGCCG-5'	2587							
5'-AGCCTCAAACCTGGACACATACTCTC-NH2-3'	2588							
FRET/TARGET SET 5								
5'-CGCCGAGATCCTCTCTCTCT-NH2-3'	2589							
5'-CTCTCTCTCTAGGCCG-3'	2590							
3'-NH2-TCTAGTGAGAACAGAAGAA-5'	2591							
5'-TCCCGGTTATCCAGAACCTCC-NH2-3'	2592							
FRET/TARGET SET 11								
5'-AGAACGCCAGCTTC(GTTTCCCAGG-NH2-3'	2593							
5'-CCAGTTGTCAGGAGCTTGTGTTAGT-3'	2594							
3'-NH2-CGGTCAGAAAAGAACAAAAGGGTTC-5'	2595							
5'-CGGAGCCCTCAAATGGACACATAGT-NH2-3'	2596							
FRET/TARGET SET 11								
5'-AGAACGCCAGCTTC(GTTTCCCAGG-NH2-3'	2597							
5'-CACTGAGGCTATGCTGCGCT-3'	2598							
3'-NH2-GTCAGAAATCTTCGGCTAGACAA-5'	2599							
5'-GGGATGTCGAACAGCTGGAAAGATCT-NH2-3'	2600							

G119 Probe Set		FRET/TARGET SET 6
p		5'-CGGCAAGCTCCCTATCGTATCCG-(biotin)-3'
		5'-CCCTCCCTATCGGATCTGGCA-3'
a		3'- <i>(biotin)</i> -GGGGAGGAATAATGAAAGATAGCATAGGC-5'
G119 Probe Set		FRET/TARGET SET 5
p		5'-GCCGAGATCACCTTACATTTCTATCGTATCG-(biotin)-3'
		5'-CCCTCCCTATCGGATCTGGCA-3'
a		3'- <i>(biotin)</i> -CTAGTGAAATGAAAGATAGCATAGGC-5'
G131 Probe Set		FRET/TARGET SET 9
p		5'-CATCTTCGGGACTGGATCCTGGCC-(biotin)-3'
		5'-GCTGATCAGGAGGAATTCTCCCTTATCT-3'
a		3'- <i>(biotin)</i> -GCCTGACCTGAAACCGG-5'
Scanned G119 region (ELISA format (No Arrestors))		FRET/TARGET SET 5
p		5'-CTCTCTCTCTCTTACATTTCTATCGTATCGGANH2-3'
p		5'-CTCTCTCTCTCTTACATTTCTATCGTATCGN-HN2-3'
p		5'-CTCTCTCTCTCTTACATTTCTATCGTATCG-NH2-3'
p		5'-CTCTCTCTCTCTTACATTTCTATCGTATCG-NH2-3'
p		5'-CTCTCTCTCTCTTACATTTCTATCGTATCG-NH2-3'
p		5'-GAAATTCTCTCTTACATTTCTATCGTATCG-NH2-3'
p		5'-GAAATTCTCTCTTACATTTCTATCGTATCG-NH2-3'
p		5'-CTCTCTTACCTCTTACATTTCTATCGTATCG-NH2-3'
p		5'-TTCCTTATCCCTGATCTGGCA-3'
p		5'-TCCCTTATCCCTGATCTGGCA-3'
p		5'-TCCCTTATCCCTGATCTGGCA-3'
p		5'-TCCCTTATCCCTGATCTGGCA-3'
Ubiquitin, mouse (m-UBIQ)		FRET/TARGET SET 7
G234 Probe Set		5'-CGGTAAGCTCCCTCTGGATGTTGTA-(biotin)-3'
p		5'-CCGGGTGCAAGGGTGTGACTA-3'
		3'- <i>(biotin)</i> -GGGGAGGAAGACCTACAACAT-5'
G234 Probe Set		FRET/TARGET SET 5
p		5'-GCCGAGATCAACCTCTCTGGATGTTGTA-(biotin)-3'
		5'-CCAGGTGCAAGGGTGTGACTA-3'
a		3'- <i>(biotin)</i> -CTAGTGAAAGACCTACAACAT-5'
G234 Probe Set		FRET/TARGET SET 6
p		5'-CGGTAAGCTCCCTCTGGATGTTGTA-(biotin)-3'
		5'-CCAGGTGCAAGGGTGTGACTA-3'
a		3'- <i>(biotin)</i> -CTAGTGAAAGACCTACAACAT-5'

a		3'-NH2-GGGAGGGAAAGACCTAACACATTA-5'	2628
	G294 Probe Set		
p		FRET/TARGET SET 6	
		5'-CGGTACGGCCCTCTGGATGTTGTAATC-NH2-3'	2629
a		5'-CCAGTGCGAGGGTGAATCA-3'	2630
		3'-NH2-GGGAGGGAAAGACCTAACACATTA-5'	2631
	T514 Probe Set		
p		FRET/TARGET SET 7	
		5'-AACGAGGCCACATTTGTAATCAGAGAGGG-NH2-3'	2632
a		5'-TGAGGGTTGACTCTTCTTCTGGA-3'	2633
		3'-NH2-GCGTGTACAACATTAGTCCTCC-5'	2634
	G750 Probe Set		
p		FRET/TARGET SET 9	
		5'-CATCTTCGGGACCTCTGGATGTTGTA-NH2-3'	2635
a		5'-GGACACAGGTGCAAGGTTGACTT-3'	2636
		3'-NH2-GCCCTGGAAAGACCTAACACAT-5'	2637
	G385 Probe Set		
p		FRET/TARGET SET 9	
		5'-CATCTTCGGGACCTCTGGATGTTGGA-NH2-3'	2638
a		5'-CCCTCTTATCTGGATCTGGCA-3'	2639
		3'-NH2-GCGCCTGAAAGTCAGAGCTAC-5'	2640

FIGURE 48

12		
1	8	C
2	5	U
3	5	U
4	2	U
5	1	U
6	2	C
7	7	G
8	7	A
9	1	U
10	1	C

SEQUENCE LISTING

<110> Third Wave Technologies

<120> Detection of RNA

<130> FORS

<160> 708

<170> PatentIn version 3.0

<210> 1

<211> 834

<212> PRT

<213> Thermus aquaticus

<400> 1

Met Glu Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15

Val Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu Lys Gly
20 25 30

Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45

Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Tyr Lys Ala Val Phe
50 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Glu
65 70 75 80

Ala Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
85 90 95

Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Phe Thr Arg Leu
100 105 110

Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Thr Leu Ala Lys
115 120 125

Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Arg
130 135 140

Asp Leu Tyr Gln Leu Val Ser Asp Arg Val Ala Val Leu His Pro Glu
145 150 155 160

Gly His Leu Ile Thr Pro Glu Trp Leu Trp Glu Lys Tyr Gly Leu Arg
165 170 175

Pro Glu Gln Trp Val Asp Phe Arg Ala Leu Val Gly Asp Pro Ser Asp
180 185 190

Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Leu Lys Leu
195 200 205

Leu Lys Glu Trp Gly Ser Leu Glu Asn Leu Leu Lys Asn Leu Asp Arg
210 215 220

Val Lys Pro Glu Asn Val Arg Glu Lys Ile Lys Ala His Leu Glu Asp
225 230 235 240

Leu Arg Leu Ser Leu Glu Leu Ser Arg Val Arg Thr Asp Leu Pro Leu
245 250 255

Glu Val Asp Leu Ala Gln Gly Arg Glu Pro Asp Arg Glu Gly Leu Arg
260 265 270

Ala Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly
275 280 285

Leu Leu Glu Ala Pro Ala Pro Leu Glu Glu Ala Pro Trp Pro Pro Pro
290 295 300

Glu Gly Ala Phe Val Gly Phe Val Leu Ser Arg Pro Glu Pro Met Trp
305 310 315 320

Ala Glu Leu Lys Ala Leu Ala Ala Cys Arg Asp Gly Arg Val His Arg
325 330 335

Ala Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly
340 345 350

Leu Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp
355 360 365

Leu Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro
370 375 380

Ser Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp
385 390 395 400

Thr Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg
405 410 415

Asn Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr
420 425 430

His Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala
435 440 445

Thr Gly Val Arg Leu Asp Val Ala Tyr Leu Gln Ala Leu Ser Leu Glu
450 455 460

Leu Ala Glu Glu Ile Arg Arg Leu Glu Glu Val Phe Arg Leu Ala
465 470 475 480

Gly His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu
485 490 495

Phe Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys Thr Gly
500 505 510

Lys Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His
515 520 525

Pro Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys
530 535 540

Asn Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly
545 550 555 560

Arg Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu
565 570 575

Ser Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu
580 585 590

Gly Gln Arg Ile Arg Arg Ala Phe Val Ala Glu Ala Gly Trp Ala Leu
595 600 605

Val Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu
610 615 620

Ser Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Lys Asp Ile
625 630 635 640

His Thr Gln Thr Ala Ser Trp Met Phe Gly Val Pro Pro Glu Ala Val
645 650 655

Asp Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu
660 665 670

Tyr Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr
675 680 685

Glu Glu Ala Val Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys
690 695 700

Val Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Lys Arg Gly
705 710 715 720

Tyr Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Asn
725 730 735

Ala Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn
740 745 750

Met Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val
755 760 765

Lys Leu Phe Pro Arg Leu Arg Glu Met Gly Ala Arg Met Leu Leu Gln
770 775 780

Val His Asp Glu Leu Leu Glu Ala Pro Gln Ala Arg Ala Glu Glu
785 790 795 800

Val Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro Leu Ala
805 810 815

Val Pro Leu Glu Val Glu Val Gly Met Gly Glu Asp Trp Leu Ser Ala
 820 830

Lys Gly

<210> 2
 <211> 839
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic

<400> 2

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 15
 5 10

Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 30
 25 30

Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 45
 40 45

Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 60
 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 60
 70 75

Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 95
 90 95

Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 110
 105 110

Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 125
 120 125

Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 140
 135 140

Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 160
 150 155 160

Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 175
 170 175

Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 190
 185 190

Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 205
 200 205

Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg

210	215	220	
Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu			
225	230	235	240
Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu			
245	250	255	
Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala			
260	265	270	
Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu			
275	280	285	
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu			
290	295	300	
Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala			
305	310	315	320
Asp Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala			
325	330	335	
Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu			
340	345	350	
Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu			
355	360	365	
Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser			
370	375	380	
Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr			
385	390	395	400
Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn			
405	410	415	
Leu Leu Lys Arg Leu Glu Gly Glu Lys Leu Leu Trp Leu Tyr His			
420	425	430	
Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr			
435	440	445	
Gly Val Arg Arg Asp Val Ala Tyr Leu Gln Ala Leu Ser Leu Glu Leu			
450	455	460	
Ala Glu Glu Ile Arg Arg Leu Glu Glu Val Phe Arg Leu Ala Gly			
465	470	475	480
His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe			
485	490	495	
Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys Thr Gly Lys			
500	505	510	
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro			

515	520	525
Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys Asn		
530	535	540
Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly Arg		
545	550	555
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser		
565	570	575
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly		
580	585	590
Gln Arg Ile Arg Arg Ala Phe Val Ala Glu Ala Gly Trp Ala Leu Val		
595	600	605
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser.		
610	615	620
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Lys Asp Ile His		
625	630	640
Thr Gln Thr Ala Ser Trp Met Phe Gly Val Pro Pro Glu Ala Val Asp		
645	650	655
Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu Tyr		
660	665	670
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu		
675	680	685
Glu Ala Val Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val		
690	695	700
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Lys Arg Gly Tyr		
705	710	720
Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Asn Ala		
725	730	735
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met		
740	745	750
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys		
755	760	765
Leu Phe Pro Arg Leu Arg Glu Met Gly Ala Arg Met Leu Leu Gln Val		
770	775	780
His Asn Glu Leu Leu Leu Glu Ala Pro Gln Ala Arg Ala Glu Glu Val		
785	790	800
Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro Leu Ala Val		
805	810	815
Pro Leu Glu Val Glu Val Gly Met Gly Glu Asp Trp Leu Ser Ala Lys		

820

825

830

Gly His His His His His His
 835

<210> 3
 <211> 842
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic

<400> 3

Met Asn Ser Glu Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val
 1 5 10 15

Leu Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu
 20 25 30

Lys Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly
 35 40 45

Phe Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Tyr Lys Ala
 50 55 60

Val Phe Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala
 65 70 75 80

Tyr Glu Ala Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro
 85 90 95

Arg Gln Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Phe Thr
 100 105 110

Arg Leu Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Thr Leu
 115 120 125

Ala Lys Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala
 130 135 140

Asp Arg Asp Leu Tyr Gln Leu Val Ser Asp Arg Val Ala Val Leu His
 145 150 155 160

Pro Glu Gly His Leu Ile Thr Pro Glu Trp Leu Trp Glu Lys Tyr Gly
 165 170 175

Leu Arg Pro Glu Gln Trp Val Asp Phe Arg Ala Leu Val Gly Asp Pro
 180 185 190

Ser Asp Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Leu
 195 200 205

Lys Leu Leu Lys Glu Trp Gly Ser Leu Glu Asn Leu Leu Lys Asn Leu
 210 215 220

Asp Arg Val Lys Pro Glu Asn Val Arg Glu Lys Ile Lys Ala His Leu			
225	230	235	240
Glu Asp Leu Arg Leu Ser Leu Glu Leu Ser Arg Val Arg Thr Asp Leu			
245	250	255	
Pro Leu Glu Val Asp Leu Ala Gln Gly Arg Glu Pro Asp Arg Glu Gly			
260	265	270	
Leu Arg Ala Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu			
275	280	285	
Phe Gly Leu Leu Glu Ala Pro Ala Pro Leu Glu Glu Ala Pro Trp Pro			
290	295	300	
Pro Pro Glu Gly Ala Phe Val Gly Phe Val Leu Ser Arg Pro Glu Pro			
305	310	315	320
Met Trp Ala Glu Leu Lys Ala Leu Ala Ala Cys Arg Gly Gly Arg Val			
325	330	335	
His Arg Ala Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala			
340	345	350	
Arg Gly Leu Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly			
355	360	365	
Leu Gly Leu Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu			
370	375	380	
Asp Pro Ser Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly			
385	390	395	400
Glu Trp Thr Glu Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu			
405	410	415	
Phe Ala Asn Leu Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp			
420	425	430	
Leu Tyr Arg Glu Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met			
435	440	445	
Glu Ala Thr Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser			
450	455	460	
Leu Glu Val Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg			
465	470	475	480
Leu Ala Gly His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg			
485	490	495	
Val Leu Phe Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys			
500	505	510	
Thr Gly Lys Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu			
515	520	525	

Ala His Pro Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys
 530 535 540
 Leu Lys Ser Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg
 545 550 555 560
 Thr Gly Arg Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly
 565 570 575
 Arg Leu Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr
 580 585 590
 Pro Leu Gly Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp
 595 600 605
 Leu Leu Val Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala
 610 615 620
 His Leu Ser Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg
 625 630 635 640
 Asp Ile His Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu
 645 650 655
 Ala Val Asp Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly
 660 665 670
 Val Leu Tyr Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile
 675 680 685
 Pro Tyr Glu Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe
 690 695 700
 Pro Lys Val Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg
 705 710 715 720
 Arg Gly Tyr Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp
 725 730 735
 Leu Glu Ala Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala
 740 745 750
 Phe Asn Met Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala
 755 760 765
 Met Val Lys Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu
 770 775 780
 Leu Gln Val His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala
 785 790 795 800
 Glu Ala Val Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro
 805 810 815
 Leu Ala Val Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu
 820 825 830

Ser Ala Lys Glu His His His His His His
 835 840
 <210> 4
 <211> 839
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic
 <400> 4

 Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15

 Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30

 Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45

 Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60

 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80

 Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95

 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110

 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125

 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile,Leu Thr Ala Asp Lys
 130 135 140

 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160

 Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175

 Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190

 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205

 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220

 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240

Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu
 355 360 365
 Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr
 385 390 395 400
 Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn
 405 410 415
 Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr His
 420 425 430
 Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Arg Asp Val Ala Tyr Leu Gln Ala Leu Ser Leu Glu Leu
 450 455 460
 Ala Glu Glu Ile Arg Arg Leu Glu Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys Thr Gly Lys
 500 505 510
 Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro
 515 520 525
 Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys Asn
 530 535 540

Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly Arg
 545 550 555 560
 Leu His Thr Arg Phe Asn Gln Thr Ala Thr Gly Arg Leu Ser
 565 570 575
 Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly
 580 585 590
 Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640
 Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 650 655
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Gly Tyr
 705 710 715 720
 Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His His
 835

<210> 5
<211> 839
<212> PRT
<213> Artificial

<220>
<223> Synthetic
<400> 5

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
1 5 10 15

Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
20 25 30

Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
35 40 45

Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
50 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
65 70 75 80

Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
85 90 95

Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
100 105 110

Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
115 120 125

Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
130 135 140

Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
145 150 155 160

Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
165 170 175

Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
180 185 190

Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
195 200 205

Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
210 215 220

Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
225 230 235 240

Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu

245	250	255
Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala 260	265	270
Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu 275	280	285
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu 290	295	300
Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala 305	310	315
Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala 325	330	335
Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu 340	345	350
Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu 355	360	365
Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser 370	375	380
Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr 385	390	395
Glu Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn 405	410	415
Leu Trp Gly Arg Leu Glu Gly Glu Arg Leu Leu Trp Leu Tyr Arg 420	425	430
Glu Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr 435	440	445
Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val 450	455	460
Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly 465	470	475
His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe 485	490	495
Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys 500	505	510
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro 515	520	525
Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser 530	535	540
Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg		

545	550	555	560
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser			
565	570	575	
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly			
580	585	590	
Gln Arg Ile Arg Arg Ala Phe Val Ala Glu Ala Gly Trp Ala Leu Val			
595	600	605	
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser			
610	615	620	
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Lys Asp Ile His			
625	630	635	640
Thr Gln Thr Ala Ser Trp Met Phe Gly Val Pro Pro Glu Ala Val Asp			
645	650	655	
Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu Tyr			
660	665	670	
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu			
675	680	685	
Glu Ala Val Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val			
690	695	700	
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Lys Arg Gly Tyr			
705	710	715	720
Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Asn Ala			
725	730	735	
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met			
740	745	750	
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys			
755	760	765	
Leu Phe Pro Arg Leu Arg Glu Met Gly Ala Arg Met Leu Leu Gln Val			
770	775	780	
His Asn Glu Leu Leu Glu Ala Pro Gln Ala Arg Ala Glu Glu Val			
785	790	795	800
Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro Leu Ala Val			
805	810	815	
Pro Leu Glu Val Glu Val Gly Met Gly Glu Asp Trp Leu Ser Ala Lys			
820	825	830	
Gly His His His His His His			
835			

<211> 839
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic

<400> 6

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15

Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30

Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45

Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80

Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95

Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110

Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125

Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140

Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160

Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175

Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190

Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205

Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220

Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240

Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255

Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Arg Val His Arg Ala
 325 330 335
 Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu
 355 360 365
 Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr
 385 390 395 400
 Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn
 405 410 415
 Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr His
 420 425 430
 Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val
 450 455 460
 Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys
 500 505 510
 Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro
 515 520 525
 Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser
 530 535 540
 Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg
 545 550 555 560

Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser
 565 570 575
 Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly
 580 585 590
 Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640
 Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 650 655
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
 705 710 715 720
 Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His
 835
 <210> 7
 <211> 839
 <212> PRT

<213> Artificial

<220>

<223> Synthetic

<400> 7

Met	Asn	Ser	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu
1				5					10					15	
Leu	Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys
	20						25						30		
Gly	Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe
	35						40					45			
Ala	Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile
	50					55					60				
Val	Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly
	65						70			75			80		
Gly	Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln
	85							90					95		
Leu	Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu
	100						105					110			
Glu	Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys
	115						120					125			
Lys	Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys
	130						135					140			
Asp	Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu
	145						150				155			160	
Gly	Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg
	165							170					175		
Pro	Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp
	180							185					190		
Asn	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu
	195							200					205		
Leu	Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg
	210						215					220			
Leu	Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu
	225						230				235			240	
Lys	Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu
	245							250					255		
Val	Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala
	260							265					270		

Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu
 355 360 365
 Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr
 385 390 395 400
 Glu Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn
 405 410 415
 Leu Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg
 420 425 430
 Glu Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Arg Asp Val Ala Tyr Leu Gln Ala Leu Ser Leu Glu Leu
 450 455 460
 Ala Glu Glu Ile Arg Arg Leu Glu Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys Thr Gly Lys
 500 505 510
 Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro
 515 520 525
 Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys Asn
 530 535 540
 Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly Arg
 545 550 555 560
 Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser
 565 570 575

Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly
 580 585 590
 Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640
 Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 650 655
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
 705 710 715 720
 Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His
 835
 <210> 8
 <211> 839
 <212> PRT
 <213> Artificial

<220>
<223> Synthetic

<400> 8

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu			
1	5	10	15
Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys			
20	25	30	
Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe			
35	40	45	
Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile			
50	55	60	
Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly			
65	70	75	80
Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln			
85	90	95	
Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu			
100	105	110	
Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys			
115	120	125	
Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys			
130	135	140	
Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu			
145	150	155	160
Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg			
165	170	175	
Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp			
180	185	190	
Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu			
195	200	205	
Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg			
210	215	220	
Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu			
225	230	235	240
Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu			
245	250	255	
Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala			
260	265	270	
Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu			

275	280	285	
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu			
290	295	300	
Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala			
305	310	315	320
Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala			
325	330	335	
Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu			
340	345	350	
Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu			
355	360	365	
Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser			
370	375	380	
Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr			
385	390	395	400
Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn			
405	410	415	
Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr His			
420	425	430	
Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr			
435	440	445	
Gly Val Arg Arg Asp Val Ala Tyr Leu Gln Ala Leu Ser Leu Glu Leu			
450	455	460	
Ala Glu Glu Ile Arg Arg Leu Glu Glu Val Phe Arg Leu Ala Gly			
465	470	475	480
His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe			
485	490	495	
Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys Thr Gly Lys			
500	505	510	
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro			
515	520	525	
Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys Asn			
530	535	540	
Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly Arg			
545	550	555	560
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Gly Arg Leu Ser			
565	570	575	
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly			

580	585	590	
Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val			
595	600	605	
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser			
610	615	620	
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His			
625	630	635	640
Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp			
645	650	655	
Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr			
660	665	670	
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu			
675	680	685	
Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val			
690	695	700	
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Gly Tyr			
705	710	715	720
Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala			
725	730	735	
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met			
740	745	750	
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys			
755	760	765	
Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val			
770	775	780	
His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val			
785	790	795	800
Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val			
805	810	815	
Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys			
820	825	830	
Glu His His His His His His			
835			
<210> 9			
<211> 839			
<212> PRT			
<213> Artificial			
<220>			
<223> Synthetic			

<400> 9

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15

Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30

Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45

Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80

Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95

Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110

Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125

Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140

Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160

Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175

Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190

Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205

Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220

Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240

Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255

Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270

Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285

Leu	Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu
290						295						300			
Gly	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala
305						310				315					320
Asp	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala
						325			330						335
Ala	Asp	Pro	Leu	Ala	Gly	Leu	Lys	Asp	Leu	Lys	Glu	Val	Arg	Gly	Leu
						340			345						350
Leu	Ala	Lys	Asp	Leu	Ala	Val	Leu	Ala	Ser	Arg	Glu	Gly	Leu	Asp	Leu
						355			360						365
Val	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser
						370			375						380
Asn	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr
						385			390			395			400
Glu	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn
						405			410						415
Leu	Trp	Gly	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg
						420			425						430
Glu	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr
						435			440				445		
Gly	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val
						450			455				460		
Ala	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly
						465			470			475			480
His	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe
						485			490						495
Asp	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Glu	Lys	Thr	Gly	Lys
						500			505						510
Arg	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro
						515			520						525
Ile	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser
						530			535			540			
Thr	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg
						545			550			555			560
Leu	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser
						565			570						575
Ser	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly
						580			585						590

Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640
 Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 650 655
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
 705 710 715 720
 Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His His
 835
 <210> 10
 <211> 842
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic
 <400> 10

Met Asn Ser Glu Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val
 1 5 10 15
 Leu Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe Phe Ala Leu
 20 25 30
 Lys Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly
 35 40 45
 Phe Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Tyr Lys Ala
 50 55 60
 Val Phe Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala
 65 70 75 80
 Tyr Glu Ala Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro
 85 90 95
 Arg Gln Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Phe Thr
 100 105 110
 Arg Leu Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Thr Leu
 115 120 125
 Ala Lys Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala
 130 135 140
 Asp Arg Asp Leu Tyr Gln Leu Val Ser Asp Arg Val Ala Val Leu His
 145 150 155 160
 Pro Glu Gly His Leu Ile Thr Pro Glu Trp Leu Trp Glu Lys Tyr Gly
 165 170 175
 Leu Arg Pro Glu Gln Trp Val Asp Phe Arg Ala Leu Val Gly Asp Pro
 180 185 190
 Ser Asp Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Leu
 195 200 205
 Lys Leu Leu Lys Glu Trp Gly Ser Leu Glu Asn Leu Leu Lys Asn Leu
 210 215 220
 Asp Arg Val Lys Pro Glu Asn Val Arg Glu Lys Ile Lys Ala His Leu
 225 230 235 240
 Glu Asp Leu Arg Leu Ser Leu Glu Leu Ser Arg Val Arg Thr Asp Leu
 245 250 255
 Pro Leu Glu Val Asp Leu Ala Gln Gly Arg Glu Pro Asp Arg Glu Gly
 260 265 270
 Leu Arg Ala Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu
 275 280 285
 Phe Gly Leu Leu Glu Ala Pro Ala Pro Leu Glu Glu Ala Pro Trp Pro
 290 295 300

Pro Pro Glu Gly Ala Phe Val Gly Phe Val Leu Ser Arg Pro Glu Pro
 305 310 315 320
 Met Trp Ala Glu Leu Lys Ala Leu Ala Ala Cys Arg Gly Gly Arg Val
 325 330 335
 His Arg Ala Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val
 340 345 350
 Arg Gly Leu Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly
 355 360 365
 Leu Asp Leu Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu
 370 375 380
 Asp Pro Ser Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly
 385 390 395 400
 Glu Trp Thr Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu
 405 410 415
 His Arg Asn Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp
 420 425 430
 Leu Tyr His Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met
 435 440 445
 Glu Ala Thr Gly Val Arg Arg Asp Val Ala Tyr Leu Gln Ala Leu Ser
 450 455 460
 Leu Glu Leu Ala Glu Glu Ile Arg Arg Leu Glu Glu Glu Val Phe Arg
 465 470 475 480
 Leu Ala Gly His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg
 485 490 495
 Val Leu Phe Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys
 500 505 510
 Thr Gly Lys Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu
 515 520 525
 Ala His Pro Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys
 530 535 540
 Leu Lys Asn Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg
 545 550 555 560
 Thr Gly Arg Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly
 565 570 575
 Arg Leu Ser Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr
 580 585 590
 Pro Leu Gly Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp
 595 600 605

Leu Leu Val Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala
 610 615 620
 His Leu Ser Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg
 625 630 635 640
 Asp Ile His Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu
 645 650 655
 Ala Val Asp Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly
 660 665 670
 Val Leu Tyr Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile
 675 680 685
 Pro Tyr Glu Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe
 690 695 700
 Pro Lys Val Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg
 705 710 715 720
 Arg Gly Tyr Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp
 725 730 735
 Leu Glu Ala Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala
 740 745 750
 Phe Asn Met Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala
 755 760 765
 Met Val Lys Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu
 770 775 780
 Leu Gln Val His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala
 785 790 795 800
 Glu Ala Val Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro
 805 810 815
 Leu Ala Val Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu
 820 825 830
 Ser Ala Lys Glu His His His His His His
 835 840
 <210> 11
 <211> 842
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic
 <400> 11
 Met Asn Ser Glu Ala Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val

1	5	10	15												
Leu	Leu	Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	Phe	Ala	Leu
			20				25							30	
Lys	Gly	Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly
			35				40						45		
Phe	Ala	Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Tyr	Lys	Ala
				50		55				60					
Val	Phe	Val	Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala
					65		70			75				80	
Tyr	Glu	Ala	Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro
					85				90				95		
Arg	Gln	Leu	Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Phe	Thr
					100			105					110		
Arg	Leu	Glu	Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Thr	Leu
					115			120					125		
Ala	Lys	lys	Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala
					130			135					140		
Asp	Arg	Asp	Leu	Tyr	Gln	Leu	Val	Ser	Asp	Arg	Val	Ala	Val	Leu	His
					145			150			155			160	
Pro	Glu	Gly	His	Leu	Ile	Thr	Pro	Glu	Trp	Leu	Trp	Glu	Lys	Tyr	Gly
					165			170					175		
Leu	Arg	Pro	Glu	Gln	Trp	Val	Asp	Phe	Arg	Ala	Leu	Val	Gly	Asp	Pro
					180			185					190		
Ser	Asp	Asn	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Leu
					195			200					205		
Lys	Leu	Leu	Lys	Glu	Trp	Gly	Ser	Leu	Glu	Asn	Leu	Leu	Lys	Asn	Leu
					210			215					220		
Asp	Arg	Val	Lys	Pro	Glu	Asn	Val	Arg	Glu	Lys	Ile	Lys	Ala	His	Leu
					225			230			235			240	
Glu	Asp	Leu	Arg	Leu	Ser	Leu	Glu	Leu	Ser	Arg	Val	Arg	Thr	Asp	Leu
					245			250					255		
Pro	Leu	Glu	Val	Asp	Leu	Ala	Gln	Gly	Arg	Glu	Pro	Asp	Arg	Glu	Gly
					260			265					270		
Leu	Arg	Ala	Phe	Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu
					275			280					285		
Phe	Gly	Leu	Leu	Glu	Ala	Pro	Ala	Pro	Leu	Glu	Glu	Ala	Pro	Trp	Pro
					290			295			300				
Pro	Pro	Glu	Gly	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Pro	Glu	Pro

305	310	315	320
Met Trp Ala Glu Leu Lys Ala Leu Ala Ala Cys Arg Gly Gly Arg Val			
325	330	335	
His Arg Ala Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala			
340	345	350	
Arg Gly Leu Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly			
355	360	365	
Leu Gly Leu Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu			
370	375	380	
Asp Pro Ser Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly			
385	390	395	400
Glu Trp Thr Glu Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu			
405	410	415	
Phe Ala Asn Leu Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp			
420	425	430	
Leu Tyr Arg Glu Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met			
435	440	445	
Glu Ala Thr Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser			
450	455	460	
Leu Glu Val Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg			
465	470	475	480
Leu Ala Gly His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg			
485	490	495	
Val Leu Phe Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys			
500	505	510	
Thr Gly Lys Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu			
515	520	525	
Ala His Pro Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys			
530	535	540	
Leu Lys Ser Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg			
545	550	555	560
Thr Gly Arg Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly			
565	570	575	
Arg Leu Ser Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr			
580	585	590	
Pro Leu Gly Gln Arg Ile Arg Arg Ala Phe Val Ala Glu Ala Gly Trp			
595	600	605	
Ala Leu Val Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala			

610	615	620
His Leu Ser Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Lys 625	630	635
		640
Asp Ile His Thr Gln Thr Ala Ser Trp Met Phe Gly Val Pro Pro Glu 645	650	655
Ala Val Asp Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Phe Gly 660	665	670
Val Leu Tyr Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile 675	680	685
Pro Tyr Glu Glu Ala Val Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe 690	695	700
Pro Lys Val Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Lys 705	710	715
		720
Arg Gly Tyr Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp 725	730	735
Leu Asn Ala Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala 740	745	750
Phe Asn Met Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala 755	760	765
Met Val Lys Leu Phe Pro Arg Leu Arg Glu Met Gly Ala Arg Met Leu 770	775	780
Leu Gln Val His Asn Glu Leu Leu Glu Ala Pro Gln Ala Arg Ala 785	790	795
		800
Glu Glu Val Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro 805	810	815
Leu Ala Val Pro Leu Glu Val Glu Val Gly Met Gly Glu Asp Trp Leu 820	825	830
Ser Ala Lys Gly His His His His His His 835	840	
<210> 12		
<211> 833		
<212> PRT		
<213> Artificial		
<220>		
<223> Synthetic		
<400> 12		
Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu 1	5	10
		15

Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30
 Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45
 Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60
 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80
 Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95
 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110
 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140
 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160
 Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175
 Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205
 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320

Asp	Leu	Leu	Ala	Leu	Ala	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala
				325					330						335
Ala	Asp	Pro	Leu	Ala	Gly	Leu	Lys	Asp	Leu	Lys	Glu	Val	Arg	Gly	Leu
				340					345						350
Leu	Ala	Lys	Asp	Leu	Ala	Val	Leu	Ala	Ser	Arg	Glu	Gly	Leu	Asp	Leu
				355					360						365
Val	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser
				370					375						380
Asn	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr
				385					390				395		400
Glu	Asp	Ala	Ala	His	Arg	Ala	Leu	Leu	Ser	Glu	Arg	Leu	His	Arg	Asn
				405					410						415
Leu	Leu	Lys	Arg	Leu	Glu	Gly	Glu	Glu	Lys	Leu	Leu	Trp	Leu	Tyr	His
				420					425				430		
Glu	Val	Glu	Lys	Pro	Leu	Ser	Arg	Val	Leu	Ala	His	Met	Glu	Ala	Thr
				435					440				445		
Gly	Val	Arg	Arg	Asp	Val	Ala	Tyr	Leu	Gln	Ala	Leu	Ser	Leu	Glu	Leu
				450					455				460		
Ala	Glu	Glu	Ile	Arg	Arg	Leu	Glu	Glu	Val	Phe	Arg	Leu	Ala	Gly	
				465					470				475		480
His	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe
				485					490						495
Asp	Glu	Leu	Arg	Leu	Pro	Ala	Leu	Gly	Lys	Thr	Gln	Lys	Thr	Gly	Lys
				500					505						510
Arg	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro
				515					520						525
Ile	Val	Glu	Lys	Ile	Leu	Gln	His	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Asn
				530					535				540		
Thr	Tyr	Val	Asp	Pro	Leu	Pro	Ser	Leu	Val	His	Pro	Arg	Thr	Gly	Arg
				545					550				555		560
Leu	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser
				565					570				575		
Ser	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly
				580					585				590		
Gln	Arg	Ile	Arg	Arg	Ala	Phe	Val	Ala	Glu	Ala	Gly	Trp	Ala	Leu	Val
				595					600				605		
Ala	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser
				610					615				620		

Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Lys Asp Ile His
 625 630 635 640

Thr Gln Thr Ala Ser Trp Met Phe Gly Val Pro Pro Glu Ala Val Asp
 645 650 655

Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu Tyr
 660 665 670

Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685

Glu Ala Val Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700

Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Lys Arg Gly Tyr
 705 710 715 720

Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Asn Ala
 725 730 735

Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750

Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765

Leu Phe Pro Arg Leu Arg Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780

His Asp Glu Leu Leu Leu Glu Ala Pro Gln Ala Arg Ala Glu Glu Val
 785 790 795 800

Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro Leu Ala Val
 805 810 815

Pro Leu Glu Val Glu Val Gly Met Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830

Gly

<210> 13
 <211> 833
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic

<400> 13

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15

Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30

Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45
 Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60
 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80
 Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95
 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110
 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140
 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160
 Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175
 Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205
 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335

Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu
 355 360 365
 Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr
 385 390 395 400
 Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn
 405 410 415
 Leu Leu Lys Arg Leu Glu Gly Glu Lys Leu Leu Trp Leu Tyr His
 420 425 430
 Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Arg Asp Val Ala Tyr Leu Gln Ala Leu Ser Leu Glu Leu
 450 455 460
 Ala Glu Glu Ile Arg Arg Leu Glu Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys Thr Gly Lys
 500 505 510
 Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro
 515 520 525
 Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys Asn
 530 535 540
 Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly Arg
 545 550 555 560
 Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser
 565 570 575
 Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly
 580 585 590
 Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640

Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 650 655
 .
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
 705 710 720
 Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 .
 Glu

<210> 14
 <211> 833
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic
 <400> 14

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15
 Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30
 Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe

35	40	45	
Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile			
50	55	60	
Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly			
65	70	75	80
Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln			
85	90	95	
Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu			
100	105	110	
Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys			
115	120	125	
Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys			
130	135	140	
Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu			
145	150	155	160
Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg			
165	170	175	
Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp			
180	185	190	
Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu			
195	200	205	
Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg			
210	215	220	
Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu			
225	230	235	240
Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu			
245	250	255	
Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala			
260	265	270	
Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu			
275	280	285	
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu			
290	295	300	
Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala			
305	310	315	320
Asp Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala			
325	330	335	
Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu			

340	345	350	
Leu Ala Lys Asp Leu Ser Val	Leu Ala Leu Arg Glu	Gly Leu Gly Leu	
355	360	365	
Pro Pro Gly Asp Asp Pro Met	Leu Leu Ala Tyr	Leu Leu Asp Pro Ser	
370	375	380	
Asn Thr Thr Pro Glu Gly Val	Ala Arg Arg Tyr	Gly Gly Glu Trp Thr	
385	390	395	400
Glu Glu Ala Gly Glu Arg Ala	Ala Leu Ser	Glu Arg Leu Phe Ala Asn	
405	410	415	
Leu Trp Gly Arg Leu Glu Gly	Glu Arg Leu	Leu Trp Leu Tyr Arg	
420	425	430	
Glu Val Glu Arg Pro Leu Ser	Ala Val	Leu Ala His Met Glu Ala Thr	
435	440	445	
Gly Val Arg Leu Asp Val Ala Tyr	Leu Arg Ala	Leu Ser Leu Glu Val	
450	455	460	
Ala Glu Glu Ile Ala Arg Leu	Glu Ala Glu Val	Phe Arg Leu Ala Gly	
465	470	475	480
His Pro Phe Asn Leu Asn Ser	Arg Asp Gln	Leu Glu Arg Val Leu Phe	
485	490	495	
Asp Glu Leu Gly Leu Pro Ala Ile	Gly Lys Thr	Glu Lys Thr Gly Lys	
500	505	510	
Arg Ser Thr Ser Ala Ala Val	Leu Glu Ala	Leu Arg Glu Ala His Pro	
515	520	525	
Ile Val Glu Lys Ile Leu	Gln Tyr Arg	Glu Leu Thr Lys Leu Lys Ser	
530	535	540	
Thr Tyr Ile Asp Pro Leu Pro	Asp Leu Ile	His Pro Arg Thr Gly Arg	
545	550	555	560
Leu His Thr Arg Phe Asn Gln	Thr Ala	Thr Gly Arg Leu Ser	
565	570	575	
Ser Ser Asp Pro Asn Leu Gln	Asn Ile Pro Val	Arg Thr Pro Leu Gly	
580	585	590	
Gln Arg Ile Arg Arg Ala Phe	Val Ala Glu	Ala Gly Trp Ala Leu Val	
595	600	605	
Ala Leu Asp Tyr Ser Gln Ile	Glu Leu Arg	Val Leu Ala His Leu Ser	
610	615	620	
Gly Asp Glu Asn Leu Ile Arg	Val Phe Gln	Glu Gly Lys Asp Ile His	
625	630	635	640
Thr Gln Thr Ala Ser Trp Met	Phe Gly Val	Pro Pro Glu Ala Val Asp	

645	650	655
Pro Leu Met Arg Arg Ala Ala Lys Thr Val Asn Phe Gly Val Leu Tyr 660	665	670
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu 675	680	685
Glu Ala Val Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val 690	695	700
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Lys Arg Gly Tyr 705	710	715
Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Asn Ala 725	730	735
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met 740	745	750
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys 755	760	765
Leu Phe Pro Arg Leu Arg Glu Met Gly Ala Arg Met Leu Leu Gln Val 770	775	780
His Asp Glu Leu Leu Leu Glu Ala Pro Gln Ala Arg Ala Glu Glu Val 785	790	795
Ala Ala Leu Ala Lys Glu Ala Met Glu Lys Ala Tyr Pro Leu Ala Val 805	810	815
Pro Leu Glu Val Glu Val Gly Met Gly Glu Asp Trp Leu Ser Ala Lys 820	825	830

Gly

<210> 15
<211> 833
<212> PRT
<213> Artificial

<220>
<223> Synthetic

<400> 15

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu 1	5	10	15
Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys 20	25	30	
Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe 35	40	45	

Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60
 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80
 Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95
 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110
 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140
 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160
 Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175
 Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205
 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu
 340 345 350

Leu	Ala	Lys	Asp	Leu	Ser	Val	Leu	Ala	Leu	Arg	Glu	Gly	Leu	Gly	Leu
355							360						365		
Pro	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser
370							375						380		
Asn	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr
385							390						395		400
Glu	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn
							405						410		415
Leu	Leu	Lys	Arg	Leu	Glu	Gly	Glu	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg
							420						425		430
Glu	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr
							435						440		445
Gly	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val
							450						455		460
Ala	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly
							465						470		475
His	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe
							485						490		495
Asp	Glu	Leu	Gly	Leu	Pro	Ala	Ile	Gly	Lys	Thr	Gln	Lys	Thr	Gly	Lys
							500						505		510
Arg	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro
							515						520		525
Ile	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser
							530						535		540
Thr	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg
							545						550		555
Leu	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser
							565						570		575
Ser	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly
							580						585		590
Gln	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Gly	Trp	Leu	Leu	Val	
							595						600		605
Ala	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser
							610						615		620
Gly	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His
							625						630		635
Thr	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp
							645						650		655

Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
 705 710 715 720
 Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu

<210> 16
 <211> 839
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic

<400> 16

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15
 Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30
 Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45
 Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80
 Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95
 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110
 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140
 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160
 Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175
 Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205
 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu
 355 360 365

Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr
 385 390 395 400
 Glu Glu Ala Gly His Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn
 405 410 415
 Leu Trp Gly Arg Leu Glu Gly Glu Arg Leu Leu Trp Leu Tyr Arg
 420 425 430
 Glu Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Arg Asp Val Ala Tyr Leu Gln Ala Leu Ser Leu Glu Leu
 450 455 460
 Ala Glu Glu Ile Arg Arg Leu Glu Glu Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys Thr Gly Lys
 500 505 510
 Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro
 515 520 525
 Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys Asn
 530 535 540
 Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly Arg
 545 550 555 560
 Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser
 565 570 575
 Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly
 580 585 590
 Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640
 Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 650 655
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670

Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
 705 710 715 720
 Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His His
 835
 <210> 17
 <211> 839
 <212> PRT
 <213> Artificial

 <220>
 <223> Synthetic

 <400> 17

 Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15

 Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30

 Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45

 Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60

 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly

65	70	75	80
Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln			
85	90	95	
Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu			
100	105	110	
Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys			
115	120	125	
Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys			
130	135	140	
Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu			
145	150	155	160
Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg			
165	170	175	
Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp			
180	185	190	
Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu			
195	200	205	
Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg			
210	215	220	
Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu			
225	230	235	240
Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu			
245	250	255	
Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala			
260	265	270	
Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu			
275	280	285	
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu			
290	295	300	
Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala			
305	310	315	320
Asp Leu Leu Ala Leu Ala Ala Ala Arg Gly Arg Val His Arg Ala			
325	330	335	
Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu			
340	345	350	
Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu			
355	360	365	
Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser			

370	375	380
Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr		
385	390	395
Glu Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu His Arg Asn		
405	410	415
Leu Trp Gly Arg Leu Glu Gly Glu Arg Leu Leu Trp Leu Tyr Arg		
420	425	430
Glu Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr		
435	440	445
Gly Val Arg Arg Asp Val Ala Tyr Leu Gln Ala Leu Ser Leu Glu Leu		
450	455	460
Ala Glu Glu Ile Arg Arg Leu Glu Glu Val Phe Arg Leu Ala Gly		
465	470	475
His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe		
485	490	495
Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys Thr Gly Lys		
500	505	510
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro		
515	520	525
Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys Asn		
530	535	540
Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly Arg		
545	550	555
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser		
565	570	575
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly		
580	585	590
Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val		
595	600	605
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser		
610	615	620
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His		
625	630	635
Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp		
645	650	655
Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr		
660	665	670
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu		

675	680	685
Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val		
690	695	700
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr		
705	710	715
720		
Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala		
725	730	735
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met		
740	745	750
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys		
755	760	765
Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val		
770	775	780
His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val		
785	790	795
800		
Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val		
805	810	815
Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys		
820	825	830
Glu His His His His His His		
835		
<210> 18		
<211> 839		
<212> PRT		
<213> Artificial		
<220>		
<223> Synthetic		
<400> 18		
Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu		
1	5	10
15		
Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys		
20	25	30
Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe		
35	40	45
Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile		
50	55	60
Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly		
65	70	75
80		

Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95
 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110
 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140
 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160
 Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175
 Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205
 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu
 355 360 365
 Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380

Asn	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr
385				390				395						400	
Glu	Glu	Ala	Gly	Glu	Arg	Ala	Ala	Leu	Ser	Glu	Arg	Leu	Phe	Ala	Asn
				405				410						415	
Leu	Leu	Lys	Arg	Leu	Glu	Gly	Glu	Arg	Leu	Leu	Trp	Leu	Tyr	Arg	
				420				425					430		
Glu	Val	Glu	Arg	Pro	Leu	Ser	Ala	Val	Leu	Ala	His	Met	Glu	Ala	Thr
				435				440					445		
Gly	Val	Arg	Arg	Asp	Val	Ala	Tyr	Leu	Gln	Ala	Leu	Ser	Glu	Leu	
				450				455					460		
Ala	Glu	Glu	Ile	Arg	Arg	Leu	Glu	Glu	Val	Phe	Arg	Leu	Ala	Gly	
				465				470					475		480
His	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe
				485				490					495		
Asp	Glu	Leu	Arg	Leu	Pro	Ala	Leu	Gly	Lys	Thr	Gln	Lys	Thr	Gly	Lys
				500				505					510		
Arg	Ser	Thr	Ser	Ala	Ala	Val	Leu	Glu	Ala	Leu	Arg	Glu	Ala	His	Pro
				515				520					525		
Ile	Val	Glu	Lys	Ile	Leu	Gln	His	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Asn
				530				535					540		
Thr	Tyr	Val	Asp	Pro	Leu	Pro	Ser	Leu	Val	His	Pro	Arg	Thr	Gly	Arg
				545				550					555		560
Leu	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser
				565				570					575		
Ser	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly
				580				585					590		
Gln	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Gly	Trp	Leu	Leu	Val	
				595				600					605		
Ala	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser
				610				615					620		
Gly	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His
				625				630					635		640
Thr	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp
				645				650					655		
Pro	Leu	Met	Arg	Arg	Ala	Ala	Lys	Thr	Ile	Asn	Phe	Gly	Val	Leu	Tyr
				660				665					670		
Gly	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu
				675				680					685		

Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
 705 710 715 720
 Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His His
 835
 <210> 19
 <211> 839
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic
 <400> 19
 Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15
 Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30
 Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45
 Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60
 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80
 Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95

Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110
 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140
 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160
 Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175
 Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205
 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu
 355 360 365
 Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr
 385 390 395 400

Glu Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn
 405 410 415
 Leu Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg
 420 425 430
 Glu Val Glu Arg Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Arg Asp Val Ala Tyr Leu Gin Ala Leu Ser Leu Glu Leu
 450 455 460
 Ala Glu Glu Ile Arg Arg Leu Glu Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Arg Leu Pro Ala Leu Gly Lys Thr Gln Lys Thr Gly Lys
 500 505 510
 Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro
 515 520 525
 Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys Asn
 530 535 540
 Thr Tyr Val Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly Arg
 545 550 555 560
 Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser
 565 570 575
 Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly
 580 585 590
 Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640
 Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 650 655
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700

Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
705 710 715 720

Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala
725 730 735

Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
740 745 750

Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
755 760 765

Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
770 775 780

His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
785 790 795 800

Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
805 810 815

Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
820 825 830

Glu His His His His His His
835

<210> 20
<211> 839
<212> PRT
<213> Artificial

<220>
<223> Synthetic

<400> 20

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
1 5 10 15

Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
20 25 30

Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
35 40 45

Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
50 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
65 70 75 80

Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
85 90 95

Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu

100	105	110	
Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys			
115	120	125	
Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys			
130	135	140	
Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu			
145	150	155	160
Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg			
165	170	175	
Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp			
180	185	190	
Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu			
195	200	205	
Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg			
210	215	220	
Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu			
225	230	235	240
Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu			
245	250	255	
Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala			
260	265	270	
Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu			
275	280	285	
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu			
290	295	300	
Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala			
305	310	315	320
Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala			
325	330	335	
Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu			
340	345	350	
Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu			
355	360	365	
Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser			
370	375	380	
Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr			
385	390	395	400
Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn			

405	410	415	
Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp	Leu Tyr His		
420	425	430	
Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met	Glu Ala Thr		
435	440	445	
Gly Val Arg Arg Asp Val Ala Tyr Leu Arg Ala Leu Ser	Glu Val		
450	455	460	
Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg	Leu Ala Gly		
465	470	475	480
His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg	Val Leu Phe		
485	490	495	
Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys	Thr Gly Lys		
500	505	510	
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu	Ala His Pro		
515	520	525	
Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys	Leu Lys Ser		
530	535	540	
Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg	Thr Gly Arg		
545	550	555	560
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly	Arg Leu Ser		
565	570	575	
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr	Pro Leu Gly		
580	585	590	
Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp	Leu Leu Val		
595	600	605	
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His	Leu Ser		
610	615	620	
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg	Asp Ile His		
625	630	635	640
Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu	Ala Val Asp		
645	650	655	
Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly	Val Leu Tyr		
660	665	670	
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile	Pro Tyr Glu		
675	680	685	
Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe	Pro Lys Val		
690	695	700	
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg	Gly Tyr		

705	710	715	720
Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala			
725		730	735
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met			
740		745	750
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys			
755		760	765
Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val			
770		775	780
His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val			
785		790	800
Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val			
805		810	815
Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys			
820		825	830
Glu His His His His His His			
835			
<210> 21			
<211> 839			
<212> PRT			
<213> Artificial			
<220>			
<223> Synthetic			
<400> 21			
Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu			
1	5	10	15
Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys			
20	25	30	
Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe			
35	40	45	
Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile			
50	55	60	
Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly			
65	70	75	80
Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln			
85	90	95	
Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu			
100	105	110	

Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140
 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160
 Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175
 Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205
 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu
 355 360 365
 Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr
 385 390 395 400
 Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn
 405 410 415

Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr His
 420 425 430
 Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Leu Asp Val Ala Tyr Leu Gln Ala Leu Ser Leu Glu Val
 450 455 460
 Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys
 500 505 510
 Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro
 515 520 525
 Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser
 530 535 540
 Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg
 545 550 555 560
 Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser
 565 570 575
 Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly
 580 585 590
 Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640
 Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 650 655
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
 705 710 715 720

Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His His
 835
 <210> 22
 <211> 839
 <212> PRT
 <213> Artificial

 <220>
 <223> Synthetic

 <400> 22

 Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15

 Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30

 Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45

 Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60

 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80

 Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95

 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110

 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125

Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140
 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160
 Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175
 Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205
 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Ala Arg Gly Arg Val His Arg Ala
 325 330 335
 Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu
 355 360 365
 Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr
 385 390 395 400
 Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn
 405 410 415
 Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr His
 420 425 430

Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Leu
 450 455 460
 Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys
 500 505 510
 Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro
 515 520 525
 Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser
 530 535 540
 Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg
 545 550 555 560
 Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser
 565 570 575
 Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly
 580 585 590
 Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640
 Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 650 655
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
 705 710 715 720
 Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735

Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His His
 835
 <210> 23
 <211> 839
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic
 <400> 23
 Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15
 Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30
 Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45
 Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60
 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80
 Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95
 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110
 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys

130	135	140
Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu		
145	150	155
Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg		
165	170	175
Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp		
180	185	190
Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu		
195	200	205
Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg		
210	215	220
Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu		
225	230	235
Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu		
245	250	255
Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala		
260	265	270
Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu		
275	280	285
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu		
290	295	300
Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala		
305	310	315
Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala		
325	330	335
Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu		
340	345	350
Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu		
355	360	365
Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser		
370	375	380
Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr		
385	390	395
Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn		
405	410	415
Leu Leu Lys Arg Leu Glu Gly Glu Lys Leu Leu Trp Leu Tyr His		
420	425	430
Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr		

435	440	445
Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val		
450	455	460
Ala Glu Glu Ile Arg Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly		
465	470	475
His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe		
485	490	495
Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys		
500	505	510
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro		
515	520	525
Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser		
530	535	540
Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg		
545	550	555
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Gly Arg Leu Ser		
555	560	575
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly		
580	585	590
Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val		
595	600	605
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser		
610	615	620
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His		
625	630	635
Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp		
645	650	655
Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr		
660	665	670
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu		
675	680	685
Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val		
690	695	700
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr		
705	710	715
Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala		
725	730	735
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met		

	740	745	750
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys			
755	760	765	
Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val			
770	775	780	
His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val			
785	790	795	800
Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val			
805	810	815	
Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys			
820	825	830	
Glu His His His His His His			
835			
<210> 24			
<211> 839			
<212> PRT			
<213> Artificial			
<220>			
<223> Synthetic			
<400> 24			
Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu			
1	5	10	15
Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys			
20	25	30	
Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe			
35	40	45	
Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile			
50	55	60	
Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly			
65	70	75	80
Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln			
85	90	95	
Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu			
100	105	110	
Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys			
115	120	125	
Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys			
130	135	140	

Asp	Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu
145					150					155					160
Gly	Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg
					165					170					175
Pro	Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp
					180					185					190
Asn	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu
					195					200					205
Leu	Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Lys	Asn	Leu	Asp	Arg	.
					210					215					220
Leu	Lys	Pro	Ala	Ile	Arg	Glu	Lys	Ile	Leu	Ala	His	Met	Asp	Asp	Leu
					225					230			235		240
Lys	Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu
					245					250			255		
Val	Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala
					260					265			270		
Phe	Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu	Phe	Gly	Leu
					275					280			285		
Leu	Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu
					290					295			300		
Gly	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala
					305					310			315		320
Asp	Leu	Leu	Ala	Leu	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	.
					325					330			335		
Ala	Asp	Pro	Leu	Ala	Gly	Leu	Lys	Asp	Leu	Lys	Glu	Val	Arg	Gly	Leu
					340					345			350		
Leu	Ala	Lys	Asp	Leu	Ala	Val	Leu	Ala	Ser	Arg	Glu	Leu	Asp	Leu	.
					355					360			365		
Val	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser
					370					375			380		
Asn	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Gly	Glu	Trp	Thr
					385					390			395		400
Glu	Asp	Ala	Ala	His	Arg	Ala	Leu	Leu	Ser	Glu	Arg	Leu	His	Arg	Asn
					405					410			415		
Leu	Leu	Lys	Arg	Leu	Glu	Gly	Glu	Glu	Lys	Leu	Leu	Trp	Leu	Tyr	His
					420					425			430		
Glu	Val	Glu	Lys	Pro	Leu	Ser	Arg	Val	Leu	Ala	His	Met	Glu	Ala	Thr
					435					440			445		

Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val 450
 455 460

Ala Glu Glu Ile Ala Arg Leu Glu Glu Val Phe Arg Leu Ala Gly 480
 465 470 475 480

His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe 495
 485 490 495

Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys 510
 500 505 510

Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro 525
 515 520 525

Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser 540
 530 535 540

Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg 560
 545 550 555 560

Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser 575
 565 570 575

Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly 590
 580 585 590

Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val 605
 595 600 605

Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser 620
 610 615 620

Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His 640
 625 630 635 640

Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp 655
 645 650 655

Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr 670
 660 665 670

Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu 685
 675 680 685

Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val 700
 690 695 700

Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr 720
 705 710 715 720

Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala 735
 725 730 735

Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met 750
 740 745 750

Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His His
 835
 <210> 25
 <211> 839
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic
 <400> 25
 Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15
 Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30
 Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45
 Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60
 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80
 Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95
 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110
 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140
 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160

Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175
 Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205
 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu
 355 360 365
 Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Glu Trp Thr
 385 390 395 400
 Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn
 405 410 415
 Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr His
 420 425 430
 Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val
 450 455 460

Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Arg Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys
 500 505 510
 Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro
 515 520 525
 Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser
 530 535 540
 Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg
 545 550 555 560
 Leu His Thr Arg Phe Asn Gln Thr Ala Thr Gly Arg Leu Ser
 565 570 575
 Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly
 580 585 590
 Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640
 Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 ° 650 655
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Gly Tyr
 705 710 715 720
 Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765

Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His His
 835
 <210> 26
 <211> 839
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic
 <400> 26
 Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15
 Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30
 Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45
 Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60
 Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80
 Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95
 Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110
 Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125
 Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140
 Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160
 Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg

165	170	175
Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp		
180	185	190
Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu		
195	200	205
Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg		
210	215	220
Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu		
225	230	235
Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu		
245	250	255
Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala		
260	265	270
Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu		
275	280	285
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu		
290	295	300
Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala		
305	310	315
Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala		
325	330	335
Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu		
340	345	350
Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu		
355	360	365
Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser		
370	375	380
Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr		
385	390	395
Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn		
405	410	415
Leu Leu Lys Arg Leu Glu Gly Glu Lys Leu Leu Trp Leu Tyr His		
420	425	430
Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr		
435	440	445
Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val		
450	455	460
Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly		

465	470	475	480
His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe			
485	490	495	
Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Gln Lys Thr Gly Lys			
500	505	510	
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro			
515	520	525	
Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser			
530	535	540	
Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg			
545	550	555	560
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser			
565	570	575	
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly			
580	585	590	
Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val			
595	600	605	
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser			
610	615	620	
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His			
625	630	635	640
Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp			
645	650	655	
Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr			
660	665	670	
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu			
675	680	685	
Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val			
690	695	700	
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr			
705	710	715	720
Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala			
725	730	735	
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met			
740	745	750	
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys			
755	760	765	
Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val			

770

775

780

His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800

Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815

Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830

Glu His His His His His His
 835

<210> 27

<211> 839

<212> PRT

<213> Artificial

<220>

<223> Synthetic

<400> 27

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15

Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30

Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45

Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80

Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95

Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110

Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125

Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140

Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160

Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175

Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190
 Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205
 Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro.Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu
 355 360 365
 Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Glu Trp Thr
 385 390 395 400
 Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn
 405 410 415
 Leu Leu Lys Arg Leu Glu Gly Glu Lys Leu Leu Trp Leu Tyr His
 420 425 430
 Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val
 450 455 460
 Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly
 465 470 475 480

His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe		
485	490	495
Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys		
500	505	510
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro		
515	520	525
Ile Val Glu Lys Ile Leu Gln His Arg Glu Leu Thr Lys Leu Lys Ser		
530	535	540
Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg		
545	550	555
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser		
565	570	575
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly		
580	585	590
Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val		
595	600	605
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser		
610	615	620
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His		
625	630	635
Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp		
645	650	655
Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr		
660	665	670
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu		
675	680	685
Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val		
690	695	700
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr		
705	710	715
Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala		
725	730	735
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met		
740	745	750
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys		
755	760	765
Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val		
770	775	780

His	Asn	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val
785					790				795						800
Ala	Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val
				805					810						815
Pro	Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys
	820						825								830
Glu	His	His	His	His	His	His									
															835
<210>	28														
<211>	839														
<212>	PRT														
<213>	Artificial														
<220>															
<223>	Synthetic														
<400>	28														
Met	Asn	Ser	Gly	Met	Leu	Pro	Leu	Phe	Glu	Pro	Lys	Gly	Arg	Val	Leu
1					5				10						15
Leu	Val	Asp	Gly	His	His	Leu	Ala	Tyr	Arg	Thr	Phe	His	Ala	Leu	Lys
	20							25							30
Gly	Leu	Thr	Thr	Ser	Arg	Gly	Glu	Pro	Val	Gln	Ala	Val	Tyr	Gly	Phe
	35						40								45
Ala	Lys	Ser	Leu	Leu	Lys	Ala	Leu	Lys	Glu	Asp	Gly	Asp	Ala	Val	Ile
	50						55								60
Val	Val	Phe	Asp	Ala	Lys	Ala	Pro	Ser	Phe	Arg	His	Glu	Ala	Tyr	Gly
	65						70			75					80
Gly	Tyr	Lys	Ala	Gly	Arg	Ala	Pro	Thr	Pro	Glu	Asp	Phe	Pro	Arg	Gln
			85					90							95
Leu	Ala	Leu	Ile	Lys	Glu	Leu	Val	Asp	Leu	Leu	Gly	Leu	Ala	Arg	Leu
			100					105							110
Glu	Val	Pro	Gly	Tyr	Glu	Ala	Asp	Asp	Val	Leu	Ala	Ser	Leu	Ala	Lys
	115						120								125
Lys	Ala	Glu	Lys	Glu	Gly	Tyr	Glu	Val	Arg	Ile	Leu	Thr	Ala	Asp	Lys
	130						135								140
Asp	Leu	Tyr	Gln	Leu	Leu	Ser	Asp	Arg	Ile	His	Val	Leu	His	Pro	Glu
	145						150			155					160
Gly	Tyr	Leu	Ile	Thr	Pro	Ala	Trp	Leu	Trp	Glu	Lys	Tyr	Gly	Leu	Arg
			165					170							175
Pro	Asp	Gln	Trp	Ala	Asp	Tyr	Arg	Ala	Leu	Thr	Gly	Asp	Glu	Ser	Asp
			180					185							190

Asn	Leu	Pro	Gly	Val	Lys	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Arg	Lys	Leu
195					200				205						
Leu	Glu	Glu	Trp	Gly	Ser	Leu	Glu	Ala	Leu	Leu	Lys	Asn	Leu	Asp	Arg
210					215				220						
Leu	Lys	Pro	Ala	Ile	Arg	Glu	Ile	Leu	Ala	His	Met	Asp	Asp	Leu	
225					230				235						240
Lys	Leu	Ser	Trp	Asp	Leu	Ala	Lys	Val	Arg	Thr	Asp	Leu	Pro	Leu	Glu
245					250				255						
Val	Asp	Phe	Ala	Lys	Arg	Arg	Glu	Pro	Asp	Arg	Glu	Arg	Leu	Arg	Ala
260					265				270						
Phe	Leu	Glu	Arg	Leu	Glu	Phe	Gly	Ser	Leu	Leu	His	Glu	Phe	Gly	Leu
275					280				285						
Leu	Glu	Ser	Pro	Lys	Ala	Leu	Glu	Glu	Ala	Pro	Trp	Pro	Pro	Pro	Glu
290					295				300						
Gly	Ala	Phe	Val	Gly	Phe	Val	Leu	Ser	Arg	Lys	Glu	Pro	Met	Trp	Ala
305					310				315						320
Asp	Leu	Leu	Ala	Leu	Ala	Ala	Arg	Gly	Gly	Arg	Val	His	Arg	Ala	
325					330				335						
Ala	Asp	Pro	Leu	Ala	Gly	Leu	Lys	Asp	Leu	Lys	Glu	Val	Arg	Gly	Leu
340					345				350						
Leu	Ala	Lys	Asp	Leu	Ala	Val	Leu	Ala	Ser	Arg	Glu	Gly	Leu	Asp	Leu
355					360				365						
Val	Pro	Gly	Asp	Asp	Pro	Met	Leu	Leu	Ala	Tyr	Leu	Leu	Asp	Pro	Ser
370					375				380						
Asn	Thr	Thr	Pro	Glu	Gly	Val	Ala	Arg	Arg	Tyr	Gly	Glu	Trp	Thr	
385					390				395						400
Glu	Asp	Ala	Ala	His	Arg	Ala	Leu	Leu	Ser	Glu	Arg	Leu	His	Arg	Asn
405					410				415						
Leu	Leu	Lys	Arg	Leu	Glu	Gly	Glu	Glu	Lys	Leu	Leu	Trp	Leu	Tyr	His
420					425				430						
Glu	Val	Glu	Lys	Pro	Leu	Ser	Arg	Val	Leu	Ala	His	Met	Glu	Ala	Thr
435					440				445						
Gly	Val	Arg	Leu	Asp	Val	Ala	Tyr	Leu	Arg	Ala	Leu	Ser	Leu	Glu	Val
450					455				460						
Ala	Glu	Glu	Ile	Ala	Arg	Leu	Glu	Ala	Glu	Val	Phe	Arg	Leu	Ala	Gly
465					470				475						480
His	Pro	Phe	Asn	Leu	Asn	Ser	Arg	Asp	Gln	Leu	Glu	Arg	Val	Leu	Phe
485					490				495						

Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys			
500	505	510	
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro			
515	520	525	
Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Asn			
530	535	540	
Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg			
545	550	555	560
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser			
565	570	575	
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly			
580	585	590	
Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val			
595	600	605	
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser			
610	615	620	
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His			
625	630	635	640
Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp			
645	650	655	
Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr			
660	665	670	
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu			
675	680	685	
Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val			
690	695	700	
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr			
705	710	715	720
Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala			
725	730	735	
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met			
740	745	750	
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys			
755	760	765	
Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val			
770	775	780	
His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val			
785	790	795	800

Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val		
805	810	815
Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys		
820	825	830
Glu His His His His His His		
835		
<210> 29		
<211> 839		
<212> PRT		
<213> Artificial		
<220>		
<223> Synthetic		
<400> 29		
Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu		
1 5 10 15		
Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys		
20 25 30		
Gly -Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe		
35 40 45		
Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile		
50 55 60		
Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly		
65 70 75 80		
Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln		
85 90 95		
Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu		
100 105 110		
Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys		
115 120 125		
Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys		
130 135 140		
Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu		
145 150 155 160		
Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg		
165 170 175		
Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp		
180 185 190		
Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu		
195 200 205		

Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
 210 215 220
 Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
 225 230 235 240
 Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu
 355 360 365
 Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr
 385 390 395 400
 Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn
 405 410 415
 Leu Leu Lys Arg Leu Glu Gly Glu Lys Leu Leu Trp Leu Tyr His
 420 425 430
 Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val
 450 455 460
 Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys
 500 505 510

Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro			
515	520	525	
Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser			
530	535	540	
Thr Tyr Val Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg			
545	550	555	560
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser			
565	570	575	
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly			
580	585	590	
Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val			
595	600	605	
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser			
610	615	620	
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His			
625	630	635	640
Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp			
645	650	655	
Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr			
660	665	670	
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu			
675	680	685	
Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val			
690	695	700	
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr			
705	710	715	720
Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala			
725	730	735	
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met			
740	745	750	
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys			
755	760	765	
Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val			
770	775	780	
His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val			
785	790	795	800
Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val			
805	810	815	

Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His His
 835
 <210> 30
 <211> 839
 <212> PRT
 <213> Artificial
 <220>
 <223> Synthetic
 <400> 30

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
 1 5 10 15

Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
 20 25 30

Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
 35 40 45

Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
 50 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
 65 70 75 80

Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
 85 90 95

Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
 100 105 110

Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
 115 120 125

Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
 130 135 140

Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
 145 150 155 160

Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
 165 170 175

Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
 180 185 190

Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
 195 200 205

Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg

210	215	220
Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu		
225	230	235
Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu		
245	250	255
Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala		
260	265	270
Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu		
275	280	285
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu		
290	295	300
Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala		
305	310	315
Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala		
325	330	335
Ala Asp Pro Leu Ala Gly Leu Lys Asp Leu Lys Glu Val Arg Gly Leu		
340	345	350
Leu Ala Lys Asp Leu Ala Val Leu Ala Ser Arg Glu Gly Leu Asp Leu		
355	360	365
Val Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser		
370	375	380
Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr		
385	390	395
400		
Glu Asp Ala Ala His Arg Ala Leu Leu Ser Glu Arg Leu His Arg Asn		
405	410	415
Leu Leu Lys Arg Leu Glu Gly Glu Glu Lys Leu Leu Trp Leu Tyr His		
420	425	430
Glu Val Glu Lys Pro Leu Ser Arg Val Leu Ala His Met Glu Ala Thr		
435	440	445
Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val		
450	455	460
Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly		
465	470	475
480		
His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe		
485	490	495
Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys		
500	505	510
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro		

515	520	525
Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser 530	535	540
Thr Tyr Ile Asp Pro Leu Pro Ser Leu Val His Pro Arg Thr Gly Arg 545	550	555
Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser 565	570	575
Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly 580	585	590
Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Gly Trp Leu Leu Val 595	600	605
Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser 610	615	620
Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His 625	630	635
Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp 645	650	655
Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr 660	665	670
Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu 675	680	685
Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val 690	695	700
Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr 705	710	715
Val Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala 725	730	735
Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met 740	745	750
Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys 755	760	765
Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val 770	775	780
His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val 785	790	795
Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val 805	810	815
Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys		

820	825	830
Glu His His His His His His		
835		
<210> 31		
<211> 839		
<212> PRT		
<213> Artificial		
<220>		
<223> Synthetic		
<400> 31		
Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu		
1 5 10 15		
Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys		
20 25 30		
Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe		
35 40 45		
Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile		
50 55 60		
Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly		
65 70 75 80		
Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln		
85 90 95		
Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu		
100 105 110		
Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys		
115 120 125		
Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys		
130 135 140		
Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu		
145 150 155 160		
Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg		
165 170 175		
Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp		
180 185 190		
Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu		
195 200 205		
Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg		
210 215 220		

Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu		
225	230	235
		240
Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu		
245	250	255
Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala		
260	265	270
Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu		
275	280	285
Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu		
290	295	300
Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala		
305	310	315
		320
Asp Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala		
325	330	335
Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu		
340	345	350
Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu		
355	360	365
Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser		
370	375	380
Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr		
385	390	395
		400
Glu Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn		
405	410	415
Leu Leu Lys Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg		
420	425	430
Glu Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr		
435	440	445
Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val		
450	455	460
Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly		
465	470	475
		480
His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe		
485	490	495
Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Gln Lys Thr Gly Lys		
500	505	510
Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro		
515	520	525

Ile	Val	Glu	Lys	Ile	Leu	Gln	Tyr	Arg	Glu	Leu	Thr	Lys	Leu	Lys	Ser
530						535					540				
Thr	Tyr	Ile	Asp	Pro	Leu	Pro	Asp	Leu	Ile	His	Pro	Arg	Thr	Gly	Arg
545						550				555					560
Leu	His	Thr	Arg	Phe	Asn	Gln	Thr	Ala	Thr	Ala	Thr	Gly	Arg	Leu	Ser
565							570							575	
Ser	Ser	Asp	Pro	Asn	Leu	Gln	Asn	Ile	Pro	Val	Arg	Thr	Pro	Leu	Gly
580							585							590	
Gln	Arg	Ile	Arg	Arg	Ala	Phe	Ile	Ala	Glu	Glu	Gly	Trp	Leu	Leu	Val
595							600					605			
Ala	Leu	Asp	Tyr	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Leu	Ser
610						615				620					
Gly	Asp	Glu	Asn	Leu	Ile	Arg	Val	Phe	Gln	Glu	Gly	Arg	Asp	Ile	His
625						630				635					640
Thr	Glu	Thr	Ala	Ser	Trp	Met	Phe	Gly	Val	Pro	Arg	Glu	Ala	Val	Asp
645						650				655					
Pro	Leu	Met	Arg	Arg	Ala	Ala	Lys	Ile	Asn	Phe	Gly	Val	Leu	Tyr	
660							665					670			
Gly	Met	Ser	Ala	His	Arg	Leu	Ser	Gln	Glu	Leu	Ala	Ile	Pro	Tyr	Glu
675							680					685			
Glu	Ala	Gln	Ala	Phe	Ile	Glu	Arg	Tyr	Phe	Gln	Ser	Phe	Pro	Lys	Val
690						695					700				
Arg	Ala	Trp	Ile	Glu	Lys	Thr	Leu	Glu	Glu	Gly	Arg	Arg	Arg	Gly	Tyr
705						710				715					720
Val	Glu	Thr	Leu	Phe	Gly	Arg	Arg	Tyr	Val	Pro	Asp	Leu	Glu	Ala	
725						730						735			
Arg	Val	Lys	Ser	Val	Arg	Glu	Ala	Ala	Glu	Arg	Met	Ala	Phe	Asn	Met
740							745					750			
Pro	Val	Gln	Gly	Thr	Ala	Ala	Asp	Leu	Met	Lys	Leu	Ala	Met	Val	Lys
755							760					765			
Leu	Phe	Pro	Arg	Leu	Glu	Glu	Met	Gly	Ala	Arg	Met	Leu	Leu	Gln	Val
770						775					780				
His	Asn	Glu	Leu	Val	Leu	Glu	Ala	Pro	Lys	Glu	Arg	Ala	Glu	Ala	Val
785						790				795					800
Ala	Arg	Leu	Ala	Lys	Glu	Val	Met	Glu	Gly	Val	Tyr	Pro	Leu	Ala	Val
805						810					815				
Pro	Leu	Glu	Val	Glu	Val	Gly	Ile	Gly	Glu	Asp	Trp	Leu	Ser	Ala	Lys
820						825						830			

Glu His His His His His His
835

<210> 32

<211> 839

<212> PRT

<213> Artificial

<220>

<223> Synthetic

<400> 32

Met Asn Ser Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu
1 5 10 15

Leu Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys
20 25 30

Gly Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe
35 40 45

Ala Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile
50 55 60

Val Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly
65 70 75 80

Gly Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln
85 90 95

Leu Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu
100 105 110

Glu Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys
115 120 125

Lys Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys
130 135 140

Asp Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu
145 150 155 160

Gly Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg
165 170 175

Pro Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp
180 185 190

Asn Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu
195 200 205

Leu Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg
210 215 220

Leu Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu
225 230 235 240

Lys Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu
 245 250 255
 Val Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala
 260 265 270
 Phe Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu
 275 280 285
 Leu Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu
 290 295 300
 Gly Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala
 305 310 315 320
 Asp Leu Leu Ala Leu Ala Ala Arg Gly Gly Arg Val His Arg Ala
 325 330 335
 Pro Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu
 340 345 350
 Leu Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu
 355 360 365
 Pro Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser
 370 375 380
 Asn Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr
 385 390 395 400
 Glu Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn
 405 410 415
 Leu Leu Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg
 420 425 430
 Glu Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr
 435 440 445
 Gly Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val
 450 455 460
 Ala Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly
 465 470 475 480
 His Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe
 485 490 495
 Asp Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Gln Lys Thr Gly Lys
 500 505 510
 Arg Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro
 515 520 525
 Ile Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser
 530 535 540

Thr Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg
 545 550 555 560
 Leu His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser
 565 570 575
 Ser Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly
 580 585 590
 Gln Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val
 595 600 605
 Ala Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser
 610 615 620
 Gly Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His
 625 630 635 640
 Thr Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp
 645 650 655
 Pro Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr
 660 665 670
 Gly Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu
 675 680 685
 Glu Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val
 690 695 700
 Arg Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr
 705 710 715 720
 Val Glu Thr Leu Phe Gly Arg Arg Tyr Val Pro Asp Leu Glu Ala
 725 730 735
 Arg Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met
 740 745 750
 Pro Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys
 755 760 765
 Leu Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val
 770 775 780
 His Asn Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val
 785 790 795 800
 Ala Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val
 805 810 815
 Pro Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys
 820 825 830
 Glu His His His His His His
 835